PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Tanne, JH				Tanne, JH			Antibiotics may prevent heart attacks	BRITISH MEDICAL JOURNAL			English	News Item																		Folsom AR, 1999, JAMA-J AM MED ASSOC, V281, P461, DOI 10.1001/jama.281.5.461; Meier CR, 1999, JAMA-J AM MED ASSOC, V281, P427, DOI 10.1001/jama.281.5.427	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1999	318	7181					417	417		10.1136/bmj.318.7181.417	http://dx.doi.org/10.1136/bmj.318.7181.417			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BF	9974442	Green Published			2022-12-28	WOS:000078670100010
J	Dvorak, AM				Dvorak, AM			An apoptotic eosinophil	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Dvorak, AM (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.								0	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1999	340	6					437	437		10.1056/NEJM199902113400605	http://dx.doi.org/10.1056/NEJM199902113400605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166HW	9971868				2022-12-28	WOS:000078571000005
J	Hiyagon, H; Hashimoto, A				Hiyagon, H; Hashimoto, A			O-16 excesses in Olivine inclusions in Yamato-86009 and Murchison chondrites and their relation to CAIs	SCIENCE			English	Article							CARBONACEOUS CHONDRITES; ALLENDE METEORITE; ISOTOPE; OXYGEN; CONSEQUENCES; COMPONENT	In situ ion microprobe analyses of oxygen isotopes in Yamato-86009 and Murchison chondrites show that they contain abundant olivine-rich inclusions that have large oxygen-16 (O-16) excesses, similar to those in spinel grains in calcium-aluminium-rich inclusions in Allende and other carbonaceous chondrites. The existence of O-16-enriched olivine-rich inclusions suggests that oxygen isotopic anomalies were more extensive in the early solar system than was previously thought a nd that their origin may be attributed to a nebular chemical process rather than to an unidentified O-16-rich carrier of presolar origin.	Univ Tokyo, Dept Earth & Planetary Sci, Bunkyo Ku, Tokyo 1130033, Japan; Hokkaido Univ, Dept Earth & Planetary Sci, Sapporo, Hokkaido 0600810, Japan	University of Tokyo; Hokkaido University	Hiyagon, H (corresponding author), Univ Tokyo, Dept Earth & Planetary Sci, Bunkyo Ku, Tokyo 1130033, Japan.	hiyagon@geoph.s.u-tokyo.ac.jp		Hashimoto, Akihiko/0000-0002-2914-2809				CLAYTON DD, 1989, ASTROPHYS J, V346, P531, DOI 10.1086/168035; CLAYTON DD, 1988, ASTROPHYS J, V334, P191, DOI 10.1086/166829; CLAYTON RN, 1977, EARTH PLANET SC LETT, V34, P209, DOI 10.1016/0012-821X(77)90005-X; CLAYTON RN, 1973, SCIENCE, V182, P485, DOI 10.1126/science.182.4111.485; CLAYTON RN, 1976, EARTH PLANET SC LETT, V30, P10, DOI 10.1016/0012-821X(76)90003-0; CLAYTON RN, 1984, EARTH PLANET SC LETT, V67, P151, DOI 10.1016/0012-821X(84)90110-9; CRAIG H, 1961, SCIENCE, V133, P1833, DOI 10.1126/science.133.3467.1833; GREENWOOD RC, 1994, GEOCHIM COSMOCHIM AC, V58, P1913, DOI 10.1016/0016-7037(94)90424-3; GROSSMAN L, 1976, GEOCHIM COSMOCHIM AC, V40, P149, DOI 10.1016/0016-7037(76)90172-1; HASHIMOTO A, 1987, GEOCHIM COSMOCHIM AC, V51, P1685, DOI 10.1016/0016-7037(87)90348-6; HASHIMOTO A, 1997, ANTARCTIC METEORITES, V22, P49; HASHIMOTO A, 1997, 22 S ANT MET NAT I P; HIYAGON H, 1998, LUNAR PLANET SCI, V29; HIYAGON H, 1997, ANTARCT METEORITE RE, V10, P249; JABEEN I, 1998, ANTARCT METEORITE RE, V11, P122; KIMURA M, 1993, GEOCHIM COSMOCHIM AC, V57, P2329, DOI 10.1016/0016-7037(93)90573-F; LATTIMER JM, 1978, ASTROPHYS J, V219, P230, DOI 10.1086/155771; LIFFMAN K, 1988, P LUN PLAN SCI C, V18, P657; MacPherson G. J., 1981, P LUNAR PLANET SCI, V12B, P1079; MACPHERSON GJ, 1984, J GEOPHYS RES, V89, pC299, DOI 10.1029/JB089iS01p0C299; MACPHERSON GJ, 1985, GEOCHIM COSMOCHIM AC, V49, P2267, DOI 10.1016/0016-7037(85)90227-3; MCKEEGAN KD, 1998, METEORIT PLANET SC S, V32; Nittler LR, 1998, NATURE, V393, P222, DOI 10.1038/30377; Nittler LR, 1997, AIP CONF PROC, P59, DOI 10.1063/1.51767; Prinn R.G.P., 1989, ORIGIN EVOLUTION PLA, P78; Thiemen M.H, 1996, CHONDRULES PROTOPLAN, P107; THIEMENS MH, 1983, SCIENCE, V219, P1073, DOI 10.1126/science.219.4588.1073; Wark D. A., 1977, P 8 LUN SCI C, V8, P95; WEN J, 1993, J GEOPHYS RES-ATMOS, V98, P12801, DOI 10.1029/93JD00565; WOOD JA, 1993, GEOCHIM COSMOCHIM AC, V57, P2377, DOI 10.1016/0016-7037(93)90575-H	30	67	67	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1999	283	5403					828	831		10.1126/science.283.5403.828	http://dx.doi.org/10.1126/science.283.5403.828			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933162				2022-12-28	WOS:000078496800039
J	Bateman, NT				Bateman, NT			Sir Geoffrey Bateman - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1999	318	7179					333	333		10.1136/bmj.318.7179.333	http://dx.doi.org/10.1136/bmj.318.7179.333			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZH	9924078	Green Published			2022-12-28	WOS:000078436700055
J	Shaw, CM; Creed, F; Tomenson, B; Riste, L; Cruickshank, JK				Shaw, CM; Creed, F; Tomenson, B; Riste, L; Cruickshank, JK			Prevalence of anxiety and depressive illness and help seeking behaviour in African Caribbeans and White Europeans: two phase general population survey	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine the prevalence of common mental disorders (anxiety and depression) and help seeking behaviour in African Caribbeans and white Europeans. Design Two phase survey in a general population sample, The first phase comprised screening with the 12 item general health questionnaire; the second phase was standardised psychiatric assessment and interview about help seeking. Setting People registered with four general practices in central Manchester. Participants Of 1467 people randomly selected from family health services authority lists, 864 were still resident 337 African Caribbeans and 275 white Europeans completed the screening phase (response rate 71%); 127 African Caribbeans and 103 white Europeans were interviewed in the second phase. Main outcome measures One month period prevalence of anxiety and depressive disorders in each ethnic group. Results 13% of African Caribbeans (95% confidence interval 10% to 16%) and 14% (10% to 18%) of white Europeans had one or more disorder. Anxiety disorders were significantly less common among African Caribbeans (3% (1% to 5%) v 9% (6% to 12%) in white Europeans). Depressive disorders were significantly more common among African Caribbean women than white women (difference 8% (1% to 15%)). Medical help seeking was similar in the two groups, but African Caribbeans with mental disorders were more likely to seek additional help from non-medical sources (12/29 v 5/29, P = 0.082). Conclusions In an inner city setting the prevalence of common mental disorders is similar in these two ethnic groups.	Univ Manchester, Sch Psychiat & Behav Sci, Manchester M13 9WL, Lancs, England; Univ Manchester, Clin Epidemiol Unit, Manchester M13 9PL, Lancs, England	University of Manchester; University of Manchester	Shaw, CM (corresponding author), Tameside Gen Hosp, Tameside & Glossop Community & Prior Serv NHS Tru, Ashton under Lyne OL6 9RW, England.			Riste, Lisa/0000-0003-2606-0717	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Amin K., 1992, POVERTY BLACK WHITE; Bhugra D, 1997, PSYCHOL MED, V27, P791, DOI 10.1017/S0033291797005369; *DEP HLTH, 1994, HLTH NAT KEY AR HDB; FINLAYJONES R, 1981, PSYCHOL MED, V11, P803, DOI 10.1017/S0033291700041301; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; Goldberg DP, 1992, MED SYMPTOMS NOT EXP; Harrison G, 1997, PSYCHOL MED, V27, P799, DOI 10.1017/S0033291796004643; KENDLER KS, 1992, ARCH GEN PSYCHIAT, V49, P716; Lloyd KR, 1998, PSYCHOL MED, V28, P1231, DOI 10.1017/S0033291798007065; MBANYA JCN, IN PRESS DIABETES CA; Meltzer H, 1995, OPCS SURVEYS PSYCHIA; Nazroo JY, 1997, ETHNICITY MENTAL HLT; Pickles A, 1995, Stat Methods Med Res, V4, P73, DOI 10.1177/096228029500400106; VAZQUEZBARQUERO JL, 1986, BRIT J PSYCHIAT, V149, P88, DOI 10.1192/bjp.149.1.88; World Health Organization, 1992, SCAN SCHED CLIN ASS	15	67	70	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1999	318	7179					302	305		10.1136/bmj.318.7179.302	http://dx.doi.org/10.1136/bmj.318.7179.302			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	163ZH	9924059	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000078436700024
J	Stevenson, GT				Stevenson, GT			Immunotherapy of non-metastatic complication of malignant disease	LANCET			English	Editorial Material									Univ Southampton, Tenovus Res Lab, Southampton SO16 6YD, Hants, England	University of Southampton	Stevenson, GT (corresponding author), Univ Southampton, Tenovus Res Lab, Southampton SO16 6YD, Hants, England.							Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; GLYNN LE, 1964, AUTOIMMUNITY; HOLLINSHEAD A, 1988, CANCER, V62, P1662, DOI 10.1002/1097-0142(19881015)62:8<1662::AID-CNCR2820620835>3.0.CO;2-X; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; SISKIND GW, 1974, FED PROC, V33, P1886; WARREN HS, 1988, CRC CR REV IMMUNOL, V8, P83	6	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 30	1999	353	9150					340	340		10.1016/S0140-6736(05)74942-4	http://dx.doi.org/10.1016/S0140-6736(05)74942-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950433				2022-12-28	WOS:000078437000003
J	Davies, PA; Pistis, M; Hanna, MC; Peters, JA; Lambert, JJ; Hales, TG; Kirkness, EF				Davies, PA; Pistis, M; Hanna, MC; Peters, JA; Lambert, JJ; Hales, TG; Kirkness, EF			The 5-HT3B subunit is a major determinant of serotonin-receptor function	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; AMINO-ACIDS; 5-HYDROXYTRYPTAMINE; CHANNEL; EXPRESSION; NEURONS; CLONING; GENE	The neurotransmitter serotonin (5-hydroxytryptamine or 5-HT) mediates rapid excitatory responses through ligand-gated channels (5-HT3 receptors). Recombinant expression of the only identified receptor subunit (5-HT3A) yields functional 5-HT3 receptors(1). However, the conductance of these homomeric receptors (sub-picosiemens) is too small to be resolved directly, and contrasts with a robust channel conductance displayed by neuronal 5-HT3 receptors (9-17pS)(2-7). Neuronal 5-HT3 receptors also display a permeability to calcium ions and a current-voltage relationship that differ from those of homomeric receptors(3-5,8) Here we describe a new class of 5-HT3-receptor subunit (5-HT3B). Transcripts of this subunit are co-expressed with the 5-HT3A subunit in the amygdala, caudate and hippocampus. Heteromeric assemblies of 5-HT3A and 5-HT3B subunits display a large single-channel conductance (16 pS), low permeability to calcium ions, and a current-voltage relationship which resembles that of characterized neuronal 5-HT3 channels. The heteromeric receptors also display distinctive pharmacological properties. Surprisingly, the M2 region of the 5-HT3B subunit lacks any of the structural features that are known to promote the conductance of related receptors. In addition to providing a new target for therapeutic agents, the 5-HT3B subunit will be a valuable resource for defining the molecular mechanisms of ion-channel function.	Inst Genom Res, Rockville, MD 20850 USA; Univ Dundee, Ninewells Hosp & Med Sch, Dept Pharmacol & Neurosci, Dundee DD1 9SY, Scotland; George Washington Univ, Med Ctr, Dept Pharmacol, Washington, DC 20037 USA	J. Craig Venter Institute; University of Dundee; George Washington University	Kirkness, EF (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.		Davies, Paul A/P-4595-2017; Pistis, Marco/A-3773-2013	Davies, Paul A/0000-0002-3973-3143; Pistis, Marco/0000-0002-4622-3205	NIDA NIH HHS [P50 DA005010] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA005010] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ADODRA S, 1995, BRIT J PHARMACOL, V115, P953, DOI 10.1111/j.1476-5381.1995.tb15903.x; Belelli D, 1995, MOL PHARMACOL, V48, P1054; BERTRAND D, 1952, P NATL ACAD SCI USA, V6971, P93; Brown AM, 1998, J PHYSIOL-LONDON, V507, P653, DOI 10.1111/j.1469-7793.1998.653bs.x; BUFTON KE, 1993, NEUROPHARMACOLOGY, V32, P1325, DOI 10.1016/0028-3908(93)90027-Z; DERKACH V, 1989, NATURE, V339, P706, DOI 10.1038/339706a0; Fletcher S, 1998, TRENDS PHARMACOL SCI, V19, P212, DOI 10.1016/S0165-6147(98)01210-3; HARGREAVES AC, 1994, MOL PHARMACOL, V46, P1120; HUSSY N, 1994, J PHYSIOL-LONDON, V481, P311, DOI 10.1113/jphysiol.1994.sp020441; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JONES KA, 1994, NEUROSCI LETT, V174, P133, DOI 10.1016/0304-3940(94)90004-3; KING FD, 1994, 5 HYDROXYTRYPTAMINE3; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MIYAKE A, 1995, MOL PHARMACOL, V48, P407; PETERS JA, 1997, RECOMBINANT CELL SUR, P119; Ronde P, 1998, J NEUROCHEM, V70, P1094; SUGITA S, 1992, NEURON, V8, P199, DOI 10.1016/0896-6273(92)90121-S; TOKUNAGA K, 1987, CANCER RES, V47, P5616; VILLARROEL A, 1992, P ROY SOC B-BIOL SCI, V249, P317, DOI 10.1098/rspb.1992.0121; WEISS B, 1995, GENOMICS, V29, P304, DOI 10.1006/geno.1995.1254; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; YANG J, 1992, J PHYSIOL-LONDON, V448, P237, DOI 10.1113/jphysiol.1992.sp019039	23	441	453	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 28	1999	397	6717					359	363		10.1038/16941	http://dx.doi.org/10.1038/16941			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9950429				2022-12-28	WOS:000078324600052
J	Heikkinen, T; Thint, M; Chonmaitree, T				Heikkinen, T; Thint, M; Chonmaitree, T			Prevalence of various respiratory viruses in the middle ear during acute otitis media	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYNCYTIAL VIRUS; CHILDREN; FLUIDS; INFECTIONS; EFFUSION; PREVENTION; BACTERIA; VACCINES; ETIOLOGY; ANTIGENS	Background Vaccines against respiratory viruses may be able to reduce the frequency of acute otitis media. Although the role of respiratory viruses in the pathogenesis of acute otitis media is well established, the relative importance of various Viruses is unknown. Methods We determined the prevalence of various respiratory viruses in the middle-ear fluid in 456 children (age, two months to seven years) with acute otitis media. At enrollment and after two to five days of antibiotic therapy, specimens of middle-ear fluid and nasal-wash specimens were obtained for viral and bacterial cultures and the detection of viral antigens. The viral cause of the infections was also assessed by serologic studies of serum samples obtained during the acute illness and convalescence. Results A specific viral cause of the respiratory tract infections was identified in 186 of the 456 children (41 percent). Respiratory syncytial virus was the most common virus identified in middle-ear fluid: it was detected in the middle-ear fluid of 48 of the 65 children (74 percent) infected by this virus (P less than or equal to 0.04 for the comparison with any other virus). Parainfluenza viruses (15 of 29 children [52 percent]) and influenzaviruses (10 of 24 children [42 percent]) were detected in the middle-ear fluid significantly more often than enteroviruses (3 of 27 children [11 percent]) or adenoviruses (1 of 23 children [4 percent]) (P less than or equal to 0.01 for all comparisons). Conclusions Respiratory syncytial virus is the principal virus invading the middle ear during acute otitis media. An effective vaccine against upper respiratory tract infections caused by respiratory syncytial virus may reduce the incidence of acute otitis media in children, (N Engl J Med 1999;340:260-4.) (C) 1999, Massachusetts Medical Society.	Univ Texas, Med Branch, Dept Pediat, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Chonmaitree, T (corresponding author), Univ Texas, Med Branch, Dept Pediat, Galveston, TX 77555 USA.	tchonmai@utmb.edu		Heikkinen, Terho/0000-0001-6504-0116	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002620] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC02620] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AROLA M, 1988, J PEDIATR-US, V113, P693, DOI 10.1016/S0022-3476(88)80380-9; AROLA M, 1990, J PEDIATR-US, V116, P697, DOI 10.1016/S0022-3476(05)82650-2; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; BERMAN S, 1995, NEW ENGL J MED, V332, P1560, DOI 10.1056/NEJM199506083322307; CHONMAITREE T, 1994, J INFECT DIS, V169, P1265, DOI 10.1093/infdis/169.6.1265; CHONMAITREE T, 1990, J INFECT DIS, V162, P546, DOI 10.1093/infdis/162.2.546; CHONMAITREE T, 1992, J PEDIATR-US, V120, P856, DOI 10.1016/S0022-3476(05)81950-X; CHONMAITREE T, 1986, PEDIATRICS, V77, P698; CHONMAITREE T, 1992, CLIN INFECT DIS, V15, P650, DOI 10.1093/clind/15.4.650; Chonmaitree T, 1996, ANN OTO RHINOL LARYN, V105, P968; Chonmaitree T, 1997, ANN NY ACAD SCI, V830, P143, DOI 10.1111/j.1749-6632.1997.tb51886.x; CLEMENTS DA, 1995, ARCH PEDIAT ADOL MED, V149, P1113, DOI 10.1001/archpedi.1995.02170230067009; CONE RW, 1993, CLIN INFECT DIS, V17, P558; CROWE JE, 1995, VACCINE, V13, P415, DOI 10.1016/0264-410X(95)98266-D; GIEBINK GS, 1994, ANN OTO RHINOL LARYN, V103, P20, DOI 10.1177/00034894941030S506; Groothuis JR, 1998, J INFECT DIS, V177, P467, DOI 10.1086/517377; GWALTNEY JM, 1995, MANDELL DOUGLAS BENN, P561; HALL CB, 1975, J INFECT DIS, V131, P1, DOI 10.1093/infdis/131.1.1; HALL CB, 1995, MANDELL DOUGLAS BENN, P1501; HEIKKINEN T, 1995, ACTA PAEDIATR, V84, P419, DOI 10.1111/j.1651-2227.1995.tb13663.x; Heikkinen T, 1996, ANN MED, V28, P23, DOI 10.3109/07853899608999070; HEIKKINEN T, 1991, AM J DIS CHILD, V145, P445, DOI 10.1001/archpedi.1991.02160040103017; HENDERSON FW, 1982, NEW ENGL J MED, V306, P1377, DOI 10.1056/NEJM198206103062301; Karron RA, 1997, J INFECT DIS, V176, P1428, DOI 10.1086/514138; KLEIN BS, 1982, J PEDIATR-US, V101, P16, DOI 10.1016/S0022-3476(82)80172-8; MANDEL EM, 1982, PEDIATR INFECT DIS J, V1, P310, DOI 10.1097/00006454-198209000-00006; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MCCAIG LF, 1998, JAMA-J AM MED ASSOC, V279, P434; Patel JA, 1996, RECENT ADVANCES IN OTITIS MEDIA, P178; Pitkaranta A, 1998, PEDIATRICS, V102, P291, DOI 10.1542/peds.102.2.291; RUUSKANEN O, 1991, PEDIATR INFECT DIS J, V10, P425, DOI 10.1097/00006454-199106000-00001; RUUSKANEN O, 1989, PEDIATR INFECT DIS J, V8, P94; SARKKINEN H, 1985, J INFECT DIS, V151, P444, DOI 10.1093/infdis/151.3.444; SARKKINEN HK, 1983, ACTA PAEDIATR SCAND, V72, P137, DOI 10.1111/j.1651-2227.1983.tb09681.x; SHURIN PA, 1979, NEW ENGL J MED, V300, P1121, DOI 10.1056/NEJM197905173002001; STOOL SE, 1989, PEDIATR INFECT DIS J, V8, pS11; UHARI M, 1995, CLIN INFECT DIS, V20, P521, DOI 10.1093/clinids/20.3.521; Wright Peter F., 1998, Pediatric Research, V43, p161A	38	345	362	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1999	340	4					260	264		10.1056/NEJM199901283400402	http://dx.doi.org/10.1056/NEJM199901283400402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YU	9920949				2022-12-28	WOS:000078318700002
J	Tomlin, PJ				Tomlin, PJ			A memorable incident - When is a spade not a spade	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1999	318	7178					256	256						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915741				2022-12-28	WOS:000078292300034
J	de Lorgeril, M; Salen, P; Paillard, F; Lacan, P; Richard, G				de Lorgeril, M; Salen, P; Paillard, F; Lacan, P; Richard, G			Lipid-lowering drugs and homocysteine	LANCET			English	Article							ACID		CHU Nord, F-42055 St Etienne, France; CHU Rennes, Dept Cardiol, Rennes, France; Hop Edouard Herriot, Federat Biochim, Lyon, France	CHU de St Etienne; CHU Rennes; CHU Lyon	de Lorgeril, M (corresponding author), CHU Nord, F-42055 St Etienne, France.							Basu TK, 1997, J NUTR, V127, P117, DOI 10.1093/jn/127.1.117; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; *EUR SOC CARD, 1998, 20 C EUR SOC CARD AU; Townend J, 1998, BLOOD REV, V12, P23, DOI 10.1016/S0268-960X(98)90027-3; Wierzbicki AS, 1998, LANCET, V351, P569, DOI 10.1016/S0140-6736(05)78556-1	5	94	95	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 16	1999	353	9148					209	210		10.1016/S0140-6736(05)77220-2	http://dx.doi.org/10.1016/S0140-6736(05)77220-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923885				2022-12-28	WOS:000078175600022
J	Morgan, S; Smith, H; Simpson, I; Liddiard, GS; Raphael, H; Pickering, RM; Mant, D				Morgan, S; Smith, H; Simpson, I; Liddiard, GS; Raphael, H; Pickering, RM; Mant, D			Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article							CONGESTIVE-HEART-FAILURE; SYSTOLIC DYSFUNCTION; UNITED-STATES; POPULATION; MORBIDITY; MORTALITY; DIAGNOSIS	Objective To assess the prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in the general practice setting by echocardiographic assessment of ventricular function. Design Cross sectional survey. Setting Four centre general practice in Poole, Dorset. Subjects 817 elderly patients aged 70-84 years. Main outcomes Echocardiographic assessment of left ventricular systolic function including measurement of ejection fraction by biplane summation method where possible, clinical symptoms, and signs of left ventricular dysfunction. Results The overall prevalence of left ventricular systolic dysfunction was 7.5% (95% confidence interval 5.8% to 9.5%); mild dysfunction (5.0%) was considerably more prevalent than moderate (1.6%) or severe dysfunction (0.7%). Measurement of ejection fraction was possible in 82% of patients (n = 667): in patients categorised as having mild, moderate, or severe dysfunction, the mean ejection fraction was 48% (SD 12.0), 38% (8.1), and 26% (7.9) respectively. At all ages the prevalence was much higher in men than in women (odds ratio 5.1, 95% confidence interval 2.6 to 10.1). No clinical symptom or sign was both sensitive and specific In around half the patients with ventricular dysfunction (52%, 32/61) heart failure had not been previously diagnosed. Conclusions Unrecognised left ventricular dysfunction is a common problem in elderly patients in the general practice setting. Appropriate treatment with angiotensin converting enzyme inhibitors has the potential to reduce hospitalisation and mortality in these patients, hut diagnosis should not be based on clinical history and examination alone. Screening is feasible in general practice, but it should not be implemented until the optimum method of identifying left ventricular dysfunction is clarified, and the cost effectiveness of screening has been shown.	Univ Southampton, Aldermoor Hlth Ctr, Southampton SO16 5ST, Hants, England; Southampton Gen Hosp, Wessex Cardiothorac Ctr, Southampton SO16 6YD, Hants, England; Univ Southampton, Southampton Gen Hosp, Southampton, Hants, England; Adam Practice, Upton Hlth Ctr, Poole H15 2HX, Dorset, England	University of Southampton; University of Southampton; University of Southampton	Morgan, S (corresponding author), Univ Southampton, Aldermoor Hlth Ctr, Southampton SO16 5ST, Hants, England.		Smith, Helen E/M-2449-2016; Mant, David CA/C-7763-2009	Smith, Helen E/0000-0003-1883-6124; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMICO AF, 1989, AM HEART J, V118, P1259, DOI 10.1016/0002-8703(89)90018-5; Badgett RG, 1997, JAMA-J AM MED ASSOC, V277, P1712, DOI 10.1001/jama.277.21.1712; BONNEUX L, 1994, AM J PUBLIC HEALTH, V84, P20, DOI 10.2105/AJPH.84.1.20; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1986, NEW ENGL J MED, V311, P1517; ERIKSSON H, 1995, J INTERN MED, V237, P135, DOI 10.1111/j.1365-2796.1995.tb01153.x; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GHALI JK, 1990, ARCH INTERN MED, V150, P769, DOI 10.1001/archinte.150.4.769; Gillespie ND, 1997, BMJ-BRIT MED J, V314, P936, DOI 10.1136/bmj.314.7085.936; Mair FS, 1996, BRIT J GEN PRACT, V46, P77; McDonagh TA, 1997, LANCET, V350, P829, DOI 10.1016/S0140-6736(97)03033-X; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; McKinnon ME, 1996, PUBLIC HEALTH, V110, P351, DOI 10.1016/S0033-3506(96)80007-2; McMurray J., 1993, European Heart Journal, V14, P133; MCMURRAY J, 1993, EUR HEART J, V14, P115; Mosterd A, 1997, AM J CARDIOL, V79, P103, DOI 10.1016/S0002-9149(96)00691-1; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PARAMESHWAR J, 1992, BRIT J GEN PRACT, V42, P287; REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; *STAT CORP, 1995, STAT STAT SOFTW REL; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	24	133	136	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					368	372		10.1136/bmj.318.7180.368	http://dx.doi.org/10.1136/bmj.318.7180.368			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933201	Green Accepted, Green Published, Green Submitted, Bronze			2022-12-28	WOS:000078572600029
J	Susin, SA; Lorenzo, HK; Zamzami, N; Marzo, I; Snow, BE; Brothers, GM; Mangion, J; Jacotot, E; Costantini, P; Loeffler, M; Larochette, N; Goodlett, DR; Aebersold, R; Siderovski, DP; Penninger, JM; Kroemer, G				Susin, SA; Lorenzo, HK; Zamzami, N; Marzo, I; Snow, BE; Brothers, GM; Mangion, J; Jacotot, E; Costantini, P; Loeffler, M; Larochette, N; Goodlett, DR; Aebersold, R; Siderovski, DP; Penninger, JM; Kroemer, G			Molecular characterization of mitochondrial apoptosis-inducing factor	NATURE			English	Article							CYTOCHROME-C; FRAGMENTATION; PROTEASE; BCL-2; DNA; REQUIREMENT; ACTIVATION; PROTEINS; RELEASE; CELLS	Mitochondria play a key part in the regulation of apoptosis (cell death)(1,2). Their intermembrane space contains several proteins that are liberated through the outer membrane in order to participate in the degradation phase of apoptosis(3-9). Here we report the identification and cloning of an apoptosis-inducing factor, AIF(5), which is sufficient to induce apoptosis of isolated nuclei. AIF is a flavoprotein of relative molecular mass 57,000 which shares homology with the bacterial oxidoreductases; it is normally confined to mitochondria but translocates to the nucleus when apoptosis is induced. Recombinant AIF causes chromatin condensation in isolated nuclei and large-scale fragmentation of DNA. It induces purified mitochondria to release the apoptogenic proteins cytochrome c and caspase-9. Microinjection of AIF into the cytoplasm of intact cells induces condensation of chromatin, dissipation of the mitochondrial transmembrane potential, and exposure of phosphatidylserine in the plasma membrane. None of these effects is prevented by the wide-ranging caspase inhibitor known as Z-VAD.fmk. Overexpression of Bcl-2, which controls the opening of mitochondrial permeability transition pores, prevents the release of AIF from the mitochondrion but does not affect its apoptogenic activity. These results indicate that AIF is a mitochondrial effector of apoptotic cell death.	CNRS, UPR 420, F-94801 Villejuif, France; Inst Pasteur, Unite Biochim Struct, F-75724 Paris 15, France; Univ Toronto, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys & Immunol, Toronto, ON M5G 2C1, Canada; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Washington; University of Washington Seattle	Kroemer, G (corresponding author), CNRS, UPR 420, 19 Rue Guy Moquet, F-94801 Villejuif, France.		Marzo, Isabel/E-6918-2016; Siderovski, David Peter/AAA-9603-2019; KROEMER, Guido/B-4263-2013; LAROCHETTE, Nathanael/R-4298-2017; Penninger, Josef M/I-6860-2013; Kroemer, Guido/AAY-9859-2020; Lorenzo, Hans-Kristian/GLR-5785-2022; Susin, Santos A/Q-6754-2017	Marzo, Isabel/0000-0002-2315-9079; Siderovski, David Peter/0000-0002-0688-8210; KROEMER, Guido/0000-0002-9334-4405; LAROCHETTE, Nathanael/0000-0002-7936-678X; Penninger, Josef M/0000-0002-8194-3777; Susin, Santos A/0000-0002-3366-1628; Lorenzo, Hans Kristian/0000-0002-7921-177X; /0000-0002-5301-1569				Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Cedano J, 1997, J MOL BIOL, V266, P594, DOI 10.1006/jmbi.1996.0804; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAGARKOVA MA, 1995, J BIOL CHEM, V270, P20239, DOI 10.1074/jbc.270.35.20239; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Robinson KM, 1996, J BIOL CHEM, V271, P4061; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Trbovich AM, 1998, CELL DEATH DIFFER, V5, P38, DOI 10.1038/sj.cdd.4400299; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wada J, 1998, P NATL ACAD SCI USA, V95, P144, DOI 10.1073/pnas.95.1.144; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZHU W, 1996, EMBO J, V15, P4139	30	3269	3454	4	301	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 4	1999	397	6718					441	446		10.1038/17135	http://dx.doi.org/10.1038/17135			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164KA	9989411				2022-12-28	WOS:000078461700050
J	Nightingale, SL				Nightingale, SL			FDA conference on human subject protection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					408	408		10.1001/jama.281.5.408	http://dx.doi.org/10.1001/jama.281.5.408			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952188				2022-12-28	WOS:000078318500008
J	Gregoire, A				Gregoire, A			ABC of sexual health - Assessing and managing male sexual problems	BRITISH MEDICAL JOURNAL			English	Review																		ACKERMAN MD, 1995, J CONSULT CLIN PSYCH, V63, P862, DOI 10.1037/0022-006X.63.6.862; BALDWIN D, 1996, DEPRESSION SEXUAL FU; BANCROFT J, 1989, HUMAN SEXUALITY ITS; BECK JG, 1995, J CONSULT CLIN PSYCH, V63, P915; Gregoire A, 1998, BMJ-BRIT MED J, V317, P759, DOI 10.1136/bmj.317.7161.759; GREGOIRE A, 1993, OIMPOTENCE INTEGRATE; HAWTON K, 1995, BRIT J PSYCHIAT, V167, P307, DOI 10.1192/bjp.167.3.307; ROSEN RC, 1995, J CONSULT CLIN PSYCH, V63, P877, DOI 10.1037/0022-006X.63.6.877	8	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1999	318	7179					315	317		10.1136/bmj.318.7179.315	http://dx.doi.org/10.1136/bmj.318.7179.315			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	163ZH	9924063	Green Published			2022-12-28	WOS:000078436700029
J	Dustin, ML; Shaw, AS				Dustin, ML; Shaw, AS			Immunology - Costimulation: Building an immunological synapse	SCIENCE			English	Editorial Material							CELL		Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Dustin, ML (corresponding author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.		Dustin, Michael/AAM-4611-2020	Shaw, Andrey/0000-0001-5685-0272; Dustin, Michael/0000-0003-4983-6389				Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; IIDA N, 1994, J BIOL CHEM, V269, P28576; LOIKE JD, 1995, J EXP MED, V181, P1763, DOI 10.1084/jem.181.5.1763; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	12	194	207	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					649	650		10.1126/science.283.5402.649	http://dx.doi.org/10.1126/science.283.5402.649			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9988658				2022-12-28	WOS:000078324400029
J	Wegh, RT; Donker, H; Oskam, KD; Meijerink, A				Wegh, RT; Donker, H; Oskam, KD; Meijerink, A			Visible quantum cutting in LiGdF4 : Eu3+ through downconversion	SCIENCE			English	Article							LUMINESCENCE; LIYF4	For mercury-free fluorescent Lamps and plasma display panels, alternative luminescent materials are required for the efficient conversion of vacuum ultraviolet radiation to visible Light. Quantum cutting involving the emission of two visible photons for each vacuum ultraviolet photon absorbed is demonstrated in Eu3+-doped LiGdF4 with the concept of downconversion. Upon excitation of Gd3+ with a high-energy photon, two visible photons can be emitted by Eu3+ through an efficient two-step energy transfer from Gd3+ to Eu3+, with a quantum efficiency that approaches 200 percent.	Univ Utrecht, Debye Inst, NL-3508 TA Utrecht, Netherlands	Utrecht University	Meijerink, A (corresponding author), Univ Utrecht, Debye Inst, POB 80 000, NL-3508 TA Utrecht, Netherlands.	a.meijerink@phys.uu.nl	Meijerink, Andries/C-4897-2009	Meijerink, Andries/0000-0003-3573-9289				AUZEL F, 1966, CR ACAD SCI B PHYS, V262, P1016; Blasse G., 1994, LUMINESCENT MAT, DOI [DOI 10.1007/978-3-642-79017-1_1, 10.1007/978-3-642-79017-1_1]; DEPP SW, 1993, SCI AM, V268, P90; GORLLERWALRAND C, 1993, J PHYS-CONDENS MAT, V5, P8359, DOI 10.1088/0953-8984/5/44/023; Henderson B., 1989, OPTICAL SPECTROSCOPY; PAPPALARDO R, 1976, J LUMIN, V14, P159, DOI 10.1016/S0022-2313(76)90592-5; Piper W. W., 1974, Journal of Luminescence, V8, P344, DOI 10.1016/0022-2313(74)90007-6; RONDA CR, 1995, J ALLOY COMPD, V225, P534, DOI 10.1016/0925-8388(94)07065-2; Sommerdijk J. L., 1974, Journal of Luminescence, V8, P341, DOI 10.1016/0022-2313(74)90006-4; Srivastava AM, 1996, J ELECTROCHEM SOC, V143, P4113, DOI 10.1149/1.1837346; VANVLIET JPM, 1989, J LUMIN, V42, P305, DOI 10.1016/0022-2313(89)90074-4; VOLLKOMMER F, 1997, PHYS BL, V53, P887; Wegh RT, 1997, PHYS REV B, V56, P13841, DOI 10.1103/PhysRevB.56.13841	13	844	887	17	349	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 29	1999	283	5402					663	666		10.1126/science.283.5402.663	http://dx.doi.org/10.1126/science.283.5402.663			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924020				2022-12-28	WOS:000078324400034
J	Zuker, CS; Ranganathan, R				Zuker, CS; Ranganathan, R			Signal transduction - The path to specificity	SCIENCE			English	Editorial Material							TYROSINE KINASE HCK; ARRESTIN/CLATHRIN INTERACTION; BETA(2)-ADRENERGIC RECEPTOR; DOMAIN; SRC; LOCALIZATION; ENDOCYTOSIS; ACTIVATION; ARRESTINS; ADAPTER		Univ Calif San Diego, Howard Hughes Med Inst, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, Dept Neurosci, La Jolla, CA 92093 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Zuker, CS (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Dept Biol, La Jolla, CA 92093 USA.							ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Tsunoda S, 1998, CURR OPIN GENET DEV, V8, P419, DOI 10.1016/S0959-437X(98)80112-3; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zhang J, 1997, RECEPTOR CHANNEL, V5, P193; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	16	21	22	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					650	651		10.1126/science.283.5402.650	http://dx.doi.org/10.1126/science.283.5402.650			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9988659				2022-12-28	WOS:000078324400030
J	Horton, R				Horton, R			The sacking of JAMA	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Horton, R (corresponding author), Lancet, London WC1B 3SL, England.							Firshein J, 1998, LANCET, V351, P196, DOI 10.1016/S0140-6736(05)78188-5; Fontanarosa PB, 1998, JAMA-J AM MED ASSOC, V280, P1618, DOI 10.1001/jama.280.18.1618; Glass RM, 1998, JAMA-J AM MED ASSOC, V279, P1309, DOI 10.1001/jama.279.16.1309; Kassirer JP, 1997, NEW ENGL J MED, V337, P700, DOI 10.1056/NEJM199709043371008; KLEIN SA, 1998, AM MED NEWS     0601; KOLATA G, 1999, NY TIMES        0116; Koop CE, 1998, JAMA-J AM MED ASSOC, V279, P550, DOI 10.1001/jama.279.7.550; Lundberg GD, 1998, JAMA-J AM MED ASSOC, V280, P1273, DOI 10.1001/jama.280.14.1273; Mark DH, 1998, JAMA-J AM MED ASSOC, V280, P1705, DOI 10.1001/jama.280.19.1705; Rennie D, 1998, JAMA-J AM MED ASSOC, V280, P213, DOI 10.1001/jama.280.3.213; RICH F, 1997, NY TIMES        1227, pA19; Sanders SA, 1999, JAMA-J AM MED ASSOC, V281, P275, DOI 10.1001/jama.281.3.275; SHELL ER, 1998, NY TIMES MAGAZI 0628, P34	13	35	35	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 23	1999	353	9149					252	253		10.1016/S0140-6736(99)00019-7	http://dx.doi.org/10.1016/S0140-6736(99)00019-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929012				2022-12-28	WOS:000078292200002
J	Raju, TNK				Raju, TNK			The Nobel chronicles	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 23	1999	353	9149					332	332		10.1016/S0140-6736(05)74886-8	http://dx.doi.org/10.1016/S0140-6736(05)74886-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929065				2022-12-28	WOS:000078292200068
J	DeVries, SH; Schwartz, EA				DeVries, SH; Schwartz, EA			Kainate receptors mediate synaptic transmission between cones and "off" bipolar cells in a mammalian retina	NATURE			English	Article							GANGLION-CELLS; RESPONSES; NEURONS; AMPA; PHOTORECEPTORS; TERMINALS; SQUIRREL; TURTLE; LIGHT	Light produces a graded hyperpolarization in retinal photoreceptors(1,2) that decreases their release of synaptic neurotransmitter(3,4). Cone photoreceptors use glutamate(5,6) as a neurotransmitter with which to communicate with two types of bipolar cell. Activation of metabotropic glutamate receptors in 'On' bipolar cells(7,8) initiates a second-messenger cascade that can amplify small synaptic inputs from cones. In contrast, it is not known how the ionotropic glutamate receptors that are activated in 'Off' bipolar cells(9,10) are optimized for transmitting small, graded signals. Here we show, by recording from a cone and a synaptically connected 'Off' bipolar cell in slices of retina from the ground squirrel, that transmission is mediated by glutamate receptors of the kainate-preferring subtype. In the dark, a cone releases sufficient neurotransmitter to desensitize most postsynaptic kainate receptors. The small postsynaptic current that persists (<5% of maximum) is quickly modulated by changes in presynaptic voltage. Since recovery from desensitization is slow (the decay time constant is roughly 500 milliseconds), little recovery can occur during the brief (roughly 100-millisecond) hyperpolarization that is produced in cones by a flash of light. By limiting the postsynaptic current, receptor desensitization prevents saturation of the 'Off' bipolar cell's voltage response and allows the synapse to operate over the cone's entire physiological voltage range.	Univ Texas, Hlth Sci Ctr, Dept Ophthalmol & Visual Sci, Houston, TX 77030 USA; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA	University of Texas System; University of Texas Health Science Center Houston; University of Chicago	DeVries, SH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Ophthalmol & Visual Sci, Houston, TX 77030 USA.							ATTWELL D, 1987, J PHYSIOL-LONDON, V387, P125, DOI 10.1113/jphysiol.1987.sp016567; BAYLOR DA, 1970, J PHYSIOL-LONDON, V207, P77, DOI 10.1113/jphysiol.1970.sp009049; COPENHAGEN DR, 1989, NATURE, V341, P536, DOI 10.1038/341536a0; DOWLING JE, 1973, NATURE, V242, P101, DOI 10.1038/242101a0; Falk G., 1988, Progress in Retinal Research, V8, P255, DOI 10.1016/0278-4327(88)90028-4; FAMIGLIETTI EV, 1976, SCIENCE, V194, P193, DOI 10.1126/science.959847; KATZ B, 1972, J PHYSIOL-LONDON, V224, P665, DOI 10.1113/jphysiol.1972.sp009918; KRAFT TW, 1988, J PHYSIOL-LONDON, V404, P199, DOI 10.1113/jphysiol.1988.sp017286; LEEPER HF, 1985, J NEUROPHYSIOL, V54, P1157, DOI 10.1152/jn.1985.54.5.1157; LINDBERG KA, 1996, J COMP NEUROL, V365, P173; LUKASIEWICZ P, 1988, J NEUROSCI, V8, P4470; MASU M, 1995, CELL, V80, P757, DOI 10.1016/0092-8674(95)90354-2; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; Mennerick S, 1996, NEURON, V17, P1241, DOI 10.1016/S0896-6273(00)80254-8; MILLER AM, 1983, J PHYSIOL-LONDON, V334, P325, DOI 10.1113/jphysiol.1983.sp014497; NAWY S, 1991, NEURON, V7, P677, DOI 10.1016/0896-6273(91)90380-I; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; PATNEAU DK, 1994, NEURON, V12, P357, DOI 10.1016/0896-6273(94)90277-1; PENN RD, 1969, NATURE, V223, P201, DOI 10.1038/223201a0; SAITO T, 1983, J GEN PHYSIOL, V81, P589, DOI 10.1085/jgp.81.4.589; TRIFONOV Y A, 1968, Biofizika, V13, P809; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; WEST RW, 1976, J COMP NEUROL, V168, P355, DOI 10.1002/cne.901680304	26	177	183	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1999	397	6715					157	160		10.1038/16462	http://dx.doi.org/10.1038/16462			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923677				2022-12-28	WOS:000078085000045
J	Blondal, T; Gudmundsson, LJ; Olafsdottir, I; Gustavsson, G; Westin, A				Blondal, T; Gudmundsson, LJ; Olafsdottir, I; Gustavsson, G; Westin, A			Nicotine nasal spray with nicotine patch for smoking cessation: Randomised trial with six year follow up	BRITISH MEDICAL JOURNAL			English	Article							DEPENDENCE; GUM	Objective To evaluate the efficacy of using a nicotine patch for 5 months with a nicotine nasal spray for 1 year. Design Placebo controlled, double blind trial. Setting Reykjavik health centre. Subjects 237 smokers aged 22-66 years living in or around Reykjavik. Interventions Nicotine patch for 5 months with nicotine nasal spray for 1 year (n = 118) or nicotine patch with placebo spray (n = 119). Treatment with patches included 15 mg of nicotine for 3 months, 10 mg for the fourth month, and 5 mg for the fifth month, whereas nicotine in the nasal spray was available for up to I year. Both groups received supportive treatment. Main outcome measure Sustained abstinence from smoking. Results The log rank test for 6 years (chi(2) = 8.5, P = 0.004) shows a significant association between abstinence from smoking and type of treatment. Sustained abstinence rates for the patch and nasal spray group and patch only group were 51% v 35% after 6 weeks (P = 0.011 (chi(2)), 95% confidence interval 1.17% to 3.32%), 37% v 25% after 3 months (P = 0.045, 1.01% to 3.08%), 31% v 16% after 6 months (P = 0.005, 1.27% to 4.50%), 27% v 11% after 12 months (P = 0.001, 1.50% to 6.14%), and 16% v 9% after 6 years (P = 0.077, 0.93% to 4.72%). Conclusions Short and long term abstinence rates show that the combination of using a nicotine patch for 5 months with a nicotine nasal spray for 1 year is a more effective method of stopping smoking than using a patch only. The low percentage of participants using the nasal spray at 1 year, and the few relapses during the second year, suggest that it is not cost effective to use a nasal spray for longer than 7 months after stopping a patch.	Reykjavik Hlth Care Ctr, IS-101 Reykjavik, Iceland; Natl Univ Hosp, Reykjavik, Iceland; Pharmacia & Upjohn Inc, S-25109 Helsingborg, Sweden	Landspitali National University Hospital; Pfizer; Pharmacia Corporation	Blondal, T (corresponding author), Reykjavik Hlth Care Ctr, Baronstigur 47, IS-101 Reykjavik, Iceland.		Stapleton, John A/I-6550-2012					Benowitz NL, 1997, NEW ENGL J MED, V337, P1230, DOI 10.1056/NEJM199710233371710; DALE LC, 1995, JAMA-J AM MED ASSOC, V274, P1353, DOI 10.1001/jama.274.17.1353; DAUGHTON DM, 1997, AM J RESP CRIT CARE, V155, pA549; FAGERSTROM KO, 1993, PSYCHOPHARMACOLOGY, V111, P271, DOI 10.1007/BF02244941; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; Green S. B., 1997, USING SPSS WINDOWS; HUGHES JR, 1995, JAMA-J AM MED ASSOC, V274, P1390, DOI 10.1001/jama.274.17.1390; JORENBY DE, 1995, JAMA-J AM MED ASSOC, V274, P1347, DOI 10.1001/jama.274.17.1347; KORNITZER M, 1995, PREV MED, V24, P41, DOI 10.1006/pmed.1995.1006; Mikkelsen K, 1994, J SMOK REL DIS, V5, P95; Paoletti P, 1996, EUR RESPIR J, V9, P643, DOI 10.1183/09031936.96.09040643; Puska P., 1995, TOB CONTROL, V4, P231, DOI [DOI 10.1136/TC.4.3.231, 10.1136/tc.4.3.231]; Sachs DPL, 1996, EUR RESPIR J, V9, P629, DOI 10.1183/09031936.96.09040629; SILAGY C, 1998, COCHRANE LIB; Stapleton JA, 1998, BRIT MED J, V316, P830, DOI 10.1136/bmj.316.7134.830; TONNESEN P, 1999, IN PRESS EUR RESP J; TONNESEN P, 1994, INTERVENTIONS SMOKER; 1991, JAMA, V226, P3133	18	148	157	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1999	318	7179					285	288		10.1136/bmj.318.7179.285	http://dx.doi.org/10.1136/bmj.318.7179.285			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZH	9924052	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000078436700018
J	Raju, TNK				Raju, TNK			The Nobel chronicles	LANCET			English	Editorial Material									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	11	11	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 30	1999	353	9150					416	416		10.1016/S0140-6736(05)75001-7	http://dx.doi.org/10.1016/S0140-6736(05)75001-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950485				2022-12-28	WOS:000078437000073
J	Sarda, P; Moreira, M; Staudacher, T				Sarda, P; Moreira, M; Staudacher, T			Argon-lead isotopic correlation in Mid-Atlantic Ridge basalts	SCIENCE			English	Article							SOUTH-ATLANTIC; MANTLE EVOLUTION; NOBLE-GASES; PB ISOTOPE; GLASSES; GEOCHEMISTRY; CONSTRAINTS; HELIUM; SR; HETEROGENEITY	Step-heating analyses for Mid-Atlantic Ridge glass samples show that maximum Ar-40/Ar-36 values correlate with Pb-206.207.208/Pb-204. These correlations hold for the whole Atlantic Ocean and therefore are unlikely to result from shallow-level contamination processes. Instead, they are taken as mixing hyperbolae between the degassed-depleted upper mantle and a recycled component characterized by high Pb-206/Pb-204 ratios (19 to 21) and Low Ar-40/Ar-36 ratios (300 to 1000). These relations imply that argon may also be a tracer of mantle recycling.	Inst Phys Globe, Lab Geochim & Cosmochim, F-75252 Paris 05, France	UDICE-French Research Universities; Universite Paris Cite	Sarda, P (corresponding author), Univ Paris 11, Dept Sci Terre, Grp Geochim Gaz Rares, F-91405 Orsay, France.		moreira, manuel/H-5329-2017	moreira, manuel/0000-0001-5845-4660				Allegre C.J., 1986, EARTH PLANET SC LETT, V81, P127; ALLEGRE CJ, 1983, NATURE, V303, P762, DOI 10.1038/303762a0; ALLEGRE CJ, 1986, NATURE, V323, P123, DOI 10.1038/323123a0; ALLEGRE CJ, 1986, EARTH PLANET SC LETT, V81, P319; CHAUVEL C, 1992, EARTH PLANET SC LETT, V110, P99, DOI 10.1016/0012-821X(92)90042-T; DOSSO L, 1993, EARTH PLANET SC LETT, V120, P443, DOI 10.1016/0012-821X(93)90256-9; DOSSO L, UNPUB; DOUGLASS J, IN PRESS J GEOPHYS R; DYMOND J, 1978, EARTH PLANET SC LETT, V38, P117, DOI 10.1016/0012-821X(78)90129-2; FANALE FP, 1971, CHEM GEOL, V8, P79, DOI 10.1016/0009-2541(71)90051-9; FARLEY KA, 1993, EARTH PLANET SC LETT, V114, P325, DOI 10.1016/0012-821X(93)90034-7; FISHER DE, 1975, NATURE, V256, P113, DOI 10.1038/256113b0; Fontignie D, 1996, EARTH PLANET SC LETT, V142, P209, DOI 10.1016/0012-821X(96)00079-9; GRAHAM DW, 1992, EARTH PLANET SC LETT, V110, P133, DOI 10.1016/0012-821X(92)90044-V; HAMELIN B, 1984, EARTH PLANET SC LETT, V67, P340, DOI 10.1016/0012-821X(84)90173-0; HANAN BB, 1986, NATURE, V322, P137, DOI 10.1038/322137a0; HIYAGON H, 1992, GEOCHIM COSMOCHIM AC, V56, P1301, DOI 10.1016/0016-7037(92)90063-O; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; JOCHUM KP, 1983, NATURE, V306, P431, DOI 10.1038/306431a0; Kunz J, 1998, SCIENCE, V280, P877, DOI 10.1126/science.280.5365.877; KURZ MD, 1982, EARTH PLANET SC LETT, V58, P1, DOI 10.1016/0012-821X(82)90099-1; MACHADO N, 1982, NATURE, V295, P226, DOI 10.1038/295226a0; Moreira M, 1998, SCIENCE, V279, P1178, DOI 10.1126/science.279.5354.1178; MOREIRA M, 1995, EARTH PLANET SC LETT, V133, P367, DOI 10.1016/0012-821X(95)00080-V; OZIMA M, 1975, GEOCHIM COSMOCHIM AC, V39, P1127, DOI 10.1016/0016-7037(75)90054-X; SARDA P, 1985, EARTH PLANET SC LETT, V72, P357, DOI 10.1016/0012-821X(85)90058-5; Schiano P, 1997, EARTH PLANET SC LETT, V150, P363, DOI 10.1016/S0012-821X(97)00098-8; SCHILLING JG, 1994, J GEOPHYS RES-SOL EA, V99, P12005, DOI 10.1029/94JB00337; STAUDACHER T, 1988, EARTH PLANET SC LETT, V89, P173, DOI 10.1016/0012-821X(88)90170-7; STAUDACHER T, 1982, EARTH PLANET SC LETT, V60, P389, DOI 10.1016/0012-821X(82)90075-9; STAUDACHER T, 1989, EARTH PLANET SC LETT, V96, P119, DOI 10.1016/0012-821X(89)90127-1; Sun S.-S., 1989, GEOLOGICAL SOC LONDO, V42, P323, DOI [10.1144/GSL.SP.1989.042.01.19, DOI 10.1144/GSL.SP.1989.042.01.19]; WHITE WM, 1982, NATURE, V296, P821, DOI 10.1038/296821a0	33	64	66	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					666	668		10.1126/science.283.5402.666	http://dx.doi.org/10.1126/science.283.5402.666			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924021				2022-12-28	WOS:000078324400035
J	Tilghman, SM				Tilghman, SM			The sins of the fathers and mothers: Genomic imprinting in mammalian development	CELL			English	Review							MATERNAL-SPECIFIC METHYLATION; IGF2R LOCUS; CPG ISLAND; BRAIN-DEVELOPMENT; DNA METHYLATION; MOUSE EMBRYO; SNRPN GENE; H19 GENE; GROWTH; MICE		Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University; Princeton University	Tilghman, SM (corresponding author), Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA.							ALLEN ND, 1995, P NATL ACAD SCI USA, V92, P10782, DOI 10.1073/pnas.92.23.10782; Barlow DP, 1997, EMBO J, V16, P6899, DOI 10.1093/emboj/16.23.6899; Bartolomei M.S., 1992, SEMIN DEV BIOL, V3, P107; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Buiting K, 1998, AM J HUM GENET, V63, P170, DOI 10.1086/301935; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; Caspary T, 1998, MOL CELL BIOL, V18, P3466, DOI 10.1128/MCB.18.6.3466; CATTANACH BM, 1986, J EMBRYOL EXP MORPH, V97, P137; Cooper D.W., 1993, Seminars in Developmental Biology, V4, P117, DOI 10.1006/sedb.1993.1014; Dean W, 1998, DEVELOPMENT, V125, P2273; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; Dittrich B, 1996, NAT GENET, V14, P163, DOI 10.1038/ng1096-163; FILSON AJ, 1993, DEVELOPMENT, V118, P731; FOLTZ DW, 1981, AM NAT, V117, P665, DOI 10.1086/283751; Hark AT, 1998, HUM MOL GENET, V7, P1979, DOI 10.1093/hmg/7.12.1979; Hurst L. D., 1997, GENOMIC IMPRINTING, P211; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; Jinno Y, 1996, HUM MOL GENET, V5, P1155, DOI 10.1093/hmg/5.8.1155; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KAFRI T, 1993, P NATL ACAD SCI USA, V90, P10558, DOI 10.1073/pnas.90.22.10558; Keverne EB, 1996, DEV BRAIN RES, V92, P91, DOI 10.1016/0165-3806(95)00209-X; Kono T, 1996, NAT GENET, V13, P91, DOI 10.1038/ng0596-91; LABOSKY PA, 1994, DEVELOPMENT, V120, P3197; Lalande M, 1996, ANNU REV GENET, V30, P173, DOI 10.1146/annurev.genet.30.1.173; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; Lerchner W, 1997, MECH DEVELOP, V61, P141, DOI 10.1016/S0925-4773(96)00630-2; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MANN JR, 1990, CELL, V62, P251, DOI 10.1016/0092-8674(90)90363-J; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; Mertineit C, 1998, DEVELOPMENT, V125, P889; Mochizuki A, 1996, GENETICS, V144, P1283; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; Nicholls RD, 1998, TRENDS GENET, V14, P194, DOI 10.1016/S0168-9525(98)01432-2; Rougeulle C, 1998, NAT GENET, V19, P15, DOI 10.1038/ng0598-15; Rougeulle C, 1997, NAT GENET, V17, P14, DOI 10.1038/ng0997-14; Rougier N, 1998, GENE DEV, V12, P2108, DOI 10.1101/gad.12.14.2108; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267; Skuse DH, 1997, NATURE, V387, P705, DOI 10.1038/42706; SMRZKA OW, 1995, HUM MOL GENET, V4, P1945, DOI 10.1093/hmg/4.10.1945; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; Tada M, 1997, EMBO J, V16, P6510, DOI 10.1093/emboj/16.21.6510; Tada T, 1998, DEV GENES EVOL, V207, P551, DOI 10.1007/s004270050146; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; THORVALDSON JL, 1998, IN PRESS GENES DEV; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; VRANA PB, 1998, IN PRESS NAT GENET; Vu TH, 1997, NAT GENET, V17, P12, DOI 10.1038/ng0997-12; Walter J., 1996, Epigenetic mechanisms of gene regulation., P195; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; Webber AL, 1998, NATURE, V391, P711, DOI 10.1038/35655; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25	65	379	399	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 22	1999	96	2					185	193		10.1016/S0092-8674(00)80559-0	http://dx.doi.org/10.1016/S0092-8674(00)80559-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	160VM	9988214	Bronze			2022-12-28	WOS:000078252200003
J	Dean, D				Dean, D			A dilemma - A half mixed compound?	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1999	318	7181					435	435		10.1136/bmj.318.7181.435	http://dx.doi.org/10.1136/bmj.318.7181.435			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BF	9974460	Green Published			2022-12-28	WOS:000078670100028
J	Josefson, D				Josefson, D			Mild cervical dysplasia often reverts to normal	BRITISH MEDICAL JOURNAL			English	News Item																		Holowaty P, 1999, JNCI-J NATL CANCER I, V91, P252, DOI 10.1093/jnci/91.3.252	1	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1999	318	7181					420	420		10.1136/bmj.318.7181.420	http://dx.doi.org/10.1136/bmj.318.7181.420			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BF	9974451	Green Published			2022-12-28	WOS:000078670100019
J	Levin, BR; Lipsitch, M; Bonhoeffer, S				Levin, BR; Lipsitch, M; Bonhoeffer, S			Evolution and disease - Population biology, evolution, and infectious disease: Convergence and synthesis	SCIENCE			English	Review							ANTIBIOTIC-RESISTANCE; ESCHERICHIA-COLI; ANTIGENIC DIVERSITY; QUANTITATIVE INVESTIGATIONS; TRANSMISSION DYNAMICS; PLASMODIUM-FALCIPARUM; DRUG-THERAPY; VIRULENCE; RECOMBINATION; VACCINATION	Traditionally, the interest of population and evolutionary biologists in infectious ii diseases has been almost exclusively in their role as agents of natural selection in higher organisms. Recently, this interest has expanded to include the genetic structure and evolution of microparasite populations, the mechanisms of pathogenesis and the immune response, and the population biology, ecology, and evolutionary consequences es of medical and public health interventions. This article describes recent work in these areas, emphasizing the ways in which quantitative, population-biological approaches have been contributing to the understanding of infectious disease and the design and evaluation of interventions for their treatment and prevention.	Emory Univ, Dept Biol, Atlanta, GA 30322 USA; Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Swiss Fed Inst Technol, Inst Expt Ecol, CH-8092 Zurich, Switzerland	Emory University; Friedrich Miescher Institute for Biomedical Research; Swiss Federal Institutes of Technology Domain; ETH Zurich	Levin, BR (corresponding author), Emory Univ, Dept Biol, 1510 Clifton Rd, Atlanta, GA 30322 USA.		Bonhoeffer, Sebastian/A-2735-2008	Bonhoeffer, Sebastian/0000-0001-8052-3925				AGUR Z, 1989, P NATL ACAD SCI USA, V86, P9626, DOI 10.1073/pnas.86.23.9626; ANDERSON R M, 1991; ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259, DOI 10.1017/S002217240002893X; ANDERSON RM, 1986, J HYG-CAMBRIDGE, V96, P305, DOI 10.1017/S0022172400066079; ANTIA R, 1994, AM NAT, V144, P457, DOI 10.1086/285686; Antia R, 1996, P NATL ACAD SCI USA, V93, P985, DOI 10.1073/pnas.93.3.985; Austin DJ, 1998, J THEOR BIOL, V194, P313, DOI 10.1006/jtbi.1997.0438; Austin DJ, 1997, P ROY SOC B-BIOL SCI, V264, P1629, DOI 10.1098/rspb.1997.0227; Barbujani G., 1999, EVOLUTION HLTH DIS; BELL GI, 1970, NATURE, V228, P739, DOI 10.1038/228739a0; Bjorkman J, 1998, P NATL ACAD SCI USA, V95, P3949, DOI 10.1073/pnas.95.7.3949; Blower SM, 1998, NAT MED, V4, P673, DOI 10.1038/nm0698-673; Bolker BM, 1996, P NATL ACAD SCI USA, V93, P12648, DOI 10.1073/pnas.93.22.12648; Bonhoeffer S, 1997, P NATL ACAD SCI USA, V94, P6971, DOI 10.1073/pnas.94.13.6971; Bonhoeffer S, 1997, P ROY SOC B-BIOL SCI, V264, P631; Bonhoeffer S, 1997, J VIROL, V71, P3275, DOI 10.1128/JVI.71.4.3275-3278.1997; Bonhoeffer S, 1997, P NATL ACAD SCI USA, V94, P12106, DOI 10.1073/pnas.94.22.12106; BOWLER LD, 1994, J BACTERIOL, V176, P333, DOI 10.1128/JB.176.2.333-337.1994; BULL JJ, 1994, EVOLUTION, V48, P1423, DOI 10.1111/j.1558-5646.1994.tb02185.x; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; Burnet FM, 1972, NATURAL HIST INFECT; CANETTI G, 1965, AM REV RESPIR DIS, V92, P687; Casper C, 1996, AM J PUBLIC HEALTH, V86, P551, DOI 10.2105/AJPH.86.4.551; *CIB FDN, 1997, CIB FDN S, V207; DUBOSE RF, 1988, P NATL ACAD SCI USA, V85, P7036, DOI 10.1073/pnas.85.18.7036; DYKHUIZEN DE, 1991, J BACTERIOL, V173, P7257, DOI 10.1128/jb.173.22.7257-7268.1991; Ehrlich P, 1913, LANCET, V2, P445; EWALD PW, 1996, EVOLUTION INFECT DIS, V71, P37; GOODING LR, 1992, CELL, V71, P5; Gupta S, 1997, P ROY SOC B-BIOL SCI, V264, P1435, DOI 10.1098/rspb.1997.0200; GUPTA S, 1994, SCIENCE, V263, P961, DOI 10.1126/science.8310293; Horn DL, 1998, CLIN INFECT DIS, V26, P1341, DOI 10.1086/516375; Kristinsson KG, 1997, MICROB DRUG RESIST, V3, P117, DOI 10.1089/mdr.1997.3.117; Lawrence JG, 1998, P NATL ACAD SCI USA, V95, P9413, DOI 10.1073/pnas.95.16.9413; Lederberg J., 1992, I MED US COMMITTEE; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; Levin BR, 1996, EMERG INFECT DIS, V2, P93, DOI 10.3201/eid0202.960203; Levin BR, 1997, CLIN INFECT DIS, V24, pS9, DOI 10.1093/clinids/24.Supplement_1.S9; Levin BR, 1999, EVOLUTION IN HEALTH AND DISEASE, P125; LEVIN BR, 1990, PARASITOLOGY, V100, pS103, DOI 10.1017/S0031182000073054; Levin Bruce R., 1994, Trends in Microbiology, V2, P76, DOI 10.1016/0966-842X(94)90538-X; Lipsitch M, 1997, P NATL ACAD SCI USA, V94, P6571, DOI 10.1073/pnas.94.12.6571; Lipsitch M, 1997, ANTIMICROB AGENTS CH, V41, P363, DOI 10.1128/AAC.41.2.363; Lipsitch M, 1998, INT J TUBERC LUNG D, V2, P187; Lipsitch M, 1997, TRENDS MICROBIOL, V5, P31, DOI 10.1016/S0966-842X(97)81772-6; LIPSITCH M, 1992, SCIENCE, V257, P112; Longini IM, 1998, STAT MED, V17, P1121, DOI 10.1002/(SICI)1097-0258(19980530)17:10&lt;1121::AID-SIM824&gt;3.0.CO;2-E; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; MASSAD E, 1993, INT J BIOMED COMPUT, V33, P65, DOI 10.1016/0020-7101(93)90060-J; MAYNARDSMITH J, 1993, P NATIONAL ACADEMY S, V90, P4384; McLean AR, 1997, P NATL ACAD SCI USA, V94, P5792, DOI 10.1073/pnas.94.11.5792; MCLEAN AR, 1992, J THEOR BIOL, V155, P69, DOI 10.1016/S0022-5193(05)80549-1; MCLEAN AR, 1992, AIDS, V6, P71, DOI 10.1097/00002030-199201000-00009; MCLEAN AR, 1991, INT J EPIDEMIOL, V20, P1107, DOI 10.1093/ije/20.4.1107; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; MOELLERING RC, 1998, AM J MED, V104, P35; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; Morse Stephen S., 1993, EMERGING VIRUSES; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; Nowak MA, 1996, P NATL ACAD SCI USA, V93, P4398, DOI 10.1073/pnas.93.9.4398; ORSKOV F, 1976, MED MICROBIOL IMMUN, V162, P73, DOI 10.1007/BF02121318; ORSKOV F, 1983, J INFECT DIS, V148, P346, DOI 10.1093/infdis/148.2.346; PALZKILL T, 1992, PROTEINS, V14, P29, DOI 10.1002/prot.340140106; PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897; PERELSON AS, 1993, MATH BIOSCI, V114, P81, DOI 10.1016/0025-5564(93)90043-A; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Rahal JJ, 1998, JAMA-J AM MED ASSOC, V280, P1233, DOI 10.1001/jama.280.14.1233; Revollo S, 1998, EXP PARASITOL, V89, P30, DOI 10.1006/expr.1998.4216; Rich SM, 1997, P NATL ACAD SCI USA, V94, P13040, DOI 10.1073/pnas.94.24.13040; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; Schrag SJ, 1996, NATURE, V381, P120, DOI 10.1038/381120b0; Schrag SJ, 1997, P ROY SOC B-BIOL SCI, V264, P1287, DOI 10.1098/rspb.1997.0178; SCHRAG SJ, 1995, TRENDS ECOL EVOL, V10, P319, DOI 10.1016/S0169-5347(00)89118-1; SELANDER RK, 1980, SCIENCE, V210, P545, DOI 10.1126/science.6999623; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; Stewart FM, 1998, THEOR POPUL BIOL, V53, P152, DOI 10.1006/tpbi.1997.1352; Stilianakis NI, 1998, J INFECT DIS, V177, P863, DOI 10.1086/515246; Tibayrenc M, 1998, INT J PARASITOL, V28, P85, DOI 10.1016/S0020-7519(97)00180-X; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	80	166	178	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1999	283	5403					806	809		10.1126/science.283.5403.806	http://dx.doi.org/10.1126/science.283.5403.806			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933155				2022-12-28	WOS:000078496800032
J	Nightingale, SL				Nightingale, SL			Journal editors act to enhance reporting of public health hazards	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					408	408		10.1001/jama.281.5.408	http://dx.doi.org/10.1001/jama.281.5.408			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952188				2022-12-28	WOS:000078318500009
J	Stanton, JA				Stanton, JA			Aesculapius: A modern tale	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Univ Florida, Coll Med, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Stanton, JA (corresponding author), Univ Florida, Coll Med, Gainesville, FL 32611 USA.							ANGELETTI LR, 1992, LANCET, V340, P223, DOI 10.1016/0140-6736(92)90480-Q; Bailey JE, 1996, ANN INTERN MED, V124, P257, DOI 10.7326/0003-4819-124-2-199601150-00011; EDELSTEIN EJ, 1975, AESCULAPIUS COLLECTI; HALPERT E, 1994, PSYCHOANAL QUART, V63, P733, DOI 10.1080/21674086.1994.11927435; SCHOUTEN J, 1967, ROD SERPENT AESCULAP	5	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					476	477		10.1001/jama.281.5.476	http://dx.doi.org/10.1001/jama.281.5.476			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	161YT	9952212	hybrid			2022-12-28	WOS:000078318500042
J	Vaux, DL; Korsmeyer, SJ				Vaux, DL; Korsmeyer, SJ			Cell death in development	CELL			English	Review							CAENORHABDITIS-ELEGANS; INTERLEUKIN-1 RECEPTOR; BACULOVIRUS INHIBITOR; DROSOPHILA EMBRYO; GENETIC-CONTROL; DEFICIENT MICE; C-ELEGANS; APOPTOSIS; PROTEASE; SURVIVAL		Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Harvard Med Sch, Dana Farber Canc Inst, Dept Pathol & Med, Boston, MA 02115 USA	Walter & Eliza Hall Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Vaux, DL (corresponding author), Walter & Eliza Hall Inst Med Res, Post Off Royal Melbourne Hosp, Melbourne, Vic 3050, Australia.		Vaux, David L/C-7249-2013	Vaux, David L/0000-0003-2703-1651				Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; [Anonymous], 1971, INSECT SOC; Bell PR, 1996, INT J PLANT SCI, V157, P1, DOI 10.1086/297314; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brison DR, 1997, BIOL REPROD, V56, P1088, DOI 10.1095/biolreprod56.5.1088; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Christensen CA, 1998, DEV BIOL, V202, P136, DOI 10.1006/dbio.1998.8980; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; del Pozo O, 1998, CURR BIOL, V8, P1129, DOI 10.1016/S0960-9822(98)70469-5; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, GENETICS, V129, P79; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Errington J, 1996, TRENDS GENET, V12, P31, DOI 10.1016/0168-9525(96)81386-2; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Georgiou T, 1998, P NATL ACAD SCI USA, V95, P2891, DOI 10.1073/pnas.95.6.2891; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; Greenberg JT, 1996, P NATL ACAD SCI USA, V93, P12094, DOI 10.1073/pnas.93.22.12094; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hall DH, 1997, J NEUROSCI, V17, P1033; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HECHT PM, 1993, GENETICS, V135, P405; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HORVITZ HR, 1982, NEUROSCI COMMENT, V1, P56; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JENSEN RB, 1995, MOL MICROBIOL, V17, P205, DOI 10.1111/j.1365-2958.1995.mmi_17020205.x; Jiang CG, 1997, DEVELOPMENT, V124, P4673; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIRK DL, 1994, CIBA F SYMP, V182, P2; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KRONHEIM SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P698, DOI 10.1016/0003-9861(92)90629-B; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lockshin R A, 1965, J Insect Physiol, V11, P803, DOI 10.1016/0022-1910(65)90159-9; Manji GA, 1997, J VIROL, V71, P4509, DOI 10.1128/JVI.71.6.4509-4516.1997; McCall K, 1998, SCIENCE, V279, P230, DOI 10.1126/science.279.5348.230; Miller DT, 1998, DEVELOPMENT, V125, P2327; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; Olie RA, 1998, CURR BIOL, V8, P955, DOI 10.1016/S0960-9822(98)70395-1; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; PRESCOTT DM, 1994, MICROBIOL REV, V58, P233, DOI 10.1128/MMBR.58.2.233-267.1994; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Ross AJ, 1998, NAT GENET, V18, P251, DOI 10.1038/ng0398-251; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; RUSSELL JH, 1980, J IMMUNOL, V125, P1256; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1995, CLIN EXP PHARMACOL P, V22, P861, DOI 10.1111/j.1440-1681.1995.tb01951.x; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Vogt CI, 1842, UNTERSUCHUNGEN ENTWI; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Well M, 1998, J CELL SCI, V111, P2707; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhou JM, 1998, J PLANT RES, V111, P353, DOI 10.1007/BF02512196	98	1291	1340	1	76	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 22	1999	96	2					245	254		10.1016/S0092-8674(00)80564-4	http://dx.doi.org/10.1016/S0092-8674(00)80564-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	160VM	9988219	Bronze			2022-12-28	WOS:000078252200008
J	Chapman, CR				Chapman, CR			Planetary science - Probing Europa's third dimension	SCIENCE			English	Editorial Material									SW Res Inst, Space Studies Dept, Boulder, CO 80302 USA		Chapman, CR (corresponding author), SW Res Inst, Space Studies Dept, Boulder, CO 80302 USA.							*AM ASTR SOC, 1998, M GEOL SOC AM TOR CA; Anderson JD, 1998, SCIENCE, V281, P2019, DOI 10.1126/science.281.5385.2019; CASSEN P, 1979, GEOPHYS RES LETT, V6, P731, DOI 10.1029/GL006i009p00731; Khurana KK, 1998, NATURE, V395, P777, DOI 10.1038/27394; KUIPER GP, 1966, JET PROPULS LAB TECH, V32, P35; Moore JM, 1998, ICARUS, V135, P127, DOI 10.1006/icar.1998.5973; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; SHOEMAKER EM, 1996, EUR OC C SAN JUAN CA; 1998, ICARUS, V135	9	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					338	339		10.1126/science.283.5400.338	http://dx.doi.org/10.1126/science.283.5400.338			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9925494				2022-12-28	WOS:000078067000030
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Cloning 3.0?	SCIENCE			English	Editorial Material									Medsite Commun, Boston, MA USA		Sikorski, R (corresponding author), Medsite Commun, Boston, MA USA.							Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					349	349						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9925496				2022-12-28	WOS:000078067000037
J	England, PM; Zhang, YN; Dougherty, DA; Lester, HA				England, PM; Zhang, YN; Dougherty, DA; Lester, HA			Backbone mutations in transmembrane domains of a ligand-gated ion channel: Implications for the mechanism of gating	CELL			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; FROG NEUROMUSCULAR-JUNCTION; SITE-SPECIFIC INCORPORATION; UNNATURAL AMINO-ACIDS; END-PLATE CURRENTS; ALPHA-SUBUNIT; LINING RESIDUES; BINDING-SITE; M2 DOMAIN; PROTEINS	An approach to identify backbone conformational changes underlying nicotinic acetylcholine receptor (nAChR) gating was developed. Specific backbone peptide bonds were replaced with an ester, which disrupts backbone hydrogen bonds at the site of mutation. At a conserved proline residue (alpha Pro221) in the first transmembrane (M1) domain, the amide-to-ester mutation provides receptors with near-normal sensitivity, although the natural amino acids tested other than Pro produce receptors that gate with a much larger EC50 than normal. Therefore, a backbone hydrogen bond at this site may interfere with normal gating. In the alpha M2 domain, the amide-to-ester mutation yielded functional receptors at 15 positions, 3 of which provided receptors with >10-fold lower EC50 than wild type. These results support a model for gating that includes significant changes of backbone conformation within the M2 domain.	CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Lester, HA (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	lester@caltech.edu			NINDS NIH HHS [NS11756, NS34407] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011756, R01NS034407, R37NS034407] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS PR, 1981, J MEMBRANE BIOL, V58, P161, DOI 10.1007/BF01870902; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; ANDERSON CR, 1973, J PHYSIOL-LONDON, V235, P655, DOI 10.1113/jphysiol.1973.sp010410; Auerbach A, 1996, J PHYSIOL-LONDON, V494, P155, DOI 10.1113/jphysiol.1996.sp021482; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Chapman E, 1997, J AM CHEM SOC, V119, P7151, DOI 10.1021/ja970826+; CHARNET P, 1990, NEURON, V2, P87; COLQUHOUN D, 1977, PROC R SOC SER B-BIO, V199, P231, DOI 10.1098/rspb.1977.0137; DEVILLERSTHIERY A, 1992, NEUROREPORT, V3, P1001, DOI 10.1097/00001756-199211000-00014; DOYKLE D, 1998, SCIENCE, V280, P69; Edelstein SJ, 1998, ADV PROTEIN CHEM, V51, P121; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; HERZ JM, 1989, J BIOL CHEM, V264, P12439; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kearney PC, 1996, NEURON, V17, P1221, DOI 10.1016/S0896-6273(00)80252-4; Kearney PC, 1996, MOL PHARMACOL, V50, P1401; Koh JT, 1997, BIOCHEMISTRY-US, V36, P11314, DOI 10.1021/bi9707685; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; LIDE DR, 1990, HDB CHEM PHYSICS, P7; MAGLEBY KL, 1972, J PHYSIOL-LONDON, V223, P173, DOI 10.1113/jphysiol.1972.sp009840; MAGLEBY KL, 1972, J PHYSIOL-LONDON, V223, P151, DOI 10.1113/jphysiol.1972.sp009839; NEHER E, 1975, P NATL ACAD SCI USA, V72, P2140, DOI 10.1073/pnas.72.6.2140; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; Nowak MW, 1998, METHOD ENZYMOL, V293, P504; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; Saks ME, 1996, J BIOL CHEM, V271, P23169, DOI 10.1074/jbc.271.38.23169; SANKARARAMAKRISHNAN R, 1992, INT J PEPT PROT RES, V39, P356; SHERIDAN RE, 1977, J GEN PHYSIOL, V70, P187; SINE SM, 1995, NEURON, V15, P229, DOI 10.1016/0896-6273(95)90080-2; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Wang HL, 1997, J GEN PHYSIOL, V109, P757, DOI 10.1085/jgp.109.6.757; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572; Zhang H, 1997, BIOCHEMISTRY-US, V36, P15856, DOI 10.1021/bi972357u; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	41	111	150	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 8	1999	96	1					89	98		10.1016/S0092-8674(00)80962-9	http://dx.doi.org/10.1016/S0092-8674(00)80962-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989500	Bronze			2022-12-28	WOS:000078023200011
J	Pinker, S				Pinker, S			Cognition - Out of the minds of babes	SCIENCE			English	Editorial Material									MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Pinker, S (corresponding author), MIT, Dept Brain & Cognit Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Pinker, Steven/GPX-7942-2022		NICHD NIH HHS [HD 18381] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018381] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMSTRONG SL, 1983, COGNITION, V13, P263, DOI 10.1016/0010-0277(83)90012-4; ARMSTRONG SL, 1997, MIND WORKS; Hinton G. E., 1986, PARALLEL DISTRIBUTED; Hobbes Thomas, 2008, LEVIATHAN-J MELVILLE; Marcus GF, 1999, SCIENCE, V283, P77, DOI 10.1126/science.283.5398.77; MARCUS GF, 1999, ALGEBRAIC MIND; Pinker Steven, 1994, LANGUAGE INSTINCT; Saffran JR, 1996, SCIENCE, V274, P1926, DOI 10.1126/science.274.5294.1926	8	31	32	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					40	41		10.1126/science.283.5398.40	http://dx.doi.org/10.1126/science.283.5398.40			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	155ZH	9917263				2022-12-28	WOS:000077976600039
J	Moore-Smith, B				Moore-Smith, B			John Norman Agate - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																		AGATE JN, PUBLICATION LIST	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					401	401		10.1136/bmj.318.7180.401	http://dx.doi.org/10.1136/bmj.318.7180.401			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933225	Green Published			2022-12-28	WOS:000078572600062
J	Roscoe, TJ; Wells, M				Roscoe, TJ; Wells, M			NHSnet-learning from academia	BRITISH MEDICAL JOURNAL			English	Article									Beighton Hlth Ctr, Inst Gen Practice & Primary Care, Sheffield S20 1BJ, S Yorkshire, England; Univ Leeds, Dept Phys, Leeds LS2 9JT, W Yorkshire, England	University of Sheffield; University of Leeds	Roscoe, TJ (corresponding author), Beighton Hlth Ctr, Inst Gen Practice & Primary Care, Sheffield S20 1BJ, S Yorkshire, England.							*DEP HLTH, 1997, CM3807; *NHS EX INF MAN GR, 1995, IMGE5216 NHS EX INF; Roscoe T, 1998, HLTH INFORMATION INT, V3, P2; Verdon FP, 1995, COMPUT J, V38, P822, DOI 10.1093/comjnl/38.10.822	4	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					377	379		10.1136/bmj.318.7180.377	http://dx.doi.org/10.1136/bmj.318.7180.377			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933204	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000078572600032
J	Imai, E; Honda, H; Hatori, K; Brack, A; Matsuno, K				Imai, E; Honda, H; Hatori, K; Brack, A; Matsuno, K			Elongation of oligopeptides in a simulated submarine hydrothermal system	SCIENCE			English	Article							PREBIOTIC SYNTHESIS; PEPTIDE FORMATION; EMERGENCE; CHEMISTRY; SPRINGS; WATER; LIFE	Oligomerization of a peptide was attempted in a flow reactor that simulated a submarine hydrothermal system. When fluid containing glycine repeatedly circulated through the hot and cold regions in the reactor, oligopeptides were made from glycine. When divalent ions (such as copper ions) were added under acidic conditions, oligoglycine was elongated up to hexaglycine, This observation suggests that prebiotic monomers could have oligomerized in the vicinity of submarine hydrothermal vents on primitive Earth.	Nagaoka Univ Technol, Dept Bioengn, Nagaoka, Niigata 9402188, Japan; CNRS, Ctr Biophys Mol, F-45071 Orleans, France	Nagaoka University of Technology; Centre National de la Recherche Scientifique (CNRS)	Matsuno, K (corresponding author), Nagaoka Univ Technol, Dept Bioengn, Nagaoka, Niigata 9402188, Japan.	kmatsuno@vos.nagaokaut.ac.jp		Hatori, Kuniyuki/0000-0003-4042-1259				BADA JL, 1995, ORIGINS LIFE EVOL B, V25, P111, DOI 10.1007/BF01581577; BRACK A, 1987, ORIGINS LIFE EVOL B, V17, P367, DOI 10.1007/BF02386475; Brinton KLF, 1998, ORIGINS LIFE EVOL B, V28, P413, DOI 10.1023/A:1006548905523; BUJDAK J, 1995, ORIGINS LIFE EVOL B, V25, P431, DOI 10.1007/BF01581994; CORLISS JB, 1979, SCIENCE, V203, P1073, DOI 10.1126/science.203.4385.1073; EDMOND JM, 1982, NATURE, V297, P187, DOI 10.1038/297187a0; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; Ferris JP, 1996, NATURE, V381, P59, DOI 10.1038/381059a0; FERRIS JP, 1992, ORIGINS LIFE EVOL B, V22, P109, DOI 10.1007/BF01808020; Huber C, 1998, SCIENCE, V281, P670, DOI 10.1126/science.281.5377.670; KAUFFMAN SA, 1986, J THEOR BIOL, V119, P1, DOI 10.1016/S0022-5193(86)80047-9; KEEFE AD, 1995, NATURE, V373, P683, DOI 10.1038/373683a0; KELLER M, 1994, NATURE, V368, P836, DOI 10.1038/368836a0; MATSUNO K, 1982, BIOSYSTEMS, V15, P1, DOI 10.1016/0303-2647(82)90012-0; MATSUNO K, 1997, VIVA ORIGINO, V25, P191; MATSUNO K, 1989, PROTOBIOLOGY PHYSICA; NAGAYAMA M, 1990, ORIGINS LIFE EVOL B, V20, P249, DOI 10.1007/BF01808107; NAKASHIMA T, 1977, INT J QUANTUM CHEM, P65; Orgel LE, 1998, ORIGINS LIFE EVOL B, V28, P227, DOI 10.1023/A:1006595411403; ORGEL LE, 1986, J THEOR BIOL, V123, P127, DOI 10.1016/S0022-5193(86)80149-7; ROBERTSON MP, 1995, NATURE, V375, P772, DOI 10.1038/375772a0; RODE BM, 1990, ORIGINS LIFE EVOL B, V20, P401, DOI 10.1007/BF01808134; RUSSELL MJ, 1988, NATURE, V336, P117, DOI 10.1038/336117a0; Shock EL, 1996, CIBA F SYMP, V202, P40; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; YANAGAWA H, 1985, J BIOCHEM-TOKYO, V97, P1521, DOI 10.1093/oxfordjournals.jbchem.a135208	26	243	250	2	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1999	283	5403					831	833		10.1126/science.283.5403.831	http://dx.doi.org/10.1126/science.283.5403.831			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933163				2022-12-28	WOS:000078496800040
J	Li, LS; Yee, C; Beavo, JA				Li, LS; Yee, C; Beavo, JA			CD3- and CD28-dependent induction of PDE7 required for T cell activation	SCIENCE			English	Article							N-TERMINAL KINASE; PROTEIN-KINASE; CYCLIC-AMP; MAP KINASE; CAMP; IDENTIFICATION; LYMPHOCYTES; INHIBITION; PHOSPHODIESTERASES; INTERLEUKIN-2	Costimulation of both the CD3 and CD28 receptors is essential for T cell activation. Induction of adenosine 3',5'-monophosphate (cAMP)-specific phosphodiesterase-7 (PDE7) was found to be a consequence of such costimulation. Increased PDE7 in T cells correlated with decreased cAMP, increased interleukin-2 expression, and increased proliferation. Selectively reducing PDE7 expression with a PDE7 antisense oligonucleotide inhibited T cell proliferation; inhibition was reversed by blocking the cAMP signaling pathways that operate through cAMP-dependent protein kinase (PKA). Thus, PDE7 induction and consequent suppression of PKA activity is required for T cell activation, and inhibition of PDE7 could be an approach to treating T cell-dependent disorders.	Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Beavo, JA (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.			li, ling song/0000-0003-4824-3389	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK21723] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aandahl EM, 1998, FASEB J, V12, P855, DOI 10.1096/fasebj.12.10.855; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bloom TJ, 1996, P NATL ACAD SCI USA, V93, P14188, DOI 10.1073/pnas.93.24.14188; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Giembycz MA, 1996, BRIT J PHARMACOL, V118, P1945, DOI 10.1111/j.1476-5381.1996.tb15629.x; HSUEH YP, 1995, J BIOL CHEM, V270, P18094, DOI 10.1074/jbc.270.30.18094; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; Li Lin, UNPUB; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; MICHAELI T, 1993, J BIOL CHEM, V268, P12925; Mischak H, 1996, MOL CELL BIOL, V16, P5409; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROBICSEK SA, 1991, BIOCHEM PHARMACOL, V42, P869, DOI 10.1016/0006-2952(91)90047-9; Seybold J, 1998, J BIOL CHEM, V273, P20575, DOI 10.1074/jbc.273.32.20575; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SHERIDAN CM, 1998, GORD RES C KIMB UN N; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; Sprenkle AB, 1997, FEBS LETT, V403, P254, DOI 10.1016/S0014-5793(97)00062-8; Tamir A, 1996, J IMMUNOL, V157, P1514; TSURUTA L, 1995, J IMMUNOL, V154, P5255; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	24	205	227	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					848	851		10.1126/science.283.5403.848	http://dx.doi.org/10.1126/science.283.5403.848			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933169				2022-12-28	WOS:000078496800046
J	Ray, K; Ananthavel, SP; Waldeck, DH; Naaman, R				Ray, K; Ananthavel, SP; Waldeck, DH; Naaman, R			Asymmetric scattering of polarized electrons by organized organic films of chiral molecules	SCIENCE			English	Article							OPTIC DICHROISM; TRANSMISSION	Electron transmission experiments demonstrate a Large asymmetry in the scattering probability of polarized electrons by thin organized films of chiral molecules. This large asymmetry results from the interaction of the electron's wavefunction with many scatterers (molecules) in the organized monolayer structure and represents a manifestation of quantum interference on the scale of supramolecular lengths.	Weizmann Inst Sci, Dept Chem Phys, IL-76100 Rehovot, Israel; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA	Weizmann Institute of Science; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Naaman, R (corresponding author), Weizmann Inst Sci, Dept Chem Phys, IL-76100 Rehovot, Israel.			Waldeck, David/0000-0003-2982-0929				BEERLAGE MJM, 1981, J PHYS B-AT MOL OPT, V14, P3245, DOI 10.1088/0022-3700/14/17/027; Blum K, 1997, ADV ATOM MOL OPT PHY, V38, P39; BONNER WA, 1991, ORIGINS LIFE EVOL B, V21, P59, DOI 10.1007/BF01809580; BONNER WA, 1975, NATURE, V258, P419, DOI 10.1038/258419a0; HEGSTROM RA, 1980, J CHEM PHYS, V73, P2329, DOI 10.1063/1.440383; JOHNSTON C, 1993, J PHYS B-AT MOL OPT, V26, P965, DOI 10.1088/0953-4075/26/5/018; KADYSHEVITCH A, 1995, PHYS REV LETT, V74, P3443, DOI 10.1103/PhysRevLett.74.3443; Kadyshevitch A, 1997, J CHEM PHYS, V107, P1288, DOI 10.1063/1.474476; Kirschner J, 1985, POLARIZED ELECT SURF; Mayer S, 1996, J PHYS B-AT MOL OPT, V29, P3497, DOI 10.1088/0953-4075/29/15/021; MAYER S, 1995, PHYS REV LETT, V74, P4803, DOI 10.1103/PhysRevLett.74.4803; MEIER F, 1984, PHYS REV LETT, V52, P1152, DOI 10.1103/PhysRevLett.52.1152; MEIER F, 1981, PHYS REV LETT, V47, P374, DOI 10.1103/PhysRevLett.47.374; Naaman R, 1998, J PHYS CHEM B, V102, P3658, DOI 10.1021/jp980427g; Nolting C, 1997, J PHYS B-AT MOL OPT, V30, P5491, DOI 10.1088/0953-4075/30/23/014; Pasteur L., 1848, ANN CHIM PHYS, V24, P442; PAZ Y, 1992, J PHYS CHEM-US, V96, P10964, DOI 10.1021/j100205a066; POPOVITZBIRO R, 1990, J AM CHEM SOC, V112, P2498, DOI 10.1021/ja00163a005; RICH A, 1982, PHYS REV LETT, V48, P1341, DOI 10.1103/PhysRevLett.48.1341; Smith IM, 1998, J PHYS B-AT MOL OPT, V31, P4029, DOI 10.1088/0953-4075/31/17/022; THOMPSON DG, 1995, J PHYS B-AT MOL OPT, V28, P2473, DOI 10.1088/0953-4075/28/12/015; ULBRICHT TL, 1962, TETRAHEDRON, V18, P629, DOI 10.1016/S0040-4020(01)92714-0; ULBRICHT TLV, 1959, Q REV CHEM SOC, V13, P48, DOI 10.1039/qr9591300048; VESTER F, 1959, NATURWISSENSCHAFTEN, V46, P68, DOI 10.1007/BF00599091	24	222	225	7	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					814	816		10.1126/science.283.5403.814	http://dx.doi.org/10.1126/science.283.5403.814			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933157				2022-12-28	WOS:000078496800034
J	Vitek, CR; Brennan, MB; Gotway, CA; Bragina, VY; Govorukina, NV; Kravtsova, ON; Rhodes, PH; Bisgard, KM; Strebel, PM				Vitek, CR; Brennan, MB; Gotway, CA; Bragina, VY; Govorukina, NV; Kravtsova, ON; Rhodes, PH; Bisgard, KM; Strebel, PM			Risk of diphtheria among schoolchildren in the Russian Federation in relation to time since last vaccination	LANCET			English	Article								Background Between 1990 and 1996, more than 110000 cases and 2900 deaths from diphtheria were reported in the Russian Federation. in 1994, because disease rates were high among children aged 7-10 years, the age of administration of the second booster dose of diphtheria vaccine was lowered from 9 years to 6 years, the age of school entry. To assess the impact of this policy change, we did a matched case-control study in three Russian cities. Methods Children aged 6-8 years who had diphtheria between September, 1994, and December, 1996, were each matched with five to seven children acting as controls who were within 3 months of age of the case and were from the same class at school. We did a matched analysis using conditional logistic regression. Findings We analysed the immunisation records of 58 cases and 306 controls. All but one case and all controls had received at least three doses of diphtheria-toxoid vaccine. 19 (33%) cases and 144 (47%) controls had received a booster dose of diphtheria toroid within the previous 2 years. Cases were more likely than were controls to have received only four doses rather than five (odds ratio 2.8 [95% CI 1.2-6.5]) and to have a time since the last dose of diphtheria toroid of 3-4 years (3.1 [1.1-9.1]) or 5-7 years (15.0 [2.5-89.0]), compared with children for whom it was 2 years or less. On multivariate analysis only a time since the last dose of 5-7 years remained significantly associated with disease (matched odds ratio adjusted for total number of doses 10.9 [1.6-75.1]). Conclusion A booster dose of diphtheria-toxoid Vaccine given to children in the Russian Federation at 6-8 years of age reduced the interval since the last dose of diphtheria toroid and improved protection against diphtheria.	Ctr Dis Control & Prevent, Child Vaccine Preventable Dis Branch, Epidemiol & Surveillance Div, Natl Immunizat Program, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Stat Anal Branch, Data Management Div, Natl Immunizat Program, Atlanta, GA 30333 USA; Minist Hlth, Sanitary Epidemiol Surveillance Div, Vladimir, Russia; Minist Hlth, Sanitary Epidemiol Surveillance Div, Nizhnii Novgorod, Russia; Minist Hlth, Sanitary Epidemiol Surveillance Div, Voronezh, Russia	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Ministry of Health of the Russian Federation; Ministry of Health of the Russian Federation; Ministry of Health of the Russian Federation	Vitek, CR (corresponding author), Ctr Dis Control, Natl Immunizat Program, Mailstop E-61, Atlanta, GA 30333 USA.							BISGARD KM, IN PRESS J INFECT DI; *CDC, 1996, MMWR-MORBID MORTAL W, V45, P693; *CDC, 1995, MMWR-MORBID MORTAL W, V44, P177; DALMOTOV VV, 1986, ZH MIKROBIOL EPIDEMI, V63, P43; DITTMANN S, 1997, CMDS0701037 WHO; Doull JA, 1925, AM J HYG, V5, P508, DOI 10.1093/oxfordjournals.aje.a119677; Galazka AM, 1996, VACCINE, V14, P845, DOI 10.1016/0264-410X(96)00021-7; GALAZKA AM, 1993, WHOEPIGEN9312; HARDY I, 1993, P M DIPHTH EUR JUL 5, P118; Hardy IRB, 1996, LANCET, V347, P1739, DOI 10.1016/S0140-6736(96)90811-9; IPSEN J, 1946, J IMMUNOL, V54, P325; MAKSIMOVA NM, 1991, THESIS MOSCOW USSR; MAKSIMOVA NM, 1987, ZH MIKROBIOL EPIDEMI, V64, P50; MAKSIMOVA NM, 1990, ZH MIKROBIOL EPIDEMI, V67, P56; MARKINA SS, 1994, HLTH POPULATION ENV, P10; *MIN HLTH, 1987, INSTR IMPR IMM POL P; *MIN HLTH, 1986, ED 450 MEAS PREV DIP; *MIN HLTH RUSS FED, 1995, DIPHTH AD CLIN CHAR; NARKEVICH MI, 1990, ZH MIKROBIOL EPIDEMI, V67, P44; *WHO, 1995, WHOEURICPCMDS02	20	25	25	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 30	1999	353	9150					355	358		10.1016/S0140-6736(98)03488-6	http://dx.doi.org/10.1016/S0140-6736(98)03488-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950440				2022-12-28	WOS:000078437000010
J	Hawkey, CJ				Hawkey, CJ			COX-2 inhibitors	LANCET			English	Article							MELOXICAM 7.5 MG; PIROXICAM 20 MG; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; SYNTHASE CYCLOOXYGENASE; 15 MG; EFFICACY; COMPARE; SAFETY; OSTEOARTHRITIS	In the past 100 years aspirin has demonstrated its value as an analgesic, anti-inflammatory, and antithrombotic agent. However, by 1938, it was clear that aspirin was gastrotoxic. Non-steroidal anti-inflammatory drugs (NSAIDs), developed since the 1960s, failed to achieve the goal of "a safer aspirin". The demonstration that inhibition of prostaglandin synthesis via a cyclo-oxygenase (COX) enzyme was central to both the therapeutic and toxic effects of aspirin and non-aspirin NSAIDs appeared to establish the principle of no gain without pain. This link may have been broken by drugs that selectively inhibit the inducible COX-2 enzyme. The COX enzyme is now a target of drug interventions against the inflammatory process. Might the "safe aspirin" be here at last?	Univ Nottingham, Queens Med Ctr, Nottingham NG7 2UH, England	University of Nottingham	Hawkey, CJ (corresponding author), Univ Nottingham, Queens Med Ctr, Nottingham NG7 2UH, England.							BJARNASON I, 1998, AM J GASTROENTEROL, V93, pA246; BROOKS P, IN PRESS BR J RHEUMA; CHAN CC, 1997, INFLAMM RES, V46, pS242; CIPOLLONE F, 1995, CLIN PHARMACOL THER, V58, P335, DOI 10.1016/0009-9236(95)90251-1; CRANKSHAW DJ, 1994, CAN J PHYSIOL PHARM, V72, P870, DOI 10.1139/y94-123; CRYER B, 1998, AM J GASTROENTEROL, V93, pA104; DAVIS R, 1994, DRUGS, V48, P431, DOI 10.2165/00003495-199448030-00008; DEPRE M, 1998, RHEUMATOL EUR S1, V27; Dequeker J, 1998, BRIT J RHEUMATOL, V37, P946; Distel M, 1996, BRIT J RHEUMATOL, V35, P68; Donnelly MT, 1998, GASTROENTEROLOGY, V114, pA107; Donnelly MT, 1997, ALIMENT PHARM THER, V11, P227, DOI 10.1046/j.1365-2036.1997.154330000.x; EHRICH E, EFFECT MK 0966 VIOXX; Ehrich Elliot, 1996, Arthritis and Rheumatism, V39, pS81; Ehrich Elliot, 1997, Arthritis and Rheumatism, V40, pS85; EHRICH EW, IN PRESS CLIN PHARM; ELLIOTT SN, 1995, GASTROENTEROLOGY, V109, P524, DOI 10.1016/0016-5085(95)90341-0; Ernkey R, 1998, ARTHRITIS RHEUM, V41, pS44; FORDHUTCHINSON AW, 1997, SELECTIVE COX 2 INHI, P117; FU JY, 1990, J BIOL CHEM, V265, P16737; GANS KR, 1990, J PHARMACOL EXP THER, V254, P180; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; GLASER K, 1995, EUR J PHARMACOL, V281, P107, DOI 10.1016/0014-2999(95)00302-2; GOEITHE HS, 1997, OSTEOARTHR CARTILAGE, V15, P283; Griffiths MM, 1998, ARTHRITIS RHEUM, V41, pS99; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; Hawkey C, 1998, BRIT J RHEUMATOL, V37, P937; Hawkey CJ, 1998, NEW ENGL J MED, V338, P727, DOI 10.1056/NEJM199803123381105; HAWKEY CJ, 1995, GASTROENTEROLOGY, V109, P614, DOI 10.1016/0016-5085(95)90353-4; HAYLLAR J, 1995, LANCET, V346, P521, DOI 10.1016/S0140-6736(95)91378-5; Hosie J, 1997, CLIN DRUG INVEST, V13, P175, DOI 10.2165/00044011-199713040-00001; Hosie J, 1996, BRIT J RHEUMATOL, V35, P39; Hubbard RC, 1996, J INVEST MED, V44, pA293; HUBBARD RC, 1998, RHEUMATOL EUR, V27, P118; HUNT R, 1998, AM J GASTROENTEROL, V93, pA247; ISAKSON P, 1997, SELECTIVE COX 2 INHI, P127; Jackson LM, 1998, GASTROENTEROLOGY, V114, pA160, DOI 10.1016/S0016-5085(98)80647-1; Jasper RD, 1997, CLIN PHARMACOL THER, V61, pPII19; Kawamori T, 1998, CANCER RES, V58, P409; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Lanza FL, 1997, GASTROENTEROLOGY, V112, pA194; Lanzo CA, 1998, BIOCHEMISTRY-US, V37, P217, DOI 10.1021/bi971691n; Linden B, 1996, BRIT J RHEUMATOL, V35, P35; Lipsky PE, 1997, J RHEUMATOL, V24, P9; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Mahler JF, 1996, TOXICOL PATHOL, V24, P717, DOI 10.1177/019262339602400607; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; McLaughlan J, 1996, GASTROENTEROLOGY, V110, pA964; Mehlisch DR, 1998, CLIN PHARMACOL THER, V63, P139; Mengle-Gaw Laurel, 1997, Arthritis and Rheumatism, V40, pS93; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; Noble S, 1996, DRUGS, V51, P424, DOI 10.2165/00003495-199651030-00007; PAIRET M, 1997, SELECTIVE COX 2 INHI, V3, P27; PASINETTE GM, IN PRESS NEUROSCIENC; Patoia L, 1996, BRIT J RHEUMATOL, V35, P61; Patrignani P, 1997, J PHYSIOL PHARMACOL, V48, P623; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Rodriguez LAG, 1998, ARCH INTERN MED, V158, P33, DOI 10.1001/archinte.158.1.33; Schmassmann A, 1998, BRIT J PHARMACOL, V123, P795, DOI 10.1038/sj.bjp.0701672; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Schwartz J, 1998, CLIN PHARMACOL THER, V63, P167; *SEARL, 1999, CEL DAT SHEET; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Simon LS, 1998, ARTHRITIS RHEUM-US, V41, P1591, DOI 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J; SMOLEN J, 1998, PROMISE SPECIFIC COX, P21; Stack WA, 1998, GASTROENTEROLOGY, V114, pA294, DOI 10.1016/S0016-5085(98)81196-7; TAVARES IA, 1995, ARZNEIMITTEL-FORSCH, V45-2, P1093; Wallace JL, 1998, GASTROENTEROLOGY, V115, P101, DOI 10.1016/S0016-5085(98)70370-1; Wojtulewski JA, 1996, BRIT J RHEUMATOL, V35, P22; Yeomans ND, 1998, NEW ENGL J MED, V338, P719, DOI 10.1056/NEJM199803123381104; Zhao Sean Z., 1997, Arthritis and Rheumatism, V40, pS88; [No title captured]	73	848	880	3	77	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 23	1999	353	9149					307	314		10.1016/S0140-6736(98)12154-2	http://dx.doi.org/10.1016/S0140-6736(98)12154-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929039				2022-12-28	WOS:000078292200040
J	O'Leary, DDM; Yates, PA; McLaughlin, T				O'Leary, DDM; Yates, PA; McLaughlin, T			Molecular development of sensory maps: Representing sights and smells in the brain	CELL			English	Review							RECEPTOR TYROSINE KINASES; POSTERIOR TECTAL MEMBRANES; MOUSE OLFACTORY-BULB; CHICK VISUAL-SYSTEM; RETINAL AXONS; RETINOTECTAL PROJECTION; TRANSMEMBRANE LIGANDS; OPTIC TECTUM; NEURAL DEVELOPMENT; TOPOGRAPHIC ORDER		Salk Inst, Mol Neurobiol Lab, La Jolla, CA 92037 USA	Salk Institute	O'Leary, DDM (corresponding author), Salk Inst, Mol Neurobiol Lab, La Jolla, CA 92037 USA.	dennis_oleary@qm.salk.edu			NEI NIH HHS [EY07025] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; Bargmann CI, 1997, CELL, V90, P585, DOI 10.1016/S0092-8674(00)80518-8; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; Braisted JE, 1997, DEV BIOL, V191, P14, DOI 10.1006/dbio.1997.8706; Brennan C, 1997, DEVELOPMENT, V124, P655; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Bulfone A, 1998, NEURON, V21, P1273, DOI 10.1016/S0896-6273(00)80647-9; CHEN G, 1994, BIOL CONTROL, V4, P157, DOI 10.1006/bcon.1994.1025; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CLOSSEK T, 1998, EUR J NEUROSCI, V10, P1574; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Connor RJ, 1998, DEV BIOL, V193, P21, DOI 10.1006/dbio.1997.8786; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ebrahimi FAW, 1998, CURR OPIN NEUROBIOL, V8, P453, DOI 10.1016/S0959-4388(98)80031-7; Feldheim DA, 1998, NEURON, V21, P1303, DOI 10.1016/S0896-6273(00)80650-9; Flanagan JG, 1997, CELL, V90, P403; Friedman GC, 1996, J NEUROSCI, V16, P5498; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; FUJLSAWA H, 1987, PROG BRAIN RES, V71, P75; Gierer A, 1998, EUR J NEUROSCI, V10, P388, DOI 10.1046/j.1460-9568.1998.00017.x; GIERER A, 1983, PROC R SOC SER B-BIO, V218, P77, DOI 10.1098/rspb.1983.0027; GIERER A, 1987, DEVELOPMENT, V101, P479; Gierer Alfred, 1995, Current Opinion in Neurobiology, V5, P91, DOI 10.1016/0959-4388(95)80092-1; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; GOTTLIEB DI, 1980, ANNU REV NEUROSCI, V3, P303, DOI 10.1146/annurev.ne.03.030180.001511; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HOLT CE, 1984, J NEUROSCI, V4, P1130; HOLT CE, 1983, PROG BRAIN RES, V58, P339, DOI 10.1016/S0079-6123(08)60035-7; Itasaki N, 1996, NEURON, V16, P55, DOI 10.1016/S0896-6273(00)80023-9; Iwasato T, 1997, NEURON, V19, P1201, DOI 10.1016/S0896-6273(00)80412-2; Karlstrom RO, 1997, TRENDS NEUROSCI, V20, P3, DOI 10.1016/S0166-2236(96)40005-4; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kobayashi H, 1997, J NEUROSCI, V17, P8339; KOBAYASHI T, 1990, Journal of Toxicological Sciences, V15, P227; LAMANTIA AS, 1992, J NEUROSCI, V12, P976; Logan C, 1996, CURR BIOL, V6, P1006, DOI 10.1016/S0960-9822(02)00645-0; Marcus RC, 1996, DEV BIOL, V180, P786, DOI 10.1006/dbio.1996.0347; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; MCLOON SC, 1991, J NEUROSCI, V11, P1470; Meima L, 1997, MOL CELL NEUROSCI, V9, P314, DOI 10.1006/mcne.1997.0621; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; OLEARY DDM, 1999, IN PRESS CURR OPIN N, V9; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; Pasterkamp RJ, 1998, J NEUROSCI, V18, P9962; POMEROY SL, 1990, J NEUROSCI, V10, P1952; Qasba P, 1998, J NEUROSCI, V18, P227; RESSIER KJ, 1993, CELL, V3, P597; Ressler Kerry J., 1994, Current Opinion in Neurobiology, V4, P588, DOI 10.1016/0959-4388(94)90061-2; Rosentreter SM, 1998, J NEUROBIOL, V37, P541, DOI 10.1002/(SICI)1097-4695(199812)37:4<541::AID-NEU4>3.3.CO;2-C; ROSKIES A, 1995, PERSPECT DEV NEUROBI, V3, P63; ROSKIES AL, 1994, SCIENCE, V265, P799, DOI 10.1126/science.8047886; SAKAGUCHI DS, 1985, J NEUROSCI, V5, P3228; SAVITT JW, 1995, NEURON, V14, P253, DOI 10.1016/0896-6273(95)90283-X; Shigetani Y, 1997, NEUROSCI RES, V27, P211, DOI 10.1016/S0168-0102(96)01151-0; SIMON DK, 1992, J NEUROSCI, V12, P1212; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; SIMON DK, 1992, NEURON, V9, P977, DOI 10.1016/0896-6273(92)90249-D; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; STUERMER CAO, 1988, J NEUROSCI, V8, P4513; SULLIVAN SL, 1995, NEURON, V15, P779, DOI 10.1016/0896-6273(95)90170-1; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; VONBOXBERG Y, 1993, NEURON, V10, P345; WALTER J, 1987, DEVELOPMENT, V101, P685; WALTER J, 1990, J PHYSIOL-PARIS, V84, P104; WALTER J, 1987, DEVELOPMENT, V101, P909; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Yoshihara Y, 1997, J NEUROSCI, V17, P5830; Yuasa J, 1996, NATURE, V382, P632, DOI 10.1038/382632a0; Zhang JH, 1996, J NEUROSCI, V16, P7182; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U	87	100	101	2	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 22	1999	96	2					255	269		10.1016/S0092-8674(00)80565-6	http://dx.doi.org/10.1016/S0092-8674(00)80565-6			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	160VM	9988220	Bronze			2022-12-28	WOS:000078252200009
J	Culnane, M; Fowler, M; Lee, SS; McSherry, G; Brady, M; O'Donnell, K; Mofenson, L; Gortmaker, SL; Shapiro, DE; Scott, G; Jimenez, E; Moore, EC; Diaz, C; Flynn, PM; Cunningham, B; Oleske, J				Culnane, M; Fowler, M; Lee, SS; McSherry, G; Brady, M; O'Donnell, K; Mofenson, L; Gortmaker, SL; Shapiro, DE; Scott, G; Jimenez, E; Moore, EC; Diaz, C; Flynn, PM; Cunningham, B; Oleske, J		Pediat AIDS Clin Trials Grp Protocol 219076	Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; TRANSMISSION; TESTS; TRIAL; MICE	Context With the success of zidovudine chemoprophylaxis for prevention of perinatal transmission of the human immunodeficiency virus (HIV), an increasing number of HIV-exposed but uninfected children will have in utero exposure to zidovudine and other antiretroviral drugs. Objective To evaluate the long-term effects of in utero exposure to zidovudine vs placebo among a randomized cohort of uninfected children. Design Prospective cohort study based on data collected during Pediatric AIDS Clinical Trials Group Protocol 076, a perinatal zidovudine HIV prevention trial, and Protocol 219, a long-term observational protocol. Setting Pediatric research clinics in the United States. Patients Two hundred thirty-four uninfected children born to 230 HIV-infected women enrolled in Protocol 076 and followed up through February 28, 1997, in Protocol 219 (122 in the zidovudine group and 112 in the placebo group). Main Outcome Measures Physical growth measurements, immunologic parameters, cognitive/developmental function, occurrence of neoplasms, and mortality data assessed every 6 months for children younger than 24 months and yearly thereafter or as clinically indicated. Baseline echocardiogram and funduscopic evaluations were collected before 36 months of age. Results Median age of children at time of last follow-up visit was 4.2 years (range, 3.2-5.6 years). There were no significant differences between children exposed to zidovudine and those who received placebo in terms of sequential data on lymphocyte subsets; weight, height, and head circumference z scores; and cognitive/ developmental function. No deaths or malignancies occurred. Two children (both exposed to zidovudine) are being followed up for abnormal, unexplained ophthalmic findings. One child exposed to zidovudine had a mild cardiomyopathy on echocardiogram at the age of 48 months; the child is clinically asymptomatic. Conclusions No adverse effects were observed in HIV-uninfected children with in utero and neonatal exposure to zidovudine followed up for as long as 5.6 years. Continued prospective evaluations of children born to HIV-infeded women who are exposed to antiretroviral or immunotherapeutic agents are critical to assess the longterm safety of interventions that prevent perinatal HIV transmission.	NIAID, Pediat Med Branch, Div AIDS, NIH, Bethesda, MD 20892 USA; NICHHD, Pediat Adolescent & Maternal AIDS Branch, NIH, Bethesda, MD 20892 USA; NIAID, Efficacy Trials Branch, Div AIDS, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pediat, Newark, NJ 07103 USA; Ohio State Univ, Columbus Childrens Hosp, Infect Dis Sect, Columbus, OH 43210 USA; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Univ Miami, Sch Med, Dept Pediat, Miami, FL USA; Univ Puerto Rico, Sch Med, Dept Pediat, San Juan, PR 00936 USA; San Juan City Hosp, Dept Pediat, San Juan, PR USA; Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA; St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; Frontier Sci & Technol Res Fdn, Amherst, NY USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Harvard T.H. Chan School of Public Health; Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Duke University; University of Miami; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; Wayne State University; St Jude Children's Research Hospital; Frontier Science Foundation	Culnane, M (corresponding author), NIAID, Pediat Med Branch, Div AIDS, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	mc38f@nih.gov	Flynn, Patricia M/N-8146-2018; Mofenson, Lynne/P-9631-2019; Oleske, James/C-1951-2016	Mofenson, Lynne/0000-0002-2818-9808; Culnane, Mary/0000-0003-2070-4454; Oleske, James/0000-0003-2305-5605				Ayers KM, 1996, FUND APPL TOXICOL, V32, P148, DOI 10.1006/faat.1996.0118; Bayley N, 1993, BAYLEY SCALES INFANT; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P2; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1086; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; HANSON C, 1997, P NAT C WOM HIV MAY; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; McCarthy D, 1972, MCCARTHY SCALES CHIL; MCKINNEY RE, 1992, PEDIATR INFECT DIS J, V11, P639; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; *MERCK CO INC, 1997, ANT PREGN REG DID LA; Olivero OA, 1997, J NATL CANCER I, V89, P1602, DOI 10.1093/jnci/89.21.1602; ROCHE AF, 1980, AM J CLIN NUTR, V33, P2041, DOI 10.1093/ajcn/33.9.2041; Sperling RS, 1998, AIDS, V12, P1805, DOI 10.1097/00002030-199814000-00012; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WADE AM, 1992, PEDIATR INFECT DIS J, V11, P1018, DOI 10.1097/00006454-199211120-00006; WEI LJ, 1985, BIOMETRIKA, V72, P359; 1997, CONFRONTING AIDS PUB	20	229	236	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					151	157		10.1001/jama.281.2.151	http://dx.doi.org/10.1001/jama.281.2.151			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155VJ	9917118	Bronze			2022-12-28	WOS:000077966800035
J	Johnson, RE; Prakash, S; Prakash, L				Johnson, RE; Prakash, S; Prakash, L			Efficient bypass of a thymine-thymine dimer by yeast DNA polymerase, Pol eta	SCIENCE			English	Article							SIMPLE REPETITIVE SEQUENCES; PIGMENTOSUM VARIANT CELLS; SACCHAROMYCES-CEREVISIAE; PROTEIN; PHOTOPRODUCTS; REPLICATION	The RAD30 gene of the yeast Saccharomyces cerevisiae is required for the error-free postreplicational repair of DNA that has been damaged by ultraviolet irradiation. Here, RAD30 is shown to encode a DNA polymerase that can replicate efficiently past a thymine-thymine cis-syn cyclobutane dimer, a lesion that normally blocks DNA polymerases. When incubated in vitro with all four nucleotides, Rad30 incorporates two adenines opposite the thymine-thymine dimer. Rad30 is the seventh eukaryotic DNA polymerase to be described and hence is named DNA polymerase eta.	Univ Texas, Med Branch, Sealy Branch Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, L (corresponding author), Univ Texas, Med Branch, Sealy Branch Mol Sci, 6-104 Med Res Bldg,11th & Mech St, Galveston, TX 77555 USA.		Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NIGMS NIH HHS [GM19261] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGERS PMJ, 1988, J BIOL CHEM, V263, P925; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Goodman MF, 1998, NATURE, V395, P221, DOI 10.1038/26111; Johnson R. M., UNPUB; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; JOHNSON RE, 1994, J BIOL CHEM, V269, P28259; McDonald JP, 1997, GENETICS, V147, P1557; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; Svoboda DL, 1998, CANCER RES, V58, P2445; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; WAHL AF, 1986, BIOCHEMISTRY-US, V25, P7821, DOI 10.1021/bi00372a006; Walker GC, 1998, P NATL ACAD SCI USA, V95, P10348, DOI 10.1073/pnas.95.18.10348; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276	17	674	685	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					1001	1004		10.1126/science.283.5404.1001	http://dx.doi.org/10.1126/science.283.5404.1001			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974380				2022-12-28	WOS:000078574800054
J	Haycox, A; Bagust, A; Walley, T				Haycox, A; Bagust, A; Walley, T			Clinical guidelines - the hidden costs	BRITISH MEDICAL JOURNAL			English	Article									Univ Liverpool, Prescribing Res Grp, Liverpool L69 3GF, Merseyside, England	University of Liverpool	Haycox, A (corresponding author), Univ Liverpool, Prescribing Res Grp, Liverpool L69 3GF, Merseyside, England.							AXON ATR, 1995, BMJ-BRIT MED J, V310, P853, DOI 10.1136/bmj.310.6983.853; Brown N, 1997, BMJ-BRIT MED J, V315, P159, DOI 10.1136/bmj.315.7101.159; DAVIES J, 1994, EFFECTIVE HLTH CARE, V8; Dent THS, 1997, BMJ-BRIT MED J, V315, P1248, DOI 10.1136/bmj.315.7118.1248; Fayers PM, 1997, LANCET, V350, P1025, DOI 10.1016/S0140-6736(97)03053-5; Freemantle N, 1997, BMJ-BRIT MED J, V315, P826, DOI 10.1136/bmj.315.7112.826; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; MANN T., 1996, CLIN GUIDELINES USIN; MCCORMICK A, 1995, OPCS SURVEYS MB5, V3; SPEARMAN M, 1997, CLIN THER, V3, P582; *STAND MED ADV COM, 1997, US STAT; THOMSON R, 1995, BMJ-BRIT MED J, V311, P237, DOI 10.1136/bmj.311.6999.237; West E, 1997, BRIT MED J, V315, P324	14	42	46	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					391	393		10.1136/bmj.318.7180.391	http://dx.doi.org/10.1136/bmj.318.7180.391			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933210	Green Published			2022-12-28	WOS:000078572600038
J	Gao, F; Bailes, E; Robertson, DL; Chen, YL; Rodenburg, CM; Michael, SF; Cummins, LB; Arthur, LO; Peeters, M; Shaw, GM; Sharp, PM; Hahn, BH				Gao, F; Bailes, E; Robertson, DL; Chen, YL; Rodenburg, CM; Michael, SF; Cummins, LB; Arthur, LO; Peeters, M; Shaw, GM; Sharp, PM; Hahn, BH			Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes	NATURE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; WILD-CAPTURED CHIMPANZEE; TANTALUS MONKEYS; LENTIVIRUS; SEQUENCE; ORGANIZATION; GENOME; TYPE-2; AFRICA; GABON	The human AIDS viruses human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) represent cross-species (zoonotic) infections(1-4). Although the primate reservoir of HIV-2 has been clearly identified as the sooty mangabey (Cercocebus atys)(2,4-7), the origin of HIV-1 remains uncertain. Viruses related to HIV-1 have been isolated from the common chimpanzee (Pan troglodytes)(8,9), but only three such SIVcpz infections have been documented(1,10,11), one of which involved a virus so divergent(11) that it might represent a different primate lentiviral lineage. In a search for the HIV-1 reservoir, rye have now sequenced the genome of a new SIVcpz strain (SIVcpzUS) and have determined, by mitochondrial DNA analysis, the subspecies identity of all known SIVcpz-infected chimpanzees. We find that two chimpanzee subspecies in Africa, the central P. t. troglodytes and the eastern P. t. schweinfurthii, harbour SIVcpz and that their respective viruses form two highly divergent (but subspecies-specific) phylogenetic lineages. All HIV-1 strains known to infect man, including HIV-1 groups M, N and O, are closely related to just one of these SIVcpz lineages, that found in P. t. troglodytes. Moreover, we find that HIV-1 group N is a mosaic of SIVcpzUS- and HTV-1-related sequences, indicating an ancestral recombination event in a chimpanzee host. These results, together with the observation that the natural range of P. t. troglodytes coincides uniquely with areas of HIV-1 group M, N and O endemicity, indicate that P. t. troglodytes is the primary reservoir for HIV-I and has been the source of at least three independent introductions of SIVcpz into the human population.	Univ Alabama Birmingham, Dept Med & Microbiol, Birmingham, AL 35294 USA; Univ Nottingham, Queens Med Ctr, Inst Genet, Nottingham NG7 2UH, England; CNRS, Lab Struct & Genet Informat, F-13402 Marseille, France; SW Fdn Biomed Res, San Antonio, TX 78245 USA; NCI, AIDS Vaccine Program, Frederick Canc Res & Dev Ctr, SAIC Frederick, Ft Detrick, MD 21702 USA; ORSTOM, Retrovirus Lab, F-34032 Rennes, France; Univ Alabama Birmingham, Howard Hughes Med Inst, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Nottingham; Centre National de la Recherche Scientifique (CNRS); Texas Biomedical Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Institut de Recherche pour le Developpement (IRD); Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham	Hahn, BH (corresponding author), Univ Alabama Birmingham, Dept Med & Microbiol, 701 S 19th St,LHRB 613, Birmingham, AL 35294 USA.	bhahn@uab.edu	Sharp, Paul M/F-5783-2010; Sharp, Paul/Y-3787-2019; Sharp, Paul M/GPX-1497-2022	Sharp, Paul M/0000-0001-9771-543X; Sharp, Paul M/0000-0001-9771-543X; Hahn, Beatrice/0000-0002-9400-9887				ADACHI J, 1994, I STAT MATH; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Chen ZW, 1997, J VIROL, V71, P3953, DOI 10.1128/JVI.71.5.3953-3960.1997; Chen ZW, 1996, J VIROL, V70, P3617, DOI 10.1128/JVI.70.6.3617-3627.1996; GAO F, 1994, J VIROL, V68, P7433, DOI 10.1128/JVI.68.11.7433-7447.1994; GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0; GILDEN RV, 1986, LANCET, V1, P678; Gonder MK, 1997, NATURE, V388, P337, DOI 10.1038/41005; Groves Colin P., 1993, P243; Gurtler LG, 1996, ARCH VIROL, P195; HIRSCH VM, 1993, VIROLOGY, V197, P426, DOI 10.1006/viro.1993.1606; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; HUET T, 1990, NATURE, V345, P356, DOI 10.1038/345356a0; JANSSENS W, 1994, AIDS RES HUM RETROV, V10, P1191, DOI 10.1089/aid.1994.10.1191; JIN MJ, 1994, EMBO J, V13, P2935, DOI 10.1002/j.1460-2075.1994.tb06588.x; KOBER B, 1997, HUMAN RETROVIRUSES A; MORIN PA, 1994, SCIENCE, V265, P1193, DOI 10.1126/science.7915048; MULLER MC, 1993, J VIROL, V67, P1227; PEETERS M, 1989, AIDS, V3, P625, DOI 10.1097/00002030-198910000-00001; PEETERS M, 1992, AIDS, V6, P447, DOI 10.1097/00002030-199205000-00002; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHARMA KD, 1994, HYDROL PROCESS, V8, P27, DOI 10.1002/hyp.3360080103; SHARP PM, 1995, PHILOS T R SOC B, V349, P41, DOI 10.1098/rstb.1995.0089; Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017; Teleki G., 1989, P312; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VandenHaesevelde MM, 1996, VIROLOGY, V221, P346, DOI 10.1006/viro.1996.0384; Zhu TF, 1998, NATURE, V391, P594, DOI 10.1038/35400	28	1022	1059	2	219	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 4	1999	397	6718					436	441		10.1038/17130	http://dx.doi.org/10.1038/17130			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164KA	9989410	Bronze			2022-12-28	WOS:000078461700049
J	Lahey, T				Lahey, T			Rejuvenating the symbols of medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									LDS Hosp, Salt Lake City, UT 84143 USA		Lahey, T (corresponding author), LDS Hosp, Salt Lake City, UT 84143 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					479	479		10.1001/jama.281.5.479	http://dx.doi.org/10.1001/jama.281.5.479			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952214	hybrid			2022-12-28	WOS:000078318500044
J	Nightingale, SL				Nightingale, SL			Lyme disease vaccine approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					408	408		10.1001/jama.281.5.408	http://dx.doi.org/10.1001/jama.281.5.408			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952188				2022-12-28	WOS:000078318500007
J	Kandela, P				Kandela, P			Venereal diseases	LANCET			English	Editorial Material											Kandela, P (corresponding author), 29 Greenlands Rd, Staines TW18 4LR, Middx, England.							1864, LANCET          0326, P351; 1841, LANCET          0529, P342; 1914, LANCET          0425, P1200; 1863, LANCET          0829, P253; 1828, LANCET          0725, P525	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 30	1999	353	9150					419	419		10.1016/S0140-6736(05)75005-4	http://dx.doi.org/10.1016/S0140-6736(05)75005-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950486				2022-12-28	WOS:000078437000074
J	Stein, CM; Pincus, T				Stein, CM; Pincus, T			Placebo-controlled studies in rheumatoid arthritis: ethical issues	LANCET			English	Article							DOUBLE-BLIND; RADIOGRAPHIC PROGRESSION; FUNCTIONAL DISABILITY; INFORMED CONSENT; DRUG-THERAPY; FOLLOW-UP; MORTALITY; DISEASE; TRIAL; METHOTREXATE		Vanderbilt Univ, Sch Med, Dept Pharmacol, Div Rheumatol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Stein, CM (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, Div Rheumatol, T 3219 MCN, Nashville, TN 37232 USA.	michael.stein@mcmail.vanderbilt.edu						Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7; BORG G, 1991, J RHEUMATOL, V18, P1015; Callahan LF, 1995, ARTHRIT CARE RES, V8, P28, DOI 10.1002/art.1790080108; CLARK PI, 1994, ANNU REV PUBL HEALTH, V15, P19; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; EGSMOSE C, 1995, J RHEUMATOL, V22, P2208; EMERY P, 1994, BRIT J RHEUMATOL, V33, P765; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P544, DOI 10.7326/0003-4819-99-4-544; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; FORRE O, 1994, ARTHRITIS RHEUM, V37, P1506; FRIES JF, 1993, ARTHRITIS RHEUM, V36, P297, DOI 10.1002/art.1780360303; Fries JF, 1996, ARTHRITIS RHEUM, V39, P616, DOI 10.1002/art.1780390412; FUCHS HA, 1992, J RHEUMATOL, V19, P1655; HANNONEN P, 1993, ARTHRITIS RHEUM-US, V36, P1501, DOI 10.1002/art.1780361104; HASLOCK I, 1989, BRIT J RHEUMATOL, V28, P458; IANNUZZI L, 1983, NEW ENGL J MED, V309, P1023, DOI 10.1056/NEJM198310273091704; INGELFINGER FJ, 1972, NEW ENGL J MED, V287, P100, DOI 10.1056/NEJM197207132870211; KIRWAN JR, 1983, CLIN RHEUM DIS, V9, P581; Kremer JM, 1997, ARTHRITIS RHEUM, V40, P984, DOI 10.1002/art.1780400533; LYNOE N, 1991, BRIT MED J, V303, P610, DOI 10.1136/bmj.303.6803.610; ODell JR, 1997, ARTHRITIS RHEUM, V40, P842, DOI 10.1002/art.1780400510; Pasero G, 1996, ARTHRITIS RHEUM, V39, P1006, DOI 10.1002/art.1780390618; PINCUS T, 1993, BRIT J RHEUMATOL, V32, P28; PINCUS T, 1995, J RHEUMATOL, V22, P1983; PINCUS T, 1995, J RHEUMATOL, V22, P1611; PINCUS T, 1994, J RHEUMATOL, V21, P1385; REILLY PA, 1990, ANN RHEUM DIS, V49, P363, DOI 10.1136/ard.49.6.363; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P922, DOI 10.1001/jama.277.11.922; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; VANRIEL PLCM, 1995, J RHEUMATOL, V22, P1797; Verheggen F W, 1997, Med Law, V16, P53; WARD MM, 1993, ARCH INTERN MED, V153, P2229, DOI 10.1001/archinte.153.19.2229; WEINBLATT ME, 1993, ARTHRITIS RHEUM-US, V36, P613, DOI 10.1002/art.1780360507; WOLFE F, 1991, J RHEUMATOL, V18, P1298; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038	36	54	54	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 30	1999	353	9150					400	403		10.1016/S0140-6736(98)01373-7	http://dx.doi.org/10.1016/S0140-6736(98)01373-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950461				2022-12-28	WOS:000078437000046
J	Beier, M; Reck, F; Wagner, T; Krishnamurthy, R; Eschenmoser, A				Beier, M; Reck, F; Wagner, T; Krishnamurthy, R; Eschenmoser, A			Chemical etiology of nucleic acid structure: Comparing pentopyranosyl-(2 '-> 4 ') oligonucleotides with RNA	SCIENCE			English	Article							PREBIOLOGICAL NATURAL-PRODUCTS; BASE-PAIRING PROPERTIES; PYRANOSYL-RNA; P-RNA; NUCLEOSIDE SYNTHESIS; DNA; CHEMISTRY; OLIGORIBONUCLEOTIDES; OLIGOMERIZATION; REPLICATION	All four members of the family of pentopyranosyl-(2'-->4') oligonucleotide systems that contain beta-ribo-, beta-xylo-, alpha-lyxo-, or alpha-arabinopyranosyl units as repeating sugar building blocks are found to be much stronger Watson-Crick base-pairing systems than RNA. The alpha-arabinopyranosyl system is the strongest of ali and in fact belongs to the strongest oligonucleotide base-pairing systems known, Whatever the chemical determinants by which nature selected RNA as a genetic system, maximization of base-pairing strengths within the domain of pentose-derived oligonucleotide systems was not the critical selection criterion.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; ETH Zurich, Organ Chem Lab, CH-8092 Zurich, Switzerland	Scripps Research Institute; Swiss Federal Institutes of Technology Domain; ETH Zurich	Eschenmoser, A (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Krishnamurthy, Ramanarayanan/AAO-6030-2020	Krishnamurthy, Ramanarayanan/0000-0001-5238-610X				BEIER M, IN PRESS HELV CHIM A; BENNUASKALMOWSKI B, 1995, TETRAHEDRON LETT, V36, P7845, DOI 10.1016/0040-4039(95)01667-7; Bolli M, 1997, CHEM BIOL, V4, P309, DOI 10.1016/S1074-5521(97)90074-0; Bolli M, 1996, CHEM BIOL, V3, P197, DOI 10.1016/S1074-5521(96)90263-X; Bolli M, 1997, HELV CHIM ACTA, V80, P1901, DOI 10.1002/hlca.19970800613; Cairns-Smith A.G., 1982, GENETIC TAKEOVER MIN; DOBOSZEWSKI B, 1995, TETRAHEDRON, V51, P5381, DOI 10.1016/0040-4020(95)00211-P; DOUGHERTY JP, 1992, J AM CHEM SOC, V114, P6254, DOI 10.1021/ja00041a058; Eschenmoser A, 1997, ORIGINS LIFE EVOL B, V27, P535, DOI 10.1023/A:1006511605323; ESCHENMOSER A, 1994, ORIGINS LIFE EVOL B, V24, P389, DOI 10.1007/BF01582017; ESCHENMOSER A, 1992, CHEM SOC REV, V21, P1, DOI 10.1039/cs9922100001; ESCHENMOSER A, 1992, HELV CHIM ACTA, V75, P218, DOI 10.1002/hlca.19920750120; ESCHENMOSER A, 1990, VERH GES DTSCH NATUR, V116, P135; ESCHENMOSER A, 1993, P RA WELCH FDN C CHE, V37, P201; FUERTES M, 1975, J ORG CHEM, V40, P2372, DOI 10.1021/jo00904a024; HASHIMOTO H, 1992, J AM CHEM SOC, V114, P6255, DOI 10.1021/ja00041a059; HUNZIKER J, 1993, HELV CHIM ACTA, V76, P259, DOI 10.1002/hlca.19930760119; JOYCE GF, 1987, P NATL ACAD SCI USA, V84, P4398, DOI 10.1073/pnas.84.13.4398; Joyce GF., 1993, COLD SPRING HARB MON, V24, P1; KIERZEK R, 1992, NUCLEIC ACIDS RES, V20, P1685, DOI 10.1093/nar/20.7.1685; Krishnamurthy R, 1996, ANGEW CHEM INT EDIT, V35, P1537, DOI 10.1002/anie.199615371; KRISHNAMURTHY R, IN PRESS ORIGINS LIF; KRISHNAMURTHY RU, UNPUB; LEMIEUX RU, 1975, J AM CHEM SOC, V97, P4069, DOI 10.1021/ja00847a034; MARKY LA, 1987, BIOPOLYMERS, V26, P1602; MARTINEZ AP, 1969, J MED CHEM, V12, P1125, DOI 10.1021/jm00306a050; MARTINEZ AP, 1969, J ORG CHEM, V34, P416, DOI 10.1021/jo01254a034; MARTINEZ AP, 1969, J ORG CHEM, V34, P92, DOI 10.1021/jo00838a022; Micura R, 1997, ANGEW CHEM INT EDIT, V36, P870, DOI 10.1002/anie.199708701; MICURA R, IN PRESS ANGEW CHEM; MULLER D, 1990, HELV CHIM ACTA, V73, P1410, DOI 10.1002/hlca.19900730526; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; ORGEL LE, 1974, ACCOUNTS CHEM RES, V7, P368, DOI 10.1021/ar50083a002; OSCARSON S, 1993, CARBOHYD RES, V247, P323, DOI 10.1016/0008-6215(93)84266-9; PITSCH S, 1995, HELV CHIM ACTA, V78, P1621, DOI 10.1002/hlca.19950780702; PITSCH S, 1993, HELV CHIM ACTA, V76, P2161, DOI 10.1002/hlca.19930760602; Prakash TP, 1997, ANGEW CHEM INT EDIT, V36, P1522, DOI 10.1002/anie.199715221; Prakash TP, 1996, CHEM COMMUN, P1793, DOI 10.1039/cc9960001793; RECK F, IN PRESS HELV CHIM A; RESMINI M, 1993, THESIS U KONSTANZ GE; Sawai H, 1996, J BIOMOL STRUCT DYN, V13, P1043, DOI 10.1080/07391102.1996.10508919; Schlonvogt I, 1996, HELV CHIM ACTA, V79, P2316, DOI 10.1002/hlca.19960790820; Singh SK, 1998, CHEM COMMUN, P455, DOI 10.1039/a708608c; Steffens R, 1997, J AM CHEM SOC, V119, P11548, DOI 10.1021/ja972597x; Stengele K. P., 1989, NUCLEIC ACIDS RES S, V21, P101; USHER DA, 1972, NATURE-NEW BIOL, V235, P207, DOI 10.1038/newbio235207a0; USHER DA, 1976, P NATL ACAD SCI USA, V73, P1149, DOI 10.1073/pnas.73.4.1149; WAGNER T, IN PRESS HELV CHIM A; Wengel J, 1997, BIOORG MED CHEM LETT, V7, P1999, DOI 10.1016/S0960-894X(97)00352-1; Zubay G, 1998, ORIGINS LIFE EVOL B, V28, P13, DOI 10.1023/A:1006551410542	50	111	114	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					699	703		10.1126/science.283.5402.699	http://dx.doi.org/10.1126/science.283.5402.699			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	162BC	9924032				2022-12-28	WOS:000078324400046
J	Luttrell, LM; Ferguson, SSG; Daaka, Y; Miller, WE; Maudsley, S; Della Rocca, GJ; Lin, FT; Kawakatsu, H; Owada, K; Luttrell, DK; Caron, MG; Lefkowitz, RJ				Luttrell, LM; Ferguson, SSG; Daaka, Y; Miller, WE; Maudsley, S; Della Rocca, GJ; Lin, FT; Kawakatsu, H; Owada, K; Luttrell, DK; Caron, MG; Lefkowitz, RJ			beta-arrestin-dependent formation of beta(2) adrenergic receptor Src protein kinase complexes	SCIENCE			English	Article							COUPLED THROMBIN RECEPTOR; HETEROTRIMERIC G-PROTEINS; BETA(2)-ADRENERGIC RECEPTOR; TYROSINE-KINASE; GAMMA-SUBUNITS; MAP KINASE; C-SRC; SIGNAL-TRANSDUCTION; ACTIVATION; PHOSPHORYLATION	The Pas-dependent activation of mitogen-activated protein (MAP) kinase pathways by many receptors coupled to heterotrimeric guanine nucleotide binding proteins (G proteins) requires the activation of Src family tyrosine kinases. Stimulation of beta(2) adrenergic receptors resulted in the assembly of a protein complex containing activated c-Src and the receptor. Src recruitment was mediated by beta-arrestin, which functions as an adapter protein, binding both c-Src and the agonist-occupied receptor. beta-Arrestin 1 mutants, impaired either in c-Src binding or in the ability to target receptors to clathrin-coated pits, acted as dominant negative inhibitors of beta(2) adrenergic receptor-mediated activation of the MAP kinases Erk1 and Erk2. These data suggest that beta-arrestin binding, which terminates receptor-C protein;coupling, also initiates a second wave of signal transduction in which the "desensitized" receptor functions as a critical structural component of a mitogenic signaling complex.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA; Kyoto Pharmaceut Univ, Inst Mol & Cellular Biol, Yamashina Ku, Kyoto 607, Japan; Glaxo Wellcome Res & Dev, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University; Duke University; Western University (University of Western Ontario); University of California System; University of California San Francisco; Kyoto Pharmaceutical University; GlaxoSmithKline	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Maudsley, Stuart/AAV-9929-2021; Maudsley, Stuart/Q-4782-2019; Lefkowitz, Robert/AAW-2649-2021; Della Rocca, Gregory/AAM-5281-2021	Maudsley, Stuart/0000-0002-1868-184X; Miller, William/0000-0001-6900-4884; Luttrell, Louis/0000-0003-2805-6949	NHLBI NIH HHS [HL16037] Funding Source: Medline; NIDDK NIH HHS [DK55524, DK02352] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002352, R01DK055524, R56DK055524] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHEN YH, 1994, J BIOL CHEM, V269, P27372; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; FAURE M, 1994, J BIOL CHEM, V269, P7851; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GARANOVSKAYA MN, 1996, BIOCHEMISTRY-US, V35, P13716; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; LUTTRELL LM, UNPUB; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SATOH T, 1992, J BIOL CHEM, V267, P24149; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WINITZ S, 1993, J BIOL CHEM, V268, P19196; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	47	1196	1227	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					655	661		10.1126/science.283.5402.655	http://dx.doi.org/10.1126/science.283.5402.655			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924018				2022-12-28	WOS:000078324400032
J	Conlon, I; Raff, M				Conlon, I; Raff, M			Size control in animal development	CELL			English	Review							DEPENDENT KINASE INHIBITOR; OLIGODENDROCYTE PRECURSOR CELLS; DROSOPHILA EMBRYOGENESIS; PHASE PROGRESSION; NERVOUS-SYSTEM; MICE LACKING; GROWTH; CYCLE; DEATH; PROLIFERATION		UCL, Dev Neurobiol Programme, MRC, Mol Cell Biol Lab, London WC1E 6BT, England	University of London; University College London	Conlon, I (corresponding author), UCL, Dev Neurobiol Programme, MRC, Mol Cell Biol Lab, Mortimer St, London WC1E 6BT, England.	i.conlon@ucl.ac.uk						Altman P.I., 1961, BLOOD OTHER BODY FLU; BARRES BA, 1994, NEURON, V12, P935, DOI 10.1016/0896-6273(94)90305-0; Baserga R, 1985, BIOL CELL REPROD; BERGMANN A, 1998, IN PRESS ONCOGENE; BIGGERS J. D., 1971, Methods in mammalian embryology, P86; BOSCH TCG, 1984, DEV BIOL, V104, P161, DOI 10.1016/0012-1606(84)90045-9; Britton JS, 1998, DEVELOPMENT, V125, P2149; Brockes JP, 1997, SCIENCE, V276, P81, DOI 10.1126/science.276.5309.81; BROOKS RF, 1988, J CELL SCI, V90, P601; BRYANT PJ, 1984, Q REV BIOL, V59, P387, DOI 10.1086/414040; BRYANT PJ, 1990, J CELL SCI, P169; Burne JF, 1996, J NEUROSCI, V16, P2064; BURSCH W, 1985, VIRCHOWS ARCH B, V50, P153; Calver AR, 1998, NEURON, V20, P869, DOI 10.1016/S0896-6273(00)80469-9; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUBOULE D, 1995, CURR OPIN GENET DEV, V5, P525, DOI 10.1016/0959-437X(95)90058-O; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FANKHAUSER G, 1952, INT REV CYTOL, V1, P165, DOI 10.1016/S0074-7696(08)60010-8; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Franklin JL, 1998, J CELL BIOL, V142, P1313, DOI 10.1083/jcb.142.5.1313; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; Gao FB, 1997, CURR BIOL, V7, P152, DOI 10.1016/S0960-9822(06)00060-1; Gao FB, 1997, J CELL BIOL, V138, P1367, DOI 10.1083/jcb.138.6.1367; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; Goss R.J., 1978, PHYSL GROWTH; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HENERY CC, 1992, DEV BIOL, V152, P233, DOI 10.1016/0012-1606(92)90131-Y; Henrique D, 1997, CURR BIOL, V7, P661, DOI 10.1016/S0960-9822(06)00293-4; HEYNER S, 1994, BIOESSAYS, V16, P55, DOI 10.1002/bies.950160109; Hong Y, 1998, DEVELOPMENT, V125, P3585; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; Johnston LA, 1998, NATURE, V394, P82, DOI 10.1038/27925; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; MADHAVAN MM, 1977, ROUX ARCH DEV BIOL, V183, P269, DOI 10.1007/BF00848459; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; METCALF D, 1963, AUST J EXP BIOL MED, V41, P437, DOI 10.1038/icb.1963.64; METCALF D, 1964, TRANSPLANTATION, V2, P387, DOI 10.1097/00007890-196405000-00008; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nijhout HF, 1998, P NATL ACAD SCI USA, V95, P3685, DOI 10.1073/pnas.95.7.3685; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Nurse P., 1985, P185; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; PURVES D, 1988, NATURE, V336, P123, DOI 10.1038/336123a0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROSSANT J, 1976, J EMBRYOL EXP MORPH, V36, P283; RUMYANTSEV PP, 1991, CARDIOLOGY, P231; Serrano N, 1997, CURR BIOL, V7, pR186, DOI 10.1016/S0960-9822(97)70085-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Simpson P, 1997, CURR OPIN GENET DEV, V7, P537, DOI 10.1016/S0959-437X(97)80083-4; TARKOWSKI AK, 1959, NATURE, V184, P1286, DOI 10.1038/1841286a0; TESSIER G, 1939, TABULAE BIOL, V19, P1; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Weigmann K, 1997, DEVELOPMENT, V124, P3555; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Wolpert L, 1996, CURR BIOL, V6, P2, DOI 10.1016/S0960-9822(02)00401-3; ZETTERBERG A, 1984, CYTOMETRY, V5, P368, DOI 10.1002/cyto.990050413; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	79	586	606	0	48	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 22	1999	96	2					235	244		10.1016/S0092-8674(00)80563-2	http://dx.doi.org/10.1016/S0092-8674(00)80563-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	160VM	9988218	Bronze			2022-12-28	WOS:000078252200007
J	Hutloff, A; Dittrich, AM; Beier, KC; Eljaschewitsch, B; Kraft, R; Anagnostopoulos, I; Kroczek, RA				Hutloff, A; Dittrich, AM; Beier, KC; Eljaschewitsch, B; Kraft, R; Anagnostopoulos, I; Kroczek, RA			ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28	NATURE			English	Article							IMMUNOGLOBULIN SUPERFAMILY; DIFFERENTIATION FACTORS; GERMINAL-CENTERS; CTLA-4; ACTIVATION; ANTIGEN; COSTIMULATION; RECOGNITION; EXPRESSION; LIGATION	The T-cell-specific cell-surface receptors CD28 and CTLA-4 are important regulators of the immune system. CD28 potently enhances those T-cell functions that are essential for an effective antigen-specific immune response(1-5), and the homologous CTLA-4 counterbalances the CD28-mediated signals and thus prevents an otherwise fatal overstimulation of the lymphoid system(6-9). Here we report the identification of a third member of this family of molecules, inducible co-stimulator (ICOS), which is a homodimeric protein of relative molecular mass 55,000-60,000 (M-r 55K-60K). Matching CD28 in potency, ICOS enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, upregulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B cells. Unlike the constitutively expressed CD28, ICOS has to be de novo induced on the T-cell surface, does not upregulate the production of interleukin-2, but superinduces the synthesis of interleukin-10, a B-cell-differentiation factor. In vivo, ICOS is highly expressed on tonsillar T cells, which are closely associated with B cells in the apical light zone of germinal centres, the site of terminal B-cell maturation. Our results indicate that ICOS is another major regulator of the adaptive immune system.	Robert Koch Inst, D-13353 Berlin, Germany; Max Delbruck Centrum, Dept Prot Chem, D-13122 Berlin, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pathol, D-12200 Berlin, Germany	Robert Koch Institute; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kroczek, RA (corresponding author), Robert Koch Inst, Nordufer 20, D-13353 Berlin, Germany.		Dittrich, Anna/GRY-6738-2022; Hutloff, Andreas/D-1781-2014; Dittrich, Anna Maria/M-5640-2013	Hutloff, Andreas/0000-0002-0572-8151; 				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; Choe J, 1998, EUR J IMMUNOL, V28, P508, DOI 10.1002/(SICI)1521-4141(199802)28:02<508::AID-IMMU508>3.0.CO;2-I; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; HARA T, 1985, J EXP MED, V161, P1513, DOI 10.1084/jem.161.6.1513; JACOBS KA, 1988, NUCLEIC ACIDS RES, V16, P4637, DOI 10.1093/nar/16.10.4637; JUNG LKL, 1984, J EXP MED, V160, P1597, DOI 10.1084/jem.160.5.1597; Kindler V, 1997, J IMMUNOL, V159, P2085; KROCZEK RA, 1994, IMMUNOL REV, V138, P39, DOI 10.1111/j.1600-065X.1994.tb00846.x; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LUCAS PJ, 1995, J IMMUNOL, V154, P5757; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; NAKANISHI K, 1984, J EXP MED, V160, P1605, DOI 10.1084/jem.160.6.1605; NUNES J, 1993, INT IMMUNOL, V5, P311, DOI 10.1093/intimm/5.3.311; PEACH RJ, 1994, J EXP MED, V180, P2049, DOI 10.1084/jem.180.6.2049; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Truneh A, 1996, MOL IMMUNOL, V33, P321, DOI 10.1016/0161-5890(95)00077-1; Tsiagbe VK, 1996, CRIT REV IMMUNOL, V16, P381; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	30	1108	1341	0	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 21	1999	397	6716					263	266		10.1038/16717	http://dx.doi.org/10.1038/16717			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159QH	9930702				2022-12-28	WOS:000078184800055
J	Bloche, MG				Bloche, MG			Clinical loyalties and the social purposes of medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MANAGED-CARE; PHYSICIANS; ETHICS	Physicians increasingly face conflicts between the ethic of undivided loyalty to patients and pressure to use clinical methods and judgment for social purposes and on behalf of third parties. The principal legal and ethical paradigms by which these conflicts are managed are inadequate, because they either deny or unsuccessfully finesse the reality of contradiction between fidelity to patients and society's other expectations of medicine. This reality needs to be more squarely acknowledged. The challenge for ethics and law is not to resolve this tension-an impossible task-but to mediate it in myriad clinical circumstances in a way that preserves the primacy of keeping faith with patients while conceding the legitimacy of society's other expectations of medicine.	Georgetown Johns Hopkins Univ Program Law & Publ H, Washington, DC USA; Georgetown Johns Hopkins Univ Program Law & Publ H, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Bloche, MG (corresponding author), Georgetown Univ, Ctr Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.							Advisory Committee on Human Radiation Experiments, 1995, FIN REP; *AM COLL PHYS, 1994, BREACH TRUST PHYS PA; *AM MED ASS COUNC, 1995, 6A95 CEJA AM MED ASS; *AM MED ASS COUNC, 1992, JAMA-J AM MED ASSOC, V270, P365; *AM PSYCH ASS, 1984, PSYCH SENT PROC; Annas C L, 1996, J Contemp Health Law Policy, V12, P325; APPELBAUM PS, 1990, INT J LAW PSYCHIAT, V13, P249, DOI 10.1016/0160-2527(90)90021-T; Baier Annette, 1994, MORAL PREJUDICES; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; BEECHER H, 1960, NEW ENGL J MED, V274, P1354; BERENSON RA, 1991, HEALTH AFFAIR, V10, P106, DOI 10.1377/hlthaff.10.4.106; BLOCHE MG, 1993, INT J LAW PSYCHIAT, V16, P301, DOI 10.1016/0160-2527(93)90002-V; Bloche MG, 1998, ANN INTERN MED, V128, P688, DOI 10.7326/0003-4819-128-8-199804150-00014; BLOCHE MG, 1996, HIV AIDS CHILDBEARIN; BOOTH W, 1993, WASHINGTON POST 1007, pA1; *BRIT MED ASS, 1982, MED BETR PART DOCT H; *BUR NAT AFF, 1997, HLTH LAW REPORTER, V6, P1154; CALAMARI JD, 1987, LAW CONTRACTS; Centers for Disease Control, 1994, MORBIDITY MORTALITY, V43, P1; DANCOHEN M, 1992, HARVARD LAW REV, V105, P959, DOI 10.2307/1341517; DIAMOND BL, 1961, STANFORD LAW REV, V14, P59, DOI 10.2307/1226566; DOBBINS R, 1995, J HEALTH CARE POOR U, V5, P214; DUKEMINIER J, 1984, WILLS TRUST ESTATES; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; FADER RR, 1986, HIST THEORY INFORMED; FINE PEM, 1993, EPIDEMIOL REV, V15, P265, DOI 10.1093/oxfordjournals.epirev.a036121; FLEMING JG, 1974, CALIF LAW REV, V62, P1025, DOI 10.2307/3479754; FRIED C, 1976, YALE LAW J, V85, P1060, DOI 10.2307/795584; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; GOSTIN LO, 1995, CORNELL LAW REV, V80, P451; Gunn J, 1998, CURR OPIN PSYCHIATR, V11, P3, DOI 10.1097/00001504-199801000-00002; HALL MA, 1992, U PENN LAW REV, V140, P1637, DOI 10.2307/3312428; HALL MA, 1988, U PENN LAW REV, V137, P431, DOI 10.2307/3312252; HAVINGHURT C, 1995, HLTH CARE CHOICES PR; HELLER J, 1972, NY TIMES        0726, P1; HILMAN AL, 1991, HLTH AFF MILLWOOD, V10, P138; JONSEN AR, 1977, PHILOS MED ETHICS; KATZ J, 1986, SILENT WORLD DOCTOR; Laumann EO, 1997, JAMA-J AM MED ASSOC, V277, P1052, DOI 10.1001/jama.277.13.1052; LEVINSKY NG, 1984, NEW ENGL J MED, V311, P1573, DOI 10.1056/NEJM198412133112412; Mashaw JL., 1983, BUREAUCRATIC JUSTICE; Mechanic D, 1998, J HEALTH POLIT POLIC, V23, P661; Nussbaum M.C., 1990, LOVES KNOWLEDGE; PELLEGRINO ED, 1993, INT J LAW PSYCHIAT, V16, P371, DOI 10.1016/0160-2527(93)90004-X; Pelligrino E D, 1986, J Contemp Health Law Policy, V2, P23; Posner R.A., 1995, OVERCOMING LAW; Proctor R. N., 1988, RACIAL HYGIENE; PROSS C, 1991, VALUE HUMAN BEING ME; PROSSER WILLIAM L., 1964, HDB LAW TORTS; RAPPEPORT J, 1981, PSYCHIAT ETHICS; Rodwin M. A., 1993, MED MONEY MORALS PHY; RODWIN MA, 1995, NEW ENGL J MED, V332, P604, DOI 10.1056/NEJM199503023320913; ROTHMAN D, 1991, STRANGERS BEDSIDE; ROTHSTEIN DC, 1995, NEWSLETT AM ACAD PSY, V16, P301; SADOFF R, 1990, ETHICAL PRACTICE PSY; SHORTELL SM, 1994, HEALTH AFFAIR, V13, P46, DOI 10.1377/hlthaff.13.5.46; STONE AA, 1985, NEW ENGL J MED, V312, P309, DOI 10.1056/NEJM198501313120511; Stone Alan, 1984, LAW PSYCHIAT MORALIT; STRATTON KR, 1994, JAMA-J AM MED ASSOC, V271, P1602, DOI 10.1001/jama.271.20.1602; *UN GAOR, 1985, UN GAOR 39 SESS NEW; Wertheimer Alan, 1987, COERCION; WING J, 1981, PSYCHIATRIC ETHICS; WOLFSBERGER W, 1967, SCIENCE, V15, P47; 1976, STEDMANS MED DICT; [No title captured]	65	75	78	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1999	281	3					268	274		10.1001/jama.281.3.268	http://dx.doi.org/10.1001/jama.281.3.268			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	157GK	9918483				2022-12-28	WOS:000078052800033
J	Villarino, ME; Burman, W; Wang, YC; Lundergan, L; Catanzaro, A; Bock, N; Jones, C; Nolan, C				Villarino, ME; Burman, W; Wang, YC; Lundergan, L; Catanzaro, A; Bock, N; Jones, C; Nolan, C			Comparable specificity of 2 commercial tuberculin reagents in persons at low risk for tuberculous infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VARIABILITY	Context One or both commercial tuberculin skin test reagents (Aplisol and Tubersol) may have a high rate of false-positive reactions. Objective To compare the reaction size and specificity of skin testing with Aplisol, Tubersol, and the standard purified protein derivative (PPD-S1), Design Double-blind trial, conducted between May 14, 1997, and October 28, 1997, in which each individual received 4 tuberculin skin reagents at sites assigned at random. Setting Health departments and universities in 6 US cities. Participants A total of 1555 persons at low risk of latent tuberculosis infection. Intervention Simultaneous skin tests with Aplisol, Tubersol, PPD-S1, and either a second PPD-S1 or PPD-S2 (a proposed new standard). Main Outcome Measure Reaction size at each injection site measured by 2 investigators blinded to type of reagent. Results Aplisol produced slightly larger reactions than Tubersol, but this difference did not significantly change skin test interpretation. The mean +/- SD reaction sizes were 3.4 +/- 4.2 mm with Aplisol, 2.1 +/- 3.2 mm with Tubersol, and 2.5 +/- 3.6 mm with PPD-S1. Assuming that all participants were uninfected and using a 10-mm cutoff, the specificities of the tests were high: Aplisol, 98.2%; Tubersol, 99.2%; and PPD-S1, 98.9%, Significant variability was not detected in interobserver, host, and lot-to-lot reagent comparisons. Conclusion Using a cutoff of at least 10 mm, testing with 3 different PPD reagents resulted in similar numbers of uninfected persons being correctly classified.	Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA; Univ Arizona, Dept Campus Hlth Serv, Tucson, AZ USA; Dept Publ Hlth, Denver, CO USA; Univ Calif San Diego, Div Pulm & Crit Care Med, San Diego, CA 92103 USA; Emory Univ, Div Infect Dis, Atlanta, GA 30322 USA; Marion Cty Hlth Dept, Indianapolis, IN USA; Seattle King Cty Dept Publ Hlth, Seattle, WA USA	Centers for Disease Control & Prevention - USA; University of Arizona; University of California System; University of California San Diego; Emory University	Villarino, ME (corresponding author), 1600 Clifton Rd NE,Mailstop E-10, Atlanta, GA 30333 USA.							BLACKSHEAR J, 1983, AM REV RESPIR DIS, V127, P254; Bloch A.B., 1995, MMWR-MORBID MORTAL W, V44, P18; CHAPARAS SD, 1985, AM REV RESPIR DIS, V132, P175; DEAN AG, 1994, EPI INFO VERSION 6; Grabau JC, 1995, PUBLIC HEALTH REP, V110, P703; LAMPHEAR BP, 1994, J INFECT DIS, V169, P703; LIFSON AR, 1993, J INFECT DIS, V168, P1048, DOI 10.1093/infdis/168.4.1048; RUPP ME, 1994, J INFECT DIS, V169, P1174, DOI 10.1093/infdis/169.5.1174; *SAS I INC, 1989, SAS STAT US GUID VER, V1; SAS INSTITUTE INC., 1989, SAS STAT US GUID VER, V2; SHANDS JW, 1994, INFECT CONT HOSP EP, V15, P758; WURTZ R, 1994, INFECT CONT HOSP EP, V15, P516	12	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					169	171		10.1001/jama.281.2.169	http://dx.doi.org/10.1001/jama.281.2.169			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155VJ	9917121				2022-12-28	WOS:000077966800038
J	Jin, XW; Shearman, LP; Weaver, DR; Zylka, MJ; De Vries, GJ; Reppert, SM				Jin, XW; Shearman, LP; Weaver, DR; Zylka, MJ; De Vries, GJ; Reppert, SM			A molecular mechanism regulating rhythmic output from the suprachiasmatic circadian clock	CELL			English	Article							VASOPRESSIN-DEFICIENT RATS; DROSOPHILA PERIOD GENE; MESSENGER-RNA; ENDOGENOUS VASOPRESSIN; NEUROSPORA-CRASSA; IN-VITRO; EXPRESSION; NUCLEUS; NEURONS; CLONING	We examined the transcriptional regulation of the clock-controlled arginine vasopressin gene in the suprachiasmatic nuclei (SCN). A core clock mechanism in mouse SCN appears to involve a transcriptional feedback loop in which CLOCK and BMAL1 are positive regulators and three mPeriod (mPer) genes are involved in negative feedback. We show that the RNA rhythm of each mPer gene is severely blunted in Clock/ Clock mice. The vasopressin RNA rhythm is abolished in the SCN of Clock/Clock animals, leading to markedly decreased peptide levels. Luciferase reporter gene assays show that CLOCK-BMAL1 heterodimers act through an E box enhancer in the vasopressin gene to activate transcription; this activation can be inhibited by the mPER and mTIM proteins. These data indicate that the transcriptional machinery of the core clockwork directly regulates a clock-controlled output rhythm.	Massachusetts Gen Hosp, Lab Dev Chronobiol, Serv Pediat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Univ Massachusetts, Dept Psychol, Ctr Neuroendocrine Studies, Amherst, MA 01003 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Amherst	Reppert, SM (corresponding author), Massachusetts Gen Hosp, Lab Dev Chronobiol, Serv Pediat, Boston, MA 02114 USA.	reppert@helix.mgh.harvard.edu	Weydahl, Andi/C-6391-2008; Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Weaver, David/0000-0001-7941-6719; de Vries, Geert/0000-0002-1263-3775	NICHD NIH HHS [R37 HD14427] Funding Source: Medline; NIMH NIH HHS [MH12067, MH11547] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD014427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH011547, F32MH012067] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; BellPedersen D, 1996, P NATL ACAD SCI USA, V93, P13096, DOI 10.1073/pnas.93.23.13096; BROWN MH, 1989, PHYSIOL BEHAV, V46, P759, DOI 10.1016/0031-9384(89)90364-8; CARTER DA, 1992, MOL BRAIN RES, V12, P315, DOI 10.1016/0169-328X(92)90133-V; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1998, CURR OPIN GENET DEV, V8, P400, DOI 10.1016/S0959-437X(98)80109-3; FERRIS CF, 1984, SCIENCE, V224, P521, DOI 10.1126/science.6538700; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GROBLEWSKI TA, 1981, BRAIN RES BULL, V6, P125, DOI 10.1016/S0361-9230(81)80036-6; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARA Y, 1990, MOL BRAIN RES, V8, P319, DOI 10.1016/0169-328X(90)90045-F; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Ingram CD, 1996, NEUROSCIENCE, V75, P635, DOI 10.1016/0306-4522(96)00274-6; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Iwasaki Y, 1997, ENDOCRINOLOGY, V138, P5266, DOI 10.1210/en.138.12.5266; Kalsbeek A, 1996, J NEUROSCI, V16, P5555, DOI 10.1523/jneurosci.16-17-05555.1996; Kalsbeek A, 1996, J NEUROENDOCRINOL, V8, P299, DOI 10.1046/j.1365-2826.1996.04597.x; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; Leloup JC, 1998, J BIOL RHYTHM, V13, P70, DOI 10.1177/074873098128999934; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; LOROS J, 1995, SEMIN NEUROSCI, V7, P3, DOI 10.1016/1044-5765(95)90012-8; LOROS JJ, 1991, MOL CELL BIOL, V11, P558, DOI 10.1128/MCB.11.1.558; McNeil GP, 1998, NEURON, V20, P297, DOI 10.1016/S0896-6273(00)80457-2; MIHAI R, 1994, NEUROSCIENCE, V62, P783, DOI 10.1016/0306-4522(94)90476-6; MIHAI R, 1994, NEUROSCI LETT, V179, P95, DOI 10.1016/0304-3940(94)90943-1; NINKINA NN, 1995, MOL BRAIN RES, V33, P233; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; REPPERT SM, 1987, TRENDS NEUROSCI, V10, P76, DOI 10.1016/0166-2236(87)90029-4; Reppert SM, 1997, CELL, V89, P487, DOI 10.1016/S0092-8674(00)80229-9; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; RIVKEES SA, 1992, BRAIN RES, V598, P332, DOI 10.1016/0006-8993(92)90203-L; Rouyer F, 1997, EMBO J, V16, P3944, DOI 10.1093/emboj/16.13.3944; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Schaffer R, 1998, CELL, V93, P1219, DOI 10.1016/S0092-8674(00)81465-8; SCHRIER RW, 1985, VASOPRESSIN; SCHWARTZ WJ, 1987, P NATL ACAD SCI USA, V84, P1694, DOI 10.1073/pnas.84.6.1694; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; SHEARMAN LP, IN PRESS NEUROSCIENC; Shipley MT, 1989, NEUROANATOMICAL TRAC, V2, P331, DOI [10.1007/978-1-4757-2055-6, DOI 10.1007/978-1-4757-2055-6]; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Takahata S, 1998, BIOCHEM BIOPH RES CO, V248, P789, DOI 10.1006/bbrc.1998.9012; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; TOMINAGA K, 1992, NEUROREPORT, V3, P809, DOI 10.1097/00001756-199209000-00022; UHL GR, 1986, SCIENCE, V232, P390, DOI 10.1126/science.3961487; VanGelder RN, 1995, CURR BIOL, V5, P1424, DOI 10.1016/S0960-9822(95)00280-6; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; WEAVER DR, 1993, MOL BRAIN RES, V20, P313, DOI 10.1016/0169-328X(93)90058-W; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; ZHOU L, 1994, ENDOCRINOLOGY, V134, P2622, DOI 10.1210/en.134.6.2622; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	61	738	755	0	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 8	1999	96	1					57	68		10.1016/S0092-8674(00)80959-9	http://dx.doi.org/10.1016/S0092-8674(00)80959-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989497	Bronze			2022-12-28	WOS:000078023200008
J	Iizasa, K; Fiske, RS; Ishizuka, O; Yuasa, M; Hashimoto, J; Ishibashi, J; Naka, J; Horii, Y; Fujiwara, Y; Imai, A; Koyama, S				Iizasa, K; Fiske, RS; Ishizuka, O; Yuasa, M; Hashimoto, J; Ishibashi, J; Naka, J; Horii, Y; Fujiwara, Y; Imai, A; Koyama, S			A Kuroko-type polymetallic sulfide deposit in a submarine silicic caldera	SCIENCE			English	Article							EAST PACIFIC RISE; IZU-OGASAWARA ARC; NORTHWESTERN PACIFIC; FLOOR SEDIMENTS; RIDGE; BASIN; GOLD	Manned submersible studies have delineated a large and actively growing Kuroko-type volcanogenic massive sulfide deposit 400 kilometers south of Tokyo in Myojin Knell submarine caldera, The sulfide body is Located on the caldera floor at a depth of 1210 to 1360 meters, has an area of 400 by 400 by 30 meters, and is notably rich in gold and silver. The discovery of a Large Kuroko-type polymetallic sulfide deposit in this are-front caldera raises the possibility that the numerous unexplored submarine silicic calderas elsewhere might have similar deposits.	Smithsonian Inst, Washington, DC 20560 USA; Geol Survey Japan, Ibaraki, Osaka 3058567, Japan; Japan Marine Sci & Technol Ctr 2 15, Yokosuka, Kanagawa 2370061, Japan; Univ Tokyo, Tokyo 1330033, Japan; Tokyo Metropolitan Fisheries Stn, Tokyo 1001511, Japan	Smithsonian Institution; National Institute of Advanced Industrial Science & Technology (AIST); Japan Agency for Marine-Earth Science & Technology (JAMSTEC); University of Tokyo	Fiske, RS (corresponding author), Smithsonian Inst, MRC-119, Washington, DC 20560 USA.	rfiske@volcano.si.edu		Imai, Akira/0000-0002-3058-9915				[Anonymous], [No title captured]; BODNAR RJ, 1984, ECON GEOL, V79, P141, DOI 10.2113/gsecongeo.79.1.141; CRAWFORD AM, 1984, MAR MINING, V4, P337; EMBLEY RW, 1988, CAN MINERAL, V26, P517; FISKE RS, 1995, P JAMSTEC S DEEP SEA, V11, P315; FOUQUET Y, 1993, ECON GEOL BULL SOC, V88, P2018, DOI 10.2113/gsecongeo.88.8.2018; FOUQUET Y, 1993, ECON GEOL BULL SOC, V88, P2154, DOI 10.2113/gsecongeo.88.8.2154; FOUQUET Y, 1988, MAR GEOL, V84, P145, DOI 10.1016/0025-3227(88)90098-9; HALBACH P, 1989, NATURE, V338, P496, DOI 10.1038/338496a0; HANNINGTON M, 1991, MAR GEOL, V101, P217, DOI 10.1016/0025-3227(91)90073-D; HANNINGTON MD, 1988, NATURE, V333, P64, DOI 10.1038/333064a0; IIZASA K, 1993, MAR GEOL, V112, P271, DOI 10.1016/0025-3227(93)90173-S; Iizasa K, 1995, MAR GEORESOUR GEOTEC, V13, P339, DOI 10.1080/10641199509388292; ISHIBASHI J, 1992, CHIKYU, V14, P489; Murakami F., 1997, J GEOGR, V106, P70; Ohmoto H, 1996, ORE GEOL REV, V10, P135, DOI 10.1016/0169-1368(95)00021-6; Ohmoto H, 1979, GEOCHEMISTRY HYDROTH, V10, P509; OHMOTO H, 1983, EC GEOL MON, V5, P1; REES CE, 1978, GEOCHIM COSMOCHIM AC, V42, P377, DOI 10.1016/0016-7037(78)90268-5; SINGER DA, 1986, US GEOLOGICAL SURVEY, V1693, P190; UEDA A, 1984, GEOCHIM COSMOCHIM AC, V48, P1837, DOI 10.1016/0016-7037(84)90037-1; Yuasa M., 1995, B VOLCANOLOGICAL SOC, V40, P277; YUASA M, 1991, J GEOGR, V100, P458	23	146	156	3	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					975	977		10.1126/science.283.5404.975	http://dx.doi.org/10.1126/science.283.5404.975			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974388				2022-12-28	WOS:000078574800045
J	Johnson, SA; Ollivier, PJ; Mallouk, TE				Johnson, SA; Ollivier, PJ; Mallouk, TE			Ordered mesoporous polymers of tunable pore size from colloidal silica templates	SCIENCE			English	Article							POLYFURFURYL ALCOHOL; POLYVINYL ACETATE; MOLECULAR-SIEVES; LAMELLAE; MONTMORILLONITE; NANOSTRUCTURES; CARBONIZATION; NANOMATERIALS; REPLICATION; FILM	Ordered mesoporous polymers have been prepared by replication of colloidal crystals made from silica spheres 35 nanometers in diameter. The pores in the colloidal crystals were filled with divinylbenzene (DVB), ethyleneglycol dimethacrylate (EDMA), or a mixture of the two. Polymerization and subsequent dissolution of the silica template Leaves a polycrystalline network of interconnected pores. When mixtures of DVB and EDMA are used, the pore size of the polymer replicas can be varied continuously between 35 and 15 nanometers because the polymer shrinks when the silica template is removed.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Mallouk, TE (corresponding author), Penn State Univ, Dept Chem, 152 Davey Lab, University Pk, PA 16802 USA.	tom@chem.psu.edu	Mallouk, Thomas E/K-7391-2012	Mallouk, Thomas E/0000-0003-4599-4208	NIGMS NIH HHS [GM-43844] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGSHAW SA, 1995, SCIENCE, V269, P1242, DOI 10.1126/science.269.5228.1242; Bandosz TJ, 1996, CHEM MATER, V8, P2023, DOI 10.1021/cm960233i; BLATTER F, 1988, SURF SCI, V203, P571, DOI 10.1016/0039-6028(88)90099-4; Chou SY, 1996, SCIENCE, V272, P85, DOI 10.1126/science.272.5258.85; DHAL PK, 1991, J AM CHEM SOC, V113, P7417, DOI 10.1021/ja00019a046; Holland BT, 1998, SCIENCE, V281, P538, DOI 10.1126/science.281.5376.538; Imhof A, 1997, NATURE, V389, P948, DOI 10.1038/40105; Johnson SA, 1998, J MATER CHEM, V8, P13, DOI 10.1039/a706791g; Johnson SA, 1997, CHEM MATER, V9, P2448, DOI 10.1021/cm9703278; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; KYOTANI T, 1994, CARBON, V32, P627, DOI 10.1016/0008-6223(94)90082-5; KYOTANI T, 1988, NATURE, V331, P331, DOI 10.1038/331331a0; KYOTANI T, 1994, CHEM MATER, V6, P2138, DOI 10.1021/cm00047a039; Lakshmi BB, 1997, CHEM MATER, V9, P857, DOI 10.1021/cm9605577; MARTIN CR, 1995, ACCOUNTS CHEM RES, V28, P61, DOI 10.1021/ar00050a002; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; Martin CR, 1996, CHEM MATER, V8, P1739, DOI 10.1021/cm960166s; MASUDA H, 1995, SCIENCE, V268, P1466, DOI 10.1126/science.268.5216.1466; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; OLIVIER JP, 1993, CHARACTERIZATION POR; OSSEOASARE K, 1990, COLLOID SURFACE, V50, P321, DOI 10.1016/0166-6622(90)80273-7; Ozin GA, 1997, ACCOUNTS CHEM RES, V30, P17, DOI 10.1021/ar960021r; Park SH, 1998, ADV MATER, V10, P1045, DOI 10.1002/(SICI)1521-4095(199809)10:13<1045::AID-ADMA1045>3.3.CO;2-U; ROY DM, 1974, NATURE, V247, P220, DOI 10.1038/247220a0; SCHIRATO BS, 1995, SCIENCE, V267, P369, DOI 10.1126/science.267.5196.369; Sokol PE, 1996, NATURE, V379, P616, DOI 10.1038/379616a0; SONOBE N, 1990, CARBON, V28, P483, DOI 10.1016/0008-6223(90)90042-W; SONOBE N, 1991, CARBON, V29, P61, DOI 10.1016/0008-6223(91)90095-Z; SONOBE N, 1988, CARBON, V26, P573, DOI 10.1016/0008-6223(88)90158-3; SONOBE N, 1988, J PHYS CHEM-US, V92, P7029, DOI 10.1021/j100335a037; van Blaaderen A, 1998, SCIENCE, V282, P887; Velev OD, 1997, NATURE, V389, P447, DOI 10.1038/38921; WEBER JN, 1971, NATURE, V233, P337, DOI 10.1038/233337a0; WHITE RL, 1972, SCIENCE, V176, P1922; Wijnhoven JEGJ, 1998, SCIENCE, V281, P802, DOI 10.1126/science.281.5378.802; WU CG, 1994, SCIENCE, V266, P1013, DOI 10.1126/science.266.5187.1013; WU CG, 1994, SCIENCE, V264, P1757, DOI 10.1126/science.264.5166.1757; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G; Zakhidov AA, 1998, SCIENCE, V282, P897, DOI 10.1126/science.282.5390.897; Zhao DY, 1998, J AM CHEM SOC, V120, P6024, DOI 10.1021/ja974025i	40	596	657	3	297	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 12	1999	283	5404					963	965		10.1126/science.283.5404.963	http://dx.doi.org/10.1126/science.283.5404.963			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974384				2022-12-28	WOS:000078574800041
J	Rodriguez, FI; Esch, JJ; Hall, AE; Binder, BM; Schaller, GE; Bleecker, AB				Rodriguez, FI; Esch, JJ; Hall, AE; Binder, BM; Schaller, GE; Bleecker, AB			A copper cofactor for the ethylene receptor ETR1 from Arabidopsis	SCIENCE			English	Article							BINDING; GENE; SIMILARITY; COMPLEXES; PLANTS	The ETR1 receptor from Arabidopsis binds the gaseous hormone ethylene, A copper ion associated with the ethylene-binding domain is required for high-affinity ethylene-binding activity. A missense mutation in the domain that renders the plant insensitive to ethylene eliminates both ethylene binding and the interaction of topper with the receptor. A sequence from the genome of the cyanobacterium Synechocystis sp, strain 6803 that shows homology to the ethylene-binding domain of ETR1 encodes a functional ethylene-binding protein. On the basis of sequence conservation between the Arabidopsis and the cyanobacterial ethylene-binding domains and on in vitro mutagenesis of ETR1, a structural model for this copper-based ethylene sensor domain is presented.	Univ Wisconsin, Dept Bot, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bleecker, AB (corresponding author), Univ Wisconsin, Dept Bot, 430 Lincoln Dr, Madison, WI 53706 USA.			Binder, Brad/0000-0002-8172-2034				Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; BENGOCHEA T, 1980, PLANTA, V148, P397, DOI 10.1007/BF00388129; BEYER EM, 1976, PLANT PHYSIOL, V58, P268, DOI 10.1104/pp.58.3.268; BURG SP, 1965, SCIENCE, V148, P1190, DOI 10.1126/science.148.3674.1190; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; HALL AJ, UNPUB; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; MUNAKATA M, 1986, INORG CHEM, V25, P2622, DOI 10.1021/ic00235a027; RODRIGUEZ FJM, UNPUB; SCHALLER GE, 1995, J BIOL CHEM, V270, P12526, DOI 10.1074/jbc.270.21.12526; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; SISLER EC, 1979, PLANT PHYSIOL, V64, P538, DOI 10.1104/pp.64.4.538; Smith P. M., 1988, Technical Services Quarterly, V6, P3, DOI 10.1300/J124v06n01_02; THOMPSON JS, 1983, J AM CHEM SOC, V105, P3522, DOI 10.1021/ja00349a026; Wilde A, 1997, FEBS LETT, V406, P89, DOI 10.1016/S0014-5793(97)00248-2; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807; Wilmotte A., 1994, MOL BIOL CYANOBACTER, P1; YU JP, 1995, PLANT MOL BIOL, V29, P331, DOI 10.1007/BF00043656; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	21	466	501	2	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					996	998		10.1126/science.283.5404.996	http://dx.doi.org/10.1126/science.283.5404.996			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974395				2022-12-28	WOS:000078574800052
J	Bodenheimer, T				Bodenheimer, T			The American Health Care System - The movement for improved quality in health care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HOSPITAL MORTALITY; MEDICARE PATIENTS; SURGERY; OUTCOMES; CHOICE; VOLUME											Angell M, 1996, NEW ENGL J MED, V335, P883, DOI 10.1056/NEJM199609193351209; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Berwick DM, 1998, INT J QUAL HEALTH C, V10, P435, DOI 10.1093/intqhc/10.5.435; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; Brook RH, 1996, JAMA-J AM MED ASSOC, V276, P476, DOI 10.1001/jama.276.6.476; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; Chassin MR, 1998, MILBANK Q, V76, P565, DOI 10.1111/1468-0009.00106; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Eddy DM, 1998, HEALTH AFFAIR, V17, P7, DOI 10.1377/hlthaff.17.4.7; Epstein AM, 1998, JAMA-J AM MED ASSOC, V279, P1691, DOI 10.1001/jama.279.21.1691; Gabel JR, 1997, HEALTH AFFAIR, V16, P103, DOI 10.1377/hlthaff.16.5.103; GRUMBACH K, 1995, JAMA-J AM MED ASSOC, V274, P1282, DOI 10.1001/jama.274.16.1282; HANNAN EL, 1992, HEALTH SERV RES, V27, P517; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; JOLLIS JG, 1994, NEW ENGL J MED, V331, P1625, DOI 10.1056/NEJM199412153312406; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; Karp HR, 1998, STROKE, V29, P46, DOI 10.1161/01.STR.29.1.46; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1992, ANNU REV PUBL HEALTH, V13, P363, DOI 10.1146/annurev.pu.13.050192.002051; Leape LL, 1998, JAMA-J AM MED ASSOC, V280, P1444, DOI 10.1001/jama.280.16.1444; Longo DR, 1997, JAMA-J AM MED ASSOC, V278, P1579, DOI 10.1001/jama.278.19.1579; McBride P, 1998, ARCH INTERN MED, V158, P1238, DOI 10.1001/archinte.158.11.1238; McCulloch D K, 1998, Eff Clin Pract, V1, P12; Millenson ML., 1997, DEMANDING MED EXCELL; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; Phillips DP, 1998, LANCET, V351, P643, DOI 10.1016/S0140-6736(98)24009-8; PRAGER LO, 1998, AM MED NEWS     1207, P38; PRAGER LO, 1998, AM MED NEWS     0302, P1; PRAGER LO, 1998, AM MED NEWS     1019, P13; PRAGER LO, 1998, AM MED NEWS     0907, P10; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; Schauffler HH, 1996, HEALTH AFFAIR, V15, P73, DOI 10.1377/hlthaff.15.1.73; WEINER JP, 1995, JAMA-J AM MED ASSOC, V273, P1503, DOI 10.1001/jama.273.19.1503	36	182	182	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1999	340	6					488	492		10.1056/NEJM199902113400621	http://dx.doi.org/10.1056/NEJM199902113400621			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	166HW	9971876				2022-12-28	WOS:000078571000028
J	Dawes, M; Hicks, NR; Fleminger, M; Goldman, D; Hamling, J; Hicks, LJ				Dawes, M; Hicks, NR; Fleminger, M; Goldman, D; Hamling, J; Hicks, LJ			Evidence based case report - Treatment for head lice	BRITISH MEDICAL JOURNAL			English	Review									Hollow Way Med Ctr, Oxford OX4 2NJ, England		Dawes, M (corresponding author), Hollow Way Med Ctr, Oxford OX4 2NJ, England.		dawes, martin/B-1750-2013	Hicks, Nicholas/0000-0002-7214-9678				*BAND, 1997, BANDOLIER, V20, P6; *BRIT MED ASS, 1998, BRIT NAT FORM, P500; BURGESS IF, 1995, BRIT MED J, V311, P752, DOI 10.1136/bmj.311.7007.752; HAYNES B, 1998, BEST EVIDENCE; OSTMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367; *OUP, 1986, OXF TXB MED, V1, P1002; Richardson W S, 1995, ACP J Club, V123, pA12; VANDERSTICHELE RH, 1995, BMJ-BRIT MED J, V311, P604, DOI 10.1136/bmj.311.7005.604; VANSERSTICHELE RH, COCHRANE LIB	9	11	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					385	386		10.1136/bmj.318.7180.385	http://dx.doi.org/10.1136/bmj.318.7180.385			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933206	Green Published			2022-12-28	WOS:000078572600034
J	Hodgson, H				Hodgson, H			Prospects of new therapeutic approaches for Crohn's disease	LANCET			English	Editorial Material							NECROSIS-FACTOR-ALPHA; CHIMERIC MONOCLONAL-ANTIBODY; INFLAMMATORY BOWEL-DISEASE; COLITIS; CA2; INTERLEUKIN-1-BETA; EXPRESSION; COMPLEX		Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Dept Gastroenterol, London W12 0HS, England	Imperial College London	Hodgson, H (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Dept Gastroenterol, London W12 0HS, England.							Bhatti M, 1998, GUT, V43, P40, DOI 10.1136/gut.43.1.40; COMINELLI F, 1990, J CLIN INVEST, V86, P972, DOI 10.1172/JCI114799; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; FEDORAK RN, 1998, GASTROENTEROLOGY, V114, pG3993; GrottrupWolfers E, 1996, EUR J CLIN INVEST, V26, P115, DOI 10.1046/j.1365-2362.1996.123262.x; PODOLSKY DK, 1993, J CLIN INVEST, V92, P372, DOI 10.1172/JCI116575; Reimund JM, 1996, J CLIN IMMUNOL, V16, P144, DOI 10.1007/BF01540912; Satsangi J, 1996, LANCET, V347, P1212, DOI 10.1016/S0140-6736(96)90734-5; Stack WA, 1997, LANCET, V349, P521, DOI 10.1016/S0140-6736(97)80083-9; STEVENS C, 1992, DIGEST DIS SCI, V37, P818, DOI 10.1007/BF01300378; STROBER W, 1993, CELL, V75, P230; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; VANDEVENTER SJH, 1997, GUT, V41, pA68; VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5	14	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 6	1999	353	9151					425	426		10.1016/S0140-6736(98)00304-3	http://dx.doi.org/10.1016/S0140-6736(98)00304-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989709				2022-12-28	WOS:000078572800005
J	Carlson, RW				Carlson, RW			A tenuous carbon dioxide atmosphere on Jupiter's moon Callisto	SCIENCE			English	Article							GALILEAN SATELLITES; GANYMEDE; SPECTROSCOPY; SURFACE; OXYGEN	An off-limb scan of Callisto was conducted by the Galileo near-infrared mapping spectrometer to search for a carbon dioxide atmosphere. Airglow in the carbon dioxide nu(3) band was observed up to 100 kilometers above the surface and indicates the presence of a tenuous carbon dioxide atmosphere with surface pressure of 7.5 x 10(-12) bar and a temperature of about 150 kelvin, close to the surface temperature. A lifetime on the order of 4 years is suggested, based on photoionization and magnetospheric sweeping. Either the atmosphere is transient and was formed recently or some process is currently supplying carbon dioxide to the atmosphere.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Carlson, RW (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr,Mail Stop 183-601, Pasadena, CA 91109 USA.							Barth CA, 1997, GEOPHYS RES LETT, V24, P2147, DOI 10.1029/97GL01927; Carlson R, 1996, SCIENCE, V274, P385, DOI 10.1126/science.274.5286.385; CARLSON RW, 1992, SPACE SCI REV, V60, P457, DOI 10.1007/BF00216865; CARLSON RW, 1976, JUPITER, P433; deGraauw T, 1997, ASTRON ASTROPHYS, V321, pL13; Delitsky ML, 1997, J GEOPHYS RES-PLANET, V102, P16385, DOI 10.1029/97JE01250; DONAHUE TM, 1967, J GEOPHYS RES, V72, P2803, DOI 10.1029/JZ072i011p02803; DUSHMAN S, 1962, SCI FDN VACUUM TECHN, P726; ENCRENAZ T, 1998, JOV SYST GAL SAT SYS; Feuchtgruber H, 1997, NATURE, V389, P159, DOI 10.1038/38236; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; Hall DT, 1998, ASTROPHYS J, V499, P475, DOI 10.1086/305604; HANEL R, 1979, SCIENCE, V206, P952, DOI 10.1126/science.206.4421.952; HAPKE B, 1981, J GEOPHYS RES, V86, P3039, DOI 10.1029/JB086iB04p03039; HERZBERG G, 1945, MOL SPECTRA MOL STRU, V2, P422; HOLSTEIN T, 1947, PHYS REV, V72, P1212, DOI 10.1103/PhysRev.72.1212; HUEBNER WF, 1992, ASTROPHYS SPACE SCI, V195, P1, DOI 10.1007/BF00644558; Johnson RE, 1998, GEOPHYS RES LETT, V25, P3257, DOI 10.1029/98GL02565; Johnson RE, 1997, ASTROPHYS J, V480, pL79, DOI 10.1086/310614; Lellouch E, 1996, ICARUS, V124, P1, DOI 10.1006/icar.1996.0186; McCord TB, 1998, J GEOPHYS RES-PLANET, V103, P8603, DOI 10.1029/98JE00788; McCord TB, 1997, SCIENCE, V278, P271, DOI 10.1126/science.278.5336.271; MOORE JS, UNPUB; PLACZEK G, 1934, HDB RADIOLOGIE, V2, P209; Rothman LS, 1998, J QUANT SPECTROSC RA, V60, P665, DOI 10.1016/S0022-4073(98)00078-8; SHOCK EL, 1993, ICARUS, V106, P464, DOI 10.1006/icar.1993.1185; SMYTHE WD, 1998, 29 LUN PLAN SCI C HO; SPENCER JR, 1987, ICARUS, V69, P297, DOI 10.1016/0019-1035(87)90107-2; TOHMATSU T, 1966, REP IONOS SPACE RES, V20, P418; ZAHNLE K, 1992, ICARUS, V95, P1, DOI 10.1016/0019-1035(92)90187-C	30	79	79	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					820	821		10.1126/science.283.5403.820	http://dx.doi.org/10.1126/science.283.5403.820			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933159				2022-12-28	WOS:000078496800036
J	Miltner, WHR; Braun, C; Arnold, M; Witte, H; Taub, E				Miltner, WHR; Braun, C; Arnold, M; Witte, H; Taub, E			Coherence of gamma-band EEG activity as a basis for associative learning	NATURE			English	Article							CAT VISUAL-CORTEX; CURRENT-DENSITY; RESPONSES; SYNCHRONIZATION; OSCILLATIONS; GENERATION; ATTENTION; STIMULUS; RHYTHMS; HUMANS	Different regions of the brain must communicate with each other to provide the basis for the integration of sensory information, sensory-motor coordination and many other functions that are critical for learning, memory, information processing, perception and the behaviour of organisms. Hebb(1) suggested that this is accomplished by the formation of assemblies of cells whose synaptic linkages are strengthened whenever the cells are activated or 'ignited' synchronously. Hebb's seminal concept has intrigued investigators since its formulation, but the technology to demonstrate its existence had been lacking until the past decade. Precious studies have shown that very fast electroencephalographic activity in the gamma band (20-70 Hz) increases during, and may be involved in, the formation of percepts and memor(2-6), linguistic processing(7), and other behavioural and preceptual functions(8-12). We show here that increased gamma-band activity is also involved in associative learning. In addition, we find that another measure, gamma-band coherence, increases between regions of the brain that receive the two classes of stimuli involved in an associative-learning procedure in humans. An increase in coherence could fulfil the criteria required for the formation of hebbian cell assemblies', binding together parts of the brain that must communicate with one another in order for associative learning to take place. In this way, coherence may be a signature for this and other types of learning.	Univ Jena, Inst Psychol, Dept Biol & Clin Psychol, D-07743 Jena, Germany; Eberhard Kals Univ, Inst Med Psychol & Behav Neurosci, D-72076 Tubingen, Germany; Univ Jena, Inst Med Stat Informat & Documentat, D-07743 Jena, Germany; Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA	Friedrich Schiller University of Jena; Eberhard Karls University of Tubingen; Friedrich Schiller University of Jena; University of Alabama System; University of Alabama Birmingham	Miltner, WHR (corresponding author), Univ Jena, Inst Psychol, Dept Biol & Clin Psychol, Steiger 3-1, D-07743 Jena, Germany.	miltner@biopsy.uni-jena.de	Braun, Christoph/J-4160-2014; Braun, Christoph/E-4561-2010	Braun, Christoph/0000-0002-7836-4010; Braun, Christoph/0000-0002-7836-4010				[Anonymous], 1991, IDENTIFICATION STOCH; Arnold M, 1998, IEEE T BIO-MED ENG, V45, P553, DOI 10.1109/10.668741; BASAR E, 1991, ACTA OTO-LARYNGOL, P25; BIGGINS CA, 1991, ELECTROEN CLIN NEURO, V79, P413, DOI 10.1016/0013-4694(91)90206-J; BROMM B, 1984, METHOD FIND EXP CLIN, V6, P405; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Gray CM, 1996, SCIENCE, V274, P109, DOI 10.1126/science.274.5284.109; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; Haykin S., 1986, ADAPTIVE FILTER THEO; Hebb Donald O., 1949, ORG BEHAV; Jefferys JGR, 1996, TRENDS NEUROSCI, V19, P202, DOI 10.1016/S0166-2236(96)10023-0; LLINAS R, 1993, P NATL ACAD SCI USA, V90, P2078, DOI 10.1073/pnas.90.5.2078; MURTHY VN, 1994, OSCILLATORY EVENT RE, P213; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pantev Christo, 1995, Brain Topography, V7, P321, DOI 10.1007/BF01195258; Perrin F, 1992, Electroencephalogr Clin Neurophysiol, V83, P171, DOI 10.1016/0013-4694(92)90033-E; PERRIN F, 1989, ELECTROEN CLIN NEURO, V72, P184, DOI 10.1016/0013-4694(89)90180-6; PULVERMULLER F, 1995, NEUROREPORT, V6, P2059, DOI 10.1097/00001756-199510010-00025; Pulvermuller F, 1997, PROG NEUROBIOL, V52, P427, DOI 10.1016/S0301-0082(97)00023-3; Rockstroh B., 1989, SLOW CORTICAL POTENT; Sheer D.E., 1984, SELF REGULATION BRAI, P64, DOI DOI 10.1007/978-3-642-69379-3_6; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SINGER W, 1990, J EXP BIOL, V153, P177; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; TIITINEN H, 1993, NATURE, V364, P59, DOI 10.1038/364059a0; Traub RD, 1996, NATURE, V383, P621, DOI 10.1038/383621a0; WASCHULEWSKIFLORUSS H, 1994, INT J NEUROSCI, V78, P21, DOI 10.3109/00207459408986042	28	591	621	1	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 4	1999	397	6718					434	436		10.1038/17126	http://dx.doi.org/10.1038/17126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164KA	9989409				2022-12-28	WOS:000078461700048
J	Baker, LC				Baker, LC			Association of managed care market share and health expenditures for fee-for-service Medicare patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL COST INFLATION; MAINTENANCE ORGANIZATIONS; HMO PENETRATION; CALIFORNIA; IMPACT	Context Managed care has the potential to transform fundamentally the structure and functioning of the entire health care system, including the care provided to patients who are not enrolled in managed care plans, Objective To determine whether increasing health maintenance organization (HMO) market share is associated with decreased expenditures for the care of patients covered by Medicare's traditional fee-for-service plan, a group cared for well outside the boundaries of managed care. Design and Setting Data from the Health Care Financing Administration were used to com pare expenditures for the care of Medicare fee-for-service beneficiaries for 802 market areas, representing the entire United States, for 1990 to 1994, These data were matched with data on system-wide (Medicare and non-Medicare) HMO market share in these areas. Patients All fee-for-service Medicare beneficiaries (1990-1994) except for those with end-stage renal disease. Main Outcome Measure Average fee-for-service expenditure per fee-for-service Medicare beneficiary by market area, Results In a regression model, increases in system-wide HMO market share were associated with declines in both Part A and Part B fee-for-service expenditures per Medicare beneficiary (P < .001), Increases from 10% market share to 20% market share were associated with 2.0% decreases in Part A fee-for-service expenditures and 1.5% decreases in Part B fee-for-service expenditures. Conclusions Managed care can have widespread effects on the health care system, Health care for individuals who are not covered by managed care organizations can be influenced by the presence of managed care. Lower expenditures in areas with high HMO market shares may indicate that traditional Medicare beneficiaries in areas with high market shares received fewer or less intensive services than traditional Medicare beneficiaries in other areas.	Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA; Natl Bur Econ Res, Cambridge, MA 02138 USA	Stanford University; National Bureau of Economic Research	Baker, LC (corresponding author), Stanford Univ, Sch Med, Dept Hlth Res & Policy, HRP Redwood Bldg,Room 253, Stanford, CA 94305 USA.			Baker, Laurence/0000-0001-5032-794X				Baker LC, 1996, AM ECON REV, V86, P389; Baker LC, 1997, J HEALTH ECON, V16, P453, DOI 10.1016/S0167-6296(96)00535-8; Baker LC, 1998, NBER FR HLTH POL RES, V1, P117; Baker LC, 1998, HEALTH AFFAIR, V17, P195, DOI 10.1377/hlthaff.17.5.195; CHERNEW M, 1995, INQUIRY-J HEALTH CAR, V32, P143; CLEMENT DG, 1992, EFFECTS RISK CONTRAC; CUTLER D, 1996, NBER WORKING PAPER S, V5751; Cutler DM, 1998, NBER FR HLTH POL RES, V1, P77; Duan N, 1983, J EC BUSINESS STATIS, V1, P115, DOI DOI 10.2307/1391852; ESCARCE J, 1998, HMO PENETRATION PRAC; FELDMAN R, 1986, J HEALTH POLIT POLIC, V10, P675, DOI 10.1215/03616878-10-4-675; FELDSTEIN PJ, 1995, MED CARE, V33, P1035, DOI 10.1097/00005650-199510000-00005; FRANK RG, 1985, INQUIRY-J HEALTH CAR, V22, P148; Gaskin DJ, 1997, INQUIRY-J HEALTH CAR, V34, P205; Hellinger F J, 1987, Health Care Financ Rev, V9, P55; HELLINGER FJ, 1995, INQUIRY-J HEALTH CAR, V32, P135; Hill JW, 1990, BIASED SELECTION TEF; LUFT HS, 1986, J HEALTH POLIT POLIC, V10, P625, DOI 10.1215/03616878-10-4-625; Makuc D, 1991, VITAL HLTH STAT HLTH; Manning WG, 1998, J HEALTH ECON, V17, P283, DOI 10.1016/S0167-6296(98)00025-3; McClellan M, 1997, J ECON MANAGE STRAT, V6, P91; MCLAUGHLIN CG, 1988, HEALTH SERV RES, V23, P421; Miller RH, 1997, HEALTH AFFAIR, V16, P7, DOI 10.1377/hlthaff.16.5.7; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; NOETHER M, 1988, J HEALTH ECON, V7, P259, DOI 10.1016/0167-6296(88)90028-8; PHELPS CE, 1992, J ECON PERSPECT, V6, P23, DOI 10.1257/jep.6.3.23; ROBINSON JC, 1991, JAMA-J AM MED ASSOC, V266, P2719, DOI 10.1001/jama.266.19.2719; Robinson JC, 1996, JAMA-J AM MED ASSOC, V276, P1060, DOI 10.1001/jama.276.13.1060; RODGERS J, 1995, DO MED HMOS REDUCE F; WELCH WP, 1994, HMOS ELDERLY, P231; ZWANZIGER J, 1994, MED CARE, V32, P1153, DOI 10.1097/00005650-199411000-00007; ZWANZIGER J, 1994, HEALTH AFFAIR, V13, P118, DOI 10.1377/hlthaff.13.4.118	32	108	108	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					432	437		10.1001/jama.281.5.432	http://dx.doi.org/10.1001/jama.281.5.432			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	161YT	9952203				2022-12-28	WOS:000078318500031
J	Glynn, RJ; Beckett, LA; Hebert, LE; Morris, MC; Scherr, PA; Evans, DA				Glynn, RJ; Beckett, LA; Hebert, LE; Morris, MC; Scherr, PA; Evans, DA			Current and remote blood pressure and cognitive decline	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELDERLY PEOPLE; ALZHEIMERS-DISEASE; LONGITUDINAL DATA; IMPAIRMENT; MORTALITY; NONRESPONSE; ASSOCIATION; COMMUNITY; MEMORY; MODELS	Context Previous studies raise the possibility that blood pressure (BP) in middle age predicts later cognitive decline. Objective To examine prospectively the relationship of BP with level of and change in cognitive function in the elderly. Design Longitudinal, population-based study comprising subjects enrolled in the East Boston component of the Established Populations for the Epidemiologic Study of the Elderly (EPESE) (1982-1983) and the Hypertension Detection and Follow-Up Program (HDFP) (1973-1974). Setting East Boston, Mass. Participants Of the 3657 participants in the EPESE with baseline BP measurements, 2068 also participated in the HDFP. Subjects were aged 65 to 102 years at baseline in the EPESE and had mental status and memory assessed at baseline and 3 and 6 years. Main Outcome Measures Numbers of errors on the Short Portable Mental Status Questionnaire and the East Boston Memory Test and rates of change in these numbers of errors. Subjects had BP measured both at baseline in the EPESE and 9 years before, as part of the HDFP. Results In analyses adjusted for age, sex, and education, there was no strong linear association between BP and cognition. The associations found were fairly small in magnitude, and varied according to which test was used to measure cognition. There was little evidence for an effect of BP on change in cognitive function with either test, or for an effect on level of function on the memory test. In analyses of level of mental status questionnaire performance, however, elevated systolic BP (greater than or equal to 160 mm Hg)9 years before baseline was associated with a 14% (95% confidence interval [CI], 4%-25%) increase in error rate, relative to the referent (130-139 mm Hg). Baseline systolic BP had a U-shaped association with the number of errors; error rates were 9% higher compared with the referent group among those with systolic BP lower than 130 mm Hg (95% CI, 1%-17%) and 7% greater (95% CI, 0%-15%) among those with elevated systolic BP. Diastolic BP 9 years before baseline also had a U-shaped association with errors on the mental status questionnaire. Conclusion The findings do not suggest a linear association of BP with cognitive decline, but they are consistent with a more complex relationship between BP and cognition than previously appreciated.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Prevent Med, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Rush Univ, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA; Rush Univ, Rush Inst Healthy Aging, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Rush University; Rush University; Rush University; Centers for Disease Control & Prevention - USA	Glynn, RJ (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.	rglynn@rics.bwh.harvard.edu			NATIONAL INSTITUTE ON AGING [P30AG010161, R01AG012106] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBERT M, 1991, INT J NEUROSCI, V57, P167, DOI 10.3109/00207459109150691; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1978, J Chronic Dis, V31, P651; [Anonymous], 1991, JAMA, V265, P3255; BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; ELIAS MF, 1993, AM J EPIDEMIOL, V138, P353, DOI 10.1093/oxfordjournals.aje.a116868; Evans D A, 1993, Ann Epidemiol, V3, P71; Forette F, 1998, LANCET, V352, P1347, DOI 10.1016/S0140-6736(98)03086-4; Gale CR, 1996, BRIT MED J, V312, P608; Gfeller JD, 1996, J CLIN PSYCHOL, V52, P191, DOI 10.1002/(SICI)1097-4679(199603)52:2<191::AID-JCLP10>3.0.CO;2-F; GLYNN RJ, 1993, AM J EPIDEMIOL, V138, P365, DOI 10.1093/oxfordjournals.aje.a116869; GLYNN RJ, 1993, J AM STAT ASSOC, V88, P984, DOI 10.2307/2290790; Glynn RJ, 1996, BMJ-BRIT MED J, V312, P364; GLYNN RJ, 1995, ARCH INTERN MED, V155, P1855; GLYNN RJ, 1995, LANCET, V345, P825, DOI 10.1016/S0140-6736(95)92964-9; Guo ZC, 1997, AM J EPIDEMIOL, V145, P1106; Kilander L, 1998, HYPERTENSION, V31, P780, DOI 10.1161/01.HYP.31.3.780; LAUNER LJ, 1995, JAMA-J AM MED ASSOC, V274, P1846, DOI 10.1001/jama.274.23.1846; LAUNER LJ, 1994, AM J EPIDEMIOL, V139, P803, DOI 10.1093/oxfordjournals.aje.a117077; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; ROSE GA, 1982, CARDIOVASCULAR SURVE, P162; SAS Institute Inc, 1997, SAS STAT SOFTW CHANG, P247; SCHERR PA, 1991, AM J EPIDEMIOL, V134, P1303, DOI 10.1093/oxfordjournals.aje.a116033; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; Sturmer T, 1996, AM J EPIDEMIOL, V143, P683; VENABLES WN, 1997, MODERN APPL STAT S P; WALLACE RB, 1985, J CHRON DIS, V38, P475, DOI 10.1016/0021-9681(85)90031-1; White H, 1996, J AM GERIATR SOC, V44, P265, DOI 10.1111/j.1532-5415.1996.tb00912.x; WHITE L, 1994, J CLIN EPIDEMIOL, V47, P363, DOI 10.1016/0895-4356(94)90157-0; WILKIE F, 1971, SCIENCE, V172, P959, DOI 10.1126/science.172.3986.959; [No title captured]; [No title captured]	34	195	204	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					438	445		10.1001/jama.281.5.438	http://dx.doi.org/10.1001/jama.281.5.438			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952204	Bronze			2022-12-28	WOS:000078318500032
J	Etzioni, A				Etzioni, A			Integrins - the glue of life	LANCET			English	Editorial Material							ADHESION MOLECULES; DISEASE		Rambam Med Ctr, Dept Pediat, IL-31096 Haifa, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology	Etzioni, A (corresponding author), Rambam Med Ctr, Dept Pediat, IL-31096 Haifa, Israel.							CARLOS TM, 1994, BLOOD, V84, P2068; Du X, 1997, THROMB HAEMOSTASIS, V78, P96; Etzioni A, 1996, PEDIATR RES, V39, P191, DOI 10.1203/00006450-199602000-00001; ETZIONI A, 1998, PRIMARY IMMUNODEFICI, P435; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; GEORGE JN, 1990, BLOOD, V75, P1383; Hogg N, 1999, J CLIN INVEST, V103, P97, DOI 10.1172/JCI3312; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kuijpers TW, 1997, J CLIN INVEST, V100, P1725, DOI 10.1172/JCI119697; Plow EF, 1997, J CLIN INVEST, V99, P1145, DOI 10.1172/JCI119267; ROSALES C, 1995, J LEUKOCYTE BIOL, V57, P189, DOI 10.1002/jlb.57.2.189; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1	14	15	15	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 30	1999	353	9150					341	343		10.1016/S0140-6736(05)74944-8	http://dx.doi.org/10.1016/S0140-6736(05)74944-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950435				2022-12-28	WOS:000078437000005
J	Nishino, I; Spinazzola, A; Hirano, M				Nishino, I; Spinazzola, A; Hirano, M			Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder	SCIENCE			English	Article							CELL GROWTH-FACTOR; GASTROINTESTINAL ENCEPHALOPATHY SYNDROME; TISSUE DISTRIBUTION; EXPRESSION; DNA; DELETIONS	Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive human disease associated with multiple deletions of skeletal muscle mitochondrial DNA (mtDNA), which have been ascribed to a defect in communication between the nuclear and mitochondrial genomes. Examination of 12 MNGIE probands revealed homozygous or compound-heterozygous mutations in the gene specifying thymidine phosphorylase (TP), Located on chromosome 22q13.32-qter. TP activity in Leukocytes from MNGIE patients was Less than 5 percent of controls, indicating that Loss-of-function mutations in TP cause the disease. The pathogenic mechanism may be related to aberrant thymidine metabolism, leading to impaired replication or maintenance of mtDNA, or both.	Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA	Columbia University	Hirano, M (corresponding author), Columbia Univ Coll Phys & Surg, Dept Neurol, 630 W 168th St,P&S 4-443, New York, NY 10032 USA.	mh29@columbia.edu	Spinazzola, Antonella/P-5791-2019; Spinazzola, Antonella/P-5298-2017; Nishino, Ichizo/G-2676-2010	Spinazzola, Antonella/0000-0003-4242-8091; Spinazzola, Antonella/0000-0003-4242-8091; Nishino, Ichizo/0000-0001-9452-112X; Hirano, Michio/0000-0002-7070-7402	NHLBI NIH HHS [R01-HL59657] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059657] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREU AL, COMMUNICATION; ASAI K, 1992, J NEUROCHEM, V59, P307, DOI 10.1111/j.1471-4159.1992.tb08905.x; BARDOSI A, 1987, ACTA NEUROPATHOL, V74, P248, DOI 10.1007/BF00688189; BERK AJ, 1973, J BIOL CHEM, V248, P2722; BESTWICK RK, 1982, J BIOL CHEM, V257, P9305; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown NS, 1998, BIOCHEM J, V334, P1; Carrozzo R, 1998, NEUROLOGY, V50, P99, DOI 10.1212/WNL.50.1.99; Corpet F, 1998, NUCLEIC ACIDS RES, V26, P323, DOI 10.1093/nar/26.1.323; DiMauro S, 1998, BBA-BIOENERGETICS, V1366, P199, DOI 10.1016/S0005-2728(98)00113-3; ECCLESTON PA, 1995, NEUROSCI LETT, V192, P137, DOI 10.1016/0304-3940(95)11622-4; FOX SB, 1995, J PATHOL, V176, P183, DOI 10.1002/path.1711760212; FRIEDKIN M, 1954, J BIOL CHEM, V207, P245; GALLO RC, 1967, J BIOL CHEM, V242, P5059; Griffiths L, 1997, BRIT J CANCER, V76, P689, DOI 10.1038/bjc.1997.447; HAGIWARA K, 1991, MOL CELL BIOL, V11, P2125, DOI 10.1128/MCB.11.4.2125; Hirano M, 1998, AM J HUM GENET, V63, P526, DOI 10.1086/301979; JOHNS DR, 1993, AM J OPHTHALMOL, V115, P108, DOI 10.1016/S0002-9394(14)73533-0; Julias JG, 1998, J VIROL, V72, P7941, DOI 10.1128/JVI.72.10.7941-7949.1998; Kim UJ, 1996, P NATL ACAD SCI USA, V93, P6297, DOI 10.1073/pnas.93.13.6297; MARSH JC, 1964, J CLIN INVEST, V43, P267, DOI 10.1172/JCI104911; Matsukawa K, 1996, BBA-MOL CELL RES, V1314, P71, DOI 10.1016/S0167-4889(96)00078-X; MORAES CT, 1991, AM J HUM GENET, V48, P492; MORRIS NR, 1963, BIOCHIM BIOPHYS ACTA, V68, P93; Papadimitriou A, 1998, NEUROLOGY, V51, P1086, DOI 10.1212/WNL.51.4.1086; Pugmire WJ, 1998, J MOL BIOL, V281, P285, DOI 10.1006/jmbi.1998.1941; SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146; THRELKELD AB, 1992, AM J OPHTHALMOL, V114, P322, DOI 10.1016/S0002-9394(14)71799-4; USUKI K, 1992, BIOCHEM BIOPH RES CO, V184, P1311, DOI 10.1016/S0006-291X(05)80025-7; WALTENBERGER J, 1992, FEBS LETT, V313, P129, DOI 10.1016/0014-5793(92)81428-O; YOSHIMURA A, 1990, BIOCHIM BIOPHYS ACTA, V1034, P107, DOI 10.1016/0304-4165(90)90160-X	33	661	679	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 29	1999	283	5402					689	692		10.1126/science.283.5402.689	http://dx.doi.org/10.1126/science.283.5402.689			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924029				2022-12-28	WOS:000078324400043
J	Santini, JT; Cima, MJ; Langer, R				Santini, JT; Cima, MJ; Langer, R			A controlled-release microchip	NATURE			English	Article							DELIVERY SYSTEMS; DRUG DELIVERY	Much previous work in methods of achieving complex drug-release patterns has focused on pulsatile release from polymeric materials in response to specific stimuli(1), such as electric(2-5) or magnetic(6,7) fields, exposure to ultrasound(7,8), light(9) or enzymes(10), and changes in pH(11) or temperature(12-14), An alternative method for achieving pulsatile release involves using microfabrication technology to develop active devices that incorporate micrometre-scale pumps, valves and flow channels to deliver liquid solutions(15,16). Here we report a solid-state silicon microchip that can provide controlled release of single or multiple chemical substances on demand. The release mechanism is based on the electrochemical dissolution of thin anode membranes covering microreservoirs filled with chemicals in solid, liquid or gel form. We have conducted proof-of-principle release studies with a prototype microchip using gold and saline solution as a model electrode material and release medium, and we have demonstrated controlled, pulsatile release of chemical substances with this device.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Langer, R (corresponding author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							BAE YH, 1987, MAKROMOL CHEM-RAPID, V8, P481; BAE YH, 1994, POLYM DRUGS DRUG ADM, P98; EDELMAN ER, 1985, J BIOMED MATER RES, V19, P67, DOI 10.1002/jbm.820190107; FISCHELGHODSIAN F, 1988, P NATL ACAD SCI USA, V85, P2403, DOI 10.1073/pnas.85.7.2403; FRANKENTHAL RP, 1982, J ELECTROCHEM SOC, V129, P1192, DOI 10.1149/1.2124085; Gravesen P., 1993, Journal of Micromechanics and Microengineering, V3, P168, DOI 10.1088/0960-1317/3/4/002; HEPEL M, 1994, POLYM DRUGS DRUG ADM, P79; HOFFMAN A S, 1986, Journal of Controlled Release, V4, P213; Jaeger RC, 1988, INTRO MICROELECTRONI; JIRAN E, 1992, THIN SOLID FILMS, V208, P23, DOI 10.1016/0040-6090(92)90941-4; KOST J, 1989, P NATL ACAD SCI USA, V86, P7663, DOI 10.1073/pnas.86.20.7663; KOST J, 1991, ADV DRUG DELIVER REV, V6, P19; Kost J, 1990, PULSED SELF REGULATE, P3; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; MATHIOWITZ E, 1989, J MEMBRANE SCI, V40, P67, DOI 10.1016/S0376-7388(00)80913-8; Merchant B, 1998, BIOLOGICALS, V26, P49, DOI 10.1006/biol.1997.0123; MILLER LL, 1988, MOL CRYST LIQ CRYST, V160, P297, DOI 10.1080/15421408808083024; Okano K, 1990, PULSED SELF REGULATE, P17; SHOJI S, 1994, J MICROMECH MICROENG, V4, P157, DOI 10.1088/0960-1317/4/4/001; SIEGEL RA, 1988, J CONTROL RELEASE, V8, P179, DOI 10.1016/0168-3659(88)90044-2; Wolf S, 1986, SILICON PROCESSING V, V1, P531; WU BM, 1997, THESIS MIT, P25	22	702	747	3	185	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 28	1999	397	6717					335	338		10.1038/16898	http://dx.doi.org/10.1038/16898			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9988626	Green Submitted			2022-12-28	WOS:000078324600045
J	van de Ven, PJG; Kaatee, R; Beutler, JJ; Beek, FJA; Woittiez, AJJ; Buskens, E; Koomans, HA; Mali, WPT				van de Ven, PJG; Kaatee, R; Beutler, JJ; Beek, FJA; Woittiez, AJJ; Buskens, E; Koomans, HA; Mali, WPT			Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial	LANCET			English	Article							PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; LUMINAL RENAL ANGIOPLASTY; FOLLOW-UP; BLOOD-PRESSURE; PALMAZ STENT; STENOSIS; HYPERTENSION; PLACEMENT	Background Percutaneous transluminal angioplasty (PTB) for ostial atherosclerotic renal-artery stenosis has poor results. Angioplasty with stent placement (PTAS) may be more effective, We undertook a randomised prospective study to compare PTA with PTAS in patients with ostial atherosclerotic renal-artery stenosis, Methods Patients with ostial atherosclerotic renal-artery stenosis were assigned to receive PTA or PTAS, Secondary PTAS was allowed if PTA failed immediately or during 6 months' follow-up, Analysis was by intention to treat, Findings 42 patients were assigned PTB and 43 were assigned PTAS, but. one patient in the PTAS group was excluded from the study. Primary success rate (<50% residual stenosis) of PTA was 57% (24 patients) compared with 88% (37 patients) for PTAS (difference between groups 31% [95% CI 12-50]), Complications were similar, At 6 months, the primary patency rate was 29% (12 patients) for PTA, and 75% (30 patients) for PTAS (46% [24-68]), Restenosis after a successful primary procedure occurred in 48% of patients for PTA and 14% for PTAS (34% [11-58]), 12 patients underwent secondary stenting for primary or late failure of PTB within the follow-up period: success was similar to that of primary PTAS, Evaluation based on intention to treat showed no difference in clinical results at six months for PTB or PTAS, Interpretation PTAS is a better technique than PTA to achieve vessel patency in ostial atherosclerotic renal-artery stenosis, Primary PTAS and primary PTA plus PTAS as rescue therapy have similar outcomes, However, the burden of reintervention after PTA outweighs the potential saving in stents, so primary PTAS is a better approach to use.	Univ Utrecht Hosp, Dept Hypertens & Nephrol, Julius Ctr Patient Orientated Res, NL-3584 GA Utrecht, Netherlands; Univ Utrecht Hosp, Julius Ctr patient Orientated Res, Dept Radiol, NL-3584 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Beutler, JJ (corresponding author), Univ Utrecht Hosp, Dept Hypertens & Nephrol, Julius Ctr Patient Orientated Res, POB 85500, NL-3584 GA Utrecht, Netherlands.	j.j.beutler@digd.azu.nl	Mali, Willem PThM/I-1123-2014	Mali, Willem PThM/0000-0003-4391-0904				Blum U, 1997, NEW ENGL J MED, V336, P459, DOI 10.1056/NEJM199702133360702; CANZANELLO VJ, 1989, HYPERTENSION, V13, P163, DOI 10.1161/01.HYP.13.2.163; DORROS G, 1995, AM J CARDIOL, V75, P1051, DOI 10.1016/S0002-9149(99)80723-1; GEYSKES GG, 1988, AM J KIDNEY DIS, V12, P252; Harden PN, 1997, LANCET, V349, P1133, DOI 10.1016/S0140-6736(96)10093-3; HENNEQUIN LM, 1994, RADIOLOGY, V191, P713, DOI 10.1148/radiology.191.3.8184051; Henry M, 1996, J VASC INTERV RADIOL, V7, P343, DOI 10.1016/S1051-0443(96)72864-6; Iannone LA, 1996, CATHETER CARDIO DIAG, V37, P243, DOI 10.1002/(SICI)1097-0304(199603)37:3<243::AID-CCD3>3.0.CO;2-C; JENSEN G, 1995, KIDNEY INT, V48, P1936, DOI 10.1038/ki.1995.494; Kaatee R, 1996, RADIOLOGY, V199, P637, DOI 10.1148/radiology.199.3.8637979; Kimura T, 1996, NEW ENGL J MED, V334, P561, DOI 10.1056/NEJM199602293340903; KLINGE J, 1989, RADIOLOGY, V171, P501, DOI 10.1148/radiology.171.2.2523080; LOSINNO F, 1994, AM J ROENTGENOL, V162, P853, DOI 10.2214/ajr.162.4.8141007; Martin L G, 1992, J Vasc Interv Radiol, V3, P619, DOI 10.1016/S1051-0443(92)72907-8; NALLY JV, 1991, AM J HYPERTENS, V4, pS749, DOI 10.1093/ajh/4.12.749S; PLOUIN PF, 1993, HYPERTENSION, V21, P89, DOI 10.1161/01.HYP.21.1.89; PLOVIN PF, 1998, HYPERTENSION, V31, P823; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; REES CR, 1991, RADIOLOGY, V181, P507, DOI 10.1148/radiology.181.2.1924796; Shanley PF, 1996, SEMIN NEPHROL, V16, P21; SPIES JB, 1990, RADIOLOGY, V177, P619; TEGTMEYER CJ, 1986, RADIOLOGY, V161, P577, DOI 10.1148/radiology.161.3.2947260; Textor SC, 1996, BLOOD PURIFICAT, V14, P305, DOI 10.1159/000170278; Tullis MJ, 1997, J VASC SURG, V25, P46, DOI 10.1016/S0741-5214(97)70320-3; van de Ven PJG, 1998, KIDNEY INT, V53, P986, DOI 10.1111/j.1523-1755.1998.00840.x; VANDEVEN PJG, 1995, LANCET, V346, P672, DOI 10.1016/S0140-6736(95)92283-0; Weibull H, 1991, Eur J Vasc Surg, V5, P291, DOI 10.1016/S0950-821X(05)80513-4; WEIBULL H, 1993, J VASC SURG, V18, P841, DOI 10.1016/0741-5214(93)90340-R; Zierler RE, 1996, AM J HYPERTENS, V9, P1055, DOI 10.1016/0895-7061(96)00196-3	29	428	431	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 23	1999	353	9149					282	286		10.1016/S0140-6736(98)04432-8	http://dx.doi.org/10.1016/S0140-6736(98)04432-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929021				2022-12-28	WOS:000078292200011
J	[Anonymous]				[Anonymous]			Suspension unfair to doctors, say peers	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																		1998, BRIT MED J, V317, P1325	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 23	1999	318	7178					267	267						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915754				2022-12-28	WOS:000078292300067
J	Beddington, RSP; Robertson, EJ				Beddington, RSP; Robertson, EJ			Axis development and early asymmetry in mammals	CELL			English	Review							TGF-BETA-FAMILY; POSTIMPLANTATION MOUSE EMBRYO; GERM LAYER FORMATION; NODAL EXPRESSION; BLASTOCYST RELATIONSHIPS; ANTERIOR NEUROECTODERM; PRIMITIVE ENDODERM; SIGNALING PATHWAY; SITUS-INVERSUS; FUSED LOCUS		Natl Inst Med Res, MRC, Div Mammalian Dev, London NW7 1AA, England; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	MRC National Institute for Medical Research; Harvard University	Beddington, RSP (corresponding author), Natl Inst Med Res, MRC, Div Mammalian Dev, Mill Hill, London NW7 1AA, England.							ACAMPORA D, 1995, DEVELOPMENT, V121, P3279; Acampora D, 1998, DEVELOPMENT, V125, P5091; AFZELIUS BA, 1985, CRC CR REV BIOCH MOL, V19, P63, DOI 10.3109/10409238509086788; Ang SL, 1996, DEVELOPMENT, V122, P243; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Antczak M, 1997, MOL HUM REPROD, V3, P1067, DOI 10.1093/molehr/3.12.1067; Beddington RSP, 1998, TRENDS GENET, V14, P277, DOI 10.1016/S0168-9525(98)01499-1; BEDDINGTON RSP, 1981, J EMBRYOL EXP MORPH, V64, P87; BEDDINGTON RSP, 1982, J EMBRYOL EXP MORPH, V69, P265; BEDDINGTON RSP, 1993, CURR OPIN GENET DEV, V3, P655, DOI 10.1016/0959-437X(93)90103-V; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; BEDDINGTON RSP, 1989, DEVELOPMENT, V106, P37; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; Belaoussoff M, 1998, DEVELOPMENT, V125, P5009; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; BROWN NA, 1990, DEVELOPMENT, V109, P1; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; CONLON FL, 1994, DEVELOPMENT, V120, P1919; CONSTAM DB, 1999, IN PRESS J CELL BIOL; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Dattani MT, 1998, NAT GENET, V19, P125, DOI 10.1038/477; De Robertis EM, 1997, COLD SPRING HARB SYM, V62, P169; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; Dufort D, 1998, DEVELOPMENT, V125, P3015; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; Filosa S, 1997, DEVELOPMENT, V124, P2843; Gardner RL, 1997, DEVELOPMENT, V124, P289; GARDNER RL, 1992, J EXP ZOOL, V264, P437, DOI 10.1002/jez.1402640409; Gardner RL, 1998, DEVELOPMENT, V125, P2397; Gardner RL, 1998, CURR TOP DEV BIOL, V39, P35, DOI 10.1016/S0070-2153(08)60452-4; GARDNER RL, 1983, INT REV EXP PATHOL, V24, P63; GARNER W, 1974, J EMBRYOL EXP MORPH, V32, P495; Gauchat D, 1998, DEVELOPMENT, V125, P1637; Gebbia M, 1997, NAT GENET, V17, P305, DOI 10.1038/ng1197-305; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Gu ZY, 1998, GENE DEV, V12, P844, DOI 10.1101/gad.12.6.844; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Hogan B, 1994, MANIPULATING MOUSE E; Houart C, 1998, NATURE, V391, P788, DOI 10.1038/35853; HSU YC, 1979, DEV BIOL, V68, P453, DOI 10.1016/0012-1606(79)90217-3; Hummel K. P., 1959, Journal of Heredity, V50, P9; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; Jiang RL, 1998, DEV BIOL, V198, P224; JOHNSON MH, 1981, CELL, V24, P71, DOI 10.1016/0092-8674(81)90502-X; Jones CM, 1996, CURR BIOL, V6, P1468, DOI 10.1016/S0960-9822(96)00751-8; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; KNOTGEN H, 1999, IN PRESS DEVELOPMENT; Kosaki K, 1998, SEMIN CELL DEV BIOL, V9, P89, DOI 10.1006/scdb.1997.0187; Lander A, 1998, SEMIN CELL DEV BIOL, V9, P35, DOI 10.1006/scdb.1997.0185; LAWSON KA, 1987, DEVELOPMENT, V101, P627; LAWSON KA, 1991, DEVELOPMENT, V113, P891; Levin M, 1998, GENE DEV, V12, P763, DOI 10.1101/gad.12.6.763; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; MATSUO I, 1995, GENE DEV, V9, P2646, DOI 10.1101/gad.9.21.2646; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; MILLER SA, 1978, J EMBRYOL EXP MORPH, V44, P181; Miller SA, 1998, ANAT REC, V250, P103; MISHINA Y, 1995, GENE DEV, V6, P432; Mochizuki T, 1998, NATURE, V395, P177, DOI 10.1038/26006; Morgan D, 1998, NAT GENET, V20, P149, DOI 10.1038/2450; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; PERRY WL, 1995, GENETICS, V141, P321; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Popperl H, 1997, DEVELOPMENT, V124, P2997; Reilly KM, 1996, CELL, V86, P743, DOI 10.1016/S0092-8674(00)80149-X; Rhinn M, 1998, DEVELOPMENT, V125, P845; ROSENQUIST TA, 1995, MECH DEVELOP, V49, P117, DOI 10.1016/0925-4773(94)00308-A; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Schauerte HE, 1998, DEVELOPMENT, V125, P2983; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P843; Sefton M, 1998, DEVELOPMENT, V125, P3111; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; SMITH LJ, 1980, J EMBRYOL EXP MORPH, V55, P257; SMITH LJ, 1985, J EMBRYOL EXP MORPH, V89, P15; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; St Amand TR, 1998, BIOCHEM BIOPH RES CO, V247, P100; SULIK K, 1994, DEV DYNAM, V201, P260, DOI 10.1002/aja.1002010309; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; Tam PPL, 1997, COLD SPRING HARB SYM, V62, P135; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Thomas P, 1997, COLD SPRING HARB SYM, V62, P115; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Varlet I, 1997, COLD SPRING HARB SYM, V62, P105; Varlet I, 1997, DEVELOPMENT, V124, P1033; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; VIEBAHN C, 1995, ANAT EMBRYOL, V192, P159; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Yamanaka Y, 1998, GENE DEV, V12, P2345, DOI 10.1101/gad.12.15.2345; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; ZEMICKAGOETZ M, 1998, DEVELOPMENT, V125, P4803; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6	111	585	597	0	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 22	1999	96	2					195	209		10.1016/S0092-8674(00)80560-7	http://dx.doi.org/10.1016/S0092-8674(00)80560-7			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	160VM	9988215	Bronze			2022-12-28	WOS:000078252200004
J	Harding, HP; Zhang, YH; Ron, D				Harding, HP; Zhang, YH; Ron, D			Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase	NATURE			English	Article							GLUCOSE-REGULATED PROTEINS; INITIATION-FACTOR 2-ALPHA; TRANSMEMBRANE PROTEIN; CULTURED-CELLS; PHOSPHORYLATION; ACTIVATION; INDUCTION; DEPLETION; SIGNALS; NUCLEUS	Protein synthesis and the folding of the newly synthesized proteins into the correct three-dimensional structure are coupled in cellular compartments of the exocytosis pathway by a process that modulates the phosphorylation level of eukaryotic initiation factor-2 alpha (eIF2 alpha) in response to a stress signal from the endoplasmic reticulum (ER)(1,2). Activation of this process leads to reduced rates of initiation of protein translation during ER stress(3). Here we describe the cloning of perk, a gene encoding a type I transmembrane ER-resident protein. PERK has a lumenal domain that is similar to the ER-stress-sensing lumenal domain of the ER-resident kinase Irel, and a cytoplasmic portion that contains a protein-kinase domain most similar to that of the known eIF2 alpha kinases, PKR and HRI. ER stress increases PERK's protein-kinase activity and PERK phosphorylates eIF2 alpha on serine residue 51, inhibiting translation of messenger RNA into protein. These properties implicate PERK in a signalling pathway that attenuates protein translation in response to ER stress.	NYU, Sch Med, Dept Med, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University; New York University	Ron, D (corresponding author), NYU, Sch Med, Dept Med, Skirball Inst Biomol Med, New York, NY 10016 USA.	ron@saturn.med.nyu.edu	Longo, Kenneth A/A-5631-2010	Harding, Heather P/0000-0002-7359-7974; Ron, David/0000-0002-3014-5636				BERRY MJ, 1985, J BIOL CHEM, V260, P1240; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; BROSTROM MA, 1995, J BIOL CHEM, V270, P4127, DOI 10.1074/jbc.270.8.4127; CHEN YS, 1995, IEEE SIGNAL PROC LET, V2, P105, DOI 10.1109/97.388909; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; FAGARD R, 1981, P NATL ACAD SCI-BIOL, V78, P866, DOI 10.1073/pnas.78.2.866; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEE A, 1993, CURR BIOL, V4, P267; MORI K, 1993, CELL, V74, P743; PRICE BD, 1992, CANCER RES, V52, P3814; PROSTKO CR, 1993, MOL CELL BIOCHEM, V128, P255, DOI 10.1007/BF01076776; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; Savinova O, 1997, METHODS, V11, P419, DOI 10.1006/meth.1996.0438; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shamu CE, 1997, CURR BIOL, V7, pR67, DOI 10.1016/S0960-9822(06)00038-8; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291	26	2411	2494	6	163	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 21	1999	397	6716					271	274		10.1038/16729	http://dx.doi.org/10.1038/16729			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159QH	9930704				2022-12-28	WOS:000078184800057
J	Braverman, IM				Braverman, IM			Protective effects of erythema nodosum in coccidioidomycosis	LANCET			English	Editorial Material							BCG		Yale Sch Med, Dept Dermatol, New Haven, CT 06520 USA	Yale University	Braverman, IM (corresponding author), Yale Sch Med, Dept Dermatol, New Haven, CT 06520 USA.							Arsura EL, 1998, CLIN INFECT DIS, V27, P1201, DOI 10.1086/514985; Bertolli J, 1997, INT J EPIDEMIOL, V26, P888, DOI 10.1093/ije/26.4.888; BRAVERMAN IM, 1998, SKIN SIGNS SYSTEMIC, P349; FAVOUR CB, 1947, ARCH INTERN MED, V80, P435, DOI 10.1001/archinte.1947.00220160014002; Kelly P, 1997, EUR RESPIR J, V10, P619; REA TH, 1997, ARCH DERMATOL, V113, P345; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; TEMPLETON AC, 1975, J NATL CANCER I, V55, P1301, DOI 10.1093/jnci/55.6.1301	8	5	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					168	168		10.1016/S0140-6736(05)77213-5	http://dx.doi.org/10.1016/S0140-6736(05)77213-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923870	hybrid			2022-12-28	WOS:000078175600007
J	Ismail, K; Everitt, B; Blatchley, N; Hull, L; Unwin, C; David, A; Wessely, S				Ismail, K; Everitt, B; Blatchley, N; Hull, L; Unwin, C; David, A; Wessely, S			Is there a Gulf War syndrome?	LANCET			English	Article							SYMPTOMS	Background UK veterans of the Gulf War report more ill health than servicemen who were not deployed to the Gulf War. We investigated whether the pattern of symptom reporting by veterans of the Gulf War differed from that in active servicemen who had not fought in the Gulf War or who had fought in other conflicts. Methods We used a population-based cross-sectional design. We sent a standardised survey that ashed about 50 physical symptoms to three UK military cohorts; men who had served in the Gulf War, those who had served in the Bosnia conflict, and men who had been in active service but not deployed to the Gulf War (Era cohort). We used exploratory factor analysis to identify underlying factors and describe the factor structure of the symptoms reported in the Gulf War cohort. Confirmatory factor analysis was used to test the fit of this factor structure in the Bosnia and Era cohorts. Findings Three factors in the Gulf War cohort together accounted for about 20% of the common variance. We labelled the factors mood, respiratory system, and peripheral nervous system, according to the symptoms that loaded on to them. In the confirmatory factor analysis, the factor structure identified in the Gulf War cohort fitted reasonably well in the Bosnia and Era cohorts. Interpretation Although results from complex modelling procedures need to be interpreted with caution, our findings do not support a unique Gulf War syndrome. The mechanisms behind increased self-reporting of symptoms need further investigation.	Guys Kings & St Thomas Med Sch, Gulf War Illness Res Unit, London SE5 8AF, England; Inst Psychiat, Dept Biostat, London, England; Minist Def, Off Natl Stat, London, England	University of London; King's College London; University of London; King's College London	Ismail, K (corresponding author), Guys Kings & St Thomas Med Sch, Gulf War Illness Res Unit, London SE5 8AF, England.		Wessely, Simon C/A-8713-2008; David, Anthony/O-1750-2019; David, Anthony S/C-1315-2011	David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X; Wessely, Simon Charles/0000-0002-6743-9929; Everitt, Barry/0000-0003-4431-6536				Cowan DN, 1998, AM J EPIDEMIOL, V148, P326; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; Dunn G, 1993, COVARIANCES LATENT V; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Fukuda K, 1998, JAMA-J AM MED ASSOC, V280, P981, DOI 10.1001/jama.280.11.981; Gray GC, 1998, AM J EPIDEMIOL, V148, P328; Haley RW, 1998, AM J EPIDEMIOL, V148, P315, DOI 10.1093/oxfordjournals.aje.a009645; Haley RW, 1998, AM J EPIDEMIOL, V148, P334; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P215, DOI 10.1001/jama.277.3.215; Kang HK, 1998, AM J EPIDEMIOL, V148, P324; Simon G, 1996, PSYCHOSOM MED, V58, P481, DOI 10.1097/00006842-199609000-00010; Wegman DH, 1997, AM J EPIDEMIOL, V146, P704	12	114	114	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					179	182		10.1016/S0140-6736(98)11339-9	http://dx.doi.org/10.1016/S0140-6736(98)11339-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923872				2022-12-28	WOS:000078175600009
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Size matters	SCIENCE			English	Editorial Material									Medsite Commun, Boston, MA USA		Sikorski, R (corresponding author), Medsite Commun, Boston, MA USA.							LAKE, 1998, NATURE BIOTECHNOL, V16, P1352	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					349	349						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9925496				2022-12-28	WOS:000078067000036
J	Singer, PA; Martin, DK; Kelner, M				Singer, PA; Martin, DK; Kelner, M			Quality end-of-life care - Patients' perspectives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVANCE DIRECTIVES; FAMILY MEMBERS; PREFERENCES	Context Quality end-of-life care is increasingly recognized as an ethical obligation of health care providers, both clinicians and organizations. However, this concept has not been examined from the perspective of patients. Objective To identify and describe elements of quality end-of-life care from the patient's perspective. Design Qualitative study using in-depth, open-ended, face-to-face interviews and content analysis. Setting Toronto, Ontario. Participants A total of 126 participants from 3 patient groups: dialysis patients (n = 48), people with human immunodeficiency virus infection (n = 40), and residents of a long-term care facility (n = 38). Outcome Measures Participants' views on end-of-life issues. Results Participants identified 5 domains of quality end-of-life care: receiving adequate pain and symptom management, avoiding inappropriate prolongation of dying, achieving a sense of control, relieving burden, and strengthening relationships with loved ones. Conclusion These domains, which characterize patients' perspectives on end-of-life care, can serve as focal points for improving the quality of end-of-life care.	Univ Toronto, Joint Ctr Bioeth, Dept Med, Toronto, ON M5G 1L4, Canada; Univ Toronto, Inst Human Dev Life Course & Aging, Toronto, ON M5G 1L4, Canada; Toronto Hosp, Toronto, ON M5T 2S8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Singer, PA (corresponding author), Univ Toronto, Joint Ctr Bioeth, Dept Med, 88 Coll St, Toronto, ON M5G 1L4, Canada.	peter.singer@utoronto.ca						Ahronheim JC, 1996, ARCH INTERN MED, V156, P2094, DOI 10.1001/archinte.156.18.2094; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; BLUSTEIN J, 1993, HASTINGS CTR REP MAY, P6; BYOCK I, 1997, DYING WELL PEACE POS, P4311; CLEARY PD, 1997, JAMA-J AM MED ASSOC, V278, P608; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; EMANUEL LL, 1995, J AM GERIATR SOC, V43, P440, DOI 10.1111/j.1532-5415.1995.tb05821.x; Feinstein AR., 1967, CLIN JUDGMENT; Field MJ, 1997, APPROACHING DEATH IM; Fischer GS, 1997, ARCH INTERN MED, V157, P801, DOI 10.1001/archinte.157.7.801; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; HARDWIG J, 1990, HASTINGS CENT REP, P5; HIGH DM, 1994, HASTINGS CENT REP, V24, pS16, DOI 10.2307/3563476; KELNER MJ, 1995, SOC SCI MED, V4, P537; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lindemann Nelson H, 1995, PATIENT FAMILY; Lynn J, 1997, J AM GERIATR SOC, V45, P526; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Manning P. K., 1998, COLLECTING INTERPRET, P463; MARTIN DK, IN PRESS ARCH INTERN; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; SINGER PA, 1995, J AM SOC NEPHROL, V6, P1410; Singer PA, 1997, J GEN INTERN MED, V12, P729, DOI 10.1046/j.1525-1497.1997.07157.x; Singer PA, 1998, ARCH INTERN MED, V158, P879, DOI 10.1001/archinte.158.8.879; Singer PA, 1998, CAN MED ASSOC J, V159, P159; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; Strauss A., 1990, BASICS QUALITATIVE R; Strauss A. L, 1994, HDB QUALITATIVE RES, V1st, P273, DOI DOI 10.1007/BF00988593; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; VIRMANI J, 1994, ARCH INTERN MED, V154, P909, DOI 10.1001/archinte.154.8.909; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709	31	798	806	2	95	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					163	168		10.1001/jama.281.2.163	http://dx.doi.org/10.1001/jama.281.2.163			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	155VJ	9917120				2022-12-28	WOS:000077966800037
J	Beecham, L				Beecham, L			Consultant physicians should be appraised annually	BRITISH MEDICAL JOURNAL			English	News Item																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1999	318	7181					419	419		10.1136/bmj.318.7181.419	http://dx.doi.org/10.1136/bmj.318.7181.419			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BF	9974448	Green Published			2022-12-28	WOS:000078670100016
J	Murray, SA				Murray, SA			Experiences with "rapid appraisal" in primary care: involving the public in assessing health needs, orientating staff and educating medical students	BRITISH MEDICAL JOURNAL			English	Article									Univ Edinburgh, Dept Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland	University of Edinburgh	Murray, SA (corresponding author), Univ Edinburgh, Dept Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland.							Anker M, 1991, World Health Stat Q, V44, P94; ANNEN H, 1995, GUIDELINES RAPID PAR; Benzeval M, 1995, TACKLING INEQUALITIE; BLACK D, 1997, THEYRE BETTER TRAINE; Chambers R., 1997, WHOSE REALITY COUNTS; Dale J, 1996, BRIT MED J, V312, P1206; Davison H, 1999, MED EDUC, V33, P55, DOI 10.1046/j.1365-2923.1999.00266.x; DIXON J, 1991, LANCET, V337, P891, DOI 10.1016/0140-6736(91)90213-9; Entwistle VA, 1998, BRIT MED J, V316, P463, DOI 10.1136/bmj.316.7129.463; GILLAM S, 1997, COPC PUBLIC HLTH EXP; GILLAM S, 1996, 73 RCGP; HOPTON JL, 1995, BRIT MED J, V310, P1369, DOI 10.1136/bmj.310.6991.1369; Johnson J. C., 1990, SELECTING ETHNOGRAPH, V22; Jordan J, 1997, BRIT J GEN PRACT, V47, P695; JUDGE K, 1994, BRIT MED J, V309, P1154; MANDERSON L, 1992, SOC SCI MED, V35, pR93; Murray S, 1997, Health Serv J, V107, P32; MURRAY SA, 1994, BRIT MED J, V308, P698, DOI 10.1136/bmj.308.6930.698; MURRAY SA, 1995, BRIT MED J, V310, P1443, DOI 10.1136/bmj.310.6992.1443; MURRAY SA, 1996, PRIMARY CARE PSYCHIA, V2, P237; NEVE H, 1995, BRIT MED J, V311, P521; NHS Executive IHSM and NHS Confederation, 1998, PUBL INT DEV STRAT P; ONG BN, 1991, SOC SCI MED, V32, P909, DOI 10.1016/0277-9536(91)90246-9; ONG BN, 1996, RAPID APPRAISAL HLTH; THOMPSON E, 1994, BRIT MED J, V309, P142	25	35	36	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1999	318	7181					440	444		10.1136/bmj.318.7181.440	http://dx.doi.org/10.1136/bmj.318.7181.440			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BF	9974462	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000078670100031
J	Turrisi, AT; Kim, K; Blum, R; Sause, WT; Livingston, RB; Komaki, R; Wagner, H; Aisner, S; Johnson, DH				Turrisi, AT; Kim, K; Blum, R; Sause, WT; Livingston, RB; Komaki, R; Wagner, H; Aisner, S; Johnson, DH			Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOUTHWEST-ONCOLOGY-GROUP; RANDOMIZED TRIAL; RADIATION-THERAPY; CHEMOTHERAPY; CARCINOMA; IRRADIATION; SURVIVAL; DISEASE	Background For small-cell lung cancer confined to one hemithorax (limited small-cell lung cancer), thoracic radiotherapy improves survival, but the best ways of integrating chemotherapy and thoracic radiotherapy remain unsettled. Twice-daily accelerated thoracic radiotherapy has potential advantages over once-daily radiotherapy. Methods We studied 417 patients with limited small-cell lung cancer. All the patients received four 21-day cycles of cisplatin plus etoposide. We randomly assigned these patients to receive a total of 45 Gy of concurrent thoracic radiotherapy, given either twice daily over a three-week period or once daily over a period of five weeks. Results Twice-daily treatment beginning with the first cycle of chemotherapy significantly improved survival as compared with concurrent once-daily radiotherapy (P = 0.04 by the log-rank test). After a median follow-up of almost 8 years, the median survival was 19 months for the once-daily group and 23 months for the twice-daily group. The survival rates for patients receiving once-daily radiotherapy were 41 percent at two years and 16 percent at five years. For patients receiving twice-daily radiotherapy, the survival rates were 47 percent at two years and 26 percent at five years. Grade 3 esophagitis was significantly more frequent with twice-daily thoracic radiotherapy, occurring in 27 percent of patients, as compared with 11 percent in the once-daily group (P < 0.001). Conclusions Four cycles of cisplatin plus etoposide and a course of radiotherapy (45 Gy, given either once or twice daily) beginning with cycle 1 of the chemotherapy resulted in overall two- and five-year survival rates of 44 percent and 23 percent, a considerable improvement in survival rates over previous results in patients with limited small-cell lung cancer. (N Engl J Med 1999;340:265-71.) (C) 1999, Massachusetts Medical Society.	Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA; Univ Wisconsin, Madison, WI USA; St Vincents Med Ctr, New York, NY USA; LDS Hosp, Salt Lake City, UT USA; Univ Washington, Seattle, WA 98195 USA; MD Anderson Canc Ctr, Houston, TX USA; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA; Vanderbilt Univ, Nashville, TN USA	Medical University of South Carolina; University of Wisconsin System; University of Wisconsin Madison; Saint Vincents Hospital Manhattan; University of Washington; University of Washington Seattle; University of Texas System; UTMD Anderson Cancer Center; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Rutgers State University New Brunswick; Rutgers State University Medical Center; Vanderbilt University	Turrisi, AT (corresponding author), Med Univ S Carolina, Dept Radiat Oncol, 171 Ashley Ave, Charleston, SC 29425 USA.	turrisi@radonc.muse.edu	Johnson, David H./A-7437-2009		NCI NIH HHS [CA23318, CA32102, CA20319] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA023318, U10CA020319, U10CA032102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRIAGADA R, 1993, NEW ENGL J MED, V329, P1848, DOI 10.1056/NEJM199312163292504; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BUNN PA, 1987, ANN INTERN MED, V106, P655, DOI 10.7326/0003-4819-106-5-655; BUNN PA, 1995, J CLIN ONCOL, V13, P1632, DOI 10.1200/JCO.1995.13.7.1632; BUNN PA, 1995, J CLIN ONCOL, V13, P2860; CARNEY DN, 1983, CANCER RES, V43, P2806; Choi NC, 1998, J CLIN ONCOL, V16, P3528, DOI 10.1200/JCO.1998.16.11.3528; COX DR, 1972, J R STAT SOC B, V34, P187; Cox DR., 1989, ANAL BINARY DATA; FRYTAK S, 1991, LUNG CANCER S, V7, P157; GRECO FA, 1976, ANN INTERN MED, V85, P294, DOI 10.7326/0003-4819-85-3-294; Gregor A, 1997, J CLIN ONCOL, V15, P2840, DOI 10.1200/JCO.1997.15.8.2840; Gregor A, 1997, EUR J CANCER, V33, P1752, DOI 10.1016/S0959-8049(97)00135-4; JOHNSON BE, 1991, P AN M AM SOC CLIN, V10, P240; JOHNSON DH, 1993, J CLIN ONCOL, V11, P879, DOI 10.1200/JCO.1993.11.5.879; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOMAKI R, 1985, AM J CLIN ONCOL-CANC, V8, P523, DOI 10.1097/00000421-198512000-00013; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; LEBEAU B, 1996, P AN M AM SOC CLIN, V15, P383; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCCRACKEN JD, 1990, J CLIN ONCOL, V8, P892, DOI 10.1200/JCO.1990.8.5.892; MURRAY N, 1993, J CLIN ONCOL, V11, P336, DOI 10.1200/JCO.1993.11.2.336; NATALE RB, 1982, CANCER TREAT REV, V9, P91, DOI 10.1016/S0305-7372(82)80085-6; *NCI, 1998, COMM TOX CRIT; PAPAC RJ, 1987, INT J RADIAT ONCOL, V13, P993; PAPAC RJ, 1988, INT J RADIAT ONCOL, V14, P213; PEREZ CA, 1984, J CLIN ONCOL, V2, P1200, DOI 10.1200/JCO.1984.2.11.1200; PERRY MC, 1987, NEW ENGL J MED, V316, P912, DOI 10.1056/NEJM198704093161504; PIGNON JP, 1992, NEW ENGL J MED, V327, P1618, DOI 10.1056/NEJM199212033272302; SHANK B, 1985, CANCER-AM CANCER SOC, V56, P2771, DOI 10.1002/1097-0142(19851215)56:12<2771::AID-CNCR2820561209>3.0.CO;2-A; SIEROCKI JS, 1979, CANCER TREAT REP, V63, P1593; TAKADA M, 1996, P AN M AM SOC CLIN, V15, P372; Turrisi AT, 1987, P AN M AM SOC CLIN, V6, P172; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0	34	1017	1054	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1999	340	4					265	271		10.1056/NEJM199901283400403	http://dx.doi.org/10.1056/NEJM199901283400403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YU	9920950				2022-12-28	WOS:000078318700003
J	Tanner, CM; Ottman, R; Goldman, SM; Ellenberg, J; Chan, P; Mayeux, R; Langston, JW				Tanner, CM; Ottman, R; Goldman, SM; Ellenberg, J; Chan, P; Mayeux, R; Langston, JW			Parkinson disease in twins - An etiologic study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TO-DOOR SURVEY; ALZHEIMERS-DISEASE; MONOZYGOTIC TWINS; QUESTIONNAIRE; CONCORDANCE; PREVALENCE; REGISTRY; VETERANS; MONKEY	Context The cause of Parkinson disease (PD) is unknown. Genetic linkages have been identified in families with PD, but whether most PD is inherited has not been determined, Objective To assess genetic inheritance of PD by studying monozygotic (MZ) and dizygotic (DZ) twin pairs. Design Twin study comparing concordance rates of PD in MZ and DZ twin pairs. Setting and Participants A total of 19 842 white male twins enrolled in the National Academy of Sciences/National Research Council World War II Veteran Twins Registry were screened for PD and standard diagnostic criteria for PD were applied. Zygosity was determined by polymerase chain reaction or questionnaire. Main Outcome Measure Parkinson disease concordance in twin pairs, stratified by zygosity and age at diagnosis. Results Of 268 twins with suspected parkinsonism and 250 presumed unaffected twin brothers, 193 twins with PD were identified (concordance-adjusted prevalence, 8.67/1000). In 71 MZ and 90 DZ pairs with complete diagnoses, pairwise concordance was similar (0.129 overall, 0.155 MZ, 0.111 DZ; relative risk, 1.39; 95% confidence interval, 0.63-3.1). In 16 pairs with diagnosis at or before age 50 years in at least 1 twin, MZ concordance was 1.0 (4 pairs), and DZ was 0.167 (relative risk, 6.0; 95% confidence interval, 1.69-21.26). Conclusions The similarity in concordance overall indicates that genetic factors do not play a major role in causing typical PD, No genetic component is evident when the disease begins after age 50 years. However, genetic factors appear to be important when disease begins at or before age 50 years.	Parkinsons Inst, Sunnyvale, CA 94089 USA; Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY USA; NINDS, NIH, Bethesda, MD 20892 USA	Columbia University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Tanner, CM (corresponding author), Parkinsons Inst, 1170 Morse Ave, Sunnyvale, CA 94089 USA.		Mayeux, Richard/E-9788-2013; Ottman, Ruth/O-2371-2013	Mayeux, Richard/0000-0001-6519-9696; Ottman, Ruth/0000-0001-7074-242X	ONR [UIONS31321] Funding Source: Medline	ONR(Office of Naval Research)		Brass Lawrence M., 1996, Neurology, V46, pA212; BREITNER JCS, 1995, ARCH NEUROL-CHICAGO, V52, P763, DOI 10.1001/archneur.1995.00540320035011; BROOKS DJ, 1995, QJM-MON J ASSOC PHYS, V88, P81; BURNS RS, 1984, CAN J NEUROL SCI, V11, P166; CEDERLOEF R, 1961, ACTA GENET STAT MED, V11, P338; Chan P, 1998, NEUROLOGY, V50, P1136, DOI 10.1212/WNL.50.4.1136; Chan P, 1998, NEUROLOGY, V50, P513, DOI 10.1212/WNL.50.2.513; Denson M A, 1995, Parkinsonism Relat Disord, V1, P35, DOI 10.1016/1353-8020(95)00010-4; DUVOISIN RC, 1981, NEUROLOGY, V31, P77, DOI 10.1212/WNL.31.1.77; DUVOISIN RC, 1992, BRAIN PATHOL, V2, P309, DOI 10.1111/j.1750-3639.1992.tb00708.x; GALLO JJ, 1995, PSYCHOL MED, V25, P1211, DOI 10.1017/S0033291700033183; Gasser T, 1998, NAT GENET, V18, P262, DOI 10.1038/ng0398-262; Gudmundsson K. R., 1967, ACTA NEUROL SCAND  S, V43, P1; HAMMOND HA, 1994, AM J HUM GENET, V55, P175; JABLON S, 1967, AM J HUM GENET, V19, P133; JANKOVIC J, 1986, ANN NEUROL, V19, P405, DOI 10.1002/ana.410190421; JOHNSON WG, 1990, MOVEMENT DISORD, V5, P187, DOI 10.1002/mds.870050302; KISSEL P, 1976, J GENET HUM, V24, P113; KOLLER W, 1986, ANN NEUROL, V19, P402, DOI 10.1002/ana.410190420; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1984, BRAIN RES, V292, P390; Marder K, 1996, NEUROLOGY, V47, P155, DOI 10.1212/WNL.47.1.155; MARSDEN CD, 1987, J NEUROL NEUROSUR PS, V50, P105, DOI 10.1136/jnnp.50.1.105; MARTTILA RJ, 1988, NEUROLOGY, V38, P1217, DOI 10.1212/WNL.38.8.1217; MAYEUX R, 1995, AM J EPIDEMIOL, V142, P820, DOI 10.1093/oxfordjournals.aje.a117721; Melcon MO, 1997, MOVEMENT DISORD, V12, P197, DOI 10.1002/mds.870120210; MORGANTE L, 1992, NEUROLOGY, V42, P1901; Page WF, 1997, PROSTATE, V33, P240; PEMBREY ME, 1972, PRACTITIONER, V209, P240; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; REICH T, 1972, ANN HUM GENET, V36, P163, DOI 10.1111/j.1469-1809.1972.tb00767.x; Seddon J. M., 1997, Investigative Ophthalmology and Visual Science, V38, pS676; SMITH C, 1974, AM J HUM GENET, V26, P454; Tanner CM, 1996, NEUROL CLIN, V14, P317, DOI 10.1016/S0733-8619(05)70259-0; TANNER CM, 1990, ANN NEUROL, V28, P267; TANNER CM, 1994, NEUROLOGY, V44, pA136; TORGERSEN S, 1979, ACTA GENET MED GEMEL, V28, P225, DOI 10.1017/S0001566000009077; Umehara F, 1991, Rinsho Shinkeigaku, V31, P306; VIEREGGE P, 1992, NEUROLOGY, V42, P1453, DOI 10.1212/WNL.42.8.1453; Wang SJ, 1996, ARCH NEUROL-CHICAGO, V53, P66, DOI 10.1001/archneur.1996.00550010084020; WARD CD, 1983, NEUROLOGY, V33, P815, DOI 10.1212/WNL.33.7.815; ZIMMERMAN T R JR, 1991, Neurology, V41, P255	44	655	672	1	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1999	281	4					341	346		10.1001/jama.281.4.341	http://dx.doi.org/10.1001/jama.281.4.341			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158JB	9929087				2022-12-28	WOS:000078111300033
J	Kmietowicz, Z				Kmietowicz, Z			New variant CJD found in tonsils	BRITISH MEDICAL JOURNAL			English	News Item																		Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1999	318	7178					215	215						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915722				2022-12-28	WOS:000078292300015
J	Zwitter, M; Nilstun, T; Knudsen, LE; Zakotnik, B; Klocker, J; Bremberg, S; Frentz, G; Klocker-Kaiser, U; Pedersen, J				Zwitter, M; Nilstun, T; Knudsen, LE; Zakotnik, B; Klocker, J; Bremberg, S; Frentz, G; Klocker-Kaiser, U; Pedersen, J			Professional and public attitudes towards unsolicited medical intervention	BRITISH MEDICAL JOURNAL			English	Article									Inst Oncol, Ljubljana 1001, Slovenia; Univ Lund, Dept Med Eth, SE-22222 Lund, Sweden; Natl Inst Occupat Hlth, DK-2100 Copenhagen, Denmark; Gen Hosp, Dept Med 1, Inst Oncol, A-9026 Klagenfurt, Austria; Copenhagen Municipal Hosp, Inst Prevent Med, DK-1399 Copenhagen C, Denmark; Gen Hosp, Ctr Mental Hlth, Klagenfurt, Austria	Institute of Oncology - Slovenia; Lund University	Zwitter, M (corresponding author), Inst Oncol, Zaloska 2, Ljubljana 1001, Slovenia.		Zwitter, Matjaz/ABE-3362-2020; Knudsen, Lisbeth E./W-9392-2018	Knudsen, Lisbeth E./0000-0002-9576-1202				Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; Dworkin Gerald, 1988, THEORY PRACTICE AUTO; Fletcher SW, 1997, NEW ENGL J MED, V336, P1180, DOI 10.1056/NEJM199704173361612; Gochman DS, 1997, HDB HLTH BEHAV RES; Harris J., 1985, VALUE LIFE; Hook EB, 1997, AM J MED GENET, V68, P485; Lloyd, 1994, PRINCIPLES HLTH CARE; MOSELEY R, 1985, J MED PHILOS, V10, P163, DOI 10.1093/jmp/10.2.163; Ponder B, 1997, SCIENCE, V278, P1050, DOI 10.1126/science.278.5340.1050; RATZAN RM, 1985, J MED PHILOS, V10, P147, DOI 10.1093/jmp/10.2.147; Reich W.T., 1995, ENCY BIOETHICS; Zwitter M., 1996, RADIOL ONCOL, V30, P310	12	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1999	318	7178					251	253						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	161MG	9915739				2022-12-28	WOS:000078292300032
J	Sirota, EB; Herhold, AB				Sirota, EB; Herhold, AB			Transient phase-induced nucleation	SCIENCE			English	Article							CRYSTAL-MELT INTERFACE; NORMAL-ALKANES; ROTATOR PHASES; N-ALKANES; X-RAY; POLYMER CRYSTALLIZATION; DENSITY-FLUCTUATIONS; SURFACE; MORPHOLOGY; PARAFFINS	A transient metastable rotator phase occurring on crystallization of hexadecane into its triclinic phase from the supercooled melt was directly observed with time-resolved synchrotron x-ray scattering. In this system, the limit of supercooling (the crystallization temperature) is determined by the thermodynamic stability of the transient phase with respect to the Liquid. The crystallization kinetics of the homologous series of n-alkanes was measured and explained in terms of a crossover from stability to "long-lived" metastability to transient metastability. This crossover allowed further confirmation of the nature of the transient phase.	ExxonMobil Res & Engn Co, Corp Res Sci Lab, Annandale, NJ 08801 USA	Exxon Mobil Corporation	Sirota, EB (corresponding author), ExxonMobil Res & Engn Co, Corp Res Sci Lab, Route 22 E, Annandale, NJ 08801 USA.	ebsirot@erenj.com	Sirota, Eric B/A-7633-2009					BENNEMA P, 1992, J CRYST GROWTH, V121, P679, DOI 10.1016/0022-0248(92)90575-4; BROADHURST MG, 1962, J CHEM PHYS, V36, P2578, DOI 10.1063/1.1732337; DENICOLO I, 1983, J CHEM PHYS, V78, P1465, DOI 10.1063/1.444835; DOUCET J, 1981, J CHEM PHYS, V75, P1523, DOI 10.1063/1.442185; EARNSHAW JC, 1992, PHYS REV A, V46, pR4494, DOI 10.1103/PhysRevA.46.R4494; EWEN B, 1980, FARADAY DISCUSS, V69, P19, DOI 10.1039/dc9806900019; Ezquerra TA, 1996, PHYS REV E, V54, P989, DOI 10.1103/PhysRevE.54.989; Gang H, 1998, EUROPHYS LETT, V43, P314, DOI 10.1209/epl/i1998-00358-9; HERHOLD AB, UNPUB; HIKOSAKA M, 1992, J MACROMOL SCI PHYS, VB31, P87, DOI 10.1080/00222349208215459; IMAI M, 1995, PHYS REV B, V52, P12696, DOI 10.1103/PhysRevB.52.12696; Keller A, 1998, POLYMER, V39, P4461, DOI 10.1016/S0032-3861(97)10320-2; KELLER A, 1994, J MATER SCI, V29, P2579, DOI 10.1007/BF00356806; Keller A, 1996, PHYS SCRIPTA, VT66, P243, DOI 10.1088/0031-8949/1996/T66/045; LIU XY, 1992, J CHEM PHYS, V97, P3600, DOI 10.1063/1.462943; LIU XY, 1993, J APPL CRYSTALLOGR, V26, P229, DOI 10.1107/S0021889892010987; LIU XY, 1994, J CRYST GROWTH, V135, P209, DOI 10.1016/0022-0248(94)90743-9; NYBURG SC, 1976, ACTA CRYSTALLOGR B, V32, P2289; Ocko BM, 1997, PHYS REV E, V55, P3164, DOI 10.1103/PhysRevE.55.3164; OLIVER MJ, 1975, J CRYST GROWTH, V30, P343, DOI 10.1016/0022-0248(75)90010-X; Olmsted PD, 1998, PHYS REV LETT, V81, P373, DOI 10.1103/PhysRevLett.81.373; OSTWALD W, 1897, Z PHYS CHEM, V22, P286; RASTOGI S, 1991, MACROMOLECULES, V24, P6384, DOI 10.1021/ma00024a003; SCHATZEL K, 1992, PHYS REV LETT, V68, P337, DOI 10.1103/PhysRevLett.68.337; Shen YC, 1996, PHYS REV LETT, V77, P3585, DOI 10.1103/PhysRevLett.77.3585; SIROTA EB, 1994, J CHEM PHYS, V101, P10873, DOI 10.1063/1.467837; SIROTA EB, 1995, J PHYS CHEM-US, V99, P798, DOI 10.1021/j100002a050; SIROTA EB, 1993, J CHEM PHYS, V98, P5809, DOI 10.1063/1.464874; Sirota EB, 1998, LANGMUIR, V14, P3133, DOI 10.1021/la970594s; Sirota EB, 1997, LANGMUIR, V13, P3849, DOI 10.1021/la9702291; SIROTA EB, 1998, SCIENCE, V281, P143; SMALL DM, 1986, PHYSICAL CHEM LIPIDS; SUTTON M, 1989, PHYS REV LETT, V62, P288, DOI 10.1103/PhysRevLett.62.288; Taggart AM, 1996, LANGMUIR, V12, P5722, DOI 10.1021/la9600816; TENWOLDE PR, 1995, PHYS REV LETT, V75, P2714, DOI 10.1103/PhysRevLett.75.2714; Terrill NJ, 1998, POLYMER, V39, P2381, DOI 10.1016/S0032-3861(97)00547-8; TURNBULL D, 1961, J CHEM PHYS, V34, P820, DOI 10.1063/1.1731681; UHLMANN DR, 1975, J CHEM PHYS, V62, P4896, DOI 10.1063/1.430402; UNGAR G, 1983, J PHYS CHEM-US, V87, P689, DOI 10.1021/j100227a032; UNGAR G, 1986, MACROMOLECULES, V19, P1317, DOI 10.1021/ma00159a006; Weinstein A, 1996, PHYS REV E, V53, pR45, DOI 10.1103/PhysRevE.53.R45; WU XZ, 1993, SCIENCE, V261, P1018, DOI 10.1126/science.261.5124.1018; YAMAMOTO T, 1995, J CHEM SOC FARADAY T, V91, P2559, DOI 10.1039/ft9959102559	43	183	186	1	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 22	1999	283	5401					529	532		10.1126/science.283.5401.529	http://dx.doi.org/10.1126/science.283.5401.529			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915698				2022-12-28	WOS:000078203300034
J	Schreiner, J; Voigt, C; Kohlmann, A; Amold, F; Mauersberger, K; Larsen, N				Schreiner, J; Voigt, C; Kohlmann, A; Amold, F; Mauersberger, K; Larsen, N			Chemical analysis of polar stratospheric cloud particles	SCIENCE			English	Article							NITRIC-ACID; AEROSOL; OZONE; WATER; HNO3	A balloon-borne gondola carrying a particle analysis system, a backscatter sonde, and pressure and temperature sensors was Launched from Kiruna, Sweden, on 25 January 1998. Measurements within polar stratospheric cloud Layers inside the Arctic polar vortex show a close correlation between Large backscatter ratios and enhanced particle-related water and nitric acid signals at low temperatures. Periodic structures in the data indicate the presence of lee waves. The H2O/HNO3 molar ratios are consistently found to be above 10 at atmospheric temperatures between 189 and 192 kelvin. Such high ratios indicate ternary solution particles of H2O, HNO3, and H2SO4 rather than the presence of solid hydrates.	Max Planck Inst Kernphys, Div Atmospher Phys, D-69029 Heidelberg, Germany; Danish Meteorol Inst, Div Middle Atmosphere Res, DK-2100 Copenhagen, Denmark	Max Planck Society; Danish Meteorological Institute DMI	Mauersberger, K (corresponding author), Max Planck Inst Kernphys, Div Atmospher Phys, POB 103 980, D-69029 Heidelberg, Germany.		Voigt, Christiane/G-3279-2010; Larsen, Niels/G-3145-2014	Voigt, Christiane/0000-0001-8925-7731; Larsen, Niels/0000-0002-1582-661X				ARNOLD F, 1989, NATURE, V338, P746, DOI 10.1038/338746a0; ARNOLD F, 1992, BER BUNSEN PHYS CHEM, V96, P339, DOI 10.1002/bbpc.19920960321; Carslaw KS, 1997, REV GEOPHYS, V35, P125, DOI 10.1029/97RG00078; Carslaw KS, 1998, J GEOPHYS RES-ATMOS, V103, P5785, DOI 10.1029/97JD03626; Carslaw KS, 1998, NATURE, V391, P675, DOI 10.1038/35589; CARSLAW KS, 1995, GEOPHYS RES LETT, V22, P1877, DOI 10.1029/95GL01668; CARSLAW KS, 1994, GEOPHYS RES LETT, V21, P2479, DOI 10.1029/94GL02799; CRUTZEN PJ, 1986, NATURE, V324, P651, DOI 10.1038/324651a0; Dornbrack A., 1998, METEOROL APPL, V5, P117, DOI DOI 10.1017/S1350482798000802; FAHEY DW, 1989, J GEOPHYS RES-ATMOS, V94, P11299, DOI 10.1029/JD094iD09p11299; FARMAN JC, 1985, NATURE, V315, P207, DOI 10.1038/315207a0; HANSON D, 1988, GEOPHYS RES LETT, V15, P855, DOI 10.1029/GL015i008p00855; KAWA SR, 1992, J GEOPHYS RES-ATMOS, V97, P7925, DOI 10.1029/91JD02016; Koop T, 1997, GEOPHYS RES LETT, V24, P2199, DOI 10.1029/97GL02148; LIU P, 1995, AEROSOL SCI TECH, V22, P293, DOI 10.1080/02786829408959748; MAUERSBERGER K, 1977, REV SCI INSTRUM, V48, P1169, DOI 10.1063/1.1135210; Murphy DM, 1998, SCIENCE, V282, P1664, DOI 10.1126/science.282.5394.1664; Peter T, 1996, SCIENCE, V273, P1352, DOI 10.1126/science.273.5280.1352; ROSEN JM, 1991, APPL OPTICS, V30, P1552, DOI 10.1364/AO.30.001552; SCHLAGER H, 1990, GEOPHYS RES LETT, V17, P1275, DOI 10.1029/GL017i009p01275; Schreiner J, 1998, AEROSOL SCI TECH, V29, P50, DOI 10.1080/02786829808965550; Tabazadeh A, 1996, J GEOPHYS RES-ATMOS, V101, P9071, DOI 10.1029/96JD00062; TABAZADEH A, 1994, GEOPHYS RES LETT, V21, P1619, DOI 10.1029/94GL01368; TOLBERT MA, 1994, SCIENCE, V264, P527, DOI 10.1126/science.264.5158.527; WORSNOP DR, 1993, SCIENCE, V259, P71, DOI 10.1126/science.259.5091.71	25	93	94	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					968	970		10.1126/science.283.5404.968	http://dx.doi.org/10.1126/science.283.5404.968			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974386				2022-12-28	WOS:000078574800043
J	Godfrey-Faussett, P				Godfrey-Faussett, P			Interpretation of cluster studies of tuberculosis	LANCET			English	Editorial Material							MYCOBACTERIUM-TUBERCULOSIS; EPIDEMIOLOGY; DIAGNOSIS		Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Godfrey-Faussett, P (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, Keppel St, London WC1E 7HT, England.							ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; GRYZBOWSKI S, 1975, B INT UNION TUBERC, V50, P90; GRYZBOWSKI S, 1978, B INT UNION TUBERC, V53, P70; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; THIERRY D, 1990, J CLIN MICROBIOL, V28, P2668, DOI 10.1128/JCM.28.12.2668-2673.1990; VANEMBDEN JD, 1993, J CLIN MICROBIOL, V31, P40; Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7	8	8	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 6	1999	353	9151					427	428		10.1016/S0140-6736(98)00352-3	http://dx.doi.org/10.1016/S0140-6736(98)00352-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989710				2022-12-28	WOS:000078572800006
J	McKay, J				McKay, J			An annoying sound	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					361	361		10.1136/bmj.318.7180.361	http://dx.doi.org/10.1136/bmj.318.7180.361			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933196	Green Published			2022-12-28	WOS:000078572600025
J	Salmon, P; Peters, S; Stanley, I				Salmon, P; Peters, S; Stanley, I			Patients' perceptions of medical explanations for somatisation disorders: qualitative analysis	BRITISH MEDICAL JOURNAL			English	Article							UNEXPLAINED PHYSICAL SYMPTOMS; CARE; SOMATIZATION; ILLNESS	Objectives To describe, from the perspective of patients, distinguishing features of doctors' attempts to explain the symptoms of somatisation disorders. Design Qualitative analysis of verbatim records of interviews in which patients recounted doctors' explanations of their symptoms. Setting Patients with persistent somatising symptoms referred from general practices in Liverpool and St Helens and Knowsley were interviewed before entry into a treatment programme. Subjects 228 of 324 patients referred were interviewed. Initial interviews were used to develop the process and technique, and the final analysis was based oil a subsample of G8 records, randomly chosen fi om the transcripts of 188 subjects who were interviewed subsequently. Results Doctors' explanations were often at odds with the patients' own thinking. Analysis showed that medical explanations could be grouped into one of three categories, defined hy the patients' perceptions. Most explanations were experienced as rejecting the reality of the symptoms. An intermediate category comprised explanations that were viewed as colluding, in which the doctor acquiesced with the patients' own biomedical theories. However, a few explanations were perceived by patients as tangible, exculpating, and involving. These explanations were experienced by patients as satisfying and empowering. Conclusions Patients with somatisation disorders feel satisfied and empowered by medical explanations that are tangible, exculpating, and involving. Empowering explanations could improve these patients' wellbeing and help to reduce tbe high demands they make on health services.	Univ Liverpool, Dept Primary Care, Liverpool L69 3GB, Merseyside, England; Univ Liverpool, Dept Clin Psychol, Liverpool L69 3GB, Merseyside, England	University of Liverpool; University of Liverpool	Stanley, I (corresponding author), Univ Liverpool, Dept Primary Care, Liverpool L69 3GB, Merseyside, England.		Salmon, Peter/H-5289-2018	Salmon, Peter/0000-0001-6450-5209				Audit Commission, 1993, WHAT SEEMS MATT COMM; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; BLAXTER M, 1983, SOC SCI MED, V17, P59, DOI 10.1016/0277-9536(83)90356-8; BORKAN J, 1995, SOC SCI MED, V40, P977, DOI 10.1016/0277-9536(94)00156-N; CRAIG T, 1990, SOMATISATION PHYSICA; Dey L, 1993, QUALITATIVE DATA ANA; GOLDBERG D, 1989, J PSYCHOSOM RES, V33, P689, DOI 10.1016/0022-3999(89)90084-6; GUBA EG, 1989, 4 GEN EVALUATION; HELMAN CG, 1985, CULT MED PSYCHIAT, V9, P1; Helman CG, 1994, CULTURE HLTH ILLNESS; HUNT LM, 1989, SOC SCI MED, V28, P945, DOI 10.1016/0277-9536(89)90324-9; KLEINMAN A, 1978, SOC SCI MED-MED ANTH, V12, P85, DOI 10.1016/0160-7987(78)90014-5; Mabeck CE, 1997, FAM PRACT, V14, P271, DOI 10.1093/fampra/14.4.271; MarchantHaycox S, 1997, PSYCHOSOMATICS, V38, P440, DOI 10.1016/S0033-3182(97)71421-X; Mayou R, 1997, BRIT MED J, V315, P561; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; *NHS EX, 1996, PAT PARTN BUILD COLL; Patton M. Q., 1990, QUALITATIVE EVALUATI; Peters S, 1998, SOC SCI MED, V46, P559, DOI 10.1016/S0277-9536(97)00200-1; PILL R, 1982, SOC SCI MED, V16, P43, DOI 10.1016/0277-9536(82)90422-1; Royal College of General Practitioners Office of Population Consensus & Survey. Department of Health, 1995, MORB STAT GEN PRACT; SALMON P, 1995, INT J PSYCHIAT MED, V25, P309; SHORTER E, 1995, J PSYCHOSOM RES, V39, P115, DOI 10.1016/0022-3999(94)00119-P; Shorter E., 1992, PARALYSIS FATIGUE HI; SIMPSON M, 1991, BRIT MED J, V303, P1385, DOI 10.1136/bmj.303.6814.1385; SMITH GR, 1994, PSYCHOSOMATICS, V35, P263, DOI 10.1016/S0033-3182(94)71774-6; SPECKENS AEM, 1995, BRIT MED J, V311, P1328, DOI 10.1136/bmj.311.7016.1328; Speckens AEM, 1996, PSYCHOL MED, V26, P745, DOI 10.1017/S0033291700037764; STILES WB, 1993, CLIN PSYCHOL REV, V13, P593, DOI 10.1016/0272-7358(93)90048-Q; STIMSON GV, 1974, SOC SCI MED, V8, P97, DOI 10.1016/0037-7856(74)90039-0; Toombs SK, 1993, MEANING ILLNESS PHEN; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	32	229	229	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					372	376		10.1136/bmj.318.7180.372	http://dx.doi.org/10.1136/bmj.318.7180.372			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	166JN	9933202	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000078572600030
J	Bradwell, AR; Harvey, TC				Bradwell, AR; Harvey, TC			Control of hypercalcaemia of parathyroid carcinoma by immunisation	LANCET			English	Article							T-CELL EPITOPES; PERIPHERAL METABOLISM; PEPTIDE VACCINE; MANAGEMENT; FEATURES; HORMONE	Background Patients with parathyroid tumours can develop extreme hypercalcaemia and osteitis fibrosa cystica. Clinical features result from the action of parathyroid hormone (PTH) on bone receptors. Because this hormone is produced in microgram quantities, inhibition of its metabolic effects with potent PTH antibodies should be possible. We tested whether an immunisation with synthetic human and bovine PTH peptides could stimulate autoantibodies against PTH. Methods A patient with metastatic parathyroid carcinoma in the lungs and pleura developed severe bone disease and extreme; hypercalcaemia that proved resistant to conventional therapy. She was immunised with 200 mu g human and bovine PTH peptides and 50 mu g human PTH. Booster doses were also given at 4 weeks and 11 weeks. The patient was then seen every week. Findings Antibodies against PTH were produced within 4 weeks of initial immunisation and titres increased with repeated doses of immunogens. Total serum calcium concentrations, which had ranged from 3.5 mmol/L to 4.2 mmol/L over the previous 18 months, fell to between 2.5 mmol/L and 3.0 mmol/L over 6 months of therapy. This fall was accompanied by striking clinical improvement. Interpretation We believe this is the first use of immunotherapy to control remote, non-metastatic complications of malignant disease. B-cell tolerance to human PTH was broken by immunisation with PTH peptides in adjuvant. This therapeutic approach could be used to control excess hormone production in several types of endocrine tumour and may have applications in other diseases.	Univ Birmingham, Sch Med, Dept Immunol, Birmingham B15 2TT, W Midlands, England; Walsall Manor Hosp NHS Trust, Dept Med, Walsall, W Midlands, England	University of Birmingham	Bradwell, AR (corresponding author), Univ Birmingham, Sch Med, Dept Immunol, Birmingham B15 2TT, W Midlands, England.	a.r.bradwell@bham.ac.uk		Bradwell, Arthur/0000-0002-1562-1606				ANDERSON BJ, 1983, SURGERY, V94, P906; BRINGHURST FR, 1988, AM J PHYSIOL, V255, pE886, DOI 10.1152/ajpendo.1988.255.6.E886; Collins MT, 1998, J CLIN ENDOCR METAB, V83, P1083, DOI 10.1210/jc.83.4.1083; Fishman P, 1997, CANCER, V79, P1461, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1461::AID-CNCR3>3.0.CO;2-E; GRILLOT D, 1993, INFECT IMMUN, V61, P3064, DOI 10.1128/IAI.61.7.3064-3067.1993; HARLOW E, 1988, ANTIBODIES LABORATOR, P178; HOLLINSHEAD A, 1988, CANCER, V62, P1662, DOI 10.1002/1097-0142(19881015)62:8<1662::AID-CNCR2820620835>3.0.CO;2-X; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; MACLENNAN R, 1965, B WORLD HEALTH ORGAN, V32, P683; MAMULA MJ, 1992, J IMMUNOL, V149, P789; MARTIN KJ, 1979, NEW ENGL J MED, V301, P1092, DOI 10.1056/NEJM197911153012005; POL S, 1994, LANCET, V344, P342, DOI 10.1016/S0140-6736(94)91384-6; SANDELIN K, 1991, SURGERY, V110, P978; SCHANTZ A, 1973, CANCER-AM CANCER SOC, V31, P600, DOI 10.1002/1097-0142(197303)31:3<600::AID-CNCR2820310316>3.0.CO;2-0; Shu SY, 1997, JAMA-J AM MED ASSOC, V278, P1972, DOI 10.1001/jama.278.22.1972; STEWART THM, 1976, ANN NY ACAD SCI, V277, P436, DOI 10.1111/j.1749-6632.1976.tb41720.x; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; WANG RB, 1995, J IMMUNOL, V154, P2784; WYNNE AG, 1992, MEDICINE, V71, P197, DOI 10.1097/00005792-199207000-00002	19	74	79	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 30	1999	353	9150					370	373		10.1016/S0140-6736(98)06469-1	http://dx.doi.org/10.1016/S0140-6736(98)06469-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950443				2022-12-28	WOS:000078437000013
J	Giesecke, J				Giesecke, J			Choosing diseases for surveillance	LANCET			English	Editorial Material									Swedish Inst Infect Dis Control, Dept Epidemiol, S-17182 Solna, Sweden	Swedish Institute for Infectious Disease Control	Giesecke, J (corresponding author), Swedish Inst Infect Dis Control, Dept Epidemiol, S-17182 Solna, Sweden.							Carter A, 1991, Can J Infect Dis, V2, P37; RUSHDY A, 1998, CDR REPORT S, V8	2	10	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 30	1999	353	9150					344	344		10.1016/S0140-6736(05)74946-1	http://dx.doi.org/10.1016/S0140-6736(05)74946-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950437				2022-12-28	WOS:000078437000007
J	Taylor, DH; Esmail, A				Taylor, DH; Esmail, A			Retrospective analysis of census data on general practitioners who qualified in south Asia: Who will replace them as they retire?	BRITISH MEDICAL JOURNAL			English	Article							UNITED-KINGDOM; MEDICAL-SCHOOLS; DROP-OUT; DOCTORS; ENGLAND	Objectives To determine the number and geographical distribution of general practitioners in the NHS who qualified medically in South Asia and to project their numbers as they retire. Design Retrospective analysis of yearly data and projection of future trends, Setting England and Wales. Subjects General practitioners who qualified medically in the countries of Bangladesh, India, Pakistan, and Sri Lanka and who were practising in the NHS on 1 October 1992, Main outcome measures Proportion and age of general practitioners who qualified in South Asia by health authority; the Benzeval and Judge measure of population need at the health authority level. Results 4192 of 25333 (16.5%) of all unrestricted general practitioners practising full time on 1 October 1992 qualified in South Asian medical schools. The proportion varied by health authority from 0.007% to 56.5%. Roughly two thirds who were practising in 1992 will have retired by 2007; in some health authorities this will represent a loss of one in four general practitioners. The practices that these doctors will leave seem to be in relatively deprived areas as measured by deprivation payments and a health authority measure of population need. Conclusion Many general practitioners who qualified in South Asian medical schools will retire within the next decade. The impact will vary greatly by health authority. Those health authorities with the greatest number of such doctors are in some of the most deprived areas in the United Kingdom and have experienced the most difficulty in filling vacancies, Various responses will be required by workforce planners to mitigate the impact of these retirements.	Duke Univ, Ctr Hlth Policy Law & Management, Durham, NC 27708 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Duke University; Harvard University; Harvard Medical School	Taylor, DH (corresponding author), Duke Univ, Ctr Hlth Policy Law & Management, Box 90253, Durham, NC 27708 USA.		Esmail, Aneez/I-6903-2013					Benzeval M, 1996, J PUBLIC HEALTH MED, V18, P33, DOI 10.1093/oxfordjournals.pubmed.a024459; *BRIT MED ASS, 1995, COR VAL MED PROF 21; CLAWSON DK, 1993, ROLES PHYSICIAN ASSI; ESMAIL A, 1994, BRIT MED J, V308, P1374; ESMAIL A, 1993, BRIT MED J, V306, P691, DOI 10.1136/bmj.306.6879.691; Lambert TW, 1997, BRIT MED J, V314, P1591, DOI 10.1136/bmj.314.7094.1591; Lambert TW, 1996, BRIT MED J, V313, P19, DOI 10.1136/bmj.313.7048.19; LEESE B, 1989, BRIT MED J, V298, P932, DOI 10.1136/bmj.298.6678.932; Mcmanus IC, 1996, BRIT MED J, V313, P173, DOI 10.1136/bmj.313.7050.173a; Parkhouse J, 1996, BRIT MED J, V312, P885; PARKHOUSE J, 1997, BRIT MED J, V314, P1890; PETCHEY R, 1996, JUNIOR DOCTORS MED C; *REV BOD DOCT DENT, 1996, 25 REP 1996; Richards P, 1997, BRIT MED J, V314, P1567, DOI 10.1136/bmj.314.7094.1567; SMITH D, 1980, OVERSEAS DOCTORS NAT; Taylor DH, 1997, BRIT MED J, V314, P1806, DOI 10.1136/bmj.314.7097.1806; Taylor DH, 1998, BRIT J GEN PRACT, V48, P1070; Taylor DH, 1997, J PUBLIC HEALTH MED, V19, P341, DOI 10.1093/oxfordjournals.pubmed.a024641; [No title captured]; 1996, GP NEWS         0719, P2	20	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1999	318	7179					306	310		10.1136/bmj.318.7179.306	http://dx.doi.org/10.1136/bmj.318.7179.306			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZH	9924060	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000078436700026
J	Bringuier, V; Chavane, F; Glaeser, L; Fregnac, Y				Bringuier, V; Chavane, F; Glaeser, L; Fregnac, Y			Horizontal propagation of visual activity in the synaptic integration field of area 17 neurons	SCIENCE			English	Article							RECEPTIVE-FIELDS; POSTSYNAPTIC POTENTIALS; STRIATE CORTEX; CAT; CONNECTIONS; RAT; ORGANIZATION; EXCITATION; INHIBITION; RESPONSES	The receptive field of a visual neuron is classically defined as the region of space (or retina) where a visual stimulus evokes a change in its firing activity. At the cortical Level, a challenging issue concerns the roles of feedforward, Local recurrent, intracortical, and cortico-cortical feedback connectivity in receptive field properties. Intracellular recordings in cat area 17 showed that the visually evoked synaptic integration field extends over a much Larger area than that established on the basis of spike activity. Synaptic depolarizing responses to stimuli flashed at increasing distances from the center of the receptive field decreased in strength, whereas their onset Latency increased. These findings suggest that subthreshold responses in the unresponsive region surrounding the classical discharge field result from the integration of visual activation waves spread by slowly conducting horizontal axons within primary visual cortex.	CNRS, Inst Alfred Fessard, Equipe Cognisci, F-98118 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Fregnac, Y (corresponding author), CNRS, Inst Alfred Fessard, Equipe Cognisci, Ave Terresse, F-98118 Gif Sur Yvette, France.		Chavane, Frederic/ABB-1487-2021	Chavane, Frederic/0000-0001-7916-2640				ALBUS K, 1975, EXP BRAIN RES, V24, P181, DOI 10.1007/BF00234062; BISHOP PO, 1971, J PHYSIOL-LONDON, V219, P625, DOI 10.1113/jphysiol.1971.sp009681; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; Borg-Graham LJ, 1998, NATURE, V393, P369, DOI 10.1038/30735; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; CREUTZFELDT O, 1968, EXP BRAIN RES, V6, P324; DAS A, 1995, NATURE, V375, P780, DOI 10.1038/375780a0; DEANGELIS GC, 1994, J NEUROPHYSIOL, V71, P347, DOI 10.1152/jn.1994.71.1.347; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P735, DOI 10.1113/jphysiol.1991.sp018733; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRINVALD A, 1994, J NEUROSCI, V14, P2545; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; HOFFMANN KP, 1971, BRAIN RES, V32, P460, DOI 10.1016/0006-8993(71)90340-4; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; HUMPHREY AL, 1985, J COMP NEUROL, V233, P159, DOI 10.1002/cne.902330203; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; KISVARDAY ZF, 1993, EUR J NEUROSCI, V5, P1558, DOI 10.1111/j.1460-9568.1993.tb00226.x; LI CY, 1994, VISION RES, V34, P2337, DOI 10.1016/0042-6989(94)90280-1; MAFFEI L, 1976, VISION RES, V16, P1131, DOI 10.1016/0042-6989(76)90253-4; MURAKOSHI T, 1993, NEUROSCI LETT, V163, P211, DOI 10.1016/0304-3940(93)90385-X; NELSON DA, 1995, NEURON, V15, P23, DOI 10.1016/0896-6273(95)90061-6; ORBAN G, 1984, STUD BRAIN FUNCT, V11, P365; PEI X, 1994, J NEUROSCI, V14, P7130; Rosenquist AC., 1985, CEREB CORTEX, P81; Salin PA, 1996, J NEUROPHYSIOL, V75, P1589, DOI 10.1152/jn.1996.75.4.1589; SALIN PA, 1995, PHYSIOL REV, V75, P107, DOI 10.1152/physrev.1995.75.1.107; SHULZ D, 1993, SOC NEUR ABSTR, V19, P638; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; TUSA RJ, 1978, J COMP NEUROL, V177, P213, DOI 10.1002/cne.901770204	30	403	405	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					695	699		10.1126/science.283.5402.695	http://dx.doi.org/10.1126/science.283.5402.695			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924031				2022-12-28	WOS:000078324400045
J	Miyoshi, H; Smith, KA; Mosier, DE; Verma, IM; Torbett, BE				Miyoshi, H; Smith, KA; Mosier, DE; Verma, IM; Torbett, BE			Transduction of human CD34(+) cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors	SCIENCE			English	Article							LENTIVIRAL VECTOR; GENE-TRANSFER; HEMATOPOIETIC-CELLS; NONDIVIDING CELLS; CORD-BLOOD; IN-VIVO; EFFICIENT; THERAPY; STEM; EXPRESSION	Efficient gene transfer into human hematopoietic stem cells (HSCs) is an important goal in the study of the hematopoietic system as well as for gene therapy of hematopoietic disorders. A Lentiviral vector based on the human immunodeficiency virus (HIV) was able to transduce human CD34(+) cells capable of stable, Long-term reconstitution of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. High-efficiency transduction occurred in the absence of cytokine stimulation and resulted in transgene expression in multiple Lineages of human hematopoietic cells for up to 22 weeks after transplantation.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Salk Institute; Scripps Research Institute	Verma, IM (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Miyoshi, Hiroyuki/G-9808-2013		NCI NIH HHS [CA44360] Funding Source: Medline; NHLBI NIH HHS [HL53670] Funding Source: Medline; NIDDK NIH HHS [DK49886] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044360] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049886] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akkina RK, 1996, J VIROL, V70, P2581, DOI 10.1128/JVI.70.4.2581-2585.1996; Bhatia M, 1998, NAT MED, V4, P1038, DOI 10.1038/2023; Bhatia M, 1997, J EXP MED, V186, P619, DOI 10.1084/jem.186.4.619; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; Blomer U, 1997, J VIROL, V71, P6641; Cheng LZ, 1998, BLOOD, V92, P83, DOI 10.1182/blood.V92.1.83.413k09_83_92; Conneally E, 1998, BLOOD, V91, P3487, DOI 10.1182/blood.V91.9.3487.3487_3487_3493; Dick J E, 1996, Semin Immunol, V8, P197, DOI 10.1006/smim.1996.0025; Hao QL, 1996, BLOOD, V88, P3306, DOI 10.1182/blood.V88.9.3306.bloodjournal8893306; Havenga M, 1997, STEM CELLS, V15, P162, DOI 10.1002/stem.150162; Hogan CJ, 1997, BLOOD, V90, P85; Kafri T, 1999, J VIROL, V73, P576, DOI 10.1128/JVI.73.1.576-584.1999; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; Kiem HP, 1998, BLOOD, V92, P1878, DOI 10.1182/blood.V92.6.1878.418k39_1878_1886; Kim VN, 1998, J VIROL, V72, P811, DOI 10.1128/JVI.72.1.811-816.1998; Kohn DB, 1996, BONE MARROW TRANSPL, V18, pS55; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Marandin A, 1998, HUM GENE THER, V9, P1497, DOI 10.1089/hum.1998.9.10-1497; MCNIECE IK, 1989, BLOOD, V74, P609; METCALF D, 1979, CLIN HAEMATOL, V8, P263; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nienhuis AW, 1997, STEM CELLS, V15, P123, DOI 10.1002/stem.5530150816; Poeschla E, 1996, P NATL ACAD SCI USA, V93, P11395, DOI 10.1073/pnas.93.21.11395; REINHARDT B, 1994, AIDS RES HUM RETROV, V10, P131, DOI 10.1089/aid.1994.10.131; Reiser J, 1996, P NATL ACAD SCI USA, V93, P15266, DOI 10.1073/pnas.93.26.15266; Schilz AJ, 1998, BLOOD, V92, P3163, DOI 10.1182/blood.V92.9.3163.421k25_3163_3171; SHULTZ LD, 1995, J IMMUNOL, V154, P180; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; Sutton RE, 1998, J VIROL, V72, P5781, DOI 10.1128/JVI.72.7.5781-5788.1998; Uchida N, 1998, P NATL ACAD SCI USA, V95, P11939, DOI 10.1073/pnas.95.20.11939; van Hennik PB, 1998, BLOOD, V92, P4013, DOI 10.1182/blood.V92.11.4013.423k53_4013_4022; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; WILLIAMS DA, 1993, BLOOD, V81, P3169; Wu Q, 1995, NUCLEIC ACIDS RES, V23, P5087, DOI 10.1093/nar/23.24.5087; Zanjani ED, 1998, EXP HEMATOL, V26, P353; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	39	539	590	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					682	686		10.1126/science.283.5402.682	http://dx.doi.org/10.1126/science.283.5402.682			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924027				2022-12-28	WOS:000078324400041
J	Gomez, TM; Spitzer, NC				Gomez, TM; Spitzer, NC			In vivo regulation of axon extension and pathfinding by growth-cone calcium transients	NATURE			English	Article							MIGRATION; DYNAMICS; BEHAVIOR	Growth cones at the tips of extending neurites migrate through complex environments in the developing nervous system and guide axons to appropriate target regions using local cues(1,2). The intracellular calcium concentration ([Ca2+](i)) of growth cones correlates with motility in vitro(3-7), but the physiological links between environmental cues and axon growth in vivo are unknown. Here we report that growth cones generate transient elevations of [Ca2+](i) as they migrate within the embryonic spinal cord and that the rate of axon outgrowth is inversely proportional to the frequency of transients. Suppressing Ca2+ transients by photorelease of a Ca2+ chelator accelerates axon extension, whereas mimicking transients with photorelease of Ca2+ slows otherwise rapid axonal growth. The frequency of Ca2+ transients is cell-type specific and depends on the position of growth cones along their pathway. Furthermore, growth-cone stalling and axon retraction, which are two important aspects of pathfinding(8-10), are associated with high frequencies of Ca2+ transients. Our results indicate that environmentally regulated growth-cone Ca2+ transients control axon growth in the developing spinal cord.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Gomez, TM (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.			Gomez, Timothy/0000-0002-1515-8228; Spitzer, Nicholas/0000-0002-3523-1103				BOVOLENTA P, 1987, J NEUROSCI, V7, P1447; CHIEN CB, 1993, NEURON, V11, P237, DOI 10.1016/0896-6273(93)90181-P; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; GHOSH A, 1992, J NEUROSCI, V12, P39; GODEMENT P, 1994, J NEUROSCI, V14, P7024; GOMEZ TM, 1995, NEURON, V14, P1233, DOI 10.1016/0896-6273(95)90270-8; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GU XN, 1994, J NEUROSCI, V14, P6325; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; Hagg T, 1997, BRAIN RES, V764, P17, DOI 10.1016/S0006-8993(97)00419-8; KATER SB, 1991, J NEUROSCI, V11, P891; KATER SB, 1988, TRENDS NEUROSCI, V11, P315, DOI 10.1016/0166-2236(88)90094-X; Komuro H, 1996, NEURON, V17, P275, DOI 10.1016/S0896-6273(00)80159-2; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; MCFARLANE S, 1995, NEURON, V15, P1017, DOI 10.1016/0896-6273(95)90091-8; MYERS PZ, 1993, J NEUROSCI, V13, P127; NIEUWKOOP JM, 1967, NORMAL TABLE XENOPUS; ROBERTS A, 1982, PHILOS T R SOC B, V296, P195, DOI 10.1098/rstb.1982.0002; SNOW DM, 1994, DEV BIOL, V166, P87, DOI 10.1006/dbio.1994.1298; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TOSNEY KW, 1985, DEV BIOL, V109, P193, DOI 10.1016/0012-1606(85)90360-4; Tymianski M, 1997, CELL CALCIUM, V21, P175, DOI 10.1016/S0143-4160(97)90042-7; Tymianski M, 1997, CELL CALCIUM, V22, P111, DOI 10.1016/S0143-4160(97)90111-1; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	25	401	412	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 28	1999	397	6717					350	355		10.1038/16927	http://dx.doi.org/10.1038/16927			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9950427				2022-12-28	WOS:000078324600050
J	Davidson, TA; Caldwell, ES; Curtis, JR; Hudson, LD; Steinberg, KP				Davidson, TA; Caldwell, ES; Curtis, JR; Hudson, LD; Steinberg, KP			Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE; PULMONARY-FUNCTION; INTENSIVE-CARE; QUESTIONNAIRE; ABNORMALITIES; PREDICTION; INJURY; RISK	Context Health-related quality of life (HRQL) is reduced in patients who survive acute respiratory distress (ARDS), but whether this decline in HRQL is caused by ARDS or other aspects of the patient's illness or injury is unknown. Objective To determine if there are differences in the HRQL of ARDS survivors and comparably ill or injured controls without ARDS. Design Prospective, matched, parallel cohort study. Setting A 411-bed municipal medical and regional level I trauma center. Patients Seventy-three pairs of ARDS survivors and severity-matched controls with the clinical risk factors for ARDS of sepsis and trauma admitted between January 1, 1994, and July 30, 1996, Main Outcome Measures The HRQL of ARDS survivors and controls, assessed by generic and pulmonary disease-specific HRQL instruments (Medical Outcomes Study 36-Item Short Form Health Survey, Standard Form [SF-36] and St George's Respiratory Questionnaire [SGRQ], respectively). Results Clinically meaningful and statistically significant reductions in HRQL scores of ARDS survivors (n = 73) were seen in 7 of 8 SF-36 domains and 3 of 3 SGRQ domains compared with matched controls (P<.001 for all reductions). The largest decrements in the HRQL were seen in physical function and pulmonary symptoms and limitations. Analysis of trauma-matched pairs (n = 46) revealed significant reductions in 7 of 8 SF-36 domains (P less than or equal to.02) and 3 of 3 SGRQ domains (P less than or equal to.003). Analysis of sepsis-matched pairs (n = 27) revealed significant reductions in 6 of 8 SF-36 domains (P less than or equal to.05) and 3 of 3 SGRQ domains (P less than or equal to.002). Conclusions Survivors of ARDS have a clinically significant reduction in HRQL that appears to be caused exclusively by ARDS and its sequelae, Reductions were primarily noted in physical functioning and pulmonary disease-specific domains.	Univ Washington, Sch Med, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Steinberg, KP (corresponding author), Harborview Med Ctr, Div Pulm & Crit Care Med, Box 359762,325 9th Ave, Seattle, WA 98104 USA.				NHLBI NIH HHS [HL 30542] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL030542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1972, JAMA, V220, P717; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Chrispin PS, 1997, ANAESTHESIA, V52, P15, DOI 10.1111/j.1365-2044.1997.015-az014.x; ELLIOTT CG, 1987, AM REV RESPIR DIS, V135, P634; ELLIOTT CG, 1981, AM REV RESPIR DIS, V123, P492; GHIO AJ, 1989, AM REV RESPIR DIS, V140, P862; GHIO AJ, 1989, AM REV RESPIR DIS, V139, P1158, DOI 10.1164/ajrccm/139.5.1158; Heyland DK, 1998, CRIT CARE MED, V26, P591, DOI 10.1097/00003246-199803000-00037; HOPKINS RO, 1996, CHEST S, V110, pS58; HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182; HUDSON LD, 1994, CHEST, V105, pS123, DOI 10.1378/chest.105.3_Supplement.123S; JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Jones PW, 1997, AM J RESP CRIT CARE, V155, P1283, DOI 10.1164/ajrccm.155.4.9105068; JONES PW, 1994, EUR RESPIR J, V7, P55, DOI 10.1183/09031936.94.07010055; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; MCHUGH LG, 1994, AM J RESP CRIT CARE, V150, P90, DOI 10.1164/ajrccm.150.1.8025779; MUELLER BA, 1990, AM J EPIDEMIOL, V132, P550, DOI 10.1093/oxfordjournals.aje.a115691; PETERS JI, 1989, AM REV RESPIR DIS, V139, P1163, DOI 10.1164/ajrccm/139.5.1163; RIDLEY S, 1994, ANAESTHESIA, V49, P192; RIDLEY SA, 1990, ANAESTHESIA, V45, P808, DOI 10.1111/j.1365-2044.1990.tb14560.x; Schelling G, 1998, CRIT CARE MED, V26, P651, DOI 10.1097/00003246-199804000-00011; Ware J.E., 1993, SF 36 HLTH SURV MAN; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weinert CR, 1997, AM J RESP CRIT CARE, V156, P1120, DOI 10.1164/ajrccm.156.4.9611047; Wilson CB, 1997, AM J RESP CRIT CARE, V156, P536, DOI 10.1164/ajrccm.156.2.9607083	26	287	294	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1999	281	4					354	360		10.1001/jama.281.4.354	http://dx.doi.org/10.1001/jama.281.4.354			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158JB	9929089	Bronze			2022-12-28	WOS:000078111300035
J	Pecoul, B; Chirac, P; Trouiller, P; Pinel, J				Pecoul, B; Chirac, P; Trouiller, P; Pinel, J			Access to essential drugs in poor countries - A lost battle?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Drugs offer a simple, cost-effective solution to many health problems, provided they are available, affordable, and properly used. However, effective treatment is lacking in poor countries for many diseases, including African trypanosomiasis, Shigella dysentery, leishmaniasis, tuberculosis, and bacterial meningitis, Treatment may be precluded because no effective drug exists, it is too expensive, or it has been withdrawn from the market. Moreover, research and development in tropical diseases have come to a near standstill. This article focuses on the problems of access to quality drugs for the treatment of diseases that predominantly affect the developing world: (1) poor-quality and counterfeit drugs; (2) lack of availability of essential drugs due to fluctuating production or prohibitive cost; (3) need to develop field-based drug research to determine optimum utilization and remotivate research and development for new drugs for the developing world; and (4) potential consequences of recent World Trade Organization agreements on the availability of old and new drugs, These problems are not independent and unrelated but are a result of the fundamental nature of the pharmaceutical market and the way it is regulated.	Fdn Med Sans Frontieres, F-75011 Paris, France		Pecoul, B (corresponding author), Fdn Med Sans Frontieres, 8 Rue St Sabin, F-75011 Paris, France.	office@paris.msf.org						*CDCP, 1993, MORT DYS AFR FOLL UP; COLLSECK A, 1998, 12 INT C AIDS JUN 28; Correa CM, 1997, URUGUAY ROUND DRUGS; CROFTON J, 1997, WHOTB6210; DOUA F, 1987, AM J TROP MED HYG, V37, P525, DOI 10.4269/ajtmh.1987.37.525; Grabowski H, 1997, PHARMACOECONOMICS, V11, P389, DOI 10.2165/00019053-199711050-00002; *HARV SCH PUBL HLT, 1996, INT STRAT TROP DIS T; *INT FED PHARM MAN, 1997, INT PROP PAT PHARM; KADDAR M, 1995, REV PRECRIRE, V157, P844; LANJOUW JO, 1998, INTRO PHARM PROD PAT; LEGROS D, 1997, 24 INT SCI COUNC TRY; O'Brien KL, 1998, JAMA-J AM MED ASSOC, V279, P1175, DOI 10.1001/jama.279.15.1175; Olliario P, 1997, TROP MED INT HEALTH, V2, P113, DOI 10.1046/j.1365-3156.1997.d01-234.x; PAQUET C, 1994, LANCET, V344, P823, DOI 10.1016/S0140-6736(94)92381-7; PAQUET C, 1993, LANCET, V342, P175, DOI 10.1016/0140-6736(93)91378-Y; Paquet C, 1995, Sante, V5, P181; PECOUL B, 1991, LANCET, V338, P862, DOI 10.1016/0140-6736(91)91511-R; PINEL J, 1997, MED MALADIES INFECT, V27, P1; ROZEK RP, 1998, EFF PAT PROT PRIC PH; Shakoor O, 1997, TROP MED INT HEALTH, V2, P839, DOI 10.1046/j.1365-3156.1997.d01-403.x; TANDON BN, 1996, EPIDEMIOL INFECT, V117, P313; *TROP DIS RES, 1995, INV ER TROP DIS RES, P9; Trouiller P, 1996, Sante, V6, P299; TROUILLER P, 1998, 8 INT C INF DIS MAY; *UNICEF SUPPL DIV, 1995, ESS DRUGS PRIC LIST; VARAINE F, 1998, 8 INT C INF DIS MAY; Velasquez German, 1998, HLTH EC DRUGS DAP SE, P25; *WHO, 1997, B WKLY EPIDEMIOL REC, V72, P313; WHO, 1996, WHO TECHN REP SER, V863; *WHO, 1996, WHO DRUG INFORMATION, V4, P182; *WHO, 1992, WHODMPCFD92; World Health Organization, 1995, WHO DRUG INF, V9, P127; World Health Organization, 1998, WORLD HLTH STAT ANN	33	217	221	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1999	281	4					361	367		10.1001/jama.281.4.361	http://dx.doi.org/10.1001/jama.281.4.361			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158JB	9929090				2022-12-28	WOS:000078111300036
J	Pust, RE				Pust, RE			Underlying cause	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1999	281	3					215	216		10.1001/jama.281.3.215	http://dx.doi.org/10.1001/jama.281.3.215			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157GK	9918461				2022-12-28	WOS:000078052800001
J	Kitamura, K; Tokunaga, M; Iwane, AH; Yanagida, T				Kitamura, K; Tokunaga, M; Iwane, AH; Yanagida, T			A single myosin head moves along an actin filament with regular steps of 5.3 nanometres	NATURE			English	Article							RABBIT SKELETAL-MUSCLE; MOLECULE ANALYSIS; SLIDING DISTANCE; ACTOMYOSIN MOTOR; FORCE MICROSCOPY; STRIATED-MUSCLE; SMOOTH-MUSCLE; F-ACTIN; ONE ATP; MOVEMENT	Actomyosin, a complex of actin filaments and myosin motor proteins, is responsible for force generation during muscle contraction. To resolve the individual mechanical events of force generation by actomyosin, we have developed a new Instrument with which we can capture and directly manipulate individual myosin subfragment-1 molecules using a scanning probe. Single subfragment-1 molecules can be visualized by using a fluorescent label. The data that we obtain using this technique are consistent with myosin moving along an actin filament with single mechanical steps of approximately 5.3 nanometres; groups of two to five rapid steps In succession often produce displacements of 11 to 30 nanometres. This multiple stepping is produced by a single myosin head during just one biochemical cycle of ATP hydrolysis.	JST, ERATO, Yanagida BioMotron Project, Osaka 5620035, Japan; Osaka Univ, Dept Biophys Engn, Osaka 5608531, Japan; Osaka Univ, Sch Med, Dept Physiol 1, Osaka 5650871, Japan; Natl Inst Genet, Struct Biol Ctr, Shizuoka 4118540, Japan; JST, Single Mol Proc Project, ICORP, Osaka 5620035, Japan	Japan Science & Technology Agency (JST); Osaka University; Osaka University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Japan Science & Technology Agency (JST)	Yanagida, T (corresponding author), JST, ERATO, Yanagida BioMotron Project, 2-4-14 Senba Higashi, Osaka 5620035, Japan.	yanagida@phys1.med.osaka-u.ac.jp	Kitamura, Kazuo/F-3379-2013; Yanagida, Toshio/D-1919-2009	Kitamura, Kazuo/0000-0002-8956-4122; Tokunaga, Makio/0000-0003-4586-8922				Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Bagshaw CR., 1993, MUSCLE CONTRACTION, DOI 10.1007/978-94-015-6839-5; Bevington PR., 2002, DATA REDUCTION ERROR; Cooke R, 1997, PHYSIOL REV, V77, P671, DOI 10.1152/physrev.1997.77.3.671; CRAIG SW, 1982, METHOD ENZYMOL, V85, P316; EGELMAN EH, 1982, NATURE, V298, P131, DOI 10.1038/298131a0; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Guilford WH, 1997, BIOPHYS J, V72, P1006, DOI 10.1016/S0006-3495(97)78753-8; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Huxley AF, 1996, J MUSCLE RES CELL M, V17, P507, DOI 10.1007/BF00123366; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1967, J MOL BIOL, V30, P383, DOI 10.1016/S0022-2836(67)80046-9; HUXLEY HE, 1969, SCIENCE, V164, P1355; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; Ishijima A, 1996, BIOPHYS J, V70, P383, DOI 10.1016/S0006-3495(96)79582-6; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; Iwane AH, 1997, BIOCHEM BIOPH RES CO, V230, P76, DOI 10.1006/bbrc.1996.5861; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KADO H, 1992, REV SCI INSTRUM, V63, P3330, DOI 10.1063/1.1142548; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KITANO M, 1990, J CRYST GROWTH, V102, P965, DOI 10.1016/0022-0248(90)90867-K; KLIBANOV AM, 1995, NATURE, V374, P596, DOI 10.1038/374596a0; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Mehta AD, 1997, P NATL ACAD SCI USA, V94, P7927, DOI 10.1073/pnas.94.15.7927; MIYATA H, 1994, J BIOCHEM, V115, P644, DOI 10.1093/oxfordjournals.jbchem.a124389; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Saito K, 1997, J MICROSC-OXFORD, V188, P255, DOI 10.1046/j.1365-2818.1997.2580814.x; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Tanaka H, 1998, BIOPHYS J, V75, P1886, DOI 10.1016/S0006-3495(98)77629-5; Tokunaga M, 1997, BIOCHEM BIOPH RES CO, V231, P566, DOI 10.1006/bbrc.1997.6144; Tokunaga M, 1997, BIOCHEM BIOPH RES CO, V235, P47, DOI 10.1006/bbrc.1997.6732; Wand M.P., 1994, KERNEL SMOOTHING; WOLEDGE RC, 1985, ENERGETIC ASPECTS MU, pCH3; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	50	446	459	1	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1999	397	6715					129	134		10.1038/16403	http://dx.doi.org/10.1038/16403			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923673				2022-12-28	WOS:000078085000035
J	Agarwal, SK; Guru, SC; Heppner, C; Erdos, MR; Collins, RM; Park, SY; Saggar, S; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Marx, SJ; Burns, AL				Agarwal, SK; Guru, SC; Heppner, C; Erdos, MR; Collins, RM; Park, SY; Saggar, S; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Marx, SJ; Burns, AL			Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription	CELL			English	Article							ENDOCRINE NEOPLASIA TYPE-1; C-JUN; PARATHYROID TUMORS; FOS PROTEINS; GENE; CELLS; AP-1; ONCOPROTEIN; MUTATIONS; DOMAIN	MEN1 is a tumor suppressor gene that encodes a 610 amino acid nuclear protein (menin) of previously unknown function. Using a yeast two-hybrid screen with menin as the bait, we have identified the transcription factor JunD as a direct menin-interacting partner. Menin did not interact directly with other Jun and Fos family members. The menin-JunD interaction was confirmed in vitro and in vive. Menin repressed transcriptional activation mediated by JunD fused to the Gal4 DNA-binding domain from a Gal4 responsive reporter, or by JunD from an AP1-responsive reporter. Several naturally occurring and clustered MEN1 missense mutations disrupted menin interaction with JunD. These observations suggest that menin's tumor suppressor function involves direct binding to JunD and inhibition of JunD activated transcription.	NIDDKD, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Agarwal, SK (corresponding author), NIDDKD, Metab Dis Branch, NIH, Bethesda, MD 20892 USA.		Agarwal, Sunita K/D-1428-2016	Agarwal, Sunita K/0000-0002-7557-3191	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043009, Z01DK043006, ZIEDK043006, ZIEDK043009] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; Agarwal SK, 1997, HUM MOL GENET, V6, P1169, DOI 10.1093/hmg/6.7.1169; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1994, FOS JUN FAMILIES TRA, P3; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BERGER I, 1991, ONCOGENE, V6, P561; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FEARON ER, 1998, GENETIC BASIS HUMAN, P229; FRANKLIN CC, 1995, BIOCHEM J, V305, P967, DOI 10.1042/bj3050967; FRIEDMAN E, 1989, NEW ENGL J MED, V321, P213, DOI 10.1056/NEJM198907273210402; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; Marx S, 1998, GENETIC BASIS HUMAN, P489; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; METIVIER C, 1993, ONCOGENE, V8, P2311; Okazaki S, 1998, BIOCHEM BIOPH RES CO, V250, P347, DOI 10.1006/bbrc.1998.9331; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Rahmsdorf HJ, 1996, J MOL MED, V74, P725, DOI 10.1007/s001090050077; RYSECK RP, 1991, ONCOGENE, V6, P533; SAMUELS HH, 1974, J CLIN INVEST, V54, P853, DOI 10.1172/JCI107825; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; Wang HL, 1996, J CELL BIOL, V135, P1151, DOI 10.1083/jcb.135.4.1151; Zhuang ZP, 1997, CANCER RES, V57, P4682	36	475	490	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 8	1999	96	1					143	152		10.1016/S0092-8674(00)80967-8	http://dx.doi.org/10.1016/S0092-8674(00)80967-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989505	Bronze			2022-12-28	WOS:000078023200016
J	Zhu, MH; John, S; Berg, M; Leonard, WJ				Zhu, MH; John, S; Berg, M; Leonard, WJ			Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFN gamma-mediated signaling	CELL			English	Article							RECEPTOR-BETA-CHAIN; DNA-BINDING ACTIVITY; GENE-EXPRESSION; INTERFERON-ALPHA; T-LYMPHOCYTES; TRANSCRIPTION; PROTEINS; CBP; ACTIVATION; P300/CBP	Using the coiled-coil region of Stat5b as the bait in a yeast two-hybrid screen, we identified the association of Nmi, a protein of unknown function previously reported as an N-Myc interactor. We further show that Nmi interacts with all STATs except Stat2. We evaluated two cytokine systems, IL-2 and lFN gamma, and demonstrate that Nmi augments STAT-mediated transcription in response to these cytokines. Interestingly, Nmi lacks an intrinsic transcriptional activation domain; instead, Nmi enhances the association of CBP/p300 coactivator proteins with Stall and Stat5, and together with CBP/p300 can augment IL-2- and IFN gamma-dependent transcription. Therefore, our data not only reveal that Nmi can potentiate STAT-dependent transcription, but also suggest that it can augment coactivator protein recruitment to at least some members of a group of sequence-specific transcription factors.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Leonard, WJ (corresponding author), NHLBI, Lab Mol Immunol, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.	wjl@helix.nih.gov	Leonard, Warren/AAA-1397-2022	John, Susan/0000-0002-5620-1982				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bao JX, 1996, ONCOGENE, V12, P2171; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GILMOUR KC, 1995, P NATL ACAD SCI USA, V92, P10772, DOI 10.1073/pnas.92.23.10772; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; JOHN S, 1995, MOL CELL BIOL, V15, P1786; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; JOHN S, 1999, IN PRESS MOL CELL BI; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin Jian-Xin, 1997, Cytokine and Growth Factor Reviews, V8, P313; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; MartinezMoczygemba M, 1997, J BIOL CHEM, V272, P20070, DOI 10.1074/jbc.272.32.20070; MINAMI Y, 1994, J IMMUNOL, V152, P5680; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; NIELSEN M, 1994, EUR J IMMUNOL, V24, P3082, DOI 10.1002/eji.1830241225; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhu MH, 1998, J BIOL CHEM, V273, P10719, DOI 10.1074/jbc.273.17.10719	62	248	255	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 8	1999	96	1					121	130		10.1016/S0092-8674(00)80965-4	http://dx.doi.org/10.1016/S0092-8674(00)80965-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989503	Bronze			2022-12-28	WOS:000078023200014
J	Pardes, H; Manton, KG; Lander, ES; Tolley, HD; Ullian, AD; Palmer, H				Pardes, H; Manton, KG; Lander, ES; Tolley, HD; Ullian, AD; Palmer, H			Medicine - Effects of medical research on health care and the economy	SCIENCE			English	Editorial Material							TRENDS		Columbia Univ, Coll Phys & Surg, Fac Med, New York, NY 10032 USA; Duke Univ, Ctr Demog Studies, Durham, NC 27708 USA; MIT, Whitehead Inst, Human Genome Project, Cambridge, MA 02138 USA; Brigham Young Univ, Dept Stat, Provo, UT 84606 USA; Hlth Care & Econ, Task Force Sci, Boston, MA 02110 USA; Pomona Coll, Dept Econ, Claremont, CA 91711 USA	Columbia University; Duke University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Brigham Young University; Claremont Colleges; Pomona College	Pardes, H (corresponding author), Columbia Univ, Coll Phys & Surg, Fac Med, New York, NY 10032 USA.							Fagan SC, 1998, NEUROLOGY, V50, P883, DOI 10.1212/WNL.50.4.883; Fotsis T, 1997, CANCER RES, V57, P2916; HORWITZ J, 1997, THESIS HARVARD U; Iglehart JK, 1997, NEW ENGL J MED, V336, P1827, DOI 10.1056/NEJM199706193362512; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; Malinow MR, 1998, NEW ENGL J MED, V338, P1009, DOI 10.1056/NEJM199804093381501; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; MOUKHEIBER Z, 1998, FORBES          0126, P76; Perls TT, 1997, NATURE, V389, P133, DOI 10.1038/38148; PRESTON SH, 1993, DEMOGRAPHIC CHANGE U; Rotman D, 1998, TECHNOL REV, V101, P34; Thomas L., 1975, LIVES CELL; Tolley HD, 1996, SOC SECUR BULL, V59, P71; Vita AJ, 1998, NEW ENGL J MED, V338, P1035, DOI 10.1056/NEJM199804093381506; WEISBROD BA, 1991, J ECON LIT, V29, P523	15	44	45	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					36	37		10.1126/science.283.5398.36	http://dx.doi.org/10.1126/science.283.5398.36			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	155ZH	9917262				2022-12-28	WOS:000077976600036
J	Foy, R; So, J; Rous, E; Scarffe, JH				Foy, R; So, J; Rous, E; Scarffe, JH			Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold	BRITISH MEDICAL JOURNAL			English	Article									Stockport Hlth Author, Stockport SK7 5BY, England; Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England	Christie NHS Foundation Trust; Christie Hospital	Foy, R (corresponding author), Univ Edinburgh, Dept Obstet & Gynaecol, Scottish Programme Clin Effecttiveness Reprod Hlt, Edinburgh EH3 9AW, Midlothian, Scotland.			Foy, Robbie/0000-0003-0605-7713				*AC MED ROYAL COLL, 1997, PRIOR SETT NHS DISC; Astrow AB, 1996, LANCET, V347, P1420, DOI 10.1016/S0140-6736(96)91675-X; *AUD COMM, 1997, HIGH PURCH COMM SPEC; Black N, 1997, BRIT MED J, V315, P1323, DOI 10.1136/bmj.315.7119.1323; Bower H, 1997, BRIT MED J, V314, P466; BUZDAR A, 1997, P AN M AM SOC CLIN, V16, P156; Calman K, 1995, POLICY FRAMEWORK COM, P18; Chan S, 1997, Oncology (Williston Park), V11, P19; CHUSTECKA Z, 1998, SCRIP, V2338, P28; Collins Harry, 1993, GOLEM WHAT EVERYONE; Halle M, 1996, BRIT MED J, V313, P774; Jonat W, 1996, EUR J CANCER, V32A, P404, DOI 10.1016/0959-8049(95)00014-3; Koch P, 1995, ANTI-CANCER DRUG, V6, P49, DOI 10.1097/00001813-199512006-00008; LEONARD RC, 1996, ANN ONCOL, V7, P19; Leonard RCF, 1997, BRIT MED J, V315, P811; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; MILLS W, 1994, BRIT J HAEMATOL, V86, P754, DOI 10.1111/j.1365-2141.1994.tb04825.x; *NHS MAN EX, 1996, PROM CLIN EFF, P20; Ross P, 1996, EUR J CANCER, V32A, pS13, DOI 10.1016/S0959-8049(96)00334-6; Sackett D. L., 1997, EVIDENCE BASED MED P; *SECR STAT HLTH, 1997, CMND3807; STEVENS A, 1997, EP BAS NEEDS ASS REV, pR38; WALLEY T, 1995, BRIT MED J, V311, P796, DOI 10.1136/bmj.311.7008.796; *WESS DEV EV COMM, 1995, 37 WESS I PUBL HLTH; 1997, DRUG THERAP B, V4, P1	25	30	30	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1999	318	7181					456	459		10.1136/bmj.318.7181.456	http://dx.doi.org/10.1136/bmj.318.7181.456			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BF	9974468	Green Published			2022-12-28	WOS:000078670100036
J	Roy, LP				Roy, LP			Review of research protocols	LANCET			English	Editorial Material									New Childrens Hosp, Ctr Kidney Res, Westmead, NSW 2145, Australia	University of Sydney	Roy, LP (corresponding author), New Childrens Hosp, Ctr Kidney Res, Westmead, NSW 2145, Australia.								0	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 6	1999	353	9151					428	428		10.1016/S0140-6736(98)00229-3	http://dx.doi.org/10.1016/S0140-6736(98)00229-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989711				2022-12-28	WOS:000078572800007
J	Wallentin, L				Wallentin, L			New antithrombotic treatment in unstable coronary syndrome - for whom?	LANCET			English	Editorial Material							ARTERY DISEASE		Univ Uppsala Hosp, Ctr Cardiovasc, Dept Cardiol, S-75185 Uppsala, Sweden	Uppsala University; Uppsala University Hospital	Wallentin, L (corresponding author), Univ Uppsala Hosp, Ctr Cardiovasc, Dept Cardiol, S-75185 Uppsala, Sweden.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Campbell RWF, 1998, CLIN CARDIOL, V21, P314, DOI 10.1002/clc.4960210504; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; Klein W, 1997, CIRCULATION, V96, P61; *PRISM STUD INV, 1998, NEW ENGL J MED, V228, P1498; Simoons ML, 1997, LANCET, V349, P1429; Theroux P, 1998, CIRCULATION, V97, P1195, DOI 10.1161/01.CIR.97.12.1195; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol E, 1998, CIRCULATION, V97, P2386; Wallentin L, 1996, LANCET, V347, P561; Wallentin L, 1996, EUR HEART J, V17, P1470	13	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	1999	353	9151					423	424		10.1016/S0140-6736(98)00362-6	http://dx.doi.org/10.1016/S0140-6736(98)00362-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989707				2022-12-28	WOS:000078572800003
J	Behrenfeld, MJ; Kolber, ZS				Behrenfeld, MJ; Kolber, ZS			Widespread iron limitation of phytoplankton in the South Pacific Ocean	SCIENCE			English	Article							RESPIRATORY ELECTRON-TRANSPORT; CHLOROPHYLL FLUORESCENCE; PROTEIN-PHOSPHORYLATION; EXCITATION-ENERGY; NORTH-ATLANTIC; HPLC-ANALYSIS; IN-SITU; PHOTOSYNTHESIS; PLASTOQUINONE; CYANOBACTERIA	Diet fluorescence patterns were discovered in phytoplankton sampled over 7000 kilometers of the South Pacific Ocean that appear indicative of iron-limiting growth conditions. These patterns were rapidly Lost after in situ iron enrichment and were not observed during a 15,000-kilometer transect in the Atlantic Ocean where iron concentrations are relatively high. Laboratory studies of marine Synechococcus sp, indicated that the patterns in the South Pacific are a unique manifestation of iron limitation on the fluorescence signature of state transitions. Results suggest that primary productivity is iron limited not only throughout the equatorial Pacific but also over much of the vast South Pacific gyre.	Rutgers State Univ, Inst Marine & Coastal Sci, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick	Behrenfeld, MJ (corresponding author), Rutgers State Univ, Inst Marine & Coastal Sci, 71 Dudley Rd, New Brunswick, NJ 08903 USA.							ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; AOKI M, 1982, BIOCHIM BIOPHYS ACTA, V682, P307, DOI 10.1016/0005-2728(82)90043-3; BEHRENFELD MJ, IN PRESS PHOTOSYNTH; BEHRENFELD MJ, 1996, NATURE, V383, P509; Belkhodja R, 1998, PHOTOSYNTH RES, V56, P265, DOI 10.1023/A:1006039917599; BURGERWIERSMA T, 1989, PLANT PHYSIOL, V91, P770, DOI 10.1104/pp.91.2.770; CAVENDERBARES KK, IN PRESS LIMNOL OCEA; Coale KH, 1996, NATURE, V383, P495, DOI 10.1038/383495a0; Dandonneau Y, 1997, DEEP-SEA RES PT II, V44, P1869, DOI 10.1016/S0967-0645(97)00020-9; DAU H, 1994, PHOTOCHEM PHOTOBIOL, V60, P1; DEBAAR HJW, 1994, PROG OCEANOGR, V33, P347, DOI 10.1016/0079-6611(94)90022-1; DUBINSKY Z, 1986, PLANT CELL PHYSIOL, V27, P1335, DOI 10.1093/oxfordjournals.pcp.a077232; DUCE RA, 1991, LIMNOL OCEANOGR, V36, P1715, DOI 10.4319/lo.1991.36.8.1715; FALKOWSKI PG, 1995, AUST J PLANT PHYSIOL, V22, P341, DOI 10.1071/PP9950341; Field CB, 1998, SCIENCE, V281, P237, DOI 10.1126/science.281.5374.237; GIESKES WW, 1986, MAR BIOL, V91, P567, DOI 10.1007/BF00392609; GREENE RM, 1994, LIMNOL OCEANOGR, V39, P1061, DOI 10.4319/lo.1994.39.5.1061; GREENE RM, 1992, PLANT PHYSIOL, V100, P565, DOI 10.1104/pp.100.2.565; GULKEMA JA, 1983, PLANT PHYSIOL, V73, P250; KOLBER Z, 1993, LIMNOL OCEANOGR, V38, P1646, DOI 10.4319/lo.1993.38.8.1646; KOLBER Z, 1999, BIOCHIM BIOPHYS ACTA, V1367, P88; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; LaRoche J, 1996, NATURE, V382, P802; LONG SP, 1994, ANNU REV PLANT PHYS, V45, P633, DOI 10.1146/annurev.pp.45.060194.003221; MARTIN JH, 1994, NATURE, V371, P123, DOI 10.1038/371123a0; MULLINEAUX CW, 1986, FEBS LETT, V205, P155, DOI 10.1016/0014-5793(86)80885-7; Mullineaux CW, 1997, NATURE, V390, P421, DOI 10.1038/37157; MURPHY LS, 1985, LIMNOL OCEANOGR, V30, P47, DOI 10.4319/lo.1985.30.1.0047; NEALE PJ, 1987, PHOTOINHIBITION, P123; OLSEN RJ, 1990, DEEP-SEA RES, V37, P1033; Partensky F, 1996, DEEP-SEA RES PT I, V43, P1191, DOI 10.1016/0967-0637(96)00056-8; SALEHIAN O, 1992, J LUMIN, V51, P91, DOI 10.1016/0022-2313(92)90021-Z; SANDMANN G, 1985, PHOTOSYNTH RES, V6, P261, DOI 10.1007/BF00049282; SCHERER S, 1988, PHOTOSYNTH RES, V15, P95, DOI 10.1007/BF00035255; Straus N.A., 1994, MOL BIOL CYANOBACTER, P731, DOI DOI 10.1007/978-94-011-0227-8_25; VASSILIEV IR, 1995, PLANT PHYSIOL, V109, P963, DOI 10.1104/pp.109.3.963; VAULOT D, IN PRESS J GEOPHYS R; VELDHUIS MJW, 1990, MAR ECOL PROG SER, V68, P121, DOI 10.3354/meps068121	39	274	281	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					840	843		10.1126/science.283.5403.840	http://dx.doi.org/10.1126/science.283.5403.840			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933166				2022-12-28	WOS:000078496800043
J	Williams, NW				Williams, NW			Serpents, staffs, and the emblems of medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Williams, NW (corresponding author), Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA.							BUNN JT, 1967, J AMER MED ASSOC, V202, P615, DOI 10.1001/jama.202.7.615; GEELHOED GW, 1988, SOUTHERN MED J, V81, P1155, DOI 10.1097/00007611-198809000-00020; MERRILL JM, 1991, J LAB CLIN MED, V117, P431; METZER WS, 1989, SOUTHERN MED J, V82, P743, DOI 10.1097/00007611-198906000-00017; Parry Donald W., 1994, TEMPLES ANCIENT WORL; RUSSEL FE, 1980, SNAKE VENOM POISONIN	6	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					475	475		10.1001/jama.281.5.475	http://dx.doi.org/10.1001/jama.281.5.475			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952211	hybrid			2022-12-28	WOS:000078318500041
J	Jardine, E; O'Toole, M; Paton, JY; Wallis, C				Jardine, E; O'Toole, M; Paton, JY; Wallis, C			Current status of long term ventilation of children in the United Kingdom: questionnaire survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To identify the number and current location of children, aged 0 to 16 years, requiring long term ventilation in the United Kingdom, and to establish their underlying diagnoses and ventilatory needs. Design Postal questionnaires sent to consultant respiratory paediatricians and all lead clinicians of intensive care and special care baby units in the United Kingdom. Subjects AU children in the United Kingdom who, when medically stable, continue to need a mechanical aid for breathing. Results 141 children requiring long term ventilation were identified from the initial questionnaire. Detailed information was then obtained on 136 children from 30 units. Thirty three children (24%) required continuous positive pressure ventilation by tracheostomy over 24 hours, and 103 received ventilation when asleep by a non-invasive mask (n = 62; 46%), tracheostomy (n = 32; 24%), or negative pressure ventilation (n = 9; 7%). Underlying conditions included neuromuscular disease (n = 62; 46%), congenital central hypoventilation syndrome (n = 18; 13%), spinal injury (n = 16; 12%), craniofacial syndromes (n = 9; 7%), bronchopulmonary dysplasia (n = 6; 4%), and others (n = 25; 18%). 93 children were cared for ar home. 43 children remained in hospital because of home circumstances, inadequate funding, or lack of provision of home carers. 96 children were of school age and 43 were attending mainstream school. Conclusions A significant increase in the number of children requiring long term ventilation in the United Kingdom has occurred over the past decade. Contributing factors include improved technology, developments in paediatric non-invasive ventilatory support, and a change in attitude towards home care. Successful discharge home and return to school is occurring even for severely disabled patients. Funding and home carers are common obstacles to discharge.	Inst Child Hlth, London WC1N 3JH, England; Great Ormond St Hosp Sick Children, London WC1N 3JH, England; Royal Hosp Sick Children, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Glasgow	Wallis, C (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N 3JH, England.	c.wallis@ich.ucl.ac.uk	Paton, James/B-9541-2008						0	97	101	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 30	1999	318	7179					295	299		10.1136/bmj.318.7179.295	http://dx.doi.org/10.1136/bmj.318.7179.295			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZH	9924054	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000078436700022
J	Vermorken, JB; Claessen, AME; van Tinteren, H; Gall, HE; Ezinga, R; Meijer, S; Scheper, RJ; Meijer, CJLM; Bloemena, E; Ransom, JH; Hanna, MG; Pinedo, HM				Vermorken, JB; Claessen, AME; van Tinteren, H; Gall, HE; Ezinga, R; Meijer, S; Scheper, RJ; Meijer, CJLM; Bloemena, E; Ransom, JH; Hanna, MG; Pinedo, HM			Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial	LANCET			English	Article							AUTOLOGOUS TUMOR-CELL; POSTOPERATIVE ADJUVANT THERAPY; HUMAN COLORECTAL-CANCER; FOLLOW-UP; FLUOROURACIL; VACCINE; LEUCOVORIN; CARCINOMA; BENEFIT	Background Colon cancer is curable by surgery, but cure rate depends on the extent of disease. We investigated whether adjuvant active specific immunotherapy (ASI) with an autologous tumour cell-BCG Vaccine with surgical resection was more beneficial than resection alone in stage II and III colon cancer. Methods In a prospective randomised trial, 254 patients with colon cancer were randomly assigned postoperative ASI or no adjuvant treatment. ASI was three weekly vaccinations starting 4 weeks after surgery, with a booster Vaccination at 6 months with 10(7) irradiated autologous tumour cells. The first Vaccinations contained 107 BCG organisms. We followed up patients for time to recurrence, and recurrence-free and overall survival. Analysis was by intention to treat. Findings The 5.3 year median follow-up (range 8 months to 8 years 11 months) showed 44% (95% CI 7-66) risk reduction for recurrence in the recurrence-free period in all patients receiving ASI (p = 0.023). Overall, there were 40 recurrences in the control group and 25 in the ASI group. Analysis by stage showed no significant benefit of ASI in stage III disease. The major impact of ASI was seen in patients with stage II disease, with a significantly longer recurrence-free period (p = 0.011) and 61% (18-81) risk reduction for recurrences. Recurrence-free survival was significantly longer with ASI (42% risk reduction for recurrence or death [0-68], p = 0.032) and there was a trend towards improved overall survival. Interpretation ASI gave significant clinical benefit in surgically resected patients with stage II colon cancer. ASI has minimal adverse reactions and should be considered in the management of stage II colon cancer.	Free Univ Amsterdam Hosp, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands; Free Univ Amsterdam Hosp, Dept Pathol, NL-1081 HV Amsterdam, Netherlands; Free Univ Amsterdam Hosp, Dept Surg, NL-1081 HV Amsterdam, Netherlands; Univ Antwerp Hosp, Dept Oncol, Antwerp, Belgium; Comprehens Canc Ctr Amsterdam, Amsterdam, Netherlands; INTRACEL Corp, Rockville, MD 20852 USA	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Antwerp	Pinedo, HM (corresponding author), Free Univ Amsterdam Hosp, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands.		Bloemena, Elisabeth/AAZ-1247-2021; Bloemena, Elisabeth/V-1095-2018	Bloemena, Elisabeth/0000-0002-0221-9538; van Tinteren, Harm/0000-0002-4626-8702				Audisio RA, 1996, ANN SURG ONCOL, V3, P349, DOI 10.1007/BF02305664; BERD D, 1990, J CLIN ONCOL, V8, P1858, DOI 10.1200/JCO.1990.8.11.1858; Cohen Alfred M., 1997, P1144; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; Haller D, 1998, P AM SOC CLIN ONCOL; HANNA MG, 1978, CANCER, V42, P2613, DOI 10.1002/1097-0142(197812)42:6<2613::AID-CNCR2820420617>3.0.CO;2-K; HANNA MG, 1979, CANCER IMMUNOL IMMUN, V7, P165; HARRIS J, 1994, P AN M AM SOC CLIN, V13, P294; HOOVER HC, 1984, CANCER RES, V44, P1671; HOOVER HC, 1985, CANCER, V55, P1236, DOI 10.1002/1097-0142(19850315)55:6<1236::AID-CNCR2820550616>3.0.CO;2-#; HOOVER HC, 1993, J CLIN ONCOL, V11, P390, DOI 10.1200/JCO.1993.11.3.390; LABIANCA R, 1995, LANCET, V345, P939; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; OConnell MJ, 1997, J CLIN ONCOL, V15, P246, DOI 10.1200/JCO.1997.15.1.246; PETERS LC, 1979, CANCER RES, V39, P1353; PETERS LC, 1980, J NATL CANCER I, V64, P1521, DOI 10.1093/jnci/64.6.1521; RANSOM JH, 1993, VACCINE RES, V2, P65; SAHASRABUDHE DM, 1986, J BIOL RESP MODIF, V5, P581; Shulman K, 1995, SEMIN ONCOL, V22, P600; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879	20	395	424	4	22	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 30	1999	353	9150					345	350		10.1016/S0140-6736(98)07186-4	http://dx.doi.org/10.1016/S0140-6736(98)07186-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950438				2022-12-28	WOS:000078437000008
J	Smith, R				Smith, R			The firing of Brother George	BRITISH MEDICAL JOURNAL			English	Editorial Material																		CLEGG H, 1960, INT RECORD MED, V173, P414; KOLATA G, 2009, NY TIMES        0424, P1; MCDANIEL CG, 1997, BRIT MED J, V315, P1560; SMITH R, 1991, BALANCING ACT ESSAYS	4	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1999	318	7178					210	210						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915712				2022-12-28	WOS:000078292300006
J	Hubbell, SP; Foster, RB; O'Brien, ST; Harms, KE; Condit, R; Wechsler, B; Wright, SJ; de Lao, SL				Hubbell, SP; Foster, RB; O'Brien, ST; Harms, KE; Condit, R; Wechsler, B; Wright, SJ; de Lao, SL			Light-gap disturbances, recruitment limitation, and tree diversity in a neotropical forest	SCIENCE			English	Article							SPECIES RICHNESS; CANOPY; HETEROGENEITY; SURVIVAL; HISTORY; GROWTH	Light gap disturbances have been postulated to play a major role in maintaining tree diversity in species-rich tropical forests. This hypothesis was tested in more than 1200 gaps in a tropical forest in Panama over a 13-year period. Caps increased seedling establishment and sapling densities, but this effect was nonspecific and broad-spectrum, and species richness per stem was identical in gaps and in nongap control sites. Spatial and temporal variation in the gap disturbance regime did not explain variation in species richness. The species composition of gaps was unpredictable even for pioneer tree species. Strong recruitment limitation appears to decouple the gap disturbance regime from control of tree diversity in this tropical forest.	Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08544 USA; Smithsonian Trop Res Inst, Balboa, Panama	Princeton University; Smithsonian Institution; Smithsonian Tropical Research Institute	Hubbell, SP (corresponding author), Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08544 USA.	shubbell@princeton.edu	Wright, Stuart Joseph/M-3311-2013	Wright, Stuart Joseph/0000-0003-4260-5676				Bazzaz F. A., 1996, PLANTS CHANGING ENV; BAZZAZ FA, 1980, ANNU REV ECOL SYST, V11, P287, DOI 10.1146/annurev.es.11.110180.001443; BECKER P, 1988, J TROP ECOL, V4, P173, DOI 10.1017/S0266467400002674; BRANDANI A, 1988, J TROP ECOL, V4, P99, DOI 10.1017/S0266467400002625; CARLISLE E, 1997, THESIS PRINCETON U; CLARK DA, 1992, ECOL MONOGR, V62, P315, DOI 10.2307/2937114; Condit R, 1996, J TROP ECOL, V12, P231, DOI 10.1017/S0266467400009433; CONDIT R, 1995, ECOL MONOGR, V65, P419, DOI 10.2307/2963497; CONDIT R, 1992, BIOSCIENCE, V42, P822, DOI 10.2307/1312081; CONNELL JH, 1978, SCIENCE, V199, P1302, DOI 10.1126/science.199.4335.1302; Croat T.B., 1978, FLORA BARRO COLORADO; DENSLOW JS, 1987, OECOLOGIA, V74, P370, DOI 10.1007/BF00378932; DENSLOW JS, 1980, BIOTROPICA, V12, P47, DOI 10.2307/2388156; DENSLOW JS, 1990, ECOLOGY, V71, P165, DOI 10.2307/1940257; DENSLOW JS, 1985, ECOLOGY, V66, P682; FINKLESTEIN S, 1998, THESIS PRINCETON U; HARMS K, UNPUB; Harms K.E, 1997, THESIS PRINCETON U; HARTSHORN G S, 1978, P617; Hubbell S. P., 1986, PLANT ECOL, P77; HUBBELL SP, 1987, REV BIOL TROP, V35, P7; HUBBELL SP, UNPUB; HURTT GC, 1995, J THEOR BIOL, V176, P1, DOI 10.1006/jtbi.1995.0170; LEIGH EC, 1982, ECOLOGY TRIPICAL FOR; ORIANS G H, 1982, Tropical Ecology, V23, P255; ORIANS GH, 1985, ECOLOGY NATURAL DIST, P307; ORIANS GH, 1987, ANNU REV ECOL SYST, V18, P431; PUGH WE, 1996, THESIS PRINCETON U; RICKLEFS RE, 1977, AM NAT, V111, P376, DOI 10.1086/283169; SCHUPP EW, 1989, ECOLOGY, V70, P562, DOI 10.2307/1940206; STRONG DR, 1977, J BIOGEOGR, V4, P215, DOI 10.2307/3038057; SWAINE MD, 1988, VEGETATIO, V75, P81, DOI 10.1007/BF00044629; TILMAN D, 1994, ECOLOGY, V75, P2, DOI 10.2307/1939377; TILMAN D, 1988; VITOUSEK PM, 1986, J ECOL, V74, P1167, DOI 10.2307/2260241; WECHSLER B, 1995, THESIS PRINCETON U; WEINER J, 1985, ECOLOGY, V66, P743, DOI 10.2307/1940535; WELDEN CW, 1991, ECOLOGY, V72, P35, DOI 10.2307/1938900; WHITMORE TC, 1989, ECOLOGY, V70, P536, DOI 10.2307/1940195	39	1034	1150	6	313	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 22	1999	283	5401					554	557		10.1126/science.283.5401.554	http://dx.doi.org/10.1126/science.283.5401.554			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915706				2022-12-28	WOS:000078203300042
J	Kohn, MJ				Kohn, MJ			Biochemistry - You are what you eat	SCIENCE			English	Editorial Material							DIET		Univ S Carolina, Dept Geol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Kohn, MJ (corresponding author), Univ S Carolina, Dept Geol Sci, Columbia, SC 29208 USA.		Kohn, Matthew/A-2562-2012	Kohn, Matthew/0000-0002-7202-4525				BRYANT JD, 1995, GEOCHIM COSMOCHIM AC, V59, P4523; Cerling TE, 1997, NATURE, V389, P153, DOI 10.1038/38229; DANSGAARD W, 1964, TELLUS, V16, P436; DENIRO MJ, 1978, GEOCHIM COSMOCHIM AC, V42, P495, DOI 10.1016/0016-7037(78)90199-0; FOLEY RA, 1993, SEASONALITY HUMAN EC, P7; Fricke HC, 1996, PALAEOGEOGR PALAEOCL, V126, P91, DOI 10.1016/S0031-0182(96)00072-7; HAYES JM, 1990, ORG GEOCHEM, V16, P1115, DOI 10.1016/0146-6380(90)90147-R; Koch P.L., 1994, P63; Kohn MJ, 1996, GEOCHIM COSMOCHIM AC, V60, P4811, DOI 10.1016/S0016-7037(96)00240-2; SCHWARCZ HP, 1991, YEARB PHYS ANTHROPOL, V34, P283; 1998, 58 ANN M SOC VERT PA; 1998, APPL STABLE ISOTOPE	12	50	63	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					335	336		10.1126/science.283.5400.335	http://dx.doi.org/10.1126/science.283.5400.335			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9925492				2022-12-28	WOS:000078067000028
J	Frey, JJ				Frey, JJ			Too sad	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					112	113		10.1001/jama.281.2.112	http://dx.doi.org/10.1001/jama.281.2.112			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155VJ	9917097				2022-12-28	WOS:000077966800001
J	Stein, EA; Illingworth, DR; Kwiterovich, PO; Liacouras, CA; Siimes, MA; Jacobson, MS; Brewster, TG; Hopkins, P; Davidson, M; Graham, K; Arensman, F; Knopp, RH; DuJovne, C; Williams, CL; Isaacsohn, JL; Jacobsen, CA; Laskarzewski, PM; Ames, S; Gormley, GJ				Stein, EA; Illingworth, DR; Kwiterovich, PO; Liacouras, CA; Siimes, MA; Jacobson, MS; Brewster, TG; Hopkins, P; Davidson, M; Graham, K; Arensman, F; Knopp, RH; DuJovne, C; Williams, CL; Isaacsohn, JL; Jacobsen, CA; Laskarzewski, PM; Ames, S; Gormley, GJ			Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; COA REDUCTASE INHIBITORS; COGNITIVE PERFORMANCE; CORONARY ATHEROSCLEROSIS; CHILDREN; PRAVASTATIN; SIMVASTATIN; CHOLESTYRAMINE; DISEASE; PLASMA	Context Heterozygous familial hypercholesterolemia (HeFH) is a common disorder associated with early coronary artery disease, especially in men. The age at which drug therapy should be started is still controversial, as is the use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). Objective To assess the lipid-lowering efficacy, biochemical safety, and effect on growth and sexual development of lovastatin in adolescent boys with HeFH. Design One-year, double-blind, placebo-controlled, balanced, 2-period, 2-arm randomized trial. In the first period (24 weeks), lovastatin was increased at 8 and 16 weeks and the dosage remained stable during the second period (24 weeks). The study was conducted between 1990 and 1994. Setting Fourteen pediatric outpatient clinics in the United States and Finland. Patients Boys aged 10 to 17 years with HeFH. Of 132 randomized subjects (67 intervention, 65 placebo), 122 (63 intervention, 59 placebo) and 110 (61 intervention, 49 placebo) completed the first and second periods, respectively. Intervention Lovastatin, starting at 10 mg/d, with a forced titration at 8 and 16 weeks to 20 and 40 mg/d, respectively, or placebo. Main Outcome Measures The primary efficacy outcome measure was low-density lipoprotein cholesterol (LDL-C). Primary safety measures were growth and sexual development. Results Compared with placebo, LDL-C levels of patients receiving lovastatin decreased significantly (P < .001) by 17%, 24%, and 27% receiving dosages of 10, 20, and 40 mg/d, respectively, and remained 25% lower than baseline at 48 weeks. Growth and sexual maturation assessed by Tanner staging and testicular volume were not significantly different between the lovastatin and placebo groups at 24 weeks (P = .85) and 48 weeks (P = .33); neither were serum hormone levels or biochemical parameters of nutrition. However, the study was underpowered to detect significant differences in safety parameters. Serum vitamin E levels were reduced with lovastatin treatment consistent with reductions in LDL-C, the major carrier of vitamin E in the circulation. Conclusions This study in adolescent boys with HeFH confirmed the LDL-C-reducing effectiveness of lovastatin. Comprehensive clinical and biochemical data on growth, hormonal, and nutritional status indicated no significant differences between lovastatin and placebo over 48 weeks, although further study is required.	Metab & Atherosclerosis Res Ctr, Cincinnati, OH 45219 USA; Med Res Labs, Highland Hts, KY USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Johns Hopkins Univ, Lipid Atherosclerosis Unit, Baltimore, MD USA; Childrens Hosp Philadelphia, Gastroenterol & Nutr, Philadelphia, PA 19104 USA; Univ Helsinki, Helsinki, Finland; Schneider Childrens Hosp, Dept Pediat, Div Adolescent Med, New Hyde Pk, NY USA; Maine Med Ctr, Div Genet, Portland, OR USA; Univ Utah, Cardiovasc Genet Res Clin, Salt Lake City, UT USA; Chicago Ctr Clin Res, Chicago, IL USA; Minneapolis Heart Inst, Minneapolis, MN USA; Lipid Ctr, Louisville, KY USA; NW Lipid Res Ctr, Seattle, WA USA; Univ Kansas, Med Ctr, Kansas City, KS 66103 USA; Amer Hlth Fdn, Valhalla, NY 10595 USA; Merck & Co Inc, Rahway, NJ 07065 USA	Oregon Health & Science University; Johns Hopkins University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Helsinki; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Utah System of Higher Education; University of Utah; Minneapolis Heart Institute Foundation; L-MARC Research Center; University of Kansas; University of Kansas Medical Center; American Health Foundation; Merck & Company	Stein, EA (corresponding author), Metab & Atherosclerosis Res Ctr, 2350 Auburn Ave, Cincinnati, OH 45219 USA.	esteinmrl@aol.com						BLACK DM, 1990, JAMA-J AM MED ASSOC, V264, P1105, DOI 10.1001/jama.1990.03450090041020; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; *CAND SIMV SURV ST, 1994, LANCET, V344, P1383; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; COLLETTI RB, 1993, PEDIATRICS, V92, P78; CUTLER N, 1995, BRIT J CLIN PHARMACO, V39, P333, DOI 10.1111/j.1365-2125.1995.tb04458.x; DONAHUE RP, 1986, J CHRON DIS, V39, P823, DOI 10.1016/0021-9681(86)90084-6; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; DUCOBU J, 1992, LANCET, V339, P1488, DOI 10.1016/0140-6736(92)92092-T; GENGO F, 1995, CLIN CARDIOL, V18, P209, DOI 10.1002/clc.4960180406; GROOT PHE, 1983, ACTA PAEDIATR SCAND, V72, P81, DOI 10.1111/j.1651-2227.1983.tb09668.x; HARRISON RWS, 1994, BRIT J CLIN PHARMACO, V37, P231, DOI 10.1111/j.1365-2125.1994.tb04268.x; HAVEL RJ, 1987, ANN INTERN MED, V107, P609, DOI 10.7326/0003-4819-107-5-609; Hollander M., 1973, NONPARAMETRIC STAT M; Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KAPLAN LA, 1987, J CLIN LAB ANAL, V1, P147, DOI 10.1002/jcla.1860010202; KINCAID HL, 1984, PEDIAT CLIN CHEM, P349; Knipscheer HC, 1996, PEDIATR RES, V39, P867, DOI 10.1203/00006450-199605000-00021; KOSTIS JB, 1994, J CLIN PHARMACOL, V34, P989, DOI 10.1002/j.1552-4604.1994.tb01971.x; Lambert M, 1996, PEDIATRICS, V97, P619; LAUER RM, 1995, JAMA-J AM MED ASSOC, V273, P1429, DOI 10.1001/jama.273.18.1429; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; McCormick DB, 1994, TIETZ TXB CLIN CHEM, P1275; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; Muldoon MF, 1997, CIRCULATION, V96, P360; Muller C, 1939, ARCH INTERN MED, V64, P675; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; *NAT CHOL ED PROGR, 1991, NIH PUBL; RIFKIND BM, 1979, CIRCULATION, V60, P427; SCHAEFER EJ, 1988, NEW ENGL J MED, V319, P1222; SCHROTT HG, 1995, AM J CARDIOL, V75, P34, DOI 10.1016/S0002-9149(99)80523-2; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SLACK J, 1969, LANCET, V2, P1380; STEIN E, 1992, Clinical Chemistry, V38, P1067; STEIN E, 1990, ARCH INTERN MED, V150, P341, DOI 10.1001/archinte.150.2.341; Stein EA, 1998, AM J CARDIOL, V82, P311, DOI 10.1016/S0002-9149(98)00421-4; STEIN EA, 1989, ARTERIOSCLEROSIS, V9, pI145; STEIN EA, 1986, CLIN CHEM, V32, P967; STEIN EA, 1982, AM J CLIN NUTR, V35, P1375, DOI 10.1093/ajcn/35.6.1375; STEINER PM, 1981, J CLIN CHEM CLIN BIO, V19, P850; STEINMETZ J, 1981, CLIN CHIM ACTA, V112, P43, DOI 10.1016/0009-8981(81)90267-9; STONE NJ, 1974, CIRCULATION, V49, P476, DOI 10.1161/01.CIR.49.3.476; SUGRUE DD, 1981, BMJ-BRIT MED J, V283, P1358, DOI 10.1136/bmj.283.6303.1358; Tonstad S, 1996, J PEDIATR-US, V129, P42, DOI 10.1016/S0022-3476(96)70188-9; WARNICK GR, 1978, J LIPID RES, V19, P65; WEIDMAN W, 1983, CIRCULATION, V67, pA411; WEST RJ, 1980, LANCET, V2, P873; WHEELER KAH, 1985, ARCH DIS CHILD, V60, P34, DOI 10.1136/adc.60.1.34; WHITEHEAD TP, 1994, CLIN CHEM HEMATOLOGY	50	160	165	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					137	144		10.1001/jama.281.2.137	http://dx.doi.org/10.1001/jama.281.2.137			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155VJ	9917116	Bronze			2022-12-28	WOS:000077966800033
J	Dinsmore, W; Evans, C				Dinsmore, W; Evans, C			ABC of sexual health - Erectile dysfunction	BRITISH MEDICAL JOURNAL			English	Article																			0	10	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					387	390		10.1136/bmj.318.7180.387	http://dx.doi.org/10.1136/bmj.318.7180.387			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933208	Green Published			2022-12-28	WOS:000078572600036
J	Daniel, BL				Daniel, BL			Mammographically occult breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Stanford Univ, Stanford, CA 94305 USA	Stanford University	Daniel, BL (corresponding author), Stanford Univ, Stanford, CA 94305 USA.								0	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1999	340	5					358	358		10.1056/NEJM199902043400505	http://dx.doi.org/10.1056/NEJM199902043400505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163WC	9929526				2022-12-28	WOS:000078428500005
J	Midgley, R; Kerr, D				Midgley, R; Kerr, D			Colorectal cancer	LANCET			English	Article							FECAL-OCCULT-BLOOD; POSTOPERATIVE ADJUVANT THERAPY; NONPOLYPOSIS COLON-CANCER; CONTROLLED TRIAL; RECTAL-CANCER; PREOPERATIVE RADIOTHERAPY; SCREENING SIGMOIDOSCOPY; RADIATION-THERAPY; PHASE-I; CARCINOMA	Colorectal cancer is a leading cause of morbidity and mortality with about 300000 new cases and 200000 deaths in Europe and the USA each year.(1,2) published trials have established a role for chemotherapy in colorectal cancer, in the adjuvant setting for Dukes C colon cancer, with an absolute survival benefit of about 5% and in advanced colorectal cancer, for which it improves quality of life and increases survival by 6-12 months. For rectal cancer, radiotherapy decreases rates of local recurrence and, in locally advanced disease, successfully palliates pain, tenesmus, and bleeding. The evolving understanding of colorectal carcinogenesis, in particular recognition of vital genes that may be mutated or lost during tumour development, has been translated into innovative gene therapy techniques. Finally it is increasingly apparent that surgical site specialisation and a multidisciplinary approach (including surgeons, pathologists, and oncologists) may lead to optimum outcomes for patients with colorectal cancer.	Univ Birmingham, CRC, Inst Canc Studies, Birmingham B17 2TJ, W Midlands, England	University of Birmingham	Kerr, D (corresponding author), Univ Birmingham, CRC, Inst Canc Studies, Birmingham B17 2TJ, W Midlands, England.	D.J.Kerr@bham.ac.uk	Professor, Zeljko Vlaisavljevic/F-3866-2016; Yip, Desmond/G-2043-2014	Professor, Zeljko Vlaisavljevic/0000-0002-8050-4705; Yip, Desmond/0000-0002-2806-2401; Kerr, Rachel/0000-0002-7240-3269				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Akiyama Y, 1997, GASTROENTEROLOGY, V112, P33, DOI 10.1016/S0016-5085(97)70216-6; Arnott SJ, 1996, LANCET, V348, P1610; BALSLEV IB, 1986, CANCER-AM CANCER SOC, V58, P22, DOI 10.1002/1097-0142(19860701)58:1<22::AID-CNCR2820580106>3.0.CO;2-Q; BENNETT DH, 1996, COLORECTAL CANC CLIN, P21; Boyle P., 1998, MANAGEMENT COLORECTA, P19; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CAWKWELL L, 1996, COLORECTAL CANC, P1; Cole DJ, 1996, HUM GENE THER, V7, P1381, DOI 10.1089/hum.1996.7.11-1381; CONRY T, 1997, MANAGEMENT COLORECTA; Cunningham D, 1995, EUR J CANCER, V31A, P1945, DOI 10.1016/0959-8049(95)00502-1; CUNNINGHAM D, 1998, P ASCO, P17; DORAN J, 1982, BRIT J SURG, V69, P711, DOI 10.1002/bjs.1800691209; Ferry DR, 1996, CLIN CANCER RES, V2, P659; FISCHER DS, 1996, FOLLOW UP CANC; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; Gastrointestinal Tumour Study Group-GiTSG, 1985, NEW ENGL J MED, V312, P1464; GERARD A, 1988, ANN SURG, V208, P606, DOI 10.1097/00000658-198811000-00011; Grady W, 1997, GASTROENTEROLOGY, V112, P297, DOI 10.1016/S0016-5085(97)70249-X; Gray R, 1997, JNCI-J NATL CANCER I, V89, P497; GRAY R, 1997, GUIDANCE COMMISSIONI; HUBER BE, 1993, CANCER RES, V53, P4619; JAMES RD, 1991, DIS COLON RECTUM, V34, P546, DOI 10.1007/BF02049892; JANSSONFRYKHOLM G, 1993, DIS COLON RECTUM, V36, P564; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KERR DJ, 1995, J CLIN ONCOL, V13, P2968, DOI 10.1200/JCO.1995.13.12.2968; KEWENTER J, 1991, CANC SCREENING, P118; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; LABIANCA R, 1995, LANCET, V345, P939; LATHE R, 1989, NATURE, V326, P87; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MACFARLANE JK, 1993, LANCET, V341, P457, DOI 10.1016/0140-6736(93)90207-W; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MCARDLE C, 1998, RECENT ADV SURG, P129; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; Midgley RS, 1998, MANAGEMENT COLORECTA, P126; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NAGASE H, 1992, CANCER RES, V52, P1734; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OCONNELL M, 1994, NEW ENGL J MED, V331, P502, DOI 10.1056/NEJM199408253310803; OConnell MJ, 1997, J CLIN ONCOL, V15, P246, DOI 10.1200/JCO.1997.15.1.246; OCONNELL MJ, 1996, P AN M AM SOC CLIN, V15, P209; OLSCHWANG S, 1993, CELL, V75, P959, DOI 10.1016/0092-8674(93)90539-3; PAHLMAN L, 1997, MANAGEMENT COLORECTA; QUIRKE P, 1986, LANCET, V2, P996, DOI 10.1016/s0140-6736(86)92612-7; RANSOHOFF DF, 1993, JAMA-J AM MED ASSOC, V269, P1278, DOI 10.1001/jama.269.10.1278; RIETHMULLER G, 1994, LANCET, V343, P1177, DOI 10.1016/S0140-6736(94)92398-1; SCOTT RJ, 1995, GUT, V36, P731, DOI 10.1136/gut.36.5.731; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SEYMOUR MT, ECCO M 1997; *SRCT, 1996, EUR J SURG, V162, P397; TOKIUE M, 1994, GUT S4, V35, pA70; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Venook AP, 1998, P AN M AM SOC CLIN, V1661, p431a; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WILKING N, 1990, CANCER, V66, P49; WILLIAMS NS, 1985, BRIT J SURG, V72, P595, DOI 10.1002/bjs.1800720804; WILLIAMS NS, 1983, BRIT J SURG, V70, P150, DOI 10.1002/bjs.1800700305; WINAWER SJ, 1980, CANCER, V45, P2959, DOI 10.1002/1097-0142(19800615)45:12<2959::AID-CNCR2820451212>3.0.CO;2-E; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879	64	329	341	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 30	1999	353	9150					391	399		10.1016/S0140-6736(98)07127-X	http://dx.doi.org/10.1016/S0140-6736(98)07127-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950460				2022-12-28	WOS:000078437000045
J	Rittenhouse, CD; Shouval, HZ; Paradiso, MA; Bear, MF				Rittenhouse, CD; Shouval, HZ; Paradiso, MA; Bear, MF			Monocular deprivation induces homosynaptic long-term depression in visual cortex	NATURE			English	Article							SYNAPTIC PLASTICITY; STRIATE CORTEX; TRANSMISSION; BLOCKADE; PERIOD	Brief monocular deprivation during early postnatal development can lead to a depression of synaptic transmission that renders visual cortical neurons unresponsive to subsequent visual stimulation through the deprived eye. The Bienenstock-Cooper-Munro (BCM) theory(1) proposes that homosynaptic mechanisms of long-term depression (LTD) account for the deprivation effects(2,3). Homosynaptic depression, by definition, occurs only at active synapses. Thus, in contrast to the commonly held view that the synaptic depression caused by monocular deprivation is simply a result of retinal inactivity, this theoretical framework indicates that the synaptic depression may actually be driven by the residual activity in the visually deprived retina(4). Here we examine the validity of this idea by comparing the consequences of brief monocular deprivation by lid suture with those of monocular inactivation by intra-ocular treatment with tetrodotoxin. Lid suture leaves the retina spontaneously active, whereas tetrodotoxin eliminates all activity. In agreement with the BCM theory, our results show that monocular lid suture causes a significantly greater depression of deprived-eye responses in kitten visual cortex than does treatment with tetrodotoxin. These findings have important implications for mechanisms of experience-dependent plasticity in the neocortex.	Brown Univ, Howard Hughes Med Inst, Providence, RI 02912 USA; Brown Univ, Dept Neurosci, Providence, RI 02912 USA	Brown University; Howard Hughes Medical Institute; Brown University	Bear, MF (corresponding author), Brown Univ, Howard Hughes Med Inst, Providence, RI 02912 USA.	mbear@brown.edu		Bear, Mark/0000-0002-9903-2541				ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; Bear MF, 1998, DAHLEM WORK, P205; BEAR MF, 1990, J NEUROSCI, V10, P909; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; BEAR MF, 1996, CORTICAL PLASTICITY, P191; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; Blais BS, 1999, P NATL ACAD SCI USA, V96, P1083, DOI 10.1073/pnas.96.3.1083; CHAPMAN B, 1986, NATURE, V324, P154, DOI 10.1038/324154a0; DUDEK SM, 1996, NEURON, V16, P1; GREUEL JM, 1987, DEV BRAIN RES, V34, P141, DOI 10.1016/0165-3806(87)90203-3; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; KAPLAN E, 1987, J PHYSIOL-LONDON, V391, P267, DOI 10.1113/jphysiol.1987.sp016737; Kirkwood A, 1997, P NATL ACAD SCI USA, V94, P3380, DOI 10.1073/pnas.94.7.3380; KIRKWOOD A, 1994, J NEUROSCI, V14, P3404; Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0; KIRKWOOD A, IN PRESS J NEUROSCI; Kojic L, 1997, DEV BRAIN RES, V101, P299, DOI 10.1016/S0165-3806(97)00083-7; MOWER GD, 1991, DEV BRAIN RES, V58, P151, DOI 10.1016/0165-3806(91)90001-Y; RAMOA AS, 1988, EXP BRAIN RES, V73, P285; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; Rossi AF, 1996, SCIENCE, V273, P1104, DOI 10.1126/science.273.5278.1104; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; STRYKER MP, 1986, J NEUROSCI, V6, P2117; von der Malsburg C, 1973, Kybernetik, V14, P85; WIESEL TN, 1965, J NEUROPHYSIOL, V28, P1060, DOI 10.1152/jn.1965.28.6.1060	27	182	189	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 28	1999	397	6717					347	350		10.1038/16922	http://dx.doi.org/10.1038/16922			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9950426				2022-12-28	WOS:000078324600049
J	Hollon, MF				Hollon, MF			Direct-to-consumer marketing of prescription drugs - Creating consumer demand	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LEADING MEDICAL JOURNALS; RESPIRATORY-INFECTIONS; ADVERTISEMENTS; COMPANIES		Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Hollon, MF (corresponding author), Univ Washington, Dept Med, Div Gen Internal Med, Box 357183, Seattle, WA 98195 USA.				BHP HRSA HHS [PHS-5-T-32 PE-10002-10] Funding Source: Medline	BHP HRSA HHS		COHEN EP, 1988, NEW ENGL J MED, V318, P373, DOI 10.1056/NEJM198802113180608; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; FREEMAN L, 1998, ADVERTISING AGE 0316, V69, pS6; GERBER P, 1988, MED J AUSTRALIA, V148, P485, DOI 10.5694/j.1326-5377.1988.tb99452.x; GOLODNER LF, 1997, CONSUMER GROUP RESPO; Greenhalgh T, 1997, BRIT MED J, V315, P1482, DOI 10.1136/bmj.315.7121.1482; Hamm RM, 1996, J FAM PRACTICE, V43, P56; HARPER J, 1997, INSIGHT NEWS    0915, V13, P40; HEMMINKI E, 1975, SOC SCI MED, V9, P111, DOI 10.1016/0037-7856(75)90103-1; HERXHEIMER A, 1993, INT J HEALTH SERV, V23, P161, DOI 10.2190/1AK2-X8CX-QQ9E-F6ED; Hueston WJ, 1997, J FAM PRACTICE, V44, P572; KESSLER DA, 1992, ANN INTERN MED, V116, P950, DOI 10.7326/0003-4819-116-11-950; LIEBMAN H, 1993, MEDIAWEEK, V3, P12; Low DE, 1998, JAMA-J AM MED ASSOC, V279, P394, DOI 10.1001/jama.279.5.394; PECK CC, 1990, JAMA-J AM MED ASSOC, V264, P2424; SCHWARTZ RK, 1989, SOC SCI MED, V28, P577, DOI 10.1016/0277-9536(89)90252-9; Siegel D, 1997, JAMA-J AM MED ASSOC, V278, P1745, DOI 10.1001/jama.278.21.1745; Stryer D, 1996, J GEN INTERN MED, V11, P575, DOI 10.1007/BF02599024; *US DEP HHS, 1997, FDA REV STAND DIR CO; *US DEP HHS, 1997, FDA PUBL HEAR DIR CO; WADE VA, 1989, LANCET, V2, P1261; WEBER J, 1993, BUSINESS WEEK   0118, P58; Weiss MC, 1996, FAM PRACT, V13, P432, DOI 10.1093/fampra/13.5.432; WHYTE J, 1993, JAMA-J AM MED ASSOC, V269, P150; WILKE M, 1998, ADVERTISING AGE 0316, V69, pS1; WILKE M, 1997, ADVERTISING AGE 0113, V68, P18; WILKES MS, 1992, ANN INTERN MED, V116, P912, DOI 10.7326/0003-4819-116-11-912; WILLCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292, DOI 10.1001/jama.272.4.292; Williams RJ, 1998, SCIENCE, V279, P1153, DOI 10.1126/science.279.5354.1153; 1985, FED REG         0909, V50, P36677; 1996, CONSUMER REPORTS JUN, V61, P62; 1994, US TODAY MAGAZIN OCT, V123, P1	32	130	131	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1999	281	4					382	384		10.1001/jama.281.4.382	http://dx.doi.org/10.1001/jama.281.4.382			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	158JB	9929096				2022-12-28	WOS:000078111300043
J	Lackmann, GM; Willnow, U; Wahn, V; Schroten, H				Lackmann, GM; Willnow, U; Wahn, V; Schroten, H			The importance of reading test results	LANCET			English	Article							CONGENITAL-SYPHILIS		Univ Dusseldorf, Zentrum Kinderheilkunde, D-40001 Dusseldorf, Germany; Univ Dusseldorf, Klin Kinderchirurg, D-40001 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Lackmann, GM (corresponding author), Univ Dusseldorf, Zentrum Kinderheilkunde, D-40001 Dusseldorf, Germany.							DORFMAN DH, 1990, NEW ENGL J MED, V323, P1299, DOI 10.1056/NEJM199011083231902; Kurzke C, 1992, Padiatr Grenzgeb, V31, P63; LUKEHART SA, 1998, HARRISONS PRINCIPLES, P1023; PIEPER CH, 1995, PEDIATR RADIOL, V25, P198, DOI 10.1007/BF02021534; TAN KL, 1973, ACTA PAEDIATR SCAND, V62, P601, DOI 10.1111/j.1651-2227.1973.tb17071.x	5	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 23	1999	353	9149					290	290		10.1016/S0140-6736(98)10170-8	http://dx.doi.org/10.1016/S0140-6736(98)10170-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929023				2022-12-28	WOS:000078292200013
J	Usher, M; Cohen, JD; Servan-Schreiber, D; Rajkowski, J; Aston-Jones, G				Usher, M; Cohen, JD; Servan-Schreiber, D; Rajkowski, J; Aston-Jones, G			The role of locus coeruleus in the regulation of cognitive performance	SCIENCE			English	Article							NEURONS INVITRO; VISUAL-ATTENTION; RAT; INHIBITION; BEHAVIOR; POPULATION; MODULATION; VIGILANCE; CERULEUS; DYNAMICS	Noradrenergic locus coeruleus (LC) neurons were recorded in monkeys performing a visual discrimination task, and a computational model was developed addressing the role of the LC brain system in cognitive performance. Changes in spontaneous and stimulus-induced patterns of LC activity correlated closely with fluctuations in behavioral performance. The model explains these fluctuations in terms of changes in electrotonic coupling among LC neurons and predicts improved performance during epochs of high coupling and synchronized LC firing. Cross correlations of simultaneously recorded LC neurons confirmed this prediction, indicating that electronic coupling in LC may play an important role in attentional modulation and the regulation of goat-directed versus exploratory behaviors.	Univ Kent, Dept Psychol, Canterbury, Kent, England; Princeton Univ, Dept Psychol, Princeton, NJ 08540 USA; Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA	University of Kent; Princeton University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Aston-Jones, G (corresponding author), Univ Penn, VAMC 151, Dept Psychiat, Univ & Woodland Ave, Philadelphia, PA 19104 USA.	gaj@mailmed.upenn.edu			NIMH NIH HHS [MH45156, MH 55309, MH47566] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH047566, P50MH045156] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELES M, 1982, ISRAEL J MED SCI, V18, P83; AGHAJANIAN GK, 1977, BRAIN RES, V136, P570, DOI 10.1016/0006-8993(77)90083-X; ASTONJONES G, 1994, J NEUROSCI, V14, P4467; BERNANDER O, 1994, NEURAL COMPUT, V6, P622, DOI 10.1162/neco.1994.6.4.622; CHRISTIE MJ, 1993, NEUROSCIENCE, V56, P129, DOI 10.1016/0306-4522(93)90568-Z; CHRISTIE MJ, 1989, J NEUROSCI, V9, P3584; Draguhn A, 1998, NATURE, V394, P189, DOI 10.1038/28184; EGAN TM, 1983, J PHYSIOL-LONDON, V345, P477, DOI 10.1113/jphysiol.1983.sp014990; Egeth HE, 1997, ANNU REV PSYCHOL, V48, P269, DOI 10.1146/annurev.psych.48.1.269; ENNIS M, 1986, BRAIN RES, V374, P299, DOI 10.1016/0006-8993(86)90424-5; FOOTE SL, 1980, P NATL ACAD SCI-BIOL, V77, P3033, DOI 10.1073/pnas.77.5.3033; FOOTE SL, 1983, PHYSIOL REV, V63, P844, DOI 10.1152/physrev.1983.63.3.844; GRANT SJ, 1988, BRAIN RES BULL, V21, P401, DOI 10.1016/0361-9230(88)90152-9; HARRIS GC, 1992, NEUROSCIENCE, V50, P253, DOI 10.1016/0306-4522(92)90420-7; HASSELMO ME, 1995, BEHAV BRAIN RES, V67, P1, DOI 10.1016/0166-4328(94)00113-T; Ishimatsu M, 1996, J NEUROSCI, V16, P5196; Ivanova S., 1997, Society for Neuroscience Abstracts, V23, P1587; JAHNSEN H, 1984, J PHYSIOL-LONDON, V349, P227, DOI 10.1113/jphysiol.1984.sp015154; Kaelbling LP, 1996, J ARTIF INTELL RES, V4, P237, DOI 10.1613/jair.301; KNIGHT BW, 1972, J GEN PHYSIOL, V59, P734, DOI 10.1085/jgp.59.6.734; Kuramoto Y., 1984, CHEM OSCILLATORS WAV; LLINAS R, 1974, J NEUROPHYSIOL, V37, P560, DOI 10.1152/jn.1974.37.3.560; MCCLELLAND JL, 1993, ATTENTION PERFORM, V14, P655; McMahon DG, 1996, BRAIN RES, V718, P89, DOI 10.1016/0006-8993(96)00043-1; MCMAHON DG, 1994, J NEUROPHYSIOL, V72, P2257, DOI 10.1152/jn.1994.72.5.2257; Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996; NELKEN I, 1990, BIOL CYBERN, V64, P51, DOI 10.1007/BF00203630; Niebur E, 1994, J Comput Neurosci, V1, P141, DOI 10.1007/BF00962722; OGREN SO, 1984, CATECHOLAMINES NEURO, P285; Osborne PB, 1996, J NEUROPHYSIOL, V76, P1559, DOI 10.1152/jn.1996.76.3.1559; RAJKOWSKI J, 1994, BRAIN RES BULL, V35, P607, DOI 10.1016/0361-9230(94)90175-9; RAYMOND JE, 1995, J EXP PSYCHOL HUMAN, V21, P653, DOI 10.1037/0096-1523.21.3.653; REEVES A, 1986, PSYCHOL REV, V93, P180, DOI 10.1037/0033-295X.93.2.180; Rumelhart D., 1986, PARALLEL DISTRIBUTED; SARA SJ, 1995, COGNITIVE BRAIN RES, V2, P181, DOI 10.1016/0926-6410(95)90007-1; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; SELDEN NRW, 1990, BEHAV BRAIN RES, V39, P29, DOI 10.1016/0166-4328(90)90119-Y; SELDEN NRW, 1990, J NEUROSCI, V10, P531; SERVANSCHREIBER D, 1990, SCIENCE, V249, P892, DOI 10.1126/science.2392679; SHERMAN A, 1992, P NATL ACAD SCI USA, V89, P2471, DOI 10.1073/pnas.89.6.2471; SIEGLER RS, 1995, COGNITIVE PSYCHOL, V28, P225, DOI 10.1006/cogp.1995.1006; STROGATZ SH, 1991, J STAT PHYS, V63, P613, DOI 10.1007/BF01029202; TAYLOR CP, 1982, SCIENCE, V218, P810, DOI 10.1126/science.7134978; Travagli R. A., 1994, Society for Neuroscience Abstracts, V20, P1734; TRAVAGLI RA, 1995, J NEUROPHYSIOL, V74, P519, DOI 10.1152/jn.1995.74.2.519; VANVREESWIJK C, 1994, J COMPUT NEUROSCI, V1, P303; WEICHSELGARTNER E, 1987, SCIENCE, V238, P778, DOI 10.1126/science.3672124	47	501	507	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 22	1999	283	5401					549	554		10.1126/science.283.5401.549	http://dx.doi.org/10.1126/science.283.5401.549			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	159YM	9915705				2022-12-28	WOS:000078203300041
J	Chyb, S; Raghu, P; Hardie, RC				Chyb, S; Raghu, P; Hardie, RC			Polyunsaturated fatty acids activate the Drosophila light-sensitive channels TRP and TRPL	NATURE			English	Article							CAPACITATIVE CALCIUM-ENTRY; PROTEIN-KINASE-C; ARACHIDONIC-ACID; CATION CHANNELS; PHOTORECEPTORS; CA2+; PHOTOTRANSDUCTION; EXPRESSION; MUTANTS; GENE	Phototransduction in invertebrate microvillar photoreceptors is thought to be mediated by the activation of phospholipase C (PLC), but how this leads to gating of the light-sensitive channels is unknown(1,2). Most attention has focused on inositol-1,4,5-trisphosphate, a second messenger produced by PLC from phosphatidylinositol-4,5-bisphosphate; however, PLC also generates diacylglycerol, a potential precursor for several polyunsaturated fatty acids, such as arachidonic acid and linolenic acid. Here we show that both of these fatty acids reversibly activate native light-sensitive channels (transient receptor potential (TRP) and TRP-like (TRPL)) in Drosophila photoreceptors as well as recombinant TRPL channels expressed in Drosophila S2 cells. Recombinant channels are activated rapidly in both whole-cell recordings and inside-out patches, with a half-maximal effector concentration for linolenic acid of similar to 10 mu M Four different Lipoxygenase inhibitors, which might be expected to lead to build-up of endogenous fatty [GRAPHICS] acids, also activate native TRP and TRPL channels in intact photoreceptors, As arachidonic acid may not be found in Drosophila, we suggest that another polyunsaturated fatty acid, such as linolenic acid, may be a messenger of excitation in Drosophila photoreceptors.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England	University of Cambridge	Hardie, RC (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.	rch14@hermes.cam.ac.uk	Padinjat, Raghu/Z-5578-2019; Chyb, Sylwester/B-5783-2009	Hardie, Roger/0000-0001-5531-3264	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; ANDERSON MP, 1990, P NATL ACAD SCI USA, V87, P7334, DOI 10.1073/pnas.87.18.7334; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; DONG YJ, 1995, AM J PHYSIOL-CELL PH, V269, pC1332, DOI 10.1152/ajpcell.1995.269.5.C1332; Hardie RC, 1997, CELL CALCIUM, V21, P431, DOI 10.1016/S0143-4160(97)90054-3; Hardie RC, 1996, J NEUROSCI, V16, P2924; HARDIE RC, 1995, CELL CALCIUM, V18, P256, DOI 10.1016/0143-4160(95)90023-3; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; KARNOVSKY MJ, 1982, J CELL BIOL, V94, P1, DOI 10.1083/jcb.94.1.1; MEVES H, 1994, PROG NEUROBIOL, V43, P175, DOI 10.1016/0301-0082(94)90012-4; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; Obukhov AG, 1996, EMBO J, V15, P5833, DOI 10.1002/j.1460-2075.1996.tb00970.x; Pearn MT, 1996, J BIOL CHEM, V271, P4937; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; Reuss H, 1997, NEURON, V19, P1249, DOI 10.1016/S0896-6273(00)80416-X; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; Shim K, 1997, EXP EYE RES, V65, P717, DOI 10.1006/exer.1997.0383; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; STARK WS, 1993, LIPIDS, V28, P345, DOI 10.1007/BF02536321; VANDERZEE L, 1995, BIOCHEM J, V305, P859, DOI 10.1042/bj3050859; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V98, P657, DOI 10.1093/oxfordjournals.jbchem.a135322; Zimmer S, 1997, N-S ARCH PHARMACOL, V355, P238	30	335	343	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 21	1999	397	6716					255	259		10.1038/16703	http://dx.doi.org/10.1038/16703			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159QH	9930700				2022-12-28	WOS:000078184800053
J	Hill, AF; Butterworth, RJ; Joiner, S; Jackson, G; Rossor, MN; Thomas, DJ; Frosh, A; Tolley, N; Bell, JE; Spencer, M; King, A; Al-Sarraj, S; Ironside, JW; Lantos, PL; Collinge, J				Hill, AF; Butterworth, RJ; Joiner, S; Jackson, G; Rossor, MN; Thomas, DJ; Frosh, A; Tolley, N; Bell, JE; Spencer, M; King, A; Al-Sarraj, S; Ironside, JW; Lantos, PL; Collinge, J			Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples	LANCET			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; STRAIN VARIATION; SCRAPIE; MICE; CJD; BSE; DIAGNOSIS; PROTEINS; ISOFORM; AGENT	Background Prion diseases are associated with the accumulation of an abnormal isoform of cellular prion protein (PrP(Sc)), which is the principal constituent of prions. Prions replicate in lymphoreticular tissues before neuroinvasion, suggesting that lymphoreticular biopsy samples may allow early diagnosis by detection of PrP(Sc) Variant Creutzfeldt-Jakob disease (variant CJD) is difficult to distinguish from common psychiatric disorders in its early stages and definitive diagnosis has relied on neuropathology. We studied lymphoreticular tissues from a necropsy series and assessed tonsillar biopsy samples as a diagnostic investigation for human prion disease. Methods Lymphoreticular tissues (68 tonsils, 64 spleens, and 40 lymph nodes) were obtained at necropsy from patients affected by prion disease and from neurological and normal controls. Tonsil biopsy sampling was done on 20 patients with suspected prion disease. Tissues were analysed by western blot to detect and type PrP(Sc), by PrP immunohistochemistry, or both. Findings All lymphoreticular tissues obtained at necropsy from patients with neuropathologically confirmed variant CJD, but not from patients with other prion diseases or controls, were positive for PrP(Sc). In addition, PrP(Sc) typing revealed a consistent pattern (designated type 4t) different from that seen in variant CJD brain (type 4) or in brain from other CJD subtypes (types 1-3). Tonsil biopsy tissue was positive in all eight patients with an adequate biopsy sample and whose subsequent course has confirmed, or is highly consistent with, a diagnosis of variant CJD and negative in all patients subsequently confirmed to have other diagnoses. Interpretation We found that if, in the appropriate clinical context, a tonsil biopsy sample was positive for PrP(Sc), variant CJD could be diagnosed, which obviates the need for a brain biopsy sample to be taken. Our results also show that variant CJD has a different pathogenesis to sporadic CJD.	St Marys Hosp, Imperial Coll Sch Med, Dept Neurogenet, London W2 1PG, England; St Marys Hosp, Specialist Prion Dis Clin, London W2 1PG, England; St Marys Hosp, Dept Neurol, London W2 1PG, England; St Marys Hosp, Dept Ear Nose & Throat Surg, London W2 1PG, England; Natl CJG Surveillance Unit, Edinburgh, Midlothian, Scotland; Inst Psychiat, Dept Neuropathol, London, England	Imperial College London; Imperial College London; Imperial College London; Imperial College London; University of London; King's College London	Collinge, J (corresponding author), St Marys Hosp, Imperial Coll Sch Med, Dept Neurogenet, Praed St, London W2 1PG, England.	j.collinge@ic.ac.uk	Hill, Andrew F./AAH-2854-2020; Hill, Andrew F./GZL-4124-2022; Rossor, Martin/C-1598-2008; Hill, Andrew F/B-4527-2009	Hill, Andrew F./0000-0001-5581-2354; Hill, Andrew F/0000-0001-5581-2354; Jackson, Graham/0000-0002-3125-2011; Rossor, Martin/0000-0001-8215-3120; Ironside, James/0000-0001-5869-2108; Spencer, Michael/0000-0002-1646-5254	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		*ADV COMM DANG PAT, 1998, TRANSM SPONG ENC AG; Bell JE, 1997, NEUROPATH APPL NEURO, V23, P26, DOI 10.1111/j.1365-2990.1997.tb01182.x; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; Brown P, 1995, Curr Opin Hematol, V2, P472; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BUDKA H, 1995, BRAIN PATHOL, V5, P319, DOI 10.1111/j.1750-3639.1995.tb00609.x; CLARKE MC, 1994, RES VET SCI, V9, P215; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; Collinge J, 1997, HUM MOL GENET, V6, P1699, DOI 10.1093/hmg/6.10.1699; Collinge J, 1998, NAT MED, V4, P1369, DOI 10.1038/3955; ESMONDE TFG, 1993, LANCET, V341, P205, DOI 10.1016/0140-6736(93)90068-R; FRASER H, 1992, E H S NEURO, P308; FRASER H, 1987, VET MICROBIOL, V13, P211, DOI 10.1016/0378-1135(87)90084-8; GOODBRAND IA, 1995, NEUROSCI LETT, V183, P127, DOI 10.1016/0304-3940(94)11131-2; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hilton DA, 1998, LANCET, V352, P703, DOI 10.1016/S0140-6736(98)24035-9; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kawashima T, 1997, LANCET, V350, P68, DOI 10.1016/S0140-6736(05)66274-5; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; Klein MA, 1998, NAT MED, V4, P1429, DOI 10.1038/4022; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; Krasemann S, 1996, MOL MED, V2, P725, DOI 10.1007/BF03401656; Lasmezas CI, 1996, J VIROL, V70, P1292; Murthy P, 1998, J LARYNGOL OTOL, V112, P41, DOI 10.1017/S0022215100139866; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; Schreuder BEC, 1998, VET REC, V142, P564, DOI 10.1136/vr.142.21.564; STETLERSTEVENSO.M, 1998, MAJOR PROBLEMS PATHO, P22; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; WELLS GAH, 1994, VET REC, V135, P40, DOI 10.1136/vr.135.2.40; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Zeidler M, 1997, LANCET, V350, P903, DOI 10.1016/S0140-6736(97)07472-2	35	539	551	0	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					183	189		10.1016/S0140-6736(98)12075-5	http://dx.doi.org/10.1016/S0140-6736(98)12075-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923873				2022-12-28	WOS:000078175600010
J	Prescott, SL; Macaubas, C; Smallacombe, T; Holt, BJ; Sly, PD; Holt, PG				Prescott, SL; Macaubas, C; Smallacombe, T; Holt, BJ; Sly, PD; Holt, PG			Development of allergen-specific T-cell memory in atopic and normal children	LANCET			English	Article							POSTNATAL MATURATION; INTERFERON-GAMMA; EARLY-CHILDHOOD; ASTHMA; RESPONSES; COMPETENCE; PREVALENCE; INDUCTION; DISEASES; INFANCY	Background In the past 20-30 years, there has been an increase in prevalence of allergic respiratory diseases, particularly amongst children. This study is a prospective analysis of the postnatal maturation of T-helper cell (Th) responses to aeroallergens in atopic and non-atopic infants. Methods We measured mononuclear-cell proliferative and cytokine responses to specific allergens and tetanus toroid in blood samples from atopic and non-atopic infants every 6 months from birth to 2 years of age. Cytokine analyses of responses to housedust-mite allergen used ELISA and reverse-transcriptase PCR. We also measured responses to Fel dl(cat allergen) and tetanus toroid. Findings Samples from 18 atopic and 13 non-atopic infants showed low-level Th2-skewed allergen-specific responses at birth, with little accompanying specific interferon-gamma production. Neonatal Th2 responses were lower in the atopic group than in the non-atopic group; the differences were significant for interleukin-4 (mRNA: beta-actin ratio 0.48 [SE 0.15] vs 0.15 [0.06], p=0.049), interleukin-6 (4750 [48] vs 1352 [51] pg/mL culture fluid, p=0.003), interleukin-10 (1162 [228] vs 485 [89], p=0.015), and interleukin-13 (7.1 [0.9] vs 0.9 [0.3], p=0.008). There was rapid suppression of Th2 responses during the first year of life in non-atopic children, but there was consolidation of responses in atopic children, associated with defective neonatal interferon-gamma production. Interpretation The continuation of fetal allergen-specific Th2 responses during infancy is a defining feature of the inductive phase of atopic disease, and is associated with decreased capacity for production of the Th1 cytokine interferon gamma by atopic neonates. These findings provide a plausible mechanism for persistence of the fetal Th2 responses during early childhood in atopic individuals and subsequent expression of disease.	TVW Telethon Inst Child Hlth Res, Div Cell Biol, W Perth, WA 6872, Australia	Telethon Kids Institute; University of Western Australia	Holt, PG (corresponding author), TVW Telethon Inst Child Hlth Res, Div Cell Biol, POB 855, W Perth, WA 6872, Australia.		Holt, Patrick G/H-1548-2011; Prescott, Susan/H-5665-2014; Sly, Peter D/F-1486-2010	Holt, Patrick G/0000-0003-1193-0935; Sly, Peter D/0000-0001-6305-2201				HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Holt PG, 1997, THORAX, V52, P1, DOI 10.1136/thx.52.1.1; Holt PG, 1996, J EXP MED, V183, P1297, DOI 10.1084/jem.183.4.1297; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P59, DOI 10.1111/j.1399-3038.1995.tb00261.x; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; Piccinni MP, 1996, EUR J IMMUNOL, V26, P2293, DOI 10.1002/eji.1830261004; Prescott SL, 1997, INT ARCH ALLERGY IMM, V113, P75, DOI 10.1159/000237512; Prescott SL, 1998, J IMMUNOL, V160, P4730; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sudo N, 1997, J IMMUNOL, V159, P1739; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WILSON CB, 1986, J CLIN INVEST, V77, P860, DOI 10.1172/JCI112383; Woolcock AJ, 1995, ALLERGY, V50, P935, DOI 10.1111/j.1398-9995.1995.tb02504.x; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261, DOI 10.1111/j.1365-2222.1997.tb01170.x	23	700	715	0	26	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					196	200		10.1016/S0140-6736(98)05104-6	http://dx.doi.org/10.1016/S0140-6736(98)05104-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923875				2022-12-28	WOS:000078175600012
J	Ward, J; Hall, W; Mattick, RP				Ward, J; Hall, W; Mattick, RP			Role of maintenance treatment in opioid dependence	LANCET			English	Article							INTRAVENOUS-DRUG-USERS; METHADONE-MAINTENANCE; FOLLOW-UP; CONTROLLED TRIAL; HEROIN-ADDICTION; RISK-FACTORS; HONG-KONG; PROGRAM; SEROCONVERSION; BUPRENORPHINE	Methadone maintenance treatment (MMT) involves the daily administration of the oral opioid agonist methadone as a treatment for opioid dependence-a persistent disorder with a substantial risk of premature death. MMT improves health and reduces illicit heroin use, infectious-disease transmission, and overdose death. However, its effectiveness is compromised if low maintenance doses of methadone (<60 mg) are used and patients are pressured to become prematurely abstinent from methadone. Pregnancy and psychiatric comorbidity are not contraindications for MMT. As an alternative to MMT, other oral opioid agents (eg, naltrexone, buprenorphine) may increase patient choice and avoid some of the more unpleasant aspects of MMT. The public-health challenge for the future is to develop and continue to deliver safe and effective forms of opioid maintenance treatment to as many opioid-dependent individuals as can benefit from them.	Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia; Australian Natl Univ, Div Psychol, Canberra, ACT, Australia	University of New South Wales Sydney; Australian National University	Hall, W (corresponding author), Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia.	ndarc1@unsw.edu.au	Hall, Wayne D/A-3283-2008	Hall, Wayne D/0000-0003-1984-0096				Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244; Anthony James C., 1995, P361; Auriacombe M, 1997, RES CLIN FORUMS, V19, P25; BALE RN, 1980, ARCH GEN PSYCHIAT, V37, P179; Ball J.C., 2012, EFFECTIVENESS METHAD; BALL JC, 1983, DRUG ALCOHOL DEPEN, V12, P119, DOI 10.1016/0376-8716(83)90037-6; BELL J, 1994, ADDICTION, V89, P463, DOI 10.1111/j.1360-0443.1994.tb00927.x; BELL J, 1994, NEW S WALES METHADON; BROWN BS, 1982, AM J DRUG ALCOHOL AB, V9, P129, DOI 10.3109/00952998209002617; Camacho LM, 1997, DRUG ALCOHOL DEPEN, V47, P11, DOI 10.1016/S0376-8716(97)00056-2; CAPLEHORN JRM, 1995, INT J ADDICT, V30, P685, DOI 10.3109/10826089509048753; DAVOLI M, 1993, INT J EPIDEMIOL, V22, P273, DOI 10.1093/ije/22.2.273; DOLE VP, 1969, NEW ENGL J MED, V280, P1372, DOI 10.1056/NEJM196906192802502; DOLE VP, 1965, JAMA-J AM MED ASSOC, V193, P80; DRUMMER OH, 1992, AM J FOREN MED PATH, V13, P346, DOI 10.1097/00000433-199212000-00017; English D.R., 1995, QUANTIFICATION DRUG; FINNEGAN LP, 1991, J PSYCHOACTIVE DRUGS, V23, P191, DOI 10.1080/02791072.1991.10472236; GEARING FR, 1974, AM J EPIDEMIOL, V100, P101, DOI 10.1093/oxfordjournals.aje.a112012; Geraghty B, 1997, J Hum Lact, V13, P227, DOI 10.1177/089033449701300312; GERSTEIN DR, 1990, TREATING DERUG PROBL, V1; GERSTEIN DR, 1990, TREAETING DRUG PROBL, V1; GILES W, 1989, AUST NZ J OBSTET GYN, V29, P225, DOI 10.1111/j.1479-828X.1989.tb01724.x; Gilman AG, 1990, GOODMAN GILMANS PHAR, V6; Goldstein A, 1995, DRUG ALCOHOL DEPEN, V40, P139, DOI 10.1016/0376-8716(95)01205-2; GREEN L, 1988, BRIT J ADDICT, V83, P305; GRONBLADH L, 1990, ACTA PSYCHIAT SCAND, V82, P223, DOI 10.1111/j.1600-0447.1990.tb03057.x; GUNNE LM, 1981, DRUG ALCOHOL DEPEN, V7, P249, DOI 10.1016/0376-8716(81)90096-X; HALL W, 1998, METHADONE MAINTENANC, P1; Hall W., 1995, 28 NAT DRUG ALC RES; Hall W., 1998, METHADONE MAINTENANC, P17; HAVASSY B, 1981, AM J PSYCHIAT, V138, P1497; HSER YI, 1993, ARCH GEN PSYCHIAT, V50, P577; Hubbard RL, 1989, DRUG ABUSE TREATMENT; *I MED, 1995, FED REG METH TREATM; KRAFT MK, 1997, AM J PSYCHIAT, V154, P1195; Ling W, 1996, ARCH GEN PSYCHIAT, V53, P401; LONGSHORE D, 1993, INT J ADDICT, V28, P983, DOI 10.3109/10826089309062178; LOWINSON JH, 1979, HDB DRUG ABUSE, P49; MADDUX JF, 1995, AM J ADDICTION, V4, P18; MADDUX JF, 1992, AM J DRUG ALCOHOL AB, V18, P63, DOI 10.3109/00952999209001612; MARKS J, 1987, LANCET, V1, P1068; Marsch LA, 1998, ADDICTION, V93, P515, DOI 10.1046/j.1360-0443.1998.9345157.x; MATTICK RP, 1998, NDARC MONOGRAPH, V34; MATTICK RP, 1998, METHADONE MAINTENANC, P123, DOI DOI 10.1002/14651858; MATTICK RP, 1998, METHADONE MAINTENANC, P265; MCAULIFFE WE, 1990, J PSYCHOACTIVE DRUGS, V22, P197, DOI 10.1080/02791072.1990.10472544; METZGER DS, 1993, J ACQ IMMUN DEF SYND, V6, P1049; MILBY JB, 1986, AM J PSYCHIAT, V143, P739; MILBY JB, 1988, J NERV MENT DIS, V176, P409, DOI 10.1097/00005053-198807000-00003; MOSS AR, 1994, AIDS, V8, P223, DOI 10.1097/00002030-199402000-00010; Neeleman J, 1997, J EPIDEMIOL COMMUN H, V51, P435, DOI 10.1136/jech.51.4.435; NEWMAN RG, 1979, LANCET, V2, P485; O'Connor PG, 1998, JAMA-J AM MED ASSOC, V279, P229, DOI 10.1001/jama.279.3.229; PAYTE JT, 1993, STATE METHADONE TREA, P119; Payte JT, 1993, STATE METHADONE TREA, P47; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; Rhoades HM, 1998, AM J PUBLIC HEALTH, V88, P34, DOI 10.2105/AJPH.88.1.34; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SIMPSON DD, 1982, ADV ALCOHOL SUBSTANC, V0002; SPUNT B, 1986, J DRUG ISSUES, V16, P569, DOI 10.1177/002204268601600406; Stimson G., 1982, HEROIN ADDICTION TRE; Stitzer M L, 1993, NIDA Res Monogr, V137, P19; Uchtenhagen A, 1997, EUR ADDICT RES, V3, P160, DOI 10.1159/000259173; VAILLANT GE, 1988, BRIT J ADDICT, V83, P1147; VANICHSENI S, 1991, INT J ADDICT, V26, P1313, DOI 10.3109/10826089109062163; WAERD J, 1998, METHADONE MAINTENANC, P305; Ward J, 1996, CNS DRUGS, V6, P440, DOI 10.2165/00023210-199606060-00004; Ward J., 1998, METHADONE MAINTENANC; Ward J., 1998, METHADONE MAINTENANC, P205; Ward J., 1998, METHADONE MAINTENANC, P59; Williamson PA, 1997, MED J AUSTRALIA, V166, P302, DOI 10.5694/j.1326-5377.1997.tb122318.x; WOODY GE, 1984, AM J PSYCHIAT, V141, P1172; YANCOVITZ SR, 1991, AM J PUBLIC HEALTH, V81, P1185, DOI 10.2105/AJPH.81.9.1185; ZWEBEN JE, 1991, J PSYCHOACTIVE DRUGS, V23, P177, DOI 10.1080/02791072.1991.10472235	74	320	347	0	30	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 16	1999	353	9148					221	226		10.1016/S0140-6736(98)05356-2	http://dx.doi.org/10.1016/S0140-6736(98)05356-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	159LW	9923893				2022-12-28	WOS:000078175600045
J	Rodriguez, E; George, N; Lachaux, JP; Martinerie, J; Renault, B; Varela, FJ				Rodriguez, E; George, N; Lachaux, JP; Martinerie, J; Renault, B; Varela, FJ			Perception's shadow: long-distance synchronization of human brain activity	NATURE			English	Article							NEURONAL RESPONSES; VISUAL-CORTEX; INTEGRATION; REFLECTS; BINDING; MONKEY; TASK; FACE	Transient periods of synchronization of oscillating neuronal discharges in the frequency range 30-80 Hz (gamma oscillations) have been proposed to act as an integrative mechanism that may bring a widely distributed set of neurons together into a coherent ensemble that underlies a cognitive act(1-4). Results of several experiments in animals provide support for this idea (see, for example, refs 4-10), In humans, gamma oscillations have been described both on the scalp(11-16) (measured by electroencephalography and magnetoencephalography) and in intracortical recordings(17), but no direct participation of synchrony in a cognitive task has been demonstrated so far. Here we record electrical brain activity from subjects who are viewing ambiguous visual stimuli (perceived either as faces or as meaningless shapes). We show for the first time, to our knowledge, that only face perception induces a long-distance pattern of synchronization, corresponding to the moment of perception itself and to the ensuing motor response. A period of strong desynchronization marks the transition between the moment of perception and the motor response. We suggest that this desynchronization reflects a process of active uncoupling of the underlying neural ensembles that is necessary to proceed from one cognitive state to another(3).	Hop La Pitie Salpetriere, CNRS, UPR 640, Lab Neurosci Cognit & Imagerie Cerebrale, F-75651 Paris 13, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Varela, FJ (corresponding author), Hop La Pitie Salpetriere, CNRS, UPR 640, Lab Neurosci Cognit & Imagerie Cerebrale, 47 Blvd Hop, F-75651 Paris 13, France.		Lachaux, Jean-Philippe/K-1681-2017; anand, amit/A-7222-2009					BRESSLER SL, 1993, NATURE, V366, P153, DOI 10.1038/366153a0; Damasio A. R., 1990, SEMIN NEUROSCI, V2, P287; DESMEDT JE, 1994, NEUROSCI LETT, V168, P126, DOI 10.1016/0304-3940(94)90432-4; Dolan RJ, 1997, NATURE, V389, P596, DOI 10.1038/39309; Freeman WJ, 1975, MASS ACTION NERVOUS; FRIEDMANHILL SR, 1995, SCIENCE, V269, P853, DOI 10.1126/science.7638604; George N, 1997, NEUROREPORT, V8, P1417, DOI 10.1097/00001756-199704140-00019; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; Jeffreys DA, 1996, VIS COGN, V3, P1, DOI 10.1080/713756729; JOLIOT M, 1994, P NATL ACAD SCI USA, V91, P11748, DOI 10.1073/pnas.91.24.11748; Kreiter AK, 1996, J NEUROSCI, V16, P2381; LACHAUX JP, UNPUB EUR J NEUROSCI; LACHAUX JP, UNPUB HUM BRAIN MAPP; LLINAS R, 1993, P NATL ACAD SCI USA, V90, P2078, DOI 10.1073/pnas.90.5.2078; Mecklenbrauker W. F. G., 1993, WIGNER DISTRIBUTION; Menon V, 1996, ELECTROEN CLIN NEURO, V98, P89, DOI 10.1016/0013-4694(95)00206-5; MOONEY CM, 1957, CAN J PSYCHOLOGY, V11, P219, DOI 10.1037/h0083717; Neuenschwander S, 1996, VISUAL NEUROSCI, V13, P575, DOI 10.1017/S0952523800008257; Pantev Christo, 1995, Brain Topography, V7, P321, DOI 10.1007/BF01195258; Roelfsema PR, 1997, NATURE, V385, P157, DOI 10.1038/385157a0; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; TallonBaudry C, 1997, J NEUROSCI, V17, P722; TIITINEN H, 1993, NATURE, V364, P59, DOI 10.1038/364059a0; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0; Varela Francisco J., 1995, Biological Research, V28, P81; Yordanova J, 1997, NEUROREPORT, V8, P3999, DOI 10.1097/00001756-199712220-00029	27	1450	1470	6	97	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 4	1999	397	6718					430	433		10.1038/17120	http://dx.doi.org/10.1038/17120			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164KA	9989408				2022-12-28	WOS:000078461700047
J	Travis, LB; Holowaty, EJ; Bergfeldt, K; Lynch, CF; Kohler, BA; Wiklund, T; Curtis, RE; Hall, P; Andersson, M; Pukkala, E; Sturgeon, J; Stovall, M				Travis, LB; Holowaty, EJ; Bergfeldt, K; Lynch, CF; Kohler, BA; Wiklund, T; Curtis, RE; Hall, P; Andersson, M; Pukkala, E; Sturgeon, J; Stovall, M			Risk of leukemia after platinum-based chemotherapy for ovarian cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							2ND MALIGNANT NEOPLASMS; LONG-TERM SURVIVORS; CISPLATIN; RADIOTHERAPY; MELPHALAN; DNA	Background Platinum-based chemotherapy is the cornerstone of modern treatment for ovarian, testicular, and other cancers, but few investigations have quantified the late sequelae of such treatment. Methods We conducted a case-control study of secondary leukemia in a population-based cohort of 28,971 women in North America and Europe who had received a diagnosis of invasive ovarian cancer between 1980 and 1993. Leukemia developed after the administration of platinum-based therapy in 96 women. These women were matched to 272 control patients. The type, cumulative dose, and duration of chemotherapy and the dose of radiation delivered to active bone marrow were compared in the two groups. Results Among the women who received platinum-based combination chemotherapy for ovarian cancer, the relative risk of leukemia was 4.0 (95 percent confidence interval, 1.4 to 11.4). The relative risks for treatment with carboplatin and for treatment with cisplatin were 6.5 (95 percent confidence interval, 1.2 to 36.6) and 3.3 (95 percent confidence interval, 1.1 to 9.4), respectively. We found evidence of a dose-response relation, with relative risks reaching 7.6 at doses of 1000 mg or more of platinum (P for trend <0.001). Radiotherapy without chemotherapy (median dose, 18.4 Gy) did not increase the risk of leukemia. Conclusions Platinum-based treatment of ovarian cancer increases the risk of secondary leukemia. Nevertheless, the substantial benefit that platinum-based treatment offers patients with advanced disease outweighs the relatively small excess risk of leukemia. (N Engl J Med 1999;340:351-7.) (C) 1999, Massachusetts Medical Society.	NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; Canc Care Ontario, Toronto, ON, Canada; Karolinska Univ Hosp, Stockholm, Sweden; Univ Iowa, Iowa City, IA USA; Dept Hlth & Senior Serv, Trenton, NJ USA; Univ Helsinki, Cent Hosp, Helsinki, Finland; Danish Canc Soc, Copenhagen, Denmark; Finnish Canc Registry, FIN-00170 Helsinki, Finland; Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cancer Care Ontario; Karolinska Institutet; Karolinska University Hospital; University of Iowa; University of Helsinki; Helsinki University Central Hospital; Danish Cancer Society; Finnish Cancer Registry; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Texas System; UTMD Anderson Cancer Center	Travis, LB (corresponding author), NCI, Div Canc Epidemiol & Genet, Execut Plaza N,Suite 408, Bethesda, MD 20892 USA.		Bergfeldt, Kjell/C-3581-2012	Wiklund, Tom/0000-0002-9384-9614				ALLEN DG, 1993, ANN ONCOL, V4, P83; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; CURTIS RE, 1992, NEW ENGL J MED, V326, P1745, DOI 10.1056/NEJM199206253262605; DONEHOWER RC, 1995, CLIN ONCOLOGY, P201; DOUPLE EB, 1988, NATL CANCER I MONOGR, V6, P315; GREENE MH, 1986, ANN INTERN MED, V105, P360, DOI 10.7326/0003-4819-105-3-360; GREENE MH, 1992, J NATL CANCER I, V84, P306, DOI 10.1093/jnci/84.5.306; KALDOR J, 1990, ACTA ONCOL, V29, P647, DOI 10.3109/02841869009090070; KALDOR JM, 1990, NEW ENGL J MED, V322, P1, DOI 10.1056/NEJM199001043220101; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; Kaye SB, 1996, J CLIN ONCOL, V14, P2113, DOI 10.1200/JCO.1996.14.7.2113; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Landis SH, 1998, CA-CANCER J CLIN, V48, P192; LUBIN JH, 1981, COMPUT BIOMED RES, V14, P138, DOI 10.1016/0010-4809(81)90031-8; McKeage MJ, 1997, J CLIN ONCOL, V15, P2691, DOI 10.1200/JCO.1997.15.7.2691; Neijt JP, 1996, NEW ENGL J MED, V334, P50, DOI 10.1056/NEJM199601043340112; OZOLS RF, 1985, CANCER TREAT REV, V12, P59, DOI 10.1016/0305-7372(85)90019-2; PARKIN DM, 1997, IARC SCI PUBLICATION, V143; POIRIER MC, 1992, CANCER RES, V52, P149; REED E, 1993, CANCER RES, V53, P3694; RIES LAG, 1997, NIH PUBLICATION; SAMUELS BL, 1995, J CLIN ONCOL, V13, P1786, DOI 10.1200/JCO.1995.13.7.1786; SELTZER V, 1995, JAMA-J AM MED ASSOC, V273, P491, DOI 10.1001/jama.1995.03520300065039; SMITH M, IN PRESS J CLIN ONCO; STOVALL M, 1989, MED PHYS, V16, P726, DOI 10.1118/1.596331; Travis LB, 1997, JNCI-J NATL CANCER I, V89, P1429, DOI 10.1093/jnci/89.19.1429; TRAVIS LB, 1994, JNCI-J NATL CANCER I, V86, P1450, DOI 10.1093/jnci/86.19.1450; Travis LB, 1996, CANCER RES, V56, P1564; VandeVaart PJM, 1997, INT J RADIAT BIOL, V72, P675; VANLEEUWEN FE, 1997, CANC PRINCIPLES PRAC, V2, P2773; VOKES EE, 1990, J CLIN ONCOL, V8, P911, DOI 10.1200/JCO.1990.8.5.911; VOKES EE, 1990, J CLIN ONCOL, V8, P1447; Williams C J, 1992, Semin Oncol, V19, P120	33	239	245	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1999	340	5					351	357		10.1056/NEJM199902043400504	http://dx.doi.org/10.1056/NEJM199902043400504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163WC	9929525				2022-12-28	WOS:000078428500004
J	Lipshultz, LI; Kim, ED				Lipshultz, LI; Kim, ED			Treatment of erectile dysfunction in men with diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ALPROSTADIL; INJECTION; IMPOTENCE; DEVICE; MALES		Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; Baylor Coll Med, Div Male Reprod Med & Surg, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Lipshultz, LI (corresponding author), Baylor Coll Med, Scott Dept Urol, 6560 Fannin,Suite 2100, Houston, TX 77030 USA.							BEMELMANS BLH, 1994, J UROLOGY, V151, P884, DOI 10.1016/S0022-5347(17)35113-3; BODANSKY HJ, 1994, DIABETIC MED, V11, P410, DOI 10.1111/j.1464-5491.1994.tb00295.x; DETEJADA IS, 1989, NEW ENGL J MED, V320, P1025, DOI 10.1056/NEJM198904203201601; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; JAWORSKI TM, 1992, UROLOGY, V40, P127, DOI 10.1016/0090-4295(92)90510-4; KADIOGLU A, 1995, EUR UROL, V27, P311; Linet OI, 1996, NEW ENGL J MED, V334, P873, DOI 10.1056/NEJM199604043341401; Montague DK, 1996, J UROLOGY, V156, P2007, DOI 10.1016/S0022-5347(01)65419-3; MONTORSI F, 1994, ACTA DIABETOL, V31, P1, DOI 10.1007/BF00580752; PadmaNathan H, 1997, NEW ENGL J MED, V336, P1, DOI 10.1056/NEJM199701023360101; Rendell MS, 1999, JAMA-J AM MED ASSOC, V281, P421, DOI 10.1001/jama.281.5.421; RYDER REJ, 1992, DIABETIC MED, V9, P893, DOI 10.1111/j.1464-5491.1992.tb01727.x; VIRAG R, 1982, LANCET, V2, P938; Werthman P, 1997, UROLOGY, V50, P809, DOI 10.1016/S0090-4295(97)00448-2; Zippe CD, 1998, UROLOGY, V52, P963, DOI 10.1016/S0090-4295(98)00443-9	15	12	13	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					465	466		10.1001/jama.281.5.465	http://dx.doi.org/10.1001/jama.281.5.465			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952210				2022-12-28	WOS:000078318500038
J	Benjamin, N				Benjamin, N			Headache relief or impotence?	LANCET			English	Editorial Material							NITRIC-OXIDE SYNTHASE; NERVOUS-SYSTEM; INHIBITION		St Bartholomews & Royal London Sch Med & Dent, Dept Clin Pharmacol, London EC1A 7BE, England	University of London; Queen Mary University London	Benjamin, N (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Clin Pharmacol, London EC1A 7BE, England.							GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Kendrick KM, 1997, NATURE, V388, P670, DOI 10.1038/41765; Lassen LH, 1997, LANCET, V349, P401, DOI 10.1016/S0140-6736(97)80021-9; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Moore PK, 1997, TRENDS PHARMACOL SCI, V18, P204, DOI 10.1016/S0165-6147(97)01064-X; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Pelligrino DA, 1996, ANESTHESIOLOGY, V85, P1367, DOI 10.1097/00000542-199612000-00018; THOMSEN LL, 1993, CEPHALALGIA, V13, P39; [No title captured]	10	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 23	1999	353	9149					256	257		10.1016/S0140-6736(05)74939-4	http://dx.doi.org/10.1016/S0140-6736(05)74939-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929015				2022-12-28	WOS:000078292200005
J	Durrington, PN; Prais, H; Bhatnagar, D; France, M; Crowley, V; Khan, J; Morgan, J				Durrington, PN; Prais, H; Bhatnagar, D; France, M; Crowley, V; Khan, J; Morgan, J			Indications for cholesterol-lowering medication: comparison of risk-assessment methods	LANCET			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY HEART-DISEASE; PREVENTION; RECOMMENDATIONS; PRAVASTATIN; GUIDELINES; PLASMA	Background Recommendations for the prescription of lipid-lowering drugs emphasise the importance of an assessment of absolute coronary heart disease (CHD) risk based on all risk factors, rather than simply the serum cholesterol concentration. If, however, the methods recommended for risk assessment are inaccurate, recommended prescribing will not occur. We compared several sets of guidelines for such treatment in a series of patients referred to a lipid clinic, to assess the difference in degree of risk of CHD at which lipid-lowering medication is recommended by each set of guidelines. Methods For a series of 570 patients (50% men) without pre-existing clinical evidence of atherosclerosis referred to a lipid clinic, we compared the algorithms, charts, and tables used by the US National Cholesterol Education Program (NCEP), the joint guidelines of the European Society of Cardiology, the European Atherosclerosis Society, and the European Society of Hypertension, and the report of the UK Standing Medical Advisory Committee with the Framingham risk equation programmed into a computer. Findings In 386 patients for whom the NCEP and UK guidelines could be compared, 62% of the men and 72% of the women mel NCEP criteria for lipid-lowering medication, whereas only 9% of the men and less than 1% of the women met the UK criteria. The Framingham equation estimated a CHD risk of more than 3% per year in 22% of the men and 7% of the women, which shows that the UK tables underestimated CHD risk. European guidelines could be applied to only 261 patients, and were reasonably accurate in assessment of a CHD risk of 2% per year. Interpretation Guidelines for the use of statin treatment in patients with CHD differ in their assessment of CHD risk. The method Of risk assessment recommended in future guidelines for CHD prevention should be critically tested in relevant groups of patients.	Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England; Cent Manchester healthcare Trust Dept, Manchester, Lancs, England	University of Manchester	Durrington, PN (corresponding author), Univ Manchester, Manchester Royal Infirm, Dept Med, Oxford Rd, Manchester M13 9WL, Lancs, England.							ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; Assmann, 1991, CARDIOVASC RISK FACT, V1, P126; ASSMANN G, 1989, HIGH DENSITY LIPOPRO, P46; BUSH TL, 1991, CIRCULATION, V83, P1287, DOI 10.1161/01.CIR.83.4.1287; DAVEYSMITH G, 1993, BRIT MED J, V306, P1367; DURRINGTON PN, 1980, ANN CLIN BIOCHEM, V17, P199, DOI 10.1177/000456328001700408; DURRINGTON PN, 1995, HYPERLIPIDAEMIA DIAG; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GROVER SA, 1995, JAMA-J AM MED ASSOC, V274, P801, DOI 10.1001/jama.274.10.801; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Haq IU, 1996, CLIN SCI, V91, P773; HEISS G, 1980, CIRCULATION, V62, P116; HUWEZ FU, 1997, BR J CARDIOL, V4, P375; IZZO C, 1981, CLIN CHEM, V27, P371; MCISAAC WJ, 1991, J GEN INTERN MED, V6, P518, DOI 10.1007/BF02598220; PEDERSEN TR, 1994, LANCET, V344, P1383; PYORALA K, 1994, EUR HEART J, V15, P1300; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Ramsay LE, 1996, LANCET, V348, P387, DOI 10.1016/S0140-6736(96)05516-X; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Shepherd J, 1996, LANCET, V348, P1339; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; *WHO EXP COMM DIAB, 1980, WHO TECHN REP SER, V46	24	77	79	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 23	1999	353	9149					278	281		10.1016/S0140-6736(98)04027-6	http://dx.doi.org/10.1016/S0140-6736(98)04027-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929020				2022-12-28	WOS:000078292200010
J	Kool, JL; Carpenter, JC; Fields, BS				Kool, JL; Carpenter, JC; Fields, BS			Effect of monochloramine disinfection of municipal drinking water on risk of nosocomial Legionnaires' disease	LANCET			English	Article							LEGIONELLA-PNEUMOPHILA; POTABLE WATER; TAP WATER; HOT WATER; PNEUMONIA; OUTBREAK; BIOFILM; CONTAMINATION; TRANSMISSION; SURVEILLANCE	Background Many Legionella infections are acquired through inhalation or aspiration of drinking water. Although about 25% of municipalities in the USA use monochloramine for disinfection of drinking water. the effect of monochloramine on the occurrence of Legionnaires' disease has never been studied. Methods We used a case-control study to compare disinfection methods for drinking water supplied to 32 hospitals that had had outbreaks of Legionnaires' disease with the disinfection method for water supplied to 48 control-hospitals, with central for selected hospital characteristics and water treatment factors. Findings Hospitals supplied with drinking water containing free chlorine as a residual disinfectant were more likely to have a reported outbreak of Legionnaires' disease than those that used water with monochloramine as a residual disinfectant (odds ratio 10.2 [95% CI 1.4-460]), This result suggests that 90% of outbreaks associated with drinking water might not have occurred if monochloramine had been used Instead of free chlorine for residual disinfection (attributable proportion 0.90 [029-1.00]). Interpretation The protective effect of monochloramine against legionella should be confirmed by other studies. Chloramination of drinking water may be a cost-effective method for control of Legionnaires' disease at the municipal level or in individual hospitals, and widespread implementation could prevent thousands of cases.	Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Resp Dis Branch, Atlanta, GA USA; Ctr Dis Control & Prevent, Hosp Infect Program, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Kool, JL (corresponding author), Univ So Calif, 313 N Figueroa St,Room 212, Los Angeles, CA 90012 USA.	jkool@ibm.net		Kool, Jacob/0000-0002-9605-2918				ALARY M, 1992, J INFECT DIS, V165, P565, DOI 10.1093/infdis/165.3.565; *AM HOSP ASS, 1993, AHA GUID HLTH CAR FI; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; ARNOW PM, 1982, J INFECT DIS, V146, P460, DOI 10.1093/infdis/146.4.460; BEST M, 1983, LANCET, V2, P307; BHOPAL RS, 1991, BRIT MED J, V302, P378, DOI 10.1136/bmj.302.6773.378; BLATT SP, 1993, AM J MED, V95, P16, DOI 10.1016/0002-9343(93)90227-G; BRADY MT, 1989, J PEDIATR-US, V115, P46, DOI 10.1016/S0022-3476(89)80327-0; BREIMAN RF, 1990, JAMA-J AM MED ASSOC, V263, P2924, DOI 10.1001/jama.263.21.2924; BROWN A, 1985, INFECTION, V13, P163, DOI 10.1007/BF01642803; BUCHHOLZ U, 1998, 38 INT C ANT AG CHEM, P583; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P416; Chen X, 1996, ENVIRON SCI TECHNOL, V30, P2078, DOI 10.1021/es9509184; CIESIELSKI CA, 1984, APPL ENVIRON MICROB, V48, P984, DOI 10.1128/AEM.48.5.984-987.1984; CORDES LG, 1981, ANN INTERN MED, V94, P195, DOI 10.7326/0003-4819-94-2-195; CUNLIFFE DA, 1990, J APPL BACTERIOL, V68, P453, DOI 10.1111/j.1365-2672.1990.tb02896.x; DICE JC, 1985, J AM WATER WORKS ASS, V77, P34; DOEBBELING BN, 1989, J HOSP INFECT, V13, P289, DOI 10.1016/0195-6701(89)90010-8; Graman PS, 1997, INFECT CONT HOSP EP, V18, P637, DOI 10.2307/30141491; Green M, 1996, J CLIN MICROBIOL, V34, P175, DOI 10.1128/JCM.34.1.175-176.1996; HANRAHAN JP, 1987, AM J EPIDEMIOL, V125, P639, DOI 10.1093/oxfordjournals.aje.a114577; HANRAHAN JP, 1984, LEGIONELLA, P224; HEIMBERGER T, 1991, J INFECT DIS, V163, P413, DOI 10.1093/infdis/163.2.413; HELMS CM, 1988, JAMA-J AM MED ASSOC, V259, P2423, DOI 10.1001/jama.259.16.2423; JOHNSON JT, 1985, LANCET, V2, P298; JOHNSTON JM, 1987, INFECT CONT HOSP EP, V8, P53, DOI 10.1017/S0195941700067072; KIRMEYER GJ, 1993, OPTIMIZING CHLORAMIN; Kool JL, 1998, INFECT CONT HOSP EP, V19, P898; Kool JL, 1998, LANCET, V351, P1030, DOI 10.1016/S0140-6736(05)78996-0; KOOL JL, 1998, 8 ANN M SOC HEALTHC, P39; LECHEVALLIER MW, 1988, APPL ENVIRON MICROB, V54, P2492, DOI 10.1128/AEM.54.10.2492-2499.1988; LEPINE L, 1995, 35 INT C ANT AG CHEM, P267; LOWRY PW, 1991, NEW ENGL J MED, V324, P109, DOI 10.1056/NEJM199101103240207; MARSTON BJ, 1994, ARCH INTERN MED, V154, P2417, DOI 10.1001/archinte.154.21.2417; Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709; MASTRO TD, 1991, J INFECT DIS, V163, P667, DOI 10.1093/infdis/163.3.667; MATULONIS U, 1993, INFECT CONT HOSP EP, V14, P571, DOI 10.1086/646639; MERMEL LA, 1995, INFECT CONT HOSP EP, V16, P76, DOI 10.1086/647060; Nafziger DA, 1998, INFECT DIS CLIN PRAC, V7, P118; NOLTE FS, 1984, J INFECT DIS, V149, P251, DOI 10.1093/infdis/149.2.251; PARRY MF, 1985, ANN INTERN MED, V103, P205, DOI 10.7326/0003-4819-103-2-205; PLOUFFE JF, 1983, APPL ENVIRON MICROB, V46, P769, DOI 10.1128/AEM.46.3.769-770.1983; PLOUFFE JF, 1983, LANCET, V2, P649; Samrakandi MM, 1997, CAN J MICROBIOL, V43, P751, DOI 10.1139/m97-108; SCHOONMAKER D, 1992, J CLIN MICROBIOL, V30, P1491, DOI 10.1128/JCM.30.6.1491-1498.1992; SELLICK JA, 1993, LEGIONELLA, P43; SHANDS KN, 1985, JAMA-J AM MED ASSOC, V253, P1412, DOI 10.1001/jama.253.10.1412; STOUT JE, 1992, NEW ENGL J MED, V326, P151, DOI 10.1056/NEJM199201163260302; Straus WL, 1996, ARCH INTERN MED, V156, P1685, DOI 10.1001/archinte.156.15.1685; SYNDER MB, 1990, J INFECT DIS, V162, P127, DOI 10.1093/infdis/162.1.127; VENEZIA RA, 1994, INFECT CONT HOSP EP, V15, P529	51	97	102	2	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 23	1999	353	9149					272	277		10.1016/S0140-6736(98)06394-6	http://dx.doi.org/10.1016/S0140-6736(98)06394-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929019				2022-12-28	WOS:000078292200009
J	Hogan, BLM				Hogan, BLM			Morphogenesis	CELL			English	Review							CHICK LIMB BUD; CELL-MIGRATION; RETINOIC ACID; MOUSE LUNG; HEDGEHOG; TRACHEAL; PATTERN; EXPRESSION; POLARITY; GENES		Vanderbilt Univ, Ctr Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Med, Dept Cell Biol, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Hogan, BLM (corresponding author), Vanderbilt Univ, Ctr Med, Howard Hughes Med Inst, Nashville, TN 37232 USA.							Altabef M, 1997, DEVELOPMENT, V124, P4547; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Bell SM, 1998, MECH DEVELOP, V74, P41, DOI 10.1016/S0925-4773(98)00065-3; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bellusci S, 1997, DEVELOPMENT, V124, P53; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Bogue CW, 1996, AM J RESP CELL MOL, V15, P163, DOI 10.1165/ajrcmb.15.2.8703472; COOKE J, 1980, NATURE, V287, P697, DOI 10.1038/287697a0; Crowe R, 1998, DEVELOPMENT, V125, P767; DEMAXIMY AA, IN PRESS MECH DEV; Grindley JC, 1997, DEV BIOL, V188, P337, DOI 10.1006/dbio.1997.8644; Groves P, 1998, SCI AM, V279, P84, DOI 10.1038/scientificamerican1298-84; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Helms JA, 1997, DEV BIOL, V187, P25, DOI 10.1006/dbio.1997.8589; Hogan BLM, 1997, COLD SPRING HARB SYM, V62, P249; Hogan BLM, 1998, CURR OPIN GENET DEV, V8, P481, DOI 10.1016/S0959-437X(98)80121-4; HORNBRUCH A, 1970, NATURE, V226, P764, DOI 10.1038/226764a0; Irvine KD, 1997, CURR OPIN CELL BIOL, V9, P867, DOI 10.1016/S0955-0674(97)80090-7; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Jung HS, 1998, DEV BIOL, V196, P11, DOI 10.1006/dbio.1998.8850; Kim SK, 1998, P NATL ACAD SCI USA, V95, P1523, DOI 10.1073/pnas.95.4.1523; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; Krasnow NA, 1997, COLD SPRING HARB SYM, V62, P235; Lee T, 1996, GENE DEV, V10, P2912, DOI 10.1101/gad.10.22.2912; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Loomis CA, 1998, DEVELOPMENT, V125, P1137; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Meinhardt H, 1996, INT J DEV BIOL, V40, P123; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Michaud JL, 1997, DEVELOPMENT, V124, P1453; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; Mollard R, 1998, AM J RESP CELL MOL, V19, P71, DOI 10.1165/ajrcmb.19.1.3158; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; NAKANISHI Y, 1989, BIOESSAYS, V11, P163, DOI 10.1002/bies.950110602; Nogawa H, 1998, DEV DYNAM, V213, P228, DOI 10.1002/(SICI)1097-0177(199810)213:2<228::AID-AJA8>3.0.CO;2-I; Noramly S, 1998, DEVELOPMENT, V125, P3775; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; Park WY, 1998, DEV BIOL, V201, P125, DOI 10.1006/dbio.1998.8994; Pepicelli CV, 1997, DEV BIOL, V192, P193, DOI 10.1006/dbio.1997.8745; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; RANCOURT DE, 1995, GENE DEV, V9, P108, DOI 10.1101/gad.9.1.108; SEKINE K, 1999, IN PRESS NAT GENET; Shannon JM, 1998, DEV DYNAM, V212, P482, DOI 10.1002/(SICI)1097-0177(199808)212:4<482::AID-AJA2>3.0.CO;2-D; SHANNON JM, 1994, DEV BIOL, V166, P600, DOI 10.1006/dbio.1994.1340; SRINIVAS S, 1999, IN PRESS DEV GENET; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; Tabin CJ, 1998, NATURE, V396, P322, DOI 10.1038/24516; Vargesson N, 1997, DEVELOPMENT, V124, P1909; Viallet JP, 1998, MECH DEVELOP, V72, P159, DOI 10.1016/S0925-4773(98)00027-6; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5; Wolpert L., 1998, PRINCIPLES DEV; Yang Y, 1997, DEVELOPMENT, V124, P4393; Zaret K, 1998, CURR OPIN GENET DEV, V8, P526, DOI 10.1016/S0959-437X(98)80006-3; Zeller R, 1997, BIOESSAYS, V19, P541, DOI 10.1002/bies.950190703	57	451	456	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 22	1999	96	2					225	233		10.1016/S0092-8674(00)80562-0	http://dx.doi.org/10.1016/S0092-8674(00)80562-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	160VM	9988217	Bronze			2022-12-28	WOS:000078252200006
J	McKenzie, D; Nimmo, F				McKenzie, D; Nimmo, F			The generation of Martian floods by the melting of ground ice above dykes	NATURE			English	Article							MARS; HISTORY; VALLES; EARTH; VENUS	The surface of Mars is cut by long linear faults with displacements of metres to kilometres, most of which are thought to have been formed by extension(1). The surface has also been modified by enormous floods, probably of water, which often flowed out of valleys formed by the largest of these faults(2). By analogy with structures on Earth(3,4), we propose here that the faults are in fact the surface expression of dykes(5), and not of large-scale tectonic movements. We use a numerical model to show that the intrusion of large dykes can generate structures like Valles Marineris. Such dykes can provide a heat source to melt ground ice, and so provide a source of water for the floods that have been inferred to originate in some of the large valleys(2).	Univ Cambridge, Inst Theoret Geophys, Bullard Labs, Dept Earth Sci, Cambridge CB3 0EZ, England	University of Cambridge	Nimmo, F (corresponding author), Univ Cambridge, Inst Theoret Geophys, Bullard Labs, Dept Earth Sci, Madingley Rd, Cambridge CB3 0EZ, England.							Baker V.R., 1982, THE CHANNELS OF MARS, DOI [10.1029/EO063i045p00862, DOI 10.1029/EO063I045P00862]; BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; *BASAL VOLC STUD P, 1983, BAS VOLC TERR PLAN; BLICHERTTOFT J, 1998, MINERAL MAG A, V62, P168; Borg LE, 1997, GEOCHIM COSMOCHIM AC, V61, P4915, DOI 10.1016/S0016-7037(97)00276-7; Carr M. H., 1977, Journal of Geophysical Research, V82, P4055, DOI 10.1029/JS082i028p04055; ERNST RE, 1995, EARTH-SCI REV, V39, P1, DOI 10.1016/0012-8252(95)00017-5; Fahrig W. F., 1987, MAFIC DYKE SWARMS, V34, P331; FAHRIG WF, 1986, DIABASE DYKE SWARMS; Lucchitta B. K., 1992, MARS, P453; Masursky H., 1977, Journal of Geophysical Research, V82, P4016, DOI 10.1029/JS082i028p04016; MCKENZIE D, 1992, J GEOPHYS RES-PLANET, V97, P15977, DOI 10.1029/92JE01559; Mege D, 1996, PLANET SPACE SCI, V44, P1499, DOI 10.1016/S0032-0633(96)00113-4; PLESCIA JB, 1982, J GEOPHYS RES, V87, P9775, DOI 10.1029/JB087iB12p09775; Schubert G., 1992, MARS, P147, DOI [10.2307/j.ctt207g59v.9, DOI 10.2307/J.CTT207G59V.9]; Schultz RA, 1997, J GEOPHYS RES-SOL EA, V102, P12009, DOI 10.1029/97JB00751; SIGURDSSON O, 1980, J GEOPHYS-Z GEOPHYS, V47, P154; SOLOMON SC, 1990, J GEOPHYS RES-SOLID, V95, P11073, DOI 10.1029/JB095iB07p11073; SQUYRES SW, 1987, ICARUS, V70, P385, DOI 10.1016/0019-1035(87)90085-6; SQUYRES SW, 1992, MARS, P526; WHITE RS, 1995, J GEOPHYS RES-SOL EA, V100, P17543, DOI 10.1029/95JB01585; ZIMBELMAN JR, 1992, J GEOPHYS RES-PLANET, V97, P18309, DOI 10.1029/92JE02054; [No title captured]	23	103	103	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 21	1999	397	6716					231	233		10.1038/16649	http://dx.doi.org/10.1038/16649			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159QH	9930697				2022-12-28	WOS:000078184800044
J	Liu, L; Li, PS; Asher, SA				Liu, L; Li, PS; Asher, SA			Entropic trapping of macromolecules by mesoscopic periodic voids in a polymer hydrogel	NATURE			English	Article							CRYSTALLINE COLLOIDAL ARRAYS; GEL-ELECTROPHORESIS; TRACER DIFFUSION; DNA; DIFFRACTION; POLYSTYRENE	The separation of macromolecules such as polymers and DNA by means of electrophoresis, gel permeation chromatography or filtration exploits size-dependent differences in the time it takes for the molecules to migrate through a random porous network. Transport through the gel matrices, which usually consist of full swollen crosslinked polymers(1-11), depends on the relative size of the macromolecule compared with the pore radius. Sufficiently small molecules are thought to adopt an approximately spherical conformation when diffusing through the gel matrix(1), whereas larger ones are forced to migrate in a snake-like fashion(3-5). Molecules of intermediate size, however, can get temporarily trapped in the largest pores of the matrix, where the molecule can extend and thus maximize its conformational entropy, This 'entropic trapping' is thought to increase the dependence of diffusion rate an molecular size(6-16). Here we report the direct experimental verification of this phenomenon. Bragg diffraction from a hydrogel containing a periodic array of monodisperse water voids confirms that polymers of different weights partition between the hydrogel matrix and the water voids according to the predictions of the entropic trapping theory. Our approach might also lead to the design of improved separation media based on entropic trapping.	Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Asher, SA (corresponding author), Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA.	asher+@pitt.edu						Asher S.A., 1986, Patent No. [US4632517A, 4632517]; ASHER SA, 1986, Patent No. 4627689; BAUMGARTNER A, 1987, J CHEM PHYS, V87, P3082, DOI 10.1063/1.453045; CASASSA EF, 1967, J POLYM SCI POL LETT, V5, P773, DOI 10.1002/pol.1967.110050907; CLARK NA, 1979, NATURE, V281, P57, DOI 10.1038/281057a0; De Gennes P.-G., 1979, SCALING CONCEPTS POL; Flory PJ., 1953, PRINCIPLES POLYM CHE, V672; GUILLOT G, 1985, MACROMOLECULES, V18, P2531, DOI 10.1021/ma00154a030; HILTNER PA, 1969, J PHYS CHEM-US, V73, P2386, DOI 10.1021/j100727a049; HOAGLAND DA, 1992, MACROMOLECULES, V25, P6696, DOI 10.1021/ma00050a046; Holtz JH, 1997, NATURE, V389, P829, DOI 10.1038/39834; KESAVAMOORTHY R, 1992, J COLLOID INTERF SCI, V153, P188, DOI 10.1016/0021-9797(92)90310-I; KIM HD, 1986, MACROMOLECULES, V19, P2737, DOI 10.1021/ma00165a013; LERMAN LS, 1982, BIOPOLYMERS, V21, P995, DOI 10.1002/bip.360210511; Liu L, 1997, J AM CHEM SOC, V119, P2729, DOI 10.1021/ja963885g; LUMPKIN OJ, 1985, BIOPOLYMERS, V24, P1573, DOI 10.1002/bip.360240812; MUTHUKUMAR M, 1989, MACROMOLECULES, V22, P1937, DOI 10.1021/ma00194a070; NEMOTO N, 1990, MACROMOLECULES, V23, P659, DOI 10.1021/ma00204a045; NOOLANDI J, 1987, PHYS REV LETT, V58, P2428, DOI 10.1103/PhysRevLett.58.2428; RIGHETTI PG, 1995, J CHROMATOGR A, V698, P3, DOI 10.1016/0021-9673(94)00068-K; RODBARD D, 1970, P NATL ACAD SCI USA, V65, P970, DOI 10.1073/pnas.65.4.970; ROTSTEIN NA, 1992, MACROMOLECULES, V25, P1316, DOI 10.1021/ma00030a018; Rousseau J, 1997, PHYS REV LETT, V79, P1945, DOI 10.1103/PhysRevLett.79.1945; RUNDQUIST PA, 1989, J CHEM PHYS, V91, P4932, DOI 10.1063/1.456734; SLATER GW, 1995, PHYS REV LETT, V75, P164, DOI 10.1103/PhysRevLett.75.164; SLATER GW, 1986, BIOPOLYMERS, V25, P431, DOI 10.1002/bip.360250305; SMISEK DL, 1990, SCIENCE, V248, P1221, DOI 10.1126/science.2349481; Teraoka I, 1996, MACROMOLECULES, V29, P2430, DOI 10.1021/ma951146z; Weissman JM, 1996, SCIENCE, V274, P959, DOI 10.1126/science.274.5289.959	29	183	186	3	118	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1999	397	6715					141	144		10.1038/16426	http://dx.doi.org/10.1038/16426			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923674				2022-12-28	WOS:000078085000039
J	Graziano, MSA; Reiss, LAJ; Gross, CG				Graziano, MSA; Reiss, LAJ; Gross, CG			A neuronal representation of the location of nearby sounds	NATURE			English	Article							VISUAL RESPONSES; PREMOTOR CORTEX; PERCEPTION; SPACE; MONKEY	Humans can accurately perceive the location of a sound source-not only the direction, but also the distance(1-9). Sounds near the head, within ducking or reaching distance, have a special saliency. However, little is known about this perception of auditory distance. The direction to a sound source can be determined by interaural differences, and the mechanisms of direction perception have been studied intensively(1); but except for studies on echolocation in the bat(10), little is known about how neurons encode information on auditory distance. Here we describe neurons in the brain of macaque monkeys (Macaca fascicularis) that represent the auditory space surrounding the head, within roughly 30 cm, These neurons, which are located in the ventral premotor cortex, have spatial receptive fields that extend a limited distance outward from the head.	Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA	Princeton University	Graziano, MSA (corresponding author), Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA.	graziano@princeton.edu		Reiss, Lina/0000-0001-7746-9796				ASHMEAD DH, 1990, PERCEPT PSYCHOPHYS, V47, P326, DOI 10.3758/BF03210871; BLAUERT J, 1997, SPAETIAL HEARING PSY; BOUSSAOUD D, 1993, EXP BRAIN RES, V93, P423; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; CLIFTON RK, 1994, J EXP PSYCHOL HUMAN, V20, P876, DOI 10.1037/0096-1523.20.4.876; Cohen J., 1983, APPL MULTIPLE REGRES; COLEMAN PD, 1968, J ACOUST SOC AM, V44, P631, DOI 10.1121/1.1911132; COLEMAN PD, 1963, PSYCHOL BULL, V60, P302, DOI 10.1037/h0045716; COLEMAN PD, 1962, J ACOUST SOC AM, V34, P345, DOI 10.1121/1.1928121; Edwards AS, 1955, J GEN PSYCHOL, V52, P327, DOI 10.1080/00221309.1955.9920247; Fogassi L, 1996, J NEUROPHYSIOL, V76, P141, DOI 10.1152/jn.1996.76.1.141; Gamble E. A., 1909, PSYCHOL REV, V16, P416, DOI DOI 10.1037/H0073666; GARDNER MB, 1969, J ACOUST SOC AM, V45, P47, DOI 10.1121/1.1911372; GENTILUCCI M, 1988, EXP BRAIN RES, V71, P475, DOI 10.1007/BF00248741; Graziano MSA, 1998, CURR OPIN NEUROBIOL, V8, P195, DOI 10.1016/S0959-4388(98)80140-2; GRAZIANO MSA, 1994, SCIENCE, V266, P1054, DOI 10.1126/science.7973661; Graziano MSA, 1997, SCIENCE, V277, P239, DOI 10.1126/science.277.5323.239; Graziano MSA, 1997, J NEUROPHYSIOL, V77, P2268, DOI 10.1152/jn.1997.77.5.2268; GRAZIANO MSA, 1996, NEUR ABS, V22, P398; MATELLI M, 1986, J COMP NEUROL, V251, P281, DOI 10.1002/cne.902510302; MERSHON DH, 1979, PERCEPTION, V8, P311, DOI 10.1068/p080311; MERSHON DH, 1975, PERCEPT PSYCHOPHYS, V18, P409, DOI 10.3758/BF03204113; Rizzolatti G, 1997, SCIENCE, V277, P190, DOI 10.1126/science.277.5323.190; RIZZOLATTI G, 1981, BEHAV BRAIN RES, V2, P147, DOI 10.1016/0166-4328(81)90053-X; SUGA N, 1979, SCIENCE, V206, P351, DOI 10.1126/science.482944; vonBekesy G., 1960, EXPT HEARING	26	229	232	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 4	1999	397	6718					428	430		10.1038/17115	http://dx.doi.org/10.1038/17115			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	164KA	9989407				2022-12-28	WOS:000078461700046
J	Taylor, DH; Whellan, DJ; Sloan, FA				Taylor, DH; Whellan, DJ; Sloan, FA			Effects of admission to a teaching hospital on the cost and quality of care for Medicare beneficiaries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGESTIVE-HEART-FAILURE; MORTALITY-RATES; NONTEACHING HOSPITALS; ADJUSTED MORTALITY; ELDERLY PATIENTS; OUTCOMES; OWNERSHIP; SEVERITY	Background and Methods We studied the effects of admission to a teaching hospital on the cost and quality of care for patients covered by Medicare (age, 65 years old or older). We used data from the National Long Term Care Survey and merged them with Medicare claims data. We selected the first hospitalization for hip fracture (802 patients), stroke (793), coronary heart disease (1007), or congestive heart failure (604) occurring between January 1, 1984, and December 31, 1994, and calculated all Medicare payments for inpatient and outpatient care during the six-month period after admission. Survival was assessed through 1995. Hospitals were classified as major or minor teaching hospitals (with minor hospitals defined as those in which the number of residents per bed was less than the median number for all teaching hospitals) or as private nonprofit, government (i.e., public), or private for-profit hospitals. Results Medicare payments for the six-month period after hospitalization were highest for patients initially admitted to teaching hospitals for the treatment of hip fracture, stroke, or coronary heart disease and for patients initially admitted to for-profit hospitals for the treatment of congestive heart failure. As compared with payments to for-profit hospitals, payments to major teaching hospitals for hip fracture were significantly higher, payments to government hospitals for coronary heart disease were lower, and payments to government and nonprofit hospitals for congestive heart failure were lower. After adjustment for patients' characteristics and social subsidies, major teaching hospitals had the lowest mortality rates (hazard ratio for death, 0.75, as compared with for-profit hospitals; 95 percent confidence interval, 0.62 to 0.91). For individual conditions, the only significant survival advantage associated with admission to major teaching hospitals was for hip fractures (hazard ratio, 0.54, as compared with for profit hospitals; 95 percent confidence interval, 0.37 to 0.79), Conclusions Although admission to a major teaching hospital may be associated with increased costs to the Medicare program, overall survival for patients with the common conditions we studied was better at these hospitals, especially for patients with hip fractures. (N Engl J Med 1999;340:293-9.) (C) 1999, Massachusetts Medical Society.	Duke Univ, Terry Sanford Inst Publ Policy, Ctr Hlth Policy Law & Management, Durham, NC 27708 USA; Duke Univ, Dept Med, Div Cardiol, Durham, NC 27708 USA; Duke Univ, Dept Econ, Durham, NC 27708 USA	Duke University; Duke University; Duke University	Taylor, DH (corresponding author), Duke Univ, Terry Sanford Inst Publ Policy, Ctr Hlth Policy Law & Management, Box 90253,122 Old Chem Bldg, Durham, NC 27708 USA.				NIA NIH HHS [2RO1-AG-09468-04A1] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009468] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allison P. D., 1995, SURVIVAL ANAL USING; *DUK U, 1988, 18C98641 HCFA DUK U; *DXCG, 1996, DXCG SOFTW VERS 02E; Ellis RP, 1996, HEALTH CARE FINANC R, V17, P101; GARBER AM, 1984, NEW ENGL J MED, V310, P1231, DOI 10.1056/NEJM198405103101906; Gattis WA, 1998, J AM COLL CARDIOL, V31, p69A, DOI 10.1016/S0735-1097(97)84005-3; Gujarati D, 2006, N BASIC ECONOMETRICS; Hanumanthu S, 1997, CIRCULATION, V96, P2842, DOI 10.1161/01.CIR.96.9.2842; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; IEZZONI LI, 1990, JAMA-J AM MED ASSOC, V264, P1426, DOI 10.1001/jama.264.11.1426; KEELER EB, 1992, JAMA-J AM MED ASSOC, V268, P1709, DOI 10.1001/jama.268.13.1709; KUHN EM, 1994, MED CARE, V32, P1098, DOI 10.1097/00005650-199411000-00003; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; PEARSON ML, 1992, JAMA-J AM MED ASSOC, V268, P1883, DOI 10.1001/jama.268.14.1883; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; *PROSP PAYM ASS CO, 1997, MED AM HLTH CAR SYST; Reis SE, 1997, J AM COLL CARDIOL, V30, P733, DOI 10.1016/S0735-1097(97)00214-3; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Rosenthal GE, 1997, JAMA-J AM MED ASSOC, V278, P485, DOI 10.1001/jama.278.6.485; SHORTELL SM, 1988, NEW ENGL J MED, V318, P1100, DOI 10.1056/NEJM198804283181705; Sloan F A, 1986, Health Aff (Millwood), V5, P68, DOI 10.1377/hlthaff.5.3.68; SLOAN FA, 1983, J HEALTH ECON, V2, P1, DOI 10.1016/0167-6296(83)90009-7; West JA, 1997, AM J CARDIOL, V79, P58, DOI 10.1016/S0002-9149(96)00676-5; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1432, DOI 10.1097/00003246-199310000-00009	24	247	247	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1999	340	4					293	299		10.1056/NEJM199901283400408	http://dx.doi.org/10.1056/NEJM199901283400408			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	161YU	9920955				2022-12-28	WOS:000078318700008
J	Holmer, AF				Holmer, AF			Direct-to-consumer prescription drug advertising builds bridges between patients and physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Pharmaceut Res & Manufacturers Amer, Washington, DC 20005 USA		Holmer, AF (corresponding author), Pharmaceut Res & Manufacturers Amer, 1100 15th St NW, Washington, DC 20005 USA.							*AG HLTH CAR POL R, 1996, SEC TERT PREV STROK; [Anonymous], 1997, Diabetes Care, V20 Suppl 1, pS1; Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; KODYSZ M, 1998, MOD MED, V66, P56; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; National Center for Health Statistics, 1988, NAT HLTH NUTR EX SUR; Nordenberg T, 1998, FDA Consum, V32, P7; PETERS KD, 1998, NATL VITAL STAT REPO, V47, P52; *PHARM RES MAN AM, 1998, NEW MED DEV DAT; Prev. Mag, 1998, NATL SURVEY CONSUMER; TANOUYE E, 1997, WALL ST J       1222, pB1; VENTURA SJ, 1998, NATL VITAL STAT REPO, V47, P1; *YANK PARTN INC, 1998, SURV PAT PHYS REL AM, P4; 1997, FDC REPORTS PIN 1020, V59, P9; 1997, ECONOMIST       0808, V344, P58; 1996, IMS HLTH; 1998, IMS HLTH        0331	21	133	133	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1999	281	4					380	382		10.1001/jama.281.4.380	http://dx.doi.org/10.1001/jama.281.4.380			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158JB	9929095				2022-12-28	WOS:000078111300042
J	Li, P; Wilding, TJ; Kim, SJ; Calejesan, AA; Huettner, JE; Zhuo, M				Li, P; Wilding, TJ; Kim, SJ; Calejesan, AA; Huettner, JE; Zhuo, M			Kainate-receptor-mediated sensory synaptic transmission in mammalian spinal cord	NATURE			English	Article							SUBSTANTIA-GELATINOSA NEURONS; DORSAL HORN; GLUTAMATE RECEPTORS; IN-VITRO; RAT; DESENSITIZATION; AMPA; 2,3-BENZODIAZEPINES; ANTAGONISM; ACTIVATION	Glutamate, the major excitatory neurotransmitter in the central nervous system, activates three different receptors that directly gate ion channels, namely receptors for AMPA (alpha-amino-3-hydroxy-5-methyl isoxozole propionic acid), NMDA (N-methyl-D-aspartate), and kainate, a structural analogue of glutamate. The contribution of AMPA and NMDA receptors to synaptic transmission and plasticity is well established(1). Recent work on the physiological function of kainate receptors has focused on the hippocampus(2), where repetitive activation of the mossy-fibre pathway generates a slow, kainate-receptor-mediated excitatory postsynaptic current (EPSC)(3-5). Here we show that high-intensity single-shock stimulation (of duration 200 microseconds) of primary afferent sensory fibres produces a fast, kainate-receptor-mediated EPSC in the superficial dorsal horn of the spinal cord. Activation of low-threshold afferent fibres generates typical AMPA-receptor-mediated EPSCs only, indicating that kainate receptors may be restricted to synapses formed by high-threshold nociceptive (pain-sensing) and thermoreceptive primary afferent fibres. Consistent with this possibility, kainate-receptor-mediated EPSCs are blocked by the analgesic mu-opiate-receptor agonist Damgo and spinal blockade of both kainate and AMPA receptors produces antinociception, Thus, spinal kainate receptors contribute to transmission of somatosensory inputs from the periphery to the brain.	Washington Univ, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Zhuo, M (corresponding author), Washington Univ, Dept Anesthesiol, St Louis, MO 63110 USA.		Huettner, James E/C-5219-2012; Zhuo, Min/A-2072-2008	Zhuo, Min/0000-0001-9062-3241	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030888] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS030888] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABA H, 1994, J PHYSIOL-LONDON, V478, P87, DOI 10.1113/jphysiol.1994.sp020232; Bleakman D, 1996, NEUROPHARMACOLOGY, V35, P1689, DOI 10.1016/S0028-3908(96)00156-6; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Cao YQ, 1998, NATURE, V392, P390, DOI 10.1038/32897; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; Coggeshall RE, 1996, DEV BRAIN RES, V92, P81, DOI 10.1016/0165-3806(95)00207-3; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; FITZGERALD M, 1994, J COMP NEUROL, V348, P225, DOI 10.1002/cne.903480205; HUANG LYM, 1985, J NEUROSCI METH, V14, P91, DOI 10.1016/0165-0270(85)90119-0; Jones KA, 1997, NEUROPHARMACOLOGY, V36, P853, DOI 10.1016/S0028-3908(97)00066-X; KUMAZAWA T, 1978, J COMP NEUROL, V177, P417, DOI 10.1002/cne.901770305; Lerma J, 1997, TRENDS NEUROSCI, V20, P9, DOI 10.1016/S0166-2236(96)20055-4; Li P, 1998, NATURE, V393, P695, DOI 10.1038/31496; LIGHT AR, 1979, J COMP NEUROL, V186, P151, DOI 10.1002/cne.901860204; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; Pelletier JC, 1996, J MED CHEM, V39, P343, DOI 10.1021/jm950740w; PETRALIA RS, 1994, J COMP NEUROL, V349, P85, DOI 10.1002/cne.903490107; TODD AJ, 1994, J NEUROSCI, V14, P774; TOLLE TR, 1993, J NEUROSCI, V13, P5009, DOI 10.1523/JNEUROSCI.13-12-05009.1993; Vignes M, 1997, NATURE, V388, P179, DOI 10.1038/40639; Wilding TJ, 1997, J NEUROSCI, V17, P2713; WILDING TJ, 1995, MOL PHARMACOL, V47, P582; WISDEN W, 1993, J NEUROSCI, V13, P3582; YAKSH TL, 1994, TXB PAIN, P165; YOSHIMURA M, 1990, J PHYSIOL-LONDON, V430, P315, DOI 10.1113/jphysiol.1990.sp018293; Zhuo M, 1998, EUR J PHARMACOL, V349, P211, DOI 10.1016/S0014-2999(98)00197-6	28	214	228	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1999	397	6715					161	164		10.1038/16469	http://dx.doi.org/10.1038/16469			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923678				2022-12-28	WOS:000078085000046
J	Asturias, FJ; Jiang, YW; Myers, LC; Gustafsson, CM; Kornberg, RD				Asturias, FJ; Jiang, YW; Myers, LC; Gustafsson, CM; Kornberg, RD			Conserved structures of mediator and RNA polymerase II holoenzyme	SCIENCE			English	Article							YEAST; TRANSCRIPTION; ACTIVATION; DOMAIN	Single particles of the mediator of transcriptional regulation (Mediator) and of RNA polymerase II holoenzyme were revealed by electron microscopy and image processing. Mediator alone appeared compact, but at high pH or in the presence of RNA polymerase II it displayed an extended conformation. Holoenzyme contained Mediator in a fully extended state, partially enveloping the globular polymerase, with points of apparent contact in the vicinity of the polymerase carboxyl-terminal domain and the DNA-binding channel. A similarity in appearance and conformational behavior of yeast and murine complexes indicates a conservation of Mediator structure among eukaryotes.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Asturias, FJ (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Fairchild Bldg, Stanford, CA 94305 USA.			Myers, Lawrence/0000-0002-6537-6856; Gustafsson, Claes/0000-0003-3531-8468	NIAID NIH HHS [AI21144] Funding Source: Medline; NIGMS NIH HHS [GM36659] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTURIAS FJ, UNPUB; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; Meredith GD, 1996, J MOL BIOL, V258, P413, DOI 10.1006/jmbi.1996.0258; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T	12	193	203	5	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					985	987		10.1126/science.283.5404.985	http://dx.doi.org/10.1126/science.283.5404.985			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974391				2022-12-28	WOS:000078574800048
J	Livnah, O; Stura, EA; Middleton, SA; Johnson, DL; Jolliffe, LK; Wilson, LA				Livnah, O; Stura, EA; Middleton, SA; Johnson, DL; Jolliffe, LK; Wilson, LA			Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation	SCIENCE			English	Article							NECROSIS-FACTOR RECEPTOR; HUMAN GROWTH-HORMONE; X-RAY-DIFFRACTION; CRYSTAL-STRUCTURE; EPO RECEPTOR; EXTRACELLULAR DOMAIN; MOLECULAR REPLACEMENT; TRANSMEMBRANE SEGMENT; PROTEIN HORMONE; HIGH-AFFINITY	Erythropoietin receptor (EPOR) is thought to be activated by Ligand-induced homodimerization. However, structures of agonist and antagonist peptide complexes of EPOR, as well as an EPO-EPOR complex, have shown that the actual dimer configuration is critical for the biological response and signal efficiency. The crystal structure of the extracellular domain of EPOR in its unliganded form at 2.4 angstrom resolution has revealed a dimer in which the individual membrane-spanning and intracellular domains would be too far apart to permit phosphorylation by JAK2. This unliganded EPOR dimer is formed from self-association of the same key binding site residues that interact with EPO-mimetic peptide and EPO Ligands. This model for a preformed dimer on the cell surface provides insights into the organization, activation, and plasticity of recognition of hematopoietic cell surface receptors.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; RW Johnson Pharmaceut Res Inst, Raritan, NJ 08869 USA	Scripps Research Institute; Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA	Jolliffe, LK (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Stura, Enrico A./A-2793-2010; fathi, mazyar/H-1722-2016	Stura, Enrico A./0000-0001-6718-2118; 	NIGMS NIH HHS [GM49497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atwell S, 1997, SCIENCE, V278, P1125, DOI 10.1126/science.278.5340.1125; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARBER DL, 1994, MOL CELL BIOL, V14, P2257, DOI 10.1128/MCB.14.4.2257; Barbone FP, 1997, J BIOL CHEM, V272, P4985, DOI 10.1074/jbc.272.8.4985; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Brosig B, 1998, PROTEIN SCI, V7, P1052; BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1991, ACTA CRYSTALLOGR A, V47, P195, DOI 10.1107/S0108767390011795; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Elliott S, 1996, J BIOL CHEM, V271, P24691, DOI 10.1074/jbc.271.40.24691; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Huang MD, 1998, J MOL BIOL, V275, P873, DOI 10.1006/jmbi.1997.1512; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; Johnson DL, 1998, BIOCHEMISTRY-US, V37, P3699, DOI 10.1021/bi971956y; Johnson DL, 1996, PROTEIN EXPRES PURIF, V7, P104, DOI 10.1006/prep.1996.0014; JOLLIFFE LK, 1995, NEPHROL DIAL TRANSPL, V10, P28, DOI 10.1093/ndt/10.supp2.28; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRANTZ SB, 1991, BLOOD, V77, P419; Laage R, 1997, EUR J BIOCHEM, V249, P540, DOI 10.1111/j.1432-1033.1997.00540.x; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Matthews DJ, 1996, P NATL ACAD SCI USA, V93, P9471, DOI 10.1073/pnas.93.18.9471; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; MIDDLETON SA, UNPUB; MIURA O, 1993, ARCH BIOCHEM BIOPHYS, V306, P200, DOI 10.1006/abbi.1993.1501; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Naismith JH, 1996, STRUCTURE, V4, P1251, DOI 10.1016/S0969-2126(96)00134-7; Naismith JH, 1996, J MOL RECOGNIT, V9, P113, DOI 10.1002/(SICI)1099-1352(199603)9:2<113::AID-JMR253>3.0.CO;2-H; NAISMITH JH, 1995, J BIOL CHEM, V270, P13303, DOI 10.1074/jbc.270.22.13303; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; SAWADA K, 1988, J CELL PHYSIOL, V137, P337, DOI 10.1002/jcp.1041370218; SAWADA K, 1987, J CLIN INVEST, V80, P357, DOI 10.1172/JCI113080; Schneider H, 1997, BLOOD, V89, P473, DOI 10.1182/blood.V89.2.473; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Sundstrom M, 1996, J BIOL CHEM, V271, P32197, DOI 10.1074/jbc.271.50.32197; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Thompson NL, 1997, PHOTOCHEM PHOTOBIOL, V65, P39, DOI 10.1111/j.1751-1097.1997.tb01875.x; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458	53	494	518	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 12	1999	283	5404					987	990		10.1126/science.283.5404.987	http://dx.doi.org/10.1126/science.283.5404.987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974392				2022-12-28	WOS:000078574800049
J	McPhaden, MJ				McPhaden, MJ			Genesis and evolution of the 1997-98 El Nino	SCIENCE			English	Review							SEA-SURFACE TEMPERATURE; WESTERN EQUATORIAL PACIFIC; ATMOSPHERE RESPONSE EXPERIMENT; MADDEN-JULIAN OSCILLATION; SOUTHERN-OSCILLATION; WARM POOL; TROPICAL PACIFIC; ENSO PREDICTION; SEASONAL CYCLE; ROSSBY WAVES	The 1997-98 El Nino was, by some measures, the strongest on record, with major climatic impacts felt around the world. A newly completed tropical Pacific atmosphere-ocean sphere-ocean observing system documented this El Nino from its rapid onset to its sudden demise in greater detail than was ever before possible. The unprecedented measurements challenge existing theories about El Nino-related climate swings and suggest why climate forecast models underpredicted the strength of the El Nino before its onset.	NOAA, Pacific Marine Environm Lab, Seattle, WA 98115 USA	National Oceanic Atmospheric Admin (NOAA) - USA	McPhaden, MJ (corresponding author), NOAA, Pacific Marine Environm Lab, 7600 Sand Point Way Ne, Seattle, WA 98115 USA.	mcphaden@pmel.noaa.gov	McPhaden, Michael J/D-9799-2016	McPhaden, Michael J/0000-0002-8423-5805				ANDERSON DLT, 1998, WEATHER, V53, P295; BALMASEDA MA, 1995, J CLIMATE, V8, P2705, DOI 10.1175/1520-0442(1995)008<2705:DASDOE>2.0.CO;2; BARNETT TP, 1991, J CLIMATE, V4, P487, DOI 10.1175/1520-0442(1991)004<0487:OEP>2.0.CO;2; BARNSTON AG, IN PRESS B AM METEOR; BATTISTI DS, 1988, J ATMOS SCI, V45, P2889, DOI 10.1175/1520-0469(1988)045<2889:DATOAW>2.0.CO;2; Blanke B, 1997, J CLIMATE, V10, P1473, DOI 10.1175/1520-0442(1997)010<1473:ETEOSW>2.0.CO;2; Boulanger JP, 1995, J GEOPHYS RES-OCEANS, V100, P25041, DOI 10.1029/95JC02956; Boulanger JP, 1996, J GEOPHYS RES-OCEANS, V101, P16361, DOI 10.1029/96JC01282; BOULANGER JP, IN PRESS CLIM DYN; Brainerd KE, 1997, J GEOPHYS RES-OCEANS, V102, P10437, DOI 10.1029/96JC03864; BUSALACCHI AJ, 1996, MODERN APPROACHES DA, P235; CANE MA, 1986, NATURE, V321, P827, DOI 10.1038/321827a0; CHANG P, 1995, J ATMOS SCI, V52, P2353, DOI 10.1175/1520-0469(1995)052<2353:IBTSCA>2.0.CO;2; Chavez FP, 1998, GEOPHYS RES LETT, V25, P3543, DOI 10.1029/98GL02729; CHEN D, 1995, SCIENCE, V269, P1699, DOI 10.1126/science.269.5231.1699; Chen YQ, 1997, MON WEATHER REV, V125, P831, DOI 10.1175/1520-0493(1997)125<0831:ASOTPO>2.0.CO;2; CHRISTY JR, 1994, NATURE, V367, P325, DOI 10.1038/367325a0; Cronin MF, 1997, J GEOPHYS RES-OCEANS, V102, P8533, DOI 10.1029/97JC00020; Goddard L, 1997, J GEOPHYS RES-OCEANS, V102, P10423, DOI 10.1029/97JC00463; Godfrey JS, 1998, J GEOPHYS RES-OCEANS, V103, P14395, DOI 10.1029/97JC03120; HARRISON DE, 1991, J GEOPHYS RES-OCEANS, V96, P3221, DOI 10.1029/90JC01775; Ji M, 1997, MON WEATHER REV, V125, P742, DOI 10.1175/1520-0493(1997)125<0742:IODAOO>2.0.CO;2; JIN FF, 1994, SCIENCE, V264, P70, DOI 10.1126/science.264.5155.70; Jones C, 1998, J CLIMATE, V11, P1057, DOI 10.1175/1520-0442(1998)011<1057:TIOTMJ>2.0.CO;2; Kaplan A, 1998, J GEOPHYS RES-OCEANS, V103, P18567, DOI 10.1029/97JC01734; Kerr RA, 1998, SCIENCE, V280, P522, DOI 10.1126/science.280.5363.522; KESSLER WS, 1993, J PHYS OCEANOGR, V23, P1192, DOI 10.1175/1520-0485(1993)023<1192:TAWDRW>2.0.CO;2; KESSLER WS, 1995, J CLIMATE, V8, P1757, DOI 10.1175/1520-0442(1995)008<1757:OEWATE>2.0.CO;2; KESSLER WS, 1995, DEEP-SEA RES PT II, V42, P295, DOI 10.1016/0967-0645(95)00041-N; KESSLER WS, 1990, J GEOPHYS RES-OCEANS, V95, P5183, DOI 10.1029/JC095iC04p05183; KESSLER WS, 1995, J GEOPHYS RES-OCEANS, V100, P10613, DOI 10.1029/95JC00382; LAGERLOEF GSE, UNPUB; LATIF M, 1994, CLIM DYNAM, V9, P167, DOI 10.1007/BF00208250; Latif M, 1997, J CLIMATE, V10, P2221, DOI 10.1175/1520-0442(1997)010<2221:GWDVOE>2.0.CO;2; LAU KM, 1986, B AM METEOROL SOC, V67, P533, DOI 10.1175/1520-0477(1986)067<0533:TDOATE>2.0.CO;2; LAU KM, IN PRESS J CLIM; LI B, 1994, J PHYS OCEANOGR, V24, P681, DOI 10.1175/1520-0485(1994)024<0681:AEOSEM>2.0.CO;2; LUTHER DS, 1983, SCIENCE, V222, P327, DOI 10.1126/science.222.4621.327; MADDEN RA, 1972, J ATMOS SCI, V29, P1109, DOI 10.1175/1520-0469(1972)029<1109:DOGSCC>2.0.CO;2; MANTUA NJ, 1994, J PHYS OCEANOGR, V24, P691, DOI 10.1175/1520-0485(1994)024<0691:EFTDOM>2.0.CO;2; Mantua NJ, 1997, B AM METEOROL SOC, V78, P1069, DOI 10.1175/1520-0477(1997)078<1069:APICOW>2.0.CO;2; Mayer DA, 1998, J GEOPHYS RES-OCEANS, V103, P18635, DOI 10.1029/98JC01464; MCPHADEN MJ, 1990, SCIENCE, V250, P1385, DOI 10.1126/science.250.4986.1385; MCPHADEN MJ, 1990, J GEOPHYS RES-OCEANS, V95, P13195, DOI 10.1029/JC095iC08p13195; MCPHADEN MJ, 1995, B AM METEOROL SOC, V76, P739; McPhaden MJ, 1998, J GEOPHYS RES-OCEANS, V103, P14169, DOI 10.1029/97JC02906; MCPHADEN MJ, 1999, P 2 HAYES S SEAS TO, P38; MOORE AM, IN PRESS J CLIM; *NAT RES COUNC, 1996, ACC LEG TOGA PROGR; PENLAND C, 1995, J CLIMATE, V8, P1999, DOI 10.1175/1520-0442(1995)008<1999:TOGOTS>2.0.CO;2; Picaut J, 1997, SCIENCE, V277, P663, DOI 10.1126/science.277.5326.663; PICAUT J, 1995, J GEOPHYS RES-OCEANS, V100, P18393, DOI 10.1029/95JC01358; Picaut J, 1996, SCIENCE, V274, P1486, DOI 10.1126/science.274.5292.1486; RASMUSSON EM, 1982, MON WEATHER REV, V110, P354, DOI 10.1175/1520-0493(1982)110<0354:VITSST>2.0.CO;2; REYNOLDS RW, 1994, J CLIMATE, V7, P929, DOI 10.1175/1520-0442(1994)007<0929:IGSSTA>2.0.CO;2; REYNOLDS RW, 1995, J CLIMATE, V8, P1571, DOI 10.1175/1520-0442(1995)008<1571:AHRGSS>2.0.CO;2; Schneider EK, 1997, J ATMOS SCI, V54, P1349, DOI 10.1175/1520-0469(1997)054<1349:ATIOGC>2.0.CO;2; SCHOPF PS, 1988, J ATMOS SCI, V45, P549, DOI 10.1175/1520-0469(1988)045<0549:VIACOM>2.0.CO;2; Slingo JM, 1996, CLIM DYNAM, V12, P325, DOI 10.1007/BF00231106; SLINGO JM, IN PRESS Q J R METEO; SUAREZ MJ, 1988, J ATMOS SCI, V45, P3283, DOI 10.1175/1520-0469(1988)045<3283:ADAOFE>2.0.CO;2; Trenberth KE, 1996, GEOPHYS RES LETT, V23, P57, DOI 10.1029/95GL03602; TRENBERTH KE, 1998, CLIVAR EXCHANGES, V3, P4; TZIPERMAN E, 1994, SCIENCE, V264, P72, DOI 10.1126/science.264.5155.72; *US DEP COMM, 1998, CLIM DIAGN B; Verbickas S, 1998, WEATHER, V53, P282, DOI [10.1002/j.1477-8696.1998.tb06401.x, DOI 10.1002/J.1477-8696.1998.TB06401.X]; WAKATA Y, 1991, J PHYS OCEANOGR, V21, P434, DOI 10.1175/1520-0485(1991)021<0434:OTROEO>2.0.CO;2; Wang B, 1998, J CLIMATE, V11, P2116, DOI 10.1175/1520-0442-11.8.2116; Weisberg RH, 1997, GEOPHYS RES LETT, V24, P779, DOI 10.1029/97GL00689; Weller RA, 1996, J CLIMATE, V9, P1959, DOI 10.1175/1520-0442(1996)009<1959:SMAASF>2.0.CO;2; WOODRUFF SD, 1987, B AM METEOROL SOC, V68, P1239, DOI 10.1175/1520-0477(1987)068<1239:ACOADS>2.0.CO;2; WYRTKI K, 1975, J PHYS OCEANOGR, V5, P572, DOI 10.1175/1520-0485(1975)005<0572:ENTDRO>2.0.CO;2; Yu LA, 1998, GEOPHYS RES LETT, V25, P3537, DOI 10.1029/98GL02628	73	1008	1061	2	141	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					950	954		10.1126/science.283.5404.950	http://dx.doi.org/10.1126/science.283.5404.950			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974381				2022-12-28	WOS:000078574800038
J	Won, YY; Davis, HT; Bates, FS				Won, YY; Davis, HT; Bates, FS			Giant wormlike rubber micelles	SCIENCE			English	Article							MICROSCOPY; DYNAMICS; VESICLES; SYSTEMS; PHASE	A Low molecular weight poly(ethyleneoxide)-poly(butadiene) (PEO-PB) diblock copolymer containing 50 weight percent PEO forms gigantic wormlike micelles at Low concentrations (<5 percent by weight) in water. Subsequent generation of free radicals with a conventional water-based redox reaction Leads: to chemical cross-linking of the PB cores without disruption of the cylindrical morphology, as evidenced by cryotransmission electron microscopy and small-angle neutron scattering experiments. These wormlike rubber micelles exhibit unusual viscoelastic properties in water.	Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Bates, FS (corresponding author), Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA.			Bates, Frank/0000-0003-3977-1278				Bates FS, 1997, PHYS REV LETT, V79, P849, DOI 10.1103/PhysRevLett.79.849; CATES ME, 1987, MACROMOLECULES, V20, P2289, DOI 10.1021/ma00175a038; CLAUSEN TM, 1992, J PHYS CHEM-US, V96, P474, DOI 10.1021/j100180a086; Hajduk DA, 1998, J PHYS CHEM B, V102, P4269, DOI 10.1021/jp973323z; Hillmyer MA, 1996, SCIENCE, V271, P976, DOI 10.1126/science.271.5251.976; Hillmyer MA, 1996, MACROMOLECULES, V29, P6994, DOI 10.1021/ma960774t; LASIC DD, 1994, ANGEW CHEM INT EDIT, V33, P1685, DOI 10.1002/anie.199416851; LIN Z, 1992, LANGMUIR, V8, P2200, DOI 10.1021/la00045a021; Odian G., 1991, PRINCIPLES POLYM, V3; PEDERSEN JS, 1995, J PHYS CHEM-US, V99, P1299, DOI 10.1021/j100004a033; REHAGE H, 1991, MOL PHYS, V74, P933, DOI 10.1080/00268979100102721; RINGSDORF H, 1988, ANGEW CHEM INT EDIT, V27, P113, DOI 10.1002/anie.198801131; Srisiri W, 1997, J AM CHEM SOC, V119, P4866, DOI 10.1021/ja970052x; Srisiri W, 1998, LANGMUIR, V14, P1921, DOI 10.1021/la970897m; STREY R, 1994, COLLOID POLYM SCI, V272, P1005, DOI 10.1007/BF00658900	15	641	664	3	196	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					960	963		10.1126/science.283.5404.960	http://dx.doi.org/10.1126/science.283.5404.960			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974383				2022-12-28	WOS:000078574800040
J	Goodnough, LT; Brecher, ME; Kanter, MH; AuBuchon, JP				Goodnough, LT; Brecher, ME; Kanter, MH; AuBuchon, JP			Medical progress - Transfusion medicine (First of two parts) - Blood transfusion	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; ACUTE LUNG INJURY; NON-B-HEPATITIS; UNITED-STATES; COLORECTAL-CANCER; TRANSMITTED VIRUSES; CELL TRANSFUSIONS; CONTROLLED TRIAL; OXYGEN DELIVERY		Washington Univ, Sch Med, Dept Med, Div Lab Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC USA; Univ N Carolina, Dept Lab Med, Chapel Hill, NC USA; So Calif Permanente Med Grp, Dept Pathol, Woodland Hills, CA USA; Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA	Washington University (WUSTL); Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; Dartmouth College	Goodnough, LT (corresponding author), Washington Univ, Sch Med, Dept Med, Div Lab Med, Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.							AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1992, HEPATOLOGY, V15, P350, DOI 10.1002/hep.1840150228; Alter HJ, 1997, NEW ENGL J MED, V336, P747, DOI 10.1056/NEJM199703133361102; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; AMMANN AJ, 1983, LANCET, V1, P956; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1983, TRANSFUSION, V23, P87; ATLAS SJ, 1994, TRANSFUSION, V34, P386, DOI 10.1046/j.1537-2995.1994.34594249048.x; AuBuchon JP, 1997, ANN INTERN MED, V127, P904, DOI 10.7326/0003-4819-127-10-199711150-00009; AuBuchon JP, 1996, TRANSFUSION, V36, P222, DOI 10.1046/j.1537-2995.1996.36396182139.x; Audet AM, 1998, ORTHOPEDICS, V21, P851; Audet AM, 1996, INT J QUAL HEALTH C, V8, P41, DOI 10.1093/intqhc/8.1.41; BARNETTE RE, 1990, TRANSFUSION, V30, P253, DOI 10.1046/j.1537-2995.1990.30390194348.x; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; BORDIN JO, 1994, BLOOD, V84, P1703; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; BUSCH MP, 1997, APPL MOL BIOL BLOOD, P123; BUSCH ORC, 1993, NEW ENGL J MED, V328, P1372, DOI 10.1056/NEJM199305133281902; Calder L, 1997, CAN MED ASSOC J, V156, pS1; *CAN COORD OFF HLT, 1998, LEUK TECHN US THEIR; Carson JL, 1998, TRANSFUSION, V38, P522, DOI 10.1046/j.1537-2995.1998.38698326331.x; Carson JL, 1998, JAMA-J AM MED ASSOC, V279, P199, DOI 10.1001/jama.279.3.199; Centers for Disease Control (CDC), 1989, MMWR Morb Mortal Wkly Rep, V38, P81; Centers for Disease Control (CDC), 1983, MMWR Morb Mortal Wkly Rep, V32, P101; Centers for Disease Control (CDC), 1989, MMWR-MORBID MORTAL W, V38, p[81, 93]; CHIU EKW, 1994, TRANSFUSION, V34, P950, DOI 10.1046/j.1537-2995.1994.341195065031.x; Churchill WH, 1998, TRANSFUSION, V38, P530, DOI 10.1046/j.1537-2995.1998.38698326332.x; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; Cookson ST, 1996, 36 INT C ANT AG CHEM, P237; DODD RY, 1994, BLOOD SUPPLY RISKS P, P1; DOMEN RE, 1995, TRANSFUS MED REV, V9, P53, DOI 10.1016/S0887-7963(05)80030-6; FAITHFULL NS, 1992, ADV EXP MED BIOL, V317, P55; FRIEDMAN BA, 1980, TRANSFUSION, V20, P179, DOI 10.1046/j.1537-2995.1980.20280169958.x; Garratty G, 1997, TRANSFUSION, V37, P357, DOI 10.1046/j.1537-2995.1997.37497265334.x; GATENBY PA, 1993, AM J REPROD IMMUNOL, V29, P88, DOI 10.1111/j.1600-0897.1993.tb00571.x; GIMBLE JG, 1992, TRANSFUSION, V32, P446, DOI 10.1046/j.1537-2995.1992.32592327719.x; GOLDMAN M, 1991, Transfusion Medicine Reviews, V5, P73, DOI 10.1016/S0887-7963(91)70194-6; GOODNOUGH LT, 1993, AM J MED, V94, P509, DOI 10.1016/0002-9343(93)90086-5; GOODNOUGH LT, 1994, TRANSFUSION MED, V4, P35, DOI 10.1111/j.1365-3148.1994.tb00241.x; GOODNOUGH LT, 1991, JAMA-J AM MED ASSOC, V265, P86, DOI 10.1001/jama.265.1.86; GOODNOUGH LT, 1995, ANN THORAC SURG, V60, P473, DOI 10.1016/0003-4975(95)98960-3; GOODNOUGH LT, 1992, TRANSFUSION, V32, P838; GOUT O, 1990, NEW ENGL J MED, V322, P383, DOI 10.1056/NEJM199002083220607; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V273, P1439, DOI 10.1001/jama.273.18.1439; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V274, P944; HEISS MM, 1994, J CLIN ONCOL, V12, P1859, DOI 10.1200/JCO.1994.12.9.1859; Hewlett IK, 1997, TRANSFUSION, V37, P346, DOI 10.1046/j.1537-2995.1997.37397240219.x; Heyland DK, 1996, CRIT CARE MED, V24, P517, DOI 10.1097/00003246-199603000-00025; HJELLE B, 1993, BLOOD, V81, P1641; HOELTGE GA, 1989, CLEV CLIN J MED, V56, P267, DOI 10.3949/ccjm.56.3.267; Hogue CW, 1998, TRANSFUSION, V38, P924, DOI 10.1046/j.1537-2995.1998.381098440856.x; HOUBIERS JGA, 1994, LANCET, V344, P573, DOI 10.1016/S0140-6736(94)91965-8; Jensen LS, 1996, LANCET, V348, P841, DOI 10.1016/S0140-6736(96)06168-5; Jensen NJ, 1996, TRANSFUSION, V36, P216, DOI 10.1046/j.1537-2995.1996.36396182138.x; JOHNSON RG, 1992, J THORAC CARDIOV SUR, V104, P307; Kanno M, 1998, NEW ENGL J MED, V338, P333, DOI 10.1056/NEJM199801293380513; KHABBAZ RF, 1993, ANN INTERN MED, V118, P448; KIM DM, 1992, TRANSFUSION, V32, P221, DOI 10.1046/j.1537-2995.1992.32392213804.x; Klein HG, 1997, TRANSFUSION, V37, P95, DOI 10.1046/j.1537-2995.1997.37197176958.x; Kleinman S, 1997, TRANSFUS MED REV, V11, P155, DOI 10.1053/tmrv.1997.0110155; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; Lam HTC, 1996, ARCH PATHOL LAB MED, V120, P810; LENFANT C, 1992, TRANSFUSION, V32, P873, DOI 10.1046/j.1537-2995.1992.32993110764.x; Lin L, 1997, TRANSFUSION, V37, P423, DOI 10.1046/j.1537-2995.1997.37497265344.x; LINDEN JV, 1992, TRANSFUSION, V32, P601, DOI 10.1046/j.1537-2995.1992.32792391030.x; Linden JV, 1997, TRANSFUSION, V37, P243, DOI 10.1046/j.1537-2995.1997.37297203534.x; LOUSSERTAJAKA I, 1994, LANCET, V343, P1393, DOI 10.1016/S0140-6736(94)92524-0; LUBAN NLC, 1994, TRANSFUSION, V34, P821, DOI 10.1046/j.1537-2995.1994.34994378286.x; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANNS A, 1992, INT J CANCER, V51, P886, DOI 10.1002/ijc.2910510609; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; MCCULLOUGH J, 1993, JAMA-J AM MED ASSOC, V269, P2239, DOI 10.1001/jama.269.17.2239; NESS PM, 1990, TRANSFUSION, V30, P688, DOI 10.1046/j.1537-2995.1990.30891020325.x; Opelz G, 1997, TRANSPLANTATION, V63, P964, DOI 10.1097/00007890-199704150-00010; Pau CP, 1996, TRANSFUSION, V36, P398, DOI 10.1046/j.1537-2995.1996.36596282582.x; PETERSEN LR, 1994, TRANSFUSION, V34, P865, DOI 10.1046/j.1537-2995.1994.341095026971.x; PILIAVIN JA, 1990, TRANSFUSION, V30, P444, DOI 10.1046/j.1537-2995.1990.30590296381.x; PINDYCK J, 1987, JAMA-J AM MED ASSOC, V257, P1186, DOI 10.1001/jama.257.9.1186; POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x; *PROV PUBL HLTH SE, 1985, MMWR-MORBID MORTAL W, V34, P1; RAO TLK, 1985, ANESTHESIOLOGY REV, V12, P49; ROYSE D, 1995, TRANSFUSION, V35, P826, DOI 10.1046/j.1537-2995.1995.351096026363.x; SAZAMA K, 1990, TRANSFUSION, V30, P583, DOI 10.1046/j.1537-2995.1990.30790385515.x; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Schreiber GB, 1998, TRANSFUSION, V38, p114S; SELIK RM, 1993, TRANSFUSION, V33, P890, DOI 10.1046/j.1537-2995.1993.331194082377.x; SHULMAN IA, 1990, ARCH PATHOL LAB MED, V114, P412; Silliman CC, 1997, TRANSFUSION, V37, P719, DOI 10.1046/j.1537-2995.1997.37797369448.x; SILVERGLEID AJ, 1989, TRANSFUSION, V29, P362, DOI 10.1046/j.1537-2995.1989.29489242806.x; SIMPSON MB, 1987, TRANSFUSION, V27, P192, DOI 10.1046/j.1537-2995.1987.27287150198.x; Spiess BD, 1998, J THORAC CARDIOV SUR, V116, P460, DOI 10.1016/S0022-5223(98)70012-1; STARKEY JM, 1989, JAMA-J AM MED ASSOC, V262, P3452, DOI 10.1001/jama.262.24.3452; Stehling LC, 1996, ANESTHESIOLOGY, V84, P732; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; Stover EP, 1998, ANESTHESIOLOGY, V88, P327, DOI 10.1097/00000542-199802000-00009; Stramer SL, 1997, TRANSFUSION, V37, pS1; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; SURGENOR DM, 1992, TRANSFUSION, V32, P876; Surgenor DM, 1998, TRANSFUSION, V38, P122, DOI 10.1046/j.1537-2995.1998.38298193094.x; SURGENOR DM, 1991, TRANSFUSION, V31, P531, DOI 10.1046/j.1537-2995.1991.31691306252.x; Theakston EP, 1997, AUST NZ J MED, V27, P62, DOI 10.1111/j.1445-5994.1997.tb00916.x; Thomson RA, 1998, TRANSFUSION, V38, P359, DOI 10.1046/j.1537-2995.1998.38498257374.x; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; TOY PTCY, 1994, ARCH PATHOL LAB MED, V118, P435; TOY PTCY, 1992, TRANSFUSION, V32, P63, DOI 10.1046/j.1537-2995.1992.32192116435.x; Valeri CR, 1998, TRANSFUSION, V38, P602, DOI 10.1046/j.1537-2995.1998.38698326341.x; VAMVAKAS EC, 1994, TRANSFUSION, V34, P471, DOI 10.1046/j.1537-2995.1994.34694295060.x; Vamvakas EC, 1996, TRANSFUS MED REV, V10, P44, DOI 10.1016/S0887-7963(96)80122-2; Vamvakas EC, 1996, TRANSFUSION, V36, P175, DOI 10.1046/j.1537-2995.1996.36296181932.x; van de Watering LMG, 1998, CIRCULATION, V97, P562; VRIELINK H, 1995, TRANSFUSION, V35, P601, DOI 10.1046/j.1537-2995.1995.35795357885.x; Wallace EL, 1998, TRANSFUSION, V38, P625, DOI 10.1046/j.1537-2995.1998.38798346630.x; WALLACE EL, 1995, TRANSFUSION, V35, P802, DOI 10.1046/j.1537-2995.1995.351096026360.x; WALLACE EL, 1993, TRANSFUSION, V33, P139, DOI 10.1046/j.1537-2995.1993.33293158046.x; Warner DO, 1998, TRANSFUSION, V38, P738, DOI 10.1046/j.1537-2995.1998.38898375512.x; 1997, MMWR MORB MORTAL WKL, V46, P553; 1995, MMWR MORB MORTAL WKL, V44, P603; 1988, MMWR MORB MORTAL WKL, V37, P745; 1982, MMWR MORB WKLY REP, V31, P652; 1988, MMWR MORB MORTAL WKL, V37, P736	122	651	676	5	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1999	340	6					438	447		10.1056/NEJM199902113400606	http://dx.doi.org/10.1056/NEJM199902113400606			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166HW	9971869				2022-12-28	WOS:000078571000006
J	Jacobs, TW; Byrne, C; Colditz, G; Connolly, JL; Schnitt, SJ				Jacobs, TW; Byrne, C; Colditz, G; Connolly, JL; Schnitt, SJ			Radial scars in benign breast-biopsy specimens and the risk of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FEMALE BREAST; ATYPICAL HYPERPLASIA; SCLEROSING LESION; CARCINOMA; WOMEN; DISEASE; FEATURES	Background Radial scars are benign breast lesions of uncertain clinical significance. In particular, it is not known whether these lesions alter the risk of breast cancer in women with benign breast disease. We conducted a case-control study of women who had benign breast lesions with or without radial scars. Methods We reviewed benign breast-biopsy specimens from 1396 women enrolled in the Nurses' Health Study, including 255 women in whom breast cancer subsequently developed and 1141 women without subsequent breast cancer (controls). The controls were matched to the women with subsequent breast cancer according to age and the year when the benign lesion was identified. The median followup after biopsy of the benign lesions was 12 years. Results Radial scars were identified in biopsy specimens from 99 women (71 percent). Most biopsy specimens with radial scars had only one radial scar (60.6 percent), and they tended to be incidental microscopical findings (median size, 4.0 mm). The women with radial scars had a risk of breast cancer that was almost twice the risk of the women without scars, regardless of the histologic type of benign breast disease (relative risk, 1.8; 95 percent confidence interval, 1.1 to 2.9). Among women who had proliferative disease without atypia as compared with women who had nonproliferative disease, the relative risk of breast cancer was 3.0 (95 percent confidence interval, 1.7 to 5.5) for those with radial scars and 1.5 (95 percent confidence interval, 1.1 to 2.1) for those without radial scars. Among women with atypical hyperplasia as compared with women with nonproliferative disease, the relative risk of breast cancer was 5.8 (95 percent confidence interval, 2.7 to 12.7) for those with radial scars and 3.8 (95 percent confidence interval, 2.4 to 5.9) for those without radial scars. Conclusions Radial scars are an independent histologic risk factor for breast cancer. (N Engl J Med 1999;340:430-6.) (C) 1999, Massachusetts Medical Society.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Schnitt, SJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, East Campus,330 Brookline Ave, Boston, MA 02215 USA.		Byrne, Celia/K-2964-2015; Colditz, Graham/A-3963-2009	Byrne, Celia/0000-0001-8289-4252; Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA050385, R01CA040356, R37CA040356, R01CA046475] Funding Source: NIH RePORTER; NCI NIH HHS [CA 46475, CA 40356, CA 50385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN JA, 1986, PATHOL ANNU, V21, P145; ANDERSEN JA, 1984, CANCER, V53, P2557, DOI 10.1002/1097-0142(19840601)53:11<2557::AID-CNCR2820531131>3.0.CO;2-D; ANDERSON TJ, 1985, J PATHOL, V147, P23, DOI 10.1002/path.1711470104; BLOODGOOD JC, 1932, AM J CANCER, V16, P103; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; CARTER CL, 1988, AM J EPIDEMIOL, V128, P467, DOI 10.1093/oxfordjournals.aje.a114995; DELATORRE M, 1993, HUM PATHOL, V24, P1294, DOI 10.1016/0046-8177(93)90262-F; DouglasJones AG, 1997, HISTOPATHOLOGY, V30, P214, DOI 10.1046/j.1365-2559.1997.d01-600.x; DUPONT WD, 1993, CANCER, V71, P1258, DOI 10.1002/1097-0142(19930215)71:4<1258::AID-CNCR2820710415>3.0.CO;2-I; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; DUPONT WD, 1994, NEW ENGL J MED, V331, P10, DOI 10.1056/NEJM199407073310103; FENOGLIO C, 1974, CANCER, V33, P691, DOI 10.1002/1097-0142(197403)33:3<691::AID-CNCR2820330313>3.0.CO;2-L; FISHER ER, 1979, AM J CLIN PATHOL, V71, P240; FISHER ER, 1983, BREAST CANCER RES TR, V3, P39, DOI 10.1007/BF01806233; FROUGE C, 1995, RADIOLOGY, V195, P623, DOI 10.1148/radiology.195.3.7753984; JENSEN RA, 1989, CANCER, V64, P1977, DOI 10.1002/1097-0142(19891115)64:10<1977::AID-CNCR2820641002>3.0.CO;2-N; Linell F, 1980, Acta Pathol Microbiol Scand Suppl, P1; LONDON SJ, 1992, JAMA-J AM MED ASSOC, V267, P1780; Marshall LM, 1997, CANCER EPIDEM BIOMAR, V6, P297; NIELSEN M, 1985, HISTOPATHOLOGY, V9, P287, DOI 10.1111/j.1365-2559.1985.tb02446.x; NIELSEN M, 1987, CANCER, V59, P1019, DOI 10.1002/1097-0142(19870301)59:5<1019::AID-CNCR2820590528>3.0.CO;2-N; Page DL, 1996, CANCER, V78, P258, DOI 10.1002/(SICI)1097-0142(19960715)78:2<258::AID-CNCR11>3.0.CO;2-V; PAGE DL, 1985, CANCER, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A; PALLI D, 1991, INT J CANCER, V47, P703, DOI 10.1002/ijc.2910470513; RICKERT RR, 1981, CANCER, V47, P561, DOI 10.1002/1097-0142(19810201)47:3<561::AID-CNCR2820470323>3.0.CO;2-0; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; *SAS I, 1989, SAS STAT US GUID VER, V2; SAS Institute, 1990, SAS PROC GUID VERS 6; Semb C, 1928, ACTA CHIR SCAND    S, V10, P1; SLOANE JP, 1993, HISTOPATHOLOGY, V23, P225, DOI 10.1111/j.1365-2559.1993.tb01194.x; TREMBLAY G, 1977, AM J SURG PATHOL, V1, P155, DOI 10.1097/00000478-197706000-00006; WEIDNER N, 1990, SEMIN DIAGN PATHOL, V7, P90; WELLINGS SR, 1984, HUM PATHOL, V15, P475, DOI 10.1016/S0046-8177(84)80083-0	33	202	209	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1999	340	6					430	436		10.1056/NEJM199902113400604	http://dx.doi.org/10.1056/NEJM199902113400604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166HW	9971867				2022-12-28	WOS:000078571000004
J	George, KM; Chatterjee, D; Gunawardana, G; Welty, D; Hayman, J; Lee, R; Small, PLC				George, KM; Chatterjee, D; Gunawardana, G; Welty, D; Hayman, J; Lee, R; Small, PLC			Mycolactone: A polyketide toxin from Mycobacterium ulcerans required for virulence	SCIENCE			English	Article								Mycobacterium ulcerans is the causative agent of Buruli ulcer, a severe human skin disease that occurs primarily in Africa and Australia, Infection with M. ulcerans results in persistent severe necrosis without an acute inflammatory response. The presence of histopathological changes distant from the site of infection suggested that pathogenesis might be toxin mediated. A polyketide-derived macrolide designated mycolactone was isolated that causes cytopathicity and cell cycle arrest in cultured L929 murine fibroblasts. Intradermal inoculation of purified toxin into guinea pigs produced a lesion similar to that of Buruli ulcer in humans. This toxin may represent one of a family of virulence factors associated with pathology in mycobacterial diseases such as leprosy and tuberculosis.	NIAID, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Abbott Labs, Abbott Pk, IL 60064 USA; Box Hill Hosp, Box Hill, Vic 3128, Australia; NIAID, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Colorado State University; Abbott Laboratories; Box Hill Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Small, PLC (corresponding author), NIAID, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.		Lee, Richard/J-4997-2013; Lee, Richard/AAX-3996-2021	Lee, Richard/0000-0002-2397-0443; Lee, Richard/0000-0002-2397-0443; HAYMAN, John/0000-0002-4174-2639				Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; CONNOR DH, 1966, ARCH PATHOL, V81, P183; George KM, 1998, INFECT IMMUN, V66, P587, DOI 10.1128/IAI.66.2.587-593.1998; HAYMAN J, 1993, J CLIN PATHOL, V46, P5, DOI 10.1136/jcp.46.1.5; HOCKMEYER WT, 1978, INFECT IMMUN, V21, P124, DOI 10.1128/IAI.21.1.124-128.1978; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HUDSON AT, 1970, BIOCHEMISTRY-US, V9, P3988, DOI 10.1021/bi00822a018; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KRIEG RE, 1974, ARCH DERMATOL, V110, P783, DOI 10.1001/archderm.110.5.783; Labro MT, 1998, INT J ANTIMICROB AG, V10, P11, DOI 10.1016/S0924-8579(98)00012-0; MAPLESTONE RA, 1992, GENE, V115, P151, DOI 10.1016/0378-1119(92)90553-2; PIMSLER M, 1988, J INFECT DIS, V157, P577, DOI 10.1093/infdis/157.3.577; Portaels F, 1997, J CLIN MICROBIOL, V35, P1097, DOI 10.1128/JCM.35.5.1097-1100.1997; READ JK, 1974, INFECT IMMUN, V9, P1114, DOI 10.1128/IAI.9.6.1114-1122.1974; Ross BC, 1997, APPL ENVIRON MICROB, V63, P4135, DOI 10.1128/AEM.63.10.4135-4138.1997; [No title captured]	16	475	491	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					854	857		10.1126/science.283.5403.854	http://dx.doi.org/10.1126/science.283.5403.854			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933171	Green Submitted			2022-12-28	WOS:000078496800048
J	Thanos, CD; Goodwill, KE; Bowie, JU				Thanos, CD; Goodwill, KE; Bowie, JU			Oligomeric structure of the human EphB2 receptor SAM domain	SCIENCE			English	Article							MAXIMUM-LIKELIHOOD; CRYSTAL-STRUCTURES; TYROSINE KINASES; PROTEIN; FUSION; TEL; LEUKEMIA; GENE; ASSOCIATION; REFINEMENT	The sterile alpha motif (SAM) domain is a protein interaction module that is present in diverse signal-transducing proteins. SAM domains are known to form homo- and hetero-oligomers. The crystal structure of the SAM domain from an Eph receptor tyrosine kinase, EphB2, reveals two Large interfaces. In one interface, adjacent monomers exchange amino-terminal peptides that insert into a hydrophobic groove on each neighbor. A second interface is composed of the carboxyl-terminal helix and a nearby Loop. A possible oligomer, constructed from a combination of these binding modes, may provide a platform for the formation of larger protein complexes.	Univ Calif Los Angeles, US DOE, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem, Los Angeles, CA 90095 USA	United States Department of Energy (DOE); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Bowie, JU (corresponding author), Univ Calif Los Angeles, US DOE, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA.	bowie@mbi.ucla.edu						Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Barr MM, 1996, MOL CELL BIOL, V16, P5597; Bornemann D, 1996, DEVELOPMENT, V122, P1621; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kyba M, 1998, DEV GENET, V22, P74, DOI 10.1002/(SICI)1520-6408(1998)22:1<74::AID-DVG8>3.3.CO;2-V; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; MILLER R, 1994, J APPL CRYSTALLOGR, V27, P613, DOI 10.1107/S0021889894000191; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PAWSON T, 1995, NATURE, V373, P575; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SHULTZ J, 1997, PROTEIN SCI, V6, P249; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; THANOS CD, UNPUB; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Tosi S, 1998, GENE CHROMOSOME CANC, V21, P223, DOI 10.1002/(SICI)1098-2264(199803)21:3<223::AID-GCC6>3.3.CO;2-B; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0	44	194	202	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					833	836		10.1126/science.283.5403.833	http://dx.doi.org/10.1126/science.283.5403.833			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933164	Green Submitted			2022-12-28	WOS:000078496800041
J	Loprinzi, CL; Kugler, JW; Sloan, JA; Rooke, TW; Quella, SK; Novotny, P; Mowat, RB; Michalek, JC; Stella, PJ; Levitt, R; Tschetter, LK; Windschitl, H				Loprinzi, CL; Kugler, JW; Sloan, JA; Rooke, TW; Quella, SK; Novotny, P; Mowat, RB; Michalek, JC; Stella, PJ; Levitt, R; Tschetter, LK; Windschitl, H			Lack of effect of coumarin in women with lymphedema after treatment for breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ELEPHANTIASIS; HEPATOTOXICITY; LYMPHOEDEMA; ARMS; LEGS; DEC	Background Lymphedema of the arms can be a serious consequence of local and regional therapy in women with breast cancer, Coumarin has been reported to be effective for the treatment of women with lymphedema; we undertook a study in which we attempted to replicate those findings. Methods We studied 140 women with chronic lymphedema of the ipsilateral arm after treatment for breast cancer. The women received 200 mg of oral coumarin or placebo twice daily for six months and then the other treatment for the following six months. The end points of the study consisted of the volume of the arm (calculated from measurements of hand and arm circumference) and the answers on a questionnaire completed by the patient about symptoms potentially related to lymphedema, Results The volumes of the arms at 6 and 12 months were virtually identical, regardless of whether coumarin or placebo was given first. After six months, the average volume of the affected arm increased by 21 ml during placebo treatment and 58 mi during coumarin treatment (P = 0.80). In addition, answers on the patients' questionnaires were similar in the two treatment groups. After six months, only 15 percent of the women in the coumarin group and 10 percent of those in the placebo group reported that the study medication had helped a moderate or large amount (P = 0.19). Coumarin was well tolerated, except that it resulted in serologic evidence of liver toxicity in 6 percent of the women. Conclusions Coumarin is not effective therapy for women who have lymphedema of the arm after treatment for breast cancer. (N Engl J Med 1999;340: 346-50.) (C) 1999, Massachusetts Medical Society.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Illinois Oncol Res Assoc, Community Clin Oncol Program, Peoria, IL USA; Toledo Community Hosp, Oncol Program CCOP, Toledo, OH USA; Siouxland Hematol Oncol Associates, Sioux Falls, SD USA; Ann Arbor Reg CCOP, Ann Arbor, MI USA; Meritcare Hosp CCOP, Fargo, ND USA; Sioux Community Canc Consortium, Sioux Falls, SD USA; Centracare Clin, St Cloud, MN USA	Mayo Clinic	Loprinzi, CL (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.				NCI NIH HHS [CA-37404, CA-25224, CA-35113] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA037404, U10CA025224, U10CA035113] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Braun H D, 1971, Munch Med Wochenschr, V113, P1630; Casley-Smith J R, 1992, Australas J Dermatol, V33, P61, DOI 10.1111/j.1440-0960.1992.tb00081.x; CASLEYSMITH JR, 1994, LYMPHOLOGY, V27, P56; CASLEYSMITH JR, 1993, ANN TROP MED PARASIT, V87, P247, DOI 10.1080/00034983.1993.11812763; Loprinzi CL, 1997, J CLIN ONCOL, V15, P3167, DOI 10.1200/JCO.1997.15.9.3167; PEZNER RD, 1986, INT J RADIAT ONCOL, V12, P2079, DOI 10.1016/0360-3016(86)90005-2; PILLER NB, 1988, BRIT J PLAST SURG, V41, P20, DOI 10.1016/0007-1226(88)90139-7; *SAS I, 1990, SAS GRAPH SOFTW REF, V1, P599; SAY CC, 1974, SURG GYNECOL OBSTET, V138, P370; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; ZANOLLA R, 1984, J SURG ONCOL, V26, P210, DOI 10.1002/jso.2930260317	16	107	116	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1999	340	5					346	350		10.1056/NEJM199902043400503	http://dx.doi.org/10.1056/NEJM199902043400503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163WC	9929524				2022-12-28	WOS:000078428500003
J	Ness, RB; Grisso, JA; Hirschinger, N; Markovic, N; Shaw, LM; Day, NL; Kline, J				Ness, RB; Grisso, JA; Hirschinger, N; Markovic, N; Shaw, LM; Day, NL; Kline, J			Cocaine and tobacco use and the risk of spontaneous abortion	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIGARETTE-SMOKING; HAIR ANALYSIS; PREGNANCY; EXPOSURE; ABUSE; CONSUMPTION; PREVALENCE; FETUS	Background Cigarette smoking and cocaine use may be risk factors for spontaneous abortion, but data supporting such a link are limited. Methods We studied the associations between cocaine and tobacco use and spontaneous abortion among pregnant adolescents and women (age range, 14 to 40 years) who sought care at an inner-city emergency department. A total of 400 adolescents and women had spontaneous abortions either at study entry or during follow-up (which lasted until 22 weeks' gestation), and 570 adolescents and women remained pregnant past 22 weeks' gestation. Cocaine use was measured at base line by self-reports and analysis of urine and hair samples, Cigarette smoking was measured by self-reports and urine analysis. Results The adolescents and women in both groups were predominantly black and of lower socioeconomic status. Among those who had spontaneous abortions, 28.9 percent used cocaine on the basis of hair analysis and 34.6 percent smoked on the basis of a urine cotinine assay, as compared with 20.5 percent and 21.8 percent, respectively, of the adolescents and women who did not have spontaneous abortions. The presence of cocaine in hair samples was independently associated with an increase in the occurrence of spontaneous abortion (odds ratio, 1.4; 95 percent confidence interval, 1.0 to 2.1) after adjustment for demographic and drug-use variables. However, the use of cocaine as measured by self-reports and by urine analysis was not. The presence of cotinine in urine was also independently associated with an increased risk of spontaneous abortion (odds ratio, 1.8; 95 percent confidence interval, 1.3 to 2.6). Twenty-four percent of the risk of spontaneous abortion could be related to cocaine or tobacco use. Conclusions Cocaine use and tobacco use were common in our study population and were associated with a significant risk of spontaneous abortion, (N Engl J Med 1999;340:333-9.) (C) 1999, Massachusetts Medical Society.	Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA; Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Pittsburgh, PA 15213 USA; New York State Psychiat Inst, New York, NY 10032 USA; Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA; Columbia Univ, Sch Publ Hlth, New York, NY USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC; New York State Psychiatry Institute; Columbia University; Columbia University	Ness, RB (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, 130 DeSoto St,517 Parran Hall, Pittsburgh, PA 15261 USA.		Day, Nancy L/H-3171-2016		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008358] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008252] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS08358] Funding Source: Medline; NIDA NIH HHS [R01 DA08252] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ARMSTRONG BG, 1992, AM J PUBLIC HEALTH, V82, P85, DOI 10.2105/AJPH.82.1.85; BINGOL N, 1987, J PEDIATR-US, V110, P350; BRUMGARTNER WA, 1992, RECENT DEV THERAPEUT, P577; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CHURCH MW, 1990, NEUROTOXICOL TERATOL, V12, P327, DOI 10.1016/0892-0362(90)90051-D; FRANK DA, 1988, PEDIATRICS, V82, P888; GRANT T, 1994, OBSTET GYNECOL, V83, P524, DOI 10.1097/00006250-199404000-00007; HADDOW JE, 1987, BRIT J OBSTET GYNAEC, V94, P678, DOI 10.1111/j.1471-0528.1987.tb03174.x; HIMMELBERGER DU, 1978, AM J EPIDEMIOL, V108, P470, DOI 10.1093/oxfordjournals.aje.a112645; KEITH LG, 1989, OBSTET GYNECOL, V73, P715; Klebanoff MA, 1998, AM J EPIDEMIOL, V148, P259; KLINE J, 1995, AM J EPIDEMIOL, V141, P417, DOI 10.1093/oxfordjournals.aje.a117444; Kline J, 1997, AM J PUBLIC HEALTH, V87, P352, DOI 10.2105/AJPH.87.3.352; Kline J.S., 1989, CONCEPTION BIRTH EPI; KOREN G, 1992, J CLIN PHARMACOL, V32, P671, DOI 10.1002/j.1552-4604.1992.tb05780.x; MACGREGOR SN, 1989, OBSTET GYNECOL, V74, P882; MAGURA S, 1992, INT J ADDICT, V27, P51; MCNAGNY SE, 1992, JAMA-J AM MED ASSOC, V267, P1106, DOI 10.1001/jama.267.8.1106; MOORE TR, 1986, AM J OBSTET GYNECOL, V155, P883, DOI 10.1016/S0002-9378(86)80044-8; RAMOSKA EA, 1989, ANN EMERG MED, V18, P48, DOI 10.1016/S0196-0644(89)80310-5; RYAN L, 1987, NEUROTOXICOL TERATOL, V9, P295, DOI 10.1016/0892-0362(87)90018-3; SAITOH M, 1969, ADV BIOL SKIN, V9, P183; Sozio J, 1998, Infect Dis Obstet Gynecol, V6, P8, DOI 10.1155/S1064744998000039; WALSH RA, 1994, HUM BIOL, V66, P1059; WILCOX AJ, 1984, AM J EPIDEMIOL, V120, P727, DOI 10.1093/oxfordjournals.aje.a113940; WINDHAM GC, 1992, AM J EPIDEMIOL, V135, P1394, DOI 10.1093/oxfordjournals.aje.a116250; WOODS JR, 1987, JAMA-J AM MED ASSOC, V257, P957, DOI 10.1001/jama.257.7.957	27	195	197	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1999	340	5					333	339		10.1056/NEJM199902043400501	http://dx.doi.org/10.1056/NEJM199902043400501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163WC	9929522				2022-12-28	WOS:000078428500001
J	Purdie, D				Purdie, D			The genesis line	LANCET			English	Editorial Material									Hull Royal Infirm, Ctr Metab Bone Dis, Hull HU3 2RW, N Humberside, England		Purdie, D (corresponding author), Hull Royal Infirm, Ctr Metab Bone Dis, 220-236 Anlady Rd, Hull HU3 2RW, N Humberside, England.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 30	1999	353	9150					404	405		10.1016/S0140-6736(98)11455-1	http://dx.doi.org/10.1016/S0140-6736(98)11455-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950462				2022-12-28	WOS:000078437000047
J	Potts, M; Walsh, J				Potts, M; Walsh, J			Making Cairo work	LANCET			English	Article							DEVELOPING-COUNTRIES	The 1994 International Conference on Population and Development set broad new goals for family planning and reproductive health. The resources available to fund these much needed programmes, however, are much smaller than was originally calculated. To divide the limited budgets for the maximum health impact, likely resource flows need to be set against the cost of various family planning and reproductive health interventions. Preliminary analysis suggests that selection of cost-effective delivery of family planning services would still meet much of the need for family planning, and that some progress could be made towards improved control of sexually transmitted diseases.	Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Potts, M (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Earl Warren Hall, Berkeley, CA 94720 USA.	potts@socrates.berkeley.edu						Barberis M, 1997, J BIOSOC SCI, V29, P219, DOI 10.1017/S0021932097002198; Berman PA, 1997, HEALTH ECON, V6, P11, DOI 10.1002/(SICI)1099-1050(199701)6:1<11::AID-HEC238>3.0.CO;2-7; Bongaarts J, 1997, STUD FAMILY PLANN, V28, P267, DOI 10.2307/2137858; CONLY, 1998, POPULATION ACTION IN; HUBER SC, 1989, J BIOSOC SCI, V21, P267, DOI 10.1017/S0021932000017971; *IFRP, 1981, SURG FAM PLANN METH; Kulczycki A, 1996, LANCET, V347, P1663, DOI 10.1016/S0140-6736(96)91491-9; MUMFORD AE, 1998, IN PRESS REPROD HLTH; POTTS M, 1991, LANCET, V338, P608, DOI 10.1016/0140-6736(91)90614-U; SADIK N, 1997, STATE WORLD POPULATI; SHELTON JD, 1992, LANCET, V340, P1334, DOI 10.1016/0140-6736(92)92505-A; SINDING SW, 1991, FAMILY PLANNING M CH; *TANZ LSMS, 1993, PREL HOUS EXP MARK S; *UN, 1995, INT C POP DEV CAIR 5; VLASSOFF M, 1998, IN PRESS GLOBAL RESO; WALSH JA, 1998, COST EFFECTIVENESS C; WATTENBERG B, 1997, NY TIMES        1123; Westoff C. F., 1995, International Family Planning Perspectives, V21, P26, DOI 10.2307/2133602; *WHO, 1996, IMPR SUCC QUAL CAR F; WINFREY W, 1996, MARK SEGM AN IND FAM; *WORLD BANK, 1991, PAK INT HOUS SURV WO	21	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 23	1999	353	9149					315	318		10.1016/S0140-6736(98)06097-8	http://dx.doi.org/10.1016/S0140-6736(98)06097-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	161MF	9929040				2022-12-28	WOS:000078292200041
J	Bjornson, CRR; Rietze, RL; Reynolds, BA; Magli, MC; Vescovi, AL				Bjornson, CRR; Rietze, RL; Reynolds, BA; Magli, MC; Vescovi, AL			Turning brain into blood: A hematopoietic fate adopted by adult neural stem cells in vivo	SCIENCE			English	Article							MOUSE BRAIN; MICE	Stem cells are found in various organs where they participate in tissue homeostasis by replacing differentiated cells Lost to physiological turnover or injury. An investigation was performed to determine whether stem cells are restricted to produce specific cell types, namely, those from the tissue in which they reside. After transplantation into irradiated hosts; genetically labeled neural stem cells were found to produce a variety of blood cell types including myeloid and lymphoid cells as well as early hematopoietic cells. Thus, neural stem cells appear to have a wider differentiation potential than previously thought.	NeuroSpheres Ltd, Calgary, AB T2N 4N1, Canada; CNR, Ist Mutagenesi, I-56124 Pisa, Italy; Ist Nazl Neurol C Besta, I-20133 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituto Neurologico Besta	Bjornson, CRR (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.		Vescovi, Angelo Luigi/A-4919-2015	Vescovi, Angelo Luigi/0000-0002-1742-4112	Telethon [A.116] Funding Source: Medline	Telethon(Fondazione Telethon)		BARTLETT PF, 1982, P NATL ACAD SCI-BIOL, V79, P2722, DOI 10.1073/pnas.79.8.2722; DIBERARDINO MA, 1997, GENOMIC POTENTIAL DI, P1; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gritti A, 1996, J NEUROSCI, V16, P1091; Loeffler Markus, 1997, P1, DOI 10.1016/B978-012563455-7/50002-7; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; TAJBAKHSH S, 1994, NEURON, V13, P813, DOI 10.1016/0896-6273(94)90248-8; TARBELL NJ, 1987, INT J RADIAT ONCOL, V13, P1065, DOI 10.1016/0360-3016(87)90046-0; VALTZ NLM, 1991, NEW BIOL, V3, P364; VESCOVI AL, IN PRESS EXP NEUROL; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581	14	1113	1262	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					534	537		10.1126/science.283.5401.534	http://dx.doi.org/10.1126/science.283.5401.534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915700				2022-12-28	WOS:000078203300036
J	Huntsman, MM; Porcello, DM; Homanics, GE; DeLorey, TM; Huguenard, JR				Huntsman, MM; Porcello, DM; Homanics, GE; DeLorey, TM; Huguenard, JR			Reciprocal inhibitory connections and network synchrony in the mammalian thalamus	SCIENCE			English	Article							SPINDLE RHYTHMICITY; RETICULAR NEURONS; RELAY NEURONS; IN-VITRO; NUCLEUS; RAT; SUBUNIT; BRAIN	Neuronal rhythmic activities within thalamocortical circuits range from partially synchronous oscillations during normal sleep to hypersynchrony associated with absence epilepsy. It has been proposed that recurrent inhibition within the thalamic reticular nucleus serves to reduce synchrony and thus prevents seizures, Inhibition and synchrony in slices from mice devoid of the gamma-aminobutyric acid type-A (GABA(A)) receptor beta(3) subunit were examined, because in rodent thalamus, beta(3) is largely restricted to reticular nucleus. in beta(3) knockout mice, GABA(A)-mediated inhibition was nearly abolished in reticular nucleus, but was unaffected in relay cells. In addition, oscillatory synchrony was dramatically intensified. Thus, recurrent inhibitory connections within reticular nucleus act as "desynchronizers."	Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol Crit Care Med, Pittsburgh, PA 15261 USA; Mol Res Inst, Palo Alto, CA 94304 USA	Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Huguenard, JR (corresponding author), Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.		Huguenard, John/I-5016-2012; Huguenard, John/K-6429-2019	Huguenard, John/0000-0002-6950-1191; Huguenard, John/0000-0002-6950-1191; Homanics, Gregg/0000-0003-3641-8153	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034774, R37NS034774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010422] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA10422] Funding Source: Medline; NINDS NIH HHS [NS34774, NS06477] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLSEN G, 1982, BRAIN RES, V236, P482, DOI 10.1016/0006-8993(82)90731-4; Cox CL, 1996, J COMP NEUROL, V366, P416; DeLorey TM, 1998, J NEUROSCI, V18, P8505; DESTEXHE A, 1994, J NEUROPHYSIOL, V72, P803, DOI 10.1152/jn.1994.72.2.803; Homanics GE, 1997, P NATL ACAD SCI USA, V94, P4143, DOI 10.1073/pnas.94.8.4143; HUGUENARD JR, 1994, J NEUROSCI, V14, P5485; HUGUENARD JR, 1994, J NEUROPHYSIOL, V71, P2576, DOI 10.1152/jn.1994.71.6.2576; JONES EG, 1975, J COMP NEUROL, V162, P285, DOI 10.1002/cne.901620302; Jones MV, 1997, J NEUROSCI, V17, P7626; Kim U, 1997, SCIENCE, V278, P130, DOI 10.1126/science.278.5335.130; KONIG P, 1994, J NEUROSCI METH, V54, P31, DOI 10.1016/0165-0270(94)90157-0; Krasowski MD, 1998, NEUROSCI LETT, V240, P81, DOI 10.1016/S0304-3940(97)00929-4; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Pinault D, 1997, J NEUROSCI, V17, P3215; SanchezVives MV, 1997, J NEUROSCI, V17, P8894; SCHEIBEL MADGE E., 1966, BRAIN RES, V1, P43, DOI 10.1016/0006-8993(66)90104-1; STERIADE M, 1988, PHYSIOL REV, V68, P649, DOI 10.1152/physrev.1988.68.3.649; STERIADE M, 1987, J NEUROPHYSIOL, V57, P260, DOI 10.1152/jn.1987.57.1.260; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; ULRICH D, 1995, NEURON, V15, P909, DOI 10.1016/0896-6273(95)90181-7; Ulrich D, 1997, J NEUROPHYSIOL, V78, P1748, DOI 10.1152/jn.1997.78.3.1748; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750; WARREN RA, 1994, J NEUROPHYSIOL, V72, P1993, DOI 10.1152/jn.1994.72.4.1993; WISDEN W, 1992, J NEUROSCI, V12, P1040; Zhang SLJ, 1997, J NEUROPHYSIOL, V78, P2280, DOI 10.1152/jn.1997.78.5.2280	25	273	275	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					541	543		10.1126/science.283.5401.541	http://dx.doi.org/10.1126/science.283.5401.541			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915702				2022-12-28	WOS:000078203300038
J	Jacobs, JJL; Kieboom, K; Marino, S; DePinho, RA; van Lohuizen, M				Jacobs, JJL; Kieboom, K; Marino, S; DePinho, RA; van Lohuizen, M			The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus	NATURE			English	Article							TRANSGENIC MICE; TUMOR SUPPRESSION; AXIAL SKELETON; LYMPHOMAGENESIS; IDENTIFICATION; TRANSFORMATION; PROTOONCOGENE; FIBROBLASTS; EXPRESSION; P16(INK4A)	The bmi-1 gene was first isolated as an oncogene that cooperates with c-myc in the generation of mouse lymphomas(1,2). We subsequently identified Bmi-1 as a transcriptional repressor belonging to the mouse Polycomb group(3-6). The Polycomb group comprises an important, conserved set of proteins that are required to maintain stable repression of specific target genes, such as homeobox-cluster genes, during development(7-9). In mice, the absence of bmi-1 expression results in neurological defects and severe proliferative defects in lymphoid cells, whereas bmi-1 overexpression induces lymphomas(4,10). Here we show that bmi-1-deficient primary mouse embryonic fibroblasts are impaired in progression into the S phase of the cell cycle and undergo premature senescence. In these fibroblasts and in bmi-1-deficient: lymphocytes, the expression of the tumour suppressors p16 and p19(Arf), which are encoded by ink4a, is raised markedly. Conversely, overexpression of bmi-1 allows fibroblast immortalization, downregulates expression of p16 and p19(Arf) and, in combination with H-ras, leads to neoplastic transformation. Removal of ink4a dramatically reduces the lymphoid and neurological defects seen in bmi-1-deficient mice, indicating that ink4a is a critical in vivo target for Bmi-1. Our results connect transcriptional repression by Polycomb-group proteins with cell-cycle control and senescence.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Netherlands Cancer Institute; Netherlands Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	van Lohuizen, M (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	lohuizen@nki.nl	Jacobs, Jacqueline/ABA-5652-2020	Jacobs, Jacqueline/0000-0002-7704-4795; DePinho, Ronald/0000-0002-5625-577X; Marino, Silvia/0000-0002-9612-2883				Akasaka T, 1996, DEVELOPMENT, V122, P1513; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Alkema MJ, 1997, J MOL BIOL, V273, P993, DOI 10.1006/jmbi.1997.1372; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BLYTH K, 1995, ONCOGENE, V10, P1717; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hara E, 1996, MOL CELL BIOL, V16, P859; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; PARO R, 1995, TRENDS GENET, V11, P295, DOI 10.1016/S0168-9525(00)89081-2; PIROTTA V, 1997, CURR OPIN GENET DEV, V7, P249; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; van Lohuizen M, 1998, CELL MOL LIFE SCI, V54, P71, DOI 10.1007/s000180050126; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; VANLOHUIZEN M, 1991, CELL, V65, P735; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	30	1289	1365	2	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 14	1999	397	6715					164	168		10.1038/16476	http://dx.doi.org/10.1038/16476			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923679				2022-12-28	WOS:000078085000047
J	Berger, A				Berger, A			The impact of new technologies in medicine - Call for papers	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					346	346		10.1136/bmj.318.7180.346	http://dx.doi.org/10.1136/bmj.318.7180.346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933178	Green Published			2022-12-28	WOS:000078572600006
J	Lipworth, BJ				Lipworth, BJ			Fortnightly review - Modern drug treatment of chronic asthma	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INHALED CORTICOSTEROIDS; BUDESONIDE; FLUTICASONE; THEOPHYLLINE; ASSOCIATION; THERAPY; DENSITY		Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland	University of Dundee	Lipworth, BJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland.	b.j.lipworth@dundee.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Boorsma M, 1996, EUR RESPIR J, V9, P1427, DOI 10.1183/09031936.96.09071427; Clark DJ, 1997, THORAX, V52, P55, DOI 10.1136/thx.52.1.55; CUMMINGS RG, 1997, NEW ENGL J MED, V3, P3378; Donnelly R, 1997, AM J RESP CRIT CARE, V156, P1746, DOI 10.1164/ajrccm.156.6.9703003; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; KIDNEY J, 1995, AM J RESP CRIT CARE, V151, P1907, DOI 10.1164/ajrccm.151.6.7767539; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LEFF JA, 1997, AM J RESP CRIT CAR S, V155, P975; Lipworth B, 1998, AM J MED, V104, P431, DOI 10.1016/S0002-9343(98)00086-2; Lipworth BJ, 1997, LANCET, V350, P18; Lipworth BJ, 1998, SEMIN RESP CRIT CARE, V19, P625, DOI 10.1055/s-2007-1009437; *M SHARP DOHM, 1998, SING PROD DAT SHEET; MAHNSTROM K, 1998, J ALLERGY CLIN IMM S, V101, pS97; MANOLITSAS ND, 1995, AM J RESP CRIT CARE, V151, P1925, DOI 10.1164/ajrccm.151.6.7767541; McCowan C, 1998, BMJ-BRIT MED J, V316, P668, DOI 10.1136/bmj.316.7132.668; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; Nakamura Y, 1998, THORAX, V53, P835, DOI 10.1136/thx.53.10.835; *NAT ASTHM ED PREV, 1997, NIH PUBL; NAVAK AS, 1998, J ALLERGY CLIN IMM S, V101, pS233; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pearson MG, 1997, THORAX, V52, pS1; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; REICIN AS, 1998, AM J RESP CRIT CARE, V157, pA416; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Roy A, 1996, EUR RESPIR J, V9, P226, DOI 10.1183/09031936.96.09020226; SAMPSON A, 1998, BRIT MED J, V16, P1257; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; Silverstein MD, 1997, J ALLERGY CLIN IMMUN, V99, P466, DOI 10.1016/S0091-6749(97)70072-1; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X; TOOGOOD JH, 1995, J ALLERGY CLIN IMMUN, V96, P157, DOI 10.1016/S0091-6749(95)70003-X; TURPIN JA, 1998, AM J RESP CRIT CARE, V157, pA456; VIRCHOW JC, 1997, J INVEST MED, V45, pA286; Wisniewski AF, 1997, THORAX, V52, P853, DOI 10.1136/thx.52.10.853	37	23	23	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 6	1999	318	7180					380	384		10.1136/bmj.318.7180.380	http://dx.doi.org/10.1136/bmj.318.7180.380			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933205	Green Published			2022-12-28	WOS:000078572600033
J	Kerschbaum, HH; Cahalan, MD				Kerschbaum, HH; Cahalan, MD			Single-channel recording of a store-operated Ca2+ channel in Jurkat T lymphocytes	SCIENCE			English	Article							CALCIUM CHANNELS; MAST-CELLS; DEPLETION; CONDUCTANCE; PERMEATION; CATIONS; MUSCLE	In T Lymphocytes, a store-operated calcium ion (Ca2+) entry mechanism termed the calcium release-activated Ca2+ channel (CRAC channel) underlies the sustained or oscillatory intracellular calcium concentration signal required for interleukin-2 gene expression and cell proliferation. The use of sodium ions as a current carrier enabled single-channel recordings of CRAC channels during activation, inactivation, and blockade of current in the presence of divalent cations. A Large conductance of 36 to 40 picosiemens indicates that 100 to 400 CRAC channels are present in T Lymphocytes.	Salzburg Univ, Inst Zool, Dept Anim Physiol, A-5020 Salzburg, Austria; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	Salzburg University; University of California System; University of California Irvine	Cahalan, MD (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.				NIGMS NIH HHS [GM-41514] Funding Source: Medline; NINDS NIH HHS [NS-14609] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014609, R37NS014609] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALMERS W, 1984, J PHYSIOL-LONDON, V353, P565, DOI 10.1113/jphysiol.1984.sp015351; BERS D, 1994, METHODS CELL BIOL, V40; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HESS P, 1986, J GEN PHYSIOL, V88, P293, DOI 10.1085/jgp.88.3.293; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Kerschbaum HH, 1998, J GEN PHYSIOL, V111, P521, DOI 10.1085/jgp.111.4.521; KERSCHBAUM HH, UNPUB; LeppleWienhues A, 1996, BIOPHYS J, V71, P787, DOI 10.1016/S0006-3495(96)79278-0; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	14	128	135	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					836	839		10.1126/science.283.5403.836	http://dx.doi.org/10.1126/science.283.5403.836			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933165				2022-12-28	WOS:000078496800042
J	Peled, A; Petit, I; Kollet, O; Magid, M; Ponomaryov, T; Byk, T; Nagler, A; Ben-Hur, H; Many, A; Shultz, L; Lider, O; Alon, R; Zipori, D; Lapidot, T				Peled, A; Petit, I; Kollet, O; Magid, M; Ponomaryov, T; Byk, T; Nagler, A; Ben-Hur, H; Many, A; Shultz, L; Lider, O; Alon, R; Zipori, D; Lapidot, T			Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4	SCIENCE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; BONE-MARROW; MULTILINEAGE HEMATOPOIESIS; IMMUNODEFICIENT MICE; SCID MICE; IN-VIVO; SDF-1; GENE; CHEMOATTRACTANT; MOUSE	Stem cell homing and repopulation are not well understood. The chemokine stromal cell-derived factor-1 (SDF-1) and its receptor CXCR4 were found to be critical for murine bone marrow engraftment by human severe combined immunodeficient (SCID) repopulating stem cells. Treatment of human cells with antibodies to CXCR4 prevented engraftment. In vitro CXCR4-dependent migration to SDF-1 of CD34(+)CD38(-/low) cells correlated with in vivo engraftment and stem cell function. Stem cell factor and interleukin-6 induced CXCR4 expression on CD34(+) cells, which potentiated migration to SDF-1 and engraftment in primary and secondary transplanted mice. Thus, up-regulation of CXCR4 expression may be useful for improving engraftment of repopulating stem cells in clinical transplantation.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Hadassah Univ Hosp, IL-91120 Jerusalem, Israel; Sourasky Med Ctr, IL-64239 Tel Aviv, Israel; Jackson Lab, Bar Harbor, ME 04609 USA	Weizmann Institute of Science; Weizmann Institute of Science; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Jackson Laboratory	Lapidot, T (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	litsvee@weizmann.weizmann.ac.il	Lapidot, Tsvee/A-1812-2010; ALON, RONEN/GRX-6987-2022; Kollet, Orit/A-6861-2008; Petit, isabelle/AAF-5620-2020	Petit, isabelle/0000-0002-9782-0683; Alon, Ronen/0000-0001-9161-6369	PHS HHS [A130389] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Cashman JD, 1997, BLOOD, V89, P4307, DOI 10.1182/blood.V89.12.4307; Christianson SW, 1997, J IMMUNOL, V158, P3578; Civin CI, 1996, BLOOD, V88, P4102, DOI 10.1182/blood.V88.11.4102.bloodjournal88114102; Deichmann M, 1997, BLOOD, V89, P3522, DOI 10.1182/blood.V89.10.3522.3522_3522_3528; Kim CH, 1998, BLOOD, V91, P100, DOI 10.1182/blood.V91.1.100.100_100_110; LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; NOLTA JA, 1994, BLOOD, V83, P3041, DOI 10.1182/blood.V83.10.3041.3041; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Sawada S, 1998, J EXP MED, V187, P1439, DOI 10.1084/jem.187.9.1439; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; SPANGRUDE GJ, 1995, BLOOD, V85, P1006, DOI 10.1182/blood.V85.4.1006.bloodjournal8541006; Sutherland H J, 1995, J Hematother, V4, P3, DOI 10.1089/scd.1.1995.4.3; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	20	1386	1505	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1999	283	5403					845	848		10.1126/science.283.5403.845	http://dx.doi.org/10.1126/science.283.5403.845			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933168				2022-12-28	WOS:000078496800045
J	Coker, WJ; Bhatt, BM; Blatchley, NF; Graham, JT				Coker, WJ; Bhatt, BM; Blatchley, NF; Graham, JT			Clinical findings for the first 1000 Gulf war veterans in the Ministry of Defence's medical assessment programme	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To review the clinical findings in the first 1000 veterans seen in the Ministry of Defence's Gulf war medical assessment programme to examine whether there was a particular illness related to service in the Gulf. Design Case series of 1000 veterans who presented to the programme between 11 October 1993 and 24 February 1997. Subjects Gulf war veterans. Main outcome measures Diagnosis of veterans' conditions according to ICD-10 (international classification of diseases, 10th revision). Cases referred for psychiatric assessment were reviewed for available diagnostic information from consultant psychiatrists. Results 588 (59%) veterans had more than one diagnosed condition, 387 (39%) had at least one condition for which no firm somatic or psychological diagnosis could be given, and in 90 (9%) veterans no other main diagnosis was made. Conditions characterised by fatigue were found in 239 (24%) of patients. At least 190 (19%) patients had a psychiatric condition, which in over half was due to post-traumatic stress disorder. Musculoskeletal disorders and respiratory conditions were also found to be relatively common (in 182 (18%) and 155 (16%) patients respectively). Conclusion Many Gulf war veterans had a wide variety of symptoms. This initial review shows no evidence or-a single illness, psychological or physical, to explain the pattern of symptoms seen in veterans in the assessment programme. As the veterans assessed by the programme were all self selected, the prevalence of illness in Gulf war veterans cannot be determined from this study. Furthermore, it is not known whether the veterans in this study were representative of sick veterans as a group.	Minist Def, Gulf Vet Illness Unit, London SW1A 2HB, England; RAF, British Def Staff, Washington, DC 20002 USA; Dutchess Kent Hosp, Catterick Garrison DL9 4DF, N Yorkshire, England		Blatchley, NF (corresponding author), Minist Def, Gulf Vet Illness Unit, Room 8276, London SW1A 2HB, England.	sma-mod.uk@btinternet.com						BEALE P, 1994, BRIT MED J, V308, P1574, DOI 10.1136/bmj.308.6943.1574c; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Fukuda K, 1998, JAMA-J AM MED ASSOC, V280, P981, DOI 10.1001/jama.280.11.981; Hyams KC, 1996, ANN INTERN MED, V125, P398, DOI 10.7326/0003-4819-125-5-199609010-00007; *I MED, 1998, AD DEP VET AFF PERS; *IOW PERS GULF STU, 1997, JAMA-J AM MED ASSOC, V277, P238; Joseph SC, 1997, MIL MED, V162, P149; REVELL T, 1995, BRIT MED J, V310, P1073, DOI 10.1136/bmj.310.6986.1073a; WEATHERALL DJ, 1996, OXFORD TXB MED, P1035	9	79	81	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 30	1999	318	7179					290	296		10.1136/bmj.318.7179.290	http://dx.doi.org/10.1136/bmj.318.7179.290			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZH	9924053	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000078436700021
J	[Anonymous]				[Anonymous]			Steps needed to solve NHS workforce problems	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 30	1999	318	7179					335	335						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZH	9924079				2022-12-28	WOS:000078436700067
J	Piner, RD; Zhu, J; Xu, F; Hong, SH; Mirkin, CA				Piner, RD; Zhu, J; Xu, F; Hong, SH; Mirkin, CA			"Dip-pen" nanolithography	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; FORCE MICROSCOPY; ORGANIC-SURFACES; NANOMETER-SCALE; THIN-FILMS; LITHOGRAPHY; RESISTS; PATTERNS	A direct-write "dip-pen" nanolithography (DPN) has been developed to deliver collections of molecules in a positive printing mode. An atomic force microscope (AFM) tip is used to write alkanethiols with 30-nanometer Linewidth resolution on a gold thin film in a manner analogous to that of a: dip pen. Molecules are delivered from the AFM tip to a solid substrate of interest via capillary transport, making DPN a potentially useful tool for creating and functionalizing nanoscale devices.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Northwestern University	Mirkin, CA (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	camirkin@chem.nwu.edu	Hong, Seunghun/B-2545-2012; Mirkin, Chad A/E-3911-2010; Piner, Richard/Y-2520-2019	Mirkin, Chad/0000-0002-6634-7627				ALVES CA, 1992, J AM CHEM SOC, V114, P1222, DOI 10.1021/ja00030a015; BAIN CD, 1989, ANGEW CHEM INT EDIT, V28, P506, DOI 10.1002/anie.198905061; BERGGREN KK, 1995, SCIENCE, V269, P1255, DOI 10.1126/science.7652572; BINGGELI M, 1994, APPL PHYS LETT, V65, P415, DOI 10.1063/1.113020; Bishop AR, 1996, CURR OPIN COLLOID IN, V1, P127, DOI 10.1016/S1359-0294(96)80053-7; Bottomley LA, 1998, ANAL CHEM, V70, p425R; Carr DW, 1997, J VAC SCI TECHNOL A, V15, P1446, DOI 10.1116/1.580559; DUBOIS LH, 1992, ANNU REV PHYS CHEM, V43, P437, DOI 10.1146/annurev.pc.43.100192.002253; Ewing A Crum, 1997, FOUNTAIN PEN COLLECT; Feldheim DL, 1998, CHEM SOC REV, V27, P1; Fujihira M, 1996, CHEM LETT, P499, DOI 10.1246/cl.1996.499; KIM E, 1995, NATURE, V376, P581, DOI 10.1038/376581a0; KIM Y, 1992, SCIENCE, V257, P375, DOI 10.1126/science.257.5068.375; Komeda T, 1998, J VAC SCI TECHNOL A, V16, P1680, DOI 10.1116/1.581142; KUMAR A, 1992, J AM CHEM SOC, V114, P9188, DOI 10.1021/ja00049a061; Lercel MJ, 1996, APPL PHYS LETT, V68, P1504, DOI 10.1063/1.115680; LU X, 1998, J PHYS CHEM B, V102, P540; Muller HU, 1995, J VAC SCI TECHNOL B, V13, P2846, DOI 10.1116/1.588302; Nyffenegger RM, 1997, CHEM REV, V97, P1195, DOI 10.1021/cr960069i; Perkins FK, 1996, APPL PHYS LETT, V68, P550, DOI 10.1063/1.116396; Piner RD, 1997, LANGMUIR, V13, P6864, DOI 10.1021/la970921w; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; Schoer JK, 1997, LANGMUIR, V13, P2323, DOI 10.1021/la960369v; SONDAGHUETHORST JAM, 1994, APPL PHYS LETT, V64, P285, DOI 10.1063/1.111182; Sugimura H, 1996, J VAC SCI TECHNOL A, V14, P1223, DOI 10.1116/1.580271; Ulman A., 1991, INTRO ULTRATHIN ORGA; Xia YN, 1996, SCIENCE, V273, P347, DOI 10.1126/science.273.5273.347; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G; XU S, 1994, APPL PHYS LETT, V64, P127; Yan L, 1998, J AM CHEM SOC, V120, P6179, DOI 10.1021/ja980770z	30	2620	2743	19	839	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					661	663		10.1126/science.283.5402.661	http://dx.doi.org/10.1126/science.283.5402.661			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924019				2022-12-28	WOS:000078324400033
J	Hardman, SMC; Cowie, MR				Hardman, SMC; Cowie, MR			Anticoagulation in heart disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ACUTE MYOCARDIAL-INFARCTION; ATRIAL-FIBRILLATION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ORAL ANTICOAGULATION; RANDOMIZED TRIAL; RISK-FACTORS; WARFARIN; THERAPY; PREVENTION; COMPLICATIONS		UCL, Sch Med, Whittington Hosp, Acad & Clin Dept Cardiovasc Med, London N19 5NF, England; Univ Aberdeen, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland	University of London; University College London; UCL Medical School; University of Aberdeen	Hardman, SMC (corresponding author), UCL, Sch Med, Whittington Hosp, Acad & Clin Dept Cardiovasc Med, Whittington Campus,St Marys Wing, London N19 5NF, England.		Cowie, Martin R/AAQ-2818-2020	Cowie, Martin R/0000-0001-7457-2552	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; [Anonymous], 1986, Arch Neurol, V43, P71; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1994, Lancet, V343, P499; BLACK JW, 1991, CIRCULATION, V89, P2509; Blackshear JL, 1996, LANCET, V348, P633; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; COPPLESTONE A, 1984, ACTA HAEMATOL-BASEL, V71, P376, DOI 10.1159/000206622; DUXBURY BM, 1982, BRIT MED J, V284, P702, DOI 10.1136/bmj.284.6317.702; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; Fitzmaurice DA, 1996, BRIT MED J, V312, P1431, DOI 10.1136/bmj.312.7044.1431; FRIEDMAN GD, 1968, CIRCULATION, V38, P533, DOI 10.1161/01.CIR.38.3.533; Fuster V, 1997, LANCET, V350, P389; Haemostasis and Thrombosis Task Force, 1998, BRIT J HAEMATOL, V101, P374; HARDMAN SMC, 1997, CURRENT ISSUES CARDI; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LEVINE MN, 1989, CHEST, V95, pS26, DOI 10.1378/chest.95.2.26S; LOWN B, 1963, NEW ENGL J MED, V269, P325, DOI 10.1056/NEJM196308152690701; Mahaffey KW, 1996, AM J CARDIOL, V77, P551, DOI 10.1016/S0002-9149(97)89305-8; MANNING WJ, 1993, NEW ENGL J MED, V328, P750, DOI 10.1056/NEJM199303183281102; Manning WJ, 1996, PROG CARDIOVASC DIS, V39, P33, DOI 10.1016/S0033-0620(96)80039-9; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; Oler A, 1996, JAMA-J AM MED ASSOC, V276, P811, DOI 10.1001/jama.276.10.811; PETERSEN P, 1989, LANCET, V1, P175; POLLER L, 1993, J CLIN PATHOL, V46, P299, DOI 10.1136/jcp.46.4.299; RIDKER PM, 1993, ANN INTERN MED, V119, P530, DOI 10.7326/0003-4819-119-6-199309150-00017; SCHMIDT R, 1991, STROKE, V22, P195, DOI 10.1161/01.STR.22.2.195; STODDARD MF, 1995, J AM COLL CARDIOL, V25, P452, DOI 10.1016/0735-1097(94)00396-8; Stoddard MF, 1996, PROG CARDIOVASC DIS, V39, P69, DOI 10.1016/S0033-0620(96)80042-9; Vadher B, 1997, BMJ-BRIT MED J, V314, P1252, DOI 10.1136/bmj.314.7089.1252; Vadher BD, 1995, CLIN LAB HAEMATOL, V17, P339; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; Wallentin L, 1996, LANCET, V347, P561; WHEELDON NM, 1995, EUR HEART J, V16, P302, DOI 10.1093/oxfordjournals.eurheartj.a060911	43	16	16	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 23	1999	318	7178					238	244						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915735				2022-12-28	WOS:000078292300028
J	Topol, EJ; Byzova, TV; Plow, EF				Topol, EJ; Byzova, TV; Plow, EF			Platelet GPIIb-IIIa blockers	LANCET			English	Article							GLYCOPROTEIN-IIB-IIIA; SIGNAL-TRANSDUCTION; LIGAND-BINDING; CELL-ADHESION; INTEGRIN; RECEPTOR; COMPLEX; ACTIVATION; EXPRESSION; THROMBOSIS	Regardless of the event that stimulates the aggregation of platelets, the receptor alpha(IIb)beta(3)-one of a family of adhesion receptors known as integrins-has a key role in the process. The past decade has seen the publication of 10 phase III (randomised) clinical trials of four members of a new class of antiplatelet drugs, the GPIIb-IIIa blockers, targeted at this important receptor. Three (abciximab, eptifibatide, and tirofiban) are licensed for human use. 10 other GbIIb-IIIa blockers are in phase II or III human studies. In all 10 placebo-controlled trials, done in the clinical settings of percutaneous coronary intervention or acute coronary syndrome in patients on aspirin, the endpoints favoured the active drug, with a risk reduction for death or non-fatal myocardial infarction of about 21% overall. With attention to heparin dose the risk of bleeding is not a major concern with these agents. The GPIIb-IIIa blockers are taking the clinician and patient out of the era of aspirin monotherapy when platelet inhibition is required.	Cleveland Clin Fdn, Dept Cardiol F25, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Topol, EJ (corresponding author), Cleveland Clin Fdn, Dept Cardiol F25, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	topole@cesmtp.ccf.org		Byzova, Tatiana/0000-0002-2615-875X; Topol, Eric/0000-0002-1478-4729				[Anonymous], 1882, LANCET, Vi, P111; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Bennett JS, 1996, TRENDS CARDIOVAS MED, V6, P31, DOI 10.1016/1050-1738(95)00126-3; Brener SJ, 1998, CIRCULATION, V98, P734, DOI 10.1161/01.CIR.98.8.734; Byzova TV, 1998, THROMB HAEMOSTASIS, V80, P726; Byzova TV, 1997, J BIOL CHEM, V272, P27183, DOI 10.1074/jbc.272.43.27183; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CALVETE JJ, 1994, THROMB HAEMOSTASIS, V72, P1; DUPERRAY A, 1989, BLOOD, V74, P1603; EGBERTSON MS, 1994, J MED CHEM, V37, P2537, DOI 10.1021/jm00042a007; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; Glanzmann E, 1918, J KINDERKR, V88, P113; Goto S, 1998, J CLIN INVEST, V101, P479, DOI 10.1172/JCI973; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; Harrington RA, 1998, CIRCULATION, V98, P251; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JORDAN RE, 1997, NEW THERAPEUTIC AGEN, P291; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; Lincoff AM, 1998, CIRCULATION, V98, P767; NURDEN AT, 1974, BRIT J HAEMATOL, V28, P253, DOI 10.1111/j.1365-2141.1974.tb06660.x; *PARAGON INV, 1996, CIRCULATION, V94, P553; Peter K, 1998, BLOOD, V92, P3240, DOI 10.1182/blood.V92.9.3240.421k21_3240_3249; Phillips DR, 1997, AM J CARDIOL, V80, pB11, DOI 10.1016/S0002-9149(97)00572-9; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SABOVIC M, 1989, THROMB HAEMOSTASIS, V62, P1083; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Senn S, 1998, LANCET, V352, P85; Shattil SJ, 1997, J CLIN INVEST, V100, pS91; Simoons ML, 1997, LANCET, V349, P1429; Tcheng JE, 1997, LANCET, V349, P1422; Tcheng JE, 1998, CIRCULATION, V98, P17; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 1998, CIRCULATION, V97, P211, DOI 10.1161/01.CIR.97.2.211; Topol EJ, 1997, JAMA-J AM MED ASSOC, V278, P479, DOI 10.1001/jama.278.6.479; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Topol EJ, 1998, LANCET, V352, P1311, DOI 10.1016/S0140-6736(05)70523-7; TOPOL EJ, 1998, AM HEART ASS M DALL; WAGNER CL, 1996, BLOOD, V88, P9907; Walter DH, 1997, LANCET, V350, P1217, DOI 10.1016/S0140-6736(97)05399-3; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703	47	401	420	1	24	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					227	231		10.1016/S0140-6736(98)11086-3	http://dx.doi.org/10.1016/S0140-6736(98)11086-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923894				2022-12-28	WOS:000078175600046
J	Lopez-Girona, A; Furnari, B; Mondesert, O; Russell, P				Lopez-Girona, A; Furnari, B; Mondesert, O; Russell, P			Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein	NATURE			English	Article							CELL-CYCLE CONTROL; FISSION YEAST; EXPORT SIGNAL; SCHIZOSACCHAROMYCES-POMBE; CHECKPOINT PATHWAY; MITOTIC INDUCER; KINASE PATHWAY; CRM1; PHOSPHORYLATION; ACTIVATION	DNA damage activates a cell-cycle checkpoint that prevents mitosis while DNA repair is under way(1). The protein Chk1 enforces this checkpoint by phosphorylating the mitotic inducer Cdc25 (refs 2-6), Phosphorylation of Cdc25 by Chk1 creates a binding site in Cdc25 for 14-3-3 proteins(5-8), but it is not known how 14-3-3 proteins regulate Cdc25. Rad24 is a 14-3-3 protein that is important in the DNA-damage checkpoint in fission yeast(9). Here we show that Rad24 controls the intracellular distribution of Cdc25. Elimination of Rad24 causes nuclear accumulation of Cdc25. Activation of the DNA-damage checkpoint causes the net nuclear export of Cdc25 by a process that requires Chk1, Rad24 and nuclear-export machinery. Mutation of a putative nuclear-export signal in Rad24 impairs the nuclear exclusion of Rad24, the damage-induced nuclear export of Cdc25 and the damage checkpoint. Thus, Rad24 appears to function as an attachable nuclear-export signal that enhances the nuclear export of Cdc25 in response to DNA damage.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Russell, P (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.	prussell@scripps.edu						BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shiozaki K, 1997, METHOD ENZYMOL, V283, P506; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; SUZUKI H, 1970, J ANTIBIOT, V23, P473, DOI 10.7164/antibiotics.23.473; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	30	458	484	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 14	1999	397	6715					172	175		10.1038/16488	http://dx.doi.org/10.1038/16488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923681				2022-12-28	WOS:000078085000049
J	Brentlinger, PE; Hernan, MA; Hernandez-Diaz, S; Azaroff, LS; McCall, M				Brentlinger, PE; Hernan, MA; Hernandez-Diaz, S; Azaroff, LS; McCall, M			Childhood malnutrition and postwar reconstruction in rural El Salvador - A community-based survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY HEALTH-CARE; NUTRITIONAL-STATUS; DEVELOPING-COUNTRIES; CHILDREN; WATER; SURVEILLANCE; SANITATION; EXPERIENCE; MORTALITY	Context The 1992 peace settlement that ended the civil war in El Salvador included land redistribution and other provisions designed to improve the socioeconomic status of ex-combatants and vulnerable civilians. Objective To describe associations between postwar social and economic assistance programs, especially land reform, and current child health status as reflected by nutrition in a population of resettled rural refugees. Design A population-based cross-sectional survey of child nutritional status and principal elements of the reconstruction process. Setting A single rural municipality in northern El Salvador, Participants A representative sample of 761 children younger than 5 years, living in 27 villages. Main Outcome Measure Prevalence of stunting (low height for age) in children younger than 5 years. Results Prevalence of stunting was 32.4%. Stunting was significantly more prevalent among children whose families cultivated less land (odds ratio [OR] for stunting per additional hectare of redistributed land cultivated, 0.64; 95% confidence interval [CI], 0.44-0.93). Less than half of newly transferred land was being cultivated by its owners. Most of the children (84.7%) lived in families cultivating 2 hectares or less of redistributed land. Stunting was also more prevalent among children whose households lacked piped water (adjusted OR, 2.72; 95% CI, 1.87-3.96) vs those who had had piped water since before the cease-fire. Conclusions Malnutrition, particularly stunting, persisted at high levels and was strongly associated with delay in full cultivation of redistributed land and in provision of water.	Phys Human Rights, Boston, MA 02116 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Univ Massachusetts, Work Environm Dept, Lowell, MA USA; Red Deer Reg Hosp, Red Deer, AB, Canada	Harvard University; Harvard T.H. Chan School of Public Health; University of Massachusetts System; University of Massachusetts Lowell	Brentlinger, PE (corresponding author), Phys Human Rights, 100 Boylston St,Suite 702, Boston, MA 02116 USA.							ALLEN LH, 1995, J NUTR, V125, pS1119; Berckmans P, 1997, NEW ENGL J MED, V337, P1842, DOI 10.1056/NEJM199712183372512; BICEGO GT, 1993, SOC SCI MED, V36, P1207, DOI 10.1016/0277-9536(93)90241-U; Brentlinger PE, 1998, INT J GYNECOL OBSTET, V61, P59, DOI 10.1016/S0020-7292(98)00002-2; Brentlinger PE, 1996, BRIT MED J, V313, P1470, DOI 10.1136/bmj.313.7070.1470; BRISCOE J, 1984, AM J PUBLIC HEALTH, V74, P1009, DOI 10.2105/AJPH.74.9.1009; *CDCP, 1994, EPI INF VERS 6 COMP; Diskin M, 1996, LAT AM RES REV, V31, P111; Durham W, 1979, SCARCITY SURVIVAL CE; EISENBERG C, 1983, NEW ENGL J MED, V308, P1028; EISENBERG C, 1990, EL SALVADOR HLTH CAR; ESREY SA, 1986, EPIDEMIOL REV, V8, P117, DOI 10.1093/oxfordjournals.epirev.a036290; GEIGER J, 1989, NEW ENGL J MED, V321, P1136, DOI 10.1056/NEJM198910193211629; GELLHORN A, 1983, CLEARINGHOUSE REP SC, V5, P1; GOLDEN MHN, 1994, EUR J CLIN NUTR, V48, pS58; *GOV EL SALV FAR M, 1992, EL AC PAZ EL SALV AC, V1; GrummerStrawn LM, 1996, B WORLD HEALTH ORGAN, V74, P369; Gutierrez G, 1996, B WORLD HEALTH ORGAN, V74, P189; Haas JD, 1996, NUTR REV, V54, pS41, DOI 10.1111/j.1753-4887.1996.tb03869.x; HERTZ E, 1994, SOC SCI MED, V39, P105, DOI 10.1016/0277-9536(94)90170-8; Martorell R, 1996, NUTR REV, V54, pS66; MARTORELL R, 1994, EUR J CLIN NUTR, V48, pS45; MARTORELL R, 1988, LINEAR GROWTH RETARD, V14; *NAT BIP COMM CENT, 1984, 040000004777 S N NAT; NEUMANN CG, 1994, EUR J CLIN NUTR, V48, pS90; OKUN DA, 1988, AM J PUBLIC HEALTH, V78, P1463, DOI 10.2105/AJPH.78.11.1463; PELLETIER DL, 1991, SOC SCI MED, V32, P887, DOI 10.1016/0277-9536(91)90244-7; POLLITT E, 1995, J NUTR, V125, pS1111; PROSTERMAN RL, 1976, COMP POLIT, V8, P339, DOI 10.2307/421404; Rawson I G, 1976, J Trop Pediatr Environ Child Health, V22, P12; RUEL MT, 1995, J NUTR, V125, P1222; Russbach R., 1994, MED GLOBAL SURVIVAL, V1, P188; SELIGSON MA, 1995, LAT AM RES REV, V30, P43; SIMON LR, 1981, EL SALVADOR REFORM 1; SPENCE J, 1997, CHAPULTEPECS 5 YEARS; STETLER HC, 1981, AM J TROP MED HYG, V30, P888, DOI 10.4269/ajtmh.1981.30.888; TAYLOR CE, 1992, INT J EPIDEMIOL, V21, P1043, DOI 10.1093/ije/21.6.1043; Torres-Rivas Edelberto, 1989, INTERPRETACION DESAR; TROWBRIDGE FL, 1979, AM J TROP MED HYG, V28, P135; *UN COM VERD EL SA, 1993, LOC ESP GUERR DOC AN; VALVERDE V, 1977, Ecology of Food and Nutrition, V6, P1, DOI 10.1080/03670244.1977.9990474; VICTORA CG, 1992, J NUTR, V122, P1105, DOI 10.1093/jn/122.5.1105; World Health Organization Expert Committee on Physical Status, 1995, WHO TECHN REP SER, V854; YUSUF ME, 1993, TROP GEOGR MED, V45, P93; 1995, LANCET, V345, P529; [No title captured]	46	14	15	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					184	190		10.1001/jama.281.2.184	http://dx.doi.org/10.1001/jama.281.2.184			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	155VJ	9917125				2022-12-28	WOS:000077966800042
J	Kessler, D; Lloyd, K; Lewis, G; Gray, DP				Kessler, D; Lloyd, K; Lewis, G; Gray, DP			Cross sectional study of symptom attribution and recognition of depression and anxiety in primary care	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; SOMATIC PRESENTATION; CONTROLLED TRIAL; SOMATIZATION	Objectives To examine the effect of patients' causal attributions of common somatic symptoms on recognition by general practitioners of cases of depression and anxiety and to test the hypothesis that normalising attributions make recognition less likely. Design Cross sectional survey. Setting One general practice of eight doctors in Bristol. Subjects 305 general practice attenders. Main outcome measure The rate of detection by general health questionnaire and the symptom interpretation questionnaire, which scores style of symptom attribution along the dimensions of psychologising, somatising, and normalising. General practitioners detected depression or anxiety in 56 (36%; 95% confidence interval 28% to 44%) of the 157 patients who scored highly on the general health questionnaire. Subjects with a normalising attributional style were less likely to be detected as cases; doctors did not make any psychological diagnosis in 46 (85%; 73% to 93%) of 54 patients who had high questionnaire and high normalising scores. Those with a psychologising style were more likely to be detected; doctors did not detect 21 (38%; 25% to 52%) of 55 patients who had high questionnaire and high psychologising scores. The somatisation scale was not associated with low detection rates. This pattern of results persisted after adjustment for age, sex, general health questionnaire score, and general practitioner. Conclusions Normalising attributions minimise symptoms and are non-pathological in character. The normalising attributional style is predominant in general practice attenders and is an important cause of low rates of detection of depression and anxiety.	Univ Exeter, Postgrad Med Sch, Inst Gen Practice, Exeter EX2 5DW, Devon, England; Univ Exeter, Wonford House Hosp, Dept Mental Hlth, Exeter EX2 5AF, Devon, England; Univ Wales Coll Med, Div Psychol Med, Cardiff CF4 4XN, S Glam, Wales	University of Exeter; University of Exeter; Cardiff University	Kessler, D (corresponding author), Gaywood House Surg, North St, Bristol BS3 3AZ, Avon, England.		lloyd, keith/H-7458-2012; Lewis, Glyn/E-9944-2012	Lewis, Glyn/0000-0001-5205-8245; PEREIRA GRAY, DENIS/0000-0001-7917-3841				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BASHIR K, 1996, PRIMARY CARE PSYCHIA, V2, P4; BLACKBURN IM, 1981, BRIT J PSYCHIAT, V139, P181, DOI 10.1192/bjp.139.3.181; BRIDGES K, 1991, PSYCHOL MED, V21, P473, DOI 10.1017/S0033291700020584; BRIDGES KW, 1985, J PSYCHOSOM RES, V29, P563, DOI 10.1016/0022-3999(85)90064-9; DOWRICK C, 1995, BMJ-BRIT MED J, V311, P1274, DOI 10.1136/bmj.311.7015.1274; GASK L, 1989, J PSYCHOSOM RES, V33, P697, DOI 10.1016/0022-3999(89)90085-8; Goldberg D, 1991, USERS GUIDE GEN HLTH; Goldberg DP., 1992, COMMON MENTAL DISORD; HOLLYMAN JA, 1988, J ROY COLL GEN PRACT, V38, P393; JOHNSTONE A, 1976, LANCET, V1, P605, DOI 10.1016/S0140-6736(76)90415-3; Kelley HH., 1971, ATTRIBUTION PERCEIV, P1, DOI DOI 10.1007/s10803-014-2195-6; KING J, 1983, ATTRIBUTION THEORY S, P170; KIRMAYER LJ, 1993, AM J PSYCHIAT, V150, P734; ROBBINS JM, 1991, PSYCHOL MED, V21, P1029, DOI 10.1017/S0033291700030026; Shepherd M, 1966, PSYCHIAT ILLNESS GEN; *STAT, 1997, STAT STAT SOFTW VERS; WEICH S, 1995, BRIT J GEN PRACT, V45, P143; ZUNG WWK, 1983, J CLIN PSYCHIAT, V44, P3	19	279	282	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1999	318	7181					436	439		10.1136/bmj.318.7181.436	http://dx.doi.org/10.1136/bmj.318.7181.436			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	168BF	9974461	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000078670100029
J	McManus, JF; Oppo, DW; Cullen, JL				McManus, JF; Oppo, DW; Cullen, JL			A 0.5-million-year record of millennial-scale climate variability in the North Atlantic	SCIENCE			English	Article							LAST GLACIAL MAXIMUM; DEEP-SEA SEDIMENTS; OXYGEN ISOTOPES; GREENLAND ICE; OCEAN CIRCULATION; HEINRICH EVENTS; SOUTHERN-OCEAN; SURFACE; TEMPERATURE; HOLOCENE	Long, continuous, marine sediment records from the subpolar North Atlantic document the glacial modulation of regional climate instability throughout the past 0.5 million years. Whenever ice sheet size surpasses a critical threshold indicated by the benthic oxygen isotope (delta(18)O) value of 3.5 per mil during each of the past five glaciation cycles, indicators of iceberg discharge and sea-surface temperature display dramatically Larger amplitudes of millennial-scale variability than when ice sheets are small. Sea-surface temperature oscillations of 1 degrees to 2 degrees C increase in size to approximately 4 degrees to 6 degrees C, and catastrophic iceberg discharges begin alternating repeatedly with brief quiescent intervals. The glacial growth associated with this amplification threshold represents a relatively small departure from the modern ice sheet configuration and sea level. Instability characterizes nearly all observed climate states, with the exception of a Limited range of baseline conditions that includes the current Holocene interglacial.	Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; Salem State Coll, Salem, MA 01970 USA	Woods Hole Oceanographic Institution; Massachusetts System of Public Higher Education; Salem State University	McManus, JF (corresponding author), Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA.	jmcmanus@whoi.edu						Alley RB, 1997, GEOLOGY, V25, P483, DOI 10.1130/0091-7613(1997)025<0483:HCIAPW>2.3.CO;2; Baumgartner A., 1975, WORLD WATER BALANCE, P1; Be A.W.H., 1971, MICROPALEONTOLOGY OC, P105; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; BOND G, 1992, NATURE, V360, P245, DOI 10.1038/360245a0; BOND G, 1993, NATURE, V365, P143, DOI 10.1038/365143a0; BOYLE EA, 1987, NATURE, V330, P35, DOI 10.1038/330035a0; BRAMLETTE MN, 1941, 196A USGS; Broecker W. S, 1984, MILANKOVITCH CLIMA 2, V126, P687; Broecker W, 1992, CLIM DYNAM, V6, P265, DOI 10.1007/BF00193540; Broecker WS, 1990, PALEOCEANOGRAPHY, V5, P469, DOI 10.1029/PA005i004p00469; BROECKER WS, 1970, REV GEOPHYS SPACE GE, V8, P169, DOI 10.1029/RG008i001p00169; BROECKER WS, 1985, NATURE, V315, P21, DOI 10.1038/315021a0; BURCKLE LH, 1993, QUATERNARY SCI REV, V12, P825, DOI 10.1016/0277-3791(93)90021-D; CHAPPELL J, 1986, NATURE, V324, P137, DOI 10.1038/324137a0; CORTIJO E, 1994, NATURE, V372, P446, DOI 10.1038/372446a0; DANSGAARD W, 1989, PHYS CH EAR, V8, P287; Denton G. H., 1981, LAST GREAT ICE SHEET, P440; Duplessy JC, 1988, PALEOCEANOGRAPHY, V3, P343, DOI 10.1029/PA003i003p00343; DUPLESSY JC, 1991, OCEANOL ACTA, V14, P311; Duplessy JC, 1996, GEOL SOC SP, P167, DOI 10.1144/GSL.SP.1996.111.01.11; EMILIANI C, 1955, J GEOL, V63, P538, DOI 10.1086/626295; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; GROUSSET FE, 1993, PALEOCEANOGRAPHY, V8, P175, DOI 10.1029/92PA02923; HEINRICH H, 1988, QUATERNARY RES, V29, P142, DOI 10.1016/0033-5894(88)90057-9; HODELL DA, 1993, PALEOCEANOGRAPHY, V8, P47, DOI 10.1029/92PA02774; Howard WR, 1997, NATURE, V388, P418, DOI 10.1038/41201; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; Keigwin LD, 1996, SCIENCE, V274, P1504, DOI 10.1126/science.274.5292.1504; KEIGWIN LD, 1989, DEEP-SEA RES, V36, P845, DOI 10.1016/0198-0149(89)90032-0; Kim ST, 1997, GEOCHIM COSMOCHIM AC, V61, P3461, DOI 10.1016/S0016-7037(97)00169-5; KIPP NG, 1976, GEOL SOC AM MEM, V145, P3, DOI DOI 10.1130/MEM145-P3; KROOPNICK P, 1980, EARTH PLANET SC LETT, V49, P469, DOI 10.1016/0012-821X(80)90088-6; LABEYRIE L, 1995, PHILOS T ROY SOC B, V348, P255, DOI 10.1098/rstb.1995.0067; LABEYRIE LD, 1987, NATURE, V327, P477, DOI 10.1038/327477a0; MACAYEAL DR, 1993, PALEOCEANOGRAPHY, V8, P775, DOI 10.1029/93PA02200; MANABE S, 1985, J GEOPHYS RES-ATMOS, V90, P2167, DOI 10.1029/JD090iD01p02167; Manabe S, 1988, J CLIMATE, V1, P841, DOI 10.1175/1520-0442(1988)001<0841:TSEOAC>2.0.CO;2; MARTINSON DG, 1987, QUATERNARY RES, V27, P1, DOI 10.1016/0033-5894(87)90046-9; Mayewski PA, 1997, J GEOPHYS RES-OCEANS, V102, P26345, DOI 10.1029/96JC03365; McIntyre A., 1976, Science, V191, P1131, DOI 10.1126/science.191.4232.1131; McIntyre A, 1996, SCIENCE, V274, P1867, DOI 10.1126/science.274.5294.1867; McManus JF, 1998, EARTH PLANET SC LETT, V155, P29, DOI 10.1016/S0012-821X(97)00201-X; OESCHGER H, 1984, CLIMATE PROCESSES CL, V5, P299; Oppo DW, 1998, SCIENCE, V279, P1335, DOI 10.1126/science.279.5355.1335; OPPO DW, 1987, EARTH PLANET SC LETT, V86, P1, DOI 10.1016/0012-821X(87)90183-X; OPPO DW, 1993, SCIENCE, V259, P1148, DOI 10.1126/science.259.5098.1148; Oppo DW, 1997, PALEOCEANOGRAPHY, V12, P51, DOI 10.1029/96PA03133; Pflaumann U, 1996, PALEOCEANOGRAPHY, V11, P15, DOI 10.1029/95PA01743; Raymo ME, 1998, NATURE, V392, P699, DOI 10.1038/33658; RUDDIMAN WF, 1977, GEOL SOC AM BULL, V88, P1813, DOI 10.1130/0016-7606(1977)88<1813:LQDOIS>2.0.CO;2; RUDDIMAN WF, 1976, GEOL SOC AM MEM, V145, P3; Sakai K, 1997, J CLIMATE, V10, P949, DOI 10.1175/1520-0442(1997)010<0949:DOOIAC>2.0.CO;2; Schrag DP, 1996, SCIENCE, V272, P1930, DOI 10.1126/science.272.5270.1930; SHACKLETON NJ, 1984, NATURE, V307, P620, DOI 10.1038/307620a0; SHACKLETON NJ, 1987, QUATERNARY SCI REV, V6, P183, DOI 10.1016/0277-3791(87)90003-5; SHACKLETON NJ, 1990, T ROY SOC EDIN-EARTH, V81, P251, DOI 10.1017/S0263593300020782; Spero HJ, 1997, NATURE, V390, P497, DOI 10.1038/37333; vanKreveld SA, 1996, MAR GEOL, V131, P21, DOI 10.1016/0025-3227(95)00143-3; WEAVER AJ, 1994, NATURE, V367, P447, DOI 10.1038/367447a0; WILLIAMS R. S, 1993, ATLAS SATELLITE OBSE, P401	62	620	660	1	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 12	1999	283	5404					971	975		10.1126/science.283.5404.971	http://dx.doi.org/10.1126/science.283.5404.971			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974387				2022-12-28	WOS:000078574800044
J	Vroomen, PCAJ; de Krom, MCTFM; Wilmink, JT; Kester, ADM; Knottnerus, JA				Vroomen, PCAJ; de Krom, MCTFM; Wilmink, JT; Kester, ADM; Knottnerus, JA			Lack of effectiveness of bed rest for sciatica	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-BACK-PAIN; MUSCULOSKELETAL; IMMOBILIZATION; COMPLICATIONS; TRIAL	Background and Methods Bed rest is widely advocated for sciatica, but its effectiveness has not been established. To study the effectiveness of bed rest in patients with a lumbosacral radicular syndrome of sufficient severity to justify treatment with bed rest for two weeks, we randomly assigned 183 subjects to either bed rest or watchful waiting for this period. The primary outcome measures were the investigator's and patient's global assessments of improvement after 2 and 12 weeks, and the secondary outcome measures were changes in functional status and in pain scores (after 2, 3, and 12 weeks), absenteeism from work, and the need for surgical intervention. Neither the investigators who assessed the outcomes nor those involved in data entry and analysis were aware of the patients' treatment assignments. Results After two weeks, 64 of the 92 patients in the bed-rest group (70 percent) reported improvement, as compared with 59 of the 91 patients in the control (watchful-waiting) group (65 percent) (adjusted odds ratio for improvement in the bed-rest group, 1.2; 95 percent confidence interval, 0.6 to 2.3). After 12 weeks, 87 percent of the patients in both groups reported improvement. The results of assessments of the intensity of pain, the bothersomeness of symptoms, and functional status revealed no significant differences between the two groups. The extent of absenteeism from work and rates of surgical intervention were similar in the two groups. Conclusions Among patients with symptoms and signs of a lumbosacral radicular syndrome, bed rest is not a more effective therapy than watchful waiting. (N Engl J Med 1999;340:418-23.) (C) 1999, Massachusetts Medical Society.	Maastricht Univ Hosp, Dept Neurol, NL-6202 AZ Maastricht, Netherlands; Maastricht Univ Hosp, Dept Radiol, NL-6202 AZ Maastricht, Netherlands; Maastricht Univ, Dept Methodol & Stat, Maastricht, Netherlands; Maastricht Univ, Dept Family Practice, Maastricht, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University	Vroomen, PCAJ (corresponding author), Maastricht Univ Hosp, Dept Neurol, P Debyelaan 25,POB 5800, NL-6202 AZ Maastricht, Netherlands.	pvr@sncu.azm.nl	Knottnerus, Andre/F-4866-2013; Knottnerus, Johannes A/A-3829-2009; Vroomen, Patrick C.A.J./O-3664-2014	Vroomen, Patrick C.A.J./0000-0003-4806-417X				Altman D.G., 1991, PRACTICAL STAT MED R; BEURSKENS AJ, 1995, SPINE, V20, P1017, DOI 10.1097/00007632-199505000-00008; BONDEPETERSEN F, 1994, ACTA PHYSIOL SCAND, V150, P65; Convertino VA, 1997, MED SCI SPORT EXER, V29, P187, DOI 10.1097/00005768-199702000-00004; COOMES EN, 1961, BMJ-BRIT MED J, V264, P20; COX DR, 1972, J R STAT SOC B, V34, P187; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DEYO RA, 1992, JAMA-J AM MED ASSOC, V268, P760, DOI 10.1001/jama.268.6.760; DEYO RA, 1986, SPINE, V11, P951, DOI 10.1097/00007632-198611000-00017; DEYO RA, 1983, JAMA-J AM MED ASSOC, V250, P1057; DITTMER DK, 1993, CAN FAM PHYSICIAN, V39, P1428; Dittmer DK, 1993, CAN FAM PHYS, V39, P1435; FERRANDO AA, 1995, AVIAT SPACE ENVIR MD, V66, P976; FORDYCE WE, 1988, AM PSYCHOL, V43, P276, DOI 10.1037/0003-066X.43.4.276; HAERER AF, 1992, DEJONGS NEUROLOGICAL, P596; HSIEH CYJ, 1992, J MANIP PHYSIOL THER, V15, P4; KLEINBAUM DG, 1994, LOGISTIC REGRESSION, P282; KOES BW, 1994, EUR J PHYS MED REHAB, V4, P86; Levine BD, 1997, CIRCULATION, V96, P517; LINTON SJ, 1993, PAIN, V54, P353, DOI 10.1016/0304-3959(93)90037-P; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; Melzack R, 1994, TXB PAIN, P337; PEDERSEN BJ, 1995, BONE, V17, P91, DOI 10.1016/8756-3282(95)00149-8; Pocock SJ., 2013, CLIN TRIALS PRACTICA; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; SUZUKI Y, 1994, ACTA PHYSIOL SCAND, V150, P5; TAKENAKA K, 1994, ACTA PHYSIOL SCAND, V150, P59; TEASELL R, 1993, CAN FAM PHYSICIAN, V39, P1440; VANLEEUWEN RB, 1986, MED CONTACT, V50, P1618; Waddell G, 1997, BRIT J GEN PRACT, V47, P647	30	122	131	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1999	340	6					418	423		10.1056/NEJM199902113400602	http://dx.doi.org/10.1056/NEJM199902113400602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166HW	9971865				2022-12-28	WOS:000078571000002
J	[Anonymous]				[Anonymous]			BMA ends link with Healthcall	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																		1997, BRIT MED J, V315, P132	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 6	1999	318	7180					403	403						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933226				2022-12-28	WOS:000078572600074
J	Iglehart, JK				Iglehart, JK			The American health care system - Medicaid	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		ATON G, 1998, AM MED NEWS     1214, P5; Bartels PL, 1998, HEALTH AFFAIR, V17, P165, DOI 10.1377/hlthaff.17.6.165; Berk ML, 1998, HEALTH AFFAIR, V17, P169, DOI 10.1377/hlthaff.17.3.169; BOVBJERG RR, 1998, 17 URB I; BRODER DS, 1998, WASHINGTON POST 1231, pA25; BRODER DS, 1999, WASHINGTON POST 0103, pC7; Budetti PP, 1998, NEW ENGL J MED, V338, P541, DOI 10.1056/NEJM199802193380809; COHEN W, 1985, HLTH CARE FINANC R S; COLBY DC, 1994, HEALTH AFFAIR, V13, P255, DOI 10.1377/hlthaff.13.2.255; Coughlin TA, 1998, HEALTH AFFAIR, V17, P118, DOI 10.1377/hlthaff.17.3.118; Ellwood MR, 1998, HEALTH AFFAIR, V17, P137, DOI 10.1377/hlthaff.17.3.137; Friedman E, 1998, Front Health Serv Manage, V14, P3; FRONSTIN P, 1998, SOURCES HLTH INS CHA; Holahan J, 1998, HEALTH AFFAIR, V17, P43, DOI 10.1377/hlthaff.17.3.43; HOLAHAN JJ, 1998, 18 URB I; HURLEY RE, 1998, MEDICAID COMMERCIAL; Iglehart JK, 1999, NEW ENGL J MED, V340, P327, DOI 10.1056/NEJM199901283400424; Iglehart JK, 1999, NEW ENGL J MED, V340, P70, DOI 10.1056/NEJM199901073400122; IGLEHART JK, 1993, NEW ENGL J MED, V328, P896, DOI 10.1056/NEJM199303253281226; KENESSON M, 1998, MEDICAID MANAGED CAR; KONDRATAS A, 1998, HLTH AFF MILLWOOD, V17, P43; Kuttner R, 1999, NEW ENGL J MED, V340, P248, DOI 10.1056/NEJM199901213400324; Kuttner R, 1999, NEW ENGL J MED, V340, P163, DOI 10.1056/NEJM199901143400226; LEVIT K, 1998, HLTH AFF MILLWOOD, V17, P66; McCue MJ, 1999, HEALTH AFFAIR, V18, P223, DOI 10.1377/hlthaff.18.1.223; Newacheck PW, 1998, NEW ENGL J MED, V338, P513, DOI 10.1056/NEJM199802193380806; Nichols LM, 1998, HEALTH AFFAIR, V17, P25, DOI 10.1377/hlthaff.17.3.25; NORTON SA, 1998, 19 URB I; Pear Robert, 1998, N Y Times Web, pA10; Rajan S, 1998, HEALTH AFFAIR, V17, P101, DOI 10.1377/hlthaff.17.3.101; SCHNEIDER A, 1998, MED ELIGIBILITY FAMI; Selden TM, 1998, HEALTH AFFAIR, V17, P192, DOI 10.1377/hlthaff.17.3.192; SMITH V, 1998, DYNAMICS CURRENT MED; Spitz B, 1998, HEALTH AFFAIR, V17, P150, DOI 10.1377/hlthaff.17.6.150; TALLON JR, 1998, MEDICAID DEVOLUTION; Wall S, 1998, HEALTH AFFAIR, V17, P64, DOI 10.1377/hlthaff.17.3.64; WIENER J, 1998, 12 URB I; Wiener JM, 1998, HEALTH AFFAIR, V17, P81, DOI 10.1377/hlthaff.17.3.81; Wiener JM, 1998, 22 URB I; WIENER JM, 1998, REPEAL BOREN AMEND A; [No title captured]	41	50	50	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1999	340	5					403	408		10.1056/NEJM199902043400525	http://dx.doi.org/10.1056/NEJM199902043400525			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163WC	9929536				2022-12-28	WOS:000078428500030
J	Saha, S; Saint, S; Tierney, LM				Saha, S; Saint, S; Tierney, LM			A balancing act	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BACTERIAL-MENINGITIS; COMPUTED-TOMOGRAPHY; LUMBAR PUNCTURE; RISKS		Univ Michigan, Med Ctr, Taubman Ctr 3116P, Div Gen Internal Med, Ann Arbor, MI 48109 USA; Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA; Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco	Saint, S (corresponding author), Univ Michigan, Med Ctr, Taubman Ctr 3116P, Div Gen Internal Med, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.		Rynning, Sten/AAL-5863-2020; Saint, Sanjay/AAF-5126-2019	Rynning, Sten/0000-0002-1497-3677; 				ARCHER BD, 1993, CAN MED ASSOC J, V148, P961; Baker Nancy D., 1994, Journal of Emergency Medicine, V12, P597, DOI 10.1016/0736-4679(94)90409-X; deShazo RD, 1997, JAMA-J AM MED ASSOC, V278, P1895, DOI 10.1001/jama.278.22.1895; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; FRANCKE EL, 1987, MED CLIN N AM, V71, P1155, DOI 10.1016/S0025-7125(16)30803-3; MELLOR D, 1992, ARCH DIS CHILD, V67, P1417, DOI 10.1136/adc.67.12.1417; MOSKOWITZ AJ, 1988, ANN INTERN MED, V108, P435, DOI 10.7326/0003-4819-108-3-435; Quagliarello VJ, 1997, NEW ENGL J MED, V336, P708, DOI 10.1056/NEJM199703063361007; RENNICK G, 1993, BRIT MED J, V306, P953, DOI 10.1136/bmj.306.6883.953; Sanford JP, 1997, SANFORD GUIDE ANTIMI	10	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1999	340	5					374	378		10.1056/NEJM199902043400508	http://dx.doi.org/10.1056/NEJM199902043400508			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163WC	9929529				2022-12-28	WOS:000078428500008
J	Earnest, DJ; Liang, FQ; Ratcliff, M; Cassone, VM				Earnest, DJ; Liang, FQ; Ratcliff, M; Cassone, VM			Immortal time: Circadian clock properties of rat suprachiasmatic cell lines	SCIENCE			English	Article							NUCLEUS; DROSOPHILA	Cell lines derived from the rat suprachiasmatic nucleus (SCN) were screened for circadian clock properties distinctive of the SCN in situ. Immortalized SCN cells generated robust rhythms in uptake of the metabolic marker 2-deoxyglucose and in their content of neurotrophins. The phase relationship between these rhythms in vitro was identical to that exhibited by the SCN in vivo. Transplantation of SCN cell lines, but not mesencephalic or fibroblast Lines, restored the circadian activity rhythm in arrhythmic, SCN-lesioned rats. Thus, distinctive oscillator, pacemaker, and clock properties of the SCN are not only retained but also maintained in an appropriate circadian phase relationship by immortalized SCN progenitors.	Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Human Anat & Med Neurobiol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station	Earnest, DJ (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Human Anat & Med Neurobiol, College Stn, TX 77843 USA.	dearnest@tamu.edu	Cassone, Vincent/AAD-5191-2022	Earnest, David/0000-0003-4433-6481	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035822] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35822] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; EARNEST DJ, IN PRESS J NEUROBIOL; *HOUGHT MIFFL, 1979, AM HER DICT ENGL LAN; Liang FQ, 1998, EXP NEUROL, V151, P184, DOI 10.1006/exnr.1998.6804; Liang FQ, 1998, NEUROSCI LETT, V242, P89, DOI 10.1016/S0304-3940(98)00062-7; MOORE RY, 1983, FED PROC, V42, P2783; NEWMAN GC, 1990, J CEREBR BLOOD F MET, V10, P510, DOI 10.1038/jcbfm.1990.93; NEWMAN GC, 1986, BRAIN RES, V381, P345, DOI 10.1016/0006-8993(86)90086-7; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Schwartz WJ, 1991, SUPRACHIASMATIC NUCL, P144; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	17	105	107	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					693	695		10.1126/science.283.5402.693	http://dx.doi.org/10.1126/science.283.5402.693			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924030				2022-12-28	WOS:000078324400044
J	Qin, XF; Schwers, S; Yu, W; Papavasiliou, F; Suh, HY; Nussenzweig, A; Rajewsky, K; Nussenzweig, MC				Qin, XF; Schwers, S; Yu, W; Papavasiliou, F; Suh, HY; Nussenzweig, A; Rajewsky, K; Nussenzweig, MC			Secondary V(D)J recombination in B-1 cells	NATURE			English	Article							LY-1 B-CELLS; TRANSGENIC MOUSE; MICE; GENE; LYMPHOCYTES; ANTIGEN; EXPRESSION; TOLERANCE; RESPONSES; APOPTOSIS	B-1 B cells are a self-renewing population of B cells that differ from conventional B cells (B-2 cells) in that they are particularly predisposed to auto-antibody production(1-3). Although much is known about the signalling pathways that control B-1-cell growth and development (reviewed in ref. 4), less is known about why these cells are prone to produce autoreactive antibodies. Here we show that B-1 cells, like germinal-centre B cells(5-8), can express recombinase-activating genes 1 and 2 (RAG1 and RAG2) and undergo secondary V(D)J recombination of immunoglobulin genes. In addition, B cells from autoimmune-prone NZB mice show high levels of RAG messenger RNA and recombination. We propose that secondary immunoglobulin-gene rearrangements outside organized lymphoid organs may contribute to the development of autoreactive antibodies.	Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Univ Cologne, Inst Genet, D-50931 Cologne, Germany	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Cologne	Nussenzweig, MC (corresponding author), Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.	nussen@rockvax.rockefeller.edu	Nussenzweig, Michel/AAE-7292-2019	QIN, FRANK XIAOFENG/0000-0002-5395-0304; Rajewsky, Klaus/0000-0002-6633-6370				ARNOLD LW, 1994, J EXP MED, V179, P1585, DOI 10.1084/jem.179.5.1585; Cascalho M, 1997, J IMMUNOL, V159, P5795; EHLICH A, 1994, CURR BIOL, V4, P573, DOI 10.1016/S0960-9822(00)00129-9; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; HAYAKAWA K, 1985, J EXP MED, V161, P1554, DOI 10.1084/jem.161.6.1554; HAYAKAWA K, 1984, P NATL ACAD SCI-BIOL, V81, P2494, DOI 10.1073/pnas.81.8.2494; HAYAKAWA K, 1983, J EXP MED, V157, P202, DOI 10.1084/jem.157.1.202; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; LALOR PA, 1989, EUR J IMMUNOL, V19, P501, DOI 10.1002/eji.1830190314; MURAKAMI M, 1994, J EXP MED, V180, P111, DOI 10.1084/jem.180.1.111; Murakami M, 1997, J EXP MED, V185, P791, DOI 10.1084/jem.185.4.791; MURAKAMI M, 1992, NATURE, V357, P77, DOI 10.1038/357077a0; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Papavasiliou F, 1997, SCIENCE, V278, P298, DOI 10.1126/science.278.5336.298; Pelanda R, 1996, IMMUNITY, V5, P229, DOI 10.1016/S1074-7613(00)80318-0; Pelanda R, 1997, IMMUNITY, V7, P765, DOI 10.1016/S1074-7613(00)80395-7; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; Sonoda E, 1997, IMMUNITY, V6, P225, DOI 10.1016/S1074-7613(00)80325-8; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STALL AM, 1988, P NATL ACAD SCI USA, V85, P3546, DOI 10.1073/pnas.85.10.3546; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TAKI S, 1993, SCIENCE, V262, P1268, DOI 10.1126/science.8235657; Tarakhovsky A, 1997, J EXP MED, V185, P981, DOI 10.1084/jem.185.6.981; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TSUBATA T, 1994, CURR BIOL, V4, P8, DOI 10.1016/S0960-9822(00)00003-8	30	60	61	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 28	1999	397	6717					355	359		10.1038/16933	http://dx.doi.org/10.1038/16933			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9950428				2022-12-28	WOS:000078324600051
J	Gregoire, A				Gregoire, A			Male sexual problems	BRITISH MEDICAL JOURNAL			English	Review									Old Manor Hosp, Salisbury, Wilts, England; Univ Southampton, Southampton SO9 5NH, Hants, England	University of Southampton	Gregoire, A (corresponding author), Old Manor Hosp, Salisbury, Wilts, England.							BRETSCHNEIDER JG, 1988, ARCH SEX BEHAV, V17, P109, DOI 10.1007/BF01542662; Cranston-Cuebas MA., 1990, ANN REV SEX RES, V1, P119, DOI 10.1080/10532528.1990.10559858; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; HIRSHKOWITZ M, 1992, UROLOGY, V39, P101, DOI 10.1016/0090-4295(92)90263-V; ROSEN RC, 1995, J CONSULT CLIN PSYCH, V63, P877, DOI 10.1037/0022-006X.63.6.877	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1999	318	7178					245	247						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915737				2022-12-28	WOS:000078292300029
J	Veenstra, DL; Saint, S; Saha, S; Lumley, T; Sullivan, SD				Veenstra, DL; Saint, S; Saha, S; Lumley, T; Sullivan, SD			Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							BLOOD-STREAM INFECTION; CONTROLLED TRIAL; BACTERIAL-COLONIZATION; QUALITY; SEPSIS; DIAGNOSIS; CULTURE; COSTS	Context Central venous catheters impregnated with chlorhexidine and silver sulfadiazine have recently been introduced for the prevention of catheter-related infections, However, there remains some uncertainty regarding the efficacy of these catheters because of conflicting reports in the literature. Objective To evaluate the efficacy of chlorhexidine-silver sulfadiazine-impregnated central venous catheters in the prevention of catheter-related bloodstream infection. Data Sources Studies identified from a computerized search of the MEDLINE database from January 1966 to January 1998, reference lists of identified articles, and queries of principal investigators and the catheter manufacturer. Study Selection Randomized trials comparing chlorhexidine-silver sulfadiazine-impregnated central venous catheters with nonimpregnated catheters were included. The outcomes assessed were catheter colonization and catheter-related bloodstream infection confirmed by catheter culture. Data Extraction Twelve studies met the inclusion criteria for catheter colonization and included a total of 2611 catheters, Eleven studies with a total of 2603 catheters met the inclusion criteria for catheter-related bloodstream infection, Most patients in these studies were from groups considered to be at high risk for catheter-related infections. Summary statistics were calculated using Mantel-Haenszel methods under a fixed-effects model. Data Synthesis The summary odds ratio for catheter colonization was 0.44 (95% confidence interval [CI], 0.36-0.54; P<.001), indicating a significant decrease in catheter colonization associated with impregnated catheters. The studies examining the outcome of primary interest, catheter-related bloodstream infection, had a summary odds ratio of 0.56 (95% CI, 0.37-0.84; P =.005). Conclusions Central venous catheters impregnated with a combination of chlorhexidine and silver sulfadiazine appear to be effective in reducing the incidence of both catheter colonization and catheter-related bloodstream infection in patients at high risk for catheter-related infections.	Univ Washington, Sch Pharm, Dept Pharm, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Veenstra, DL (corresponding author), Univ Washington, Sch Pharm, Dept Pharm, POB 357630, Seattle, WA 98195 USA.	veenstra@u.washington.edu	Saint, Sanjay/AAF-5126-2019		AHRQ HHS [HS07834-03S1, HS/HL08368-01A1] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1997, CENTR VEN CATH ARR R; Appavu S. K., 1994, Chest, V106, p176S; Bach A, 1996, J ANTIMICROB CHEMOTH, V37, P315, DOI 10.1093/jac/37.2.315; Bach A, 1995, ZBL BAKT-INT J MED M, V283, P140; Bach A, 1995, ZBL BAKT-INT J MED M, V283, P208; BACH A, 1994, ANESTHESIOLOGY, V81, pA261; BACH A, 1993, 33 INT C ANT AG CHEM; BOOTH FVM, 1996, CRIT CARE MED S1, V24, pA45; Ciresi DL, 1996, AM SURGEON, V62, P641; Civetta JM, 1996, CRIT CARE MED, V24, P1660, DOI 10.1097/00003246-199610000-00010; CLEMENCE MA, 1994, 34 INT C ANT AG CHEM; COBB DK, 1992, NEW ENGL J MED, V327, P1062, DOI 10.1056/NEJM199210083271505; COLLIN GR, IN PRESS CHEST; *CTR DEV RAD HLTH, 1998, POT HYP REACT CHLORH; DAROUICHE R, 1998, CRIT CARE MED S, V26, pA128; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; FAN ST, 1989, EUR J CLIN MICROBIOL, V8, P142, DOI 10.1007/BF01963898; George SJ, 1997, EUR J ANAESTH, V14, P428, DOI 10.1046/j.1365-2346.1997.00168.x; Hannan M, 1996, CLIN INTENSIVE CARE, V7, P56; Heard SO, 1998, ARCH INTERN MED, V158, P81, DOI 10.1001/archinte.158.1.81; HENNEKENS CH, 1987, STAT MED, V6, P397, DOI 10.1002/sim.4780060337; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P1089, DOI 10.1001/jama.279.14.1089; JENDRESKY L, 1995, INFECT CONTROL HOS 2, V16, P38; KAMAL GD, 1991, JAMA-J AM MED ASSOC, V265, P2364, DOI 10.1001/jama.265.18.2364; Khan KS, 1996, ARCH INTERN MED, V156, P661, DOI 10.1001/archinte.156.6.661; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; Logghe C, 1997, J HOSP INFECT, V37, P145, DOI 10.1016/S0195-6701(97)90184-5; Loo S, 1997, ANAESTH INTENS CARE, V25, P637, DOI 10.1177/0310057X9702500607; LOVELL RD, 1995, INFECT CONTROL HOS 2, V16, P24; Maki Dennis G., 1994, P155; Maki DG, 1997, ANN INTERN MED, V127, P257, DOI 10.7326/0003-4819-127-4-199708150-00001; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; *NAT NOS INF SURV, 1996, AM J INFECT CONTROL, V24, P380; Oda T, 1997, ANESTHESIOLOGY, V87, P1242, DOI 10.1097/00000542-199711000-00031; Pearson ML, 1996, AM J INFECT CONTROL, V24, P262; Pearson ML, 1997, ANN INTERN MED, V127, P304, DOI 10.7326/0003-4819-127-4-199708150-00009; Pemberton LB, 1996, ARCH SURG-CHICAGO, V131, P986; PETITTI D, 1994, META ANAL DECISION A; PFEIFFER J, 1994, INFECT CONTROL HOS 2, V15, P24; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Raad I, 1997, ANN INTERN MED, V127, P267, DOI 10.7326/0003-4819-127-4-199708150-00002; Ramsay J, 1994, CRIT CARE MED, V22, pA115; RAYMOND NJ, 1995, INFECT CONTROL HOS 2, V16, P24; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P222; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sherertz RJ, 1997, J CLIN MICROBIOL, V35, P641, DOI 10.1128/JCM.35.3.641-646.1997; SiegmanIgra Y, 1997, J CLIN MICROBIOL, V35, P928, DOI 10.1128/JCM.35.4.928-936.1997; Tennenberg S, 1997, ARCH SURG-CHICAGO, V132, P1348; TRAZZERA S, 1995, CRIT CARE MED, V23, pA152; vanHeerden PV, 1996, ANAESTH INTENS CARE, V24, P330, DOI 10.1177/0310057X9602400305; YUSUF S, 1987, STAT MED, V6, P281, DOI 10.1002/sim.4780060314	51	366	390	1	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1999	281	3					261	267		10.1001/jama.281.3.261	http://dx.doi.org/10.1001/jama.281.3.261			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157GK	9918482				2022-12-28	WOS:000078052800032
J	Bjorksten, B				Bjorksten, B			Allergy priming early in life	LANCET			English	Editorial Material							INFANCY		Linkoping Univ Hosp, Dept Hlth & Environm, Div Paediat, S-58185 Linkoping, Sweden	Linkoping University	Bjorksten, B (corresponding author), Linkoping Univ Hosp, Dept Hlth & Environm, Div Paediat, S-58185 Linkoping, Sweden.							Bjorksten B, 1998, EUR RESPIR J, V12, P432, DOI 10.1183/09031936.98.12020432; BJORKSTEN B, IN PRESS CLIN EXP AL; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P59, DOI 10.1111/j.1399-3038.1995.tb00261.x; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; STANNEGARD O, 1979, CLIN ALLERGY, V9, P637; Sudo N, 1997, J IMMUNOL, V159, P1739; UIBO R, IN PRESS INT ARCH AL; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D	10	57	57	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					167	168		10.1016/S0140-6736(05)77212-3	http://dx.doi.org/10.1016/S0140-6736(05)77212-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923869				2022-12-28	WOS:000078175600006
J	Alon, U; Surette, MG; Barkai, N; Leibler, S				Alon, U; Surette, MG; Barkai, N; Leibler, S			Robustness in bacterial chemotaxis	NATURE			English	Article							ESCHERICHIA-COLI; CHEB METHYLESTERASE; ADAPTATION; MODEL; METHYLATION; EXCITATION; COMPONENTS; MODULATION; MECHANISM; BEHAVIOR	Networks of interacting proteins orchestrate the responses of living cells to a variety of external stimuli(1), but how sensitive is the functioning of these protein networks to variations in their biochemical parameters? One possibility is chat to achieve appropriate function, the reaction rate constants and enzyme concentrations need to be adjusted in a precise manner, and any deviation from these 'fine-tuned' values ruins the network's performance. An alternative possibility is that key properties of biochemical networks are robust(2); that is, they are insensitive to the precise values of the biochemical parameters. Here we address this issue in experiments using chemotaxis of Escherichia coli, one of the best-characterized sensory systems(3,4). We focus on how response and adaptation to attractant signals vary with systematic changes in the intracellular concentration of the components of the chemotaxis network. We find that some properties, such as steady-state behaviour and adaptation time, show strong variations in response to varying protein concentrations. In contrast, the precision of adaptation is robust and does not vary with the protein concentrations. This is consistent with a recently proposed molecular mechanism for exact adaptation, where robustness is a direct consequence of the network's architecture(2).	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada	Princeton University; Princeton University; University of Calgary	Leibler, S (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	leibler@princeton.edu						Alon U, 1998, EMBO J, V17, P4238, DOI 10.1093/emboj/17.15.4238; ASAKURA S, 1984, J MOL BIOL, V176, P349, DOI 10.1016/0022-2836(84)90494-7; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BERG HC, 1975, P NATL ACAD SCI USA, V72, P3235, DOI 10.1073/pnas.72.8.3235; BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; BERG HC, 1990, BIOPHYS J, V58, P919, DOI 10.1016/S0006-3495(90)82436-X; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Fell D., 1997, UNDERSTANDING CONTRO; Grishanin RN, 1997, J BACTERIOL, V179, P24, DOI 10.1128/jb.179.1.24-30.1997; HAURI DC, 1995, BIOPHYS J, V68, P708, DOI 10.1016/S0006-3495(95)80232-8; KIRSCH ML, 1993, J BIOL CHEM, V268, P25350; Levin MD, 1998, BIOPHYS J, V74, P175, DOI 10.1016/S0006-3495(98)77777-X; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; RUSSELL CB, 1989, J BACTERIOL, V171, P3609, DOI 10.1128/jb.171.7.3609-3618.1989; SEGALL JE, 1986, P NATL ACAD SCI USA, V83, P8987, DOI 10.1073/pnas.83.23.8987; SEGEL LA, 1986, J THEOR BIOL, V120, P151, DOI 10.1016/S0022-5193(86)80171-0; SIMMS SA, 1985, J BIOL CHEM, V260, P161; Spiro PA, 1997, P NATL ACAD SCI USA, V94, P7263, DOI 10.1073/pnas.94.14.7263; STEWART RC, 1988, COLD SPRING HARB SYM, V53, P27, DOI 10.1101/SQB.1988.053.01.007; STOCK J, 1985, CELL, V42, P683, DOI 10.1016/0092-8674(85)90125-4; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; WEIS RM, 1988, P NATL ACAD SCI USA, V85, P83, DOI 10.1073/pnas.85.1.83; WEIS RM, 1990, J BACTERIOL, V172, P1099, DOI 10.1128/jb.172.2.1099-1105.1990; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987	30	839	862	2	96	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1999	397	6715					168	171		10.1038/16483	http://dx.doi.org/10.1038/16483			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923680				2022-12-28	WOS:000078085000048
J	Pickering, TG				Pickering, TG			Advances in the treatment of hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ISOLATED SYSTOLIC HYPERTENSION; ANTIHYPERTENSIVE TREATMENT; DOUBLE-BLIND; DISEASE; RISK		New York Presbyterian Hosp, Hypertens Ctr, New York, NY 10021 USA	NewYork-Presbyterian Hospital	Pickering, TG (corresponding author), New York Presbyterian Hosp, Hypertens Ctr, 520 E 70th St, New York, NY 10021 USA.							Appel Lawrence J., 1995, Annals of Epidemiology, V5, P119, DOI 10.1016/1047-2797(94)00056-Y; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Ascherio A, 1998, CIRCULATION, V98, P1198, DOI 10.1161/01.CIR.98.12.1198; Black HR, 1997, ARCH INTERN MED, V157, P2413; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; CURB JD, 1996, JAMA-J AM MED ASSOC, V227, P1356; de Lorgeril M, 1998, ARCH INTERN MED, V158, P1181, DOI 10.1001/archinte.158.11.1181; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Forette F, 1998, LANCET, V352, P1347, DOI 10.1016/S0140-6736(98)03086-4; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Hansson L, 1998, J HYPERTENS, V16, pS22; Hole DJ, 1998, J HYPERTENS, V16, P119, DOI 10.1097/00004872-199816010-00017; *JOINT NAT COMM PR, 1997, ARCH INTERN MED, V157, P2446; Lever AF, 1998, LANCET, V352, P179, DOI 10.1016/S0140-6736(98)03228-0; Messerli FH, 1998, JAMA-J AM MED ASSOC, V279, P1903, DOI 10.1001/jama.279.23.1903; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; Pahor M, 1998, ARCH INTERN MED, V158, P1340, DOI 10.1001/archinte.158.12.1340; Philipp T, 1997, BMJ-BRIT MED J, V315, P154, DOI 10.1136/bmj.315.7101.154; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597	23	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					114	116		10.1001/jama.281.2.114	http://dx.doi.org/10.1001/jama.281.2.114			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155VJ	9917098				2022-12-28	WOS:000077966800002
J	Hultman, CM; Sparen, P; Takei, N; Murray, RM; Cnattingius, S				Hultman, CM; Sparen, P; Takei, N; Murray, RM; Cnattingius, S			Prenatal and perinatal risk factors for schizophrenia, affective psychosis, and reactive psychosis of early onset: case-control study	BRITISH MEDICAL JOURNAL			English	Article							OBSTETRIC COMPLICATIONS; INTRAUTERINE GROWTH; ABRUPTIO PLACENTAE; HEAD CIRCUMFERENCE; PREGNANCY; BIRTH; METAANALYSIS; DETERMINANTS; MORTALITY; DELIVERY	Objective To examine prenatal and perinatal risk factors for subsequent development of schizophrenia and affective and reactive psychosis. Design Three population based, case-control studies conducted within a Sweden-wide cohort of all children born during 1973-9. This was done by linking individual data from the Swedish birth register, which represents 99% of all births in Sweden, to the Swedish inpatient register. Subjects Patients listed in inpatient register as having been first admitted to hospital aged 15-21 years with a main diagnosis of schizophrenia (n = 167), affective psychosis (n = 198), or reactive psychosis (n = 292). For each case, five controls were selected. Main outcome measures Risks of schizophrenia and affective and reactive psychosis in relation to pregnancy and perinatal characteristics. Results Schizophrenia was positively associated with multiparity (odds ratio 2.0), maternal bleeding during pregnancy (odds ratio 3.5), and birth in late winter (odds ratio 1.4). Affective psychosis was associated with uterine atony (odds ratio 2.2) and late winter birth (odds ratio 1.5). Reactive psychosis was related to multiparity (odds ratio 2.1). An increased risk for schizophrenia was found in boys who were small for their gestational age at birth (odds ratio 3.2), who were number four or more in birth order (odds ratio 3.6), and whose mothers had had bleeding during late pregnancy (odds ratio 4.0). Conclusions A few specific pregnancy and perinatal factors were associated with the subsequent development of psychotic disorder, particularly schizophrenia, in early adult life. The association of small size for gestational age and bleeding during pregnancy with increased risk of early onset schizophrenia among males could reflect placental insufficiency.	Uppsala Univ, Ulleraker, Dept Neurosci Psychiat, S-75017 Uppsala 17, Sweden; Stockholm Ctr Hlth Soc Transit, Huddinge, Sweden; Hamamatsu Univ Sch Med, Dept Psychiat & Neurol, Hamamatsu, Shizuoka 43131, Japan; Inst Psychiat, Dept Psychol Med, London SE5 8AF, England; Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden	Uppsala University; Hamamatsu University School of Medicine; University of London; King's College London; Karolinska Institutet	Hultman, CM (corresponding author), Uppsala Univ, Ulleraker, Dept Neurosci Psychiat, S-75017 Uppsala 17, Sweden.	christina.hultman@ullpsyk.uu.se	Murray, Robin M/F-8658-2012; Takei, Nori/AAC-8578-2019; Takei, Nori/GWZ-7464-2022	Murray, Robin M/0000-0003-0829-0519; Sparen, Par/0000-0002-5184-8971; Geddes, John/0000-0002-5281-5960				Aberg A, 1992, Int J Technol Assess Health Care, V8 Suppl 1, P20; Alda M, 1996, ACTA PSYCHIAT SCAND, V93, P447, DOI 10.1111/j.1600-0447.1996.tb10676.x; Bennedsen BE, 1998, SCHIZOPHR RES, V33, P1, DOI 10.1016/S0920-9964(98)00065-6; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P32; BUKA SL, 1993, ARCH GEN PSYCHIAT, V50, P151; CASTLE DJ, 1995, SCHIZOPHRENIA BULL, V21, P1; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; David AS, 1997, PSYCHOL MED, V27, P1311, DOI 10.1017/S0033291797005680; DONE DJ, 1991, BRIT MED J, V302, P1576, DOI 10.1136/bmj.302.6792.1576; ERICSON A, 1984, ACTA PAEDIATR SCAND, V73, P69, DOI 10.1111/j.1651-2227.1984.tb09900.x; Geddes JR, 1995, BRIT J PSYCHIAT, V167, P786, DOI 10.1192/bjp.167.6.786; Hafner H, 1997, CAN J PSYCHIAT, V42, P139; HANSEN H, 1992, ACTA PSYCHIAT SCAND, V86, P55, DOI 10.1111/j.1600-0447.1992.tb03226.x; Hoek HW, 1998, SOC PSYCH PSYCH EPID, V33, P373, DOI 10.1007/s001270050068; Hultman CM, 1997, BRIT J PSYCHIAT, V170, P128, DOI 10.1192/bjp.170.2.128; Jones PB, 1998, AM J PSYCHIAT, V155, P355, DOI 10.1176/ajp.155.3.355; Kramer MS, 1997, OBSTET GYNECOL, V89, P221, DOI 10.1016/S0029-7844(96)00478-4; KRAMER MS, 1990, PEDIATRICS, V86, P707; Kunugi H, 1996, SCHIZOPHR RES, V20, P165; Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x; McNeil T.S.K, 1995, MCNEIL SJOSTROM SCAL; MCNEIL TF, 1995, EPIDEMIOL REV, V17, P107, DOI 10.1093/oxfordjournals.epirev.a036165; McNeil TF, 1996, SCHIZOPHR RES, V22, P41, DOI 10.1016/0920-9964(96)00045-X; MOORE RY, 1985, NIH PUBLICATION, P33; MURRAY RM, 1994, BRIT J PSYCHIAT, V165, P6, DOI 10.1192/S0007125000293148; NAEYE RL, 1980, OBSTET GYNECOL, V55, P701; *NAT BOARD HEATHL, 1984, 4 NAT BOARD HLTH WEL; *NAT BOARD HLTH WE, 1984, COUNT COUNC PLAN ONE; SACKER A, 1995, BRIT J PSYCHIAT, V166, P734, DOI 10.1192/bjp.166.6.734; STEPHENS JH, 1982, J NERV MENT DIS, V170, P657, DOI 10.1097/00005053-198211000-00004; van Os J, 1998, BRIT J PSYCHIAT, V172, P324, DOI 10.1192/bjp.172.4.324; Verdoux H, 1997, AM J PSYCHIAT, V154, P1220; WRIGHT P, 1995, AM J PSYCHIAT, V152, P1711; 1992, INT J TECHNOL ASSESS, V8, P182	35	227	232	0	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 13	1999	318	7181					421	426		10.1136/bmj.318.7181.421	http://dx.doi.org/10.1136/bmj.318.7181.421			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BF	9974454	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000078670100022
J	Davis, RW; Fuiman, LA; Williams, TM; Collier, SO; Hagey, WP; Kanatous, SB; Kohin, S; Horning, M				Davis, RW; Fuiman, LA; Williams, TM; Collier, SO; Hagey, WP; Kanatous, SB; Kohin, S; Horning, M			Hunting behavior of a marine mammal beneath the Antarctic fast ice	SCIENCE			English	Article							DIVING BEHAVIOR; WEDDELL SEALS; ELEPHANT SEALS; ROSS SEA; MOVEMENTS	The hunting behavior of a marine mammal was studied beneath the Antarctic fast ice with an animal-borne video system and data recorder. Weddell seals stalked Large Antarctic cod and the smaller subice fish Pagothenia borchgrevinki, often with the under-ice surface for backlighting, which implies that vision is important for hunting. They approached to within centimeters of cod without startling the fish. Seals flushed P. borchgrevinki by blowing air into subice crevices or pursued them into the platelet ice. These observations highlight the broad range of insights that are possible with simultaneous recordings of video, audio, three-dimensional dive paths, and Locomotor effort.	Texas A&M Univ, Dept Marine Biol, Galveston, TX 77553 USA; Univ Texas Austin, Dept Marine Sci, Port Aransas, TX 78373 USA; Univ Calif Santa Cruz, Dept Biol, Santa Cruz, CA 95064 USA; Pisces Design, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA	Texas A&M University System; University of Texas System; University of Texas Austin; University of California System; University of California Santa Cruz; University of California System; University of California San Diego	Davis, RW (corresponding author), Texas A&M Univ, Dept Marine Biol, 5007 Ave U, Galveston, TX 77553 USA.	davisr@tamug.tamu.edu	Horning, Markus/I-3019-2015; Fuiman, Lee A/L-9514-2017	Horning, Markus/0000-0001-6178-4935; Fuiman, Lee A/0000-0003-2667-2684				ANDRIASHEV AP, 1986, P ZOOLOGICAL I USSR, V153, P9; BERTRAM G. C. L., 1940, SCI REPTS BRITISH GRAHAM LAND EXPED 1984 1987 BRIT MUS [NAT HIST], V1, P1; BOWDITCH N, 1995, AM PRACTICAL NAVIGAT, P113; BOYD IL, 1991, POLAR BIOL, V11, P259, DOI 10.1007/BF00238460; CALHAEM I, 1969, New Zealand Journal of Marine and Freshwater Research, V3, P181; Castellini M.A., 1992, ANN CYCLES DIVING BE; CROXALL JP, 1985, J ANIM ECOL, V54, P1, DOI 10.2307/4616; DAVIS RW, 1992, MARINE MAMMAL SENSORY SYSTEMS, P631; Dearborn J. H., 1965, Journal of Mammalogy, V46, P37, DOI 10.2307/1377814; Dehnhardt G, 1998, NATURE, V394, P235, DOI 10.1038/28303; DEVRIES AL, 1981, J ROY SOC NEW ZEAL, V11, P329, DOI 10.1080/03036758.1981.10423324; DUNSTONE N, 1993, ZOOLOGICAL SOC LONDO, V65; Fedak M.A., 1993, Symposia of the Zoological Society of London, V66, P333; GREEN K, 1987, AUST WILDLIFE RES, V14, P475; HINDELL MA, 1991, AUST J ZOOL, V39, P595, DOI 10.1071/ZO9910595; Janssen J., 1991, ANTARCT J US, V26, P174; KOOYMAN GL, 1975, J MAMMAL, V56, P563, DOI 10.2307/1379469; KOOYMAN GL, 1980, J COMP PHYSIOL, V138, P335, DOI 10.1007/BF00691568; Kooyman GL, 1981, WEDDELL SEAL CONSUMM, P148, DOI DOI 10.1017/CBO9780511735653; LAVIGNE DM, 1975, COMP BIOCHEM PHYS B, V52, P325, DOI 10.1016/0305-0491(75)90073-5; LEBOEUF BJ, 1988, CAN J ZOOL, V66, P446, DOI 10.1139/z88-064; LYTHGOE JN, 1970, NATURE, V227, P995; NELSON KH, 1981, CURRENT PERSPECTIVES; RAYMOND JA, 1975, MAR TECHNOL SOC J, V9, P32; SCHREER JF, 1995, MAR MAMMAL SCI, V11, P85, DOI 10.1111/j.1748-7692.1995.tb00277.x; SINIFF DB, 1977, ECOL MONOGR, V47, P319, DOI 10.2307/1942520; Stirling I., 1971, Antarctic Res Ser Washington, V18, P141; STIRLING I, 1969, ECOLOGY, V50, P573, DOI 10.2307/1936247; STIRLING I, 1969, New Zealand Journal of Marine and Freshwater Research, V3, P191; Testa J.W., 1985, P561; TESTA JW, 1994, CAN J ZOOL, V72, P1700, DOI 10.1139/z94-229; THOMAS JA, 1982, J ACOUST SOC AM, V72, P1730, DOI 10.1121/1.388667; Thompson D., 1993, Symposia of the Zoological Society of London, V66, P349; WARTZOK D, 1992, CAN J ZOOL, V70, P1712, DOI 10.1139/z92-238; WARTZOK D, 1979, 3 BIENN C BIOL MAR M; Wilson EA, 1907, NAT HIST, V2, P1	36	252	258	0	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					993	996		10.1126/science.283.5404.993	http://dx.doi.org/10.1126/science.283.5404.993			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974394				2022-12-28	WOS:000078574800051
J	Ryu, SJ; Zhou, S; Ladurner, AG; Tjian, R				Ryu, SJ; Zhou, S; Ladurner, AG; Tjian, R			The transcriptional cofactor complex CRSP is required for activity of the enhancer-binding protein Sp1	NATURE			English	Article							RNA-POLYMERASE-II; GENE-TRANSCRIPTION; HORMONE RECEPTOR; ACTIVATION; COACTIVATORS; CLONING; PURIFICATION; COMPONENTS; MEDIATOR; DOMAIN	Activation of gene transcription in metazoans is a multistep process that is triggered by factors that recognize transcriptional enhancer sites in DNA, These factors work with co-activators to direct transcriptional initiation by the RNA polymerase II apparatus(1), One class of co-activator, the TAF(II) subunits of transcription factor TFIID, can serve as targets of activators and as proteins that recognize core promoter sequences necessary for transcription initiation(2-5). Transcriptional activation by enhancer-binding factors such as Sp1 (ref, 6) requires TFIID, but the identity of other necessary cofactors has remained unknown. Here we describe a new human factor, CRSP, that is required together with the TAF(II)s for transcriptional activation by Sp1. Purification of CRSP identifies a complex of approximate relative molecular mass 700,000 (M(r)similar to 700K) that contains nine subunits with M-r values ranging from 33K to 200K. Cloning of genes encoding CRSP subunits reveals that CRSP33 is a homologue of the yeast mediator subunit Med7 (ref. 7), whereas CRSP150 contains a domain conserved in yeast mediator subunit Rgr1 (ref. 8), CRSP p200 is identical to the nuclear hormone-receptor co-activator subunit TRIP2/PBP9,10. CRSPs 34, 77 and 130 are new proteins, but the amino terminus of CRSP70 is homologous to elongation factor TFIIS11. Immunodepletion studies confirm that these subunits have an essential cofactor function. The presence of common subunits in distinct cofactor complexes suggests a combinatorial mechanism of co-activator assembly during transcriptional activation.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Tjian, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, 401 Barker Hall, Berkeley, CA 94720 USA.		Ryu, Soojin/GWV-4004-2022	Ladurner, Andreas/0000-0003-3835-232X; Ryu, Soojin/0000-0002-7059-0160				Brandsen J, 1997, NAT STRUCT BIOL, V4, P900, DOI 10.1038/nsb1197-900; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LeRoy G, 1998, J BIOL CHEM, V273, P7134, DOI 10.1074/jbc.273.12.7134; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; ONATE SA, 1995, SCIENCE, V270, P1354; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; Yoshikawa H, 1998, GENOMICS, V49, P237, DOI 10.1006/geno.1998.5246; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	30	294	312	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 4	1999	397	6718					446	450		10.1038/17141	http://dx.doi.org/10.1038/17141			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164KA	9989412	Green Published			2022-12-28	WOS:000078461700051
J	Hasselbacher, P				Hasselbacher, P			A vision of health care for the next millennium	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					402	402		10.1001/jama.281.5.402-b	http://dx.doi.org/10.1001/jama.281.5.402-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952183				2022-12-28	WOS:000078318500001
J	Meier, CR; Derby, LE; Jick, SS; Vasilakis, C; Jick, H				Meier, CR; Derby, LE; Jick, SS; Vasilakis, C; Jick, H			Antibiotics and risk of subsequent first-time acute myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; CHLAMYDIA-PNEUMONIAE; ASSOCIATION; INFECTIONS; TWAR; AZITHROMYCIN; HYPERTENSION; DATABASE	Context Increasing evidence supports the hypothesis of a causal association between certain bacterial infections and increased risk of developing acute myocardial infarction. If such a causal association exists, subjects who used antibiotics active against the bacteria, regardless of indication, might be at lower risk of developing acute myocardial infarction than nonusers. Objective To determine whether previous use of antibiotics decreases the risk of developing a first-time acute myocardial infarction, Design Population-based case-control analysis. Setting The United Kingdom-based General Practice Research Database comprising 350 general practices. Patients A total of 3315 case patients aged 75 years or younger with a diagnosis of first-time acute myocardial infarction between 1992 and 1997 and 13139 controls without myocardial infarction matched to cases for age, sex, general practice attended, and calendar time. Main Outcome Measures Use of antibiotics among those who did or did not have a first-time acute myocardial infarction. Results Cases were significantly less likely to have used tetracycline antibiotics (adjusted odds ratio [OR], 0.70; 95% confidence interval [CI], 0.55-0.90) or quinolones (adjusted OR, 0.45; 95% CI, 0.21-0.95). No effect was found for previous use of macrolides (primarily erythromycin), sulfonamides, penicillins, or cephalosporins. Conclusions The findings from this large case-control analysis provide further, albeit indirect, evidence for an association between bacterial infections with organisms susceptible to tetracycline or quinolone antibiotics and the risk of acute myocardial infarction. These results of preliminary nature should stimulate more research to further explore the role of infections in the etiology of acute myocardial infarction.	Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA	Boston University	Meier, CR (corresponding author), Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, 11 Muzzey St, Lexington, MA 02421 USA.			Jick, Hershel/0000-0003-4270-5992; Jick, Susan/0000-0002-2215-1067				Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; FALCK G, 1994, SCAND J INFECT DIS, V26, P179, DOI 10.3109/00365549409011782; GRAYSTON JT, 1993, CIRCULATION, V87, P1408, DOI 10.1161/01.CIR.87.4.1408; GRAYSTON JT, 1986, NEW ENGL J MED, V315, P161, DOI 10.1056/NEJM198607173150305; Gupta S, 1997, BRIT MED J, V314, P1778, DOI 10.1136/bmj.314.7097.1778; Gupta S, 1997, CIRCULATION, V96, P404; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; HAMMERSCHLAG MR, 1992, ANTIMICROB AGENTS CH, V36, P1573, DOI 10.1128/AAC.36.7.1573; HAMMERSCHLAG MR, 1994, ANTIMICROB AGENTS CH, V38, P1873, DOI 10.1128/AAC.38.9.1873; Jick H, 1997, LANCET, V350, P1045, DOI 10.1016/S0140-6736(05)70451-7; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H, 1996, PHARMACOTHERAPY, V16, P321; Jick H, 1997, EPIDEMIOLOGY, V8, P446, DOI 10.1097/00001648-199707000-00017; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Kauppinen M, 1995, CLIN INFECT DIS, V21, pS244, DOI 10.1093/clind/21.Supplement_3.S244; MATTILA KJ, 1989, BRIT MED J, V298, P779, DOI 10.1136/bmj.298.6676.779; Meier CR, 1998, LANCET, V351, P1467, DOI 10.1016/S0140-6736(97)11084-4; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; Wimmer MLJ, 1996, STROKE, V27, P2207, DOI 10.1161/01.STR.27.12.2207	22	142	145	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					427	431		10.1001/jama.281.5.427	http://dx.doi.org/10.1001/jama.281.5.427			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952202	Bronze			2022-12-28	WOS:000078318500030
J	Rendell, MS; Rajfer, J; Wicker, PA; Smith, MD				Rendell, MS; Rajfer, J; Wicker, PA; Smith, MD		Sildenafil Diabetes Study Grp	Sildenafil for treatment of erectile dysfunction in men with diabetes - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NITRIC-OXIDE; PHYSIOLOGY; IMPOTENCE	Context Erectile dysfunction is common in men with diabetes. Objective To assess the efficacy and safety of oral sildenafil citrate in the treatment of erectile dysfunction in men with diabetes. Design A multicenter, randomized, double-blind, placebo-controlled, flexible dose-escalation study conducted May through November 1996. Setting Patients' homes and 19 clinical practice centers in the United States. Patients A total of 268 men (mean age, 57 years) with erectile dysfunction (mean duration, 5.6 years) and diabetes (mean duration, 12 years). Interventions Patients were randomized to receive sildenafil (n = 136) or placebo (n = 132) as needed, but not more than once daily, for 12 weeks. Patients took the study drug or placebo 1 hour before anticipated sexual activity. The starting dose of sildenafil citrate was 50 mg; with the option to adjust the dose to 100 mg or 25 mg based on efficacy and tolerability, to be taken as needed. Main Outcome Measures Self-reported ability to achieve and maintain an erection for sexual intercourse according to the International Index of Erectile Function and adverse events. Results Two hundred fifty-two patients (94%) completed the study(131/136 in the sildenafil group, 121/132 in the placebo group). By intention-to-treat analysis, at 12 weeks, 74 (56%) of 131 patients in the sildenafil group reported improved erections compared with 13 (10%) of 127 patients in the placebo group (P < .001). The proportion of men with at least 1 successful attempt at sexual intercourse was 61% (71/117) for the sildenafil group vs 22% (25/114) for the placebo group (P < .001). Adverse events related to treatment were reported for 22 (16%) of 136 patients taking sildenafil and 1 (1%) of 132 patients receiving placebo. The most common adverse events were headache (11% sildenafil, 2% placebo), dyspepsia (9% sildenafil, 0% placebo), and respiratory tract disorder (6% sildenafil, 2% placebo), predominantly sinus congestion or drainage. The incidence of cardiovascular adverse events was comparable for both groups (3% sildenafil, 5% placebo). Conclusion Oral sildenafil is an effective and well-tolerated treatment for erectile dysfunction in men with diabetes.	Creighton Diabet Ctr, Omaha, NE 68131 USA; Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Torrance, CA USA; Pfizer Inc, Pfizer Cent Res, Groton, CT 06340 USA; Pfizer Cent Res, Sandwich, Kent, England	Creighton University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Pfizer; Pfizer	Rendell, MS (corresponding author), Creighton Diabet Ctr, 601 N 30th St,Suite 6715, Omaha, NE 68131 USA.							ANDERSSON KE, 1995, PHYSIOL REV, V75, P191, DOI 10.1152/physrev.1995.75.1.191; BELL DSH, 1992, UROLOGY, V40, P36, DOI 10.1016/0090-4295(92)90433-W; Boolell M, 1996, Int J Impot Res, V8, P47; BRAUNSTEIN GD, 1987, MT SINAI J MED, V54, P236; BURNETT AL, 1995, BIOL REPROD, V52, P485, DOI 10.1095/biolreprod52.3.485; Burnett AL, 1997, J UROLOGY, V157, P320, DOI 10.1016/S0022-5347(01)65369-2; *CDCP, 1997, NAT DIAB FACT SHEET; DETEJADA IS, 1988, UROL CLIN N AM, V15, P17; DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; FLEISS J, 1986, DESIGN ANAL CLIN EXP, P49; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; HARRIS M, 1979, DIABETES, V28, P1039; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; MCCULLOCH DK, 1980, DIABETOLOGIA, V18, P279; MCCULLOCH DK, 1986, DIABETIC MED, V3, P485, DOI 10.1111/j.1464-5491.1986.tb00800.x; Price DE, 1998, DIABETIC MED, V15, P821, DOI 10.1002/(SICI)1096-9136(199810)15:10<821::AID-DIA697>3.0.CO;2-P; Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0; RUBIN A, 1958, JAMA-J AM MED ASSOC, V168, P498, DOI 10.1001/jama.1958.03000050010003; RUNDLES RW, 1945, MEDICINE, V24, P111, DOI 10.1097/00005792-194505000-00001; Seftel AD, 1997, UROLOGY, V50, P1016, DOI 10.1016/S0090-4295(97)00512-8; Whitehead E D, 1990, Clin Geriatr Med, V6, P771; WHITEHEAD ED, 1987, GERIATRICS, V42, P77; ZEMEL P, 1988, AM J CARDIOL, V61, pH27, DOI 10.1016/0002-9149(88)91102-2	24	454	483	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					421	426		10.1001/jama.281.5.421	http://dx.doi.org/10.1001/jama.281.5.421			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952201	Bronze			2022-12-28	WOS:000078318500029
J	Polderman, KH; Thijs, LG; Girbes, ARJ				Polderman, KH; Thijs, LG; Girbes, ARJ			Interobserver variability in the use of APACHE II scores	LANCET			English	Article									Free Univ Amsterdam Hosp, Surg Unit, NL-1007 MB Amsterdam, Netherlands; Free Univ Amsterdam Hosp, Med Intens Care Unit, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Polderman, KH (corresponding author), Free Univ Amsterdam Hosp, Surg Unit, NL-1007 MB Amsterdam, Netherlands.		Polderman, Kees H/K-3623-2012					KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kollef MH, 1998, NEW HORIZ-SCI PRACT, V6, P1	2	43	45	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 30	1999	353	9150					380	380		10.1016/S0140-6736(05)74953-9	http://dx.doi.org/10.1016/S0140-6736(05)74953-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950452				2022-12-28	WOS:000078437000022
J	Leadbetter, JR; Schmidt, TM; Graber, JR; Breznak, JA				Leadbetter, JR; Schmidt, TM; Graber, JR; Breznak, JA			Acetogenesis from H-2 plus CO2 by spirochetes from termite guts	SCIENCE			English	Article							SP-NOV; MASTOTERMES DARWINIENSIS; RETICULITERMES FLAVIPES; PHYLOGENETIC ANALYSIS; HINDGUT; ACETATE; METHANOGENS; BACTERIUM; SEQUENCE; SPERATUS	Pure cultures of termite gut spirochetes were obtained and were shown to catalyze the synthesis of acetate from H-2 plus CO2. The 16S ribosomal DNA sequences of two strains were 98 percent similar and were affiliated with those of the genus Treponema. However, neither was closely related to any known treponeme. These findings imply an important role for spirochetes in termite nutrition, help to reconcile the dominance of acetogenesis over methanogenesis as an H-2 sink in termite hindguts, suggest that the motility of termite gut protozoa by means of attached spirochetes may be based on interspecies H-2 transfer, and underscore the importance of termites as a rich reservoir of novel microbial diversity.	Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA; Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Breznak, JA (corresponding author), Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA.			Leadbetter, Jared/0000-0002-7033-0844; Schmidt, Thomas/0000-0002-8209-6055				Berchtold M, 1996, SYST APPL MICROBIOL, V19, P66, DOI 10.1016/S0723-2020(96)80011-7; BERCHTOLD M, 1994, FEMS MICROBIOL LETT, V123, P269, DOI 10.1111/j.1574-6968.1994.tb07235.x; BRAUMAN A, 1992, SCIENCE, V257, P1384, DOI 10.1126/science.257.5075.1384; Breznak J.A., 1994, ACETOGENESIS, P303; BREZNAK JA, 1986, APPL ENVIRON MICROB, V52, P623, DOI 10.1128/AEM.52.4.623-630.1986; BREZNAK JA, 1988, ARCH MICROBIOL, V150, P282, DOI 10.1007/BF00407793; Breznak JA, 1984, BERGEYS MANUAL SYSTE, V1, P67; Breznak JA, 1973, CRC CR REV MICROBIOL, V2, P457; Breznak John A., 1994, P137; CANALEPAROLA E, 1992, PROKARYOTES HDB BIOL, V4, P3524; CLARK JE, 1982, J BACTERIOL, V151, P507, DOI 10.1128/JB.151.1.507-509.1982; CLEVELAND LR, 1964, PROC R SOC SER B-BIO, V159, P668, DOI 10.1098/rspb.1964.0025; Daniels Lacy, 1994, P512; Drake H.L., 1994, ACETOGENESIS, P3; Ebert A, 1997, APPL ENVIRON MICROB, V63, P4039, DOI 10.1128/AEM.63.10.4039-4046.1997; EUTICK ML, 1978, J INSECT PHYSIOL, V24, P363, DOI 10.1016/0022-1910(78)90076-8; KANE MD, 1991, ARCH MICROBIOL, V156, P91, DOI 10.1007/BF00290979; KANE MD, 1991, ARCH MICROBIOL, V156, P99, DOI 10.1007/BF00290980; Kim KS, 1998, APPL ENVIRON MICROB, V64, P1919; Leadbetter JR, 1996, APPL ENVIRON MICROB, V62, P3620, DOI 10.1128/AEM.62.10.3620-3631.1996; LEIDY J, 1874, J ACAD NAT SCI-PHILA, V8, P425; LILBURN TG, UNPUB; MARGULIS L, 1992, HDB BIOL BACTERIA EC, V4, P3965; Mikx FHM, 1997, ORAL MICROBIOL IMMUN, V12, P249, DOI 10.1111/j.1399-302X.1997.tb00387.x; Ochiai S, 1997, MICROBIOL IMMUNOL, V41, P445, DOI 10.1111/j.1348-0421.1997.tb01877.x; OCHIAI S, 1998, INT J SYST BACTERIOL, V48, P327; OHKUMA M, 1995, FEMS MICROBIOL LETT, V134, P45, DOI 10.1111/j.1574-6968.1995.tb07912.x; Ohkuma M, 1998, FEMS MICROBIOL LETT, V164, P389, DOI 10.1111/j.1574-6968.1998.tb13114.x; Ohkuma M, 1996, APPL ENVIRON MICROB, V62, P461, DOI 10.1128/AEM.62.2.461-468.1996; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; Oremland R. S., 1988, BIOL ANAEROBIC MICRO, P641; PASTER BJ, 1991, J BACTERIOL, V173, P6101, DOI 10.1128/JB.173.19.6101-6109.1991; Paster BJ, 1996, APPL ENVIRON MICROB, V62, P347, DOI 10.1128/AEM.62.2.347-352.1996; STACKEBRANDT E, 1994, INT J SYST BACTERIOL, V44, P846, DOI 10.1099/00207713-44-4-846; STRUNK O, 1997, ARB SOFTWARE PHYLOGE; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; WINTER JU, 1980, ARCH MICROBIOL, V124, P73, DOI 10.1007/BF00407031; Wyss C, 1996, INT J SYST BACTERIOL, V46, P745, DOI 10.1099/00207713-46-3-745	38	221	230	2	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					686	689		10.1126/science.283.5402.686	http://dx.doi.org/10.1126/science.283.5402.686			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924028				2022-12-28	WOS:000078324400042
J	Chen, J; Radford, MJ; Wang, Y; Marciniak, TA; Krumholz, HM				Chen, J; Radford, MJ; Wang, Y; Marciniak, TA; Krumholz, HM			Do "America's best hospitals" perform better for acute myocardial infarction?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COOPERATIVE CARDIOVASCULAR PROJECT; MEDICARE PATIENTS; QUALITY; CARE; MORTALITY; DISEASE	Background "America's Best Hospitals," an influential list published annually by U.S. News & World Report, assesses the quality of hospitals. It is not known whether patients admitted to hospitals ranked at the top in cardiology have lower short-term mortality from acute myocardial infarction than those admitted to other hospitals or whether differences in mortality are explained by differential use of recommended therapies. Methods Using data from the Cooperative Cardiovascular Project on 149,177 elderly Medicare beneficiaries with acute myocardial infarction in 1994 or 1995, we examined the care and outcomes of patients admitted to three types of hospitals: those ranked high in cardiology (top-ranked hospitals); hospitals not in the top rank that had on-site facilities for cardiac catheterization, coronary angioplasty, and bypass surgery (similarly equipped hospitals); and the remaining hospitals (non-similarly equipped hospitals). We compared 30-day mortality; the rates of use of aspirin, beta-blockers, and reperfusion; and the relation of differences in rates of therapy to shortterm mortality. Results Admission to a top-ranked hospital was associated with lower adjusted 30-day mortality (odds ratio, 0.87; 95 percent confidence interval, 0.76 to 1.00; P = 0.05 for top-ranked hospitals vs. the others). Among patients without contraindications to therapy, top-ranked hospitals had significantly higher rates of use of aspirin (96.2 percent, as compared with 88.6 percent for similarly equipped hospitals and 83.4 percent for non-similarly equipped hospitals; P < 0.01) and beta-blockers (75.0 percent vs. 61.8 percent and 58.7 percent, P < 0.01), but lower rates of reperfusion therapy (61.0 percent vs. 70.7 percent and 65.6 percent, P = 0.03). The survival advantage associated with admission to top-ranked hospitals was less strong after we adjusted for factors including the use of aspirin and beta-blockers (odds ratio, 0.94; 95 percent confidence interval, 0.82 to 1.08; P = 0.38). Conclusions Admission to a hospital ranked high on the list of "America's Best Hospitals" was associated with lower 30-day mortality among elderly patients with acute myocardial infarction. A substantial portion of the survival advantage may be associated with these hospitals' higher rates of use of aspirin and beta-blocker therapy. (N Engl J Med 1999;340: 286-92.) (C) 1999, Massachusetts Medical Society.	Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Chron Dis Epidemiol, New Haven, CT 06520 USA; Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; Qualidigm, Middletown, CT USA; US Hlth Care Financing Adm, Baltimore, MD 21207 USA	Yale University; Yale University; Yale University	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.		, Harlan/AAI-2875-2020	Radford, Martha/0000-0001-7503-9557	PHS HHS [500-96-P549] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AM HOSP ASS, 1994, ANN SURV HOSP DAT; [Anonymous], 1988, LANCET, V2, P349; Boscarino J A, 1997, Am J Med Qual, V12, P196, DOI 10.1177/0885713X9701200406; *BUR CENS, 1991, STAT METR AR DAT BOO; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Donabedian A., 1980, EXPLORATIONS QUALITY, V1, P77; EHRLICH RH, 1997, 1997 INDEX HOSP QUAL; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Green J, 1997, JAMA-J AM MED ASSOC, V277, P1152, DOI 10.1001/jama.277.14.1152; Hill CA, 1997, INQUIRY-J HEALTH CAR, V34, P80; *HLTH CAR FIN ADM, 1997, PUBL HLTH CAR FIN AD; Huff ED, 1997, J CLIN EPIDEMIOL, V50, P1395, DOI 10.1016/S0895-4356(97)00218-7; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LAMBERTHUBER DA, 1994, CLIN PERFORMANCE QUA, V2, P219; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; Normand SLT, 1996, JAMA-J AM MED ASSOC, V275, P1322, DOI 10.1001/jama.275.17.1322; Roberts WC, 1997, AM J CARDIOL, V80, P1258; Rosenthal GE, 1996, J GEN INTERN MED, V11, P366, DOI 10.1007/BF02600049; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; *STAT CORP, 1997, STAT STAT SOFTW REL, P235; WINSLOW R, 1995, WALL STREET J   0721, pB1; WINSLOW R, 1995, WALL STREET J   0718, pB2; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1995, US NEWS WORLD R 0724, P46; 1995, MOD HEALTHCARE, V25, P92; 1997, US NEWS WORLD R 0728, P56; 1996, US NEWS WORLD R 0812, P52	29	241	254	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1999	340	4					286	292		10.1056/NEJM199901283400407	http://dx.doi.org/10.1056/NEJM199901283400407			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YU	9920954	Bronze			2022-12-28	WOS:000078318700007
J	Firlik, AD; Welch, WC				Firlik, AD; Welch, WC			Brown-Sequard syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Firlik, AD (corresponding author), Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA.								0	11	11	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1999	340	4					285	285		10.1056/NEJM199901283400406	http://dx.doi.org/10.1056/NEJM199901283400406			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YU	9920953				2022-12-28	WOS:000078318700006
J	Iglehart, JK				Iglehart, JK			The American health care system - Medicare	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PHYSICIANS											Aaron HJ, 1995, HEALTH AFFAIR, V14, P8, DOI 10.1377/hlthaff.14.4.8; ASTON G, 1998, AM MED NEWS     0914, P1; Ball RM, 1995, HEALTH AFFAIR, V14, P62, DOI 10.1377/hlthaff.14.4.62; Bernstein J, 1999, HEALTH AFFAIR, V18, P180, DOI 10.1377/hlthaff.18.1.180; Brett AS, 1998, NEW ENGL J MED, V339, P1705, DOI 10.1056/NEJM199812033392312; Butler SM, 1999, HEALTH AFFAIR, V18, P8, DOI 10.1377/hlthaff.18.1.8; CASSELCK, 1999, HLTH AFF MILLWOOD, V18, P118; Davis M, 1999, HEALTH AFFAIR, V18, P231, DOI 10.1377/hlthaff.18.1.231; FISHMAN LE, 1996, MEDICARE PAYMENT ED; FUCHS VR, 1998, HLTH AFF MILLWOOD, V18, P1; HSIAO WC, 1988, NEW ENGL J MED, V319, P835, DOI 10.1056/NEJM198809293191305; Iezzoni LI, 1998, NEW ENGL J MED, V339, P1933, DOI 10.1056/NEJM199812243392613; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1247, DOI 10.1056/NEJM199004263221728; IGLEHART JK, 1992, NEW ENGL J MED, V327, P1467, DOI 10.1056/NEJM199211123272027; Iglehart JK, 1998, NEW ENGL J MED, V338, P402, DOI 10.1056/NEJM199802053380620; Iglehart JK, 1999, NEW ENGL J MED, V340, P70, DOI 10.1056/NEJM199901073400122; Kahn CN, 1999, HEALTH AFFAIR, V18, P37, DOI 10.1377/hlthaff.18.1.37; Kassirer JP, 1998, NEW ENGL J MED, V339, P1697, DOI 10.1056/NEJM199812033392308; Kassirer JP, 1998, NEW ENGL J MED, V339, P1925, DOI 10.1056/NEJM199812243392609; Kuttner R, 1999, NEW ENGL J MED, V340, P248, DOI 10.1056/NEJM199901213400324; Kuttner R, 1999, NEW ENGL J MED, V340, P163, DOI 10.1056/NEJM199901143400226; Kuttner R, 1998, NEW ENGL J MED, V339, P1952, DOI 10.1056/NEJM199812243392625; McBride TD, 1998, HEALTH AFFAIR, V17, P170, DOI 10.1377/hlthaff.17.6.170; McKusick D, 1999, HEALTH AFFAIR, V18, P194, DOI 10.1377/hlthaff.18.1.194; *MED PAYM ADV COMM, 1998, REP C CONT CHANG MED; MOON M, 1993, MED NOW FUTURE; Neuman P, 1999, HEALTH AFFAIR, V18, P150, DOI 10.1377/hlthaff.18.1.150; Nissenson AR, 1999, HEALTH AFFAIR, V18, P161, DOI 10.1377/hlthaff.18.1.161; SERAFINI MW, 1998, NATL J          1121, P2774; SHEILS J, 1998, RETHINKING MED ELIGI; Smith S, 1998, HEALTH AFFAIR, V17, P128, DOI 10.1377/hlthaff.17.5.128; *STUD PAN CAP CHOI, 1998, STRUCT MED CHOIC; Vladeck BC, 1999, HEALTH AFFAIR, V18, P22, DOI 10.1377/hlthaff.18.1.22; Waidmann TA, 1998, HEALTH AFFAIR, V17, P156, DOI 10.1377/hlthaff.17.2.156; Welch HG, 1996, NEW ENGL J MED, V335, P324, DOI 10.1056/NEJM199608013350506; Whitelaw NA, 1999, HEALTH AFFAIR, V18, P132, DOI 10.1377/hlthaff.18.1.132; Wilensky GR, 1999, HEALTH AFFAIR, V18, P92, DOI 10.1377/hlthaff.18.1.92	37	45	45	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1999	340	4					327	332		10.1056/NEJM199901283400424	http://dx.doi.org/10.1056/NEJM199901283400424			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YU	9935359				2022-12-28	WOS:000078318700033
J	Weinblatt, ME; Kremer, JM; Bankhurst, AD; Bulpitt, KJ; Fleischmann, RM; Fox, RI; Jackson, CG; Lange, M; Burge, DJ				Weinblatt, ME; Kremer, JM; Bankhurst, AD; Bulpitt, KJ; Fleischmann, RM; Fox, RI; Jackson, CG; Lange, M; Burge, DJ			A trial of etanercept, a recombinant tumor necrosis factor receptor : Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FACTOR-ALPHA; COMBINATION; RESORPTION; EFFICACY; THERAPY	Background Patients treated with methotrexate for rheumatoid arthritis often improve but continue to have active disease. This study was undertaken to determine whether the addition of etanercept, a soluble tumor necrosis factor receptor (p75):Fc fusion protein (TNFR:Fc), to methotrexate therapy would provide additional benefit to patients who had persistent rheumatoid arthritis despite receiving methotrexate. Methods In a 24-week, double-blind trial, we randomly assigned 89 patients with persistently active rheumatoid arthritis despite at least 6 months of methotrexate therapy at a stable dose of 15 to 25 mg per week (or as low as 10 mg per week for patients unable to tolerate higher doses) to receive either etanercept (25 mg) or placebo subcutaneously twice weekly while continuing to receive methotrexate. The primary measure of clinical response was the American College of Rheumatology criteria for a 20 percent improvement in measures of disease activity (ACR 20) at 24 weeks. Results The addition of etanercept to methotrexate therapy resulted in rapid and sustained improvement. At 24 weeks, 71 percent of the patients receiving etanercept plus methotrexate and 27 percent of those receiving placebo plus methotrexate met the ACR 20 criteria (P < 0.001); 39 percent of the patients receiving etanercept plus methotrexate and 3 percent of those receiving placebo plus methotrexate met the ACR 50 criteria (for a 50 percent improvement) (P < 0.001). Patients receiving etanercept plus methotrexate had significantly better outcomes according to all measures of disease activity. The only adverse events associated with etanercept were mild injection-site reactions, and no patient withdrew from the study because of adverse events associated with etanercept. Conclusions In patients with persistently active rheumatoid arthritis, the combination of etanercept and methotrexate was safe and well tolerated and provided significantly greater clinical benefit than methotrexate alone. (N Engl J Med 1999;340:253-9,) (C) 1999, Massachusetts Medical Society.	Brigham & Womens Hosp, Boston, MA 02115 USA; Albany Med Coll, Albany, NY 12208 USA; Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Metroplex Clin Res Ctr, Dallas, TX USA; Scrips Clin, La Jolla, CA USA; Univ Utah, Med Ctr, Salt Lake City, UT USA; Immunex Corp, Seattle, WA USA	Harvard University; Brigham & Women's Hospital; Albany Medical College; University of New Mexico; University of California System; University of California Los Angeles; Metroplex Clinical Research Center; Utah System of Higher Education; University of Utah; Immunex Corporation	Weinblatt, ME (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.							ALARCON GS, 1997, ARTHRITIS ALLIED CON, V1, P679; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BECKHAM JC, 1992, J CLIN IMMUNOL, V12, P353, DOI 10.1007/BF00920793; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; BRENNAN FM, 1989, LANCET, V2, P244; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; *FOOD DRUG ADM, 1998, GUID IND CLIN DEV PR; FRIES JF, 1982, J RHEUMATOL, V9, P789; HOCHBERG MC, 1992, ARTHRITIS RHEUM, V35, P498, DOI 10.1002/art.1780350502; KREMER JM, 1986, ARTHRITIS RHEUM, V29, P822, DOI 10.1002/art.1780290702; LIPSKY PE, 1994, HARRISONS PRINCIPLES, P1880; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Moreland LW, 1998, J INVEST MED, V46, p229A; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; SAEZLLORENS X, 1991, J INFECT DIS, V163, P1267, DOI 10.1093/infdis/163.6.1267; SAKLATVALA J, 1986, NATURE, V322, P547, DOI 10.1038/322547a0; THORNTON SC, 1991, CLIN EXP IMMUNOL, V86, P79; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; VONASMUTH EJU, 1991, J IMMUNOL, V147, P3869; WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303; WEINBLATT ME, 1997, TXB RHEUMATOLOGY, V1, P771	22	1648	1715	1	55	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1999	340	4					253	259		10.1056/NEJM199901283400401	http://dx.doi.org/10.1056/NEJM199901283400401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YU	9920948	Bronze			2022-12-28	WOS:000078318700001
J	Navari, RM; Reinhardt, RR; Gralla, RJ; Kris, MG; Hesketh, PJ; Khojasteh, A; Kindler, H; Grote, TH; Pendergrass, K; Grunberg, SM; Carides, AD; Gertz, BJ				Navari, RM; Reinhardt, RR; Gralla, RJ; Kris, MG; Hesketh, PJ; Khojasteh, A; Kindler, H; Grote, TH; Pendergrass, K; Grunberg, SM; Carides, AD; Gertz, BJ		L-754,030 Antiemetic Trials Grp	Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	34th Annual Meeting of the American-Society-of-Clinical-Oncology	MAY 14-19, 1998	LOS ANGELES, CA	Amer Soc Clin Oncol			CHEMOTHERAPY-INDUCED EMESIS; TACHYKININ NK1 RECEPTOR; INDUCED DELAYED EMESIS; HIGH-DOSE CISPLATIN; ONDANSETRON PLUS DEXAMETHASONE; PATIENTS RECEIVING CISPLATIN; DOUBLE-BLIND; CANCER-CHEMOTHERAPY; RANDOMIZED TRIAL; INDUCED NAUSEA	Background The localization of substance P in brain-stem regions associated with vomiting, and the results of studies in ferrets, led us to postulate that a neurokinin-1-receptor antagonist would be an antiemetic in patients receiving anticancer chemotherapy. Methods in a multicenter, double-blind, placebo-controlled trial involving 159 patients who had not previously received cisplatin, we evaluated the prevention of acute emesis (occurring within 24 hours) and delayed emesis (occurring on days 2 to 5) after a single dose of cisplatin therapy (70 mg or more per square meter of body-surface area). Before receiving cisplatin, all the patients received granisetron (10 mu g per kilogram of body weight intravenously) and dexamethasone (20 mg orally). The patients were randomly assigned to one of three treatments in addition to granisetron and dexamethasone: 400 mg of an oral trisubstituted morpholine acetal (also known as L-754,030) before cisplatin and 300 mg on days 2 to 5 (group 1), 400 mg of L-754,030 before cisplatin and placebo on days 2 to 5 (group 2), or placebo before cisplatin and placebo on days 2 to 5 (group 3). Additional medication was available at any time to treat occurrences of vomiting or nausea. Results In the acute-emesis phase, 93 percent of the patients in groups 1 and 2 combined and 67 percent of those in group 3 had no vomiting (P<0.001). In the delayed-emesis phase, 82 percent of the patients in group 1, 78 percent of those in group 2, and 33 percent of those in group 3 had no vomiting (P<0.001 for the comparison between group 1 or 2 and group 3). The median nausea score in the delayed-emesis phase was significantly lower in group 1 than in group 3 (P=0.003). No serious adverse events were attributed to L-754,030. Conclusions The neurokinin-1-receptor antagonist L-754,030 prevents delayed emesis after treatment with cisplatin. Moreover, combining L-754,030 with granisetron plus dexamethasone improves the prevention of acute emesis. (N Engl J Med 1999;340: 190-5.) (C) 1999, Massachusetts Medical Society.	Merck Res Labs, Clin Pharmacol, Rahway, NJ 07065 USA; Simon Williamson Clin, Birmingham, AL USA; Ochsner Med Ctr, New Orleans, LA USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; St Elizabeths Med Ctr, Boston, MA USA; Capital Comprehens Canc Care Clin, Jefferson City, MO USA; Roswell Pk Canc Inst, Buffalo, NY 14263 USA; Salem Res Grp, Winston Salem, NC USA; Res Med Ctr, Kansas City, MO USA; Fletcher Allen Hlth Ctr, Burlington, VT USA	Merck & Company; Ochsner Health System; Memorial Sloan Kettering Cancer Center; St. Elizabeth's Medical Center; Roswell Park Cancer Institute; University of Vermont Medical Center	Navari, RM (corresponding author), Merck Res Labs, Clin Pharmacol, RY33-600, Rahway, NJ 07065 USA.							BORISON HL, 1983, DRUGS, V25, P8, DOI 10.2165/00003495-198300251-00003; Demulder PHM, 1990, ANN INTERN MED, V113, P834, DOI 10.7326/0003-4819-113-11-834; GANDARA DR, 1993, EUR J CANCER, V29A, pS35, DOI 10.1016/S0959-8049(05)80259-X; Gardner C. J., 1994, British Journal of Pharmacology, V112, p516P; Gardner CJ, 1996, REGUL PEPTIDES, V65, P45, DOI 10.1016/0167-0115(96)00071-7; GRALLA RJ, 1987, MED CLIN N AM, V71, P289, DOI 10.1016/S0025-7125(16)30871-9; Gralla RJ, 1996, ONCOLOGY, V53, P86, DOI 10.1159/000227646; GRALLA RJ, 1991, RECENT RES CANCER, V121, P68; Griffin AM, 1996, ANN ONCOL, V7, P189; Hesketh P, 1996, ONCOLOGY, V53, P73, DOI 10.1159/000227644; HESKETH PJ, 1994, J CLIN ONCOL, V12, P596, DOI 10.1200/JCO.1994.12.3.596; Hesketh PJ, 1997, J CLIN ONCOL, V15, P103, DOI 10.1200/JCO.1997.15.1.103; IRELAND SJ, 1987, BRIT J PHARMACOL, V90, P151, DOI 10.1111/j.1476-5381.1987.tb16835.x; Kris MG, 1996, CANCER, V78, P2193, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2193::AID-CNCR22>3.0.CO;2-T; KRIS MG, 1985, J CLIN ONCOL, V3, P1379, DOI 10.1200/JCO.1985.3.10.1379; Kris MG, 1997, J NATL CANCER I, V89, P817, DOI 10.1093/jnci/89.11.817; KRIS MG, 1992, SEMIN ONCOL, V19, P23; KRIS MG, 1989, J CLIN ONCOL, V7, P108, DOI 10.1200/JCO.1989.7.1.108; KRIS MG, 1985, CANCER, V55, P527, DOI 10.1002/1097-0142(19850201)55:3<527::AID-CNCR2820550310>3.0.CO;2-2; KRIS MG, 1993, CANCER, V72, P3436, DOI 10.1002/1097-0142(19931201)72:11+<3436::AID-CNCR2820721610>3.0.CO;2-Z; LASZLO J, 1981, NEW ENGL J MED, V305, P948, DOI 10.1056/NEJM198110153051609; *NAT CANC I, 1998, COMM TOX CRIT VERS 2; NAVARI RM, 1995, J CLIN ONCOL, V13, P2408, DOI 10.1200/JCO.1995.13.9.2408; Osoba D, 1996, ONCOLOGY, V53, P92, DOI 10.1159/000227647; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; PASSALACQUA R, 1992, ANN ONCOL, V3, P481, DOI 10.1093/oxfordjournals.annonc.a058241; Perez EA, 1996, CLIN THER, V18, P578, DOI 10.1016/S0149-2918(96)80209-8; ROILA F, 1992, LANCET, V340, P96; ROILA F, 1991, J CLIN ONCOL, V9, P675, DOI 10.1200/JCO.1991.9.4.675; Roila F, 1990, Clin Oncol (R Coll Radiol), V2, P268, DOI 10.1016/S0936-6555(05)80953-7; RUFF P, 1994, ONCOLOGY, V51, P113; RUFF P, 1994, ONCOLOGY, V51, P243; Singh L, 1997, EUR J PHARMACOL, V321, P209, DOI 10.1016/S0014-2999(96)00950-8; SMITH DB, 1991, LANCET, V338, P487, DOI 10.1016/0140-6736(91)90555-4; Tattersall FD, 1996, NEUROPHARMACOLOGY, V35, P1121, DOI 10.1016/S0028-3908(96)00020-2; TATTERSALL FD, 1998, P AN M AM SOC CLIN, V17, pA253	36	263	293	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1999	340	3					190	195		10.1056/NEJM199901213400304	http://dx.doi.org/10.1056/NEJM199901213400304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	159YJ	9917226				2022-12-28	WOS:000078202900004
J	Horton, R				Horton, R			The information wars	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Horton, R (corresponding author), Lancet, London WC1B 3SL, England.							Bachrach S, 1998, SCIENCE, V281, P1459, DOI 10.1126/science.281.5382.1459; Bailar JC, 1997, NEW ENGL J MED, V337, P559, DOI 10.1056/NEJM199708213370810; Barnes DE, 1998, JAMA-J AM MED ASSOC, V279, P1566, DOI 10.1001/jama.279.19.1566; Clarke M, 1998, JAMA-J AM MED ASSOC, V280, P280, DOI 10.1001/jama.280.3.280; Clarke M, 1998, LANCET, V351, P1451; Hersh WR, 1998, JAMA-J AM MED ASSOC, V280, P1347, DOI 10.1001/jama.280.15.1347; Horton R, 1997, J CLIN EPIDEMIOL, V50, P981, DOI 10.1016/S0895-4356(97)00156-X; Horton R, 1998, CAN MED ASSOC J, V159, P245; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; Hurwitz, 1998, NARRATIVE BASED MED; Jefferson T, 1999, BMJ-BRIT MED J, V318, P135, DOI 10.1136/bmj.318.7176.135; MCGLYNN EA, 1998, HLTH INFORMATION SYS; Petros A, 1998, BMJ-BRIT MED J, V317, P882, DOI 10.1136/bmj.317.7162.882; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; RUSSELL B, 1946, HIST W PHILOS, P36; SACKETT DL, 1997, EVIDENCE BASED MED; SUTHERLAND J, 1998, LONDON REV BOOK 0107, P3; Yellon DM, 1996, LANCET, V347, P1159, DOI 10.1016/S0140-6736(96)90613-3	18	9	9	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					164	165		10.1016/S0140-6736(05)77210-X	http://dx.doi.org/10.1016/S0140-6736(05)77210-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923867				2022-12-28	WOS:000078175600004
J	Rosenberg, LE				Rosenberg, LE			Medicine - Physician-scientists - Endangered and essential	SCIENCE			English	Article							CLINICAL INVESTIGATOR		Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Rosenberg, LE (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							AHRENS EA, 1994, CAREERS CLIN RES; Ahrens Jr. E. H., 1992, CRISIS CLIN RES; CULLITON BJ, 1995, NAT MED, V1, P281, DOI 10.1038/nm0495-281; GILL GN, 1984, AM SCHOLAR, V53, P353; GOLDSTEIN JL, 1986, J CLIN INVEST, V78, P848, DOI 10.1172/JCI112652; Goldstein JL, 1997, J CLIN INVEST, V99, P2803, DOI 10.1172/JCI119470; Nathan DG, 1998, JAMA-J AM MED ASSOC, V280, P1427, DOI 10.1001/jama.280.16.1427; Schechter AN, 1998, JAMA-J AM MED ASSOC, V280, P1440, DOI 10.1001/jama.280.16.1440; Schrier RW, 1997, ACAD MED, V72, P589, DOI 10.1097/00001888-199707000-00010; SHULMAN LE, 1996, ACAD MED, V71, P398; THEIR S, 1980, CLIN RES, V28, P248; THOMPSON J, 1997, JAMA-J AM MED ASSOC, V278, P244; Williams GH, 1997, JAMA-J AM MED ASSOC, V278, P227, DOI 10.1001/jama.278.3.227; WYNGAARDEN JB, 1979, NEW ENGL J MED, V301, P1254, DOI 10.1056/NEJM197912063012303	14	197	200	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					331	332		10.1126/science.283.5400.331	http://dx.doi.org/10.1126/science.283.5400.331			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9925491				2022-12-28	WOS:000078067000025
J	Zemb, T; Dubois, M; Deme, B; Gulik-Krzywicki, T				Zemb, T; Dubois, M; Deme, B; Gulik-Krzywicki, T			Self-assembly of flat nanodiscs in salt-free catanionic surfactant solutions	SCIENCE			English	Article							SPONTANEOUS VESICLE FORMATION; CATIONIC SURFACTANTS; AQUEOUS MIXTURES; PHASE-BEHAVIOR; SCATTERING	Discs of finite size are a very rare form of stable surfactant self-assembly. It is shown that mixing of two oppositely charged single-chain surfactants can produce rigid nanodiscs as well as swollen lamellar liquid crystals with frozen bilayers. The crucial requirement for obtaining nanodisc self-assembly is the use of H+ and OH- as counterions. These counterions then form water and lower the conductivity to 10 microsiemens per centimeter. In the case of cationic component excess, a dilute solution of nanodiscs is in thermodynamic equilibrium with a lamellar phase. The diameter of the cationic nanodiscs is continuously adjustable from a few micrometers to 30 nanometers, with the positive charge Located mainly around the edges.	CEA Saclay, Serv Chim Mol, F-91191 Gif Sur Yvette, France; Inst Max Von Laue Paul Langevin, F-38042 Grenoble 9, France; CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Institut Laue-Langevin (ILL); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Zemb, T (corresponding author), CEA Saclay, Serv Chim Mol, F-91191 Gif Sur Yvette, France.		ZEMB, Thomas N/E-5958-2010; Demé, Bruno/AAG-1620-2021	Demé, Bruno/0000-0002-9523-7662				[Anonymous], 1992, INTERMOLECULAR SURFA; DUBOIS M, 1991, LANGMUIR, V7, P1352, DOI 10.1021/la00055a011; DUBOIS M, 1994, LANGMUIR, V10, P1615, DOI 10.1021/la00017a048; FROMHERZ P, 1985, BER BUNSENEGES PHYS, V85, P891; FURHOP JH, 1993, CHEM REV, V93, P1565; HOFFMANN H, 1987, BER BUNSEN PHYS CHEM, V91, P99, DOI 10.1002/bbpc.19870910206; Horbaschek K, 1998, J COLLOID INTERF SCI, V206, P439, DOI 10.1006/jcis.1998.5690; Hyde S., 1997, LANGUAGE SHAPE; KALER EW, 1992, J PHYS CHEM-US, V96, P6698, DOI 10.1021/j100195a033; KALER EW, 1989, SCIENCE, V245, P1371, DOI 10.1126/science.2781283; Khan A., 1997, CATIONIC SURFACTANTS, P37; Laughlin R.G., 1994, AQUEOUS PHASE BEHAV; LENEVEU DM, 1977, BIOPHYS J, V18, P209, DOI 10.1016/S0006-3495(77)85608-7; LOCKHART NC, 1980, J COLLOID INTERF SCI, V74, P509, DOI 10.1016/0021-9797(80)90220-9; Ninham BW, 1997, LANGMUIR, V13, P2097, DOI 10.1021/la960974y; Ricoul F, 1998, EUR PHYS J B, V4, P333, DOI 10.1007/s100510050388; SAFRAN SA, 1990, SCIENCE, V248, P354, DOI 10.1126/science.248.4953.354; Soderman O, 1997, LANGMUIR, V13, P5531, DOI 10.1021/la960790j; TAMORI K, 1992, COLLOID POLYM SCI, V270, P885, DOI 10.1007/BF00657733; TARDIEU A, 1973, J MOL BIOL, V75, P711, DOI 10.1016/0022-2836(73)90303-3; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111	21	299	305	2	122	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					816	819		10.1126/science.283.5403.816	http://dx.doi.org/10.1126/science.283.5403.816			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933158				2022-12-28	WOS:000078496800035
J	Kong, YY; Yoshida, H; Sarosi, I; Tan, HL; Timms, E; Capparelli, C; Morony, S; Oliveira-dos-Santos, AJ; Van, G; Itie, A; Khoo, W; Wakeham, A; Dunstan, CR; Lacey, DL; Mak, TW; Boyle, WJ; Penninger, JM				Kong, YY; Yoshida, H; Sarosi, I; Tan, HL; Timms, E; Capparelli, C; Morony, S; Oliveira-dos-Santos, AJ; Van, G; Itie, A; Khoo, W; Wakeham, A; Dunstan, CR; Lacey, DL; Mak, TW; Boyle, WJ; Penninger, JM			OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis	NATURE			English	Article							COLONY-STIMULATING FACTOR; T-CELL-RECEPTOR; BETA-DEFICIENT MICE; DENDRITIC CELLS; ABNORMAL-DEVELOPMENT; GERMINAL-CENTERS; MARROW CULTURES; TNF RECEPTOR; BONE-MARROW; OP/OP MICE	The tumour-necrosis-factor-family molecule osteoprotegerin ligand (OPGL; also known as TRANCE, RANKL and Cop) has been identified as a potential osteoclast differentiation factor and regulator of interactions between T cells and dendritic cells in vitro. Mice with a disrupted opgl gene show severe osteopetrosis and a defect in tooth eruption, and completely lack osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis. Although dendritic cells appear normal, opgl-deficient mice exhibit defects in early differentiation of T and B lymphocytes. Surprisingly, opgl-deficient mice lack all lymph nodes but have normal splenic structure and Peyer's patches. Thus OPGL is a new regulator of lymph-node organogenesis and lymphocyte development and Is an essential osteoclast differentiation factor in vivo	Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Amgen; Amgen	Penninger, JM (corresponding author), Ontario Canc Inst, Amgen Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.	jpenning@amgen.com	Penninger, Josef M/I-6860-2013; Dunstan, Colin/G-6214-2013	Penninger, Josef M/0000-0002-8194-3777; Dunstan, Colin/0000-0001-7586-4071				Akagawa KS, 1996, BLOOD, V88, P4029, DOI 10.1182/blood.V88.10.4029.bloodjournal88104029; Alimzhanov MB, 1997, P NATL ACAD SCI USA, V94, P9302, DOI 10.1073/pnas.94.17.9302; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Anderson G, 1996, ANNU REV IMMUNOL, V14, P73, DOI 10.1146/annurev.immunol.14.1.73; BAILEY RP, 1975, AM J ANAT, V142, P15, DOI 10.1002/aja.1001420103; BEGG SK, 1993, J EXP MED, V177, P237, DOI 10.1084/jem.177.1.237; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; DeBenedette MA, 1997, J IMMUNOL, V158, P551; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Felix R, 1996, EUR J ENDOCRINOL, V134, P143, DOI 10.1530/eje.0.1340143; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Irving BA, 1998, SCIENCE, V280, P905, DOI 10.1126/science.280.5365.905; KANIS JA, 1995, BONE, V17, pS101, DOI 10.1016/8756-3282(95)00194-I; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; KURIHARA N, 1989, BLOOD, V74, P1295; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; Mostov K, 1997, SCIENCE, V276, P219, DOI 10.1126/science.276.5310.219; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Popoff SN, 1996, MOL MED TODAY, V2, P349, DOI 10.1016/1357-4310(96)81801-6; Reddi AH, 1997, CELL, V89, P159, DOI 10.1016/S0092-8674(00)80193-2; Rennert PD, 1998, IMMUNITY, V9, P71, DOI 10.1016/S1074-7613(00)80589-0; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; Rosen CJ, 1997, ENDOCRIN METAB CLIN, V26, P295, DOI 10.1016/S0889-8529(05)70248-6; Saoulli K, 1998, J EXP MED, V187, P1849, DOI 10.1084/jem.187.11.1849; SEITZ M, 1985, ANN RHEUM DIS, V44, P438, DOI 10.1136/ard.44.7.438; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEINMAN RM, 1979, J EXP MED, V149, P1, DOI 10.1084/jem.149.1.1; TAKAHASHI N, 1991, ENDOCRINOLOGY, V128, P1792, DOI 10.1210/endo-128-4-1792; Teitelbaum SL, 1996, MT SINAI J MED, V63, P399; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	50	2651	2825	4	134	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 28	1999	397	6717					315	323		10.1038/16852	http://dx.doi.org/10.1038/16852			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9950424				2022-12-28	WOS:000078324600040
J	Delbanco, T; Hartman, EE				Delbanco, T; Hartman, EE			A 40-year-old woman considering contraception, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Peterson HB, 1998, JAMA-J AM MED ASSOC, V279, P1651, DOI 10.1001/jama.279.20.1651	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1999	281	4					374	374		10.1001/jama.281.4.374	http://dx.doi.org/10.1001/jama.281.4.374			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158JB	9929092				2022-12-28	WOS:000078111300038
J	Dearnaley, DP; Khoo, VS; Norman, AR; Meyer, L; Nahum, A; Tait, D; Yarnold, J; Horwich, A				Dearnaley, DP; Khoo, VS; Norman, AR; Meyer, L; Nahum, A; Tait, D; Yarnold, J; Horwich, A			Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial	LANCET			English	Article							PELVIC RADIOTHERAPY; ACUTE TOXICITY; TECHNICAL ASPECTS; THERAPY; CARCINOMA; MORBIDITY	Background Radical radiotherapy is commonly used to treat localised prostate cancer. Late chronic side-effects limit the dose that can be given, and may be linked to the volume of normal tissues irradiated. Conformal radiotherapy allows a smaller amount of rectum and bladder to be treated, by shaping the high-dose volume to the prostate. We assessed the ability of this new technology to lessen the risk of radiation-related effects in a randomised controlled trial of conformal versus conventional radiotherapy. Methods We recruited men with prostate cancer for treatment with a standard dose of 64 Gy in daily 2 Gy fractions. The men were randomly assigned conformal or conventional radiotherapy treatment. The primary endpoint was the development of late radiation complications (>3 months after treatment) measured with the Radiation Therapy and Oncology Group (RTOG) score. Indicators of disease (cancer) control were also recorded. Findings In the 225 men treated, significantly fewer men developed radiation-induced proctitis and bleeding in the conformal group than in the conventional group (37 vs 56% greater than or equal to RTOG grade 1, p = 0.004; 5 vs 15% greater than or equal to RTOG grade 2, p = 0.01). There were no differences between groups in bladder function after treatment (53 vs 59% greater than or equal to grade 1, p = 0.34; 20 vs 23% greater than or equal to grade 2, p = 0.61). After median follow-up of 3.6 years there was no significant difference between groups in local tumour control (conformal 78% [95% CI 66-86], conventional 83% [69-90]). Interpretation Conformal techniques significantly lowered the risk of late radiation-induced proctitis after radiotherapy for prostate cancer. Widespread introduction of these radiotherapy treatment methods is appropriate. Our results are the basis for dose-escalation studies to improve local tumour control.	Royal Marsden NHS Trust, Dept Radiotherapy & Oncol, Sutton SM2 5PT, Surrey, England; Inst Canc Res, Sutton SM2 5PT, Surrey, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Dearnaley, DP (corresponding author), Royal Marsden NHS Trust, Dept Radiotherapy & Oncol, Downs Rd, Sutton SM2 5PT, Surrey, England.		Dearnaley, David P/J-2318-2014	Dearnaley, David P/0000-0002-3954-2806; Nahum, Alan/0000-0002-6429-9502				[Anonymous], 1995, RADIOTHER ONCOL, V35, P17; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BURNET NG, 1992, LANCET, V339, P1570, DOI 10.1016/0140-6736(92)91833-T; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Dearnaley DP, 1997, LANCET, V349, P892, DOI 10.1016/S0140-6736(97)22013-1; FUKS Z, 1993, RADIOTHER ONCOL, V29, P219, DOI 10.1016/0167-8140(93)90250-C; HANKS GE, 1995, INT J RADIAT ONCOL, V31, P25, DOI 10.1016/0360-3016(94)00366-S; Hanks GE, 1998, INT J RADIAT ONCOL, V41, P501, DOI 10.1016/S0360-3016(98)00089-3; Huddart RA, 1996, RADIOTHER ONCOL, V39, P19, DOI 10.1016/0167-8140(96)01717-3; *INT COMM RAD UN M, 1993, 50 ICRU INT COMM RAD; Laverdiere J, 1997, INT J RADIAT ONCOL, V37, P247, DOI 10.1016/S0360-3016(96)00513-5; LAWTON CA, 1991, INT J RADIAT ONCOL, V21, P935, DOI 10.1016/0360-3016(91)90732-J; LEIBEL SA, 1994, INT J RADIAT ONCOL, V28, P55, DOI 10.1016/0360-3016(94)90141-4; LITWIN MS, 1995, JAMA-J AM MED ASSOC, V273, P129, DOI 10.1001/jama.273.2.129; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; MAYLES WPM, 1993, RADIOTHER ONCOL, V29, P184, DOI 10.1016/0167-8140(93)90245-4; Mettlin C, 1997, PROSTATE, V32, P221, DOI 10.1002/(SICI)1097-0045(19970801)32:3<221::AID-PROS9>3.0.CO;2-N; MIDDLETON RG, 1995, J UROLOGY, V154, P2144, DOI 10.1016/S0022-5347(01)66718-1; NEAL AJ, 1995, RADIOTHER ONCOL, V37, P29, DOI 10.1016/0167-8140(95)01619-R; Nguyen LN, 1998, UROLOGY, V51, P991, DOI 10.1016/S0090-4295(98)00028-4; NIEMIERKO A, 1993, INT J RADIAT ONCOL, V25, P135, DOI 10.1016/0360-3016(93)90156-P; OLDHAM M, 1995, BRIT J RADIOL, V68, P882, DOI 10.1259/0007-1285-68-812-882; PILEPICH MV, 1995, UROLOGY, V45, P616, DOI 10.1016/S0090-4295(99)80053-3; Pollack A, 1996, INT J RADIAT ONCOL, V34, P555, DOI 10.1016/0360-3016(95)02103-5; SAILER SL, 1994, INT J RADIAT ONCOL, V30, P439, DOI 10.1016/0360-3016(94)90026-4; SANDLER HM, 1995, INT J RADIAT ONCOL, V33, P797, DOI 10.1016/0360-3016(95)00219-7; SHEARER RJ, 1992, BRIT J UROL, V69, P521, DOI 10.1111/j.1464-410X.1992.tb15601.x; Tait DM, 1997, RADIOTHER ONCOL, V42, P121, DOI 10.1016/S0167-8140(96)01870-1; TENHAKEN RK, 1989, INT J RADIAT ONCOL, V16, P193, DOI 10.1016/0360-3016(89)90029-1; VIJAYAKUMAR S, 1993, INT J RADIAT ONCOL, V25, P359, DOI 10.1016/0360-3016(93)90361-X; WILLIAMS MV, 1984, INT J RADIAT ONCOL, V10, P1703, DOI 10.1016/0360-3016(84)90532-7; Zelefsky MJ, 1998, INT J RADIAT ONCOL, V41, P491, DOI 10.1016/S0360-3016(98)00091-1	32	546	556	0	25	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 23	1999	353	9149					267	272		10.1016/S0140-6736(98)05180-0	http://dx.doi.org/10.1016/S0140-6736(98)05180-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929018				2022-12-28	WOS:000078292200008
J	Gunn, J				Gunn, J			Ashworth revisited	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1999	318	7178					271	271						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915760				2022-12-28	WOS:000078292300070
J	Marvel, MK; Epstein, RM; Flowers, K; Beckman, HB				Marvel, MK; Epstein, RM; Flowers, K; Beckman, HB			Soliciting the patient's agenda - Have we improved?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								Context Previous research indicates physicians frequently choose a patient problem to explore before determining the patient's full spectrum of concerns, Objective To examine the extent to which experienced family physicians in various practice settings elicit the agenda of concerns patients bring to the office. Design A cross-sectional survey using linguistic analysis of a convenience sample of 264 patient-physician interviews, Setting and Participants Primary care offices of 29 board-certified family physicians practicing in rural Washington (n =1; 3 %), semirural Colorado (n = 20; 69%), and urban settings in the United States and Canada (n = 8; 27%), Nine participants had fellowship training in communication skills and family counseling. Main Outcome Measures Patient-physician verbal interactions, including physician solicitations of patient concerns, rate of completion of patient responses, length of time for patient responses, and frequency of late-arising patient concerns. Results Physicians solicited patient concerns in 199 interviews (75.4%), Patients' initial statements of concerns were completed in 74 interviews (28.0%). Physicians redirected the patient's opening statement after a mean of 23.1 seconds. Patients allowed to complete their statement of concerns used only 6 seconds more on average than those who were redirected before completion of concerns. Late-arising concerns were more common when physicians did not solicit patient concerns during the interview (34.9% vs 14.9%), Fellowship-trained physicians were more likely to solicit patient concerns and allow patients to complete their initial statement of concerns (44% vs 22%). Conclusions Physicians often redirect patients' initial descriptions of their concerns, Once redirected, the descriptions are rarely completed. Consequences of incomplete initial descriptions include late-arising concerns and missed opportunities to gather potentially important patient data. Soliciting the patient's agenda takes little time and can improve interview efficiency and yield increased data.	Ft Collins Family Med Residency Program, Ft Collins, CO USA; Highland Hosp, Primary Care Inst, Rochester, NY USA; Univ Rochester, Dept Family Med, Rochester, NY USA; Univ Rochester, Dept Psychiat, Rochester, NY USA; Univ Rochester, Dept Med, Rochester, NY USA; Inst Estudis Salut, Barcelona, Spain	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Marvel, MK (corresponding author), Family Med Ctr, 1025 Pennock Pl, Ft Collins, CO 80524 USA.							Beckman H., 1989, COMMUNICATING MED PA, P223; BECKMAN HB, 1984, ANN INTERN MED, V101, P692, DOI 10.7326/0003-4819-101-5-692; COULEHAN J, 1997, MED INTERVIEW MASTER; DUGDALE DC, IN PRESS J GEN INT M; Epstein RM, 1998, ANN INTERN MED, V128, P435, DOI 10.7326/0003-4819-128-6-199803150-00003; FRANKEL R, 1989, COMMUNICATING MED PA, P86; Heath C., 1986, BODY MOVEMENT SPEECH, DOI [10.1017/CBO9780511628221, DOI 10.1017/CBO9780511628221]; Kaplan CB, 1997, J GEN INTERN MED, V12, pS49, DOI 10.1046/j.1525-1497.12.s2.7.x; KAPLAN SH, 1995, MED CARE, V33, P1176, DOI 10.1097/00005650-199512000-00002; Levinson D., 1987, GUIDE CLIN INTERVIEW; Lipkin Jr Mack, 1997, BEHAV MED PRIMARY CA, P1; Smith RC, 1998, ANN INTERN MED, V128, P118, DOI 10.7326/0003-4819-128-2-199801150-00008; SMITH RC, 1996, PATIENS STORY INTEGR; STEWART M, 1986, FAM PRACT, V3, P164, DOI 10.1093/fampra/3.3.164	14	466	474	1	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1999	281	3					283	287		10.1001/jama.281.3.283	http://dx.doi.org/10.1001/jama.281.3.283			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157GK	9918487	Bronze			2022-12-28	WOS:000078052800038
J	Lanzavecchia, A; Iezzi, G; Viola, A				Lanzavecchia, A; Iezzi, G; Viola, A			From TCR engagement to T cell activation: A kinetic view of T cell behavior	CELL			English	Review							RECEPTOR OCCUPANCY; ANTIGEN; LIGANDS; DISCRIMINATION; THRESHOLDS; RESPONSES; CD4		Basel Inst Immunol, CH-4005 Basel, Switzerland		Lanzavecchia, A (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.	lanzavecchia@bii.ch	Agatea, Lisa/L-8267-2016; Viola, Antonella/A-4321-2015	Iezzi, Giandomenica/0000-0001-5841-495X; Viola, Antonella/0000-0002-0125-9271				BOISE LH, 1995, CURR OPIN IMMUNOL, V7, P620, DOI 10.1016/0952-7915(95)80067-0; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; Cai ZL, 1997, J EXP MED, V185, P641, DOI 10.1084/jem.185.4.641; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Delon J, 1998, IMMUNITY, V9, P467, DOI 10.1016/S1074-7613(00)80630-5; Itoh Y, 1997, J EXP MED, V186, P757, DOI 10.1084/jem.186.5.757; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; Kersh GJ, 1996, NATURE, V380, P495, DOI 10.1038/380495a0; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; Madrenas J, 1997, J EXP MED, V185, P219, DOI 10.1084/jem.185.2.219; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Preckel T, 1997, J EXP MED, V185, P1803, DOI 10.1084/jem.185.10.1803; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Torigoe C, 1998, SCIENCE, V281, P568, DOI 10.1126/science.281.5376.568; Tuosto L, 1998, EUR J IMMUNOL, V28, P2131, DOI 10.1002/(SICI)1521-4141(199807)28:07<2131::AID-IMMU2131>3.0.CO;2-Q; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; Valitutti S, 1996, J EXP MED, V183, P1917, DOI 10.1084/jem.183.4.1917; Viola A, 1997, J EXP MED, V186, P1775, DOI 10.1084/jem.186.10.1775; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Viola A, 1997, EUR J IMMUNOL, V27, P3080, DOI 10.1002/eji.1830271146; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	28	289	305	3	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 8	1999	96	1					1	4		10.1016/S0092-8674(00)80952-6	http://dx.doi.org/10.1016/S0092-8674(00)80952-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989490	Bronze			2022-12-28	WOS:000078023200001
J	Willis, TG; Jadayel, DM; Du, MQ; Peng, HZ; Perry, AR; Abdul-Rauf, M; Price, H; Karran, L; Majekodunmi, O; Wlodarska, I; Pan, LX; Crook, T; Hamoudi, R; Isaacson, PG; Dyer, MJS				Willis, TG; Jadayel, DM; Du, MQ; Peng, HZ; Perry, AR; Abdul-Rauf, M; Price, H; Karran, L; Majekodunmi, O; Wlodarska, I; Pan, LX; Crook, T; Hamoudi, R; Isaacson, PG; Dyer, MJS			Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types	CELL			English	Article							POLYMERASE CHAIN-REACTION; FOLLICULAR LYMPHOMA; TISSUE; GENE; TRANSFORMATION; P53; VISUALIZATION; ABNORMALITIES; ACTIVATION; APOPTOSIS	MALT B cell lymphomas with t(1;14)(p22;q32) showed a recurrent breakpoint upstream of the promoter of a novel gene, Bcl10. Bcl10 is a cellular homolog of the equine herpesvirus-2 E10 gene: both contain an amino-terminal caspase recruitment domain (CARD) homologous to that found in several apoptotic molecules. Bcl10 and E10 activated NF-KB but caused apoptosis of 293 cells. Bcl10 expressed in a MALT lymphoma exhibited a frameshift mutation resulting in truncation distal to the CARD. Truncated Bcl10 activated NF-KB but did not induce apoptosis. Wild-type Bcl10 suppressed transformation, whereas mutant forms had lost this activity and displayed gain-of-function transforming activity. Similar mutations were detected in other tumor types, indicating that Bcl10 may be commonly involved in the pathogenesis of human malignancy.	Inst Canc Res, Acad Dept Haematol & Cytogenet, Sutton SM2 5NG, Surrey, England; Inst Canc Res, Canc Gene Cloning Ctr, Sutton SM2 5NG, Surrey, England; Inst Canc Res, Sect Cell Biol & Expt Pathol, Sutton SM2 5NG, Surrey, England; UCL, Sch Med, Dept Histopathol, London WC1E 6JJ, England; Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium; Katholieke Univ Leuven VIB, Louvain, Belgium	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; University of London; University College London; UCL Medical School; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven	Dyer, MJS (corresponding author), Inst Canc Res, Acad Dept Haematol & Cytogenet, Sutton SM2 5NG, Surrey, England.	mdyer@icr.ac.uk	; Dyer, Martin/F-2691-2014	Price, Helen/0000-0003-1537-4390; Du, Ming-Qing/0000-0002-1017-5045; Dyer, Martin/0000-0002-5033-2236; Hamoudi, Rifat/0000-0002-1402-0868				ALBERT T, 1994, ONCOGENE, V9, P759; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Gutierrez MI, 1998, BLOOD, V92, P600, DOI 10.1182/blood.V92.2.600.414k33_600_606; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HUSSELL T, 1993, J PATHOL, V169, P221, DOI 10.1002/path.1711690208; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; ISAACSON PG, 1995, J CLIN PATHOL, V48, P395, DOI 10.1136/jcp.48.5.395; JAIN VK, 1993, J IMMUNOL, V150, P5418; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Lee WC, 1996, CANCER RES, V56, P4297; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MATHEW S, 1994, CANCER RES, V54, P6265; Matolcsy A, 1996, BLOOD, V88, P3937, DOI 10.1182/blood.V88.10.3937.bloodjournal88103937; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Mertens F, 1997, CANCER RES, V57, P2765; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; Pan LX, 1997, AM J PATHOL, V150, P1245; Park D, 1996, J FOOD LIPIDS, V3, P1, DOI 10.1111/j.1745-4522.1996.tb00050.x; Peng H, 1997, HISTOPATHOLOGY, V30, P425, DOI 10.1046/j.1365-2559.1997.5450786.x; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; TELFORD EAR, 1995, J MOL BIOL, V249, P520, DOI 10.1006/jmbi.1995.0314; Thangavelu M, 1997, BLOOD, V89, P3371, DOI 10.1182/blood.V89.9.3371; THORNE M, 1998, CURR BIOL, V8, P885; TILLY H, 1994, BLOOD, V84, P1043; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Willis TG, 1997, BLOOD, V90, P2456; Willis TG, 1998, BLOOD, V91, P1873, DOI 10.1182/blood.V91.6.1873.1873_1873_1881; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1992, CANCER GENET CYTOGEN, V58, P35, DOI 10.1016/0165-4608(92)90130-Z; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; ZUTTER M, 1991, BLOOD, V78, P1062	46	518	567	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 8	1999	96	1					35	45		10.1016/S0092-8674(00)80957-5	http://dx.doi.org/10.1016/S0092-8674(00)80957-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989495	Bronze			2022-12-28	WOS:000078023200006
J	Bell, R				Bell, R			ABC of sexual health - Homosexual men and women	BRITISH MEDICAL JOURNAL			English	Review									St Marys Hosp, London, England	Imperial College London	Bell, R (corresponding author), St Marys Hosp, London, England.							COXAN A, 1996, BETWEEN SHEETS; *GEN MED COUNC, 1998, GOOD MED PRACT; Wellings K, 1994, SEXUAL BEHAV BRITAIN	3	9	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1999	318	7181					452	455		10.1136/bmj.318.7181.452	http://dx.doi.org/10.1136/bmj.318.7181.452			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BF	9974466	Green Published			2022-12-28	WOS:000078670100034
J	Remy, I; Wilson, IA; Michnick, SW				Remy, I; Wilson, IA; Michnick, SW			Erythropoietin receptor activation by a ligand-induced conformation change	SCIENCE			English	Article							RESONANCE ENERGY-TRANSFER; DIHYDROFOLATE-REDUCTASE; PROTEIN HORMONE; CELLS; DIMERIZATION; COMPLEX	Erythropoietin and other cytokine receptors are thought to be activated through hormone-induced dimerization and autophosphorylation of JAK kinases associated with the receptor intracellular domains, An in vivo protein fragment complementation assay was used to obtain evidence for an alternative mechanism in which unliganded erythropoietin receptor dimers exist in a conformation that prevents activation of JAK2 but then undergo a ligand-induced conformation change that allows JAK2 to be activated, These results are consistent with crystallographic evidence of distinct dimeric configurations for unliganded and ligand-bound forms of the erythropoietin receptor.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Universite de Montreal; Scripps Research Institute	Michnick, SW (corresponding author), Univ Montreal, Dept Biochim, Casier Postal 6128,Succursale Ctrville, Montreal, PQ H3C 3J7, Canada.				NIGMS NIH HHS [GM49497] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CODY V, 1992, ANTI-CANCER DRUG DES, V7, P483; Damjanovich S, 1997, P NATL ACAD SCI USA, V94, P13134, DOI 10.1073/pnas.94.24.13134; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; GUO CM, 1995, J BIOL CHEM, V270, P27562, DOI 10.1074/jbc.270.46.27562; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; ISRAEL DI, 1993, P NATL ACAD SCI USA, V90, P4290, DOI 10.1073/pnas.90.9.4290; Johnson DL, 1998, BIOCHEMISTRY-US, V37, P3699, DOI 10.1021/bi971956y; KAUFMAN RJ, 1985, P NATL ACAD SCI USA, V82, P689, DOI 10.1073/pnas.82.3.689; KAUFMAN RJ, 1978, J BIOL CHEM, V253, P5852; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Pelletier JN, 1997, PROTEIN ENG, V10, P89; Pelletier JN, 1998, P NATL ACAD SCI USA, V95, P12141, DOI 10.1073/pnas.95.21.12141; REMY I, UNPUB; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Wrighton NC, 1997, NAT BIOTECHNOL, V15, P1261, DOI 10.1038/nbt1197-1261	24	498	528	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					990	993		10.1126/science.283.5404.990	http://dx.doi.org/10.1126/science.283.5404.990			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974393				2022-12-28	WOS:000078574800050
J	Eisenberg, L				Eisenberg, L			Would cloned humans really be like sheep?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PLASTICITY; BRAIN		Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Eisenberg, L (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							Ashworth D, 1998, NATURE, V394, P329, DOI 10.1038/28521; BENES FM, 1994, ARCH GEN PSYCHIAT, V51, P477; Berg P, 1998, SCIENCE, V282, P413, DOI 10.1126/science.282.5388.413; BLACK FL, 1975, SCIENCE, V187, P515, DOI 10.1126/science.163483; BLACK FL, 1992, SCIENCE, V258, P1739, DOI 10.1126/science.1465610; Catalano SM, 1998, SCIENCE, V281, P559, DOI 10.1126/science.281.5376.559; EISENBERG L, 1995, AM J PSYCHIAT, V152, P1563, DOI 10.1176/ajp.152.11.1563; EISENBERG L, 1972, SCIENCE, V176, P123, DOI 10.1126/science.176.4031.123; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; GROBSTEIN C, 1964, SCIENCE, V143, P643, DOI 10.1126/science.143.3607.643; Hamdy S, 1998, NAT NEUROSCI, V1, P64, DOI 10.1038/264; HARLAN JR, 1975, SCIENCE, V188, P618, DOI 10.1126/science.188.4188.617; Hughes JB, 1997, SCIENCE, V278, P689, DOI 10.1126/science.278.5338.689; MOGILNER A, 1993, P NATL ACAD SCI USA, V90, P3593, DOI 10.1073/pnas.90.8.3593; National Research Council Committee on Genetic Vulnerability of Major Crops, 1972, GEN VULN MAJ CROPS; Needham, 1959, HIST EMBRYOLOGY; Nelson CA, 1997, CHILD DEV, V68, P970, DOI 10.1111/j.1467-8624.1997.tb01974.x; ORMEROD WE, 1976, SCIENCE, V191, P815, DOI 10.1126/science.2977; Penn AA, 1998, SCIENCE, V279, P2108, DOI 10.1126/science.279.5359.2108; SCHLAUG G, 1995, SCIENCE, V267, P699, DOI 10.1126/science.7839149; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; Signer EN, 1998, NATURE, V394, P329, DOI 10.1038/28524; Sterr A, 1998, J NEUROSCI, V18, P4417; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; WANG XQ, 1995, NATURE, V378, P71, DOI 10.1038/378071a0; WIESEL TN, 1982, 1981 NOB PRIZ LECT S; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wilmut I, 1997, NATURE, V386, P200, DOI 10.1038/386200a0; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010	29	19	19	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1999	340	6					471	475		10.1056/NEJM199902113400612	http://dx.doi.org/10.1056/NEJM199902113400612			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166HW	9971875				2022-12-28	WOS:000078571000012
J	Parry, J				Parry, J			A memorable patient - Postmortem movements	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					393	393		10.1136/bmj.318.7180.393	http://dx.doi.org/10.1136/bmj.318.7180.393			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933211	Green Published, Bronze			2022-12-28	WOS:000078572600039
J	Havlir, DV; Barnes, PF				Havlir, DV; Barnes, PF			Tuberculosis in patients with human immunodeficiency virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RESISTANT MYCOBACTERIUM-TUBERCULOSIS; CD4 CELL COUNTS; NEW-YORK-CITY; PULMONARY TUBERCULOSIS; HIV-INFECTION; ANTIRETROVIRAL THERAPY; CONTROLLED TRIAL; LOS-ANGELES; AIDS; RECOMMENDATIONS		Univ Texas, Ctr Hlth, CPIDC, Tyler, TX 75708 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT); University of California System; University of California San Diego	Barnes, PF (corresponding author), Univ Texas, Ctr Hlth, CPIDC, 11937 US Hwy 271, Tyler, TX 75708 USA.	pbarnes@uthct.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035222, R01AI027285, U01AI027670] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27285, AI27670, AI35222] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		*ADV COMM EL TUB, 1989, MMWR-MORBID MORTAL W, V38, P236; *ADV COMM EL TUB A, 1989, MMWR-MORBID MORTAL W, V38, P243; ALLAN WGL, 1977, AM REV RESPIR DIS, V115, P727; ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Asch SM, 1997, AM J RESP CRIT CARE, V155, P378, DOI 10.1164/ajrccm.155.1.9001340; Barnes PF, 1997, JAMA-J AM MED ASSOC, V278, P1159, DOI 10.1001/jama.278.14.1159; Barnes PF, 1997, AM J RESP CRIT CARE, V156, P1022; Barnes PF, 1996, AM J RESP CRIT CARE, V153, P1448, DOI 10.1164/ajrccm.153.4.8616580; Barnes PF, 1997, AM J RESP CRIT CARE, V155, P1497, DOI 10.1164/ajrccm.155.5.9154847; Barnes PF, 1996, CURR TOP MICROBIOL, V215, P197; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Behr MA, 1997, CLIN INFECT DIS, V25, P806, DOI 10.1086/515550; BRINDLE RJ, 1993, AM REV RESPIR DIS, V147, P958, DOI 10.1164/ajrccm/147.4.958; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Catanzaro A, 1997, AM J RESP CRIT CARE, V155, P1804, DOI 10.1164/ajrccm.155.5.9154896; Chaisson RE, 1996, AM J RESP CRIT CARE, V154, P1034, DOI 10.1164/ajrccm.154.4.8887603; Chin DP, 1996, AM J RESP CRIT CARE, V153, P1982, DOI 10.1164/ajrccm.153.6.8665065; Choudhri SH, 1997, CLIN INFECT DIS, V25, P104, DOI 10.1086/514513; COX SR, 1998, 5 C RETR OPP INF CHI, V1, P144; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DOSTER B, 1973, AM REV RESPIR DIS, V107, P177; DUBE MP, 1992, AM J MED, V93, P520, DOI 10.1016/0002-9343(92)90579-Z; FEE MJ, 1995, CLIN INFECT DIS, V20, P938, DOI 10.1093/clinids/20.4.938; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Friedman LN, 1996, NEW ENGL J MED, V334, P828, DOI 10.1056/NEJM199603283341304; GARAY SM, 1995, SEM RESP CRIT CARE M, V16, P187, DOI 10.1055/s-2007-1009828; Garrait V, 1997, J IMMUNOL, V159, P2824; Goletti D, 1996, J IMMUNOL, V157, P1271; GONZALEZMONTANE.LJ, 1997, TUBERCLE LUNG DIS, V75, P341; GORDIN F, 1998, 5 C RETR OPP INF CHI, V1, P223; Gordin FM, 1997, NEW ENGL J MED, V337, P315, DOI 10.1056/NEJM199707313370505; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HAVLIR D, 1995, J INFECT DIS, V171, P537, DOI 10.1093/infdis/171.3.537; Hopewell PC, 1997, SEMIN RESP CRIT CARE, V18, P471, DOI 10.1055/s-2007-1009362; ISEMAN MD, 1993, NEW ENGL J MED, V329, P1435; JONES BE, 1993, AM REV RESPIR DIS, V148, P1292, DOI 10.1164/ajrccm/148.5.1292; Jones BE, 1997, AM J RESP CRIT CARE, V156, P1270, DOI 10.1164/ajrccm.156.4.9609143; JONES BE, 1994, AM J RESP CRIT CARE, V150, P1499, DOI 10.1164/ajrccm.150.6.7952606; KATZ DJ, 1993, AM REV RESPIR DIS, V147, P1283, DOI 10.1164/ajrccm/147.5.1283; Lutfey M, 1996, AM J RESP CRIT CARE, V153, P837, DOI 10.1164/ajrccm.153.2.8564140; Markowitz N, 1997, ANN INTERN MED, V126, P123, DOI 10.7326/0003-4819-126-2-199701150-00005; McGregor MM, 1996, AM J RESP CRIT CARE, V154, P1462, DOI 10.1164/ajrccm.154.5.8912765; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Moore RD, 1996, AM J RESP CRIT CARE, V154, P1013, DOI 10.1164/ajrccm.154.4.8887600; Munsiff SS, 1997, CLIN INFECT DIS, V25, P1465, DOI 10.1086/516146; Nakata K, 1997, AM J RESP CRIT CARE, V155, P996, DOI 10.1164/ajrccm.155.3.9117038; Narita M, 1998, AM J RESP CRIT CARE, V158, P157, DOI 10.1164/ajrccm.158.1.9712001; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; Park MM, 1996, AM J RESP CRIT CARE, V153, P317, DOI 10.1164/ajrccm.153.1.8542137; PATEL KB, 1995, NEW ENGL J MED, V332, P336, DOI 10.1056/NEJM199502023320518; Peloquin CA, 1996, ANN PHARMACOTHER, V30, P919, DOI 10.1177/106002809603000901; Perlman DC, 1997, CLIN INFECT DIS, V25, P242, DOI 10.1086/514546; PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204; Pulido F, 1997, ARCH INTERN MED, V157, P227, DOI 10.1001/archinte.157.2.227; Ridzon R, 1998, AM J RESP CRIT CARE, V157, P1881, DOI 10.1164/ajrccm.157.6.9712009; SCHWANDER S, 1995, TUBERCLE LUNG DIS, V76, P210, DOI 10.1016/S0962-8479(05)80007-3; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SUN E, 1996, 11 INT C AIDS VANC B, V1, P18; THESTRUPPEDERSE.K, 1996, 11 INT C AIDS VANC B, V1, P18; Toossi Z, 1997, J ACQ IMMUN DEF SYND, V15, P325, DOI 10.1097/00042560-199708150-00001; TURETT GS, 1995, CLIN INFECT DIS, V21, P1238, DOI 10.1093/clinids/21.5.1238; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542; Whalen C, 1996, AM J RESP CRIT CARE, V153, P1977, DOI 10.1164/ajrccm.153.6.8665064; Whalen C, 1997, AIDS, V11, P455, DOI 10.1097/00002030-199704000-00008; Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201; ZHANG M, 1994, J CLIN INVEST, V94, P2435, DOI 10.1172/JCI117611; 1991, MMWR MORB MORTAL WKL, V40, P585; 1991, MMWR MORB MORTAL WKL, V40, P27; 1997, MMWR MORB MORTAL WKL, V46, P800; 1996, MMWR MORB MORTAL WKL, V45, P921	78	306	325	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1999	340	5					367	373		10.1056/NEJM199902043400507	http://dx.doi.org/10.1056/NEJM199902043400507			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163WC	9929528				2022-12-28	WOS:000078428500007
J	Coulter, A; Entwistle, V; Gilbert, D				Coulter, A; Entwistle, V; Gilbert, D			Sharing decisions with patients: Is the information good enough?	BRITISH MEDICAL JOURNAL			English	Editorial Material							PERCEPTIONS; PARTICIPATE; OUTCOMES		Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB25, Scotland	University of Aberdeen	Coulter, A (corresponding author), Kings Fund, Policy & Dev, London W1M 0AN, England.		Entwistle, Vikki Ann/I-9266-2019; Coulter, Angela/N-6998-2019	Entwistle, Vikki Ann/0000-0002-0856-4025; Coulter, Angela/0000-0002-6308-8375				Audit Commission, 1993, WHAT SEEMS MATT COMM; Cockburn J, 1997, BRIT MED J, V315, P520, DOI 10.1136/bmj.315.7107.520; Coulter A, 1997, J Health Serv Res Policy, V2, P112; COULTER A, 1994, FAM PRACT, V11, P67, DOI 10.1093/fampra/11.1.67; COULTER A, 1998, INFORMING PATIENTS A; ENGLAND SL, 1992, SOC SCI MED, V34, P1217, DOI 10.1016/0277-9536(92)90314-G; Entwistle VA, 1998, INT J TECHNOL ASSESS, V14, P47, DOI 10.1017/S0266462300010527; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; *NHS EX, 1998, 1 CLASS SERV QUAL NE; *NHS EX, 1996, PAT PARTN BUILD COLL; Ritchie J., 1994, ANAL QUALITATIVE DAT, P173, DOI [10.4324/9780203413081, DOI 10.4324/9780203413081_CHAPTER_9]; SCHULMAN BA, 1979, MED CARE, V17, P267, DOI 10.1097/00005650-197903000-00004; STRULL WM, 1984, JAMA-J AM MED ASSOC, V252, P2990, DOI 10.1001/jama.252.21.2990	14	375	392	1	29	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1999	318	7179					318	322		10.1136/bmj.318.7179.318	http://dx.doi.org/10.1136/bmj.318.7179.318			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZH	9924064	Green Published			2022-12-28	WOS:000078436700030
J	Gottlieb, S				Gottlieb, S			Fibre does not protect against colon cancer	BRITISH MEDICAL JOURNAL			English	News Item																		Fuchs CS, 1999, NEW ENGL J MED, V340, P169, DOI 10.1056/NEJM199901213400301	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1999	318	7179					281	281		10.1136/bmj.318.7179.281	http://dx.doi.org/10.1136/bmj.318.7179.281			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZH	9924043	Green Published			2022-12-28	WOS:000078436700009
J	Greenhalgh, T				Greenhalgh, T			Narrative based medicine - Narrative based medicine in an evidence based world	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DONT		Royal Free & UCL, Sch Med, Dept Primary Care & Populat, London N19 5NF, England	University of London; University College London; UCL Medical School	Greenhalgh, T (corresponding author), Royal Free & UCL, Sch Med, Dept Primary Care & Populat, London N19 5NF, England.	p.greenhalgh@ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				ASCH DA, 1995, ANN INTERN MED, V122, P846, DOI 10.7326/0003-4819-122-11-199506010-00007; DAWSON NV, 1987, J GEN INTERN MED, V2, P183, DOI 10.1007/BF02596149; ELWYN GJ, 1997, SHARED DECISION MAKI; EVANS JG, 1995, AGE AGEING, V24, P461, DOI 10.1093/ageing/24.6.461; FISH S, 1995, DOING WHAT COMES NAT; Freedman L, 1996, BMJ-BRIT MED J, V313, P569; GREENHAIGH T, 1998, GP TRAINING HDB; HART JT, 1993, BRIT MED J, V306, P1337, DOI 10.1136/bmj.306.6888.1337-b; HEATH I, 1995, MYSTERY GEN PRACTICE, P17; Hunter K, 1996, THEOR MED, V17, P225, DOI 10.1007/BF00489447; Hunter KM, 1996, J MED PHILOS, V21, P303; Hurwitz Brian., 1998, NARRATIVE BASED MED, P202; Kahneman D., 1982, JUDGEMENT UNCERTAINT; LEDER D, 1990, THEOR MED, V11, P9, DOI 10.1007/BF00489234; MATTINGLY C, 1994, SOC SCI MED, V38, P811, DOI 10.1016/0277-9536(94)90153-8; MCWHINNEY IR, 1978, J MED PHILOS, V3, P293, DOI 10.1093/jmp/3.4.293; Osgood C.E., 1975, CROSS CULTURAL UNIVE; Popper K. R., 1963, CONJECTURES REFUTAT; Sacket D, 1991, CLIN EPIDEMIOLOGY BA, V2nd; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Stewart M., 1995, PATIENT CTR MED PATIENT CTR MED; Tanenbaum S, 1995, J Eval Clin Pract, V1, P97; TANENBAUM SJ, 1993, NEW ENGL J MED, V329, P1268, DOI 10.1056/NEJM199310213291713; Whitehead A., 1925, SCI MODERN WORLD	25	281	292	0	34	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 30	1999	318	7179					323	325		10.1136/bmj.318.7179.323	http://dx.doi.org/10.1136/bmj.318.7179.323			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	163ZH	9924065	Green Submitted, Green Published			2022-12-28	WOS:000078436700032
J	Reddel, H; Ware, S; Marks, G; Salome, C; Jenkins, C; Woolcock, A				Reddel, H; Ware, S; Marks, G; Salome, C; Jenkins, C; Woolcock, A			Differences between asthma exacerbations and poor asthma control	LANCET			English	Article							ADRENERGIC-RECEPTORS; FLOW; INFECTIONS; SYMPTOMS; CHILDREN; VIRUSES; PRECIPITANTS; MECHANISMS; RESPONSES	Background Increased variation in peak expiratory flow (PEF) is characteristic of poorly controlled asthma, and measurement of diurnal variability of PEF has been recommended for assessment of asthma severity, including during exacerbations. We aimed to test whether asthma exacerbations had the same PEF characteristics as poor asthma control. Methods Electronic PEF records from 43 patients with initially poorly controlled asthma were examined for all exacerbations that occurred after PEF reached a plateau with inhaled corticosteroid treatment. Diurnal variability of PEF was compared during exacerbations, run-in (poor asthma control), and the period of stable asthma before each exacerbation. Findings Diurnal variability was 21.3% during poor asthma control and improved to 53% (stable asthma) with inhaled corticosteroid treatment. 40 exacerbations occurred in 26 patients over 2-16 months; 38 (95%) of exacerbations were associated with symptoms of clinical respiratory infection. During exacerbations, consecutive PEF values fell linearly over several days then improved linearly. However, diurnal variability during exacerbations (7.7%) was not significantly higher than during stable asthma (5.4%, p = 0.1). PEF data were consistent with impaired response to inhaled beta(2)-agonist during exacerbations but not during poorly controlled asthma. Interpretation Asthmatics remain vulnerable to exacerbations during clinical respiratory infections, even after asthma is brought under control. Calculation of diurnal variability may fail to detect important changes in lung function. PEF variation is strikingly different during exacerbations compared with poor asthma control, suggesting differences in beta(2)-adrenoceptor function between these conditions.	Royal Prince Alfred Hosp, Inst Resp Med, Camperdown, NSW 2050, Australia; Univ Sydney, Camperdown, NSW 2050, Australia	University of Sydney; University of Sydney	Reddel, H (corresponding author), Royal Prince Alfred Hosp, Inst Resp Med, POB M77, Camperdown, NSW 2050, Australia.	hkr@mail.med.usyd.edu.au	Reddel, Helen/ABD-6338-2021; Marks, Guy B./F-5058-2013; Reddel, Helen/AAC-3394-2020	Marks, Guy B./0000-0002-8976-8053; Reddel, Helen/0000-0002-6695-6350; Jenkins, Christine/0000-0003-2717-5647				Abisheganaden J., 1996, Singapore Medical Journal, V37, P252; BAI TR, 1992, LUNG, V170, P125; BAI TR, 1992, AM J RESP CELL MOL, V6, P647, DOI 10.1165/ajrcmb/6.6.647; BARDIN PG, 1992, CLIN EXP ALLERGY, V22, P809, DOI 10.1111/j.1365-2222.1992.tb02825.x; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, P838, DOI 10.1164/ajrccm.152.3.7663795; BEASLEY R, 1988, THORAX, V43, P679, DOI 10.1136/thx.43.9.679; BUCKNER CK, 1981, J CLIN INVEST, V67, P376, DOI 10.1172/JCI110045; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; ChanYeung M, 1996, AM J RESP CRIT CARE, V154, P889, DOI 10.1164/ajrccm.154.4.8887581; Corne JM, 1997, THORAX, V52, P380, DOI 10.1136/thx.52.4.380; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708, DOI 10.1164/ajrccm.157.6.9707163; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; GERN JE, 1995, AM J RESP CRIT CARE, V152, pS40, DOI 10.1164/ajrccm/152.4_Pt_2.S40; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; GIBSON PG, 1995, ANN INTERN MED, V123, P488, DOI 10.7326/0003-4819-123-7-199510010-00002; Global Initiative for Asthma (GINA), POCK GUID ASTHM MAN; GOLDIE RG, 1986, BRIT J CLIN PHARMACO, V22, P669, DOI 10.1111/j.1365-2125.1986.tb02956.x; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; HETZEL MR, 1977, BMJ-BRIT MED J, V1, P808, DOI 10.1136/bmj.1.6064.808; Higgins B, 1997, EUR RESPIR J, V10, pS45; HOGG JC, 1984, CLIN CHEST MED, V5, P567; JEDERLINIC PJ, 1989, J INTENSIVE CARE MED, V4, P166; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; KERSTJENS HAM, 1994, THORAX, V49, P1109, DOI 10.1136/thx.49.11.1109; LIN RY, 1994, CHEST, V106, P452, DOI 10.1378/chest.106.2.452; MARKS GB, 1995, J ALLERGY CLIN IMMUN, V96, P441, DOI 10.1016/S0091-6749(95)70285-7; Meijer GG, 1996, AM J RESP CRIT CARE, V153, P237, DOI 10.1164/ajrccm.153.1.8542122; *NAT ASTHM ED PREV, 1997, NIH PUBL; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; REBUCK AS, 1971, AM J MED, V51, P788, DOI 10.1016/0002-9343(71)90307-X; Reddel HK, 1998, EUR RESPIR J, V12, P309, DOI 10.1183/09031936.98.12020309; Reddel HK, 1998, EUR RESPIR J, V12, P853, DOI 10.1183/09031936.98.12040853; VANAALDEREN WMC, 1988, ACTA PAEDIATR SCAND, V77, P269; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	35	182	187	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 30	1999	353	9150					364	369		10.1016/S0140-6736(98)06128-5	http://dx.doi.org/10.1016/S0140-6736(98)06128-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950442				2022-12-28	WOS:000078437000012
J	Schapira, AHV				Schapira, AHV			Science, medicine, and the future - Parkinson's disease	BRITISH MEDICAL JOURNAL			English	Review									Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, London, England; UCL, Neurol Inst, London, England	University of London; University College London; University of London; University College London	Schapira, AHV (corresponding author), Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, London, England.	schapira@rfhsm.ac.uk	Schapira, Anthony H V/A-1245-2010	Schapira, Anthony H V/0000-0002-3018-3966				Fahn S, 1998, ANN NEUROL, V43, P551, DOI 10.1002/ana.410430502; Gasser T, 1998, NAT GENET, V18, P262, DOI 10.1038/ng0398-262; GOLBE LI, 1995, ETIOLOGY PARKINSONS, P115; Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207; Hirsch EC, 1998, ANN NEUROL, V44, pS115, DOI 10.1002/ana.410440717; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; Murer MG, 1998, ANN NEUROL, V43, P561, DOI 10.1002/ana.410430504; Mytilineou C, 1997, J NEUROCHEM, V68, P434; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Schapira AHV, 1998, ANN NEUROL, V44, pS89, DOI 10.1002/ana.410440714; Seaton TA, 1997, BRAIN RES, V777, P110; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; Tatton NA, 1998, ANN NEUROL, V44, pS142, DOI 10.1002/ana.410440721; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572	17	131	150	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 30	1999	318	7179					311	314		10.1136/bmj.318.7179.311	http://dx.doi.org/10.1136/bmj.318.7179.311			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZH	9924061	Green Published			2022-12-28	WOS:000078436700027
J	Mangura, BT; Reichman, LB				Mangura, BT; Reichman, LB			Periodic chest radiography: unnecessary, expensive, but still pervasive	LANCET			English	Editorial Material							HOSPITAL EMPLOYEES; TUBERCULOSIS; EPIDEMIOLOGY		Univ Med & Dent New Jersey, New Jersey Med Sch, Natl TB Ctr, Newark, NJ 07107 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Reichman, LB (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Natl TB Ctr, 65 Bergen St, Newark, NJ 07107 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL003015] Funding Source: NIH RePORTER; NHLBI NIH HHS [K07 HL03015-05] Funding Source: Medline; PHS HHS [U78/CCU208802-05] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARRETTCONNOR E, 1980, AM REV RESPIR DIS, V122, P153; BATES JH, 1995, CHEST, V108, P1690, DOI 10.1378/chest.108.6.1690; *CDC, 1982, DHHS PUBL; *CDC, 1994, MMWR-MORBID MORTAL W, V43, P40; COPE R, 1982, AM REV RESPIR DIS, V125, P106; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; GOTTRIDGE J, 1989, ARCH INTERN MED, V149, P1660, DOI 10.1001/archinte.149.7.1660; HERMANS RD, 1994, P WORKSH ENG CONTR A, P94; LARDIZABEL A, 1996, AM J RESP CRIT CARE, V153, P328; LORDI GM, 1985, JAMA-J AM MED ASSOC, V253, P1780; LOTTE A, 1965, B INT UNION TUBERC, V38, P61; LUNN JA, 1989, J SOC OCCUP MED, V39, P30; Manusov E G, 1996, Fam Med, V28, P645; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; Meijer J, 1971, Bull Int Union Tuberc, V45, P5; ORR P, 1993, TUBERCULOSIS COMPREH, P531; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; Reichman LB, 1996, CHEST, V109, P301, DOI 10.1378/chest.109.2.301; ROBIN ED, 1986, CHEST, V90, P258, DOI 10.1378/chest.90.2.258; SNIDER DE, 1984, AM J INFECT CONTROL, V12, P305, DOI 10.1016/0196-6553(84)90001-4; STYBLO K, 1967, B WORLD HEALTH ORGAN, V37, P819; TAPE TG, 1986, ANN INTERN MED, V104, P663, DOI 10.7326/0003-4819-104-5-663; Toman K., 1979, TUBERCULOSIS CASE FI; *US FDA, 1983, 838204 US FDA US DEP; *WHO, 1983, HOSP PEER REV, V8, P63; 1998, AM HOSP ASS HOSP STA	27	10	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 23	1999	353	9149					319	320		10.1016/S0140-6736(98)10144-7	http://dx.doi.org/10.1016/S0140-6736(98)10144-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929041				2022-12-28	WOS:000078292200042
J	Dunlap, JC				Dunlap, JC			Molecular bases for circadian clocks	CELL			English	Review							DROSOPHILA PERIOD GENE; RNA-BINDING PROTEIN; OPEN READING FRAME; SP STRAIN PCC-7942; NEUROSPORA-CRASSA; TEMPERATURE COMPENSATION; SUPRACHIASMATIC NUCLEUS; MESSENGER-RNA; RHYTHMIC EXPRESSION; CONIDIATION RHYTHM		Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Dunlap, JC (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.		Dunlap, Jay/L-6232-2013	Dunlap, Jay/0000-0003-1577-0457	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034985, R37GM034985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044651, K05MH001186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34985] Funding Source: Medline; NIMH NIH HHS [MH44651, MH01186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; ARONSON BD, 1994, P NATL ACAD SCI USA, V91, P7683, DOI 10.1073/pnas.91.16.7683; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; Ballario P, 1997, TRENDS MICROBIOL, V5, P458, DOI 10.1016/S0966-842X(97)01144-X; Ballario P, 1998, MOL MICROBIOL, V29, P719, DOI 10.1046/j.1365-2958.1998.00955.x; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Barinaga M, 1998, SCIENCE, V281, P1429, DOI 10.1126/science.281.5382.1429; BellPedersen D, 1996, P NATL ACAD SCI USA, V93, P13096, DOI 10.1073/pnas.93.23.13096; BellPedersen D, 1996, MOL CELL BIOL, V16, P513; BELLPEDERSEN D, 1992, GENE DEV, V6, P2382, DOI 10.1101/gad.6.12a.2382; BEST JD, 1999, IN PRESS J NEUROSCI; BLOCK GD, 1995, SEMIN NEUROSCI, V7, P37, DOI 10.1016/1044-5765(95)90015-2; Bunning E, 1973, PHYSL CLOCK; Campbell SS, 1998, SCIENCE, V279, P396, DOI 10.1126/science.279.5349.396; CARRE I, 1996, SEMIN CELL DEV BIOL, V7, P2039; Carre IA, 1995, PLANT CELL, V7, P2039, DOI 10.2307/3870149; Chang B, 1998, GENES GENET SYST, V73, P71, DOI 10.1266/ggs.73.71; Cheng YZ, 1998, MOL CELL BIOL, V18, P6505, DOI 10.1128/MCB.18.11.6505; Cheng YZ, 1998, J NEUROSCI, V18, P741; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dembinska ME, 1997, J BIOL RHYTHM, V12, P157, DOI 10.1177/074873049701200207; DIECKMANN C, 1980, SCIENCE, V207, P896, DOI 10.1126/science.6444467; Dunlap J, 1998, SCIENCE, V280, P1548, DOI 10.1126/science.280.5369.1548; Dunlap JC, 1998, CURR OPIN GENET DEV, V8, P400, DOI 10.1016/S0959-437X(98)80109-3; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; DUNLAP JC, 1999, IN PRESS GENES CELLS; DUNLAP JC, 1998, LIGHT TIME MICROBIAL, P279; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; FELDMAN JF, 1973, GENETICS, V75, P606; FLEISSNER G, 1992, DISCUSS NEUROSCI, V8, P79; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; Foulkes NS, 1996, P NATL ACAD SCI USA, V93, P14140, DOI 10.1073/pnas.93.24.14140; FRANCIS CD, 1979, PLANT PHYSIOL, V64, P1000, DOI 10.1104/pp.64.6.1000; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Golden SS, 1998, CURR OPIN MICROBIOL, V1, P669, DOI 10.1016/S1369-5274(98)80113-6; Golden SS, 1997, ANNU REV PLANT PHYS, V48, P327, DOI 10.1146/annurev.arplant.48.1.327; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; Hall JC, 1998, ADV GENET, V38, P135, DOI 10.1016/S0065-2660(08)60143-1; HALL JC, 1998, CURR OPIN NEUROBIOL; Hamblen MJ, 1998, GENETICS, V149, P165; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; Hastings J. Woodland, 1976, MOL BASIS CIRCADIAN; Hege DM, 1997, J BIOL RHYTHM, V12, P300, DOI 10.1177/074873049701200402; Heintzen C, 1997, P NATL ACAD SCI USA, V94, P8515, DOI 10.1073/pnas.94.16.8515; Herzog ED, 1998, NAT NEUROSCI, V1, P708, DOI 10.1038/3708; Hicks KA, 1996, SCIENCE, V274, P790, DOI 10.1126/science.274.5288.790; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Honma S, 1998, BIOCHEM BIOPH RES CO, V250, P83, DOI 10.1006/bbrc.1998.9275; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Katagiri S, 1998, J BIOL RHYTHM, V13, P452, DOI 10.1177/074873098129000282; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; King DP, 1997, GENETICS, V146, P1049; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; Kutsuna S, 1998, J BACTERIOL, V180, P2167, DOI 10.1128/JB.180.8.2167-2174.1998; Lakin-Thomas PL, 1998, J BIOL RHYTHM, V13, P268, DOI 10.1177/074873098129000101; LakinThomas PL, 1997, CHRONOBIOL INT, V14, P445, DOI 10.3109/07420529709001467; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; Lee K, 1998, FUNGAL GENET BIOL, V23, P269, DOI 10.1006/fgbi.1998.1044; Lee K, 1998, FUNGAL GENET BIOL, V23, P259, DOI 10.1006/fgbi.1998.1043; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; Liu QY, 1996, GENETICS, V143, P1163; Liu Y, 1996, MOL MICROBIOL, V20, P1071, DOI 10.1111/j.1365-2958.1996.tb02547.x; Liu Y, 1998, SCIENCE, V281, P825, DOI 10.1126/science.281.5378.825; Liu Y, 1997, CELL, V89, P477, DOI 10.1016/S0092-8674(00)80228-7; LIU Y, 1995, GENE DEV, V9, P1469, DOI 10.1101/gad.9.12.1469; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; LOROS JJ, 1989, SCIENCE, V243, P385, DOI 10.1126/science.2563175; Loros JJ, 1998, CURR OPIN MICROBIOL, V1, P698, DOI 10.1016/S1369-5274(98)80118-5; Luo CH, 1998, EMBO J, V17, P1228, DOI 10.1093/emboj/17.5.1228; MATTERN DL, 1982, P NATL ACAD SCI-BIOL, V79, P825, DOI 10.1073/pnas.79.3.825; McClung CR, 1997, FREE RADICAL BIO MED, V23, P489, DOI 10.1016/S0891-5849(97)00109-3; McNeil GP, 1998, NEURON, V20, P297, DOI 10.1016/S0896-6273(00)80457-2; MENCKEN HL, 1919, PREJUDICES 1 SEREIS, P308; Merrow MW, 1997, P NATL ACAD SCI USA, V94, P3877, DOI 10.1073/pnas.94.8.3877; Millar AJ, 1996, P NATL ACAD SCI USA, V93, P15491, DOI 10.1073/pnas.93.26.15491; Millar AJ, 1997, BIOESSAYS, V19, P209, DOI 10.1002/bies.950190306; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Millar AJ, 1998, ANN BOT-LONDON, V81, P581, DOI 10.1006/anbo.1998.0595; Mittag M, 1997, FEBS LETT, V411, P245, DOI 10.1016/S0014-5793(97)00701-1; MIYAMOTO Y, 1998, SCIENCE, V95, P6087; Morgan LW, 1997, GENETICS, V146, P525; Morris ME, 1998, SCIENCE, V279, P1544, DOI 10.1126/science.279.5356.1544; MROSOVSKY N, 1989, EXPERIENTIA, V45, P696, DOI 10.1007/BF01974561; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; Nakashima H, 1996, SEMIN CELL DEV BIOL, V7, P765, DOI 10.1006/scdb.1996.0094; Newby LM, 1996, J NEUROBIOL, V31, P117, DOI 10.1002/(SICI)1097-4695(199609)31:1<117::AID-NEU10>3.0.CO;2-I; NEWBY LM, 1993, GENETICS, V135, P1077; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; OISHI K, 1999, IN PRESS BIOCH BIOPH, V260; OISHI K, 1998, IN PRESS NEUROSCI LE, V258; Onai K, 1998, MOL GEN GENET, V259, P264, DOI 10.1007/s004380050812; Onai K, 1997, GENETICS, V146, P101; Peixoto AA, 1998, P NATL ACAD SCI USA, V95, P4475, DOI 10.1073/pnas.95.8.4475; PITTENDRIGH CS, 1961, HARVEY LECT, P93; PITTENDRIGH CS, 1959, NATURE, V184, P169, DOI 10.1038/184169a0; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Reppert SM, 1995, CELL, V83, P1059, DOI 10.1016/0092-8674(95)90131-0; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; Roenneberg T, 1998, J BIOL RHYTHM, V13, P167, DOI 10.1177/074873098129000011; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; Ruoff P, 1996, NATURWISSENSCHAFTEN, V83, P514, DOI 10.1007/BF01141953; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sakamoto K, 1998, J BIOL CHEM, V273, P27039, DOI 10.1074/jbc.273.42.27039; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Sauman I, 1996, NEURON, V17, P889, DOI 10.1016/S0896-6273(00)80220-2; Sawyer LA, 1997, SCIENCE, V278, P2117, DOI 10.1126/science.278.5346.2117; Schaffer R, 1998, CELL, V93, P1219, DOI 10.1016/S0092-8674(00)81465-8; SCHWARTZ WJ, 1995, SEMIN NEUROSCI, V7, P53, DOI 10.1016/1044-5765(95)90017-9; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; SHEARMAN LP, 1999, IN PRESS NEUROREPORT; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Shinohara ML, 1998, J BIOL CHEM, V273, P446, DOI 10.1074/jbc.273.1.446; Sidote D, 1998, MOL CELL BIOL, V18, P2004, DOI 10.1128/MCB.18.4.2004; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; SOGIN ML, 1994, NOBEL S, V84, P181; Somers DE, 1998, DEVELOPMENT, V125, P485; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Stanewsky R, 1997, EMBO J, V16, P5006, DOI 10.1093/emboj/16.16.5006; Sugano S, 1998, P NATL ACAD SCI USA, V95, P11020, DOI 10.1073/pnas.95.18.11020; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; Suzuki S, 1996, GENETICS, V143, P1175; Sweeney BM., 1987, RHYTHMIC PHENOMENA P; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; TAKUMI T, 1999, IN PRESS GENES CELLS; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; Tomioka K, 1998, J INSECT PHYSIOL, V44, P587, DOI 10.1016/S0022-1910(98)00046-8; Tosini G, 1998, NEUROREPORT, V9, P1001, DOI 10.1097/00001756-199804200-00009; Tsinoremas NF, 1996, EMBO J, V15, P2488, DOI 10.1002/j.1460-2075.1996.tb00606.x; TSINOREMAS NF, 1994, J BIOL CHEM, V269, P16143; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; Wang ZY, 1997, PLANT CELL, V9, P491, DOI 10.1105/tpc.9.4.491; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; Whitmore D, 1998, NAT NEUROSCI, V1, P701, DOI 10.1038/3703; WINFREE AT, 1972, J INSECT PHYSIOL, V18, P181, DOI 10.1016/0022-1910(72)90118-7; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; Yan OY, 1998, P NATL ACAD SCI USA, V95, P8660, DOI 10.1073/pnas.95.15.8660; Yang ZH, 1998, NEURON, V21, P215, DOI 10.1016/S0896-6273(00)80528-0; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; Zheng CC, 1998, PLANT PHYSIOL, V116, P27, DOI 10.1104/pp.116.1.27; ZIMMERMAN WF, 1968, J INSECT PHYSIOL, V14, P669, DOI 10.1016/0022-1910(68)90226-6; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	171	2186	2283	9	453	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 22	1999	96	2					271	290		10.1016/S0092-8674(00)80566-8	http://dx.doi.org/10.1016/S0092-8674(00)80566-8			20	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	160VM	9988221	hybrid			2022-12-28	WOS:000078252200010
J	Keys, DN; Lewis, DL; Selegue, JE; Pearson, BJ; Goodrich, LV; Johnson, RL; Gates, J; Scott, MP; Carroll, SB				Keys, DN; Lewis, DL; Selegue, JE; Pearson, BJ; Goodrich, LV; Johnson, RL; Gates, J; Scott, MP; Carroll, SB			Recruitment of a hedgehog regulatory circuit in butterfly eyespot evolution	SCIENCE			English	Article							CUBITUS-INTERRUPTUS; IMAGINAL DISKS; TARGET GENES; DROSOPHILA; EXPRESSION; PATTERN; WINGS; PLASTICITY; PROTEINS; SIGNAL	The origin of new morphological characters is a long-standing problem in evolutionary biology. Novelties arise through changes in development, but the nature of these changes is largely unknown. In butterflies, eyespots have evolved as new pattern elements that develop from special organizers called foci. Formation of these foci is associated with novel expression patterns of the Hedgehog signaling protein, its receptor Patched, the transcription factor Cubitus interruptus, and the engrailed target gene that break the conserved compartmental restrictions on this regulatory circuit in insect wings. Redeployment of preexisting regulatory circuits may be a general mechanism underlying the evolution of novelties.	Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; Stanford Univ, Med Ctr, Howard Hughes Med Inst, Beckman Ctr, Palo Alto, CA 94304 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; Stanford University	Carroll, SB (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, 1525 Linden Dr, Madison, WI 53706 USA.			Pearson, Bret/0000-0002-3473-901X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018162] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [F32 GM18162] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BLAIR S, 1992, DEVELOPMENT, V119, P339; BRAKEFIELD PM, 1991, ECOL ENTOMOL, V16, P291, DOI 10.1111/j.1365-2311.1991.tb00220.x; Brakefield PM, 1996, NATURE, V384, P236, DOI 10.1038/384236a0; BRAKEFIELD PM, 1995, DEV BIOL, V168, P98, DOI 10.1006/dbio.1995.1064; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; CARROLL SB, 1994, SCIENCE, V265, P109, DOI 10.1126/science.7912449; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; FRENCH V, 1995, DEV BIOL, V168, P112, DOI 10.1006/dbio.1995.1065; Hepker J, 1997, DEVELOPMENT, V124, P549; Johnson RL, 1998, CURR OPIN GENET DEV, V8, P450, DOI 10.1016/S0959-437X(98)80117-2; KEYS DN, UNPUB; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MONTEIRO A, 1995, EVOLUTION, V48, P1147; MULLER GB, 1991, ANNU REV ECOL SYST, V22, P229, DOI 10.1146/annurev.es.22.110191.001305; Mullor JL, 1997, DEVELOPMENT, V124, P1227; Nijhout H.F., 1991, DEV EVOLUTION BUTTER; NIJHOUT HF, 1980, DEV BIOL, V80, P267, DOI 10.1016/0012-1606(80)90403-0; NIJHOUT HF, 1994, DEVELOPMENT, P225; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; SCHWARTZ C, 1995, DEVELOPMENT, V121, P1625; SLUSARSKI DC, 1995, GENETICS, V139, P229; Strigini M, 1997, DEVELOPMENT, V124, P4697; Tabin CJ, 1997, TRENDS CELL BIOL, V7, P442, DOI 10.1016/S0962-8924(97)01159-8	26	230	231	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					532	534		10.1126/science.283.5401.532	http://dx.doi.org/10.1126/science.283.5401.532			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915699				2022-12-28	WOS:000078203300035
J	Unwin, C; Blatchley, N; Coker, W; Ferry, S; Hotopf, M; Hull, L; Ismail, K; Palmer, I; David, A; Wessely, S				Unwin, C; Blatchley, N; Coker, W; Ferry, S; Hotopf, M; Hull, L; Ismail, K; Palmer, I; David, A; Wessely, S			Health of UK servicemen who served in Persian Gulf War	LANCET			English	Article							POSTTRAUMATIC-STRESS-DISORDER; VIETNAM VETERANS HEALTH; SELF-REPORTED HEALTH; US VETERANS; EXPOSURE; POPULATION; PREVALENCE; COMBAT; RECALL; SCALE	Background Various symptoms in military personnel in the Persian Gulf War 1990-91 have caused international speculation and concern. We investigated UK servicemen. Methods We did a cross-sectional postal survey on a random sample of Gulf War veterans (Gulf War cohort, n=4248) and, stratified for age and rank, servicemen deployed to the Bosnia conflict (Bosnia cohort, n=4250) and those serving during the Gulf War but not deployed there (Era cohort, n=4246). We asked about deployment, exposures, symptoms, and illnesses. We analysed men only. Our outcome measures were physical health, functional capacity (SF-36), the general health questionnaire, the Centers for Disease Control and Prevention (CDC) multisymptom criteria for Gulf war illness, and post-traumatic stress reactions. Findings There were 8195 (65.1%) valid responses. The Gulf War cohort reported symptoms and disorders significantly more frequently than those in the Bosnia and Era cohorts, which were similar. Perception of physical health and ability were significantly worse in the Gulf War cohort than in the other cohorts, even after adjustment for confounders. Gulf War veterans were more likely than the Bosnia cohort to have substantial fatigue (odds ratio 22 [95% CI 1.9-2.6]), symptoms of post-traumatic stress (2.6 [1.9-3.4]), and psychological distress (1.6 [1/.4-1.8]), and were nearly twice as likely to reach the CDC case definition (25 [2.2-2.8]). In the Gulf War, Bosnia, and Era cohorts, respectively, 61.9%, 36.8%, and 36.4% met the CDC criteria, which fell to 25.3%, 11.8%, and 12.2% for severe symptoms. Potentially harmful exposures were reported most frequently by the Gulf War cohort. All exposures showed associations with all of the outcome measures in the three cohorts. Exposures specific to the Gulf were associated with all outcomes. Vaccination against biological warfare and multiple routine vaccinations were associated with the CDC multisymptom syndrome in the Gulf War cohort. Interpretation Service in the Gulf War was associated with various health problems over and above those associated with deployment to an unfamiliar hostile environment. Since associations of ill health with adverse events and exposures were found in all cohorts, however, they may not be unique and causally implicated in Gulf-War-related illness. A specific mechanism may link vaccination against biological warfare agents and later ill health, but the risks of illness must be considered against the protection of servicemen.	Guys Kings & St Thomas Med Sch, Gulf War Illness Res Unit, London SE5 8AF, England; USAF, Med Operat Agcy, Washington, DC 20330 USA; Off Natl Stat, London, England; Royal Def Med Coll, London, England	University of London; King's College London; United States Department of Defense; United States Air Force	Wessely, S (corresponding author), Guys Kings & St Thomas Med Sch, Gulf War Illness Res Unit, London SE5 8AF, England.	s.wessely@iop.bpmf.ac.uk	David, Anthony S/C-1315-2011; David, Anthony/O-1750-2019; Hotopf, Matthew/E-4971-2010; Wessely, Simon C/A-8713-2008	David, Anthony S/0000-0003-0967-774X; David, Anthony/0000-0003-0967-774X; Wessely, Simon Charles/0000-0002-6743-9929; Ismail, Khalida/0000-0001-6084-449X				Andreski P, 1998, PSYCHIAT RES, V79, P131, DOI 10.1016/S0165-1781(98)00026-2; Baker DG, 1997, ARCH INTERN MED, V157, P2076, DOI 10.1001/archinte.157.18.2076; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Coker W J, 1996, J R Nav Med Serv, V82, P141; DAVIDSON LM, 1986, J CONSULT CLIN PSYCH, V54, P303, DOI 10.1037/0022-006X.54.3.303; DECOUFLE P, 1992, AM J EPIDEMIOL, V135, P312, DOI 10.1093/oxfordjournals.aje.a116285; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; Eaker S, 1998, AM J EPIDEMIOL, V147, P74; Friedman A, 1996, NAT MED, V2, P1382, DOI 10.1038/nm1296-1382; Fukuda K, 1998, JAMA-J AM MED ASSOC, V280, P981, DOI 10.1001/jama.280.11.981; Goldberg D.P, 1972, DETECTION PSYCHIAT I; Gray GC, 1996, NEW ENGL J MED, V335, P1505, DOI 10.1056/NEJM199611143352007; Gray GC, 1998, AM J EPIDEMIOL, V148, P328; Haley RW, 1998, AM J EPIDEMIOL, V148, P315, DOI 10.1093/oxfordjournals.aje.a009645; HOPWOOD DG, 1988, ARCH ENVIRON HEALTH, V43, P234, DOI 10.1080/00039896.1988.9934939; Hyams KC, 1996, ANN INTERN MED, V125, P398, DOI 10.7326/0003-4819-125-5-199609010-00007; Hynes S., 1992, WAR IMAGINED 1 WORLD; Joseph SC, 1997, MIL MED, V162, P149; Kang HK, 1996, NEW ENGL J MED, V335, P1498, DOI 10.1056/NEJM199611143352006; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; KIPEN HM, 1995, AM J PUBLIC HEALTH, V85, P574, DOI 10.2105/AJPH.85.4.574; KORGESKI GP, 1983, AM J PSYCHIAT, V140, P1443; Leed E., 1979, MANS LAND COMBAT IDE; *NAT SURV RES TEAM, 1998, C FED SPONS GULF WAR; OToole BI, 1996, INT J EPIDEMIOL, V25, P319, DOI 10.1093/ije/25.2.319; OToole BI, 1996, INT J EPIDEMIOL, V25, P307, DOI 10.1093/ije/25.2.307; PITMAN RK, 1989, AM J PSYCHIAT, V146, P667; Rook GAW, 1997, LANCET, V349, P1831, DOI 10.1016/S0140-6736(97)01164-1; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238, DOI 10.1001/jama.277.3.238; SIMON GE, 1995, EPIDEMIOL REV, V17, P221, DOI 10.1093/oxfordjournals.epirev.a036180; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WHITEMAN DC, 1995, ARCH ENVIRON HEALTH, V50, P281, DOI 10.1080/00039896.1995.9935955; WRIGHT K, 1995, OPERAETION DESERT SH; Wynn ML, 1997, NEUROLOGY, V48, P2044; 1997, PRESIDENTIAL ADVISOR	35	442	443	0	23	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					169	178		10.1016/S0140-6736(98)11338-7	http://dx.doi.org/10.1016/S0140-6736(98)11338-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	159LW	9923871				2022-12-28	WOS:000078175600008
J	Mao, CD; Sun, WQ; Shen, ZY; Seeman, NC				Mao, CD; Sun, WQ; Shen, ZY; Seeman, NC			A nanomechanical device based on the B-Z transition of DNA	NATURE			English	Article							DOUBLE-CROSSOVER MOLECULES; RESONANCE ENERGY-TRANSFER; JUNCTION; SHUTTLE	The assembly of synthetic, controllable molecular mechanical systems(1-7) is one of the goals of nanotechnology. Protein-based molecular machines, often driven by an energy source such as ATP, are abundant in biology(8,9). It has been shown previously that branched motifs of DNA can provide components for the assembly of nanoscale objects(10), links(11) and arrays(12). Here we show that such structures can also provide the basis for dynamic assemblies: switchable molecular machines. We have constructed a supramolecular device consisting of two rigid DNA 'double-crossover' (DX) molecules connected by 4.5 double-helical turns. One domain of each DX molecule is attached to the connecting helix. To effect switchable motion in this assembly, we use the transition between the B and Z(13,14) forms of DNA. In conditions that favour B-DNA, the two unconnected domains of the DX molecules lie on the same side of the central helix, In Z-DNA-promoting conditions, however, these domains switch to opposite sides of the helix. This relative repositioning is detected by means of fluorescence resonance energy transfer spectroscopy, which measures the relative proximity of two dye molecules attached fa the free ends of the DX molecules, The switching event induces atomic displacements of 20-60 Angstrom.	NYU, Dept Chem, New York, NY 10003 USA	New York University	Seeman, NC (corresponding author), NYU, Dept Chem, New York, NY 10003 USA.		Mao, Chengde/GPP-1546-2022					Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; BEHE M, 1981, P NATL ACAD SCI-BIOL, V78, P1619, DOI 10.1073/pnas.78.3.1619; BISSELL RA, 1994, NATURE, V369, P133, DOI 10.1038/369133a0; CHATTOPADHYAYA R, 1990, J MOL BIOL, V211, P189, DOI 10.1016/0022-2836(90)90020-M; CHEN JH, 1991, NATURE, V350, P631, DOI 10.1038/350631a0; CLEGG RM, 1992, BIOCHEMISTRY-US, V31, P4846, DOI 10.1021/bi00135a016; DADO GP, 1993, J AM CHEM SOC, V115, P12609, DOI 10.1021/ja00079a060; FU TJ, 1993, BIOCHEMISTRY-US, V32, P3211, DOI 10.1021/bi00064a003; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; JaresErijman EA, 1996, J MOL BIOL, V257, P597, DOI 10.1006/jmbi.1996.0188; Li XJ, 1996, J AM CHEM SOC, V118, P6131, DOI 10.1021/ja960162o; Livoreil A, 1997, J AM CHEM SOC, V119, P12114, DOI 10.1021/ja9720826; MA RI, 1986, NUCLEIC ACIDS RES, V14, P9745, DOI 10.1093/nar/14.24.9745; Mao CD, 1997, NATURE, V386, P137, DOI 10.1038/386137b0; Murakami H, 1997, J AM CHEM SOC, V119, P7605, DOI 10.1021/ja971438a; Nedelec FJ, 1997, NATURE, V389, P305, DOI 10.1038/38532; POHL FM, 1972, J MOL BIOL, V67, P375, DOI 10.1016/0022-2836(72)90457-3; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; SEEMAN NC, 1988, J BIOMOL STRUCT DYN, V5, P997, DOI 10.1080/07391102.1988.10506445; SEEMAN NC, 1993, MATER RES SOC SYMP P, V292, P123; Seeman NC, 1998, ANNU REV BIOPH BIOM, V27, P225, DOI 10.1146/annurev.biophys.27.1.225; SHEARDY RD, 1993, J MOL BIOL, V231, P475, DOI 10.1006/jmbi.1993.1295; Smith SS, 1997, P NATL ACAD SCI USA, V94, P2162, DOI 10.1073/pnas.94.6.2162; Winfree E, 1998, NATURE, V394, P539, DOI 10.1038/28998; Yang XP, 1998, BIOPOLYMERS, V45, P69, DOI 10.1002/(SICI)1097-0282(199801)45:1<69::AID-BIP6>3.3.CO;2-W; Zahn S, 1998, ANGEW CHEM INT EDIT, V37, P305, DOI 10.1002/(SICI)1521-3773(19980216)37:3<305::AID-ANIE305>3.0.CO;2-T; ZELKOVICH L, 1995, NATURE, V374, P790	27	686	724	10	205	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1999	397	6715					144	146		10.1038/16437	http://dx.doi.org/10.1038/16437			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923675				2022-12-28	WOS:000078085000040
J	Mohlke, KL; Purkayastha, AA; Westrick, RJ; Smith, PL; Petryniak, B; Lowe, JB; Ginsburg, D				Mohlke, KL; Purkayastha, AA; Westrick, RJ; Smith, PL; Petryniak, B; Lowe, JB; Ginsburg, D			Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase	CELL			English	Article							DOLICHOS-BIFLORUS AGGLUTININ; VONWILLEBRAND DISEASE; TRANSGENIC MICE; FACTOR-VIII; MOUSE CHROMOSOME-11; BINDING-SITES; FACTOR GENE; BLOOD-GROUP; FACTOR-IX; CELLS	We have identified altered lineage-specific expression of an N-acetylgalactosaminyltransferase gene, Galgt2, as the gain-of-function mechanism responsible for the action of the Mvwf locus, a major modifier of plasma von Willebrand factor (VWF) level in RIIIS/J mice. A switch of Galgt2 gene expression from intestinal epithelial cell-specific to a pattern restricted to the vascular endothelial cell bed leads to aberrant posttranslational modification and rapid clearance of WVF from plasma. Transgenic expression of Galgt2 directed to vascular endothelial cells reproduces the low VWF phenotype, confirming this switch in lineage-specific gene expression as the likely molecular mechanism for Mvwf. These findings identify alterations in glycosyltransferase function as a potential general mechanism for the genetic modification of plasma protein levels.	Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ginsburg, D (corresponding author), Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.	ginsburg@umich.edu			NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039693, R37HL039693] Funding Source: NIH RePORTER; NCI NIH HHS [CA71932] Funding Source: Medline; NHLBI NIH HHS [HL39693] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; BEDELL MA, 1995, GENE DEV, V9, P455, DOI 10.1101/gad.9.4.455; Bedell MA, 1996, NAT GENET, V12, P229, DOI 10.1038/ng0396-229; Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; Cunningham JM, 1996, SEMIN HEMATOL, V33, P9; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; DUTTLINGER R, 1993, DEVELOPMENT, V118, P705; GILL JC, 1987, BLOOD, V69, P1691; GINSBURG D, 1992, BLOOD, V79, P2507; Ihara Y, 1998, P NATL ACAD SCI USA, V95, P2526, DOI 10.1073/pnas.95.5.2526; Kolatkar AR, 1998, J BIOL CHEM, V273, P19502, DOI 10.1074/jbc.273.31.19502; Kornfeld S, 1998, J CLIN INVEST, V101, P1293, DOI 10.1172/JCI3140; Lip GYH, 1997, CARDIOVASC RES, V34, P255, DOI 10.1016/S0008-6363(97)00039-4; LYONS SE, 1992, J BIOL CHEM, V267, P4424; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mohlke KL, 1998, GENOMICS, V54, P19, DOI 10.1006/geno.1998.5553; Mohlke KL, 1997, J LAB CLIN MED, V130, P252, DOI 10.1016/S0022-2143(97)90019-6; Mohlke KL, 1996, P NATL ACAD SCI USA, V93, P15352, DOI 10.1073/pnas.93.26.15352; Nichols WC, 1997, MEDICINE, V76, P1, DOI 10.1097/00005792-199701000-00001; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; NICHOLS WC, 1994, BLOOD, V83, P3225; NICHOLS WC, 1991, P NATL ACAD SCI USA, V88, P3857, DOI 10.1073/pnas.88.9.3857; ORSTAVIK KH, 1985, AM J HUM GENET, V37, P89; ORSTAVIK KH, 1989, BLOOD, V73, P990; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; PONDER BAJ, 1983, DEV BIOL, V96, P535, DOI 10.1016/0012-1606(83)90191-4; PONDER BAJ, 1985, J EMBRYOL EXP MORPH, V87, P229; RAND JH, 1987, ARTERIOSCLEROSIS, V7, P287, DOI 10.1161/01.ATV.7.3.287; RODEGHIERO F, 1987, BLOOD, V69, P454; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; Schwarz HP, 1997, THROMB HAEMOSTASIS, V78, P571; SMITH PL, 1994, J BIOL CHEM, V269, P15162; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; SODETZ JM, 1979, J BIOL CHEM, V254, P754; Stoddart JH, 1996, BLOOD, V88, P1692; SWEENEY JD, 1990, BLOOD, V76, P2258; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; UITERDIJK HG, 1986, GENET RES, V47, P125, DOI 10.1017/S0016672300022953; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; WatkinsChow D, 1996, MAMM GENOME, V6, pS201	49	131	134	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 8	1999	96	1					111	120		10.1016/S0092-8674(00)80964-2	http://dx.doi.org/10.1016/S0092-8674(00)80964-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989502	Bronze			2022-12-28	WOS:000078023200013
J	Easterbrooke, J				Easterbrooke, J			The emperor has no clothes on	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1999	318	7181					473	473		10.1136/bmj.318.7181.473	http://dx.doi.org/10.1136/bmj.318.7181.473			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BF	9974486	Green Published			2022-12-28	WOS:000078670100074
J	Gasner, MR; Maw, KL; Feldman, GE; Fujiwara, PI; Frieden, TR				Gasner, MR; Maw, KL; Feldman, GE; Fujiwara, PI; Frieden, TR			The use of legal action in New York City to ensure treatment of tuberculosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM	Background and Methods After an increase in the number of cases of tuberculosis, New York City passed regulations to address the problem of nonadherence to treatment regimens. The commissioner of health can issue orders compelling a person to be examined for tuberculosis, to complete treatment, to receive treatment under direct observation, or to be detained for treatment. On the basis of a review of patients' records, we evaluated the use of these legal actions between April 1993 and April 1995. Results Among more than 8000 patients with tuberculosis, regulatory orders were issued for less than 4 percent. Among patients with a variety of social problems, only a minority required regulatory intervention: 10 percent of those with injection-drug use, 16 percent of those with alcohol abuse, 17 percent of those who were homeless, 29 percent of those who used "crack" cocaine, and 38 percent of those with a history of incarceration. A total of 150 patients were ordered to undergo directly observed therapy, 139 patients to be detained during therapy, 12 patients to be examined for tuberculosis, and 3 patients to complete treatment. These 304 patients had a median of three prior hospitalizations related to tuberculosis and one episode of leaving the hospital against medical advice. Repeatedly noncompliant patients and those who left the hospital against medical advice were more likely than others to be detained. The median length of detention was 3 weeks for infectious patients and 28 weeks for noninfectious patients. As compared with patients ordered to receive directly observed therapy, the patients who were detained remained infectious longer, had left hospitals against medical advice more often, and were less likely to accept directly observed therapy voluntarily. Altogether, excluding those who died or moved, 96 percent of the patients completed treatment, and 2 percent continued to receive treatment for multidrug-resistant tuberculosis. Conclusions For most patients with tuberculosis, even those with severe social problems, completion of treatment can usually be achieved without regulatory intervention. Patients were detained on the basis of their history of tuberculosis, rather than on the basis of their social characteristics, and the less restrictive measure of mandatory directly observed therapy was often effective. (N Engl J Med 1999;340:359-66.) (C) 1999, Massachusetts Medical Society.	New York City Dept Hlth, Bur TB Control, New York, NY 10013 USA; Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA	Fujiwara, PI (corresponding author), New York City Dept Hlth, Bur TB Control, 125 Worth St,Rm 214,Box 74, New York, NY 10013 USA.			Frieden, Thomas/0000-0002-4759-2256				ANNAS GJ, 1993, NEW ENGL J MED, V328, P585, DOI 10.1056/NEJM199302253280825; Bayer Ronald, 1992, TUBERCULOSIS REVIVAL; *BUR TUB CONTR, 1995, INF SUMM 1994; *BUR TUB CONTR, 1998, INF SUMM 1997; *BUR TUB CONTR, 1996, INF SUMM 1995; Burman WJ, 1997, CHEST, V112, P57, DOI 10.1378/chest.112.1.57; Dean A., 1995, EPI INFO VERSION 6 0; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Fujiwara PI, 1997, CLIN CHEST MED, V18, P135, DOI 10.1016/S0272-5231(05)70363-4; LERNER B, 1998, CONTAGION CONFINEMEN; Oscherwitz T, 1997, JAMA-J AM MED ASSOC, V278, P843, DOI 10.1001/jama.278.10.843; *SAS I, 1993, SAS STAT SOFTW SYNT; Singleton L, 1997, JAMA-J AM MED ASSOC, V278, P838, DOI 10.1001/jama.278.10.838	13	75	78	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1999	340	5					359	366		10.1056/NEJM199902043400506	http://dx.doi.org/10.1056/NEJM199902043400506			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163WC	9929527				2022-12-28	WOS:000078428500006
J	Fisher, ES; Welch, HG				Fisher, ES; Welch, HG			Avoiding the unintended consequences of growth in medical care - How might more be worse?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; BYPASS GRAFT-SURGERY; HEALTH-CARE; OUTCOMES; LESIONS; CANCER; BREAST; BENEFICIARIES; PREVALENCE; DIAGNOSIS	The United States has experienced dramatic growth in both the technical capabilities and share of resources devoted to medical care. While the benefits of more medical care are widely recognized, the possibility that harm may result from growth has received little attention. Because harm from more medical care is unexpected, findings of harm are discounted or ignored. We suggest that such findings may indicate a more general problem and deserve serious consideration, First, we delineate 2 levels of decision making where more medical care may be introduced: (1) decisions about whether or not to use a discrete diagnostic or therapeutic intervention and (2) decisions about whether to add system capacity, eg, the decision to purchase another scanner or employ another physician. Second, we explore how more medical care at either level may lead to harm. More diagnosis creates the potential for labeling and detection of pseudodisease-disease that would never become apparent to patients during their lifetime without testing. More treatment may lead to tampering, interventions to correct random rather than systematic variation, and lower treatment thresholds, where the risks outweigh the potential benefits. Because there are more diagnoses to treat and more treatments to provide, physicians may be more likely to make mistakes and to be distracted from the issues of greatest concern to their patients. Finally, we turn to the fundamental challenge-reducing the risk of harm from more medical care. We identify 4 ways in which inadequate information and improper reasoning may allow harmful practices to be adopted-a constrained model of disease, excessive extrapolation, a missing level of analysis, and the assumption that more is better.	Dartmouth Coll, Sch Med, Ctr Evaluat Clin Sci, Hanover, NH 03755 USA; Dept Vet Affairs Med Ctr, VA Outcomes Grp, White River Jct, VT USA	Dartmouth College; VA Outcomes Group	Fisher, ES (corresponding author), Dartmouth Coll, Sch Med, Ctr Evaluat Clin Sci, 7251 Strasenburgh Hall, Hanover, NH 03755 USA.							Albertsen PC, 1998, JAMA-J AM MED ASSOC, V280, P975, DOI 10.1001/jama.280.11.975; [Anonymous], 1989, NEW ENGL J MED, V321, P406; BARRY MJ, 1995, MED CARE, V33, P771, DOI 10.1097/00005650-199508000-00003; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Beam CA, 1996, ARCH INTERN MED, V156, P209, DOI 10.1001/archinte.156.2.209; BEESON PB, 1980, MEDICINE, V59, P79, DOI 10.1097/00005792-198003000-00001; BERGMAN AB, 1967, NEW ENGL J MED, V276, P1008, DOI 10.1056/NEJM196705042761804; BERWICK DM, 1991, MED CARE, V29, P1212, DOI 10.1097/00005650-199112000-00004; BIRKETT NJ, 1986, J HYPERTENS, V4, P369, DOI 10.1097/00004872-198606000-00019; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BUNKER JP, 1994, MILBANK Q, V72, P225, DOI 10.2307/3350295; CADMAN D, 1987, AM J PUBLIC HEALTH, V77, P45, DOI 10.2105/AJPH.77.1.45; CARLSON R, 1975, END MED; Chamberlain DA, 1997, LANCET, V350, P461; CHRISCHILLES EA, 1992, ANN INTERN MED, V117, P634, DOI 10.7326/0003-4819-117-8-634; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Deyo RA, 1997, NEW ENGL J MED, V336, P1176, DOI 10.1056/NEJM199704173361611; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; Dyson DC, 1998, NEW ENGL J MED, V338, P15, DOI 10.1056/NEJM199801013380103; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P287, DOI 10.1001/jama.263.2.287; ELMORE JG, 1994, NEW ENGL J MED, V331, P1493, DOI 10.1056/NEJM199412013312206; EZZAT S, 1994, ARCH INTERN MED, V154, P1838; Farmer ER, 1996, HUM PATHOL, V27, P528, DOI 10.1016/S0046-8177(96)90157-4; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; FISHER ES, 1994, NEW ENGL J MED, V331, P989, DOI 10.1056/NEJM199410133311506; Gavin JR, 1997, DIABETES CARE, V20, P1183; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; HAMPTON ML, 1974, AM J DIS CHILD, V128, P58, DOI 10.1001/archpedi.1974.02110260060010; HARACH HR, 1985, CANCER, V56, P531, DOI DOI 10.1002/1097-0142(19850801)56:3!; Illich I., 1976, MED NEMESIS EXPROPRI; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; KASSIRER JP, 1993, NEW ENGL J MED, V329, P570, DOI 10.1056/NEJM199308193290810; Kiefe CI, 1998, J GEN INTERN MED, V13, P357, DOI 10.1046/j.1525-1497.1998.00115.x; KORNICK J, 1990, RADIOLOGY, V177, P463, DOI 10.1148/radiology.177.2.2217786; KRUMHOLZ HM, 1995, CIRCULATION, V92, P2841, DOI 10.1161/01.CIR.92.10.2841; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEDERLE FA, 1988, ARCH INTERN MED, V148, P1753, DOI 10.1001/archinte.148.8.1753; Levine S., 1983, HDB HLTH HLTH CARE H, P394; Matchar DB, 1997, HEALTH SERV RES, V32, P325; McKeown T., 1979, MED HIST, DOI DOI 10.1515/9781400854622; MONTIE JE, 1989, CANCER, V63, P381, DOI 10.1002/1097-0142(19890115)63:2<381::AID-CNCR2820630230>3.0.CO;2-O; MOSER KM, 1994, JAMA-J AM MED ASSOC, V271, P223, DOI 10.1001/jama.271.3.223; *NAT CTR HLTH STAT, 1996, 76200 US DEP HLTH HU; *NAT CTR HLTH STAT, 1996, HLTH US 1995; NEASE RF, 1995, JAMA-J AM MED ASSOC, V273, P1185, DOI 10.1001/jama.273.15.1185; Newhouse J., 1993, FREE ALL; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; Pincus HA, 1998, JAMA-J AM MED ASSOC, V279, P526, DOI 10.1001/jama.279.7.526; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; Reid MC, 1998, ANN INTERN MED, V128, P354, DOI 10.7326/0003-4819-128-5-199803010-00003; ROSAI J, 1991, AM J SURG PATHOL, V15, P209, DOI 10.1097/00000478-199103000-00001; Sackett D. L., 1997, EVIDENCE BASED MED P; SCHERKENBACH WW, 1991, DEMING ROUTE QUALITY; SCHNITT SJ, 1992, AM J SURG PATHOL, V16, P1133, DOI 10.1097/00000478-199212000-00001; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Steinbrook R, 1998, NEW ENGL J MED, V338, P1541, DOI 10.1056/NEJM199805213382111; STRAUSS MJ, 1986, JAMA-J AM MED ASSOC, V255, P1143, DOI 10.1001/jama.255.9.1143; TANASESCU DE, 1982, RADIOLOGY, V145, P453, DOI 10.1148/radiology.145.2.7134452; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Tu JV, 1997, ANN INTERN MED, V126, P13, DOI 10.7326/0003-4819-126-1-199701010-00002; URBAN BA, 1993, AM J ROENTGENOL, V160, P783, DOI 10.2214/ajr.160.4.8456665; Verrilli D, 1996, JAMA-J AM MED ASSOC, V275, P1189, DOI 10.1001/jama.275.15.1189; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; Welch HG, 1996, ANN INTERN MED, V124, P577, DOI 10.7326/0003-4819-124-6-199603150-00007; Welch HG, 1998, JAMA-J AM MED ASSOC, V280, P1525, DOI 10.1001/jama.280.17.1525; Wennberg DE, 1998, JAMA-J AM MED ASSOC, V279, P1278, DOI 10.1001/jama.279.16.1278; Wennberg JE, 1998, DARTMOUTH ATLAS HLTH; Wilson RM, 1995, MED J AUSTRALIA, V163, P458, DOI 10.5694/j.1326-5377.1995.tb124691.x; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	75	197	197	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					446	453		10.1001/jama.281.5.446	http://dx.doi.org/10.1001/jama.281.5.446			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	161YT	9952205				2022-12-28	WOS:000078318500033
J	Higenbottam, T; Stenmark, K; Simonneau, G				Higenbottam, T; Stenmark, K; Simonneau, G			Treatments for severe pulmonary hypertension	LANCET			English	Editorial Material							EXPRESSION; PROSTACYCLIN; LUNGS; GENE		Univ Sheffield, Sch Med, Div Clin Sci, Sheffield S10 2RX, S Yorkshire, England; Univ Colorado, Hlth Sci Ctr, Dept Crit Care Med & Dev Biol, Denver, CO USA; Univ Paris 11, Hop Antoine Beclere, Serv Pneumol, Clamart, France	University of Sheffield; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; UDICE-French Research Universities; Universite Paris Saclay	Higenbottam, T (corresponding author), Univ Sheffield, Sch Med, Div Clin Sci, Sheffield S10 2RX, S Yorkshire, England.		stenmark, kurt/AAH-3124-2022; stenmark, kurt/AFI-6776-2022; Simonneau, Gerald/ABE-6614-2020					Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; BOTNEY MD, 1992, AM J PATHOL, V140, P357; CHRISTMAN BW, 1992, NEW ENGL J MED, V327, P70, DOI 10.1056/NEJM199207093270202; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Higenbottam T, 1998, HEART, V80, P151, DOI 10.1136/hrt.80.2.151; HIGENBOTTAM W, 1997, 9702 TREND I HLTH SE; KAPANCI Y, 1990, AM J PATHOL, V136, P881; Katayama Y, 1998, CIRCULATION, V98, P2429, DOI 10.1161/01.CIR.98.22.2429; Mayer E, 1996, ANN THORAC SURG, V61, P1788, DOI 10.1016/0003-4975(96)00169-5; Nichols WC, 1997, NAT GENET, V15, P277, DOI 10.1038/ng0397-277; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; Sandoval J, 1998, J AM COLL CARDIOL, V32, P297, DOI 10.1016/S0735-1097(98)00238-1; Sitbon O, 1998, EUR RESPIR J, V12, P265, DOI 10.1183/09031936.98.12020265; Stenmark KR, 1997, ANNU REV PHYSIOL, V59, P89, DOI 10.1146/annurev.physiol.59.1.89; TUDER RM, 1994, AM J PATHOL, V144, P275; Voelkel NF, 1996, ANN NY ACAD SCI, V796, P186, DOI 10.1111/j.1749-6632.1996.tb32580.x; Wang JA, 1998, LANCET, V352, P290, DOI 10.1016/S0140-6736(05)60264-4	19	21	26	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 30	1999	353	9150					338	340		10.1016/S0140-6736(98)00330-4	http://dx.doi.org/10.1016/S0140-6736(98)00330-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950432				2022-12-28	WOS:000078437000002
J	Moshfegh, K; Wuillemin, WA; Redondo, M; Lammle, B; Beer, JH; Liechti-Gallati, S; Meyer, BJ				Moshfegh, K; Wuillemin, WA; Redondo, M; Lammle, B; Beer, JH; Liechti-Gallati, S; Meyer, BJ			Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study	LANCET			English	Article							CORONARY-THROMBOSIS; WHOLE-BLOOD; SMOKING; IIIA; NOREPINEPHRINE; AGGREGATION; PREVENTION; DISEASE; STROKE; GENE	Background The platelet membrane glycoprotein Ia/IIa plays a major part in platelet function as a primary receptor for collagen. A previous report showed a Variation of glycoprotein Ia/IIa receptor density and function associated with two silent and linked polymorphisms (807C/T and 873G/A) within the glycoprotein la gene; Because platelet thrombus formation is implicated in the pathogenesis of acute myocardial infarction, we investigated these polymorphisms among patients who had had a myocardial infarction. Methods We did a 2/1 case-control study including 177 patients (median age 57.0 [range 32-72] years) and 89 controls with same age and sex. Distributions of the 807C/T and 873G/A polymorphisms were investigated by genotyping DNA by PCR, single-strand conformation polymorphism analysis, and sequencing. Findings The prevalence of the homozygous 807T/873A genotype was 2.9 times higher among patients with myocardial infarction than among controls (16.4% vs 5.6%, p = 0.022). There was an association between patients homozygous for the 807T/873A allele and myocardial infarction (odds ratio 3.3 [95% CI 1.2-8.8]), which was strongest in a subgroup of smokers. The homozygous 807T/873A genotype remained an independent risk factor for myocardial infarction (p = 0.005) when age, sex, smoking, hypertension, diabetes, body-mass index, LDL-cholesterol and HDL-cholesterol, and fibrinogen were adjusted for by logistic regression. Interpretation The 807T/873A homozygosity of the platelet glycoprotein Ia/IIa gene polymorphism, associated with differences in surface collagen receptor density and activity, appears to be an independent risk factor for acute myocardial infarction. Our findings need to be confirmed in a larger, prospective study that includes patients from different populations and cardiovascular risk groups.	Univ Hosp Bern, Inselspital, Dept Med, Div Cardiol, CH-3010 Bern, Switzerland; Univ Hosp Bern, Inselspital, Cent Haematol Lab, CH-3010 Bern, Switzerland; Univ Hosp Bern, Inselspital, Dept Mol Genet, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Meyer, BJ (corresponding author), Univ Hosp Bern, Inselspital, Dept Med, Div Cardiol, CH-3010 Bern, Switzerland.	bmeyer@insel.ch	Laemmle, Bernhard/AAJ-1216-2020	Laemmle, Bernhard/0000-0003-4538-5154; Beer, Jurg Hans/0000-0002-7199-0406				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BEUTLER E, 1990, HUM GENET, V85, P9; BEUTLER E, 1992, GENOMICS, V12, P795, DOI 10.1016/0888-7543(92)90311-F; Burke AP, 1997, NEW ENGL J MED, V336, P1276, DOI 10.1056/NEJM199705013361802; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Carroll VA, 1997, ARTERIOSCL THROM VAS, V17, P114, DOI 10.1161/01.ATV.17.1.114; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; CRYER PE, 1976, NEW ENGL J MED, V295, P573, DOI 10.1056/NEJM197609092951101; Davies MJ, 1995, EUR HEART J, V16, P3, DOI 10.1093/eurheartj/16.suppl_L.3; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; *EFF PLAT GLYC IIB, 1997, CIRCULATION, V96, P1445; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; HUANG EM, 1981, BLOOD, V57, P685; KIRCHHOFER D, 1995, BLOOD, V86, P3815, DOI 10.1182/blood.V86.10.3815.bloodjournal86103815; Kunicki TJ, 1997, BLOOD, V89, P1939, DOI 10.1182/blood.V89.6.1939; KUNICKI TJ, 1993, BLOOD, V82, P2693; Newman PJ, 1997, LANCET, V349, P370, DOI 10.1016/S0140-6736(97)80002-5; NURDEN AT, 1995, THROMB HAEMOSTASIS, V74, P345; Nurden AT, 1997, LANCET, V350, P1189, DOI 10.1016/S0140-6736(05)63447-2; RICHARD I, 1995, NAT GENET, V10, P259, DOI 10.1038/ng0795-259; Ridker PM, 1997, LANCET, V349, P385, DOI 10.1016/S0140-6736(97)80010-4; SHARP DS, 1995, THROMB HAEMOSTASIS, V74, P730; SIESS W, 1982, CIRCULATION, V66, P44, DOI 10.1161/01.CIR.66.1.44; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Walter DH, 1997, LANCET, V350, P1217, DOI 10.1016/S0140-6736(97)05399-3; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703	30	178	195	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 30	1999	353	9150					351	354		10.1016/S0140-6736(98)06448-4	http://dx.doi.org/10.1016/S0140-6736(98)06448-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950439				2022-12-28	WOS:000078437000009
J	Young, C; Burrows, R; Katz, J; Beynon, H				Young, C; Burrows, R; Katz, J; Beynon, H			Hypercalcaemia in sarcoidosis	LANCET			English	Article									Royal Free Hosp, Dept Rheumatol, London NW3 2QG, England; Royal Free Hosp, Dept Endocrinol, London NW3 2QG, England; Hammersmith Hosp, Dept Renal Med, London, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Imperial College London	Young, C (corresponding author), Royal Free Hosp, Dept Rheumatol, Pond St, London NW3 2QG, England.							BIA MJ, 1991, AM J KIDNEY DIS, V18, P702, DOI 10.1016/S0272-6386(12)80613-5; HARTMANN F, 1975, MED KLIN, V70, P904; Sharma OP, 1996, CHEST, V109, P535, DOI 10.1378/chest.109.2.535; Tomita A, 1995, Nihon Rinsho, V53, P949; Zeimer HJ, 1998, AM J PATHOL, V152, P17	5	11	11	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 30	1999	353	9150					374	374		10.1016/S0140-6736(98)08251-8	http://dx.doi.org/10.1016/S0140-6736(98)08251-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950444				2022-12-28	WOS:000078437000014
J	Zrenner, E				Zrenner, E			No cause for alarm over retinal side-effects of sildenafil	LANCET			English	Editorial Material							CLINICAL ELECTRORETINOGRAPHY; STANDARD		Univ Tubingen, Hosp Eye, Dept Pathophysiol Vis & Neuroophthalmol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Zrenner, E (corresponding author), Univ Tubingen, Hosp Eye, Dept Pathophysiol Vis & Neuroophthalmol, D-72076 Tubingen, Germany.							[Anonymous], 1982, DOC OPHTHALMOL, V33, P103; HOFFMANN ML, 1978, A GRAEF ARCH KLIN EX, V206, P237, DOI 10.1007/BF02387335; JACOBI PC, 1993, DOC OPHTHALMOL, V85, P95, DOI 10.1007/BF01371126; MARMOR MF, 1995, DOC OPHTHALMOL, V89, P199, DOI 10.1007/BF01203373; SCHNEIDER T, 1986, INVEST OPHTH VIS SCI, V27, P1395; SCHNEIDER T, 1987, DRUG INDUCED OCULAR, P183; Wallis R, 1998, OPHTHAL RES S1, V30, P68; ZRENNER E, 1982, DOC OPHTHALMOL, V33, P493; ZRENNER E, 1998, KLIN MONATSBL AUGENH, V6, P212	9	21	21	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 30	1999	353	9150					340	341		10.1016/S0140-6736(05)74943-6	http://dx.doi.org/10.1016/S0140-6736(05)74943-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950434				2022-12-28	WOS:000078437000004
J	Viola, A; Schroeder, S; Sakakibara, Y; Lanzavecchia, A				Viola, A; Schroeder, S; Sakakibara, Y; Lanzavecchia, A			T lymphocyte costimulation mediated by reorganization of membrane microdomains	SCIENCE			English	Article							CELL ACTIVATION; ANTIGEN RECEPTORS; CAVEOLAE; DOMAINS; KINASE; PURIFICATION; LOCALIZATION; PROTEIN; BINDING; CD28	Although dispensable, costimulation through CD28 facilitates activation of naive T lymphocytes. CD28 engagement Led to the redistribution and clustering of membrane and intracellular kinase-rich raft microdomains at the site of T cell receptor (TCR) engagements. Although not affecting TCR down-regulation, this process Led to higher and more stable tyrosine phosphorylation of several substrates and higher consumption of Lck. These results may provide a general mechanism for amplifying receptor signaling by reorganization of membrane microdomains.	Basel Inst Immunol, CH-4005 Basel, Switzerland		Viola, A (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.	viola@bii.ch	Agatea, Lisa/L-8267-2016; Viola, Antonella/A-4321-2015	Viola, Antonella/0000-0002-0125-9271				Bachmann MF, 1997, IMMUNITY, V7, P549, DOI 10.1016/S1074-7613(00)80376-3; Beeson C, 1996, J EXP MED, V184, P777, DOI 10.1084/jem.184.2.777; Cai ZL, 1997, J EXP MED, V185, P641, DOI 10.1084/jem.185.4.641; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CINEK T, 1992, J IMMUNOL, V149, P2262; DOro U, 1997, IMMUNITY, V7, P619, DOI 10.1016/S1074-7613(00)80383-0; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Hudrisier D, 1998, J IMMUNOL, V161, P553; Klasen S, 1998, INT IMMUNOL, V10, P481, DOI 10.1093/intimm/10.4.481; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; Lowin-Kropf B, 1998, J CELL BIOL, V140, P861, DOI 10.1083/jcb.140.4.861; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Reif K, 1998, IMMUNITY, V8, P395, DOI 10.1016/S1074-7613(00)80545-2; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tuosto L, 1998, EUR J IMMUNOL, V28, P2131, DOI 10.1002/(SICI)1521-4141(199807)28:07<2131::AID-IMMU2131>3.0.CO;2-Q; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Viola A, 1997, J EXP MED, V186, P1775, DOI 10.1084/jem.186.10.1775; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1987, J IMMUNOL, V138, P2169; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	41	822	847	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 29	1999	283	5402					680	682		10.1126/science.283.5402.680	http://dx.doi.org/10.1126/science.283.5402.680			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924026				2022-12-28	WOS:000078324400040
J	Rew, DA; Woltmann, G; Wardlaw, AJ				Rew, DA; Woltmann, G; Wardlaw, AJ			Laser-scanning cytometry	LANCET			English	Editorial Material							FLOW-CYTOMETRY; MULTIPARAMETER ANALYSIS; TUMORS		Univ Leicester, Glenfield Hosp, Adv Laser Cytometry Facil, Leicester LE3 9QP, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Rew, DA (corresponding author), Univ Leicester, Glenfield Hosp, Adv Laser Cytometry Facil, Leicester LE3 9QP, Leics, England.			Woltmann, Gerrit/0000-0002-9253-6034; Wardlaw, Andrew/0000-0001-6583-0791; Rew, David/0000-0002-4518-2667				Bedner E, 1998, CYTOMETRY, V33, P1, DOI 10.1002/(SICI)1097-0320(19980901)33:1<1::AID-CYTO1>3.0.CO;2-P; Bedner E, 1998, CYTOMETRY, V33, P47, DOI 10.1002/(SICI)1097-0320(19980901)33:1&lt;47::AID-CYTO6&gt;3.0.CO;2-8; Clatch RJ, 1998, CYTOMETRY, V34, P36, DOI 10.1002/(SICI)1097-0320(19980215)34:1<36::AID-CYTO6>3.0.CO;2-C; Clatch RJ, 1998, CYTOMETRY, V34, P3, DOI 10.1002/(SICI)1097-0320(19980215)34:1<3::AID-CYTO2>3.0.CO;2-L; Clatch RJ, 1997, ARCH PATHOL LAB MED, V121, P585; Deptala A, 1998, CYTOMETRY, V33, P376, DOI 10.1002/(SICI)1097-0320(19981101)33:3<376::AID-CYTO13>3.0.CO;2-Q; Gorczyca W, 1997, ACTA CYTOL, V41, P98, DOI 10.1159/000332313; KAMENTSKY LA, 1991, CYTOMETRY, V12, P381, DOI 10.1002/cyto.990120502; Kamentsky LA, 1997, CYTOMETRY, V27, P117, DOI 10.1002/(SICI)1097-0320(19970201)27:2<117::AID-CYTO3>3.0.CO;2-D; Luther E, 1996, CYTOMETRY, V23, P272, DOI 10.1002/(SICI)1097-0320(19960401)23:4<272::AID-CYTO2>3.0.CO;2-J; MARTINREAY DG, 1994, AM J CLIN PATHOL, V102, P432, DOI 10.1093/ajcp/102.4.432; Musco ML, 1998, CYTOMETRY, V33, P290, DOI 10.1002/(SICI)1097-0320(19981101)33:3<290::AID-CYTO2>3.0.CO;2-L; Sasaki K, 1996, CYTOMETRY, V23, P106, DOI 10.1002/(SICI)1097-0320(19960201)23:2<106::AID-CYTO3>3.0.CO;2-I; STYLES JA, 1998, CYTOMETRY S, V9, P41; WATSON JV, 1992, INTRO FLOW CYTOMETRY; Woltmann G, 1998, CYTOMETRY, V33, P362, DOI 10.1002/(SICI)1097-0320(19981101)33:3<362::AID-CYTO11>3.0.CO;2-R; WOLTMANN G, IN PRESS THORAX	17	9	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 23	1999	353	9149					255	256		10.1016/S0140-6736(05)74940-0	http://dx.doi.org/10.1016/S0140-6736(05)74940-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929014				2022-12-28	WOS:000078292200004
J	Edlund, T; Jessell, TM				Edlund, T; Jessell, TM			Progression from extrinsic to intrinsic signaling in cell fate specification: A view from the nervous system	CELL			English	Review							DEPENDENT KINASE INHIBITOR; NEURAL CREST CELLS; NEUROTRANSMITTER BIOSYNTHETIC GENES; RESTRICTIVE SILENCER FACTOR; MYOGENIC DIFFERENTIATION; REGULATORY MECHANISMS; TRANSCRIPTION FACTORS; SKELETAL-MUSCLE; POLYCOMB-GROUP; EGF RECEPTOR		Umea Univ, Dept Microbiol, S-90187 Umea, Sweden; Columbia Univ, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, New York, NY 10032 USA	Umea University; Columbia University; Howard Hughes Medical Institute	Edlund, T (corresponding author), Umea Univ, Dept Microbiol, S-90187 Umea, Sweden.							ALTABA ARI, 1995, MOL CELL NEUROSCI, V6, P106, DOI 10.1006/mcne.1995.1011; Anderson D, 1997, MOL CELLULAR APPROAC, P26; ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ARTINGER KB, 1992, DEV BIOL, V149, P149, DOI 10.1016/0012-1606(92)90271-H; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; Benveniste RJ, 1998, DEVELOPMENT, V125, P4757; BLENZ M, 1995, BIOESSAYS, V17, P775; Bohner AP, 1997, DEVELOPMENT, V124, P915; Boyes J, 1998, J MOL BIOL, V279, P529, DOI 10.1006/jmbi.1998.1783; Burrows RC, 1997, NEURON, V19, P251, DOI 10.1016/S0896-6273(00)80937-X; Campbell G, 1998, DEVELOPMENT, V125, P4483; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; Castillo SO, 1998, MOL CELL NEUROSCI, V11, P36, DOI 10.1006/mcne.1998.0673; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; Cepko CL, 1998, CURR TOP DEV BIOL, V36, P51; CHAIN DG, 1995, J NEUROSCI, V15, P7592; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; Chien CT, 1996, P NATL ACAD SCI USA, V93, P13239, DOI 10.1073/pnas.93.23.13239; Dale JK, 1997, CELL, V90, P257, DOI 10.1016/S0092-8674(00)80334-7; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; Dupin E, 1998, CURR TOP DEV BIOL, V36, P1; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Eagleson KL, 1997, DEVELOPMENT, V124, P1623; ElShamy WM, 1998, NEURON, V21, P1003, DOI 10.1016/S0896-6273(00)80619-4; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Ericson J, 1997, COLD SPRING HARB SYM, V62, P451; Ezzeddine ZD, 1997, DEVELOPMENT, V124, P1055; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Frantz GD, 1996, NEURON, V17, P55, DOI 10.1016/S0896-6273(00)80280-9; Gage FH, 1998, CURR OPIN NEUROBIOL, V8, P671, DOI 10.1016/S0959-4388(98)80098-6; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; Ghosh A, 1998, CELL, V95, P303, DOI 10.1016/S0092-8674(00)81762-6; Gould A, 1998, NEURON, V21, P39, DOI 10.1016/S0896-6273(00)80513-9; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; GROVES AK, 1995, DEVELOPMENT, V121, P887; HABECKER BA, 1994, SCIENCE, V264, P1602, DOI 10.1126/science.8202714; Habecker BA, 1997, J BIOL CHEM, V272, P30421, DOI 10.1074/jbc.272.48.30421; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; Harper JW, 1997, CANCER SURV, V29, P91; HARRIS WA, 1991, NEURON, V6, P499, DOI 10.1016/0896-6273(91)90053-3; Henrique D, 1997, GENE DEV, V11, P603, DOI 10.1101/gad.11.5.603; Hirsch MR, 1998, DEVELOPMENT, V125, P599; Hollyday M, 1983, Prog Clin Biol Res, V110 Pt A, P183; Hong Y, 1998, DEVELOPMENT, V125, P3585; Horsfield J, 1998, DEVELOPMENT, V125, P5069; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Jacobs D, 1998, GENETICS, V149, P1809; Jarman AP, 1998, MECH DEVELOP, V76, P117, DOI 10.1016/S0925-4773(98)00116-6; JOHNSON WA, 1990, NATURE, V343, P467, DOI 10.1038/343467a0; Kanekar S, 1997, NEURON, V19, P981, DOI 10.1016/S0896-6273(00)80391-8; LANDIS SC, 1990, TRENDS NEUROSCI, V13, P344, DOI 10.1016/0166-2236(90)90147-3; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; LEDOUARIN NM, 1986, SCIENCE, V231, P1515, DOI 10.1126/science.3952494; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lehner CF, 1997, J CELL SCI, V110, P523; Liem KF, 1997, CELL, V91, P127, DOI 10.1016/S0092-8674(01)80015-5; Lillien L, 1998, MOL CELL NEUROSCI, V10, P296, DOI 10.1006/mcne.1997.0659; LILLIEN L, 1992, DEVELOPMENT, V115, P253; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; Lillien L, 1998, CURR OPIN NEUROBIOL, V8, P37, DOI 10.1016/S0959-4388(98)80006-8; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; Lo LC, 1998, DEVELOPMENT, V125, P609; LO LC, 1995, NEURON, V15, P527, DOI 10.1016/0896-6273(95)90142-6; Lo LC, 1997, CURR BIOL, V7, P440, DOI 10.1016/S0960-9822(06)00191-6; Lu BW, 1998, CURR OPIN GENET DEV, V8, P392, DOI 10.1016/S0959-437X(98)80108-1; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; MANDEL G, 1995, CELL, V80, P949; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MCCONNELL SK, 1995, NEURON, V15, P761, DOI 10.1016/0896-6273(95)90168-X; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MICHELSOHN AM, 1992, NEURON, V8, P589, DOI 10.1016/0896-6273(92)90285-L; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Morrow EM, 1998, J NEUROSCI, V18, P3738; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Neophytou C, 1997, DEVELOPMENT, V124, P2345; Nonchev S, 1997, COLD SPRING HARB SYM, V62, P313; Olson EC, 1998, MOL CELL NEUROSCI, V12, P281, DOI 10.1006/mcne.1998.0712; Panchision D, 1998, CURR OPIN CELL BIOL, V10, P727, DOI 10.1016/S0955-0674(98)80114-2; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Paro R, 1998, CIBA F SYMP, V214, P51; Pattyn A, 1997, DEVELOPMENT, V124, P4065; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Piette J, 1997, EXP CELL RES, V234, P193, DOI 10.1006/excr.1997.3588; Raff MC, 1998, INT J DEV BIOL, V42, P263; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; SCHIER AF, 1992, NATURE, V356, P804, DOI 10.1038/356804a0; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; SCHWARTZ JH, 1993, P NATL ACAD SCI USA, V90, P8310, DOI 10.1073/pnas.90.18.8310; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sidow A, 1996, CURR OPIN GENET DEV, V6, P715, DOI 10.1016/S0959-437X(96)80026-8; Simpson P, 1997, CURR OPIN GENET DEV, V7, P537, DOI 10.1016/S0959-437X(97)80083-4; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Slack F, 1997, ANNU REV GENET, V31, P611, DOI 10.1146/annurev.genet.31.1.611; Sockanathan S, 1998, CELL, V94, P503, DOI 10.1016/S0092-8674(00)81591-3; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; Stevens CF, 1998, CURR BIOL, V8, pR708, DOI 10.1016/S0960-9822(98)70454-3; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Swanson DJ, 1997, J BIOL CHEM, V272, P27382, DOI 10.1074/jbc.272.43.27382; Tanabe Y, 1998, CELL, V95, P67, DOI 10.1016/S0092-8674(00)81783-3; TEMPLE S, 1986, CELL, V44, P773, DOI 10.1016/0092-8674(86)90843-3; Thomsen GH, 1997, TRENDS GENET, V13, P209, DOI 10.1016/S0168-9525(97)01117-7; Thor S, 1997, NEURON, V18, P397, DOI 10.1016/S0896-6273(00)81241-6; Tikoo R, 1998, J NEUROBIOL, V36, P431, DOI 10.1002/(SICI)1097-4695(19980905)36:3<431::AID-NEU10>3.3.CO;2-N; Tikoo R, 1997, J BIOL CHEM, V272, P442; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VANLOOKEREN, 1998, J COMP NEUROL, V397, P181; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5; Watanabe G, 1998, DEV BRAIN RES, V108, P77, DOI 10.1016/S0165-3806(98)00032-7; Wenner P, 1995, J NEUROSCI, V15, P8191; Wilson PA, 1997, NEURON, V18, P699, DOI 10.1016/S0896-6273(00)80311-6; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; Yang CY, 1998, J NEUROCHEM, V71, P1813; Zabludoff SD, 1998, CELL GROWTH DIFFER, V9, P1; Zellmer E, 1995, J NEUROSCI, V15, P8109; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zorn AM, 1997, CURR BIOL, V7, pR501, DOI 10.1016/S0960-9822(06)00248-X	140	406	412	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 22	1999	96	2					211	224		10.1016/S0092-8674(00)80561-9	http://dx.doi.org/10.1016/S0092-8674(00)80561-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	160VM	9988216	Bronze			2022-12-28	WOS:000078252200005
J	Rodionov, O; Lobocka, M; Yarmolinsky, M				Rodionov, O; Lobocka, M; Yarmolinsky, M			Silencing of genes flanking the P1 plasmid centromere	SCIENCE			English	Article							INTEGRATION HOST FACTOR; COLI F-PLASMID; ESCHERICHIA-COLI; PARTITION COMPLEX; NEGATIVE CONTROL; MINI-F; PROTEIN; REPLICATION; CHROMOSOME; REGION	Partition modules stabilize bacterial plasmids and chromosomes by actively promoting their segregation into daughter cells. The partition module of plasmid P1 is typical and consists of a centromere site, parS, and genes that encode proteins ParA and ParB. We show that ParB can silence genes flanking parS (to which ParB binds), apparently by polymerizing along the DNA from a nucleation site at parS. Wild-type ParB contacts an extensive region of P1 DNA; silencing-defective ParB proteins, which were found to be partition-defective, are Less able to spread. Hence, the silenced structure appears to function in partitioning.	NCI, Biochem Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yarmolinsky, M (corresponding author), NCI, Biochem Lab, 37 Convent Dr, Bethesda, MD 20892 USA.	myarmo@helix.nih.gov	B, Łobocka Małgorzata/I-3844-2019; Lobocka, Malgorzata/K-4496-2019	Lobocka, Malgorzata/0000-0003-0679-5193	DIVISION OF BASIC SCIENCES - NCI [Z01BC005267] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELES AL, 1984, J MOL BIOL, V173, P307, DOI 10.1016/0022-2836(84)90123-2; ABELES AL, 1985, J MOL BIOL, V185, P261, DOI 10.1016/0022-2836(85)90402-4; ABELES AL, 1986, J MOL BIOL, V189, P387; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; BIEK DP, 1994, P NATL ACAD SCI USA, V91, P8027, DOI 10.1073/pnas.91.17.8027; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; CHATTORAJ D, 1984, P NATL ACAD SCI-BIOL, V81, P6456, DOI 10.1073/pnas.81.20.6456; DARN M, 1994, J MOL BIOL, V236, P1289; DAVIS MA, 1992, MOL MICROBIOL, V6, P1141, DOI 10.1111/j.1365-2958.1992.tb01552.x; DIEDERICH L, 1992, PLASMID, V28, P14, DOI 10.1016/0147-619X(92)90032-6; FUMMELL BE, 1993, J BIOL CHEM, V268, P3616; FUNNELL BE, 1991, J BIOL CHEM, V266, P14328; FUNNELL BE, 1988, P NATL ACAD SCI USA, V85, P6657, DOI 10.1073/pnas.85.18.6657; FUNNELL BE, 1994, BIOCHIMIE, V76, P924, DOI 10.1016/0300-9084(94)90017-5; GALLIE DR, 1987, J MOL BIOL, V193, P465, DOI 10.1016/0022-2836(87)90260-9; GERDES K, UNPUB; Hanai R, 1996, J BIOL CHEM, V271, P17469, DOI 10.1074/jbc.271.29.17469; HAYES F, 1993, P NATL ACAD SCI USA, V90, P9228, DOI 10.1073/pnas.90.19.9228; HELSBERG M, 1986, J BACTERIOL, V165, P1043, DOI 10.1128/jb.165.3.1043-1045.1986; Jensen RB, 1998, P NATL ACAD SCI USA, V95, P8550, DOI 10.1073/pnas.95.15.8550; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; Kim SK, 1998, P NATL ACAD SCI USA, V95, P1523, DOI 10.1073/pnas.95.4.1523; Lin DCH, 1998, CELL, V92, P675, DOI 10.1016/S0092-8674(00)81135-6; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; Lobocka M, 1996, J MOL BIOL, V259, P366, DOI 10.1006/jmbi.1996.0326; LOBOCKA M, UNPUB; LYNCH AS, 1995, P NATL ACAD SCI USA, V92, P1896, DOI 10.1073/pnas.92.6.1896; MARTIN KA, 1991, J BACTERIOL, V173, P3630, DOI 10.1128/JB.173.12.3630-3634.1991; MILLER JH, 1975, METHOD ENZYMOL, V43, P737; Mohl DA, 1997, CELL, V88, P675, DOI 10.1016/S0092-8674(00)81910-8; MORALES VM, 1991, GENE, V97, P39, DOI 10.1016/0378-1119(91)90007-X; NICHOLS BP, 1983, METHOD ENZYMOL, V101, P155; PAPP PP, 1994, J BIOL CHEM, V269, P23563; RODIONOV O, UNPUB; RUSSO EA, 1996, EPIGENETIC MECHANISM; SOM T, 1982, MOL GEN GENET, V187, P375, DOI 10.1007/BF00332615; TAKANO T, 1976, VIROLOGY, V70, P198, DOI 10.1016/0042-6822(76)90252-X; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6	39	195	195	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 22	1999	283	5401					546	549		10.1126/science.283.5401.546	http://dx.doi.org/10.1126/science.283.5401.546			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915704	Green Submitted			2022-12-28	WOS:000078203300040
J	Hofmann, T; Obukhov, AG; Schaefer, M; Harteneck, C; Gudermann, T; Schultz, G				Hofmann, T; Obukhov, AG; Schaefer, M; Harteneck, C; Gudermann, T; Schultz, G			Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol	NATURE			English	Article							CAPACITATIVE CALCIUM-ENTRY; STORE DEPLETION; MAST-CELLS; G-PROTEIN; RECEPTOR; EXPRESSION; CA2+; CLONING	Eukaryotic cells respond to many hormones and neurotransmitters with increased activity of the enzyme phospholipase C and a subsequent rise in the concentration of intracellular free calcium ([Ca2+](i))(1). The increase in [Ca2+](i) occurs as a result of the release of Ca2+ from intracellular stores and an influx of Ca2+ through the plasma membrane(2-4); this influx of Ca2+ may(5) or may not(6) be store-dependent. Drosophila transient receptor potential (TRP) proteins and some mammalian homologues (TRPC proteins) are thought to mediate capacitative Ca2+ entry(7-9). Here we describe the molecular mechanism of store-depletion-independent activation of a subfamily of mammalian TRPC channels. We find that hTRPC6 is a non-selective cation channel that is activated by diacylglycerol in a membrane-delimited fashion, independently of protein kinases C activated by diacylglycerol, Although hTRPC3, the closest structural relative of hTRPC6, is activated in the same way, TRPCs i, 4 and 5 and the vanilloid receptor subtype 1 are unresponsive to the lipid mediator. Thus, hTRPC3 and hTRPC6 represent the first members of a new functional family of second-messenger-operated cation channels, which are activated by diacylglycerol.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schultz, G (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.	gschultz@zedat.fu-berlin.de	Obukhov, Alexander G/C-7246-2008	Obukhov, Alexander G/0000-0002-3862-6004				BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; FASOLATO C, 1993, P NATL ACAD SCI USA, V90, P3068, DOI 10.1073/pnas.90.7.3068; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; Helliwell RM, 1997, J PHYSIOL-LONDON, V499, P417, DOI 10.1113/jphysiol.1997.sp021938; Hille B., 1992, IONIC CHANNELS EXCIT; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Migas I, 1996, AM J PHYSIOL-CELL PH, V271, pC1194; Montell C, 1998, CURR OPIN NEUROBIOL, V8, P389, DOI 10.1016/S0959-4388(98)80066-4; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; Mori Y, 1998, NEUROREPORT, V9, P507; NEHER E, 1977, ANNU REV BIOPHYS BIO, V6, P345, DOI 10.1146/annurev.bb.06.060177.002021; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Scott K, 1998, CURR OPIN NEUROBIOL, V8, P383, DOI 10.1016/S0959-4388(98)80065-2; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6296	27	1177	1212	0	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 21	1999	397	6716					259	263		10.1038/16711	http://dx.doi.org/10.1038/16711			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159QH	9930701				2022-12-28	WOS:000078184800054
J	Rivera, C; Voipio, J; Payne, JA; Ruusuvuori, E; Lahtinen, H; Lamsa, K; Pirvola, U; Saarma, M; Kaila, K				Rivera, C; Voipio, J; Payne, JA; Ruusuvuori, E; Lahtinen, H; Lamsa, K; Pirvola, U; Saarma, M; Kaila, K			The K+/Cl- co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation	NATURE			English	Article							K-CL COTRANSPORTER; HIPPOCAMPAL-NEURONS; PYRAMIDAL NEURONS; MESSENGER-RNAS; IONIC BASIS; RAT; INHIBITION; GANGLIA; CELLS; BRAIN	GABA (gamma-aminobutyric acid) is the main inhibitory transmitter in the adult brain, and it exerts its fast hyperpolarizing effect through activation of anion (predominantly Cl-)-permeant GABA(A) receptors(1), However, during early neuronal development, GABA(A)-receptor-mediated responses are often depolarizing(2,3), which may be a key factor in the control of several Ca2+-dependent developmental phenomena, including neuronal proliferation, migration and targeting(4-6). To date, however, the molecular mechanism underlying this shift in neuronal electrophysiological phenotype is unknown. Here we show that, in pyramidal neurons of the rat hippocampus, the ontogenetic change in GABA(A)-mediated responses from depolarizing to hyperpolarizing is coupled to a developmental induction of the expression of the neuronal Cl--extruding K+/Cl- co-transporter, KCC2 (ref. 7). Antisense oligonucleotide inhibition of KCC2 expression produces a marked positive shift in the reversal potential of GABA, responses in functionally mature hippocampal pyramidal neurons. These data support the conclusion that KCC2 is the main Cl- extruder to promote fast hyperpolarizing postsynaptic inhibition in the brain.	Univ Helsinki, Dept Biosci, Div Anim Physiol, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Viikki Bioctr, FIN-00014 Helsinki, Finland; Univ Calif Davis, Sch Med, Dept Human Physiol, Davis, CA 95616 USA	University of Helsinki; University of Helsinki; University of California System; University of California Davis	Kaila, K (corresponding author), Univ Helsinki, Dept Biosci, Div Anim Physiol, FIN-00014 Helsinki, Finland.	kai.kaila@helsinki.fi	Lamsa, Karri/T-2025-2019; Rivera, Claudio/ABE-2499-2021; Kaila, Kai/R-8528-2016	Rivera, Claudio/0000-0003-2462-6561; Voipio, Juha/0000-0001-7096-1286; Kaila, Kai/0000-0003-0668-5955; Lamsa, Karri/0000-0002-4609-1337				BAYER SA, 1987, PROG NEUROBIOL, V29, P57, DOI 10.1016/0301-0082(87)90015-3; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; BENGTSTROM M, 1991, NUCLEIC ACIDS RES S, V24, P288; Bevensee Mark O., 1998, P211; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clayton GH, 1998, DEV BRAIN RES, V108, P307, DOI 10.1016/S0165-3806(98)00045-5; Clayton GH, 1998, DEV BRAIN RES, V109, P281, DOI 10.1016/S0165-3806(98)00078-9; DESCHENES M, 1976, BRAIN RES, V118, P486, DOI 10.1016/0006-8993(76)90318-8; GILLEN C, 1993, J BIOL CHEM, V271, P16237; KAILA K, 1994, PROG NEUROBIOL, V42, P489, DOI 10.1016/0301-0082(94)90049-3; KAILA K, 1993, J PHYSIOL-LONDON, V464, P273, DOI 10.1113/jphysiol.1993.sp019634; LoTurco JJ, 1995, NEURON, V15, P1287, DOI 10.1016/0896-6273(95)90008-X; MISGELD U, 1986, SCIENCE, V232, P1413, DOI 10.1126/science.2424084; Moshnyakov M, 1996, MOL BRAIN RES, V43, P141, DOI 10.1016/S0169-328X(96)00168-4; Pasternack M, 1996, NEUROPHARMACOLOGY, V35, P1279, DOI 10.1016/S0028-3908(96)00075-5; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; PAYNE JA, 1997, AM J PHYSIOL, V42, pC1516; PIRVOLA U, 1992, P NATL ACAD SCI USA, V89, P9915, DOI 10.1073/pnas.89.20.9915; RIVERA C, 1997, SOC NEUROSCI ABSTR, V23; SERAFINI R, 1995, J PHYSIOL-LONDON, V488, P371, DOI 10.1113/jphysiol.1995.sp020973; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; SUTOR B, 1995, PERSPECT DEV NEUROBI, V2, P409; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P512, DOI 10.1152/jn.1989.61.3.512; vandenPol AN, 1996, J NEUROSCI, V16, P4283; WU WI, 1992, J NEUROSCI, V12, P3935; YUSTE R, 1991, NEURON, V6, P333, DOI 10.1016/0896-6273(91)90243-S; ZHANG L, 1991, J PHYSIOL-LONDON, V444, P25, DOI 10.1113/jphysiol.1991.sp018864	28	1567	1611	2	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 21	1999	397	6716					251	255		10.1038/16697	http://dx.doi.org/10.1038/16697			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159QH	9930699				2022-12-28	WOS:000078184800052
J	Perrier, A; Desmarais, S; Miron, MJ; de Moerloose, P; Lepage, R; Slosman, D; Didier, D; Unger, PF; Patenaude, JV; Bounameaux, H				Perrier, A; Desmarais, S; Miron, MJ; de Moerloose, P; Lepage, R; Slosman, D; Didier, D; Unger, PF; Patenaude, JV; Bounameaux, H			Non-invasive diagnosis of venous thromboembolism in outpatients	LANCET			English	Article							DEEP-VEIN THROMBOSIS; SUSPECTED PULMONARY-EMBOLISM; SERIAL IMPEDANCE PLETHYSMOGRAPHY; D-DIMER LEVELS; LUNG-SCAN; ULTRASONOGRAPHY; MANAGEMENT; PLASMA; ANGIOGRAPHY; PROBABILITY	Background We designed a simple and integrated diagnostic algorithm for acute venous thromboembolism based on clinical probability assessment of deep-vein thrombosis (DVT) or pulmonary embolism (PE), plasma D-dimer measurement, lower-limb venous compression ultrasonography, and lung scan to reduce the need for phlebography and pulmonary angiography. Methods 918 consecutive patients presenting at the emergency ward of the Geneva University Hospital, Geneva, Switzerland, and Hopital Saint-Luc, Montreal, Canada, with clinically suspected venous thromboembolism were entered into a sequential diagnostic protocol. Patients in whom venous thromboembolism was deemed absent were not given anticoagulants and were followed up for 3 months. Findings A normal D-dimer concentration (<500 mu g/L by a rapid ELISA) ruled out venous thromboembolism in 286 (31%) members of the study cohort, whereas DVT by ultrasonography established the diagnosis in 157 (17%). Lung scan was diagnostic in 80 (9%) of the remaining patients. Venous thromboembolism was also deemed absent in patients with low to intermediate clinical probability of DVT and a normal venous ultrasonography (236 [26%] patients), and in patients with a low clinical probability of PE and a non-diagnostic result on lung scan (107 [12%] patients). Pulmonary angiography and phlebography were done in only 50 (5%) and 2 (<1%) of the patients, respectively. Hence, a non-invasive diagnosis was possible in 866 (94%) members of the entire cohort. The 3-month thromboembolic risk in patients not given anticoagulants, based on the results of the diagnostic protocol, was 1.8% (95% CI 0.9-3.1). Interpretation A diagnostic strategy combining clinical assessment, D-dimer, ultrasonography, and lung scan gave a non-invasive diagnosis in the vast majority of outpatients with suspected venous thromboembolism, and appeared to be safe.	Univ Hosp Geneva, Med Clin 1, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Div Angiol, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Div Haemostasis, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Div Radiodiagnost & Intervent Radiol, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Div Med & Surg Emergency, CH-1211 Geneva 14, Switzerland; Univ Montreal, Hop St Luc, Dept Internal & Vasc Med, Quebec City, PQ, Canada; Univ Montreal, Hop St Luc, Haematol Lab, Quebec City, PQ, Canada	University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; Universite de Montreal; Universite de Montreal	Perrier, A (corresponding author), Univ Hosp Geneva, Med Clin 1, 24 Rue Micheli du Crest, CH-1211 Geneva 14, Switzerland.	arnaud.perrier@medecine.unige.ch	Perrier, Arnaud/M-2263-2014					ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; BARRITT DW, 1960, LANCET, V1, P1309; BECKER DM, 1989, ARCH INTERN MED, V149, P1731, DOI 10.1001/archinte.149.8.1731; Becker DM, 1996, ARCH INTERN MED, V156, P939, DOI 10.1001/archinte.156.9.939; Borg JY, 1997, THROMB HAEMOSTASIS, V77, P602; BOUNAMEAUX H, 1991, LANCET, V337, P196, DOI 10.1016/0140-6736(91)92158-X; Bounameaux H, 1997, QJM-INT J MED, V90, P437, DOI 10.1093/qjmed/90.7.437; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; Cogo A, 1998, BRIT MED J, V316, P17, DOI 10.1136/bmj.316.7124.17; DAngelo A, 1996, THROMB HAEMOSTASIS, V75, P412; deMoerloose P, 1996, THROMB HAEMOSTASIS, V75, P11; GINSBERG JS, 1995, THROMB HAEMOSTASIS, V73, P35; Ginsberg JS, 1997, ARCH INTERN MED, V157, P1077, DOI 10.1001/archinte.157.10.1077; GOLDHABER SZ, 1993, JAMA-J AM MED ASSOC, V270, P2819, DOI 10.1001/jama.270.23.2819; GOODMAN LR, 1995, AM J ROENTGENOL, V164, P1369, DOI 10.2214/ajr.164.6.7754875; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, ARCH INTERN MED, V149, P511, DOI 10.1001/archinte.149.3.511; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL RD, 1994, ARCH INTERN MED, V154, P289, DOI 10.1001/archinte.154.3.289; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; Janssen MCH, 1997, THROMB HAEMOSTASIS, V77, P262; KAKKAR VV, 1969, LANCET, V2, P230; LAGERSTEDT CI, 1985, LANCET, V2, P515; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; MIRON MJ, 1998, J GEN INTERN MED, V13, P205; MORABIA A, 1994, J GEN INTERN MED, V9, P496, DOI 10.1007/BF02599219; MOSER KM, 1994, BRIT MED J, V309, P1525, DOI 10.1136/bmj.309.6968.1525; Perrier A, 1997, ARCH INTERN MED, V157, P2309, DOI 10.1001/archinte.157.20.2309; Perrier A, 1996, ARCH INTERN MED, V156, P531, DOI 10.1001/archinte.156.5.531; Perrier A, 1997, AM J RESP CRIT CARE, V156, P492, DOI 10.1164/ajrccm.156.2.9702032; PERRIER A, 1998, J GEN INTERN MED, V13, P235; PRANDONI P, 1991, THROMB HAEMOSTASIS, V65, P233; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; RAIMONDI P, 1993, THROMB RES, V69, P125, DOI 10.1016/0049-3848(93)90009-D; RemyJardin M, 1996, RADIOLOGY, V200, P699, DOI 10.1148/radiology.200.3.8756918; SLUZEWSKI M, 1991, EUR J RADIOL, V13, P174, DOI 10.1016/0720-048X(91)90023-O; Turkstra F, 1997, ANN INTERN MED, V126, P775, DOI 10.7326/0003-4819-126-10-199705150-00005; vanRossum AB, 1996, THORAX, V51, P23, DOI 10.1136/thx.51.1.23; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008; WORSLEY DF, 1994, ARCH INTERN MED, V154, P2737, DOI 10.1001/archinte.1994.00420230134016	44	634	641	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 16	1999	353	9148					190	195		10.1016/S0140-6736(98)05248-9	http://dx.doi.org/10.1016/S0140-6736(98)05248-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923874				2022-12-28	WOS:000078175600011
J	Straus, SE				Straus, SE			Bridging the gulf in war syndromes	LANCET			English	Editorial Material									NIAID, Clin Invest Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Straus, SE (corresponding author), NIAID, Clin Invest Lab, NIH, Bethesda, MD 20892 USA.							Da Costa JM., 1871, AM J MED SCI, V61, P17; DEFRAITES RF, 1992, 123 ARM RES COMM FOR; Fukuda K, 1998, JAMA-J AM MED ASSOC, V280, P981, DOI 10.1001/jama.280.11.981; Grant RT, 1925, HEART-J STUD CIRC, V12, P121; *HLTH CONS SERV PE, 1996, REC RES INF SYST; LEWIS T, 1940, SOLDIERS HEAERT EFFO; *OFF SECR DEF AC T, 1994, REP DEF SCI BOARD TA; Rook GAW, 1997, LANCET, V349, P1831, DOI 10.1016/S0140-6736(97)01164-1; Wood P, 1941, BMJ-BRIT MED J, V1941, P845, DOI 10.1136/bmj.1.4196.845; Wood P, 1941, Br Med J, V1, P805	10	15	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					162	163		10.1016/S0140-6736(98)00399-7	http://dx.doi.org/10.1016/S0140-6736(98)00399-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923865				2022-12-28	WOS:000078175600002
J	Van Beneden, CA; Keene, WE; Strang, RA; Werker, DH; King, AS; Mahon, B; Hedberg, K; Bell, A; Kelly, MT; Balan, VK; Mac Kenzie, WR; Fleming, D				Van Beneden, CA; Keene, WE; Strang, RA; Werker, DH; King, AS; Mahon, B; Hedberg, K; Bell, A; Kelly, MT; Balan, VK; Mac Kenzie, WR; Fleming, D			Multinational outbreak of Salmonella enterica serotype newport infections due to contaminated alfalfa sprouts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MICROBIAL HAZARDS; SEEDS; EPIDEMIOLOGY	Context In December 1995, reported Salmonella enterica serotype Newport (SN) infections increased sharply in Oregon and British Columbia but not elsewhere in North America. Similar unexplained increases had been noted in 6 other states in the fall of 1995. Objective To determine the source of the outbreak(s). Design Case-control studies, environmental investigations, bacterial subtyping, and surveillance information review. Settings Oregon and British Columbia communities (winter 1995-1996) and Georgia, Oklahoma, Pennsylvania, Vermont, Virginia, and West Virginia (fall 1995). Participants Oregon and British Columbia residents with culture-confirmed SN infections and onset from December 1, 1995, through February 29, 1996, and healthy community controls. Main Outcome Measures Odds ratio (OR) of illness associated with exposures; distribution patterns and culture of alfalfa seeds and sprouts; subtyping of SN isolates. Results We identified 133 cases in Oregon and British Columbia; 124 (93%) occurred in patients older than 18 years; 87 (65%) were female. Case patients were more likely than community control subjects to report having eaten alfalfa sprouts in the 5 days preceding illness (41% [17/41] vs 4% [3/75]; OR, 17.0; 95% confidence interval, 4.3-96.0). Case isolates shared a distinctive pulsed-field gel electrophoresis (PFGE) pattern. The SN was grown from seeds and alfalfa sprouts. The distribution of 1 seed lot to multiple growers corresponded to the distribution of cases. Distribution of a second seed lot from the same European wholesaler corresponded to the location of the fall outbreak, which was characterized by a similar demographic profile. The PFGE pattern of fall outbreak isolates and confiscated sprouts and seeds was indistinguishable from the Oregon and British Columbia outbreak and differed from background isolates. Conclusions The SN-contaminated alfalfa seeds were distributed to multiple growers across North America in 1995 and resulted in a protracted international outbreak scattered over many months. Current sprouting methods are inadequate to protect consumers from such events. Alfalfa sprouts may be an elusive but important vehicle for salmonellosis and other enteric infections.	Oregon Hlth Div, Acute & Communicable Dis Program, Portland, OR 97212 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Epidem Intelligence Serv, Atlanta, GA USA; Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V6T 1W5, Canada; British Columbia Ctr Dis Control, Epidemiol Serv, Vancouver, BC, Canada; Hlth Canada, Lab Ctr Dis Control, Field Epidemiol Training Program, Ottawa, ON K1A 0L2, Canada; Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA; British Columbia Ctr Dis Control, Prov Lab, Vancouver, BC, Canada; Oregon State Publ Hlth Lab, Portland, OR USA	Oregon Health & Science University; Centers for Disease Control & Prevention - USA; University of British Columbia; Health Canada; Centers for Disease Control & Prevention - USA	Van Beneden, CA (corresponding author), Oregon Hlth Div, Acute & Communicable Dis Program, 800 NE Oregon St,Suite 772, Portland, OR 97212 USA.		Kenzie, William R Mac/F-1528-2013	Kenzie, William R Mac/0000-0001-7723-0339				ANDERSON ES, 1956, J CLIN PATHOL, V9, P94, DOI 10.1136/jcp.9.2.94; ANDREWS WH, 1982, J ASSOC OFF ANA CHEM, V65, P241; [Anonymous], 1995, EP INF COMP PROGR VE; *AOAC, 1995, OFF METH AN AOAC ITN, pCH17; BENENSON AS, 1995, CONTROL COMMUNICABLE, P412; Bennett J., 1987, CLOSING GAP BURDEN U; Beuchat LR, 1997, INT J FOOD MICROBIOL, V34, P329, DOI 10.1016/S0168-1605(96)01202-0; BRYAN FL, 1968, J MILK FOOD TECHNOL, V31, P131, DOI 10.4315/0022-2747-31.5.131; Buck P., 1998, 47 ANN EP INT SERV C; *CDC, 1974, FOODB WAT DIS OUTB A, P23; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P741; CHALKER RB, 1988, REV INFECT DIS, V10, P111; *FDA, 1992, BACT AN MAN, pCH5; GLYNN MK, 1998, 47 ANN EP INT SERV C; HEDBERG CW, 1994, CLIN INFECT DIS, V18, P671, DOI 10.1093/clinids/18.5.671; Herwaldt BL, 1997, NEW ENGL J MED, V336, P1548, DOI 10.1056/NEJM199705293362202; *HLTH PROT BRANCH, 1978, COMP ANAL METHODS, V2; Itoh Y, 1998, APPL ENVIRON MICROB, V64, P1532; Jaquette CB, 1996, APPL ENVIRON MICROB, V62, P2212, DOI 10.1128/AEM.62.7.2212-2215.1996; Lehmacher A, 1995, EPIDEMIOL INFECT, V115, P501, DOI 10.1017/S0950268800058660; Mahon BE, 1997, J INFECT DIS, V175, P876, DOI 10.1086/513985; MOUZIN E, 1997, 6 ANN EP INT SERV C; PONKA A, 1995, LANCET, V345, P462, DOI 10.1016/S0140-6736(95)90451-4; Puohiniemi R, 1997, J CLIN MICROBIOL, V35, P2487, DOI 10.1128/JCM.35.10.2487-2491.1997; Tauxe R, 1997, J FOOD PROTECT, V60, P1400, DOI 10.4315/0362-028X-60.11.1400; TAYLOR DE, 1992, J BACTERIOL, V174, P2332, DOI 10.1128/JB.174.7.2332-2337.1992; WEGENER HC, 1997, P ABSTR INT S SALM S, P587	27	128	131	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					158	162		10.1001/jama.281.2.158	http://dx.doi.org/10.1001/jama.281.2.158			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155VJ	9917119	Bronze			2022-12-28	WOS:000077966800036
J	Desai, A; Verma, S; Mitchison, TJ; Walczak, CE				Desai, A; Verma, S; Mitchison, TJ; Walczak, CE			Kin I kinesins are microtubule-destabilizing enzymes	CELL			English	Article							DYNAMIC INSTABILITY; SACCHAROMYCES-CEREVISIAE; GTP HYDROLYSIS; EGG EXTRACTS; CELL-CYCLE; REAL-TIME; PROTEIN; MOTOR; IDENTIFICATION; ENDS	Using in vitro assays with purified proteins, we show that XKCM1 and XKIF2, two distinct members of the internal catalytic domain (Kin I) kinesin subfamily, catalytically destabilize microtubules using a novel mechanism. Both XKCM1 and XKIF2 influence microtubule stability by targeting directly to microtubule ends where they induce a destabilizing conformational change. ATP hydrolysis recycles XKCM1/XKIF2 for multiple rounds of action by dissociating a XKCM1/ XKIF2-tubulin dimer complex released upon microtubule depolymerization. These results establish Kin I kinesins as microtubule-destabilizing enzymes, distinguish them mechanistically from kinesin superfamily members that use ATP hydrolysis to translocate along microtubules, and have important implications for the regulation of microtubule dynamics and for the intracellular functions and evolution of the kinesin superfamily.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard Medical School	Desai, A (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	arshad.desai@embl-heidelberg.de						BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPLOW M, 1994, J CELL BIOL, V127, P779, DOI 10.1083/jcb.127.3.779; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; CASSIMERIS L, 1993, CELL MOTIL CYTOSKEL, V26, P275, DOI 10.1002/cm.970260402; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; COHN SA, 1993, METHOD CELL BIOL, V39, P75, DOI 10.1016/S0091-679X(08)60162-4; Cottingham FR, 1997, J CELL BIOL, V138, P1041, DOI 10.1083/jcb.138.5.1041; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DeZwaan TM, 1997, J CELL BIOL, V138, P1023, DOI 10.1083/jcb.138.5.1023; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.bb.21.060192.001045; EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; Hartman JJ, 1998, CELL, V93, P277, DOI 10.1016/S0092-8674(00)81578-0; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Horwitz S B, 1994, Ann Oncol, V5 Suppl 6, pS3; Huyett A, 1998, J CELL SCI, V111, P295; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; Maney T, 1998, J CELL BIOL, V142, P787, DOI 10.1083/jcb.142.3.787; MCNALLY FJ, 1993, CELL, V75, P419, DOI 10.1016/0092-8674(93)90377-3; McNally FJ, 1996, CURR OPIN CELL BIOL, V8, P23, DOI 10.1016/S0955-0674(96)80044-5; MELKI R, 1989, BIOCHEMISTRY-US, V28, P9143, DOI 10.1021/bi00449a028; MICKEY B, 1995, J CELL BIOL, V130, P909, DOI 10.1083/jcb.130.4.909; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Morfini G, 1997, J CELL BIOL, V138, P657, DOI 10.1083/jcb.138.3.657; Muller-Reichert T, 1998, P NATL ACAD SCI USA, V95, P3661, DOI 10.1073/pnas.95.7.3661; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; Pierce DW, 1997, NATURE, V388, P338, DOI 10.1038/41009; Saunders W, 1997, J CELL BIOL, V137, P417, DOI 10.1083/jcb.137.2.417; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Tran PT, 1997, J STRUCT BIOL, V118, P107, DOI 10.1006/jsbi.1997.3844; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Walczak CE, 1997, J CELL BIOL, V136, P859, DOI 10.1083/jcb.136.4.859; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Waters JC, 1996, CURR BIOL, V6, P361, DOI 10.1016/S0960-9822(02)00495-5; Wein H, 1996, J CELL BIOL, V133, P595, DOI 10.1083/jcb.133.3.595; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95	46	562	581	0	20	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 8	1999	96	1					69	78		10.1016/S0092-8674(00)80960-5	http://dx.doi.org/10.1016/S0092-8674(00)80960-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989498	Bronze			2022-12-28	WOS:000078023200009
J	Duhaut, P; Bornet, H; Pinede, L; Demolombe-Rague, S; Loire, R; Seydoux, D; Ninet, J; Pasquier, J				Duhaut, P; Bornet, H; Pinede, L; Demolombe-Rague, S; Loire, R; Seydoux, D; Ninet, J; Pasquier, J			Giant cell arteritis and thyroid dysfunction: multicentre case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POLYMYALGIA RHEUMATICA; HYPOTHYROIDISM; DISEASE		E Herriot Hosp, Dept Internal Med, Lyon 03, France; Univ Lyon 1, Fac Med, Dept Nucl Med, F-69365 Lyon, France; Louis Pradel Hosp, Pathol Lab, Lyon, France; Soc Secours Miniere de la Loire, Control Grp, St Etienne, France	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon	Duhaut, P (corresponding author), E Herriot Hosp, Dept Internal Med, Lyon 03, France.	duhaut@cismsun.univ-lyonl.fr						BARRIER JH, 1992, J RHEUMATOL, V19, P1733; DASGUPTA B, 1990, BRIT MED J, V301, P96, DOI 10.1136/bmj.301.6743.96; NICHOLSON GC, 1984, AUST NZ J MED, V14, P487, DOI 10.1111/j.1445-5994.1984.tb03622.x; THOMAS RD, 1974, BRIT MED J, V2, P408, DOI 10.1136/bmj.2.5916.408; WISEMAN P, 1989, BRIT MED J, V298, P647, DOI 10.1136/bmj.298.6674.647	5	13	13	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 13	1999	318	7181					434	435		10.1136/bmj.318.7181.434	http://dx.doi.org/10.1136/bmj.318.7181.434			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BF	9974458	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000078670100027
J	Eriksson, JG; Forsen, T; Tuomilehto, J; Winter, PD; Osmond, C; Barker, DJP				Eriksson, JG; Forsen, T; Tuomilehto, J; Winter, PD; Osmond, C; Barker, DJP			Catch-up growth in childhood and death from coronary heart disease: longitudinal study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BODY-MASS INDEX; FOLLOW-UP; CARDIOVASCULAR-DISEASE; BIRTH-WEIGHT; FETAL; MEN; MORTALITY; AGE; OVERWEIGHT; INSULIN	Objective To examine whether catch-up growth during childhood modifies the increased risk of death from coronary heart disease that is associated with reduced intrauterine growth. Design Follow up study of men whose body size at birth, was recorded and who had an average of 10 measurements taken of their height and weight through childhood. Setting Helsinki, Finland. Subjects 3041 men who were born in Helsinki University Central Hospital during 1924-33 and who went to school in Helsinki. Main outcome measures Hazard ratios fur death from coronary heart disease. Results Death from coronary heart disease was associated with low birth weight and, more strongly, with a low ponderal index at birth. Men who died from coronary heart disease had an above average body mass index at all ages from 7 to 15 years. In a simultaneous regression the hazard ratio for death from the disease increased by 14% (95%, confidence interval 8% to 19%; P < 0.0001) for each unit (kg/m(3)) decrease in ponderal index at birth and by 22% (10% to 36%; P = 0.0001) for each unit (kg/m(2)) increase in body mass index at 11 years of age. Body mass index in childhood was strongly related to maternal body mass index, which in turn was related to coronary heart disease. The extent of crowding in the home during childhood, although related to, body mass index in childhood, was not related to later coronary heart disease. Conclusion The highest death rates from coronary heart disease occurred in boys who were thin at birth but whose weight caught up so that they had an average or above average body mass from the age of 7 years. Death from coronary heart disease may be a consequence of poor prenatal nutrition followed by improved postnatal nutrition.	Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton S016 6YD, Hants, England; Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet & Genet Epidemiol Unit, SF-00300 Helsinki, Finland	University of Southampton; Finland National Institute for Health & Welfare	Barker, DJP (corresponding author), Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton S016 6YD, Hants, England.	david.barker@mrc.soton.ac.uk	Fahimifar, Sepideh/M-5303-2019	Osmond, Clive/0000-0002-9054-4655				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; CASEY VA, 1992, AM J CLIN NUTR, V56, P14, DOI 10.1093/ajcn/56.1.14; Forsen T, 1997, BRIT MED J, V315, P837, DOI 10.1136/bmj.315.7112.837; FRISCH RE, 1990, BAILLIERE CLIN OB GY, V4, P419, DOI 10.1016/S0950-3552(05)80302-5; GUILLAUME M, 1995, INT J OBESITY, V19, pS5; GUNNELL D, 1996, J EPIDEMIOL COMMUNIT, V50, P580; Gunnell DJ, 1998, AM J CLIN NUTR, V67, P1111, DOI 10.1093/ajcn/67.6.1111; GUO SS, 1994, AM J CLIN NUTR, V59, P810, DOI 10.1093/ajcn/59.4.810; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hales CN, 1996, BIOCHEM SOC T, V24, P341, DOI 10.1042/bst0240341; Law CM, 1996, J HYPERTENS, V14, P935; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; MARMOT MG, 1984, LANCET, V1, P1003; Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; NIETO FJ, 1992, AM J EPIDEMIOL, V136, P201, DOI 10.1093/oxfordjournals.aje.a116486; PITTS GC, 1986, GROWTH, V50, P419; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; ROBINSON SM, 1991, BRIT J OBSTET GYNAEC, V98, P1223, DOI 10.1111/j.1471-0528.1991.tb15393.x; ROLLANDCACHERA MF, 1998, HUMAN GROWTH DEV, P51; ROYSTON P, 1991, STAT MED, V10, P675, DOI 10.1002/sim.4780100502; TANNER JM, 1989, FOETUS MAN; Vanhala M, 1998, BRIT MED J, V317, P319, DOI 10.1136/bmj.317.7154.319; WAALER HT, 1984, ACTA MED SCAND, P1; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301; YLIAHO T, 1991, TETAALAINEN HELSINGI	31	836	852	0	35	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 13	1999	318	7181					427	431		10.1136/bmj.318.7181.427	http://dx.doi.org/10.1136/bmj.318.7181.427			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BF	9974455	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000078670100024
J	Pulska, T; Pahkala, K; Laippala, P; Kivela, SL				Pulska, T; Pahkala, K; Laippala, P; Kivela, SL			Follow up study of longstanding depression as predictor of mortality in elderly people living in the community	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; POPULATION; FINLAND		Univ Oulu, Dept Publ Hlth Sci & Gen Practice, FIN-90220 Oulu, Finland; Prov State Off Western Finland, Hlth & Social Serv, Reg Serv Unit, Vaasa, Finland; Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland	University of Oulu; Tampere University; Tampere University; Tampere University Hospital	Pulska, T (corresponding author), Univ Oulu, Dept Publ Hlth Sci & Gen Practice, Aapistie 1, FIN-90220 Oulu, Finland.	Tuula.Pulska@Oulu.Fi						KIVELA SL, 1988, ACTA PSYCHIAT SCAND, V78, P401, DOI 10.1111/j.1600-0447.1988.tb06358.x; PAHKALA K, 1995, SOC PSYCH PSYCH EPID, V30, P99, DOI 10.1007/BF00802037; Pulska T, 1997, INT J GERIATR PSYCH, V12, P942, DOI 10.1002/(SICI)1099-1166(199709)12:9<942::AID-GPS668>3.0.CO;2-Z; ROSENGREN A, 1993, BRIT MED J, V307, P1102, DOI 10.1136/bmj.307.6912.1102; THOMAS C, 1992, J GERONTOL, V47, pS80, DOI 10.1093/geronj/47.2.S80	5	42	42	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1999	318	7181					432	433		10.1136/bmj.318.7181.432	http://dx.doi.org/10.1136/bmj.318.7181.432			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	168BF	9974456	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000078670100025
J	Geier, E; Pfeifer, G; Wilm, M; Lucchiari-Hartz, M; Baumeister, W; Eichmann, K; Niedermann, G				Geier, E; Pfeifer, G; Wilm, M; Lucchiari-Hartz, M; Baumeister, W; Eichmann, K; Niedermann, G			A giant protease with potential to substitute for some functions of the proteasome	SCIENCE			English	Article							TRIPEPTIDYL-PEPTIDASE-II; RAT-LIVER; INHIBITION; LACTACYSTIN; PROTEINS; CELLS	An alanyl-alanyl-phenylalanyl-7-amino-4-methylcoumarin-hydrolyzing protease particle copurifying with 265 proteasomes was isolated and identified as tripeptidyl peptidase II(TPPII), a cytosolic subtilisin-like peptidase of unknown function. The particle is larger than the 265 proteasome and has a rod-shaped, dynamic supramolecular structure. TPPII exhibits enhanced activity in proteasome inhibitor-adapted cells and degrades polypeptides by exo- as well as predominantly trypsin-like endoproteolytic cleavage. TPPII may thus participate in extralysosomal polypeptide degradation and may in part account for nonproteasomal epitope generation as postulated for certain major histocompatibility complex class I alleles, In addition, TPPII may be able to substitute for some metabolic functions of the proteasome.	Max Planck Inst Immunobiol, D-79108 Freiburg, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany	Max Planck Society; Max Planck Society; European Molecular Biology Laboratory (EMBL)	Niedermann, G (corresponding author), Max Planck Inst Immunobiol, Stubeweg 51, D-79108 Freiburg, Germany.	niedermann@immunbio.mpg.de		Wilm, Matthias/0000-0002-5461-6834				BALOW RM, 1983, J BIOL CHEM, V258, P1622; BALOW RM, 1986, J BIOL CHEM, V261, P2409; Benham AM, 1998, J IMMUNOL, V161, P83; Bermpohl F, 1998, FEBS LETT, V428, P152, DOI 10.1016/S0014-5793(98)00515-8; Bush KT, 1997, J BIOL CHEM, V272, P9086; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GEIER E, UNPUB; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KIRSCHKE H, 1977, ACTA BIOL MED GER, V36, P185; MACPHERSON E, 1987, BIOCHEM J, V248, P259, DOI 10.1042/bj2480259; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; NISHIMURA T, 1983, EUR J BIOCHEM, V137, P23, DOI 10.1111/j.1432-1033.1983.tb07790.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Ramos PC, 1998, CELL, V92, P489, DOI 10.1016/S0092-8674(00)80942-3; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rose C, 1996, NATURE, V380, P403, DOI 10.1038/380403a0; Tamura N, 1998, CELL, V95, P637, DOI 10.1016/S0092-8674(00)81634-7; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; TOMKINSON B, 1994, BIOCHEM J, V304, P517, DOI 10.1042/bj3040517; Walz J, 1998, J STRUCT BIOL, V121, P19, DOI 10.1006/jsbi.1998.3958; Wang X, 1998, J IMMUNOL, V160, P788; WILM M, UNPUB; Zhou MY, 1996, J BIOL CHEM, V271, P24769, DOI 10.1074/jbc.271.40.24769	28	301	323	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 12	1999	283	5404					978	981		10.1126/science.283.5404.978	http://dx.doi.org/10.1126/science.283.5404.978			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974389				2022-12-28	WOS:000078574800046
J	Bunevicius, R; Kazanavicius, G; Zalinkevicius, R; Prange, AJ				Bunevicius, R; Kazanavicius, G; Zalinkevicius, R; Prange, AJ			Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONE-BINDING GLOBULIN; THYROID-HORMONE; CEREBRAL-CORTEX	Background Patients with hypothyroidism are usually treated with thyroxine (levothyroxine) only, although both thyroxine and triiodothyronine are secreted by the normal thyroid gland. Whether thyroid secretion of triiodothyronine is physiologically important is unknown. Methods We compared the effects of thyroxine alone with those of thyroxine plus triiodothyronine (liothyronine) in 33 patients with hypothyroidism. Each patient was studied for two five-week periods. During one period, the patient received his or her usual dose of thyroxine. During the other, the patient received a regimen in which 50 mu g of the usual dose of thyroxine was replaced by 12.5 mu g of triiodothyronine. The order in which each patient received the two treatments was randomized. Biochemical, physiologic, and psychological tests were performed at the end of each treatment period. Results The patients had tower serum free and total thyroxine concentrations and higher serum total triiodothyronine concentrations after treatment with thyroxine plus triiodothyronine than after thyroxine alone, whereas the serum thyrotropin concentrations were similar after both treatments. Among 17 scores on tests of cognitive performance and assessments of mood, 6 were better or closer to normal after treatment with thyroxine plus triiodothyronine. Similarly, among 15 visual-analogue scales used to indicate mood and physical status, the results for 10 were significantly better after treatment with thyroxine plus triiodothyronine. The pulse rate and serum sex hormone-binding globulin concentrations were slightly higher after treatment with thyroxine plus triiodothyronine, but blood pressure, serum lipid concentrations, and the results of neurophysiologic tests were similar after the two treatments. Conclusions In patients with hypothyroidism, partial substitution of triiodothyronine for thyroxine may improve mood and neuropsychological function; this finding suggests a specific effect of the triiodothyronine normally secreted by the thyroid gland. (N Engl J Med 1999;340:424-9.) (C)1999. Massachusetts Medical Society.	Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC 27599 USA; Kaunas Med Univ, Inst Endocrinol, Kaunas, Lithuania	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Lithuanian University of Health Sciences	Prange, AJ (corresponding author), Univ N Carolina, Sch Med, Dept Psychiat, Campus Box 7160,Room 254,Wing D, Chapel Hill, NC 27599 USA.							American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Brent Gregory A., 1996, P883; COOKE RG, 1992, J CLIN PSYCHIAT, V53, P16; DYCK PJ, 1978, ANN NEUROL, V4, P502, DOI 10.1002/ana.410040605; Esposito S, 1997, PSYCHOPHARMACOL BULL, V33, P205; First M.B., 1990, USERS GUIDE STRUCTUR; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HODIN RA, 1990, J CLIN INVEST, V85, P101, DOI 10.1172/JCI114398; Kimura J., 1989, ELECTRODIAGNOSIS DIS, V2nd; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Leonard Jack L., 1996, P125; McNair D. M, 1992, PROFILE MOOD STATES; PILO A, 1990, AM J PHYSIOL, V258, pE715, DOI 10.1152/ajpendo.1990.258.4.E715; SARNE DH, 1988, J CLIN ENDOCR METAB, V66, P740, DOI 10.1210/jcem-66-4-740; SILVA JE, 1984, J CLIN INVEST, V74, P1035, DOI 10.1172/JCI111471; SILVA JE, 1985, ENDOCRINOLOGY, V116, P1627, DOI 10.1210/endo-116-4-1627; SMITH RN, 1970, BRIT MED J, V4, P145, DOI 10.1136/bmj.4.5728.145; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; TAYLOR S, 1970, BRIT MED J, V2, P270, DOI 10.1136/bmj.2.5704.270; TERASAKI T, 1988, BIOCHEMISTRY-US, V27, P3624, DOI 10.1021/bi00410a015; VISSER TJ, 1982, P NATL ACAD SCI-BIOL, V79, P5080, DOI 10.1073/pnas.79.16.5080; Wechsler D., 1981, WAIS R MANUAL WECHSL; WEINTRAUB S, 1985, PRINCIPLES BEHAV NEU, V26, P71	24	302	316	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1999	340	6					424	429		10.1056/NEJM199902113400603	http://dx.doi.org/10.1056/NEJM199902113400603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166HW	9971866	Green Published			2022-12-28	WOS:000078571000003
J	Horton, R				Horton, R			The uses of error	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Horton, R (corresponding author), Lancet, London WC1B 3SL, England.							BLOCHE MG, 1999, JAMA-J AM MED ASSOC, V281, P267; GAWANDE A, 1999, NEW YORKER      0201, P40; Horton R, 1998, LANCET, V351, P1900	3	22	22	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 6	1999	353	9151					422	423		10.1016/S0140-6736(99)00036-7	http://dx.doi.org/10.1016/S0140-6736(99)00036-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989706				2022-12-28	WOS:000078572800002
J	Rosen, H; Hajdu, R; Silver, L; Kropp, H; Dorso, K; Kohler, J; Sundelof, JG; Huber, J; Hammond, GG; Jackson, JJ; Gill, CJ; Thompson, R; Pelak, BA; Epstein-Toney, JH; Lankas, G; Wilkening, RR; Wildonger, KJ; Blizzard, TA; DiNinno, FP; Ratcliffe, RW; Heck, JV; Kozarich, JW; Hammond, ML				Rosen, H; Hajdu, R; Silver, L; Kropp, H; Dorso, K; Kohler, J; Sundelof, JG; Huber, J; Hammond, GG; Jackson, JJ; Gill, CJ; Thompson, R; Pelak, BA; Epstein-Toney, JH; Lankas, G; Wilkening, RR; Wildonger, KJ; Blizzard, TA; DiNinno, FP; Ratcliffe, RW; Heck, JV; Kozarich, JW; Hammond, ML			Reduced immunotoxicity and preservation of antibacterial activity in a releasable side-chain carbapenem antibiotic	SCIENCE			English	Article							PENICILLIN-BINDING PROTEINS; STAPHYLOCOCCUS-AUREUS; RESISTANCE; VANCOMYCIN; L-749,345; PRIMATES	A carbapenem antibiotic, L-786,392, was designed so that the side chain that provides high-affinity binding to the penicillin-binding proteins responsible for bacterial resistance was also the structural basis for ameliorating immunopathology. Expulsion of the side chain upon opening of the beta-lactam ring retained antibacterial activity while safely expelling the immunodominant epitope. L-786,392 was well tolerated in animal safety studies and had significant in vitro and in vivo activities against methicillin- and vancomycin-resistant Staphylococci and vancomycin-resistant Enterococci.	Merck Res Labs, Rahway, NJ 07065 USA	Merck & Company	Rosen, H (corresponding author), Merck Res Labs, Rahway, NJ 07065 USA.		Silver, Lynn L/A-7789-2009	Silver, Lynn L/0000-0002-8416-0487				BRANDER C, 1995, J IMMUNOL, V155, P2670; COYETTE J, 1977, EUR J BIOCHEM, V75, P225, DOI 10.1111/j.1432-1033.1977.tb11521.x; DELENCASTRE H, 1994, J ANTIMICROB CHEMOTH, V33, P7, DOI 10.1093/jac/33.1.7; GEORGOPAPADAKOU NH, 1982, ANTIMICROB AGENTS CH, V22, P172, DOI 10.1128/AAC.22.1.172; Gill CJ, 1998, ANTIMICROB AGENTS CH, V42, P1996, DOI 10.1128/AAC.42.8.1996; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; GRALNICK H, 1971, JAMA-J AM MED ASSOC, V199, P725; HAJDU R, UNPUB; HARTMAN BJ, 1984, J BACTERIOL, V158, P513, DOI 10.1128/JB.158.2.513-516.1984; Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8; Hiramatsu K, 1997, AM J INFECT CONTROL, V25, P405; HUBER J, 1994, 34TH INT C ANT AG CH, P126; Jacoby G, 1997, ANTIMICROB AGENTS CH, V41, P1830, DOI 10.1128/AAC.41.8.1830; KLAUS MV, 1973, J GERONTOL, V28, P312, DOI 10.1093/geronj/28.3.312; KNUDSEN LF, 1947, J AM STAT ASSOC, V42, P282, DOI 10.2307/2280657; Lankas GR, 1996, TOXICOLOGY, V108, P207, DOI 10.1016/0300-483X(96)03305-7; LEVINE BB, 1976, MANUAL CLIN IMMUNOLO, P637; Michel M, 1997, LANCET, V349, P1901, DOI 10.1016/S0140-6736(96)11192-2; Petz LD, 1986, MANUAL CLIN LAB IMMU, P613; SPRATT BG, 1977, EUR J BIOCHEM, V72, P341, DOI 10.1111/j.1432-1033.1977.tb11258.x; Sundelof JG, 1997, ANTIMICROB AGENTS CH, V41, P1743, DOI 10.1128/AAC.41.8.1743	21	31	34	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					703	706		10.1126/science.283.5402.703	http://dx.doi.org/10.1126/science.283.5402.703			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924033				2022-12-28	WOS:000078324400047
J	Brown, AD; Garber, AM				Brown, AD; Garber, AM			Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEGATIVE CERVICAL SMEARS; QUALITY-CONTROL; SCREENING POLICIES; BREAST-CANCER; PAP SMEARS; SYSTEM; EFFICACY; CYTOLOGY; MODEL; PROVIDE	Context ThinPrep, AutoPap, and Papnet are 3 new technologies that increase the sensitivity and cost of cervical cancer screening. Objective To estimate the cost-effectiveness of these technological enhancements to Papanicolaou (Pap) tests, Design We estimated the increase in sensitivity from using these technologies by combining results of 8 studies meeting defined criteria. We used published literature and additional sources for cost estimates. To estimate overall cost-effectiveness, we applied a 9-state time-varying transition state model to these data and information about specific populations. Setting A hypothetical program serving a cohort of 20- to 65-year-old women who begin screening at the same age and are representative of the US population. Results The new technologies increased life expectancy by 5 hours to 1.6 days, varying with the technology and the frequency of screening. All 3 technologies also increased the cost per woman screened by $30 to $257 (1996 US dollars). AutoPap dominated ThinPrep in the base case. At each screening interval, AutoPap increased survival at the lowest cost, The cost per year of life saved rose from $7777 with quadrennial screening to $166 000 with annual screening. Papnet produced more life-years at a higher cost per year of life saved. However, when used with triennial screening, each of them produced more life-years at lower cost than conventional Pap testing every 2 years. The cost-effectiveness ratio of each technology improved with increases in the prevalence of disease, decreases in the sensitivity of conventional Pap testing, and increases in the improvement in sensitivity produced by the technology. Conclusions Technologies to increase the sensitivity of Pap testing are more cost-effective when incorporated into infrequent screening. Increases in sensitivity and de creases in cost may eventually make each technology more cost-effective.	Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA 94305 USA; Univ Oxford, Dept Publ Hlth & Primary Care, Oxford OX3 7LF, England	Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Oxford	Garber, AM (corresponding author), Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, 30 Alta Rd, Stanford, CA 94305 USA.	garber@stanford.edu	Garber, Alan M/F-1476-2010					[Anonymous], 1986, BMJ-BRIT MED J, V293, P659; Bedrossian C, 1998, AM J CLIN PATHOL, V109, P10; Benneyan JC, 1996, ANN OPER RES, V67, P235, DOI 10.1007/BF02187031; Bolick DR, 1998, ACTA CYTOL, V42, P209, DOI 10.1159/000331548; BOON ME, 1993, DIAGN CYTOPATHOL, V9, P411, DOI 10.1002/dc.2840090408; BOON ME, 1994, MODERN PATHOL, V7, P957; BUCKNER S, 1997, ACTA CYTOL, V41, P1544; CHAMBERLAIN J, 1986, SCREENING CANC UTERI, P161; COLGAN TJ, 1995, ACTA CYTOL, V39, P1191; *COMM GYN PRACT AM, 1998, ACOG COMMITTEE OPINI, V1, P1; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; Doornewaard H, 1997, ACTA CYTOL, V41, P74, DOI 10.1159/000332308; EDDY D, 1978, RATIONALE CANC SCR 3; EDDY D, 1980, SCREENING CANC THEOR, P308; EDDY DM, 1987, CANCER, V60, P1117, DOI 10.1002/1097-0142(19870901)60:5<1117::AID-CNCR2820600533>3.0.CO;2-H; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; Food and Drug Administration (FDA), 1994, PESTICIDE ANAL MANUA, V3, P1; HUTCHINSON M, 1995, ACTA CYTOL, V39, P968; Hutchinson ML, 1996, ACTA CYTOL, V40, P4; Jenny J, 1997, ACTA CYTOL, V41, P82, DOI 10.1159/000332310; JOHANNESSON M, 1993, J HEALTH ECON, V12, P459, DOI 10.1016/0167-6296(93)90005-Y; KAMINSKY FC, 1995, ACTA CYTOL, V39, P232; KAMINSKY FC, 1995, ACTA CYTOL, V39, P239; Keeney RL, 1993, DECISIONS MULTIPLE O, DOI DOI 10.1017/CBO9781139174084; KeyhaniRofagha S, 1996, DIAGN CYTOPATHOL, V14, P316, DOI 10.1002/(SICI)1097-0339(199605)14:4<316::AID-DC7>3.0.CO;2-D; Koss LG, 1997, HUM PATHOL, V28, P1196, DOI 10.1016/S0046-8177(97)90258-6; KOSS LG, 1993, CANCER-AM CANCER SOC, V71, P1406, DOI 10.1002/cncr.2820710405; KOSS LG, 1994, AM J CLIN PATHOL, V101, P220, DOI 10.1093/ajcp/101.2.220; Lee KR, 1996, ACTA CYTOL, V40, P895; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; Luce BR, 1996, COST EFFECTIVENESS H, P176; Mandelblatt J, 1997, AM J PUBLIC HEALTH, V87, P1182, DOI 10.2105/AJPH.87.7.1182; McGoogan E, 1996, ACTA CYTOL, V40, P107; McMeekin, 1997, Medscape Womens Health, V2, P1; Miller WC, 1998, J CLIN EPIDEMIOL, V51, P219, DOI 10.1016/S0895-4356(97)00264-3; *NEOP INC, 1996, AUT 300 QC AUT PAP S, P10; NIH, 1996, CERV CANC NAT I HLTH, P1; O'Leary TJ, 1998, JAMA-J AM MED ASSOC, V279, P235, DOI 10.1001/jama.279.3.235; PARKIN DM, 1986, J EPIDEMIOL COMMUN H, V40, P143, DOI 10.1136/jech.40.2.143; Raab SS, 1997, AM J CLIN PATHOL, V108, P525; Radensky PW, 1998, ACTA CYTOL, V42, P246, DOI 10.1159/000331553; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; Roberts JM, 1997, MED J AUSTRALIA, V167, P466, DOI 10.5694/j.1326-5377.1997.tb126672.x; Rosenthal DL, 1996, ACTA CYTOL, V40, P120; SCHIFFMAN MH, 1995, CANCER-AM CANCER SOC, V76, P1888, DOI 10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H; SHEETS EE, 1995, J GYNECOL TECH, V1, P27; SHERMAN ME, 1995, ACTA CYTOL, V39, P983; SLAGEL DD, 1995, DIAGN CYTOPATHOL, V13, P26, DOI 10.1002/dc.2840130107; STOLER M, 1996, ACTA CYTOL, V40, P1045; Tezuka F, 1996, ACTA CYTOL, V40, P513; Torrance GW, 1996, COST EFFECTIVENESS H, P276; vanBallegooijen M, 1997, BRIT J CANCER, V76, P651, DOI 10.1038/bjc.1997.440; Wilbur DC, 1996, ACTA CYTOL, V40, P127; 1997, EC REPORT PRESIDENT	55	98	100	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1999	281	4					347	353		10.1001/jama.281.4.347	http://dx.doi.org/10.1001/jama.281.4.347			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158JB	9929088				2022-12-28	WOS:000078111300034
J	Madhok, R; Capell, HA				Madhok, R; Capell, HA			Outstanding issues in use of disease-modifying agents in rheumatoid arthritis	LANCET			English	Editorial Material							COMBINATION THERAPY; CONTROLLED TRIAL; 2ND-LINE DRUGS; METHOTREXATE; SULFASALAZINE; EFFICACY; TOXICITY		Glasgow Royal Infirm, Ctr Rheumat Dis, Glasgow G4 0SF, Lanark, Scotland	University of Glasgow	Madhok, R (corresponding author), Glasgow Royal Infirm, Ctr Rheumat Dis, Glasgow G4 0SF, Lanark, Scotland.							Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7; CAPELL HA, 1993, ANN RHEUM DIS, V52, P423, DOI 10.1136/ard.52.6.423; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; FELSON DT, 1994, ARTHRITIS RHEUM, V37, P1487, DOI 10.1002/art.1780371012; Fries JF, 1996, ARTHRITIS RHEUM, V39, P616, DOI 10.1002/art.1780390412; KLOPPENBURG M, 1994, ARTHRITIS RHEUM, V37, P629, DOI 10.1002/art.1780370505; Moreland LW, 1997, ARTHRITIS RHEUM, V40, P397, DOI 10.1002/art.1780400302; Moreland LW, 1998, ARTHRITIS RHEUM, V41, pS155; Munro R, 1998, ANN RHEUM DIS, V57, P88, DOI 10.1136/ard.57.2.88; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; ROONEY PJ, 1978, BRIT J CLIN PHARMACO, V5, P453, DOI 10.1111/j.1365-2125.1978.tb01654.x; tenWolde S, 1996, LANCET, V347, P347, DOI 10.1016/S0140-6736(96)90535-8; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; vanderHeide A, 1996, ANN INTERN MED, V124, P699, DOI 10.7326/0003-4819-124-8-199604150-00001; WOLFE F, 1995, CLIN RHEUMATOLOGY IN, P619; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	16	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 23	1999	353	9149					257	258		10.1016/S0140-6736(05)74938-2	http://dx.doi.org/10.1016/S0140-6736(05)74938-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929016				2022-12-28	WOS:000078292200006
J	Cannom, DS; Prystowsky, EN				Cannom, DS; Prystowsky, EN			Management of ventricular arrhythmias - Detection, drugs, and devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; SIGNAL-AVERAGED ELECTROCARDIOGRAM; CORONARY-ARTERY DISEASE; SUDDEN CARDIAC DEATH; LONG-TERM SURVIVAL; ANTIARRHYTHMIC DRUGS; PROGNOSTIC-SIGNIFICANCE; INCREASED MORTALITY; CATHETER ABLATION	Objective To review evaluation and treatment of patients with ventricular arrhythmias, based on recent studies, with an emphasis on randomized controlled trials. Data Sources MEDLINE search of English-language publications of ventricular arrhythmias and their references from 1966 through April 27, 1998. References to articles were also scanned to broaden the search. Study Selection Randomized controlled trials and all large nonrandomized trials of arrhythmias and arrhythmia therapy were reviewed. In addition, studies that led to changes in approach to patients with arrhythmias were reviewed. Data Extraction We reviewed articles jointly for pertinent studies and information. Data Synthesis The goals of treatment of the patient with ventricular arrhythmias are to suppress symptoms and prevent a fatal event. The steps in providing such therapy include defining the cardiac anatomy, assessing arrhythmia risk through noninvasive or invasive testing, and prescribing treatment based on these results. Patients may be separated into high- and low-risk groups to help identify appropriate treatment. While low-risk groups may benefit from reassurance or medications such as P-blockers or verapamil, high-risk groups have been more difficult to treat. Recent randomized trials of implantable cardioverter defibrillators for ventricular arrhythmias suggest that they may provide better protection for high-risk patients than do antiarrhythmic medications. Conclusions Treatment and understanding of risk from ventricular arrhythmias have advanced substantially in recent years. Classifying patients as being at high or low risk for fatal arrhythmias allows the physician to identify appropriate treatments for the high-risk patient without exposing the low-risk patient to unnecessary treatment-related risks.	Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; Good Samaritan Hosp, Los Angeles, CA USA; St Vincent Hosp, Indianapolis, IN USA; N Side Cardiol PL, Clin Electrophysiol Lab, Indianapolis, IN USA; Duke Univ, Med Ctr, Durham, NC USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Duke University	Cannom, DS (corresponding author), 1245 Wilshire Blvd,703, Los Angeles, CA 90017 USA.	dcannom@lacard.com						ANDERSON JL, 1994, CIRCULATION, V90, P2843, DOI 10.1161/01.CIR.90.6.2843; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1994, J Am Coll Cardiol, V23, P1521; BIGGER JT, 1981, BRIT HEART J, V45, P717; BLANCHARD SM, 1994, PACE, V17, P2315, DOI 10.1111/j.1540-8159.1994.tb02382.x; BREITHARDT G, 1991, J AM COLL CARDIOL, V17, P999, DOI 10.1016/0735-1097(91)90822-Q; Brugada J, 1998, CIRCULATION, V97, P457; BUJA G, 1993, AM J CARDIOL, V72, P973, DOI 10.1016/0002-9149(93)91118-2; BUXTON AE, 1993, PROG CARDIOVASC DIS, V36, P215, DOI 10.1016/0033-0620(93)90015-6; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; Camm AJ, 1996, CIRCULATION, V93, P1043; COX JL, 1989, CIRCULATION, V79, P163; DAOUD E, 1995, CURR OPIN CARDIOL, V10, P21, DOI 10.1097/00001573-199501000-00005; DAY CP, 1990, BRIT HEART J, V63, P342; Domanski MJ, 1997, CIRCULATION, V95, P2694, DOI 10.1161/01.CIR.95.12.2694; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; FISHER JD, 1977, AM HEART J, V93, P658, DOI 10.1016/S0002-8703(77)80018-5; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GOMES JA, 1987, J AM COLL CARDIOL, V10, P349; GRABOYS TB, 1982, AM J CARDIOL, V50, P437, DOI 10.1016/0002-9149(82)90307-1; Gregoratos G, 1998, J AM COLL CARDIOL, V31, P1175; Haverkamp W, 1997, J AM COLL CARDIOL, V30, P487, DOI 10.1016/S0735-1097(97)00190-3; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; HOOK BG, 1991, J AM COLL CARDIOL, V17, P985; JULIAN DG, 1982, LANCET, V1, P1142; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; KATONA PG, 1975, J APPL PHYSIOL, V39, P801, DOI 10.1152/jappl.1975.39.5.801; Katz A, 1996, CIRCULATION, V94, P154; KELLY P, 1990, J AM COLL CARDIOL, V15, P267, DOI 10.1016/S0735-1097(10)80046-4; KELLY PA, 1988, J AM COLL CARDIOL, V11, P1278, DOI 10.1016/0735-1097(88)90292-6; KENNEDY HL, 1985, NEW ENGL J MED, V312, P193, DOI 10.1056/NEJM198501243120401; KENNEDY HL, 1976, AM J CARDIOL, V38, P141, DOI 10.1016/0002-9149(76)90140-5; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; KOSTIS JB, 1981, CIRCULATION, V63, P1351, DOI 10.1161/01.CIR.63.6.1351; Krahn Andrew D., 1997, Cardiology Clinics, V15, P313; KUCHAR DL, 1987, J AM COLL CARDIOL, V9, P531, DOI 10.1016/S0735-1097(87)80045-1; LIE KI, 1975, CIRCULATION, V52, P755, DOI 10.1161/01.CIR.52.5.755; LOWN B, 1971, CIRCULATION, V44, P130, DOI 10.1161/01.CIR.44.1.130; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; MAGGIONI AP, 1993, CIRCULATION, V87, P312, DOI 10.1161/01.CIR.87.2.312; MASON JW, 1993, NEW ENGL J MED, V329, P452, DOI 10.1056/NEJM199308123290702; MASON JW, 1993, NEW ENGL J MED, V329, P445, DOI 10.1056/NEJM199308123290701; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; MINARDO JD, 1988, NEW ENGL J MED, V319, P257, DOI 10.1056/NEJM198808043190501; MIROWSKI M, 1983, ANN INTERN MED, V98, P585, DOI 10.7326/0003-4819-98-5-585; Mitchell LB, 1997, CURR OPIN CARDIOL, V12, P33, DOI 10.1097/00001573-199701000-00006; MITCHELL LB, 1987, NEW ENGL J MED, V317, P1681, DOI 10.1056/NEJM198712313172701; MOSS AJ, 1979, CIRCULATION, V60, P998, DOI 10.1161/01.CIR.60.5.998; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; MYERBURG RJ, 1993, ANN INTERN MED, V119, P1187, DOI 10.7326/0003-4819-119-12-199312150-00006; NACCARELLI GV, 1981, BRIT HEART J, V46, P152; NEWMAN D, 1992, AM J CARDIOL, V69, P899, DOI 10.1016/0002-9149(92)90789-2; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; PEDERSEN TR, 1994, LANCET, V344, P1383; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Poole JE, 1995, CARDIAC ELECTROPHYSI, P812; POWELL AC, 1993, CIRCULATION, V88, P1083, DOI 10.1161/01.CIR.88.3.1083; PRYSTOWSKY EN, 1988, PACE, V11, P225, DOI 10.1111/j.1540-8159.1988.tb04545.x; Prystowsky EN, 1996, CONTROL CLIN TRIALS, V17, pS28, DOI 10.1016/S0197-2456(96)00042-6; PRYSTOWSKY EN, 1996, ATHEROSCLEROSIS CORO, P1257; PRYSTOWSKY EN, 1982, CARDIAC EMERGENCIES, P353; PRYSTOWSKY EN, 1994, CARDIAC ARRH INT APP; RAEDER EA, 1992, NEW ENGL J MED, V326, P271; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; RUBERMAN W, 1977, NEW ENGL J MED, V297, P750, DOI 10.1056/NEJM197710062971404; SIMSON MB, 1981, CIRCULATION, V64, P235, DOI 10.1161/01.CIR.64.2.235; STANTON MS, 1989, J AM COLL CARDIOL, V14, P209, DOI 10.1016/0735-1097(89)90074-0; STEVENSON WG, 1993, CIRCULATION, V88, P1647, DOI 10.1161/01.CIR.88.4.1647; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; THOMAS AC, 1988, PACE, V11, P2053, DOI 10.1111/j.1540-8159.1988.tb06349.x; WINKLE RA, 1977, AM J CARDIOL, V39, P487, DOI 10.1016/S0002-9149(77)80155-0; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0	73	39	41	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					172	179		10.1001/jama.281.2.172	http://dx.doi.org/10.1001/jama.281.2.172			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155VJ	9917122	Bronze			2022-12-28	WOS:000077966800039
J	Nogales, E; Whittaker, M; Milligan, RA; Downing, KH				Nogales, E; Whittaker, M; Milligan, RA; Downing, KH			High-resolution model of the microtubule	CELL			English	Article							MOTOR-PROTEIN COMPLEX; 3-DIMENSIONAL STRUCTURE; ALPHA-TUBULIN; BETA-TUBULIN; INDIVIDUAL MICROTUBULES; CRYOELECTRON MICROSCOPY; LIMITED PROTEOLYSIS; BINDING-SITE; AMINO-ACIDS; LATTICE	A high-resolution model of the microtubule has been obtained by docking the crystal structure of tubulin into a 20 Angstrom map of the microtubule. The excellent fit indicates the similarity of the tubulin conformation in both polymers and defines the orientation of the tubulin structure within the microtubule. Long C-terminal helices form the crest on the outside of the protofilament, while long loops define the microtubule lumen. The exchangeable nucleotide in beta-tubulin is exposed at the plus end of the microtubule, while the proposed catalytic residue in alpha-tubulin is exposed at the minus end. Extensive longitudinal interfaces between monomers have polar and hydrophobic components. At the lateral contacts, a nucleotide-sensitive helix interacts with a loop that contributes to the binding site of taxol in beta-tubulin.	Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Scripps Research Institute	Nogales, E (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA.	enogales@ibl.gov			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052468, P01GM051487] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51487, GM52468, GM46033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOS LA, 1979, NATURE, V279, P607, DOI 10.1038/279607a0; AMOS LA, 1974, J CELL SCI, V14, P523; ANDREU JM, 1993, CELL MOTIL CYTOSKEL, V26, P1, DOI 10.1002/cm.970260102; Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BROWN HR, 1983, ARCH BIOCHEM BIOPHYS, V220, P46, DOI 10.1016/0003-9861(83)90385-5; BURNS RG, 1993, MICROTUBULES, P3; CHAU MF, 1998, IN PRESS BIOCHEMISTR; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; CHRETIEN D, 1992, J CELL BIOL, V117, P1031, DOI 10.1083/jcb.117.5.1031; DAI K, 1994, J BACTERIOL, V175, P130; dePereda JM, 1996, BIOCHEMISTRY-US, V35, P14184, DOI 10.1021/bi961356j; Derry WB, 1998, CANCER RES, V58, P1177; Evangelio JA, 1998, CELL MOTIL CYTOSKEL, V39, P73, DOI 10.1002/(SICI)1097-0169(1998)39:1<73::AID-CM7>3.0.CO;2-H; Fan J, 1996, J MOL BIOL, V259, P325, DOI 10.1006/jmbi.1996.0322; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HIROSE K, 1995, J MOL BIOL, V251, P329, DOI 10.1006/jmbi.1995.0437; HOENGER A, 1995, NATURE, V376, P271, DOI 10.1038/376271a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; LUDUENA R F, 1992, Current Opinion in Cell Biology, V4, P53, DOI 10.1016/0955-0674(92)90058-K; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MANDELKOW EM, 1985, J MOL BIOL, V185, P311, DOI 10.1016/0022-2836(85)90406-1; MARTIN SR, 1993, BIOPHYS J, V65, P578, DOI 10.1016/S0006-3495(93)81091-9; MARUTA H, 1986, J CELL BIOL, V103, P571, DOI 10.1083/jcb.103.2.571; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MITCHISON TJ, 1993, SCIENCE, V261, P1044, DOI 10.1126/science.8102497; NICHOLLS A, 1993, GRASP GRAPHICAL REPR; Nogales E, 1997, J STRUCT BIOL, V118, P119, DOI 10.1006/jsbi.1997.3841; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; REIJO RA, 1994, MOL BIOL CELL, V5, P29, DOI 10.1091/mbc.5.1.29; SACKETT DL, 1986, J BIOL CHEM, V261, P9070; SACKETT DL, 1995, PROTEIN-STRUCT FUNCT, P255; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; Sosa H, 1996, J MOL BIOL, V260, P743, DOI 10.1006/jmbi.1996.0434; WALKER RA, 1989, J CELL BIOL, V108, P931, DOI 10.1083/jcb.108.3.931; Wilson PJ, 1997, CELL MOTIL CYTOSKEL, V37, P20, DOI 10.1002/(SICI)1097-0169(1997)37:1<20::AID-CM3>3.3.CO;2-7	42	928	955	1	71	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 8	1999	96	1					79	88		10.1016/S0092-8674(00)80961-7	http://dx.doi.org/10.1016/S0092-8674(00)80961-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989499	Bronze			2022-12-28	WOS:000078023200010
J	Yuzhakov, A; Kelman, Z; O'Donnell, M				Yuzhakov, A; Kelman, Z; O'Donnell, M			Trading places on DNA-a three-point switch underlies primer handoff from primase to the replicative DNA polymerase	CELL			English	Article							ONE HOLOENZYME PARTICLE; LAGGING-STRAND REPLICATION; ESCHERICHIA-COLI; SLIDING CLAMPS; BINDING PROTEIN; III HOLOENZYME; MACHINE; LOADER; HELICASE; ANTIGEN	This study reports a primase-to-polymerase switch in E. coli that closely links primase action with extension by DNA polymerase III holoenzyme. We find that primase tightly grips its RNA primer, protecting it from the action of other proteins. However, primase must be displaced before the beta sliding clamp can be assembled on the primed site. A single subunit of the holoenzyme, chi, is dedicated to this primase displacement task. The displacement mechanism depends on a third protein, SSB. Primase requires contact to SSB for its grip on the primed site. The chi subunit also binds SSB, upon which the primase-to-SSB contact is destabilized leading to dissociation of primase and assembly of beta onto the RNA primer. The conservation of this three-point switch, in which two proteins exchange places on DNA via mutually exclusive interaction with a third protein, is discussed.	Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA; Cornell Univ, Coll Med, Grad Program Mol Biol, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Cornell University	O'Donnell, M (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	odonnel@rockvax.rockefeller.edu		O'Donnell, Michael/0000-0001-9002-4214	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38839] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CHASE JW, 1984, J BIOL CHEM, V259, P805; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; KELMAN Z, 1995, GENE, V166, P177, DOI 10.1016/0378-1119(95)00556-7; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KELMAN Z, 1995, METHODS ENZYMOLOGY D; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MEYER RR, 1982, J BACTERIOL, V150, P433, DOI 10.1128/JB.150.1.433-435.1982; MOK M, 1987, J BIOL CHEM, V262, P16644; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; RICHE D, 1989, Science and Sports, V4, P41, DOI 10.1016/S0765-1597(89)80006-1; SILVER LL, 1982, J BIOL CHEM, V257, P1696; STAYTON MM, 1983, J BIOL CHEM, V258, P3205; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; Sun WL, 1998, J MOL BIOL, V276, P689, DOI 10.1006/jmbi.1997.1471; TOUGU K, 1994, J BIOL CHEM, V269, P4675; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; Turner J, 1995, METHOD ENZYMOL, V262, P442; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	32	186	187	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 8	1999	96	1					153	163		10.1016/S0092-8674(00)80968-X	http://dx.doi.org/10.1016/S0092-8674(00)80968-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989506	Bronze			2022-12-28	WOS:000078023200017
J	Lewis, M; Elwyn, GJ				Lewis, M; Elwyn, GJ			Should we accept all comers?	BRITISH MEDICAL JOURNAL			English	Editorial Material													Elwyn, G./L-4292-2015; Elwyn, Glyn/B-4798-2009	Elwyn, Glyn/0000-0002-0917-6286					0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					407	407		10.1136/bmj.318.7180.407	http://dx.doi.org/10.1136/bmj.318.7180.407			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933234	Green Published			2022-12-28	WOS:000078572600078
J	Hinchcliffe, EH; Li, C; Thompson, EA; Maller, JL; Sluder, G				Hinchcliffe, EH; Li, C; Thompson, EA; Maller, JL; Sluder, G			Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in Xenopus egg extracts	SCIENCE			English	Article							CELL-FREE-EXTRACTS; SEA-URCHIN EGGS; SPINDLE POLES; DNA-SYNTHESIS; CYCLE; NUCLEAR; REPLICATION; DIVISION	The abnormally high number of centrosomes found in many human tumor cells can lead directly to aneuploidy and genomic instability through the formation of multipolar mitotic spindles. To facilitate investigation of the mechanisms that control centrosome reproduction, a frog egg extract arrested in S phase of the cell cycle that supported repeated assembly of daughter centrosomes was developed, Multiple rounds of centrosome reproduction were blocked by selective inactivation of cyclin-dependent kinase 2-cyclin E (Cdk2-E) and were restored by addition of purified Cdk2-E. Confocal immunomicroscopy revealed that cyclin E was Localized at the centrosome. These results demonstrate that Cdk2-E activity is required for centrosome duplication during S phase and suggest a mechanism that could coordinate centrosome reproduction with cycles of DNA synthesis and mitosis.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sluder, G (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA.	Greenfield.Sluder@ummed.edu						BAILLY E, 1992, J CELL SCI, V101, P529; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hartley RS, 1997, DEV BIOL, V188, P312, DOI 10.1006/dbio.1997.8647; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hinchcliffe EH, 1998, J CELL BIOL, V140, P1417, DOI 10.1083/jcb.140.6.1417; HINCHCLIFFE EH, UNPUB; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; LACEY KR, IN PRESS P NATL ACAD; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MAZIA D, 1984, EXP CELL RES, V153, P1, DOI 10.1016/0014-4827(84)90442-7; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; PALAZZO RE, 1992, SCIENCE, V256, P219, DOI 10.1126/science.1566068; REMPEL RE, 1995, J BIOL CHEM, V270, P6842; SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; SLUDER G, 1987, J EXP ZOOL, V244, P89, DOI 10.1002/jez.1402440111; SLUDER G, 1985, J CELL BIOL, V100, P887, DOI 10.1083/jcb.100.3.887; Sluder G, 1997, J CELL SCI, V110, P421; Strausfeld UP, 1996, J CELL SCI, V109, P1555; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; TOURNIER F, 1991, P NATL ACAD SCI USA, V88, P9929, DOI 10.1073/pnas.88.22.9929; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5	28	415	428	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					851	854		10.1126/science.283.5403.851	http://dx.doi.org/10.1126/science.283.5403.851			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933170				2022-12-28	WOS:000078496800047
J	Roth, WK; Weber, M; Seifried, E				Roth, WK; Weber, M; Seifried, E			Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ALANINE AMINOTRANSFERASE; UNITED-STATES; DONORS; INFECTION; RISK; REPLICATION	Background Despite sensitive antibody-based blood-donor screening, a residual risk of transfusion-transmitted viral infections exists. Only direct monitoring by sensitive nucleic-acid tests would provide data accurately to measure the risk and to assess risk-reduction procedures. We investigated the feasibility and efficacy of routine screening of donors for hepatitis C virus (HCV), hepatitis B virus (HBV), and HIV-1 by PCR. Methods For PCR testing, individual donor plasma samples were pooled (96 x 100 mu L) overnight by two automatic pipetting machines. Viruses were concentrated by centrifugation and nucleic acids were extracted. HCV PCR was done on the Cobas Amplicor system (Hoffmann-La Roche, Mannheim, Germany). HBV and HIV-1 sequences were amplified by single (non-nested) in-house PCRs and detected by agarose-gel electrophoresis. Detection limits were 1000-5000 genome equivalents/mL. in the donor blood. Findings PCR testing was done in parallel to antibody screening with a maximum throughput of 3000 samples in 7-8 h. Positive samples were identified 1-2 days later. 111 of 373423 donations (107 of 4500 pools) were PCR and antibody/antigen-confirmed positive. We found one HCV POP-positive antibody-negative donation with normal alanine aminotransferase and one HCV PCR-positive donation with an elevated alanine aminotransferase (100 IU), which was negative in the AxSYM 2.0 and Matrix 1.0, but positive after control in the Abbott Prism test (Abbott GmbH, Wiesbaden, Germany). Interpretation PCR is a suitable and fast blood-donor screening procedure and contributes to a reduction in viral transmission by transfusion of blood components. In our selected donor population, the yield of detected contaminated donations from donors in the time window in which they are highly infectious but do not have any symptoms or detectable antigen and antibody concentrations (diagnostic window), confirms theoretical estimates.	Red Cross Blood Donor Serv, Inst Transfus Med & Immunohaematol, D-60528 Frankfurt, Germany		Seifried, E (corresponding author), Red Cross Blood Donor Serv, Inst Transfus Med & Immunohaematol, Sandhofstr 1, D-60528 Frankfurt, Germany.							Busch MP, 1995, TRANSFUSION, V35, P903, DOI 10.1046/j.1537-2995.1995.351196110893.x; Diekamp U, 1997, BEITR INFUS, V34, P5; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; Gluck D, 1997, INFUSIONSTHERAPIE, V24, P167; Herrera GA, 1997, TRANSFUSION, V37, P836, DOI 10.1046/j.1537-2995.1997.37897424407.x; Hewlett IK, 1997, TRANSFUSION, V37, P346, DOI 10.1046/j.1537-2995.1997.37397240219.x; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; LIVAK KJ, 1995, PCR METH APPL, V4, P357; *P EHRL I, 1998, BUNDESANZEIGER, V53, P3835; Prince AM, 1997, TRANSFUSION, V37, P211, DOI 10.1046/j.1537-2995.1997.37297203526.x; RUSTER B, 1995, ANAL BIOCHEM, V224, P597, DOI 10.1006/abio.1995.1092; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SHINDO M, 1992, J INFECT DIS, V166, P424, DOI 10.1093/infdis/166.2.424; Vrielink H, 1997, TRANSFUSION, V37, P845, DOI 10.1046/j.1537-2995.1997.37897424409.x; WHETSELL AJ, 1992, J CLIN MICROBIOL, V30, P845, DOI 10.1128/JCM.30.4.845-853.1992; YUKOSUKA O, 1993, DIAGNOSTIC MOL MICRO, P322; ZAYCSCHMIDT EM, 1997, INFUSIONSTHER TRANSF, V24, P195	18	215	233	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 30	1999	353	9150					359	363		10.1016/S0140-6736(98)06318-1	http://dx.doi.org/10.1016/S0140-6736(98)06318-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950441				2022-12-28	WOS:000078437000011
J	Andersen, RE; Wadden, TA; Bartlett, SJ; Zemel, B; Verde, TJ; Franckowiak, SC				Andersen, RE; Wadden, TA; Bartlett, SJ; Zemel, B; Verde, TJ; Franckowiak, SC			Effects of lifestyle activity vs structured aerobic exercise in obese women - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WEIGHT-LOSS; LIPOPROTEINS; MAINTENANCE; LIPIDS; HEALTH	Context Physical inactivity contributes to weight. gain, but only 22% of Americans are regularly active. Objective To examine short- and long-term changes in weight, body composition, and cardiovascular risk profiles produced by diet combined with either structured aerobic exercise or moderate-intensity lifestyle activity. Design Sixteen-week randomized controlled trial with 1-year follow-up, conducted from August 1995 to December 1996. Participants and Setting Forty obese women (mean body mass index [weight in kilograms divided by the square of height in meters], 32.9 kg/m(2); mean weight, 89.2 kg) with a mean age of 42.9 years (range, 21-60 years) seen in a university-based weight management program. Interventions Structured aerobic exercise or moderate lifestyle activity; low-fat diet of about 1200 kcal/d. Main Outcome Measures Changes in body weight, body composition, cardiovascular risk profiles, and physical fitness at 16 weeks and at 1 year. Results Mean (SD) weight losses during the 16-week treatment program were 8.3 (3.8) kg for the aerobic group and 7.9 (4.2) kg for the lifestyle group (within groups, P<.001; between groups, P=.08). The aerobic group lost significantly less fat-free mass (0.5 [1.3] kg) than the lifestyle group (1.4 [1.3] kg; P=.03), During the 1-year follow-up, the aerobic group regained 1.6 [5.5] kg, while the lifestyle group regained 0.08 (4.6) kg. At week 16, serum triglyceride levels and total cholesterol levels were reduced significantly (P<.001) from baseline (16.3% and 10.1% reductions, respectively) but did not differ significantly between groups and were not different from baseline or between groups at week 68. Conclusions A program of diet plus lifestyle activity may offer similar health benefits and be a suitable alternative to diet plus structured aerobic activity for obese women.	Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21224 USA; Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Cabrini Coll, Dept Sports Sci, Radnor, PA USA	Johns Hopkins University; Johns Hopkins University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Andersen, RE (corresponding author), Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, 5501 Hopkins Bayview Cir,JHAAC 5B-81, Baltimore, MD 21224 USA.		Zemel, Babette S./D-1117-2009; Bartlett, Susan J./J-9864-2012; Bartlett, Susan Joan/AAD-4103-2020; Davey Smith, George/A-7407-2013	Zemel, Babette S./0000-0002-6164-7348; Bartlett, Susan Joan/0000-0001-9755-2490; Davey Smith, George/0000-0002-1407-8314	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009241] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH000702] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32DK09241-01] Funding Source: Medline; NIMH NIH HHS [K02-MH00702-08] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[AHA Nutrition Committee American Heart Association guidelines for weight manage- ment programs for healthy adults], 1994, HEART DIS STROKE, V3, P221; Andersen RE, 1997, METABOLISM, V46, P857, DOI 10.1016/S0026-0495(97)90070-6; ANDERSEN RE, 1995, AM J CLIN NUTR, V62, P350, DOI 10.1093/ajcn/62.2.350; ANDERSEN RE, 1995, MED SCI SPORT EXER, V27, P1457; ANDERSEN RE, 1992, HLTH FITNESS CLUB LE; ANDERSEN RE, 1996, LIFESTYLE WEIGHT MAN; Beck A.T., 1987, MANUAL BECK DEPRESSI; BLAIR SN, 1992, MED EXERCISE NUTRITI, V1, P54; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Brownell K. D., 1994, LEARN PROGRAM WEIGHT; BROWNELL KD, 1992, J CONSULT CLIN PSYCH, V60, P505, DOI 10.1037/0022-006X.60.4.505; Coleman KJ, 1997, MED SCI SPORT EXER, V29, P1535, DOI 10.1097/00005768-199711000-00022; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; KAYMAN S, 1990, AM J CLIN NUTR, V52, P800, DOI 10.1093/ajcn/52.5.800; Kenney WL, 1995, ACSMS GUIDELINES EXE; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; *METR LIF INS CO, 1983, STAT B, V64, P2; Moser C. D., 1996, Medicine and Science in Sports and Exercise, V28, pS44; NORUSIS MJ, 1992, SPSS PCPLUS ADV STAT; OLSON MS, 1998, ACSM HLTH FITNESS J, V2, P32; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PAVLOU KN, 1989, AM J CLIN NUTR, V49, P1115, DOI 10.1093/ajcn/49.5.1115; PENNINGTON JAT, 1998, BOWES CHURCHS FOOD V; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; SELDELL JC, 1997, HORM METAB RES, V29, P155; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; Wadden TA, 1997, J CONSULT CLIN PSYCH, V65, P269, DOI 10.1037/0022-006X.65.2.269; WADDEN TA, 1992, TREATMENT SERIOUSLY, P290	28	435	445	0	46	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1999	281	4					335	340		10.1001/jama.281.4.335	http://dx.doi.org/10.1001/jama.281.4.335			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158JB	9929086				2022-12-28	WOS:000078111300032
J	Dunn, AL; Marcus, BH; Kampert, JB; Garcia, ME; Kohl, HW; Blair, SN				Dunn, AL; Marcus, BH; Kampert, JB; Garcia, ME; Kohl, HW; Blair, SN			Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALL-CAUSE MORTALITY; DEPENDENT DIABETES-MELLITUS; WOMEN; EXERCISE; MEN; HEALTHY; LIPOPROTEINS; CARDIOLOGY; PREVENTION; MODEL	Context Even though the strong association between physical inactivity and ill health is well documented, 60% of the population is inadequately active or completely inactive. Traditional methods of prescribing exercise have not proven effective for increasing and maintaining a program of regular physical activity. Objective To compare the 24-month intervention effects of a lifestyle physical activity program with traditional structured exercise on improving physical activity, cardiorespiratory fitness, and cardiovascular disease risk factors. Design Randomized clinical trial conducted from August 1, 1993, through July 31, 1997. Participants Sedentary men (n = 116) and women (n = 119) with self-reported physical activity of less than 36 and 34 kcal/kg per day, respectively. Interventions Six months of intensive and 18 months of maintenance intervention on either a lifestyle physical activity or a traditional structured exercise program. Main Outcome Measures Primary outcomes were physical activity assessed by the 7-Day Physical Activity Recall and peak oxygen consumption (VO2peak) by a maximal exercise treadmill test. Secondary outcomes were plasma lipid and lipoprotein cholesterol concentrations, blood pressure, and body composition. All measures were obtained at baseline and at 6 and 24 months. Results Both the lifestyle and structured activity groups had significant and comparable improvements in physical activity and cardiorespiratory fitness from baseline to 24 months. Adjusted mean changes (95% confidence intervals [CIs]) were 0.84 (95% CI, 0.42-1.25 kcal/kg per day; P<.001) and 0.69 (95% CI, 0.25-1.12 kcal/kg day; P=.002) for activity, and 0.77 (95% CI, 0.18-1.36 mL/kg per minute; P=.01) and 1.34 (95% CI, 0.72-1.96 mL/kg per minute; P<.001) for VO2peak for the lifestyle and structured activity groups, respectively. There were significant and comparable reductions in systolic blood pressure (-3.63 [95% CI, -5.54 to -1.72 mm Hg; P<.001] and -3.26 [95% CI, -5.26 to -1.25 mm Hg; P=.002]) and diastolic blood pressure (-5.38 [95% CI, -6.90 to -3.86 mm Hg; P<.001] and -5.14 [95% CI, -6.73 to -3.54 mm Hg; P<.001) for the lifestyle and structured activity groups, respectively. Neither group significantly changed their weight (-0.05 [95% CI, -1.05 to 0.96 kg; P=.93] and 0.69 [95% CI, -0.37 to 1.74 kg; P=.20]), but each group significantly reduced their percentage of body fat (-2.39% [95% CI, -2.92% to -1.85%; P<.001] and -1.85% [95% CI, -2.41% to -1.28%; P<.001]) in the lifestyle and structured activity groups, respectively. Conclusions In previously sedentary healthy adults, a lifestyle physical activity intervention is as effective as a structured exercise program in improving physical activity, cardiorespiratory fitness, and blood pressure.	Cooper Inst Aerob Res, Dallas, TX 75230 USA; Miriam Hosp, Providence, RI 02906 USA; Brown Univ, Sch Med, Providence, RI 02912 USA; Baylor Coll Med, Houston, TX 77030 USA; Vanderbilt Univ, Med Ctr, Nashville, TN USA	Cooper Institute; Lifespan Health Rhode Island; Miriam Hospital; Brown University; Baylor College of Medicine; Vanderbilt University	Dunn, AL (corresponding author), Cooper Inst Aerob Res, 12330 Preston Rd, Dallas, TX 75230 USA.	adunn@cooperinst.org			NCI NIH HHS [CA01757] Funding Source: Medline; NHLBI NIH HHS [HL-48597] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048597] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1991, GUID EX TEST PRESCR; Bandura A., 1986, SOCIAL FDN THOUGHT A; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; BLAIR SN, 1985, AM J EPIDEMIOL, V122, P794, DOI 10.1093/oxfordjournals.aje.a114163; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BLAIR SN, 1992, MED EXERCISE NUTRITI, V1, P54; BRUCE RA, 1977, NEW ENGL J MED, V296, P671, DOI 10.1056/NEJM197703242961206; BUCHNER DM, 1992, ANNU REV PUBL HEALTH, V13, P469, DOI 10.1146/annurev.publhealth.13.1.469; Calfas KJ, 1996, PREV MED, V25, P225, DOI 10.1006/pmed.1996.0050; Dishman RK., 1994, PHYS ACTIVITY FITNES, P214; Dunn AL, 1998, MED SCI SPORT EXER, V30, P1076, DOI 10.1097/00005768-199807000-00009; Dunn AL, 1997, PREV MED, V26, P883, DOI 10.1006/pmed.1997.0218; ELMER PJ, 1995, PREV MED, V24, P378, DOI 10.1006/pmed.1995.1062; EPSTEIN LH, 1985, BEHAV THER, V16, P345, DOI 10.1016/S0005-7894(85)80002-2; FLETCHER GF, 1992, CIRCULATION, V86, P340, DOI 10.1161/01.CIR.86.1.340; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HOLLOSZY JO, 1993, MED SCI SPORT EXER, V25, P1; JACKSON AS, 1978, BRIT J NUTR, V40, P497, DOI 10.1079/BJN19780152; JACKSON AS, 1980, MED SCI SPORT EXER, V12, P175; KING AC, 1995, CIRCULATION, V91, P2596, DOI 10.1161/01.CIR.91.10.2596; Kohl HW, 1998, MED SCI SPORT EXER, V30, P275, DOI 10.1097/00005768-199802000-00016; LEE IM, 1994, PHYSICAL ACTIVITY FI, P814; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; Marcus B H, 1992, Am J Health Promot, V6, P424; Marcus BH, 1998, AM J HEALTH PROMOT, V12, P246, DOI 10.4278/0890-1171-12.4.246; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Pereira M A, 1997, Med Sci Sports Exerc, V29, pS1; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; SAS Institute Inc, 1989, SAS STAT US GUID VER; SEARLE SR, 1980, AM STAT, V34, P216, DOI 10.2307/2684063; SIMKINSILVERMAN L, 1995, PREV MED, V24, P509, DOI 10.1006/pmed.1995.1081; Stefanick ML, 1998, NEW ENGL J MED, V339, P12, DOI 10.1056/NEJM199807023390103; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; Wing RR, 1998, DIABETES CARE, V21, P350, DOI 10.2337/diacare.21.3.350; WOOD PD, 1991, NEW ENGL J MED, V325, P461, DOI 10.1056/NEJM199108153250703	37	759	766	0	87	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1999	281	4					327	334		10.1001/jama.281.4.327	http://dx.doi.org/10.1001/jama.281.4.327			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	158JB	9929085				2022-12-28	WOS:000078111300031
J	Wassarman, PM				Wassarman, PM			Mammalian fertilization: Molecular aspects of gamete adhesion, exocytosis, and fusion	CELL			English	Review							SPERM-EGG BINDING; ZONA-PELLUCIDA GLYCOPROTEIN; O-LINKED OLIGOSACCHARIDES; GUINEA-PIG SPERM; MOUSE SPERM; ACROSOME REACTION; RECEPTOR ACTIVITY; EXTRACELLULAR-MATRIX; SPERMATOGENIC CELLS; DISINTEGRIN DOMAIN		CUNY Mt Sinai Sch Med, Dept Cell Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Wassarman, PM (corresponding author), CUNY Mt Sinai Sch Med, Dept Cell Biol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	p_wassarman@smtplink.mssm.edu						ABDULLAH M, 1989, J CELL BIOL, V108, P367, DOI 10.1083/jcb.108.2.367; ALLEN CA, 1995, J CELL SCI, V108, P767; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Arnoult C, 1996, P NATL ACAD SCI USA, V93, P13004, DOI 10.1073/pnas.93.23.13004; Arnoult C, 1996, J CELL BIOL, V134, P637, DOI 10.1083/jcb.134.3.637; Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850; BABA T, 1994, J BIOL CHEM, V269, P31845; Bigler D, 1997, TRENDS CELL BIOL, V7, P220, DOI 10.1016/S0962-8924(97)01058-1; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; BLEIL JD, 1980, DEV BIOL, V76, P185, DOI 10.1016/0012-1606(80)90371-1; BLEIL JD, 1988, P NATL ACAD SCI USA, V85, P6778, DOI 10.1073/pnas.85.18.6778; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; BLEIL JD, 1986, J CELL BIOL, V102, P1363, DOI 10.1083/jcb.102.4.1363; BLEIL JD, 1983, DEV BIOL, V95, P317, DOI 10.1016/0012-1606(83)90032-5; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BOOKBINDER LH, 1995, SCIENCE, V269, P86, DOI 10.1126/science.7604284; Bork P, 1996, SCIENCE, V271, P1431, DOI 10.1126/science.271.5254.1431; BURKS DJ, 1995, SCIENCE, V269, P83, DOI 10.1126/science.7541556; CARDULLO RA, 1993, METHOD ENZYMOL, V225, P136; Chen J, 1998, P NATL ACAD SCI USA, V95, P6193, DOI 10.1073/pnas.95.11.6193; CHENG A, 1994, J CELL BIOL, V125, P867, DOI 10.1083/jcb.125.4.867; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; CORNWALL GA, 1991, BIOL REPROD, V44, P913, DOI 10.1095/biolreprod44.5.913; Darszon A, 1996, CURR TOP DEV BIOL, V34, P117, DOI 10.1016/S0070-2153(08)60710-3; Diekman AB, 1997, BIOL REPROD, V57, P1136, DOI 10.1095/biolreprod57.5.1136; DOSTALOVA Z, 1995, EUR J BIOCHEM, V230, P329, DOI 10.1111/j.1432-1033.1995.tb20567.x; Eddy E. M., 1994, P29; EISENBACH M, 1998, IN PRESS BIOESSAYS; Evans JP, 1997, DEV BIOL, V187, P94, DOI 10.1006/dbio.1997.8612; EVANS JP, 1995, J CELL SCI, V108, P3267; Evans JP, 1998, BIOL REPROD, V59, P145, DOI 10.1095/biolreprod59.1.145; FLORMAN HM, 1984, DEV BIOL, V106, P243, DOI 10.1016/0012-1606(84)90079-4; FLORMAN HM, 1994, DEV BIOL, V165, P152, DOI 10.1006/dbio.1994.1242; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; FLORMAN HM, 1982, DEV BIOL, V91, P121, DOI 10.1016/0012-1606(82)90015-X; Florman HM, 1998, BIOL REPROD, V59, P12, DOI 10.1095/biolreprod59.1.12; Foster JA, 1997, J BIOL CHEM, V272, P12714, DOI 10.1074/jbc.272.19.12714; FRY MR, 1992, BIOL REPROD, V47, P751, DOI 10.1095/biolreprod47.5.751; Gao Z, 1998, J BIOL CHEM, V273, P3415, DOI 10.1074/jbc.273.6.3415; GONG XH, 1995, SCIENCE, V269, P1718, DOI 10.1126/science.7569899; GRAVES BJ, 1995, NAT STRUCT BIOL, V2, P181, DOI 10.1038/nsb0395-181; GWATKIN RBL, 1977, FERTILIZATION MECH M; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Johnston DS, 1998, J BIOL CHEM, V273, P1888, DOI 10.1074/jbc.273.4.1888; Jury JA, 1997, BIOCHEM J, V321, P577, DOI 10.1042/bj3210577; Jury JK, 1998, MOL REPROD DEV, V51, P92, DOI 10.1002/(SICI)1098-2795(199809)51:1<92::AID-MRD11>3.0.CO;2-W; KINLOCH RA, 1995, P NATL ACAD SCI USA, V92, P263, DOI 10.1073/pnas.92.1.263; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; Lievano A, 1996, FEBS LETT, V388, P150, DOI 10.1016/0014-5793(96)00515-7; Litscher ES, 1996, BIOCHEMISTRY-US, V35, P3980, DOI 10.1021/bi952722m; LITSCHER ES, 1995, BIOCHEMISTRY-US, V34, P4662, DOI 10.1021/bi00014a020; Liu CY, 1996, P NATL ACAD SCI USA, V93, P5431, DOI 10.1073/pnas.93.11.5431; Lu QX, 1997, DEVELOPMENT, V124, P4121; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; MORTILLO S, 1991, DEVELOPMENT, V113, P141; MUGA A, 1994, BIOCHEMISTRY-US, V33, P4444, DOI 10.1021/bi00181a002; Myles DG, 1997, BIOL REPROD, V56, P320, DOI 10.1095/biolreprod56.2.320; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; Niidome T, 1997, J PEPT RES, V49, P563; Rankin T, 1996, DEVELOPMENT, V122, P2903; RICHARDSON RT, 1994, DEV BIOL, V165, P688, DOI 10.1006/dbio.1994.1285; Riffo MS, 1996, J EXP ZOOL, V275, P459, DOI 10.1002/(SICI)1097-010X(19960815)275:6&lt;459::AID-JEZ8&gt;3.0.CO;2-N; ROCHWERGER L, 1992, DEV BIOL, V153, P83, DOI 10.1016/0012-1606(92)90093-V; ROLDAN ERS, 1994, SCIENCE, V266, P1578, DOI 10.1126/science.7985030; Romero A, 1997, NAT STRUCT BIOL, V4, P783, DOI 10.1038/nsb1097-783; ROSIERE TK, 1992, DEV BIOL, V154, P309, DOI 10.1016/0012-1606(92)90070-W; Saling P, 1996, SCIENCE, V271, P1434, DOI 10.1126/science.271.5254.1434; SHUR BD, 1989, IN PRESS GUIDEBOOK E; Snell WJ, 1996, CELL, V85, P629, DOI 10.1016/S0092-8674(00)81230-1; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; Toshimori K, 1998, BIOL REPROD, V59, P22, DOI 10.1095/biolreprod59.1.22; Tsai JY, 1996, SCIENCE, V271, P1432, DOI 10.1126/science.271.5254.1432; van Huijsduijnen RH, 1998, GENE, V206, P273, DOI 10.1016/S0378-1119(97)00597-0; Visconti PE, 1998, BIOL REPROD, V59, P1, DOI 10.1095/biolreprod59.1.1; WALENSKY LD, 1995, J CELL BIOL, V130, P857, DOI 10.1083/jcb.130.4.857; WARD CR, 1994, J BIOL CHEM, V269, P13254; WARD CR, 1992, J BIOL CHEM, V267, P14061; WARD CR, 1984, DEV BIOL, V104, P287, DOI 10.1016/0012-1606(84)90084-8; Wassarman Paul M., 1994, P79; WASSARMAN PM, 1995, CURR OPIN CELL BIOL, V7, P658, DOI 10.1016/0955-0674(95)80107-3; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; WASSARMAN PM, 1991, INT REV CYTOL, V130, P85, DOI 10.1016/S0074-7696(08)61502-8; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1; WASSARMAN PM, 1987, SCIENCE, V235, P553, DOI 10.1126/science.3027891; Wassarman PM, 1997, P ROY SOC B-BIOL SCI, V264, P323, DOI 10.1098/rspb.1997.0046; Wassarman PM, 1996, J CELL SCI, V109, P2001; WASSARMAN PM, 1995, CURR TOP DEV BIOL, V30, P1, DOI 10.1016/S0070-2153(08)60562-1; WASSARMAN PM, 1999, IN PRESS GUIDEBOOK E; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yamagata K, 1998, J BIOL CHEM, V273, P10470, DOI 10.1074/jbc.273.17.10470; Yanagimachi R., 1994, P189; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105; Zhu XL, 1997, P NATL ACAD SCI USA, V94, P4704, DOI 10.1073/pnas.94.9.4704	97	377	399	1	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 22	1999	96	2					175	183		10.1016/S0092-8674(00)80558-9	http://dx.doi.org/10.1016/S0092-8674(00)80558-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	160VM	9988213	Bronze			2022-12-28	WOS:000078252200002
J	Wylie, C				Wylie, C			Germ cells	CELL			English	Review							LEUKEMIA INHIBITORY FACTOR; MATERNAL-EFFECT MUTATIONS; EARLY XENOPUS EMBRYOS; KINESIN-LIKE PROTEIN; DROSOPHILA-MELANOGASTER; MOUSE EMBRYOS; STEM-CELLS; CAENORHABDITIS-ELEGANS; TRANSCRIPTION FACTOR; ANTERIOR-POSTERIOR		Univ Minnesota, Sch Med, Dev Gemet Ctr, Dept Pediat, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wylie, C (corresponding author), Univ Minnesota, Sch Med, Dev Gemet Ctr, Dept Pediat, Minneapolis, MN 55455 USA.				NICHD NIH HHS [R01-HD33440] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033440] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEAMS HW, 1974, INT REV CYTOL, V39, P413, DOI 10.1016/S0074-7696(08)60944-4; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; Broihier HT, 1998, DEVELOPMENT, V125, P655; BUEHR M, 1993, DEV DYNAM, V198, P182, DOI 10.1002/aja.1001980304; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CAPOWSKI EE, 1991, GENETICS, V129, P1061; CHIQUOINE AD, 1954, ANAT REC, V118, P135, DOI 10.1002/ar.1091180202; CHRISTERSON LB, 1994, GENE DEV, V8, P614, DOI 10.1101/gad.8.5.614; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; CLARK JM, 1975, DEV BIOL, V47, P136, DOI 10.1016/0012-1606(75)90269-9; CLEINE JH, 1986, J EMBRYOL EXP MORPH, V94, P83; Cooke JE, 1996, DEV BIOL, V174, P14, DOI 10.1006/dbio.1996.0047; DEFELICI M, 1991, DEV BIOL, V147, P281, DOI 10.1016/S0012-1606(05)80025-9; DENIS H, 1993, TRENDS GENET, V9, P7, DOI 10.1016/0168-9525(93)90065-P; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; Donovan PJ, 1998, APMIS, V106, P134, DOI 10.1111/j.1699-0463.1998.tb01328.x; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; Forbes A, 1998, DEVELOPMENT, V125, P679; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; FUJIMOTO T, 1976, ANAT REC, V185, P139, DOI 10.1002/ar.1091850203; FUJIWARA Y, 1994, P NATL ACAD SCI USA, V91, P12258, DOI 10.1073/pnas.91.25.12258; GARDNER RL, 1979, J EMBRYOL EXP MORPH, V52, P141; Gearhart J, 1998, SCIENCE, V282, P1061, DOI 10.1126/science.282.5391.1061; GILLESPIE DE, 1995, GENE DEV, V9, P2495, DOI 10.1101/gad.9.20.2495; GINSBURG M, 1990, DEVELOPMENT, V110, P521; GODIN I, 1991, DEVELOPMENT, V113, P1451; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GODIN I, 1990, DEVELOPMENT, V108, P357; GOMPERTS M, 1994, DEVELOPMENT, V120, P135; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Guedes S, 1997, DEVELOPMENT, V124, P731; GURDON JB, 1974, CONTROL GENE EXPRESS; Hadorn E., 1978, P556; HADORN E, 1963, DEV BIOL, V7, P617, DOI 10.1016/0012-1606(63)90146-5; HALL PA, 1989, DEVELOPMENT, V106, P619; Hara T, 1998, DEV BIOL, V201, P144, DOI 10.1006/dbio.1998.8990; HARRISON DE, 1973, P NATL ACAD SCI USA, V70, P3184, DOI 10.1073/pnas.70.11.3184; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Holdeman R, 1998, DEVELOPMENT, V125, P2457; Houston DW, 1998, DEVELOPMENT, V125, P171; Hudson C, 1998, MECH DEVELOP, V73, P159, DOI 10.1016/S0925-4773(98)00047-1; Humphrey RR, 1929, ANAT REC, V42, P301, DOI 10.1002/ar.1090420306; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; JAGLARZ MK, 1995, DEVELOPMENT, V121, P3495; JAGLARZ MK, 1994, DEVELOPMENT, V120, P83; JONGENS TA, 1992, CELL, V70, P569, DOI 10.1016/0092-8674(92)90427-E; JONGENS TA, 1994, GENE DEV, V8, P2123, DOI 10.1101/gad.8.18.2123; KANEKO Y, 1991, J CELL PHYSIOL, V147, P224, DOI 10.1002/jcp.1041470206; Karagenc L, 1996, DEV GENET, V19, P290, DOI 10.1002/(SICI)1520-6408(1996)19:4<290::AID-DVG2>3.3.CO;2-S; Kelly WG, 1998, DEVELOPMENT, V125, P2451; KEMPHUES KJ, 1997, C ELEGANS, V0002, P00335; Kirk DL, 1997, ANNU REV GENET, V31, P359, DOI 10.1146/annurev.genet.31.1.359; KLOC M, 1993, SCIENCE, V262, P1712, DOI 10.1126/science.7505061; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; KOBAYASHI S, 1989, DEVELOPMENT, V107, P733; Korf I, 1998, DEVELOPMENT, V125, P2469; Koshimizu U, 1996, DEVELOPMENT, V122, P1235; KU M, 1993, DEVELOPMENT, V119, P1161; LANTZ V, 1994, GENE DEV, V8, P598, DOI 10.1101/gad.8.5.598; LAWSON KA, 1994, CIBA F SYMP, V182, P68; LITTLEFIELD CL, 1991, DEV BIOL, V143, P378, DOI 10.1016/0012-1606(91)90088-K; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MARZIALI G, 1993, DEV BIOL, V157, P182, DOI 10.1006/dbio.1993.1122; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; MEININGER CJ, 1992, BLOOD, V79, P958; Moore LA, 1998, DEVELOPMENT, V125, P667; Nakamura A, 1996, SCIENCE, V274, P2075, DOI 10.1126/science.274.5295.2075; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; NEWMARK PA, 1994, DEVELOPMENT, V120, P1303; Newmark PA, 1997, DEVELOPMENT, V124, P3197; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; NIEUWKOOP P, 1981, PRIMORDIAL GERM CELL, P182; NIEUWKOOP PD, 1979, PRIMORDIAL GERM CELL, P187; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; PELLAS TC, 1991, P NATL ACAD SCI USA, V88, P8787, DOI 10.1073/pnas.88.19.8787; RAFF JW, 1989, CELL, V57, P611, DOI 10.1016/0092-8674(89)90130-X; Ransick A, 1996, P NATL ACAD SCI USA, V93, P6759, DOI 10.1073/pnas.93.13.6759; RESNICK JL, 1992, NATURE, V359, P550, DOI 10.1038/359550a0; REUTER R, 1994, DEVELOPMENT, V120, P1123; Robb DL, 1996, CELL, V87, P823, DOI 10.1016/S0092-8674(00)81990-X; Rongo C, 1996, TRENDS GENET, V12, P102, DOI 10.1016/0168-9525(96)81421-1; Rongo C, 1997, COLD SPRING HARB SYM, V62, P1; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SAVAGE RM, 1993, DEV BIOL, V157, P371, DOI 10.1006/dbio.1993.1142; SCHEDL T, 1997, C ELEGANS, V2, P241; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCHUPBACH T, 1989, GENETICS, V121, P101; Seydoux G, 1997, DEVELOPMENT, V124, P2191; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; SMITH LD, 1966, DEV BIOL, V14, P330, DOI 10.1016/0012-1606(66)90019-4; SNOW MHL, 1981, J EMBRYOL EXP MORPH, V65, P269; Sonnenblick BP, 1941, P NATL ACAD SCI USA, V27, P484, DOI 10.1073/pnas.27.10.484; STEVENS LC, 1970, DEV BIOL, V21, P364, DOI 10.1016/0012-1606(70)90130-2; STEVENS LC, 1968, J EMBRYOL EXP MORPH, V20, P329; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Swift CH, 1914, AM J ANAT, V15, P483, DOI DOI 10.1002/AJA.1000150404; Tam PPL, 1996, DEV BIOL, V178, P124, DOI 10.1006/dbio.1996.0203; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; TORPEY NP, 1990, DEVELOPMENT, V110, P1185; Van Doren M, 1998, NATURE, V396, P466, DOI 10.1038/24871; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WARRIOR R, 1994, DEV BIOL, V166, P180, DOI 10.1006/dbio.1994.1306; WHITINGTON PM, 1975, J EMBRYOL EXP MORPH, V33, P57; Williamson A, 1996, ANNU REV CELL DEV BI, V12, P365, DOI 10.1146/annurev.cellbio.12.1.365; Wylie C, 1996, DEVELOPMENT, V122, P2987; Wylie CC, 1997, TRENDS CELL BIOL, V7, P459, DOI 10.1016/S0962-8924(97)01151-3; WYLIE CC, 1985, DEV BIOL, V112, P66, DOI 10.1016/0012-1606(85)90119-8; Yoon C, 1997, DEVELOPMENT, V124, P3157; ZALOKAR M, 1976, DEV BIOL, V49, P425, DOI 10.1016/0012-1606(76)90185-8; Zhang J, 1998, CELL, V94, P515, DOI 10.1016/S0092-8674(00)81592-5; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0	124	338	351	0	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 22	1999	96	2					165	174		10.1016/S0092-8674(00)80557-7	http://dx.doi.org/10.1016/S0092-8674(00)80557-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	160VM	9988212	Bronze			2022-12-28	WOS:000078252200001
J	Jackson, L; Benson, P; Sneller, VP; Butler, JC; Thompson, RS; Chen, RT; Lewis, LS; Carlone, G; DeStefano, F; Holder, P; Lezhava, T; Williams, WW				Jackson, L; Benson, P; Sneller, VP; Butler, JC; Thompson, RS; Chen, RT; Lewis, LS; Carlone, G; DeStefano, F; Holder, P; Lezhava, T; Williams, WW			Safety of revaccination with pneumococcal polysaccharide vaccine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELDERLY PERSONS; ANTIBODY; EFFICACY; CHILDREN; DISEASE; ADULTS	Context Revaccination of healthy adults with pneumococcal polysaccharide vaccine (PPV) within several years of first vaccination has been associated with a higher than expected frequency and severity of local injection site reactions. The risk of adverse events associated with revaccination of elderly and chronically ill persons 5 or more years after first vaccination, as is currently recommended, has not been well defined. Objective To determine whether revaccination with PPV at least 5 years after first Vaccination is associated with more frequent or more serious adverse events than those following first vaccination. Design Comparative intervention study conducted between April 1996 and August 1997. Participants Persons aged 50 to 74 years either who had never been Vaccinated with PPV (n = 901) or who had been vaccinated once at least 5 years prior to enrollment (n=513). Intervention PPV vaccination. Main Outcome Measures Postvaccination local injection site reactions and prevaccination concentrations of type-specific antibodies. Results Those who were revaccinated were more likely than those who received their first vaccinations to report a local injection site reaction of at least 10.2 cm (4 in) in diameter within 2 days of vaccination: 11 % (55/513) vs 3% (29/901) (relative risk [RR], 3.3; 95% confidence interval [CI], 2.1-5.1). These reactions resolved by a median of 3 days following vaccination. The highest rate was among revaccinated patients who were immunocompetent and did not have chronic illness: 15% (33/228) compared with 3% (10/337) among comparable patients receiving their first vaccinations (RR, 4.9; 95% CI, 2.4-9.7), The risk of these local reactions was significantly correlated with prevaccination geometric mean antibody concentrations. Conclusions Physicians and patients should be aware that self-limited local injection site reactions occur more frequently following revaccination compared with first vaccination; however, this risk does not represent a contraindication to revaccination with PPV for recommended groups.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Immunizat Studies Program, Seattle, WA 98101 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA USA; Ctr Dis Control & Prevent, Vaccine Safety Datalink Project, Atlanta, GA USA	Group Health Cooperative; University of Washington; University of Washington Seattle; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Jackson, L (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Immunizat Studies Program, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.		Chen, Robert T/AIA-8164-2022	Chen, Robert T/0000-0002-3094-8367	PHS HHS [200-95-0947] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Advisory Committee on Immunization Practices, 1997, MMWR-MORBID MORTAL W, V46, P1; BORGONO JM, 1978, P SOC EXP BIOL MED, V157, P148, DOI 10.3181/00379727-157-40010; CARLSON AJ, 1979, P SOC EXP BIOL MED, V161, P558; Chen RT, 1997, PEDIATRICS, V99, P765, DOI 10.1542/peds.99.6.765; DAVIDSON M, 1994, ARCH INTERN MED, V154, P2209, DOI 10.1001/archinte.154.19.2209; FINE MJ, 1994, ARCH INTERN MED, V154, P2666, DOI 10.1001/archinte.1994.00420230051007; HILLEMAN MR, 1981, REV INFECT DIS S, V3, P31; KAPLAN J, 1986, AM J PEDIAT HEMATOL, V8, P80; KONRADSEN HB, 1995, CLIN INFECT DIS, V21, P616, DOI 10.1093/clinids/21.3.616; LAWRENCE EM, 1983, AM J DIS CHILD, V137, P846, DOI 10.1001/archpedi.1983.02140350024007; LINNEMANN CC, 1986, ARCH INTERN MED, V146, P1554, DOI 10.1001/archinte.146.8.1554; MUFSON MA, 1991, VACCINE, V9, P403, DOI 10.1016/0264-410X(91)90126-Q; MUSHER DM, 1993, CLIN INFECT DIS, V17, P66, DOI 10.1093/clinids/17.1.66; Nichol KL, 1997, AM J INFECT CONTROL, V25, P223, DOI 10.1016/S0196-6553(97)90008-0; QUATAERT SA, 1995, CLIN DIAGN LAB IMMUN, V2, P590, DOI 10.1128/CDLI.2.5.590-597.1995; RIGAUPEREZ JG, 1983, PEDIATR INFECT DIS J, V2, P199, DOI 10.1097/00006454-198305000-00005; RODRIGUEZ R, 1995, J GEN INTERN MED, V10, P511, DOI 10.1007/BF02602403; Sankilampi U, 1997, VACCINE, V15, P1133, DOI 10.1016/S0264-410X(96)00317-9; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; Snow R, 1995, PUBLIC HEALTH REP, V110, P720	20	168	181	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1999	281	3					243	248		10.1001/jama.281.3.243	http://dx.doi.org/10.1001/jama.281.3.243			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157GK	9918479	Bronze			2022-12-28	WOS:000078052800029
J	Steiner, MC; Ward, MJ; Ali, NJ				Steiner, MC; Ward, MJ; Ali, NJ			Dementia and snoring	LANCET			English	Article							OBSTRUCTIVE SLEEP-APNEA; LUNG-DISEASE		Kings Mill Hosp, Dept Med, Sutton in Ashfield NG17 4JL, Notts, England		Ali, NJ (corresponding author), Kings Mill Hosp, Dept Med, Sutton in Ashfield NG17 4JL, Notts, England.							BRADLEY TD, 1986, AM REV RESPIR DIS, V134, P920, DOI 10.1164/arrd.1986.134.5.920; FLENLEY DC, 1985, CLIN CHEST MED, V6, P651; FLETCHER EC, 1987, AM REV RESPIR DIS, V135, P525; STRADLING JR, 1995, THORAX, V50, P683, DOI 10.1136/thx.50.6.683; WEITZENBLUM E, 1988, AM REV RESPIR DIS, V138, P345, DOI 10.1164/ajrccm/138.2.345	5	3	3	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					204	204		10.1016/S0140-6736(98)08303-2	http://dx.doi.org/10.1016/S0140-6736(98)08303-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923877				2022-12-28	WOS:000078175600014
J	Viner, R				Viner, R			Politics, power, and pediatrics	LANCET			English	Article									Middlesex Hosp, Dept Paediat, London W1N 8AA, England	University of London; University College London	Viner, R (corresponding author), Middlesex Hosp, Dept Paediat, London W1N 8AA, England.		Viner, Russell M/A-1441-2009	Viner, Russell M/0000-0003-3047-2247				Cone TE, 1979, HIST AM PEDIAT; DWORK D, 1993, CO ENCY HIST MED, P1072; DWORK D, 1987, WAR GOOD BABIES OTHE; Ellis J.D., 1990, PHYSICIAN LEGISLATOR; GRAEBNER W, 1980, J AM HIST, V67, P612, DOI 10.2307/1889870; HAGGERTY RJ, 1997, PEDIARICS, V99, P426; Hodgkin P, 1996, BRIT MED J, V313, P1568, DOI 10.1136/bmj.313.7072.1568; JACOBI A, 1882, INFANT FEEDING INFAN, P10; JACOBI A, 1909, COLLECTANEA JACOBI, P51; Klaus Alisa, 1993, EVERY CHILD LION ORI; LOUDON ISL, 1979, BRIT MED J, V1, P1191, DOI 10.1136/bmj.1.6172.1191; Morse JL, 1932, J PEDIATR-US, V1, P1, DOI 10.1016/S0022-3476(32)80038-7; REMPEL G, 1983, HITLERS CHILDREN HIT; ROBERTS I, 1995, BRIT MED J, V311, P1381, DOI 10.1136/bmj.311.7017.1381; SOLOMAN SG, 1993, DOCTORS POLITICS SOC, P140; STEEDMAN C, 1990, CHILDHOOD CULTURE CL; VINER R, 1997, HLTH CHILDREN NEW WO; 1997, LANCET, V349, P891	18	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					232	234		10.1016/S0140-6736(98)02320-4	http://dx.doi.org/10.1016/S0140-6736(98)02320-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923895				2022-12-28	WOS:000078175600047
J	Forrest, BG				Forrest, BG			William James Archibald Craig - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1999	318	7181					468	468		10.1136/bmj.318.7181.468	http://dx.doi.org/10.1136/bmj.318.7181.468			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BF	9974479	Green Published			2022-12-28	WOS:000078670100062
J	Tattersall, MHN; Thomas, H				Tattersall, MHN; Thomas, H			Recent advances - Oncology	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CANCER-PATIENTS; PATIENTS PERCEPTIONS; BREAST-CANCER; SURVIVAL; THERAPY; CARE; CHEMOTHERAPY; METASTASES; SURGEONS; DISEASE		Univ Sydney, Dept Canc Med, Sydney, NSW 2006, Australia; Univ Surrey, European Inst Hlth & Med Sci, Guildford GU2 5XH, Surrey, England	University of Sydney; University of Surrey	Tattersall, MHN (corresponding author), Univ Sydney, Dept Canc Med, Sydney, NSW 2006, Australia.	Mtatt@med.usyd.edu.au						Abe O, 1998, LANCET, V352, P930; BANNING A, 1991, PAIN, V47, P129, DOI 10.1016/0304-3959(91)90195-4; Barton R, 1994, Clin Oncol (R Coll Radiol), V6, P354, DOI 10.1016/S0936-6555(05)80184-0; Berrino F, 1997, TUMORI J, V83, P9, DOI 10.1177/030089169708300105; BLEYER WA, 1997, EUR J CANCER, V33, P1430; Body JJ, 1996, CANCER TREAT REV, V22, P265, DOI 10.1016/S0305-7372(96)90020-1; DRANOFF G, 1995, ADV IMMUNOL, V58, P417, DOI 10.1016/S0065-2776(08)60624-0; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Fallowfield L, 1997, EUR J CANCER, V33, P2221, DOI 10.1016/S0959-8049(97)00253-0; Griffin AM, 1996, ANN ONCOL, V7, P189; Grilli R, 1998, ANN ONCOL, V9, P365, DOI 10.1023/A:1008201331167; Hacker NF, 1998, INT J GYNECOL CANCER, V8, P1, DOI 10.1046/j.1525-1438.1998.97111.x; Hancock BW, 1997, BRIT MED J, V314, P36, DOI 10.1136/bmj.314.7073.36; Janjan NA, 1997, CANCER-AM CANCER SOC, V80, P1628, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1628::AID-CNCR13>3.0.CO;2-1; JUNOR EJ, 1994, BRIT J CANCER, V70, P363, DOI 10.1038/bjc.1994.307; KEHOE S, 1994, BRIT J CANCER, V70, P1014, DOI 10.1038/bjc.1994.440; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; Mayor S, 1998, BRIT MED J, V316, P576; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; MUNRO AJ, 1989, BRIT J CANCER, V60, P370, DOI 10.1038/bjc.1989.287; Pardoll DM, 1998, NAT MED, V4, P525, DOI 10.1038/nm0598supp-525; Richards M, 1997, BRIT J CANCER, V76, P634, DOI 10.1038/bjc.1997.437; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; Selby P, 1996, LANCET, V348, P313, DOI 10.1016/S0140-6736(96)02482-8; SMYTH JF, 1994, BRIT MED J, V309, P457, DOI 10.1136/bmj.309.6952.457; The Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales, 1995, POL FRAM COMM CANC S; TURNER JH, 1989, J CLIN ONCOL, V7, P1926, DOI 10.1200/JCO.1989.7.12.1926; Weijer C, 1996, CLIN INVEST MED, V19, P179; Whelan TJ, 1997, CANCER-AM CANCER SOC, V80, P1518, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1518::AID-CNCR21>3.0.CO;2-7; Wiklund T, 1996, EUR J CANCER, V32A, P269, DOI 10.1016/0959-8049(95)00520-X; 1995, LANCET, V345, P1251	32	21	22	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 13	1999	318	7181					445	448		10.1136/bmj.318.7181.445	http://dx.doi.org/10.1136/bmj.318.7181.445			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BF	9974463	Green Published			2022-12-28	WOS:000078670100032
J	Schmitz, JE; Kuroda, MJ; Santra, S; Sasseville, VG; Simon, MA; Lifton, MA; Racz, P; Tenner-Racz, K; Dalesandro, M; Scallon, BJ; Ghrayeb, J; Forman, MA; Montefiori, DC; Rieber, EP; Letvin, NL; Reimann, KA				Schmitz, JE; Kuroda, MJ; Santra, S; Sasseville, VG; Simon, MA; Lifton, MA; Racz, P; Tenner-Racz, K; Dalesandro, M; Scallon, BJ; Ghrayeb, J; Forman, MA; Montefiori, DC; Rieber, EP; Letvin, NL; Reimann, KA			Control of viremia in simian immunodeficiency virus infection by CD8(+) lymphocytes	SCIENCE			English	Article							CELL DEPLETION; DISEASE	Clinical evidence suggests that cellular immunity is involved in controlling human immunodeficiency virus-1 (HIV-1) replication. An animal model of acquired immune deficiency syndrome (AIDS), the simian immunodeficiency virus (SIV)-infected rhesus monkey, was used to show that virus replication is not controlled in monkeys depleted of CD8(+) Lymphocytes during primary SIV infection. Eliminating CD8(+) lymphocytes from monkeys during chronic SIV infection resulted in a rapid and marked increase in viremia that was again suppressed coincident with the reappearance of SIV-specific CD8(+) T cells. These results confirm the importance of cell-mediated immunity in controlling HIV-1 infection and support the exploration of vaccination approaches for preventing infection that will elicit these immune responses.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Viral Pathogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, New England Reg Primate Res Ctr, Southborough, MA 01772 USA; Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany; Centocor Inc, Malvern, PA 19355 USA; Beckman Coulter, Miami, FL 33196 USA; Duke Univ, Med Ctr, Durham, NC 27710 USA; Tech Univ Dresden, Inst Immunol, D-01101 Dresden, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Bernhard Nocht Institut fur Tropenmedizin; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Beckman Coulter Inc.; Duke University; Technische Universitat Dresden	Schmitz, JE (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Viral Pathogenesis, Boston, MA 02215 USA.		Schmitz, Joern/A-4929-2018	Schmitz, Joern/0000-0001-8803-0922	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR013150, P51RR000168] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-13150, RR-00168, P51 RR000168] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CASTRO BA, 1992, CLIN IMMUNOL IMMUNOP, V65, P227, DOI 10.1016/0090-1229(92)90151-D; CHAKRABARTI L, 1994, J VIROL, V68, P6634, DOI 10.1128/JVI.68.10.6634-6643.1994; *COMM AN HARV MED, 1996, GUID CAR US LAB AN; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KURODA M, UNPUB; Kuroda MJ, 1998, J EXP MED, V187, P1373, DOI 10.1084/jem.187.9.1373; Langlois AJ, 1998, J VIROL, V72, P6950, DOI 10.1128/JVI.72.8.6950-6955.1998; LETVIN NL, 1994, CURRENT TOPICS MICRO, V188; Neville DM, 1996, J IMMUNOTHER, V19, P85, DOI 10.1097/00002371-199603000-00001; Phillips AN, 1996, SCIENCE, V271, P497, DOI 10.1126/science.271.5248.497; REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; SCHMITZ J, UNPUB; Seth A, 1998, P NATL ACAD SCI USA, V95, P10112, DOI 10.1073/pnas.95.17.10112; Tenner-Racz K, 1998, J EXP MED, V187, P949, DOI 10.1084/jem.187.6.949; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484	16	1853	1911	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					857	860		10.1126/science.283.5403.857	http://dx.doi.org/10.1126/science.283.5403.857			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933172				2022-12-28	WOS:000078496800049
J	Auwaerter, PG				Auwaerter, PG			Infectious mononucleosis in middle age	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPSTEIN-BARR-VIRUS; RESPONSES; CELLS		Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Auwaerter, PG (corresponding author), 10755 Falls Rd,Suite 360, Lutherville, MD 21093 USA.							ANDERSSON J, 1988, AM J MED, V85, P107; AXELROD P, 1990, AM FAM PHYSICIAN, V42, P1599; Callan MFC, 1996, NAT MED, V2, P906, DOI 10.1038/nm0896-906; CAMERON D, 1973, CLIN STUDY INFECT MO, P18; Davidsohn I, 1937, J AMER MED ASSOC, V108, P289, DOI 10.1001/jama.1937.02780040039009; Downey H, 1923, ARCH INTERN MED, V32, P82, DOI 10.1001/archinte.1923.00110190085006; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; EVANS AS, 1969, GEN PRACT, V40, P127; FINKEL M, 1964, MIL MED, V129, P533, DOI 10.1093/milmed/129.6.533; FLEISHER GR, 1981, J PEDIATR-US, V98, P16, DOI 10.1016/S0022-3476(81)80525-2; GLADE PR, 1973, INFECT MONONUCLEOSIS, P1; HALEVY J, 1988, AM J MED SCI, V295, P122, DOI 10.1097/00000441-198802000-00006; HEATH CW, 1972, AM J EPIDEMIOL, V95, P46, DOI 10.1093/oxfordjournals.aje.a121369; HENKE CE, 1973, AM J EPIDEMIOL, V98, P483, DOI 10.1093/oxfordjournals.aje.a121577; HENLE G, 1970, J INFECT DIS, V121, P303, DOI 10.1093/infdis/121.3.303; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HENLE W, 1971, J INFECT DIS, V124, P58, DOI 10.1093/infdis/124.1.58; HORWITZ CA, 1983, MEDICINE, V62, P256, DOI 10.1097/00005792-198307000-00005; Linde A, 1996, SCAND J INFECT DIS S, V100, P83; LINDERHOLM M, 1994, J CLIN MICROBIOL, V32, P259, DOI 10.1128/JCM.32.1.259-261.1994; MARKIN RS, 1987, GASTROENTEROLOGY, V93, P1210, DOI 10.1016/0016-5085(87)90246-0; MARKIN RS, 1994, LIVER, V14, P1; NYE FJ, 1973, J HYG-CAMBRIDGE, V71, P145, DOI 10.1017/S0022172400046313; PATTENGALE PK, 1974, NEW ENGL J MED, V291, P1145, DOI 10.1056/NEJM197411282912201; Paul JR, 1932, AM J MED SCI, V183, P90, DOI 10.1097/00000441-193201000-00010; PULLEN H, 1967, LANCET, V2, P1176; Rickinson AB, 1997, ANNU REV IMMUNOL, V15, P405, DOI 10.1146/annurev.immunol.15.1.405; SCHOOLEY RT, 1995, MANDELL DOUGLAS BENN, P1364; SHELDON PJ, 1973, LANCET, V1, P1153; Sprunt TP, 1920, B JOHNS HOPKINS HOSP, V31, P410; STRAUS SE, 1988, J INFECT DIS, V157, P405, DOI 10.1093/infdis/157.3.405; STRAUS SE, 1993, ANN INTERN MED, V118, P45, DOI 10.7326/0003-4819-118-1-199301010-00009; STRAUSS SE, 1989, INFECTIOUS MONONUCLE, P8; THORLEYLAWSON DA, 1985, J EXP MED, V162, P45, DOI 10.1084/jem.162.1.45; Tynell E, 1996, J INFECT DIS, V174, P324, DOI 10.1093/infdis/174.2.324; ZAHAVI J, 1967, J AMER MED ASSOC, V200, P1181	36	59	63	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					454	459		10.1001/jama.281.5.454	http://dx.doi.org/10.1001/jama.281.5.454			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952206				2022-12-28	WOS:000078318500034
J	Kobashigawa, JA; Leaf, DA; Lee, N; Gleeson, MP; Liu, HH; Hamilton, MA; Moriguchi, JD; Kawata, N; Einhorn, K; Herlihy, E; Laks, H				Kobashigawa, JA; Leaf, DA; Lee, N; Gleeson, MP; Liu, HH; Hamilton, MA; Moriguchi, JD; Kawata, N; Einhorn, K; Herlihy, E; Laks, H			A controlled trial of exercise rehabilitation after heart transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORTHOTOPIC CARDIAC TRANSPLANTATION; REST; REJECTION; FAILURE	Background In patients who have received a cardiac transplant, the denervated donor heart responds abnormally to exercise and exercise tolerance is reduced. The role of physical exercise in the treatment of patients who have undergone cardiac transplantation has not been determined. We assessed the effects of training on the capacity for exercise early after cardiac transplantation. Methods Twenty-seven patients who were discharged within two weeks after receiving a heart transplant were randomly assigned to participate in a six-month structured cardiac-rehabilitation program (exercise group, 14 patients) or to undergo unstructured therapy at home (control group,13 patients). Each patient in the exercise group underwent an individualized program of muscular-strength and aerobic training under the guidance of a physical therapist, whereas control patients received no formal exercise training. Cardiopulmonary stress testing was performed at base line (within one month after heart transplantation) and six months later. Results As compared with the control group, the exercise group had significantly greater increases in peak oxygen consumption (mean increase, 4.4 mi per kilogram of body weight per minute [49 percent] vs. 1.9 ml per kilogram per minute [18 percent]; P = 0.01) and workload (mean increase, 35 W [59 percent] vs. 12 W [18 percent]; P = 0.01) and a greater reduction in the ventilatory equivalent for carbon dioxide (mean decrease, 13 [20 percent] vs. 6 [11 percent]; P = 0.02). The mean dose of prednisone, the number of patients taking antihypertensive medications, the average number of episodes of rejection and of infection during the study period, and weight gain did not differ significantly between the groups. Conclusions When initiated early after cardiac transplantation, exercise training increases the capacity for physical work. (N Engl J Med 1999;340: 272-7.) (C) 1999, Massachusetts Medical Society.	Univ Calif Los Angeles, Sch Med, Div Cardiothorac Surg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Div Cardiol, Los Angeles, CA 90095 USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Med Ctr, Dept Rehabil Serv, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Kobashigawa, JA (corresponding author), Univ Calif Los Angeles, Med Ctr, Ctr Hlth Sci 47 123, Div Cardiol, 10833 Leconte Ave, Los Angeles, CA 90095 USA.			Kobashigawa, Jon/0000-0001-9308-3172				CAMPEAU L, 1970, AM J CARDIOL, V25, P523, DOI 10.1016/0002-9149(70)90590-4; CHAN SY, 1994, CIRCULATION, V90, P204, DOI 10.1161/01.CIR.90.1.204; CSUKA M, 1985, AM J MED, V78, P77, DOI 10.1016/0002-9343(85)90465-6; DEGRE SG, 1987, AM J CARDIOL, V60, P926, DOI 10.1016/0002-9149(87)91055-1; DREXLER H, 1992, CIRCULATION, V85, P1621, DOI 10.1161/01.CIR.85.4.1621; HARTMANN A, 1993, EUR J NUCL MED, V20, P146; HOSENPUD JD, 1989, CIRCULATION, V80, P525, DOI 10.1161/01.CIR.80.3.525; Hosenpud JD, 1998, J HEART LUNG TRANSPL, V17, P656; KAVANAGH T, 1988, CIRCULATION, V77, P162, DOI 10.1161/01.CIR.77.1.162; KAVANAGH T, 1991, HERZ, V16, P243; KETEYIAN S J, 1989, Medicine and Science in Sports and Exercise, V21, pS55; KOBASHIGAWA JA, 1993, J HEART LUNG TRANSPL, V12, P355; KOBASHIGAWA JA, 1997, EXERCISE HEART FAILU, P97; MANCINI DM, 1992, CIRCULATION, V85, P1364, DOI 10.1161/01.CIR.85.4.1364; MILLER LW, 1994, J HEART LUNG TRANSPL, V13, P381; NISET G, 1991, SPORTS MED, V12, P359, DOI 10.2165/00007256-199112060-00003; QUIGG RJ, 1989, J AM COLL CARDIOL, V14, P338, DOI 10.1016/0735-1097(89)90183-6; SAVIN WM, 1983, J AM COLL CARDIOL, V1, P722; SCHULER S, 1987, TRANSPLANT P, V19, P2506; SQUIRES RW, 1990, J CARDIOPULM REHABIL, V10, P159; VONSCHEIDT W, 1991, AM HEART J, V121, P1480, DOI 10.1016/0002-8703(91)90155-B	21	169	180	2	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1999	340	4					272	277		10.1056/NEJM199901283400404	http://dx.doi.org/10.1056/NEJM199901283400404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YU	9920951				2022-12-28	WOS:000078318700004
J	Parry, BL; Daley, J				Parry, BL; Daley, J			A 45-year-old woman with premenstrual dysphoric disorder	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; MENSTRUAL-CYCLE; DEPRESSION; FLUOXETINE; WOMEN; PSYCHOSIS; SYMPTOMS; TENSION		Univ Calif San Diego, Program Consultat Liaison Psychiat & Behav Med, San Diego, CA USA; Univ San Diego, Med Ctr, San Diego, CA 92110 USA	University of California System; University of California San Diego; University of San Diego	Parry, BL (corresponding author), Beth Israel Deaconesss Med Ctr, Div Gen Med, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							AITKEN RCB, 1969, P ROY SOC MED, V62, P989, DOI 10.1177/003591576906201005; ALTSHULER LL, 1995, HARVARD REV PSYCHIAT, V2, P233, DOI 10.3109/10673229509017143; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BELFER ML, 1971, ARCH GEN PSYCHIAT, V25, P540; BROCKINGTON IF, 1988, J AFFECT DISORDERS, V14, P287, DOI 10.1016/0165-0327(88)90046-8; Chandra P S, 1989, Int J Soc Psychiatry, V35, P343, DOI 10.1177/002076408903500407; Chang A M, 1995, Health Care Women Int, V16, P551; DALTON D, 1964, PREMENSTRUAL SYNDROM; DALTON K, 1987, BRIT MED J, V295, P1027, DOI 10.1136/bmj.295.6605.1027-a; DAN AJ, 1994, PREMENSTRUAL DYSPHOR, P201; ENDO M, 1978, J CLIN PSYCHIAT, V39, P456; GLADIS MM, 1987, AM J PSYCHIAT, V144, P1592; GLICK H, 1993, ACTA PSYCHIAT SCAND, V88, P149, DOI 10.1111/j.1600-0447.1993.tb03430.x; GRAZE KK, 1990, ACTA PSYCHIAT SCAND, V81, P201, DOI 10.1111/j.1600-0447.1990.tb06479.x; HALBREICH U, 1985, ACTA PSYCHIAT SCAND, V71, P331, DOI 10.1111/j.1600-0447.1985.tb02532.x; HALLMAN J, 1986, ACTA PSYCHIAT SCAND, V73, P403, DOI 10.1111/j.1600-0447.1986.tb02703.x; HALLONQUIST JD, 1993, BIOL PSYCHIAT, V33, P207, DOI 10.1016/0006-3223(93)90141-Y; HAMILTON JA, 1984, PSYCHIAT ANN, V14, P426, DOI 10.3928/0048-5713-19840601-07; HARRISON WM, 1990, ARCH GEN PSYCHIAT, V47, P270; HARRISON WM, 1989, J CLIN PSYCHIAT, V50, P136; HURT SW, 1992, AM J PSYCHIAT, V149, P525; JANIGER O, 1972, PSYCHOSOMATICS, V13, P226; MACKENZIE TB, 1986, J AFFECT DISORDERS, V10, P15, DOI 10.1016/0165-0327(86)90044-3; MATTSSON B, 1974, ACTA PSYCHIAT SCAND, P75; MENKES DB, 1992, BRIT MED J, V305, P346, DOI 10.1136/bmj.305.6849.346; MOST AF, 1981, INT J NURS STUD, V18, P61, DOI 10.1016/0020-7489(81)90009-2; Parry B., 1994, PREMENSTRUAL DYSPHOR, P47; PARRY B, 1985, PREMENSTRUAL SYNDROM, P87; PARRY BL, 1991, NEUROPSYCHOPHARMACOL, V5, P127; PARRY BL, 1995, AM J PSYCHIAT, V152, P404; PARRY BL, 1993, AM J PSYCHIAT, V150, P1417; PARRY BL, 1979, COMPR PSYCHIAT, V20, P347, DOI 10.1016/0010-440X(79)90006-3; PARRY BL, 1992, ART PSYCHOPHARMACOLO; POST RM, 1986, BRIT J PSYCHIAT, V149, P191, DOI 10.1192/bjp.149.2.191; PRICE WA, 1986, J CLIN PSYCHIAT, V47, P415; RICHARDSON JTE, 1995, SOC SCI MED, V41, P761, DOI 10.1016/0277-9536(95)00042-6; RICKELS K, 1989, LANCET, V1, P777; SCHUCKIT MA, 1975, DIS NERV SYST, V36, P516; SINGER K, 1974, BRIT J PSYCHIAT, V124, P50, DOI 10.1192/bjp.124.1.50; Snowden R, 1983, PATTERNS PERCEPTIONS; STEINER M, 1995, NEW ENGL J MED, V332, P1529, DOI 10.1056/NEJM199506083322301; STEINER M, 1980, ACTA PSYCHIAT SCAND, V61, P96, DOI 10.1111/j.1600-0447.1980.tb00569.x; STONE AB, 1991, J CLIN PSYCHIAT, V52, P290; SUNDBLAD C, 1992, ACTA PSYCHIAT SCAND, V85, P39, DOI 10.1111/j.1600-0447.1992.tb01440.x; SUNDBLAD C, 1993, NEUROPSYCHOPHARMACOL, V9, P133, DOI 10.1038/npp.1993.52; VANDENAKKER OBA, 1987, ACTA GENET MED GEMEL, V36, P541, DOI 10.1017/S0001566000006929; WATSON NR, 1989, LANCET, V2, P730, DOI 10.1016/S0140-6736(89)90784-8; WETZEL RD, 1975, BRIT J PSYCHIAT, V127, P219, DOI 10.1192/bjp.127.3.219; Wise PM, 1996, SCIENCE, V273, P67, DOI 10.1126/science.273.5271.67; WOOD SH, 1992, OBSTET GYNECOL, V80, P339	50	2	3	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1999	281	4					368	373		10.1001/jama.281.4.368	http://dx.doi.org/10.1001/jama.281.4.368			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	158JB	9929091				2022-12-28	WOS:000078111300037
J	Falvo, MR; Taylor, RM; Helser, A; Chi, V; Brooks, FP; Washburn, S; Superfine, R				Falvo, MR; Taylor, RM; Helser, A; Chi, V; Brooks, FP; Washburn, S; Superfine, R			Nanometre-scale rolling and sliding of carbon nanotubes	NATURE			English	Article							ATOMIC-SCALE; FRICTION; NANOTRIBOLOGY; MICROSCOPE; ANISOTROPY; MOTION; C-60	Understanding the relative motion of objects in contact is essential for controlling macroscopic lubrication and adhesion, for comprehending biological macromolecular interfaces, and for developing submicrometre-scale electromechanical devices(1,2) An object undergoing lateral motion while in contact with a second object can either roll or slide. The resulting energy loss and mechanical wear depend largely on which mode of motion occurs. At the macroscopic scale, rolling(3) is preferred over sliding, and it is expected to have an equally important role in the microscopic domain. Although progress has been made in our understanding of the dynamics of sliding at the atomic level(4), we have no comparable insight into rolling owing to a lack of experimental data on microscopic length scales. Here we produce controlled rolling of carbon nanotubes on graphite surfaces using an atomic force microscope. We measure the accompanying energy loss and compare this with sliding. Moreover, by reproducibly rolling a nanotube to expose different faces to the substrate and to an external probe, we are able to study the object over its complete surface.	Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Comp Sci, Chapel Hill, NC 27599 USA; Univ N Carolina, N Carolina Ctr Nanoscale Mat, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Superfine, R (corresponding author), Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27599 USA.		Superfine, Richard/A-1968-2012	Superfine, Richard/0000-0002-2569-071X				Baur C, 1997, J VAC SCI TECHNOL B, V15, P1577, DOI 10.1116/1.589404; BHUSHAN B, 1995, NATURE, V374, P607, DOI 10.1038/374607a0; BHUSHAN B, 1993, APPL PHYS LETT, V62, P3253, DOI 10.1063/1.109090; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Chaudhury MK, 1996, J APPL PHYS, V80, P30, DOI 10.1063/1.362819; EBBESEN TW, 1995, CARBON, V33, P973, DOI 10.1016/0008-6223(95)00025-9; EBBESEN TW, 1992, NATURE, V358, P220, DOI 10.1038/358220a0; Falvo MR, 1997, NATURE, V389, P582, DOI 10.1038/39282; FINCH M, 1995, ACM S INT 3D GRAPH; Hertel T, 1998, J PHYS CHEM B, V102, P910, DOI 10.1021/jp9734686; HIRANO M, 1991, PHYS REV LETT, V67, P2642, DOI 10.1103/PhysRevLett.67.2642; Israelachvili J.N., 1991, INTERMOLECULAR SURFA; Johnson KL, 1994, CONTACT MECH; JOHNSON KL, 1997, MICRONANOTRIBOLOGY I, P157; KENDALL K, 1975, WEAR, V33, P351, DOI 10.1016/0043-1648(75)90288-4; LUTHI R, 1994, SCIENCE, V266, P1979, DOI 10.1126/science.266.5193.1979; Mason M., 1985, ROBOT HANDS MECH MAN; MATE CM, 1987, PHYS REV LETT, V59, P1942, DOI 10.1103/PhysRevLett.59.1942; OVERNEY RM, 1994, PHYS REV LETT, V72, P3546, DOI 10.1103/PhysRevLett.72.3546; Persson B. N. J., 1998, SLIDING FRICTION PHY; PRESCOTT J, 1936, MECH PARTICLES RIGID; Rapoport L, 1997, NATURE, V387, P791, DOI 10.1038/42910; Schwarz UD, 1997, PHYS REV B, V56, P6987, DOI 10.1103/PhysRevB.56.6987; Sheehan PE, 1996, SCIENCE, V272, P1158, DOI 10.1126/science.272.5265.1158; TAYLOR RM, 1993, SIGGRAPH 93	25	406	427	3	142	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 21	1999	397	6716					236	238		10.1038/16662	http://dx.doi.org/10.1038/16662			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159QH	9930698				2022-12-28	WOS:000078184800046
J	Udachin, KA; Ripmeester, JA				Udachin, KA; Ripmeester, JA			A complex clathrate hydrate structure showing bimodal guest hydration	NATURE			English	Article							STRUCTURE-H HYDRATE; GAS HYDRATE; FLUORIDE; MEXICO; GULF	Interactions between hydrophobic groups in water(1), as well as biomolecular hydration more generally(2-4), are intimately connected to the structure of liquid water around hydrophobic solutes. Such considerations have focused interest on clathrate hydrates: crystals in which a hydrogen-bonded network of water molecules encages hydrophobic guest molecules with which the water interacts only by non-directional van der Waals forces. Three structural families of clathrate hydrates have hitherto been recognized: cubic structure I (2MS . 6M(L). 46H(2)O) (ref, 5), cubic structure II (16M(S). 8M(L). 136H(2)O) (ref. 5) and hexagonal structure H (M-L. 3M(S). 2M(S). 34H(2)O) (refs 6, 7) hydrates (here M-L and M-S are the hydrophobic guest sites associated with large and small cavities, respectively). Here we report a new hydrate structure: 1.67 choline hydroxide;tetra-n-propylammonium fluoride . 30.33H(2)O. This structure has a number of unusual features; in particular the choline guest exhibits both hydrophobic and hydrophilic modes of hydration. Formally the structure consists of alternating stacks of structure H and structure II hydrates, and might conceivably be found in those settings (such as seafloor deposits over natural-gas fields) in which clathrate hydrates form naturally.	Natl Res Council Canada, Steacie Inst Mol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Ripmeester, JA (corresponding author), Natl Res Council Canada, Steacie Inst Mol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.		Ripmeester, John A/G-1950-2011					[Anonymous], [No title captured]; BLOKZIJL W, 1993, ANGEW CHEM INT EDIT, V32, P1545, DOI 10.1002/anie.199315451; BOUQUIERE JP, 1994, ACTA CRYSTALLOGR B, V50, P566, DOI 10.1107/S0108768194002211; DAVIDSON DW, 1986, GEOCHIM COSMOCHIM AC, V50, P619, DOI 10.1016/0016-7037(86)90110-9; DYADIN YA, 1988, J INCLUSION PHENOM, V6, P565, DOI 10.1007/BF00656337; Gies H., 1991, INCLUSION COMPOUNDS, V5, P1; HEADGORDON T, 1995, P NATL ACAD SCI USA, V92, P8308, DOI 10.1073/pnas.92.18.8308; Jeffrey G. A., 1984, INCLUSION COMPOUNDS, V1, P135; KVENVOLDEN KA, 1994, ANN NY ACAD SCI, V715, P232, DOI 10.1111/j.1749-6632.1994.tb38838.x; LIPKOWSKI J, 1992, J INCLUS PHENOM MOL, V13, P295, DOI 10.1007/BF01042788; Lipscomb LA, 1996, BIOPOLYMERS, V38, P177, DOI 10.1002/(SICI)1097-0282(199602)38:2<177::AID-BIP4>3.0.CO;2-S; Martorana V, 1997, BIOPHYS J, V73, P31, DOI 10.1016/S0006-3495(97)78044-5; RIPMEESTER JA, 1987, NATURE, V325, P135, DOI 10.1038/325135a0; SASSEN R, 1994, ORG GEOCHEM, V22, P1029, DOI 10.1016/0146-6380(94)90036-1; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SLOAN ED, 1996, CLATHRATE HYDRATES N; Smelik EA, 1996, Z KRISTALLOGR, V211, P84; Udachin KA, 1997, SUPRAMOL CHEM, V8, P173, DOI 10.1080/10610279708034933	18	78	80	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 4	1999	397	6718					420	423		10.1038/17097	http://dx.doi.org/10.1038/17097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164KA	9989406				2022-12-28	WOS:000078461700043
J	Self, M				Self, M			The sharp edge of Damocles	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1999	318	7179					339	339		10.1136/bmj.318.7179.339	http://dx.doi.org/10.1136/bmj.318.7179.339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZH	9924087	Green Published			2022-12-28	WOS:000078436700071
J	Boerner, DE; Kurtz, RD; Craven, JA; Ross, GM; Jones, FW; Davis, WJ				Boerner, DE; Kurtz, RD; Craven, JA; Ross, GM; Jones, FW; Davis, WJ			Electrical conductivity in the Precambrian lithosphere of western Canada	SCIENCE			English	Article							PROTEROZOIC ULTRAPOTASSIC ROCKS; UPPER-MANTLE; CHURCHILL PROVINCE; SEDIMENTARY BASIN; WYOMING CRATON; BENEATH; ENRICHMENT; ANISOTROPY; XENOLITHS; NEODYMIUM	The subcrustal lithosphere underlying the southern Archean Churchill Province (ACP) in western Canada is at Least one order of magnitude more electrically conductive than the Lithosphere beneath adjacent Paleoproterozoic crust. The measured electrical properties of the Lithosphere underlying most of the Paleoproterozoic crust can be explained by the conductivity of olivine. Mantle xenolith and geological mapping evidence indicate that the Lithosphere beneath the southern ACP was substantially modified as a result of being trapped between two nearly synchronous Paleoproterozoic subduction zones. Tectonically induced metasomatism thus may have enhanced the subcrustal Lithosphere conductivity of the southern ACP.	Geol Survey Canada, Ottawa, ON K1A 0E9, Canada; Geol Survey Canada, Ottawa, ON K1A 0E8, Canada; Geol Survey Canada, Calgary, AB T2L 2A7, Canada; Univ Alberta, Dept Phys, Edmonton, AB T6G 2J1, Canada	Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada; Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada; Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada; University of Alberta	Boerner, DE (corresponding author), Geol Survey Canada, 615 Booth St, Ottawa, ON K1A 0E9, Canada.			Davis, William/0000-0002-3628-5613				ANDERSON DL, 1984, GEOPHYS RES LETT, V11, P637, DOI 10.1029/GL011i007p00637; BELL DR, 1992, SCIENCE, V255, P1391, DOI 10.1126/science.255.5050.1391; BLUNDY JD, 1991, NATURE, V349, P321, DOI 10.1038/349321a0; BOERNER DE, 1995, GEOLOGY, V23, P297, DOI 10.1130/0091-7613(1995)023<0297:BPFUTW>2.3.CO;2; Boerner DE, 1996, J GEOPHYS RES-SOL EA, V101, P13775, DOI 10.1029/96JB00171; Boerner DE, 1998, CAN J EARTH SCI, V35, P175, DOI 10.1139/e97-104; CARLSON RW, 1994, EARTH PLANET SC LETT, V126, P457, DOI 10.1016/0012-821X(94)90124-4; CARTER SR, 1978, SCIENCE, V202, P743, DOI 10.1126/science.202.4369.743; CONSTABLE S, 1992, J GEOPHYS RES-SOL EA, V97, P3397, DOI 10.1029/91JB02453; DAVIS WJ, 1995, 1995 ALB BAS TRANS W, P330; DUDAS FO, 1987, GEOLOGY, V15, P22, DOI 10.1130/0091-7613(1987)15<22:RMPEOT>2.0.CO;2; FOLEY S, 1992, LITHOS, V28, P235; GRAND SP, 1987, J GEOPHYS RES-SOLID, V92, P14065, DOI 10.1029/JB092iB13p14065; HENDRY HE, 1994, GEOL ASS CAN ABSTR P, V13, pA54; HIRSCH LM, 1993, GEOPHYS J INT, V114, P36, DOI 10.1111/j.1365-246X.1993.tb01464.x; HOFFMAN PF, 1988, ANNU REV EARTH PL SC, V16, P543, DOI 10.1146/annurev.ea.16.050188.002551; KARATO S, 1990, NATURE, V347, P272, DOI 10.1038/347272a0; LASTOVICKOVA M, 1993, PHYS EARTH PLANET IN, V81, P315, DOI 10.1016/0031-9201(93)90138-Y; Lucas S.B., 1997, GEOLOGICAL ASS CANAD, V22, pA93; MARESCHAL M, 1995, NATURE, V375, P134, DOI 10.1038/375134a0; MARESCHAL M, 1981, GEOPHYS J ROY ASTR S, V67, P125, DOI 10.1111/j.1365-246X.1981.tb02736.x; MENZIES MA, 1987, MANTLE METASOMATISM, P313; NELSON DR, 1986, GEOCHIM COSMOCHIM AC, V50, P231, DOI 10.1016/0016-7037(86)90172-9; OBRIEN HE, 1995, GEOCHIM COSMOCHIM AC, V59, P4539, DOI 10.1016/0016-7037(95)99266-J; PASTERIS JD, 1991, CAN MINERAL, V29, P1; PEARSON DG, 1994, CONTRIB MINERAL PETR, V115, P449, DOI 10.1007/BF00320978; PETERSON TD, 1993, CAN MINERAL, V31, P801; PETERSON TD, 1994, MINER PETROL, V51, P251, DOI 10.1007/BF01159732; ROSS GM, 1995, GEOLOGY, V23, P195, DOI 10.1130/0091-7613(1995)023<0195:PCOBTW>2.3.CO;2; RUDNICK RL, 1993, EOS T AM GEOPHYS UN, V74, P320; SCHULTZ A, 1993, GEOPHYS RES LETT, V20, P2941, DOI 10.1029/93GL02833; Watson EB., 1990, CONTINENTAL MANTLE, P111	32	53	55	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					668	670		10.1126/science.283.5402.668	http://dx.doi.org/10.1126/science.283.5402.668			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924022				2022-12-28	WOS:000078324400036
J	Patchett, PJ; Ross, GM; Gleason, JD				Patchett, PJ; Ross, GM; Gleason, JD			Continental drainage in North America during the Phanerozoic from Nd isotopes	SCIENCE			English	Article							CRUSTAL EVOLUTION; CANADIAN CORDILLERA; RIVER; SEDIMENTS; TURBIDITES; SUBDUCTION; DENUDATION; BASINS; SYSTEM; MANTLE	Neodymium (Nd) isotopic data show consistent patterns in the sources of sedimentary rocks in North America at a continental scale. Between 600 and 450 million years ago (Ma), ancient continental shield sources dominated. Around 450 Ma, detritus from the Caledonian-Appalachian mountains overwhelmed sediment from all older sources, and is documented over Large areas of the southern, western, and northern margins of North America. This material continued to dominate the sediment supply until about 150 Ma, probably due to cannibalistic recycling of sedimentary rocks formed earlier. Around 150 Ma, the rising western Cordillera delivered new and different detritus to the sedimentary system.	Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA; Geol Survey Canada, Calgary, AB T2L 2A7, Canada; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	University of Arizona; Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada; University of Arizona	Patchett, PJ (corresponding author), Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA.							ANDERSEN CB, 1995, GEOLOGY, V23, P983; ARCHER AW, 1995, J GEOL, V103, P611, DOI 10.1086/629784; Bock B, 1996, CAN J EARTH SCI, V33, P1612, DOI 10.1139/e96-122; Bock B, 1998, SEDIMENTOLOGY, V45, P635, DOI 10.1046/j.1365-3091.1998.00168.x; Boghossian ND, 1996, J GEOL, V104, P259, DOI 10.1086/629824; BURGESS PM, 1997, GEOL SOC AM BULL, V108, P1515; Cameron EM, 1997, CHEM GEOL, V137, P243, DOI 10.1016/S0009-2541(96)00168-4; Cookenboo HO, 1998, GEOLOGY, V26, P391, DOI 10.1130/0091-7613(1998)026<0391:ROPCOT>2.3.CO;2; Dickin A.P., 1990, GEOLOGICAL ASS CANAD, V38, P79; Dickinson W.R., 1988, NEW PERSPECTIVES BAS, P3, DOI [DOI 10.1007/978-1-4612-3788-4_1, 10.1007/978-1-4612-3788-4_1]; EMBRY AF, 1991, GEOLOGY N AM, VE, P261; ETTENSOHN F. R., 1985, CATSKILL DELTA GSA S, P65, DOI DOI 10.1130/SPE201-P65; FROST CD, 1989, AM J SCI, V289, P744, DOI 10.2475/ajs.289.6.744; Garzione CN, 1997, CAN J EARTH SCI, V34, P1603, DOI 10.1139/e17-129; Gibson D.W., 1989, W CANADA SEDIMENTARY, P219; GLEASON JD, 1994, GEOLOGY, V22, P347, DOI 10.1130/0091-7613(1994)022<0347:NILOTT>2.3.CO;2; GLEASON JD, 1998, GEOL SOC AM ABSTR, V30, pA145; GOLDSTEIN SJ, 1988, EARTH PLANET SC LETT, V87, P249, DOI 10.1016/0012-821X(88)90013-1; GOLDSTEIN SL, 1984, EARTH PLANET SC LETT, V70, P221, DOI 10.1016/0012-821X(84)90007-4; GOLDSTEIN SL, 1988, NATURE, V336, P733, DOI 10.1038/336733a0; GORDEY SP, 1991, GEOLOGY N AM G, V2, P219; GRAHAM SA, 1975, GEOL SOC AM BULL, V86, P273, DOI 10.1130/0016-7606(1975)86<273:HMFFDI>2.0.CO;2; GURNIS M, 1992, SCIENCE, V255, P1556, DOI 10.1126/science.255.5051.1556; Holmden C, 1998, GEOLOGY, V26, P567, DOI 10.1130/0091-7613(1998)026<0567:IEFGDB>2.3.CO;2; Ludwig W, 1998, AM J SCI, V298, P265, DOI 10.2475/ajs.298.4.265; MCLENNAN SM, 1993, J GEOL, V101, P295, DOI 10.1086/648222; MCLENNAN SM, 1990, GEOCHIM COSMOCHIM AC, V54, P2015, DOI 10.1016/0016-7037(90)90269-Q; MICHARD A, 1985, GEOCHIM COSMOCHIM AC, V49, P601, DOI 10.1016/0016-7037(85)90051-1; MILLER RG, 1984, EARTH PLANET SC LETT, V68, P459, DOI 10.1016/0012-821X(84)90130-4; MILLIMAN JD, 1983, J GEOL, V91, P1, DOI 10.1086/628741; MILLIMAN JD, 1992, J GEOL, V100, P525, DOI 10.1086/629606; MITROVICA JX, 1989, TECTONICS, V8, P1079, DOI 10.1029/TC008i005p01079; PATCHETT PJ, 1989, J GEOL, V97, P685, DOI 10.1086/629352; PATCHETT PJ, IN PRESS GEOL SOC AM; PINET P, 1988, TECTONICS, V7, P563, DOI 10.1029/TC007i003p00563; Pysklywec RN, 1997, EARTH PLANET SC LETT, V148, P447, DOI 10.1016/S0012-821X(97)00045-9; RICHARDS MA, 1984, J GEOPHYS RES, V89, P5987, DOI 10.1029/JB089iB07p05987; RICHARDS MA, 1998, GEOLOGY, V26, P687; SAMSON SD, 1991, AUST J EARTH SCI, V38, P595, DOI 10.1080/08120099108727994; SUMMERFIELD MA, 1994, J GEOPHYS RES-SOL EA, V99, P13871, DOI 10.1029/94JB00715	40	60	63	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					671	673		10.1126/science.283.5402.671	http://dx.doi.org/10.1126/science.283.5402.671			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924023				2022-12-28	WOS:000078324400037
J	Wu, KJ; Polack, A; Dalla-Favera, R				Wu, KJ; Polack, A; Dalla-Favera, R			Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC	SCIENCE			English	Article							CELL-PROLIFERATION; HEAVY-CHAIN; RIBONUCLEOTIDE REDUCTASE; GROWTH-INHIBITION; MESSENGER-RNA; EXPRESSION; TRANSCRIPTION; ACTIVATION; PROTEIN-2; CYCLE	The protein encoded by the c-MYC proto-oncogene is a transcription factor that can both activate and repress the expression of target genes, but few of its transcriptional targets have been identified. Here, c-MYC is shown to repress the expression of the heavy subunit of the protein ferritin (H-ferritin), which sequesters intracellular iron, and to stimulate the expression of the iron regulatory protein-2 (IRP2), which increases the intracellular iron pool. Downregulation of the expression of H-ferritin gene was required for cell transformation by c-MYC. These results indicate that c-MYC coordinately regulates genes controlling intracellular iron concentrations and that this function is essential for the control of cell proliferation and transformation by c-MYC.	Columbia Univ, Dept Pathol, Div Oncol, New York, NY 10032 USA; GSF Munich, Natl Res Inst Environm & Hlth, Inst Clin Mol Biol & Tumor Genet, D-81377 Munich, Germany	Columbia University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Dalla-Favera, R (corresponding author), Columbia Univ, Dept Pathol, Div Oncol, New York, NY 10032 USA.	rd10@columbia.edu	Wu, Kou-Juey/P-4654-2015		NCI NIH HHS [CA-37165] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037165] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEAUMONT C, 1989, J BIOL CHEM, V264, P7498; BEVILACQUA MA, 1995, BIOCHEM J, V311, P769, DOI 10.1042/bj3110769; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; BRODIE C, 1993, CANCER RES, V53, P3968; BROXMEYER HE, 1991, P NATL ACAD SCI USA, V88, P770, DOI 10.1073/pnas.88.3.770; CAZZOLA M, 1990, BLOOD, V75, P1903; Coccia EM, 1997, EUR J BIOCHEM, V250, P764, DOI 10.1111/j.1432-1033.1997.00764.x; Cooper CE, 1996, J BIOL CHEM, V271, P20291, DOI 10.1074/jbc.271.34.20291; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HAMPSON IN, 1992, NUCLEIC ACIDS RES, V20, P2899, DOI 10.1093/nar/20.11.2899; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HENTZE MW, 1986, P NATL ACAD SCI USA, V83, P7226, DOI 10.1073/pnas.83.19.7226; HOYES KP, 1992, CANCER RES, V52, P4591; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Kulp KS, 1996, TOXICOL APPL PHARM, V139, P356, DOI 10.1006/taap.1996.0176; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIAU G, 1991, J BIOL CHEM, V266, P18819; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MATTIA E, 1990, BIOCHEM J, V267, P553, DOI 10.1042/bj2670553; Polack A, 1996, P NATL ACAD SCI USA, V93, P10411, DOI 10.1073/pnas.93.19.10411; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SANTAMBROGIO P, 1993, J BIOL CHEM, V268, P12744; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Vet JAM, 1997, BBA-MOL BASIS DIS, V1360, P39, DOI 10.1016/S0925-4439(96)00063-4	37	272	279	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 29	1999	283	5402					676	679		10.1126/science.283.5402.676	http://dx.doi.org/10.1126/science.283.5402.676			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924025				2022-12-28	WOS:000078324400039
J	Ashina, M; Lassen, LH; Bendtsen, L; Jensen, R; Olesen, J				Ashina, M; Lassen, LH; Bendtsen, L; Jensen, R; Olesen, J			Effect of inhibition of nitric oxide synthase on chronic tension-type headache: a randomised crossover trial	LANCET			English	Article							SPINAL-CORD; NERVOUS-SYSTEM; PAIN; RAT; HUMANS; PATHOPHYSIOLOGY; NOCICEPTION; NEURONS	Background Studies in animals have shown that nitric oxide plays an important part in central sensitisation and that inhibitors of nitric oxide synthase (NOS) decrease sensitisation in models of persistent pain. The efficacy of inhibitors of NOS has not been tested in patients with tension-type chronic headache. We aimed to show whether NG-monomethyl-L-arginine hydrochloride (L-NM MA), an inhibitor of NOS, is effective in relieving pain ip such patients. Methods We undertook a randomised double-blind, crossover trial of 16 patients with chronic-tension-type headache. Patients were assigned intravenous infusion of 6 mg/kg L-NMMA or placebo on 2 days separated by at least 1 week in a randomised order. Headache intensity was measured on a 100 mm visual analogue scale, and on a verbal rating scale at baseline and at 30 min, 60 min, and 120 min after start of treatment. The primary endpoint was reduction of pain intensity on the visual analogue scale by the active treatment compared with placebo. Findings L-NMMA reduced pain intensity on the visual analogue scale significantly more than placebo: 120 min after start of treatment, the mean pain score was decreased from 49 to 33 with L-NMMA and from 44 to 40 with placebo (p = 0.01). Pain intensity on the verbal rating scale was also significantly lower for treatment with L-NMMA than for treatment with placebo (p = 0.02). Interpretation Inhibition of NOS had an analgesic effect in chronic tension-type headache. Further tests are required before clinical application.	Univ Copenhagen, Glostrup Hosp, Dept Neurol, DK-2600 Copenhagen, Denmark	University of Copenhagen	Ashina, M (corresponding author), Univ Copenhagen, Glostrup Hosp, Dept Neurol, DK-2600 Copenhagen, Denmark.	ashina@dadlnet.dk		Ashina, Messoud/0000-0003-0951-5804; Olesen, Jes/0000-0002-6712-2702; Bendtsen, Lars/0000-0002-4810-4998				ANDERSON CR, 1992, NEUROSCI LETT, V139, P280, DOI 10.1016/0304-3940(92)90571-N; Bendtsen L, 1996, PAIN, V65, P259, DOI 10.1016/0304-3959(95)00239-1; Blitzer ML, 1996, J AM COLL CARDIOL, V28, P591, DOI 10.1016/0735-1097(96)00218-5; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; CODERRE TJ, 1994, EUR J NEUROSCI, V6, P1328, DOI 10.1111/j.1460-9568.1994.tb00323.x; GARTHWAITE J, 1993, SEMIN NEUROSCI, V5, P171, DOI 10.1016/S1044-5765(05)80050-8; HALEY JE, 1992, NEUROPHARMACOLOGY, V31, P251, DOI 10.1016/0028-3908(92)90175-O; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hao JX, 1996, PAIN, V66, P313, DOI 10.1016/0304-3959(96)03039-4; HAYNES WG, 1993, J HYPERTENS, V11, P1375, DOI 10.1097/00004872-199312000-00009; HOLTHUSEN H, 1995, J PHYSIOL-LONDON, V487, P253, DOI 10.1113/jphysiol.1995.sp020876; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; KindgenMilles D, 1996, PAIN, V64, P139, DOI 10.1016/0304-3959(95)00081-X; Lassen LH, 1997, LANCET, V349, P401, DOI 10.1016/S0140-6736(97)80021-9; Mao JR, 1997, PAIN, V72, P355, DOI 10.1016/S0304-3959(97)00063-8; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MELLER ST, 1994, NEUROSCIENCE, V60, P367, DOI 10.1016/0306-4522(94)90250-X; MELLER ST, 1993, PAIN, V52, P127, DOI 10.1016/0304-3959(93)90124-8; MINAMI T, 1995, PAIN, V61, P285, DOI 10.1016/0304-3959(94)00183-F; MIZUKAWA K, 1989, J COMP NEUROL, V279, P281, DOI 10.1002/cne.902790210; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORRIS R, 1994, EUR J NEUROSCI, V6, P876, DOI 10.1111/j.1460-9568.1994.tb00998.x; OLESEN J, 1995, BRIT MED J, V310, P479, DOI 10.1136/bmj.310.6978.479; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; Roche AK, 1996, PAIN, V66, P331, DOI 10.1016/0304-3959(96)03025-4; RUSSELL MB, 1992, CEPHALALGIA, V12, P369, DOI 10.1111/j.1468-2982.1992.00369.x; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; Woolf Clifford J., 1994, Current Opinion in Neurobiology, V4, P525, DOI 10.1016/0959-4388(94)90053-1	29	120	124	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 23	1999	353	9149					287	289		10.1016/S0140-6736(98)01079-4	http://dx.doi.org/10.1016/S0140-6736(98)01079-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929022				2022-12-28	WOS:000078292200012
J	Fielden, JM; Bradbury, NS				Fielden, JM; Bradbury, NS			Observational study of defibrillation in theatre	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Royal United Hosp NHS Trust, Bath BA1 3NG, Avon, England		Fielden, JM (corresponding author), Royal Berkshire Hosp, Reading RG1 5AN, Berks, England.	jonathan@jfielden.demon.cu.uk						ALDERSON K, 1996, TIMES           0302, P3; BELL JH, 1995, ANAESTHESIA, V50, P692, DOI 10.1111/j.1365-2044.1995.tb06095.x; CHAMBERLAIN D, 1992, RESUSCITATION, V24, P111, DOI 10.1016/0300-9572(92)90016-6; *RES COUNC UK, 1994, ADV LIF SUPP HDB; THAM KY, 1994, BRIT MED J, V309, P1408, DOI 10.1136/bmj.309.6966.1408a	5	11	11	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 23	1999	318	7178					232	233						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915731				2022-12-28	WOS:000078292300024
J	Mond, NC				Mond, NC			A grateful patient - Not what he wanted	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1999	318	7178					237	237						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915734				2022-12-28	WOS:000078292300027
J	Sanders, SA; Reinisch, JM				Sanders, SA; Reinisch, JM			Would you say you "had sex" if ... ?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BEHAVIOR; UNIVERSITY	Context The current public debate regarding whether oral sex constitutes having "had sex" or sexual relations has reflected a lack of empirical data on how Americans as a population define these terms. Objective To determine which interactions individuals would consider as having" had sex." Methods A question was included in a survey conducted in 1991 that explored sexual behaviors and attitudes among a random stratified sample of 599 students representative of the undergraduate population of a state university in the Midwest. Participants The participants originated from 29 states, including all 4 US Census Bureau geographic regions. Approximately 79% classified themselves as politically moderate to conservative. Main Outcome Measure Percentage of respondents who believed the interaction described constituted having "had sex." Results individual attitudes varied regarding behaviors defined as having "had sex": 59% (95% confidence interval, 54%-63%) of respondents indicated that oral-genital contact did not constitute having "had sex" with a partner, Nineteen percent responded similarly regarding penile-anal intercourse. Conclusions The findings support the view that Americans hold widely divergent opinions about what behaviors do and do not constitute having "had sex.".	Indiana Univ, Kinsey Inst Res Sex Gender & Reprod, Bloomington, IN 47405 USA; R2 Sci Commun INc, Bloomington, IN USA; Copenhagen Univ Hosp, Inst Prevent Med, Copenhagen, Denmark	Indiana University System; Indiana University Bloomington; University of Copenhagen	Reinisch, JM (corresponding author), Indiana Univ, Kinsey Inst Res Sex Gender & Reprod, Bloomington, IN 47405 USA.				NICHD NIH HHS [HD20263] Funding Source: Medline; NIDA NIH HHS [DA05056] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020263] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAKER P, 1998, WASHINGTON POST 0815, pA6; CHILMAN CS, 1983, ADOLESCENT SEXUALITY, P74; Feldman L, 1997, Can J Hum Sex, V6, P197; Flexner S. B., 1993, RANDOM HOUSE UNABRID; HEROLD ES, 1983, J SEX RES, V19, P327, DOI 10.1080/00224498309551194; KIM W, 1998, TIME CANADA     0202, P151; KLEIN M, 1996, PLAYBOY, V43, P64; MAHONEY ER, 1980, J SEX RES, V16, P87; *MERR INC, 1993, WEBST 3 NEW INT DICT; Nolan J.R., 1990, BLACKS LAW DICT; REINISCH JM, 1988, AM PSYCHOL, V43, P921, DOI 10.1037/0003-066X.43.11.921; REINISCH JM, 1995, FAM PLANN PERSPECT, V27, P79, DOI 10.2307/2135910; SHEERAN P, 1993, EUR J SOC PSYCHOL, V23, P39, DOI 10.1002/ejsp.2420230104; Simpson J. A., 1989, OXFORD ENGLISH DICT	14	351	356	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1999	281	3					275	277		10.1001/jama.281.3.275	http://dx.doi.org/10.1001/jama.281.3.275			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	157GK	9918484				2022-12-28	WOS:000078052800034
J	Groves, MR; Hanlon, N; Turowski, P; Hemmings, BA; Barford, D				Groves, MR; Hanlon, N; Turowski, P; Hemmings, BA; Barford, D			The structure of the protein phosphatase 2A PR65/A subunit reveals the conformation of its 15 tandemly repeated HEAT motifs	CELL			English	Article							SMALL-T-ANTIGEN; SV40 SMALL-T; REGULATORY SUBUNITS; TUMOR-ANTIGENS; CELL-GROWTH; B-SUBUNIT; A-SUBUNIT; IDENTIFICATION; NUCLEAR; FAMILY	The PR65/A subunit of protein phosphatase 2A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit, generating functionally diverse heterotrimers. Mutations of the beta isoform of PR65 are associated with lung and colon tumors. The crystal structure of the PR65/A alpha subunit, at 2.3 Angstrom resolution, reveals the conformation of its 15 tandemly repeated HEAT sequences, degenerate motifs of similar to 39 amino acids present in a variety of proteins, including huntingtin and importin beta. Individual motifs are composed of a pair of antiparallel or helices that assemble in a mainly linear, repetitive fashion to form an elongated molecule characterized by a double layer of cw helices. Left-handed rotations at three interrepeat interfaces generate a novel left-hand superhelical conformation. The protein interaction interface is formed from the intrarepeat turns that are aligned to form a continuous ridge.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Friedrich Miescher Inst, CH-4058 Basel, Switzerland	University of Oxford; Friedrich Miescher Institute for Biomedical Research	Barford, D (corresponding author), Univ Oxford, Dept Biochem, Lab Mol Biophys, S Parks Rd, Oxford OX1 3QU, England.	davidb@biop.ox.ac.uk		Groves, Matthew/0000-0001-9859-5177				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN SC, 1989, J BIOL CHEM, V264, P7267; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Enenkel C, 1996, P NATL ACAD SCI USA, V93, P12986, DOI 10.1073/pnas.93.23.12986; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Goodford P, 1996, J CHEMOMETR, V10, P107; Gusella JF, 1998, CURR OPIN NEUROBIOL, V8, P425, DOI 10.1016/S0959-4388(98)80071-8; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHI B, 1990, J VIROL, V64, P5649, DOI 10.1128/JVI.64.11.5649-5651.1990; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Malik HS, 1997, P NATL ACAD SCI USA, V94, P13738, DOI 10.1073/pnas.94.25.13738; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILLWARD TA, 1998, IN PRESS TRENDS BIOC; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Park HW, 1997, SCIENCE, V276, P21; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RAAG R, 1988, J MOL BIOL, V200, P553, DOI 10.1016/0022-2836(88)90542-6; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SAITO T, 1995, BIOCHEMISTRY-US, V34, P7376, DOI 10.1021/bi00022a010; Snaith HA, 1996, J CELL SCI, V109, P3001; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; THUNNISSEN AMWH, 1994, NATURE, V367, P750, DOI 10.1038/367750a0; Turowski P, 1997, EUR J BIOCHEM, V248, P200, DOI 10.1111/j.1432-1033.1997.t01-1-00200.x; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; Wang CY, 1998, GENE DEV, V12, P1409, DOI 10.1101/gad.12.10.1409; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WERA S, 1995, J BIOL CHEM, V270, P21374, DOI 10.1074/jbc.270.36.21374; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Zhao Y, 1997, J BIOL CHEM, V272, P8256, DOI 10.1074/jbc.272.13.8256; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	64	343	352	1	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 8	1999	96	1					99	110		10.1016/S0092-8674(00)80963-0	http://dx.doi.org/10.1016/S0092-8674(00)80963-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989501	Bronze			2022-12-28	WOS:000078023200012
J	Gumbsch, P; Gao, H				Gumbsch, P; Gao, H			Dislocations faster than the speed of sound	SCIENCE			English	Article							TRANSITION-METALS	It is thought that dislocations cannot surpass the sound barrier at the shear wave velocity because the energy spent in radiation has a singularity there. Atomistic simulations show that dislocations can move faster than the speed of sound if they are created as supersonic dislocations at a strong stress concentration and are subjected to high shear stresses. This behavior is important for the understanding of low-temperature deformation processes such as mechanical twinning and may be relevant for the dynamics of tectonic faults. The motion of the dislocations at a speed of root 2 times the shear wave velocity can be understood from a Linear elastic analysis, but many of the peculiarities of the supersonic dislocations are dominated by nonlinear effects that require a realistic atomistic description.	Max Planck Inst Met Forsch, D-70174 Stuttgart, Germany; Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA	Max Planck Society; Stanford University	Gumbsch, P (corresponding author), Max Planck Inst Met Forsch, Seestr 92, D-70174 Stuttgart, Germany.		Gao, Huajian/F-9360-2010; Gumbsch, Peter/E-5879-2012	Gao, Huajian/0000-0002-8656-846X; Gumbsch, Peter/0000-0001-7995-228X				ACKLAND GJ, 1987, PHILOS MAG A, V56, P15, DOI 10.1080/01418618708204464; ARCHULETA RJ, 1982, B SEISMOL SOC AM, V72, P1927; ESHELBY JD, 1949, P PHYS SOC LOND A, V62, P307, DOI 10.1088/0370-1298/62/5/307; Finkel' V. M., 1970, Fizika Metallov i Metallovedenie, V29, P1248; FINNIS MW, 1984, PHILOS MAG A, V50, P45, DOI 10.1080/01418618408244210; Friedel J., 1964, DISLOCATIONS; GAO H, IN PRESS J MECH PHYS; Gumbsch P, 1996, Z METALLKD, V87, P341; Hirth J. P., 1972, THEORY DISLOCATIONS; Nabarro FRN, 1967, THEORY CRYSTAL DISLO; ROSAKIS AJ, 1998, 9817 CALTECH SM; ROSAKIS P, 1995, INT J SOLIDS STRUCT, V32, P2711, DOI 10.1016/0020-7683(94)00293-6; SCHIOTZ J, 1995, PHIL MAG LETT, V72, P245, DOI 10.1080/09500839508242458; Weertman J., 1980, DISLOCATIONS SOLIDS, V3, P1; Weertman J.., 1969, MATH THEORY DISLOCAT, P178	15	209	216	2	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					965	968		10.1126/science.283.5404.965	http://dx.doi.org/10.1126/science.283.5404.965			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974385				2022-12-28	WOS:000078574800042
J	Riis, P				Riis, P			Conference problems - Spoken words losing their identity	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					386	386		10.1136/bmj.318.7180.386	http://dx.doi.org/10.1136/bmj.318.7180.386			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933207	Green Published			2022-12-28	WOS:000078572600035
J	Michaelides, AP; Psomadaki, ZD; Dilaveris, PE; Richter, DJ; Andrikopoulos, GK; Aggeli, KD; Stefanadis, CI; Toutouzas, PK				Michaelides, AP; Psomadaki, ZD; Dilaveris, PE; Richter, DJ; Andrikopoulos, GK; Aggeli, KD; Stefanadis, CI; Toutouzas, PK			Improved detection of coronary artery disease by exercise electrocardiography with the use of right precordial leads	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EMISSION COMPUTED-TOMOGRAPHY; INFERIOR MYOCARDIAL-INFARCTION; ISCHEMIC-HEART-DISEASE; ST-SEGMENT ELEVATION; TL-201 TOMOGRAPHY; STRESS TESTS; V4R; ANGIOPLASTY; DIAGNOSIS	Background Exercise electrocardiography is an imperfect test for the detection of coronary artery disease. We attempted to improve the diagnostic accuracy of exercise testing as a noninvasive method for the detection of coronary artery disease by using a combination of the left and right precordial leads. Methods We studied 245 patients (218 men and 27 women) ranging from 32 to 74 years of age (mean [+/-SD], 52 +/- 8) who underwent treadmill exercise testing, thallium-201 scintigraphy, and coronary arteriography. During exercise testing, each patient had one electrocardiogram recorded with the standard 12 leads and 3 right precordial leads (V3R, V4R, and V5R), with the results for each set of leads recorded and analyzed separately. Results On the basis of coronary arteriography, 34 patients had normal coronary arteries, 85 had single-vessel disease, 84 had two-vessel disease, and 42 had three-vessel disease. The sensitivities of the standard 12-lead exercise electrocardiogram, exercise electrocardiography incorporating right precordial leads, and thallium-201 scintigraphy were 52 percent, 89 percent, and 87 percent, respectively, for the detection of single-vessel disease; 71 percent, 94 percent, and 96 percent for the detection of two-vessel disease; 83 percent, 95 percent, and 98 percent for the detection of three-vessel disease; and 66 per cent, 92 percent, and 93 percent for the detection of any coronary artery disease. The specificities of the three methods for the detection of any coronary artery disease were 88 percent, 88 percent, and 82 percent, respectively. Conclusions Use of right precordial leads along with the standard six left precordial leads during exercise electrocardiography greatly improves the sensitivity of exercise testing for the diagnosis of coronary artery disease. (N Engl J Med 1999;340:340-5.) (C) 1999, Massachusetts Medical Society.	Univ Athens, Sch Med, Dept Cardiol, Hippokrat Hosp, GR-11527 Athens, Greece	Athens Medical School; Hippokration General Hospital; National & Kapodistrian University of Athens	Michaelides, AP (corresponding author), 47 Agiou Gerasimou St, Athens 15771, Greece.		Stefanadis, Christodoulos/ABH-2232-2020; Richter, Dimitris/AFW-3761-2022	Stefanadis, Christodoulos/0000-0001-5974-6454; DILAVERIS, POLYCHRONIS/0000-0003-0399-4111; Richter, Dimitrios/0000-0003-0245-4690				ANDERSEN HR, 1990, AM HEART J, V119, P490, DOI 10.1016/S0002-8703(05)80269-8; BARTEL AG, 1974, CIRCULATION, V49, P348, DOI 10.1161/01.CIR.49.2.348; BRAAT SH, 1985, J AM COLL CARDIOL, V5, P1308, DOI 10.1016/S0735-1097(85)80341-7; BRAAT SH, 1984, AM J CARDIOL, V53, P1538, DOI 10.1016/0002-9149(84)90575-7; CANDELLRIERA J, 1981, AM HEART J, V101, P281, DOI 10.1016/0002-8703(81)90191-5; CHARLAP S, 1989, AM J CARDIOL, V64, P577, DOI 10.1016/0002-9149(89)90481-5; CHOUHAN L, 1989, AM J CARDIOL, V64, P938, DOI 10.1016/0002-9149(89)90847-3; COLBY J, 1983, J AM COLL CARDIOL, V2, P21, DOI 10.1016/S0735-1097(83)80372-6; DEPASQUALE EE, 1988, CIRCULATION, V77, P316, DOI 10.1161/01.CIR.77.2.316; GIANROSSI R, 1989, CIRCULATION, V80, P87, DOI 10.1161/01.CIR.80.1.87; GOLDSCHLAGER N, 1976, ANN INTERN MED, V85, P277, DOI 10.7326/0003-4819-85-3-277; KRUEGER DW, 1989, AM J CARDIOL, V63, P107, DOI 10.1016/0002-9149(89)91088-6; MADDAHI J, 1989, J AM COLL CARDIOL, V14, P1689, DOI 10.1016/0735-1097(89)90017-X; MAHMARIAN JJ, 1990, J AM COLL CARDIOL, V15, P318, DOI 10.1016/S0735-1097(10)80055-5; MARTIN CM, 1972, CIRCULATION, V46, P956, DOI 10.1161/01.CIR.46.5.956; MCHENRY PL, 1972, AM J CARDIOL, V30, P747, DOI 10.1016/0002-9149(72)90149-X; MCNEER JF, 1978, CIRCULATION, V57, P64, DOI 10.1161/01.CIR.57.1.64; MICHAELIDES AP, 1990, AM HEART J, V120, P292, DOI 10.1016/0002-8703(90)90072-6; QUINONES MA, 1992, CIRCULATION, V85, P1026, DOI 10.1161/01.CIR.85.3.1026; RITCHIE JL, 1995, J AM COLL CARDIOL, V25, P521, DOI 10.1016/0735-1097(95)90027-6; TAMAKI N, 1984, J AM COLL CARDIOL, V4, P1213, DOI 10.1016/S0735-1097(84)80140-0; VANTRAIN KF, 1990, J NUCL MED, V31, P1168; [No title captured]	23	72	73	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1999	340	5					340	345		10.1056/NEJM199902043400502	http://dx.doi.org/10.1056/NEJM199902043400502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163WC	9929523				2022-12-28	WOS:000078428500002
J	Vainio, S; Heikkila, M; Kispert, A; Chin, N; McMahon, AP				Vainio, S; Heikkila, M; Kispert, A; Chin, N; McMahon, AP			Female development in mammals is regulated by Wnt-4 signalling	NATURE			English	Article							MULLERIAN-INHIBITING SUBSTANCE; ADRENAL HYPOPLASIA CONGENITA; SIDE-CHAIN-CLEAVAGE; SEX DETERMINATION; Y-CHROMOSOME; 3-BETA-HYDROXYSTEROID DEHYDROGENASE; MOLECULAR-GENETICS; TRANSGENIC MICE; FETAL MOUSE; EXPRESSION	In the mammalian embryo, both sexes are initially morphologically Indistinguishable: specific hormones are required for sex-specific development. Mullerian inhibiting substance and testosterone secreted by the differentiating embryonic testes result in the loss of female (Mullerian) or promotion of male (Wolffian) reproductive duct development, respectively. The signalling molecule Wnt-4 is crucial for female sexual development. At birth, sexual development in males with a mutation in Wnt-4 appears to be normal; however, Wnt-4-mutant females are masculinized-the Mullerian duct is absent white the Wolffian duct continues to develop. Wnt-4 is initially required in both sexes for formation of the Mullerian duct, then Wnt-4 in the developing ovary appears to suppress the development of Leydig cells; consequently, Wnt-4-mutant females ectopically activate testosterone biosynthesis. Wnt-4 may also be required for maintenance of the female germ line. Thus, the establishment of sexual dimorphism is under the control of both local and systemic signals.	Harvard Univ, Biolabs, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Univ Oulu, Fac Sci, Dept Biochem, Oulu 90570, Finland; Univ Oulu, Fac Med, Dept Biochem, Oulu 90570, Finland; Univ Oulu, Bioctr Oulu, Oulu 90570, Finland	Harvard University; Finland National Institute for Health & Welfare; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu	McMahon, AP (corresponding author), Harvard Univ, Biolabs, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.	amcmahon@biosun.harvard.edu	McMahon, Andrew P/ABE-7520-2020	Vainio, Seppo/0000-0001-9319-3566				Andersson S, 1996, J CLIN ENDOCR METAB, V81, P130, DOI 10.1210/jc.81.1.130; BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; BISHOP CE, 1985, NATURE, V315, P70, DOI 10.1038/315070a0; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BUEHR M, 1993, DEVELOPMENT, V117, P273; BURGOYNE PS, 1988, PHILOS T R SOC B, V322, P63, DOI 10.1098/rstb.1988.0114; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; ENDERS GC, 1994, DEV BIOL, V163, P331, DOI 10.1006/dbio.1994.1152; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; GRECO TL, 1994, ENDOCRINOLOGY, V135, P262, DOI 10.1210/en.135.1.262; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; Hogan B, 1994, MANIPULATING MOUSE E; JOST A, 1953, RECENT PROG HORM RES, V8, P379; Kent J, 1996, DEVELOPMENT, V122, P2813; Kispert A, 1996, DEVELOPMENT, V122, P3627; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LYET L, 1995, BIOL REPROD, V52, P444, DOI 10.1095/biolreprod52.2.444; MCLAREN A, 1991, BIOESSAYS, V13, P151, DOI 10.1002/bies.950130402; McLaren A, 1998, CURR BIOL, V8, pR175, DOI 10.1016/S0960-9822(98)70104-6; McLaren A, 1995, NATO ADV SCI INST SE, V279, P1; Miller C, 1998, DEVELOPMENT, V125, P3201; Morel Y, 1997, STEROIDS, V62, P176, DOI 10.1016/S0039-128X(96)00178-X; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Mustonen MVJ, 1997, BIOCHEM J, V325, P199, DOI 10.1042/bj3250199; Nordqvist K, 1997, INT J DEV BIOL, V41, P627; NORDQVIST K, 1994, NAT GENET, V7, P7, DOI 10.1038/ng0594-7; PALMER SJ, 1991, DEVELOPMENT, V112, P265; Parr BA, 1998, NATURE, V395, P707, DOI 10.1038/27221; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Swain A, 1998, NATURE, V391, P761, DOI 10.1038/35799; VIGIER B, 1987, DEVELOPMENT, V100, P43; ZAMBONI L, 1983, J EXP ZOOL, V228, P173, DOI 10.1002/jez.1402280204; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0	41	910	959	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 4	1999	397	6718					405	409		10.1038/17068	http://dx.doi.org/10.1038/17068			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164KA	9989404				2022-12-28	WOS:000078461700038
J	Nightingale, SL				Nightingale, SL			Reporting adverse events and product problems electronically	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					408	408		10.1001/jama.281.5.408	http://dx.doi.org/10.1001/jama.281.5.408			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952188				2022-12-28	WOS:000078318500010
J	Jakosky, BM				Jakosky, BM			Mars - Water, climate, and life	SCIENCE			English	Editorial Material									Univ Colorado, Atmospher & Space Phys Lab, Boulder, CO 80309 USA; Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Jakosky, BM (corresponding author), Univ Colorado, Atmospher & Space Phys Lab, Campus Box 392, Boulder, CO 80309 USA.							Acuna MH, 1998, SCIENCE, V279, P1676, DOI 10.1126/science.279.5357.1676; Albee AL, 1998, SCIENCE, V279, P1671, DOI 10.1126/science.279.5357.1671; *AM GEOPH UN, 1998, FALL M AM GEOPH UN 6; Brain DA, 1998, J GEOPHYS RES-PLANET, V103, P22689, DOI 10.1029/98JE02074; Carr M.H, 1996, WATER MARS; CHRISTENSEN PR, 1992, J GEOPHYS RES-PLANET, V97, P7719, DOI 10.1029/92JE00453; Jakosky BM, 1998, J GEOPHYS RES-PLANET, V103, P19359, DOI 10.1029/98JE01892; Jakosky Bruce, 1998, SEARCH LIFE OTHER PL; Malin MC, 1998, SCIENCE, V279, P1681, DOI 10.1126/science.279.5357.1681; Zuber MT, 1998, SCIENCE, V282, P2053, DOI 10.1126/science.282.5396.2053	10	11	11	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					648	649		10.1126/science.283.5402.648	http://dx.doi.org/10.1126/science.283.5402.648			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9988657				2022-12-28	WOS:000078324400028
J	Eyre-Walker, A; Keightley, PD				Eyre-Walker, A; Keightley, PD			High genomic deleterious mutation rates in hominids	NATURE			English	Article							GENES; POPULATIONS; DROSOPHILA; MOUSE; RISK	It has been suggested that humans may suffer a high genomic deleterious mutation rate(1,2). Here we test this hypothesis by applying a variant of a molecular approach(3) to estimate the deleterious mutation rate in hominids from the level of selective constraint in DNA sequences. Under conservative assumptions, we estimate that an average of 4.2 amino-acid-altering mutations per diploid per generation have occurred in the human lineage since humans separated from chimpanzees. Of these mutations, we estimate that at least 38% have been eliminated by natural selection, indicating that there have been more than 1.6 new deleterious mutations per diploid genome per generation. Thus, the deleterious mutation rate specific to protein-coding sequences alone is close to the upper limit tolerable by a species such as humans that has a low reproductive rate(4), indicating that the effects of deleterious mutations may have combined synergistically, Furthermore, the level of selective constraint in hominid protein-coding sequences is atypically low, A large number of slightly deleterious mutations may therefore have become fixed in hominid lineages.	Univ Sussex, Ctr Study Evolut, Brighton BN1 9QG, E Sussex, England; Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Sussex; University of Sussex; University of Edinburgh	Eyre-Walker, A (corresponding author), Univ Sussex, Ctr Study Evolut, Brighton BN1 9QG, E Sussex, England.	A.C.Eyre-Walker@susx.ac.uk	Eyre-Walker, Adam/G-6216-2011	Eyre-Walker, Adam/0000-0001-5527-8729				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; CHARLESWORTH B, 1990, NATURE, V347, P380, DOI 10.1038/347380a0; Crow JF, 1997, P NATL ACAD SCI USA, V94, P8380, DOI 10.1073/pnas.94.16.8380; Drake JW, 1998, GENETICS, V148, P1667; DURET L, 1994, NUCLEIC ACIDS RES, V22, P2360, DOI 10.1093/nar/22.12.2360; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; Goodman M, 1998, MOL PHYLOGENET EVOL, V9, P585, DOI 10.1006/mpev.1998.0495; HAMMER MF, 1995, NATURE, V378, P376, DOI 10.1038/378376a0; Hill K., 1996, ACHE LIFE HIST ECOLO, DOI 10.4324/9781351329248; Howell N., 1979, DEMOGRAPHY DOBE KUNG; Ina Y, 1998, J MOL EVOL, V46, P521, DOI 10.1007/PL00006333; Keightley PD, 1996, GENETICS, V144, P1993; KIMURA M, 1966, GENETICS, V54, P1337; Kimura M., 1983, NEUTRAL THEORY MOL; KONDRASHOV AS, 1995, J THEOR BIOL, V175, P583, DOI 10.1006/jtbi.1995.0167; KONDRASHOV AS, 1993, HUM MUTAT, V2, P229, DOI 10.1002/humu.1380020312; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; LANDE R, 1994, EVOLUTION, V48, P1460, DOI [10.2307/2410240, 10.1111/j.1558-5646.1994.tb02188.x]; Li W. H, 1997, MOL EVOLUTION; Melancon T., 1982, THESIS PENNSYLVANIA; MOHRENWEISER HW, 1981, P NATL ACAD SCI-BIOL, V78, P5729, DOI 10.1073/pnas.78.9.5729; MULLER HJ, 1950, AM J HUM GENET, V2, P111; NEEL JV, 1988, AM J HUM GENET, V42, P663; Nishida T., 1990, P63; OHTA T, 1995, J MOL EVOL, V40, P56, DOI 10.1007/BF00166595; Ophir R, 1997, GENE, V205, P191, DOI 10.1016/S0378-1119(97)00398-3; SIMMONS MJ, 1977, ANNU REV GENET, V11, P49, DOI 10.1146/annurev.ge.11.120177.000405; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; WOLFE KH, 1989, NATURE, V337, P283, DOI 10.1038/337283a0; WOLFE KH, 1993, J MOL EVOL, V37, P441, DOI 10.1007/BF00178874	30	286	289	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 28	1999	397	6717					344	347		10.1038/16915	http://dx.doi.org/10.1038/16915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9950425				2022-12-28	WOS:000078324600048
J	Leyman, B; Geelen, D; Quintero, FJ; Blatt, MR				Leyman, B; Geelen, D; Quintero, FJ; Blatt, MR			A tobacco syntaxin with a role in hormonal control of guard cell ion channels	SCIENCE			English	Article							CALCIUM CHANNELS; ABSCISIC-ACID; EXOCYTOSIS; RECEPTOR; MEMBRANE; ENDOCYTOSIS; SECRETION; PROTEINS; HOMOLOG; CLONING	The plant hormone abscisic acid (ABA) regulates potassium and chloride ion channels at the plasma membrane of guard cells, Leading to stomatal closure that reduces transpirational water loss from the leaf. The tobacco Nt-SYR1 gene encodes a syntaxin that is associated with the plasma membrane. Syntaxins and related SNARE proteins aid intracellular vesicle trafficking, fusion, and secretion. Disrupting Nt-Syr1 function by cleavage with Clostridium botulinum type C toxin or competition with a soluble fragment of Nt-Syr1 prevents potassium and chloride ion channel response to ABA in guard cells and implicates Nt-Syr1 in an ABA-signaling cascade.	Univ London Wye Coll, Lab Plant Physiol & Biophys, Ashford TN25 5AH, Kent, England	Imperial College London	Blatt, MR (corresponding author), Univ London Wye Coll, Lab Plant Physiol & Biophys, Ashford TN25 5AH, Kent, England.		Quintero, Francisco J./AAG-2924-2019; Quintero, Francisco J/C-3086-2014	Quintero, Francisco J./0000-0001-8718-2975; Quintero, Francisco J/0000-0001-8718-2975; Blatt, Michael R/0000-0003-1361-4645				AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BATTEY NH, 1993, NEW PHYTOL, V125, P307, DOI 10.1111/j.1469-8137.1993.tb03883.x; Blatt MR, 1997, PHYSIOL PLANTARUM, V100, P481, DOI 10.1034/j.1399-3054.1997.1000309.x; Conceicao ADS, 1997, PLANT CELL, V9, P571, DOI 10.2307/3870508; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DANIELS MJ, 1994, PLANT PHYSIOL, V106, P1325, DOI 10.1104/pp.106.4.1325; EIDNE KA, 1994, MEMBRANE PROTEIN EXP, P1; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Grabov A, 1997, PLANT J, V12, P203, DOI 10.1046/j.1365-313X.1997.12010203.x; Grabov A, 1998, P NATL ACAD SCI USA, V95, P4778, DOI 10.1073/pnas.95.8.4778; Harlow E., 1988, ANTIBODIES LABORATOR, P1; Homann U, 1998, PLANTA, V206, P329, DOI 10.1007/s004250050408; Igarashi M, 1996, J CELL BIOL, V134, P205, DOI 10.1083/jcb.134.1.205; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KAISER CA, 1997, MOL CELLULAR BIOL YE, P91; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lauber MH, 1997, J CELL BIOL, V139, P1485, DOI 10.1083/jcb.139.6.1485; Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199; LEYMAN B, UNPUB; Linial M, 1997, J PHYSIOL-LONDON, V504, P251, DOI 10.1111/j.1469-7793.1997.251be.x; LOUGUET P, 1990, BIOCHEM PHYSIOL PFL, V186, P273, DOI 10.1016/S0015-3796(11)80218-0; LOUVAINLANEUVE AD, 1995, J BIOL CHEM, V270, P23828; LUBBERT H, 1987, P NATL ACAD SCI USA, V84, P4332, DOI 10.1073/pnas.84.12.4332; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; Montecucco C, 1995, Q REV BIOPHYS, V28, P423, DOI 10.1017/S0033583500003292; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; OConnor V, 1997, P NATL ACAD SCI USA, V94, P12186, DOI 10.1073/pnas.94.22.12186; Sambrook J., 1989, MOL CLONING; SCHROEDER JI, 1995, PLANT MOL BIOL, V28, P353, DOI 10.1007/BF00020385; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Solsona C, 1998, BIOPHYS J, V74, P1061, DOI 10.1016/S0006-3495(98)74030-5; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; Thiel G, 1998, PLANT MOL BIOL, V38, P111, DOI 10.1023/A:1006038122009; Willmer C., 1996, STOMATA, P1; ZHANG RE, 1995, GENE, V159, P293, DOI 10.1016/0378-1119(95)00152-V	39	175	192	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					537	540		10.1126/science.283.5401.537	http://dx.doi.org/10.1126/science.283.5401.537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915701				2022-12-28	WOS:000078203300037
J	Rabinowitz, HK; Diamond, JJ; Markham, FW; Hazelwood, CE				Rabinowitz, HK; Diamond, JJ; Markham, FW; Hazelwood, CE			A program to increase the number of family physicians in rural and underserved areas - Impact after 22 years	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-SCHOOL ADMISSIONS; HEALTH-SERVICE-CORPS; PRIMARY CARE; FOLLOW-UP; RETENTION; STUDENTS	Context The shortage of physicians in rural areas is a longstanding and serious problem, and national and state policymakers and educators continue to face the challenge of finding effective ways to increase the supply of rural physicians. Objective To determine the direct and long-term impact of the Physician Shortage Area Program (PSAP) of Jefferson Medical College (JMC) on the rural physician workforce. Design Retrospective cohort study. Participants and Setting A total of 206 PSAP graduates from the classes of 1978 to 1991. Main Outcome Measures The PSAP graduates currently practicing family medicine in rural and underserved areas of Pennsylvania, compared with all allopathic medical school graduates in the state, and with all US and international allopathic graduates. All PSAP graduates were also compared with their non-PSAP peers at JMC regarding their US practice location. medical specialty, and retention for the past 5 to 10 years. Results The PSAP graduates account for 21% (32/150) of family physicians practicing in rural Pennsylvania who graduated from one of the state's 7 medical schools, even though they represent only 1% (206/14 710) of graduates from those schools (relative risk [RR], 19.1). Among all US and international medical school graduates, PSAP graduates represent 12% of all family physicians in rural Pennsylvania. Results were similar for PSAP graduates practicing in underserved areas. Overall, PSAP graduates were much more likely than their non-PSAP classmates at JMC to practice in a rural area of the United States (34% vs 11 %; RR, 3.0), to practice in an underserved area (30% vs 9 %; RR, 3.2), to practice family medicine (52 % vs 13 %; RR, 4.0), and to have combined a career in family practice with practice in a rural area (21% vs 2%; RR, 8.5). Of PSAP graduates, 84% were practicing in either a rural or small metropolitan area, or one of the primary care specialties. Program retention has remained high, with the number of PSAP graduates currently practicing rural family medicine equal to 87% of those practicing between 5 and 10 years ago, and the number practicing in underserved areas, 94%. Conclusions The PSAP, after more than 22 years, has had a disproportionately large impact on the rural physician workforce, and this effect has persisted over time. Based on these program results, policymakers and medical schools can have a substantial impact on the shortage of physicians in rural areas.	Thomas Jefferson Univ, Jefferson Med Coll, Ctr Med Educ Res & Policy, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Family Med, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Rabinowitz, HK (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Ctr Med Educ Res & Policy, 1015 Walnut St,Suite 401, Philadelphia, PA 19107 USA.				BHP HRSA HHS [1U76MB00002-01] Funding Source: Medline	BHP HRSA HHS		ADKINS RJ, 1987, J MED EDUC, V62, P810; *AM AC FAM PHYS, 1992, SURV GRAD FAM PRACT; Blumenthal D, 1997, NEW ENGL J MED, V337, P1550, DOI 10.1056/NEJM199711203372113; Boulger J G, 1991, J Rural Health, V7, P105, DOI 10.1111/j.1748-0361.1991.tb00713.x; Brazeau N K, 1990, Fam Med, V22, P350; COOPER JK, 1972, J MED EDUC, V47, P939; *COUNC GRAD MED ED, 1992, IMPR ACC HLTH CAR PH; *COUNC GRAD MED ED, 1995, 1995 PHYS WORKF FUND; Council on Graduate Medical Education, 1998, PHYS DISTR HLTH CAR; CULLEN JC, 1997, J AM BOARD FAM PRACT, V10, P272; CULLISON S, 1976, JAMA-J AM MED ASSOC, V235, P502, DOI 10.1001/jama.235.5.502; Donaldson M, 1996, PRIMARY CARE AM HLTH; Ernst R. L., 1985, PHYSICIAN LOCATION S; Flexner A., 1910, MEDICAL ED US CANADA; Hojat M, 1996, ED HLTH, V9, P99; IGLEHART JK, 1995, NEW ENGL J MED, V333, P1017; JOLLY P, 1996, AAMC DATA BOOK STAT; KASSEBAUM DG, 1993, ACAD MED, V68, P232, DOI 10.1097/00001888-199303000-00019; LOHR KN, 1996, NATIONS PHYSICIAN WO; MATTSON DE, 1973, J MED EDUC, V48, P323; Mullan F, 1997, NEW ENGL J MED, V336, P1601, DOI 10.1056/NEJM199705293362212; PATHMAN DE, 1992, JAMA-J AM MED ASSOC, V268, P1552; Pathman DE, 1996, ACAD MED, V71, P963, DOI 10.1097/00001888-199609000-00010; PEAR R, 1997, NY TIMES        0301, pA9; *PENNS DEP HLTH, 1996, HLTH PROF 1996 PENNS; Pusey WA, 1925, J AMER MED ASSOC, V84, P281, DOI 10.1001/jama.1925.26620300002013; RABINOWITZ HK, 1983, JAMA-J AM MED ASSOC, V249, P1038, DOI 10.1001/jama.249.8.1038; RABINOWITZ HK, 1988, NEW ENGL J MED, V319, P480, DOI 10.1056/NEJM198808253190805; RABINOWITZ HK, 1986, J MED EDUC, V61, P598; RABINOWITZ HK, 1993, NEW ENGL J MED, V328, P934, DOI 10.1056/NEJM199304013281307; RABINOWITZ HK, IN PRESS J RURAL HLT; RANDOLPH L, 1997, PHYSICIAN CHARACTERI; ROSENBLATT RA, 1992, JAMA-J AM MED ASSOC, V268, P1559, DOI 10.1001/jama.268.12.1559; SCHROEDER SA, 1995, LANCET, V345, P1001, DOI 10.1016/S0140-6736(95)90753-X; U. S. Bureau of the Census, 1996, STAT ABSTR US; US Bureau of Census, 1991, 1990 CENS POP HOUS; VERBY JE, 1991, JAMA-J AM MED ASSOC, V266, P110, DOI 10.1001/jama.266.1.110; WHITCOMB ME, 1991, IMPACT FEDERAL FUNDI; Xu G, 1997, ACAD MED, V72, P1026, DOI 10.1097/00001888-199712000-00004	39	197	201	1	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1999	281	3					255	260		10.1001/jama.281.3.255	http://dx.doi.org/10.1001/jama.281.3.255			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157GK	9918481	Bronze			2022-12-28	WOS:000078052800031
J	Schneider, MME; Borleffs, JCC; Stolk, RP; Jaspers, CAJJ; Hoepelman, AIM				Schneider, MME; Borleffs, JCC; Stolk, RP; Jaspers, CAJJ; Hoepelman, AIM			Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRIMETHOPRIM-SULFAMETHOXAZOLE; INFECTION; AIDS	Background Prophylactic drugs for Pneumocystis carinii pneumonia (PCP) are strongly recommended for HIV-1-infected patients with CD4 cell counts of less than 200 cells/mu L. Because of the highly active antiretroviral therapy (HAART) currently available, we speculated that prophylaxis can be discontinued in patients with CD4 cell counts of more than 200 cells/mu L. Methods In this prospective observational study, PCP prophylaxis (primary or secondary) was discontinued in HIV-1-infected patients whose CD4 cell count had increased above 200 cells/mu L (documented twice with an interval of at least 1 month) as a result of HAART. Patients and their CD4 cell counts were monitored every 3 months. The primary endpoint of the study was the occurrence or reoccurrence of PCP. Findings 78 patients were enrolled: 62 patients were receiving prophylaxis for primary prevention of PCP and 16 patients for secondary prevention of PCP. At the time of discontinuation of prophylaxis, the mean CD4 cell count was 347 cells/mu L, and HIV-1-RNA was not detectable in 61 patients. The lowest mean CD4 cell count during prophylaxis was 79 cells/mu L. Patients stopped prophylaxis 9.8 (SD 6.4) months after they started HAART, The mean follow-up after discontinuation of prophylaxis was 12.7 (SD 7.6) months, and none of the patients developed PCP (97.5% one-sided CI 0-4.4%). Interpretation The preliminary results of this study indicate that PCP prophylaxis can be stopped safely in HIV-1-infected patients whose CD4 cell counts have increased above 200 cells/mu L after treatment with HAART.	Univ Utrecht Hosp, Dept Internal Med, Div Infect Dis & AIDS, NL-3508 GA Utrecht, Netherlands; Univ Utrecht Hosp, Eijkman Winkler Inst, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Julius Ctr Patient Oriented Res, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University	Schneider, MME (corresponding author), Univ Utrecht Hosp, Dept Internal Med, Div Infect Dis & AIDS, POB 85500, NL-3508 GA Utrecht, Netherlands.		Stolk, Ronald P/B-2341-2013	Stolk, Ronald P/0000-0002-0518-1205				Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; Macdonald JC, 1998, J INFECT DIS, V177, P1182, DOI 10.1086/515281; MOORE RD, 1998, 5 C RETR OPP INF CHI, P184; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; Roederer M, 1998, NAT MED, V4, P145, DOI 10.1038/nm0298-145; ROWE PM, 1998, LANCET, V350, P720; SCHNEIDER MME, 1995, J INFECT DIS, V171, P1632, DOI 10.1093/infdis/171.6.1632; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; Sepkowitz KA, 1998, LANCET, V351, P228, DOI 10.1016/S0140-6736(05)78279-9; Tural C, 1998, J INFECT DIS, V177, P1080, DOI 10.1086/517399; *USPHS IDSA PREV O, 1997, MMWR-MORBID MORTAL W, V46, P1; Whitcup SM, 1997, JAMA-J AM MED ASSOC, V277, P1519, DOI 10.1001/jama.277.19.1519	19	136	140	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					201	203		10.1016/S0140-6736(98)07204-3	http://dx.doi.org/10.1016/S0140-6736(98)07204-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923876				2022-12-28	WOS:000078175600013
J	Baxby, D				Baxby, D			Edward Jenner's Inquiry after 200 years	BRITISH MEDICAL JOURNAL			English	Article																			0	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					390	390		10.1136/bmj.318.7180.390	http://dx.doi.org/10.1136/bmj.318.7180.390			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933209	Green Published			2022-12-28	WOS:000078572600037
J	Coxon, JP; Gallen, IW				Coxon, JP; Gallen, IW			Laterality of lower limb amputation in diabetic patients: retrospective audit	BRITISH MEDICAL JOURNAL			English	Article							ULCERATION; RISK		Wycombe Gen Hosp, Children Diabet Ctr, High Wycombe HP11 2TT, Bucks, England		Gallen, IW (corresponding author), Wycombe Gen Hosp, Children Diabet Ctr, High Wycombe HP11 2TT, Bucks, England.							CTERCTEKO GC, 1981, BRIT J SURG, V68, P608, DOI 10.1002/bjs.1800680904; Lehto S, 1996, DIABETES CARE, V19, P607, DOI 10.2337/diacare.19.6.607; MOSS SE, 1992, ARCH INTERN MED, V152, P610, DOI 10.1001/archinte.152.3.610; REIBER GE, 1996, DIABETIC MED, V13, P6; VEVES A, 1992, DIABETOLOGIA, V35, P660, DOI 10.1007/BF00400259	5	8	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					367	367		10.1136/bmj.318.7180.367	http://dx.doi.org/10.1136/bmj.318.7180.367			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933199	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000078572600028
J	Jeffcoate, WJ				Jeffcoate, WJ			Chronic fatigue syndrome and functional hypoadrenia - fighting vainly the old ennui	LANCET			English	Editorial Material									City Hosp, Dept Endocrinol & Diabet, Nottingham NH5 1PB, England	University of Nottingham	Jeffcoate, WJ (corresponding author), City Hosp, Dept Endocrinol & Diabet, Nottingham NH5 1PB, England.							Clark PM, 1998, CLIN ENDOCRINOL, V49, P287; DEMITRACK MA, 1991, J CLIN ENDOCR METAB, V73, P1224, DOI 10.1210/jcem-73-6-1224; JEFFCOATE WJ, IN PRESS ANN CLIN BI; Leese G, 1996, J CLIN ENDOCR METAB, V81, P1867, DOI 10.1210/jc.81.5.1867; McKenzie R, 1998, JAMA-J AM MED ASSOC, V280, P1061, DOI 10.1001/jama.280.12.1061; TATTERSALL R, IN PRESS MED HIST; 1987, LANCET, V2, P1002	7	8	8	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 6	1999	353	9151					424	425		10.1016/S0140-6736(98)00325-0	http://dx.doi.org/10.1016/S0140-6736(98)00325-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989708				2022-12-28	WOS:000078572800004
J	Rahi, JS; Dezateux, C				Rahi, JS; Dezateux, C		British Congenital Cataract Interest Grp	National cross sectional study of detection of congenital and infantile cataract in the United Kingdom: role of childhood screening and surveillance	BRITISH MEDICAL JOURNAL			English	Article							AMBLYOPIA; SURGERY	Objectives To determine the mode of detection and timing of ophthalmic assessment of a nationally representative group of children with congenital and infantile cataract. Design Cross sectional study. Setting United Kingdom. Subjects All children burn in the United Kingdom and aged 15 years or under in whom congenital or infantile cataract was ne newly diagnosed between October 1995 and September 1996. Main outcome measures Proportion of cases detected through routine ocular examination and proportion assessed by an ophthalmologist by 3 months and 1 year of age. Results Data were complete for 235 (95%,) of 248 children identified. Of these, 83 (35%) were detected at the routine newborn examination and 30 (12%) at the 6-8 week examination; 82 children presented symptomatically. 137 (57%) children had been assessed by an ophthalmologist by the age of 3 months but 78 (33%) were not examined until after: 1 year of age. In 91 cases the child's carers suspected an eye defect before cataract was diagnosed. Conclusions A substantial proportion of children with congenital and infantile cataract are not diagnosed by 3 months of age, although routine ocular examination of all newborn and young infants is recommended nationally. Strategies to achieve earlier detection through screening and surveillance are required.				j.rahi@ich.ucl.ac.uk	Dezateux, Carol/A-3416-2009	Dezateux, Carol/0000-0001-9787-6276; Rahi, Jugnoo/0000-0002-5718-9209				AULD R, 1989, BR ORTHOPT J, V46, P30; *BRIT PAED SURV UN, 1997, 11 ANN REP 1996 1997; CAMPOS E, 1995, SURV OPHTHALMOL, V40, P23, DOI 10.1016/S0039-6257(95)80044-1; DAVIES PA, 1972, CLIN DEVEL MED, V44, P241; DEWINTER M, 1995, SCREENING CHILD HLTH; Foster A, 1997, PAEDIAT OPHTHALMOLOG, P3; HALL DM, 1996, HLTH ALL CHILDREN 3; HALL DMB, 1988, BRIT MED J, V296, P823, DOI 10.1136/bmj.296.6625.823; HALL SM, 1982, BRIT MED J, V285, P1096, DOI 10.1136/bmj.285.6348.1096; HING S, 1990, BRIT J OPHTHALMOL, V74, P73, DOI 10.1136/bjo.74.2.73; JOHNSON A, 1989, BMJ-BRIT MED J, V299, P545, DOI 10.1136/bmj.299.6698.545; Kirkwood B., 1988, BR K ESSENTIALS MED; Lambert SR, 1996, SURV OPHTHALMOL, V40, P427, DOI 10.1016/S0039-6257(96)82011-X; LLOYD IC, 1992, EYE, V6, P184, DOI 10.1038/eye.1992.37; LLOYD IC, 1995, BRIT J OPHTHALMOL, V79, P802, DOI 10.1136/bjo.79.9.802; Rahi J. S., 1998, IOVS, V39, pS899; Rahi JS, 1998, ARCH DIS CHILD, V78, P364, DOI 10.1136/adc.78.4.364; Rappo PD, 1996, PEDIATRICS, V98, P153; Robinson R, 1998, BMJ-BRIT MED J, V316, P1; *ROYAL COLL OPHTH, 1994, OPHTH SERV CHILDRE R; RUTTUM MS, 1987, PEDIATRICS, V79, P814; Shuttleworth GN, 1997, EYE, V11, P744, DOI 10.1038/eye.1997.189; STAYTE M, 1993, BRIT J OPHTHALMOL, V77, P228, DOI 10.1136/bjo.77.4.228; Taylor D, 1998, EYE, V12, P9, DOI 10.1038/eye.1998.5; TAYLOR DSI, 1982, T OPHTHAL SOC UK, V102, P441; VAEGAN TD, 1979, T OPHTHAL SOC UK, V99, P432; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; World Health Organization, 1992, INT STAT CLASS DIS H	28	69	72	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					362	365		10.1136/bmj.318.7180.362	http://dx.doi.org/10.1136/bmj.318.7180.362			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933197	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000078572600026
J	Sherlaw-Johnson, C; Gallivan, S; Jenkins, D				Sherlaw-Johnson, C; Gallivan, S; Jenkins, D			Withdrawing low risk women from cervical screening programmes: mathematical modelling study	BRITISH MEDICAL JOURNAL			English	Article							HUMAN PAPILLOMAVIRUS; CANCER; PREVALENCE; MANAGEMENT; SMEARS; HPV	Objective To evaluate the impact of policies for removing women before the recommended age of 64 from screening programmes for cervical cancer in the United Kingdom. Design A mathematical model of the clinical course of precancerous lesions which accounts for the influence of infection with the human papillomavirus, the effects of screening on the progression of disease, and the accuracy of the testing procedures. Two policies are compared: one in which women are withdrawn from the programme if their current smear is negative and they have a recent history of regular, negative results and one in which women are withdrawn if their current smear test is negative and a simultaneous test is negative for exposure to high risk types of human papillomavirus. Setting United Kingdom cervical screening programme. Main outcome measures The incidence of invasive cervical cancer and the use of resources. Results Early withdrawal of selected women from the programme is predicted to give rise to resource savings of up to 25% for smear tests and 18% for colposcopies when withdrawal occurs from age 50, the youngest age considered in the study. An increase in the incidence of invasive cervical cancer, by up to 2 cases/100 000 women each year is predicted. Testing for human papillomavirus infection to determine which women should be withdrawn from the programme makes little difference to outcome. Conclusions This model systematically analyses the consequences of screening options using available data and the clinical course of precancerous lesions. If further audit studies confirm the model's forecasts, a policy of early withdrawal might be considered. This would be likely to release substantial resources which could be channelled into other aspects of health care or may be more effectively used within the cervical screening programme to counteract the possible increase in cancer incidence that early withdrawal might bring.	Univ London Univ Coll, Dept Math, Clin Operat Res Unit, London WC1E 6BT, England; Univ Nottingham, Queens Med Ctr, Div Pathol, Nottingham NG7 2UH, England	University of London; University College London; University of Nottingham	Sherlaw-Johnson, C (corresponding author), Univ London Univ Coll, Dept Math, Clin Operat Res Unit, Gower St, London WC1E 6BT, England.	c.sherlaw-johnson@ucl.ac.uk						AUSTOKER J, 1994, BRIT MED J, V309, P241, DOI 10.1136/bmj.309.6949.241; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; Cruickshank ME, 1997, BRIT J OBSTET GYNAEC, V104, P586, DOI 10.1111/j.1471-0528.1997.tb11537.x; *DEP HLTH, 1996, STAT B DEP HLTH; DUNCAN I, 1992, GUIDELINES CLIN PRAC; Jenkins D, 1996, INT J CANCER, V65, P768; JENKINS D, 1998, PAPILLOMAVIRUS REP, V9, P89; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; MANDELBLATT J, 1991, AM J OBSTET GYNECOL, V164, P644, DOI 10.1016/S0002-9378(11)80040-2; MANSELL ME, 1994, BRIT J OBSTET GYNAEC, V101, P807, DOI 10.1111/j.1471-0528.1994.tb11952.x; MELKERT PWJ, 1993, INT J CANCER, V53, P919, DOI 10.1002/ijc.2910530609; *OFF NAT STAT, 1998, EST NEWL DIAGN CAS C; ORBELL S, 1995, J ROY SOC MED, V88, P389; PARKIN DM, 1982, PUBLIC HEALTH, V96, P3, DOI 10.1016/S0033-3506(82)80023-1; Rozendaal L, 1996, INT J CANCER, V68, P766, DOI 10.1002/(SICI)1097-0215(19961211)68:6<766::AID-IJC13>3.0.CO;2-Z; Sasieni PD, 1996, BRIT J CANCER, V73, P1001, DOI 10.1038/bjc.1996.196; SCHIFFMAN MH, 1994, EARLY DETECTION CANC, P265; SHERLAWJOHNSON C, 1994, J CLIN PATHOL, V47, P430, DOI 10.1136/jcp.47.5.430; VANWIJNGAARDEN WJ, 1993, BRIT MED J, V306, P967, DOI 10.1136/bmj.306.6883.967; VANWIJNGAARDEN WJ, 1993, BRIT MED J, V306, P1409, DOI 10.1136/bmj.306.6889.1409-c	21	35	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					356	360		10.1136/bmj.318.7180.356	http://dx.doi.org/10.1136/bmj.318.7180.356			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933195	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000078572600023
J	Fagoonee, I; Wilson, HB; Hassell, MP; Turner, JR				Fagoonee, I; Wilson, HB; Hassell, MP; Turner, JR			The dynamics of zooxanthellae populations: A long-term study in the field	SCIENCE			English	Article							CORAL STYLOPHORA-PISTILLATA; REEF CORALS; DENSITY; TEMPERATURE; PATTERNS	Coral bleaching characterized by the expulsion of symbiotic algae (zooxanthellae) is an increasing problem worldwide. Global warming has been implicated as one cause, but the phenomenon cannot be fully comprehended without an understanding of the variability of zooxanthellae populations in field conditions. Results from a 6-year field study are presented, providing evidence of density regulation but also of large variability in the zooxanthellae population with regular episodes of very Low densities. These bleaching events are Likely to be part of a constant variability in zooxanthellae density caused by environmental fluctuations superimposed on a strong seasonal cycle in abundance.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, Ascot SL5 7PY, Berks, England; Univ Mauritus, Fac Sci, Dept Biol Sci, Reduit, Mauritius; Univ Wales, Sch Ocean Sci, Menai Bridge LL59 5EY, Gwynedd, Wales	Imperial College London; University of Mauritius	Hassell, MP (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Silwood Pk, Ascot SL5 7PY, Berks, England.	m.hassell@ic.ac.uk						BROWN BE, 1994, MAR ECOL PROG SER, V105, P209, DOI 10.3354/meps105209; COOK CB, 1990, CORAL REEFS, V9, P45, DOI 10.1007/BF00686721; DENNIS B, 1994, ECOL MONOGR, V64, P205, DOI 10.2307/2937041; DREW E A, 1972, Journal of Experimental Marine Biology and Ecology, V9, P71, DOI 10.1016/0022-0981(72)90008-1; DUBINSKY Z, 1984, PROC R SOC SER B-BIO, V222, P203, DOI 10.1098/rspb.1984.0059; FALKOWSKI PG, 1993, BIOSCIENCE, V43, P606, DOI 10.2307/1312147; Fitt WK, 1995, BIOL BULL, V189, P298, DOI 10.2307/1542147; GATES RD, 1990, CORAL REEFS, V8, P193, DOI 10.1007/BF00265010; GLADFELTER EH, 1983, BIOL BULL, V165, P811, DOI 10.2307/1541480; GLYNN PW, 1991, TRENDS ECOL EVOL, V6, P175, DOI 10.1016/0169-5347(91)90208-F; GLYNN PW, 1993, CORAL REEFS, V12, P1, DOI 10.1007/BF00303779; GOREAU TJ, 1994, AMBIO, V23, P176; HOEGHGULDBERG O, 1989, MAR ECOL PROG SER, V57, P173, DOI 10.3354/meps057173; Jones RJ, 1997, PHILOS T ROY SOC B, V352, P457, DOI 10.1098/rstb.1997.0033; Kushmaro A, 1996, NATURE, V380, P396, DOI 10.1038/380396a0; LESSER MP, 1990, CORAL REEFS, V8, P225, DOI 10.1007/BF00265015; MARSH J A JR, 1970, Ecology (Washington D C), V51, P255, DOI 10.2307/1933661; MCCLOSKEY LR, 1984, PROC R SOC SER B-BIO, V222, P215, DOI 10.1098/rspb.1984.0060; MUSCATINE L, 1989, PROC R SOC SER B-BIO, V236, P311, DOI 10.1098/rspb.1989.0025; MUSCATINE L, 1977, BIOSCIENCE, V27, P454, DOI 10.2307/1297526; Rowan R, 1997, NATURE, V388, P265, DOI 10.1038/40843; Stimson J, 1997, J EXP MAR BIOL ECOL, V214, P35, DOI 10.1016/S0022-0981(96)02753-0; SZMANT AM, 1990, MAR BIOL, V104, P119, DOI 10.1007/BF01313165; WILKERSON FP, 1988, CORAL REEFS, V7, P29, DOI 10.1007/BF00301979; [No title captured]	25	161	173	6	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					843	845		10.1126/science.283.5403.843	http://dx.doi.org/10.1126/science.283.5403.843			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933167				2022-12-28	WOS:000078496800044
J	Belich, MP; Salmeron, A; Johnston, LH; Ley, SC				Belich, MP; Salmeron, A; Johnston, LH; Ley, SC			TPL-2 kinase regulates the proteolysis of the NF-kappa B-inhibitory protein NF-kappa B1 p105	NATURE			English	Article							DNA-BINDING SUBUNIT; TYROSINE KINASE; P50 SUBUNIT; ACTIVATION; PRECURSOR; PHOSPHORYLATION; GENERATION; PATHWAY; SIGNAL; ALPHA	The transcription factor NF-kappa B is composed of homodimeric and heterodimeric complexes of Rel/NF-kappa B-family polypeptides, which include Rel-A, c-Rel, Rel-B, NF-kappa B1/p50 and NF-kappa B2/p52 (ref. 1), The NF-kappa B1 gene encodes a larger precursor protein, p105, from which p50 is produced constitutively by proteasome-mediated removal of the p105 carboxy terminus(2.-5). The p105 precursor also acts as an NF kappa B-inhibitory protein, retaining associated p50, c-Rel and Rel-A proteins in the cytoplasm through its carboxy terminus(6,7). Following cell stimulation by agonists, p105 is proteolysed more rapidly and released Rel subunits translocate into the nucleus(8-10). Here we show that TPL-2 (ref. 11), which is homologous to MAP-kinase-kinase kinases in its catalytic domain(12), forms a complex with the carboxy terminus of p105, TPL-2 was originally identified, in a carboxy-terminal-deleted form, as an oncoprotein in rats(11) and is more than 90% identical to the human oncoprotein COT13. Expression of TPL-2 results in phosphorylation and increased degradation of p105 while maintaining p50 production. This releases associated Rel subunits or p50-Rel heterodimers to generate active nuclear NF-kappa B. Furthermore, kinase-inactive TPL-2 blocks the degradation of p105 induced by tumour-necrosis factor-alpha. TPL-2 is therefore a component of a new signalling pathway that controls proteolysis of NF-kappa B1 p105.	Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England; Natl Inst Med Res, Div Yeast Genet, London NW7 1AA, England	MRC National Institute for Medical Research; MRC National Institute for Medical Research	Ley, SC (corresponding author), Natl Inst Med Res, Div Cellular Immunol, Ridgeway,Mill Hill, London NW7 1AA, England.							ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; AOKI M, 1993, J BIOL CHEM, V268, P22723; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Huby RDJ, 1997, J CELL BIOL, V137, P1639, DOI 10.1083/jcb.137.7.1639; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	30	182	192	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 28	1999	397	6717					363	368		10.1038/16946	http://dx.doi.org/10.1038/16946			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9950430				2022-12-28	WOS:000078324600053
J	Doherty, R				Doherty, R			A memorable patient - Long term follow up	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1999	318	7178					233	233						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915732				2022-12-28	WOS:000078292300025
J	Lisman, JE; Fallon, JR				Lisman, JE; Fallon, JR			Neuroscience - What maintains memories?	SCIENCE			English	Editorial Material							LONG-TERM POTENTIATION; ACTIVATED PROTEIN-KINASE; REQUIREMENT; PLASTICITY; MOLECULES		Brandeis Univ, Dept Biol, Waltham, MA 02254 USA; Brown Univ, Dept Neurosci, Providence, RI 02912 USA	Brandeis University; Brown University	Lisman, JE (corresponding author), Brandeis Univ, Dept Biol, Waltham, MA 02254 USA.	lis-man@binah.cc.brandeis.edu; justin_fallon@brown.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD052083, R01HD023924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS039321] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD052083, R01 HD023924] Funding Source: Medline; NINDS NIH HHS [P01 NS039321] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; Crino P, 1998, P NATL ACAD SCI USA, V95, P2313, DOI 10.1073/pnas.95.5.2313; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCMAHAN UJ, 1989, DEV NEUROSCI-BASEL, V11, P227, DOI 10.1159/000111903; Megeath LJ, 1998, J NEUROSCI, V18, P672; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; Otmakhov N, 1997, J NEUROSCI, V17, P5357; REIST N, COMMUNICATION; Sanes JR, 1997, CURR OPIN NEUROBIOL, V7, P93, DOI 10.1016/S0959-4388(97)80126-2; Scheetz AJ, 1997, P NATL ACAD SCI USA, V94, P14770, DOI 10.1073/pnas.94.26.14770; Steward O, 1997, NEURON, V18, P9, DOI 10.1016/S0896-6273(01)80041-6; Tiedge H, 1999, SCIENCE, V283, P186, DOI 10.1126/science.283.5399.186; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3	25	66	70	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 15	1999	283	5400					339	340		10.1126/science.283.5400.339	http://dx.doi.org/10.1126/science.283.5400.339			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9925495				2022-12-28	WOS:000078067000031
J	Alm, RA; Ling, LSL; Moir, DT; King, BL; Brown, ED; Doig, PC; Smith, DR; Noonan, B; Guild, BC; deJonge, BL; Carmel, G; Tummino, PJ; Caruso, A; Uria-Nickelsen, M; Mills, DM; Ives, C; Gibson, R; Merberg, D; Mills, SD; Jiang, Q; Taylor, DE; Vovis, GF; Trost, TJ				Alm, RA; Ling, LSL; Moir, DT; King, BL; Brown, ED; Doig, PC; Smith, DR; Noonan, B; Guild, BC; deJonge, BL; Carmel, G; Tummino, PJ; Caruso, A; Uria-Nickelsen, M; Mills, DM; Ives, C; Gibson, R; Merberg, D; Mills, SD; Jiang, Q; Taylor, DE; Vovis, GF; Trost, TJ			Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori	NATURE			English	Article							ESCHERICHIA-COLI; DIVERSITY; STRAINS	Helicobacter pylori, one of the most common bacterial pathogens of humans, colonizes the gastric mucosa, where it appears to persist throughout the host's life unless the patient is treated. Colonization induces chronic gastric inflammation which can progress to a variety of diseases, ranging in severity from superficial gastritis and peptic ulcer to gastric cancer and mucosal-associated lymphoma(1). Strain-specific genetic diversity has been proposed to be involved in the organism's ability to cause different diseases or even be beneficial to the infected host(2,3) and to participate in the lifelong chronicity of infection(4). Here we compare the complete genomic sequences of two unrelated H. pylori isolates. This is, to our knowledge, the first such genomic comparison. H. pylori was believed to exhibit a large degree of genomic and allelic diversity, but we find that the overall genomic organization, gene order and predicted proteomes (sets of proteins encoded by the genomes) of the two strains are quite similar, Between 6 to 7% of the genes are specific to each strain, with almost half of these genes being clustered in a single hypervariable region.	Astra Res Ctr Boston, Cambridge, MA 02139 USA; Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Canadian Bacterial Dis Network, Edmonton, AB T6G 2H7, Canada; Genome Therapeut Corp, Waltham, MA 02453 USA	University of Alberta; University of Alberta	Alm, RA (corresponding author), Astra Res Ctr Boston, 128 Sidney St, Cambridge, MA 02139 USA.	richard.alm@arch.us.astra.com	King, Benjamin/AAI-1492-2019; DeJonge, Boudewijn/AAR-6717-2020	King, Benjamin/0000-0001-6463-1336; Ling, Losee/0000-0002-5368-6777				Akopyants NS, 1998, MOL MICROBIOL, V28, P37, DOI 10.1046/j.1365-2958.1998.00770.x; AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P6221, DOI 10.1093/nar/20.23.6221; Atherton JC, 1997, GASTROENTEROLOGY, V112, P92, DOI 10.1016/S0016-5085(97)70223-3; Blaser MJ, 1997, LANCET, V349, P1020, DOI 10.1016/S0140-6736(96)09133-7; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; COVER TL, 1992, ANNU REV MED, V43, P135, DOI 10.1146/annurev.me.43.020192.001031; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; Fock KM, 1998, GASTROENTEROLOGY, V114, pA596, DOI 10.1016/S0016-5085(98)82429-3; Han J, 1997, MOL CELLS, V7, P544; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Jiang Q, 1996, MOL MICROBIOL, V20, P833, DOI 10.1111/j.1365-2958.1996.tb02521.x; Kansau I, 1996, RES MICROBIOL, V147, P661, DOI 10.1016/0923-2508(96)84023-X; Lee WK, 1997, APPL ENVIRON MICROB, V63, P4866, DOI 10.1128/AEM.63.12.4866-4871.1997; Logan RPH, 1996, LANCET, V348, P1462, DOI 10.1016/S0140-6736(05)65885-0; Sakagami T, 1996, GUT, V39, P639, DOI 10.1136/gut.39.5.639; Saunders NJ, 1998, MOL MICROBIOL, V27, P1091, DOI 10.1046/j.1365-2958.1998.00768.x; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Suerbaum S, 1998, GENE, V210, P151, DOI 10.1016/S0378-1119(98)00065-1; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483	20	1481	2145	2	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1999	397	6715					176	180		10.1038/16495	http://dx.doi.org/10.1038/16495			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923682				2022-12-28	WOS:000078085000050
J	Johansson, CB; Momma, S; Clarke, DL; Risling, M; Lendahl, U; Frisen, J				Johansson, CB; Momma, S; Clarke, DL; Risling, M; Lendahl, U; Frisen, J			Identification of a neural stem cell in the adult mammalian central nervous system	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; SUBVENTRICULAR ZONE; CNS PRECURSOR; GENE-TRANSFER; RAT-BRAIN; FOREBRAIN; NEURONS; IMMUNOREACTIVITY; EXPRESSION; GENERATION	New neurons are continuously added in specific regions of the adult mammalian central nervous system. These neurons are derived from multipotent stem cells whose identity has been enigmatic. In this work, we present evidence that ependymal cells are neural stem cells. Ependymal cells give rise to a rapidly proliferating cell type that generates neurons that migrate to the olfactory bulb. In response to spinal cord injury, ependymal cell proliferation increases dramatically to generate migratory cells that differentiate to astrocytes and participate in scar formation. These data demonstrate that ependymal cells are neural stem cells and identify a novel process in the response to central nervous system injury.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Med Nobel Inst, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Frisen, J (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.			Lendahl, Urban/0000-0001-9543-8141				ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; Davidson BL, 1997, EXP NEUROL, V144, P125, DOI 10.1006/exnr.1996.6398; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DELBIGIO MR, 1995, GLIA, V14, P1, DOI 10.1002/glia.440140102; Doetsch F, 1997, J NEUROSCI, V17, P5046; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; Gage FH, 1998, NATURE, V392, P18; Goldman SA, 1998, TRENDS NEUROSCI, V21, P107, DOI 10.1016/S0166-2236(97)01191-0; Gritti A, 1996, J NEUROSCI, V16, P1091; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; KAWAMATA S, 1995, ACTA ANAT, V152, P205; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; MCKAY R, 1997, SCIENCE, V276, P6671; MITSIADIS TA, 1995, J CELL BIOL, V130, P407, DOI 10.1083/jcb.130.2.407; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SANES JR, 1989, TRENDS NEUROSCI, V12, P21, DOI 10.1016/0166-2236(89)90152-5; SVENDSEN CN, 1995, EXP BRAIN RES, V102, P407; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Weiss S, 1996, J NEUROSCI, V16, P7599; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	36	1534	1691	4	125	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 8	1999	96	1					25	34		10.1016/S0092-8674(00)80956-3	http://dx.doi.org/10.1016/S0092-8674(00)80956-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989494	Bronze			2022-12-28	WOS:000078023200005
J	Rudd, CE				Rudd, CE			Adaptors and molecular scaffolds in immune cell signaling	CELL			English	Review							TYROSINE KINASE; CLONING; PROTEIN; SLP-76		Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Rudd, CE (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.		Rudd, Christopher E/GOH-2021-2022; Rudd, Christopher E/ABF-7259-2021	Rudd, Christopher E/0000-0001-5295-9019; 				Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; Fang N, 1996, J IMMUNOL, V157, P3769; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Liu J, 1998, P NATL ACAD SCI USA, V95, P8779, DOI 10.1073/pnas.95.15.8779; LIU SK, 1999, IN PRESS CURR BIOL; LUPHER ML, 1999, IN PRESS J BIOL CHEM, V274; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Peterson EJ, 1998, CURR OPIN IMMUNOL, V10, P337, DOI 10.1016/S0952-7915(98)80173-8; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; RAAB M, 1997, IMMUNITY, V6, P1; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rudd CE, 1998, CURR BIOL, V8, pR805, DOI 10.1016/S0960-9822(07)00505-2; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; WARDENBURG JB, 1996, J BIOL CHEM, V271, P19642; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; ZHANG W, 1998, IMMUNITY, V9, P1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	28	191	195	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 8	1999	96	1					5	8		10.1016/S0092-8674(00)80953-8	http://dx.doi.org/10.1016/S0092-8674(00)80953-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989491	Bronze			2022-12-28	WOS:000078023200002
J	Almond, S				Almond, S			Memorable patients - High altitude medicine	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1999	318	7181					455	455		10.1136/bmj.318.7181.455	http://dx.doi.org/10.1136/bmj.318.7181.455			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BF	9974467	Green Published			2022-12-28	WOS:000078670100035
J	Mintova, S; Olson, NH; Valtchev, V; Bein, T				Mintova, S; Olson, NH; Valtchev, V; Bein, T			Mechanism of zeolite a nanocrystal growth from colloids at room temperature	SCIENCE			English	Article							MOLECULAR-SIEVE CRYSTALS; LIGHT-SCATTERING; ELECTRON-MICROSCOPY; TPA-SILICALITE-1; FILMS; CRYSTALLIZATION; SPECTROSCOPY; NUCLEATION; LAYERS; NMR	The formation and growth of crystal nuclei of zeolite A from clear solutions at room temperature were studied with Low-dose, high-resolution transmission electron microscopy in field emission mode and with in situ dynamic Light scattering. Single zeolite A crystals nucleated in amorphous gel particles of 40 to 80 nanometers within 3 days at room temperature. The resulting nanoscale single crystals (10 to 30 nanometers) were embedded in the amorphous gel particles. The gel particles were consumed during further crystal growth at room temperature, forming a colloidal suspension of zeolite A nanocrystals of 40 to 80 nanometers, On heating this suspension at 80 degrees C, solution-mediated transport resulted in additional substantial crystal growth.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; Purdue Univ, Dept Biol, W Lafayette, IN 47907 USA; Bulgarian Acad Sci, Cent Lab Mineral & Crystallog, Sofia 1000, Bulgaria	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Bulgarian Academy of Sciences	Bein, T (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.		Mintova, Svetlana/N-7933-2018; Bein, Thomas/G-7686-2014	Mintova, Svetlana/0000-0002-0738-5244; Bein, Thomas/0000-0001-7248-5906	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033050, R01GM033050] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33050] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baerlocher C., 1996, ATLAS ZEOLITE STRUCT; BEHRENS P, 1996, COMPREHENSIVE SUPRAM, V7, P721; Bein T, 1996, CHEM MATER, V8, P1636, DOI 10.1021/cm960148a; Breck D. W., 1974, ZEOLITE MOL SIEVES; BURKETT SL, 1994, J PHYS CHEM-US, V98, P4647, DOI 10.1021/j100068a027; BURKETT SL, 1996, COMPREHENSIVE SUPRAM, V7, P465; Corkery RW, 1997, ZEOLITES, V18, P379, DOI 10.1016/S0144-2449(97)81256-0; CUNDY CS, 1995, ZEOLITES, V15, P342, DOI 10.1016/0144-2449(94)00042-Q; DAVIS ME, 1992, CHEM MATER, V4, P756, DOI 10.1021/cm00022a005; DOKTER WH, 1995, ANGEW CHEM INT EDIT, V34, P73, DOI 10.1002/anie.199500731; DOUGHERTY J, 1995, ZEOLITES, V15, P640, DOI 10.1016/0144-2449(95)00045-8; FENG S, 1994, SCIENCE, V265, P1839, DOI 10.1126/science.265.5180.1839; FENG S, 1994, NATURE, V368, P834, DOI 10.1038/368834a0; GIER TE, 1991, NATURE, V349, P508, DOI 10.1038/349508a0; Gora L, 1997, ZEOLITES, V18, P119, DOI 10.1016/S0144-2449(96)00144-3; Gora L, 1997, ZEOLITES, V18, P132, DOI 10.1016/S0144-2449(96)00163-7; KESSLER H, 1996, COMPREHENSIVE SUPRAM, V7, P425; Mintova S, 1997, ADV MATER, V9, P585; OZIN GA, 1992, ADV MATER, V4, P612, DOI 10.1002/adma.19920041003; PERSSON AE, 1994, ZEOLITES, V14, P557, DOI 10.1016/0144-2449(94)90191-0; Ravishankar R, 1998, J PHYS CHEM B, V102, P2633, DOI 10.1021/jp973147u; REGEV O, 1994, ZEOLITES, V14, P314, DOI 10.1016/0144-2449(94)90103-1; SAND LB, 1987, ZEOLITES, V7, P387, DOI 10.1016/0144-2449(87)90001-7; SCHOEMAN BJ, 1994, ZEOLITES, V14, P110, DOI 10.1016/0144-2449(94)90004-3; Schoeman BJ, 1997, ZEOLITES, V18, P97, DOI 10.1016/S0144-2449(96)00134-0; Tsapatsis M, 1996, MICROPOROUS MATER, V5, P381, DOI 10.1016/0927-6513(95)00069-0; TWOMEY TAM, 1994, ZEOLITES, V14, P162, DOI 10.1016/0144-2449(94)90150-3; YAN YA, 1995, J AM CHEM SOC, V117, P9990, DOI 10.1021/ja00145a008; Zhu GS, 1998, CHEM MATER, V10, P1483, DOI 10.1021/cm980061k	29	540	556	12	453	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					958	960		10.1126/science.283.5404.958	http://dx.doi.org/10.1126/science.283.5404.958			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974382				2022-12-28	WOS:000078574800039
J	Dimitrakopoulos, CD; Purushothaman, S; Kymissis, J; Callegari, A; Shaw, JM				Dimitrakopoulos, CD; Purushothaman, S; Kymissis, J; Callegari, A; Shaw, JM			Low-voltage organic transistors on plastic comprising high-dielectric constant gate insulators	SCIENCE			English	Article							FIELD-EFFECT TRANSISTOR; THIN-FILM TRANSISTORS; HIGH-MOBILITY; SEMICONDUCTOR; PENTACENE; TRANSPORT; SILICON; DEVICE	The gate bias dependence of the field-effect mobility in pentacene-based insulated gate field-effect transistors (IGFETs) was interpreted on the basis of the interaction of charge carriers with localized trap levels in the band gap. This understanding was used to design and fabricate IGFETs with mobility of more than 0.3 square centimeter per volt per second and current modulation of 10(5), with the use of amorphous metal oxide gate insulators. These values were obtained at operating voltage ranges as low as 5 volts, which are much smaller than previously reported results. An all-room-temperature fabrication process sequence was used, which enabled the demonstration of high-performance organic IGFETs on transparent plastic substrates, at Low operating voltages for organic devices.	IBM Corp, Div Res, Thomas J Watson Res Ctr, Yorktown Heights, NY 10598 USA	International Business Machines (IBM)	Dimitrakopoulos, CD (corresponding author), IBM Corp, Div Res, Thomas J Watson Res Ctr, POB 218, Yorktown Heights, NY 10598 USA.		Kymissis, Ioannis/A-5994-2010	Kymissis, Ioannis/0000-0001-7417-1759; Dimitrakopoulos, Christos/0000-0003-1059-3498				Bao Z, 1996, APPL PHYS LETT, V69, P4108, DOI 10.1063/1.117834; BROWN AR, 1995, SCIENCE, V270, P972, DOI 10.1126/science.270.5238.972; Brown AR, 1997, SYNTHETIC MET, V88, P37, DOI 10.1016/S0379-6779(97)80881-8; BURROUGHES JH, 1988, NATURE, V335, P137, DOI 10.1038/335137a0; Dimitrakopoulos CD, 1996, J APPL PHYS, V80, P2501, DOI 10.1063/1.363032; Dimitrakopoulos CD, 1998, SYNTHETIC MET, V92, P47, DOI 10.1016/S0379-6779(98)80021-0; DIMITRAKOPOULOS CD, UNPUB; DODABALAPUR A, 1995, SCIENCE, V268, P270, DOI 10.1126/science.268.5208.270; Dodabalapur A, 1998, APPL PHYS LETT, V73, P142, DOI 10.1063/1.121736; Frenkel J, 1938, PHYS REV, V54, P647, DOI 10.1103/PhysRev.54.647; GARNIER F, 1994, SCIENCE, V265, P1684, DOI 10.1126/science.265.5179.1684; HOROWITZ G, 1995, J PHYS III, V5, P355, DOI 10.1051/jp3:1995132; Horowitz G, 1998, ADV MATER, V10, P365, DOI 10.1002/(SICI)1521-4095(199803)10:5<365::AID-ADMA365>3.0.CO;2-U; HOROWITZ G, 1992, SYNTHETIC MET, V51, P419, DOI 10.1016/0379-6779(92)90297-V; HOROWITZ G, 1989, SOLID STATE COMMUN, V72, P381, DOI 10.1016/0038-1098(89)90121-X; Laquindanum JG, 1996, CHEM MATER, V8, P2542, DOI 10.1021/cm9603664; LECOMBER PG, 1970, PHYS REV LETT, V25, P509, DOI 10.1103/PhysRevLett.25.509; Lin Y. Y., 1996, ANN DEV RES C, V54, P80; Lin YY, 1997, IEEE T ELECTRON DEV, V44, P1325, DOI 10.1109/16.605476; MADRU M, 1987, CHEM PHYS LETT, V142, P103, DOI 10.1016/0009-2614(87)87259-7; MUZIKANTE I, 1995, ACTA PHYS POL A, V88, P389, DOI 10.12693/APhysPolA.88.389; Service RF, 1996, SCIENCE, V273, P879; Sze S M, 1981, PHYS SEMICONDUCTOR D, P442; TSUMURA A, 1986, APPL PHYS LETT, V49, P1210, DOI 10.1063/1.97417	24	797	834	1	173	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					822	824		10.1126/science.283.5403.822	http://dx.doi.org/10.1126/science.283.5403.822			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933160				2022-12-28	WOS:000078496800037
J	MacFadden, BJ; Solounias, N; Cerling, TE				MacFadden, BJ; Solounias, N; Cerling, TE			Ancient diets, ecology, and extinction of 5-million-year-old horses from Florida	SCIENCE			English	Article							CARBON ISOTOPES; NORTH-AMERICA; PHOTOSYNTHESIS; EVOLUTION; CLIMATE; WORLD	Six sympatric species of 5-million-year-old (Late Hemphillian) horses from Florida existed during a time of major global change and extinction in terrestrial ecosystems. Traditionally, these horses were interpreted to have fed on abrasive grasses because of their high-crowned teeth. However, carbon isotopic and tooth microwear data indicate that these horses were not ail C-4 grazers but also included mixed feeders and C-3 browsers. The late Hemphillian Florida sister species of the modern genus Equus was principally a browser, unlike the grazing diet of modern equids. Late Hemphillian horse extinctions in Florida involved two grazing and one browsing species.	Univ Florida, Florida Museum Nat Hist, Gainesville, FL 32611 USA; New York Inst Technol, New York Coll Osteopath Med, Dept Anat, Old Westbury, NY 11568 USA; Univ Utah, Dept Geol & Geophys, Salt Lake City, UT 84112 USA	State University System of Florida; University of Florida; New York Institute Technology; Utah System of Higher Education; University of Utah	MacFadden, BJ (corresponding author), Univ Florida, Florida Museum Nat Hist, Gainesville, FL 32611 USA.	bmacfadd@flmnh.ufl.edu		Cerling, Thure/0000-0002-3590-294X				BENNETT DK, 1980, SYST ZOOL, V29, P272, DOI 10.2307/2412662; Cerling T.E., 1997, STABLE ISOTOPES INTE, P363; CERLING TE, 1993, NATURE, V361, P344, DOI 10.1038/361344a0; EHLERINGER JR, 1991, TRENDS ECOL EVOL, V6, P95, DOI 10.1016/0169-5347(91)90183-X; Ehleringer JR, 1997, OECOLOGIA, V112, P285, DOI 10.1007/s004420050311; EISENBERG JF, 1983, MAMMALIAN RAD; FARQUHAR GD, 1989, ANNU REV PLANT PHYS, V40, P503, DOI 10.1146/annurev.pp.40.060189.002443; HULBERT RC, 1988, J VERTEBR PALEONTOL, V7, P451; Hulbert Richard C. Jr, 1992, Papers in Florida Paleontology, V6, P1; Janis C.M., 1988, Memoires du Museum National d'Histoire Naturelle Serie C Sciences de la Terre, V53, P367; KOCH PL, 1992, NATURE, V358, P319, DOI 10.1038/358319a0; Kowalevsky V., 1873, MEM ACAD IMP SCI ST, V20; LEETHORP JA, 1987, S AFR J SCI, V83, P712; MacFadden B.J., 1992, FOSSIL HORSES; MacFadden BJ, 1997, TRENDS ECOL EVOL, V12, P182, DOI 10.1016/S0169-5347(97)01049-5; Macfadden BJ, 1996, J VERTEBR PALEONTOL, V16, P103, DOI 10.1080/02724634.1996.10011288; MACFADDEN BJ, 1986, PALEOBIOLOGY, V12, P355, DOI 10.1017/S0094837300003109; MacFadden BJ, 1998, PALEOBIOLOGY, V24, P274; Matthew WD, 1926, Q REV BIOL, V1, P139, DOI 10.1086/394242; Myers RL, 1990, ECOSYSTEMS FLORIDA; QUADE J, 1992, CHEM GEOL, V94, P183, DOI 10.1016/0168-9622(92)90011-X; Simpson G. G., 1953, MAJOR FEATURES EVOLU, DOI DOI 10.7312/SIMP93764; SOLOUNIAS N, 1988, PALEOBIOLOGY, V14, P287, DOI 10.1017/S009483730001201X; SOLOUNIAS N, 1993, J ZOOL, V229, P421, DOI 10.1111/j.1469-7998.1993.tb02646.x; Walker EP., 1975, MAMMALS WORLD; WANG Y, 1994, PALAEOGEOGR PALAEOCL, V107, P269, DOI 10.1016/0031-0182(94)90099-X; Webb S. D., 1983, COEVOLUTION, P267; WEBB SD, 1977, ANNU REV ECOL SYST, V8, P355, DOI 10.1146/annurev.es.08.110177.002035; Webb SD, 1995, PALEOCLIMATE AND EVOLUTION, WITH EMPHASIS ON HUMAN ORIGINS, P91; Wunderlin R.P., 1998, GUIDE VASCULAR PLANT	30	165	179	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1999	283	5403					824	827		10.1126/science.283.5403.824	http://dx.doi.org/10.1126/science.283.5403.824			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933161				2022-12-28	WOS:000078496800038
J	Rosing, MT				Rosing, MT			C-13-depleted carbon microparticles in > 3700-Ma sea-floor sedimentary rocks from west Greenland	SCIENCE			English	Article							SUPRACRUSTAL BELT; EARTH; LIFE; RECORD	Turbiditic and pelagic sedimentary rocks from the Isua supracrustal belt in west Greenland [more than 3700 million years ago (Ma)] contain reduced carbon that is Likely biogenic. The carbon is present as 2- to 5-micrometer graphite globules and has an isotopic composition of delta(13)C that is about -19 per mil (Pee Dee belemnite standard). These data and the mode of occurrence indicate that the reduced carbon represents biogenic detritus, which was perhaps derived from planktonic organisms.	Geol Museum, DK-1350 Kobenhavn K, Denmark; Danish Lithosphere Ctr, DK-1350 Kobenhavn, Denmark		Rosing, MT (corresponding author), Geol Museum, Oster Voldgade 5-7, DK-1350 Kobenhavn K, Denmark.		Rosing, Minik/A-9977-2013	Rosing, Minik/0000-0001-7559-661X				Appel PWU, 1998, TERRA NOVA, V10, P57; BOAK JL, 1982, EARTH PLANET SC LETT, V59, P155, DOI 10.1016/0012-821X(82)90123-6; Bouma A.H, 1962, SEDIMENTOLOGY SOME F, P168; Eiler JM, 1997, NATURE, V386, P665, DOI 10.1038/386665a0; FREI R, IN PRESS GEOCHIM COS; GILL RCO, 1981, SPEC PUBL GEOL SOC A, V7, P313; Gruau G, 1996, CHEM GEOL, V133, P225, DOI 10.1016/S0009-2541(96)00092-7; Komiya T, 1995, EOS T, V76, P700; MCLENNAN SM, 1990, GEOCHIM COSMOCHIM AC, V54, P2015, DOI 10.1016/0016-7037(90)90269-Q; Mojzsis SJ, 1996, NATURE, V384, P55, DOI 10.1038/384055a0; MOLAK B, 1996, SLOVAK GEOL MAG, V1, P27; MOORBATH S, 1998, MINERAL MAG A, V62, P1019; Naraoka H, 1996, CHEM GEOL, V133, P251, DOI 10.1016/S0009-2541(96)00076-9; Nutman AP, 1997, GEOCHIM COSMOCHIM AC, V61, P2475, DOI 10.1016/S0016-7037(97)00097-5; Nutman AP, 1997, CHEM GEOL, V141, P271, DOI 10.1016/S0009-2541(97)00084-3; NUTMAN TB, 1986, J INFECT DIS, V154, P1; OEHLER DZ, 1977, PRECAMBRIAN RES, V5, P221, DOI 10.1016/0301-9268(77)90029-8; PERRY EC, 1977, EARTH PLANET SC LETT, V36, P280, DOI 10.1016/0012-821X(77)90210-2; Rose NM, 1996, AM J SCI, V296, P1004, DOI 10.2475/ajs.296.9.1004; Rosing MT, 1996, GEOLOGY, V24, P43, DOI 10.1130/0091-7613(1996)024<0043:EPOESS>2.3.CO;2; SCHIDLOWSKI M, 1979, GEOCHIM COSMOCHIM AC, V43, P189, DOI 10.1016/0016-7037(79)90238-2; SCHIDLOWSKI M, 1988, NATURE, V333, P313, DOI 10.1038/333313a0; SCHULTZE S, 1998, MINERAL MAG A, V62, P1356; Shanmugam G, 1997, EARTH-SCI REV, V42, P201, DOI 10.1016/S0012-8252(97)81858-2; SHOPF JW, 1994, P NATL ACAD SCI USA, V91, P6735; Whitehouse M. J., 1998, MINERAL MAG A, V62A, P1649, DOI [10.1180/minmag.1998.62A.3.197, DOI 10.1180/MINMAG.1998.62A.3.197]	26	447	464	3	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					674	676		10.1126/science.283.5402.674	http://dx.doi.org/10.1126/science.283.5402.674			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924024				2022-12-28	WOS:000078324400038
J	Meikle, PJ; Hopwood, JJ; Clague, AE; Carey, WF				Meikle, PJ; Hopwood, JJ; Clague, AE; Carey, WF			Prevalence of lysosomal storage disorders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; PALMITOYL PROTEIN THIOESTERASE; DISEASES; DIAGNOSIS; MUTATIONS; GENE	Context Lysosomal storage disorders represent a group of at least 41 genetically distinct, biochemically related, inherited diseases. Individually. these disorders are con considered rare, although high prevalence values have been reported in some populations. These disorders are devastating for individuals and their families and result in considerable use of resources from health care systems; however, the magnitude of the problem is not well defined. To date, no comprehensive study has been performed on the prevalence of these disorders as a group. Objective To determine the prevalence of lysosomal storage disorders individually and as a group in the Australian population. Design Retrospective case studies. Setting Australia, from January 1, 1980, through December 31, 1996. Main Outcome Measure Enzymatic diagnosis of a lysosomal storage disorder. Results Twenty-seven different lysosomal storage disorders were diagnosed in 545 individuals. The prevalence ranged from 1 per 57 000 live births for Gaucher disease to 1 per 4.2 million live births for sialidosis. Eighteen of 27 disorders had more than 10 diagnosed cases. As a group of disorders, the combined prevalence was 1 per 7700 live births. There was no significant increase in the rate of either clinical diagnoses or prenatal diagnoses of lysosomal storage disorders during the study period. Conclusions Individually, lysosomal storage disorders are rare genetic diseases. However. as a group, they are relatively common and represent an important health problem in Australia.	Womens & Childrens Hosp, Dept Chem Pathol, Lysosomal Dis Res Unit, Adelaide, SA, Australia; Womens & Childrens Hosp, Dept Chem Pathol, Natl Referal Lab, Adelaide, SA, Australia; Queensland Hlth Pathol Serv, Div Chem Pathol, Brisbane, Qld, Australia	Womens & Childrens Hospital Australia; Womens & Childrens Hospital Australia; Queensland Health	Meikle, PJ (corresponding author), Womens & Childrens Hosp, Dept Chem Pathol, Lysosomal Dis Res Unit, 72 King William Rd, N Adelaide, SA 5006, Australia.		Meikle, Peter J/B-4023-2009	Meikle, Peter/0000-0002-2593-4665				ARVIO M, 1993, ACTA PAEDIATR, V82, P587, DOI 10.1111/j.1651-2227.1993.tb12761.x; Beutler E, 1995, METABOLIC MOL BASES, P2641; CLAUSSEN M, 1992, AM J MED GENET, V42, P536, DOI 10.1002/ajmg.1320420422; Coelho JC, 1997, EUR J PEDIATR, V156, P650, DOI 10.1007/s004310050685; CZARTORYSKA B, 1993, PEDIATR NEUROL, V11, P295; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Hellsten E, 1996, EMBO J, V15, P5240, DOI 10.1002/j.1460-2075.1996.tb00909.x; Hopwood JJ, 1997, ORGANELLE DIS, P7; KRASNOPOLSKAYA KD, 1993, J INHERIT METAB DIS, V16, P994, DOI 10.1007/BF00711517; LOWRY RB, 1990, HUM GENET, V85, P389; Meikle PJ, 1997, CLIN CHEM, V43, P1325; Michelakakis H., 1995, Genetic Counseling, V6, P43; NEUFELD EF, 1995, METABOLIC MOL BASES, V2, P2465; OZAND PT, 1990, J INHERIT METAB DIS, V13, P849, DOI 10.1007/BF01800209; PETERSEN GM, 1983, AM J HUM GENET, V35, P1258; Rider J A, 1988, Am J Med Genet Suppl, V5, P21; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; VANDEKAMP JJP, 1981, CLIN GENET, V20, P152; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0	20	1492	1594	1	124	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1999	281	3					249	254		10.1001/jama.281.3.249	http://dx.doi.org/10.1001/jama.281.3.249			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157GK	9918480	Bronze			2022-12-28	WOS:000078052800030
J	Fleck, BW				Fleck, BW			Therapy for retinopathy of prematurity	LANCET			English	Editorial Material							DIODE-LASER PHOTOCOAGULATION; THRESHOLD RETINOPATHY		Univ Edinburgh, Royal Infirm, Dept Ophthalmol, Edinburgh EH3 9HA, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh	Fleck, BW (corresponding author), Univ Edinburgh, Royal Infirm, Dept Ophthalmol, Edinburgh EH3 9HA, Midlothian, Scotland.							CAPONE A, 1993, AM J OPHTHALMOL, V116, P444, DOI 10.1016/S0002-9394(14)71402-3; CUNNINGHAM S, 1995, LANCET, V346, P1464, DOI 10.1016/S0140-6736(95)92475-2; Elsas FJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P417; GARNER A, 1984, ARCH OPHTHALMOL-CHIC, V102, P1130; Matsuo T, 1997, JPN J OPHTHALMOL, V41, P428, DOI 10.1016/S0021-5155(97)00077-4; McGregor M L, 1998, J AAPOS, V2, P360, DOI 10.1016/S1091-8531(98)90035-0; MCNAMARA JA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1714, DOI 10.1001/archopht.1992.01080240054029; Nagata M, 1968, JPN J OPHTHALMOL, V22, P419; O'Keefe M, 1998, BRIT J OPHTHALMOL, V82, P1246, DOI 10.1136/bjo.82.11.1246; Pearce IA, 1998, BRIT J OPHTHALMOL, V82, P1254, DOI 10.1136/bjo.82.11.1254; White JE, 1997, J PEDIAT OPHTH STRAB, V34, P83	11	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					166	167		10.1016/S0140-6736(05)77211-1	http://dx.doi.org/10.1016/S0140-6736(05)77211-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923868				2022-12-28	WOS:000078175600005
J	Petersen, RB				Petersen, RB			Antemortem diagnosis of variant Creutzfeldt-Jakob disease	LANCET			English	Editorial Material							BSE		Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA	Case Western Reserve University	Petersen, RB (corresponding author), Case Western Reserve Univ, Dept Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.		Petersen, Robert/B-5075-2011	Petersen, Robert/0000-0002-3154-0072				Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Collinge J, 1997, NATURE, V386, P233, DOI 10.1038/386233a0; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hilton DA, 1998, LANCET, V352, P703, DOI 10.1016/S0140-6736(98)24035-9; Parchi P, 1997, NATURE, V386, P232, DOI 10.1038/386232a0; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Schreuder BEC, 1998, VET REC, V142, P564, DOI 10.1136/vr.142.21.564	8	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					163	164		10.1016/S0140-6736(05)77209-3	http://dx.doi.org/10.1016/S0140-6736(05)77209-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923866				2022-12-28	WOS:000078175600003
J	Nelken, I; Rotman, Y; Bar Yosef, O				Nelken, I; Rotman, Y; Bar Yosef, O			Responses of auditory-cortex neurons to structural features of natural sounds	NATURE			English	Article							COMODULATION MASKING RELEASE; MODULATION; REPRESENTATION; CAT	Sound-processing strategies that use the highly non-random structure off natural sounds may confer evolutionary advantage to many species. Auditory processing of natural sounds has been studied almost exclusively in the context of species-specific vocalizations(1-4), although these form only a small part of the acoustic biotope(5), To study the relationships between properties of natural soundscapes and neuronal processing mechanisms in the auditory system, we analysed sound from a range of different environments. Here we show that for many non-animal sounds and background mixtures of animal sounds, energy in different frequency bands is coherently modulated. Co-modulation of different frequency bands in background noise facilitates the detection of tones in noise by humans, a phenomenon known as co-modulation masking release (CMR)(6,7). We show that comodulation also improves the ability of auditory-cortex neurons to detect tones in noise, and we propose that this property of auditory neurons may underlie behavioural CMR. This correspondence may represent an adaptation of the auditory system for the use of an attribute of natural sounds to facilitate real-world processing tasks.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Physiol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Nelken, I (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Physiol, POB 12272, IL-91120 Jerusalem, Israel.	israel@music.md.huji.ac.il	Nelken, Israel/B-7753-2011; Rotman, Yaron/AAK-8032-2020	Nelken, Israel/0000-0002-6645-107X; Rotman, Yaron/0000-0002-7549-8216				AERTSEN AMHJ, 1979, BIOL CYBERN, V32, P175, DOI 10.1007/BF00337394; CARLYON RP, 1989, HEARING RES, V42, P37, DOI 10.1016/0378-5955(89)90116-0; EGGERMONT JJ, 1994, HEARING RES, V74, P51, DOI 10.1016/0378-5955(94)90175-9; HALL JW, 1984, J ACOUST SOC AM, V76, P50, DOI 10.1121/1.391005; KLUMP GM, 1995, HEARING RES, V87, P157, DOI 10.1016/0378-5955(95)00087-K; Pelleg-Toiba R., 1991, Journal of Basic and Clinical Physiology and Pharmacology, V2, P257; RAUSCHECKER JP, 1995, SCIENCE, V268, P111, DOI 10.1126/science.7701330; RHODE WS, 1995, 18 ASS RES OT M ST P, P127; RICHARDS DG, 1980, AM NAT, V115, P381, DOI 10.1086/283568; SCHOONEVELDT GP, 1989, J ACOUST SOC AM, V85, P273, DOI 10.1121/1.397734; SCHREINER CE, 1988, HEARING RES, V32, P49, DOI 10.1016/0378-5955(88)90146-3; STEINSCHNEIDER M, 1990, BRAIN RES, V519, P158, DOI 10.1016/0006-8993(90)90074-L; SUGA N, 1992, PHILOS T ROY SOC B, V336, P423, DOI 10.1098/rstb.1992.0078; Wang XQ, 1995, J NEUROPHYSIOL, V74, P2685, DOI 10.1152/jn.1995.74.6.2685	15	243	247	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 14	1999	397	6715					154	157		10.1038/16456	http://dx.doi.org/10.1038/16456			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923676				2022-12-28	WOS:000078085000044
J	Bilwes, AM; Alex, LA; Crane, BR; Simon, MI				Bilwes, AM; Alex, LA; Crane, BR; Simon, MI			Structure of CheA, a signal-transducing histidine kinase	CELL			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DNA GYRASE; INTERMOLECULAR COMPLEMENTATION; MULTISTEP PHOSPHORELAY; BACTERIAL CHEMOTAXIS; PROTEIN STRUCTURES; BACILLUS-SUBTILIS; DIFFRACTION DATA; DOMAIN	Histidine kinases allow bacteria, plants, and fungi to sense and respond to their environment. The 2.6 Angstrom resolution crystal structure of Thermotoga maritima CheA (290-671) histidine kinase reveals a dimer where the functions of dimerization, ATP binding, and regulation are segregated into domains. The kinase domain is unlike Ser/Thr/Tyr kinases but resembles two ATPases, Gyrase B and Hsp90. Structural analogies within this superfamily suggest that the P1 domain of CheA provides the nucleophilic histidine and activating glutamate for phosphotransfer. The regulatory domain, which binds the homologous receptor-coupling protein CheW, topologically resembles two SH3 domains and provides different protein recognition surfaces at each end. The dimerization domain forms a central four-helix bundle about which the kinase and regulatory domains pivot on conserved hinges to modulate transphosphorylation. Different subunit conformations suggest that relative domain motions link receptor response to kinase activity.	CALTECH, Dept Biol, Pasadena, CA 91125 USA; CALTECH, Dept Chem, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Simon, MI (corresponding author), CALTECH, Dept Biol, Pasadena, CA 91125 USA.	simonm@cco.caltech.edu		Bilwes Crane, Alexandrine/0000-0001-9922-0692	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019296] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19296] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Appleby JL, 1996, CELL, V86, P845, DOI 10.1016/S0092-8674(00)80158-0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bates AD, 1997, CURR BIOL, V7, pR778, DOI 10.1016/S0960-9822(06)00403-9; BOURRET RB, 1993, J BACTERIOL, V175, P2097, DOI 10.1128/JB.175.7.2097-2101.1993; BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CHOU KC, 1988, P NATL ACAD SCI USA, V85, P4295, DOI 10.1073/pnas.85.12.4295; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Crane BR, 1997, ACTA CRYSTALLOGR D, V53, P23, DOI 10.1107/S0907444996007263; EISENHABER F, 1995, CRIT REV BIOCHEM MOL, V30, P1, DOI 10.3109/10409239509085139; FREDRICK KL, 1994, J BACTERIOL, V176, P2727, DOI 10.1128/JB.176.9.2727-2735.1994; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Holdgate GA, 1997, BIOCHEMISTRY-US, V36, P9663, DOI 10.1021/bi970294+; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Kato M, 1997, CELL, V88, P717, DOI 10.1016/S0092-8674(00)81914-5; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; KOFOID EC, 1988, P NATL ACAD SCI USA, V85, P4981, DOI 10.1073/pnas.85.14.4981; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McEvoy MM, 1998, P NATL ACAD SCI USA, V95, P7333, DOI 10.1073/pnas.95.13.7333; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morrison TB, 1997, J BACTERIOL, V179, P5543, DOI 10.1128/jb.179.17.5543-5550.1997; OOSAWA K, 1988, CELL, V53, P89, DOI 10.1016/0092-8674(88)90490-4; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Swanson RV, 1996, J BACTERIOL, V178, P484, DOI 10.1128/jb.178.2.484-489.1996; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; SWANSON RV, 1993, MOL MICROBIOL, V8, P435, DOI 10.1111/j.1365-2958.1993.tb01588.x; SWANSON RV, 1993, BIOCHEMISTRY-US, V32, P7623, DOI 10.1021/bi00081a004; Varughese KI, 1998, MOL CELL, V2, P485, DOI 10.1016/S1097-2765(00)80148-3; Welch M, 1998, NAT STRUCT BIOL, V5, P25, DOI 10.1038/nsb0198-25; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; ZHOU HJ, 1995, BIOCHEMISTRY-US, V34, P13858, DOI 10.1021/bi00042a018; Zhou HJ, 1997, BIOCHEMISTRY-US, V36, P699, DOI 10.1021/bi961663p	51	373	382	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 8	1999	96	1					131	141		10.1016/S0092-8674(00)80966-6	http://dx.doi.org/10.1016/S0092-8674(00)80966-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989504	Bronze			2022-12-28	WOS:000078023200015
J	Mahajan-Miklos, S; Tan, MW; Rahme, LG; Ausubel, FM				Mahajan-Miklos, S; Tan, MW; Rahme, LG; Ausubel, FM			Molecular mechanisms of bacterial virulence elucidated using a Pseudomonas aeruginosa Caenorhabditis elegans pathogenesis model	CELL			English	Article							ESCHERICHIA-COLI; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; SENSITIVE MUTANT; GENE; PATHOGENICITY; SYRINGAE; IDENTIFICATION; LONGEVITY; DIAPAUSE	The human opportunistic pathogen Pseudomonas aeruginosa strain PA14 kills Caenorhabditis elegans. Using systematic mutagenesis of PA14 to identify mutants that fail to kill C. elegans and a C. elegans mutant that lacks P-glycoproteins, we identified phenazines, secreted P. aeruginosa pigments, as one of the mediators of killing. Analysis of C. elegans mutants with altered responses to oxidative stress suggests that phenazines exert their toxic effects on C. elegans through the generation of reactive oxygen species. Finally, we show that phenazines and other P. aeruginosa factors required for C. elegans killing are also required for pathogenesis in plants and mice, illustrating that this model tackles the dual challenges of identifying bacterial virulence factors as well as host responses to them.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Soc Fellows, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Shriners Burns Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Ausubel, FM (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.							ANDERSON DM, 1985, PHYTOPATHOLOGY, V75, P104, DOI 10.1094/Phyto-75-104; ANDREW PA, 1976, NEMATOLOGICA, V22, P451, DOI 10.1163/187529276X00454; Arrigo AP, 1998, BIOL CHEM, V379, P19; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BRENNER S, 1974, GENETICS, V77, P71; BROEKS A, 1995, EMBO J, V14, P1858, DOI 10.1002/j.1460-2075.1995.tb07178.x; Camhi S L, 1995, New Horiz, V3, P170; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; DORING D, 1993, PSEUDOMONAS AERUGINO, P245; ESSAR DW, 1990, J BACTERIOL, V172, P884, DOI 10.1128/jb.172.2.884-900.1990; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; HARTMAN PS, 1982, GENETICS, V102, P159; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; ISHII N, 1993, MECH AGEING DEV, V68, P1, DOI 10.1016/0047-6374(93)90135-E; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; KENNEDY EP, 1996, ESCHERICHIA COLI SAL, P1064; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KING EO, 1954, J LAB CLIN MED, V44, P301; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LI XZ, 1995, ANTIMICROB AGENTS CH, V39, P1948, DOI 10.1128/AAC.39.9.1948; Lindquist S, 1992, CURR OPIN GENET DEV, V2, P748, DOI 10.1016/S0959-437X(05)80135-2; LOUBENS I, 1993, MOL MICROBIOL, V10, P329, DOI 10.1111/j.1365-2958.1993.tb01959.x; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; Mavrodi DV, 1998, J BACTERIOL, V180, P2541, DOI 10.1128/JB.180.9.2541-2548.1998; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; Miller J.H., 1972, EXPT MOL GENETICS; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; MUKHOPADHYAY P, 1988, J BACTERIOL, V170, P5479, DOI 10.1128/jb.170.12.5479-5488.1988; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; OHMAN DE, 1990, PSEUDOMONAS : BIOTRANSFORMATIONS, PATHOGENESIS, AND EVOLVING BIOTECHNOLOGY, P28; POOLE K, 1994, J ANTIMICROB CHEMOTH, V34, P453, DOI 10.1093/jac/34.4.453; POOLE K, 1993, MOL MICROBIOL, V10, P529, DOI 10.1111/j.1365-2958.1993.tb00925.x; RAHME LG, 1995, SCIENCE, V268, P1899, DOI 10.1126/science.7604262; Rahme LG, 1997, P NATL ACAD SCI USA, V94, P13245, DOI 10.1073/pnas.94.24.13245; Sage AE, 1997, MOL MICROBIOL, V23, P43, DOI 10.1046/j.1365-2958.1997.1681542.x; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SORENSEN RU, 1993, PSEUDOMONAS AERUGINO, P43; Strauss EJ, 1997, SCIENCE, V276, P707, DOI 10.1126/science.276.5313.707; STROM MS, 1986, J BACTERIOL, V165, P367, DOI 10.1128/jb.165.2.367-372.1986; Sulston J., 1988, NEMATODE CAENORHABDI, P587; TAN MW, 1999, IN PRESS P NATL ACAD; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TURNER JM, 1986, ADV MICROB PHYSIOL, V27, P211, DOI 10.1016/S0065-2911(08)60306-9; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; WILSON R, 1988, INFECT IMMUN, V56, P2515, DOI 10.1128/IAI.56.9.2515-2517.1988; Wood R E, 1976, Hosp Pract, V11, P91	50	580	624	4	76	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 8	1999	96	1					47	56		10.1016/S0092-8674(00)80958-7	http://dx.doi.org/10.1016/S0092-8674(00)80958-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989496	Bronze			2022-12-28	WOS:000078023200007
J	Penninger, JM; Crabtree, GR				Penninger, JM; Crabtree, GR			The actin cytoskeleton and lymphocyte activation	CELL			English	Review							T-CELL ACTIVATION; CDC42; VAV		Univ Toronto, Ontario Canc Inst, Amgen Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Dept Immunol, Toronto, ON M5G 2C1, Canada; Stanford Univ, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Howard Hughes Medical Institute; Stanford University	Penninger, JM (corresponding author), Univ Toronto, Ontario Canc Inst, Amgen Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada.		Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777				CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DEPETRIS S, 1973, NATURE-NEW BIOL, V241, P257, DOI 10.1038/newbio241257a0; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Kong YY, 1998, J EXP MED, V188, P2099, DOI 10.1084/jem.188.11.2099; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302	19	185	188	2	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 8	1999	96	1					9	12		10.1016/S0092-8674(00)80954-X	http://dx.doi.org/10.1016/S0092-8674(00)80954-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989492	Bronze			2022-12-28	WOS:000078023200003
J	Crawford, VLS; Beringer, TRO; Stout, RW				Crawford, VLS; Beringer, TRO; Stout, RW			Comparison of residential and nursing home care before and after the 1993 community care policy	BRITISH MEDICAL JOURNAL			English	Article									Queens Univ Belfast, Dept Geriatr Med, Belfast BT9 7BL, Antrim, North Ireland; Royal Victoria Hosp, Dept Hlth Care Elderly, Belfast BT12 6BA, Antrim, North Ireland	Queens University Belfast	Crawford, VLS (corresponding author), Queens Univ Belfast, Dept Geriatr Med, Whitla Med Bldg, Belfast BT9 7BL, Antrim, North Ireland.							Department of Health and Social Services NI, 1990, PEOPL 1 COMM CAR NO; MAHONEY F I, 1965, Md State Med J, V14, P61; NUTTALL SR, 1994, J I ACTUARIES, V21, P1; PATTIE AH, 1981, BRIT J CLIN PSYCHOL, V20, P173, DOI 10.1111/j.2044-8260.1981.tb00515.x; Qureshi K N, 1974, Age Ageing, V3, P152, DOI 10.1093/ageing/3.3.152	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					366	366		10.1136/bmj.318.7180.366	http://dx.doi.org/10.1136/bmj.318.7180.366			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	166JN	9933198	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000078572600027
J	Hassler, DM; Dammasch, IE; Lemaire, P; Brekke, P; Curdt, W; Mason, HE; Vial, JC; Wilhelm, K				Hassler, DM; Dammasch, IE; Lemaire, P; Brekke, P; Curdt, W; Mason, HE; Vial, JC; Wilhelm, K			Solar wind outflow and the chromospheric magnetic network	SCIENCE			English	Article							TRANSITION REGION; SUMER TELESCOPE; CORONAL HOLES; QUIET SUN; SOHO; SPECTROMETER	Observations of outflow velocities in coronal holes (regions of open coronal magnetic field) have recently been obtained with the Solar and Heliospheric Observatory (SOHO) spacecraft. Velocity maps of Ne7+ from its bright resonance line at 770 angstroms, formed at the base of the corona, show a relationship between outflow velocity and chromospheric magnetic network structure, suggesting that the solar wind is rooted at its base to this structure, emanating from localized regions along boundaries and boundary intersections of magnetic network cells. This apparent relation to the chromospheric magnetic network and the relatively large outflow velocity signatures will improve understanding of the complex structure and dynamics at the base of the corona and the source region of the solar wind.	SW Res Inst, Boulder, CO 80302 USA; Max Planck Inst Aeron, D-37191 Katlenburg, Germany; Univ Paris 11, Inst Astrophys Spatiale, CNRS, Unite Mixte, F-91405 Orsay, France; Univ Oslo, Inst Theoret Astrophys, N-0315 Oslo, Norway; Univ Cambridge, Cambridge CB3 9EW, England	Max Planck Society; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; University of Oslo; University of Cambridge	Hassler, DM (corresponding author), SW Res Inst, 1050 Walnut St, Boulder, CO 80302 USA.		Wilhelm, Klaus/H-3812-2019					Andretta V, 1997, ASTROPHYS J, V489, P375, DOI 10.1086/304760; AWAYA T, 1979, NUCL INSTRUM METHODS, V165, P317, DOI 10.1016/0029-554X(79)90287-8; BAKER S, 1984, NUCL INSTRUM METH A, V221, P437, DOI 10.1016/0167-5087(84)90016-4; BOCKASTEN K, 1963, P PHYS SOC LOND, V81, P522, DOI 10.1088/0370-1328/81/3/321; Brekke P, 1995, ASTR SOC P, V81, P589; Brekke P, 1997, SOL PHYS, V175, P349, DOI 10.1023/A:1004985226553; BREKKE P, 1993, ASTROPHYS J SUPPL S, V87, P443, DOI 10.1086/191810; Chae J, 1997, ASTROPHYS J, V480, P817, DOI 10.1086/303999; COVINGTON J, 1998, EOS S, V79, pS265; CUSHMAN GW, 1976, ASTROPHYS J, V207, pL61, DOI 10.1086/182179; DAMMASCH IE, IN PRESS ASTRON ASTR; DAMMASCH IE, IN PRESS P SOHO 7 WO; DeForest CE, 1997, SOL PHYS, V175, P393, DOI 10.1023/A:1004955223306; DERE KP, 1986, ASTROPHYS J, V305, P947, DOI 10.1086/164308; DOWDY JF, 1986, SOL PHYS, V105, P35, DOI 10.1007/BF00156374; Dupree AK, 1996, ASTROPHYS J, V467, pL121, DOI 10.1086/310215; FAWCETT BC, 1961, P PHYS SOC LOND, V78, P1223, DOI 10.1088/0370-1328/78/6/318; Fleck B., 1995, SOL PHYS, V162; FRANK Z, 1998, EOS S, V79, pS254; GABRIEL AH, 1976, PHILOS T R SOC A, V281, P339, DOI 10.1098/rsta.1976.0031; GABRIEL AH, 1977, P IAU C, V36, P375; HASSLER DM, 1991, ASTROPHYS J, V372, P710, DOI 10.1086/170014; Hassler DM, 1997, SOL PHYS, V175, P375, DOI 10.1023/A:1004959324214; KRIEGER AS, 1973, SOL PHYS, V29, P505, DOI 10.1007/BF00150828; Lemaire P, 1997, SOL PHYS, V170, P105, DOI 10.1023/A:1004994702333; Marsch E, 1997, SOL PHYS, V176, P87, DOI 10.1023/A:1004975703854; ORRALL FQ, 1983, ASTROPHYS J, V216, pL65; PETER H, IN PRESS ASTROPHYS J; ROTTMAN GJ, 1982, ASTROPHYS J, V260, P326, DOI 10.1086/160257; ROTTMAN GJ, 1990, ASTROPHYS J, V358, P693, DOI 10.1086/169023; SIEGMUND OHW, 1995, P SOC PHOTO-OPT INS, V2518, P344, DOI 10.1117/12.218388; Warren HP, 1997, ASTROPHYS J, V490, pL187, DOI 10.1086/311041; Wilhelm K, 1998, ASTROPHYS J, V500, P1023, DOI 10.1086/305756; Wilhelm K, 1997, SOL PHYS, V170, P75, DOI 10.1023/A:1004923511980; Wilhelm K, 1995, SOL PHYS, V162, P189, DOI 10.1007/BF00733430; ZIRKER JB, 1977, CORONAL HOLES HIGH S	36	252	259	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					810	813		10.1126/science.283.5403.810	http://dx.doi.org/10.1126/science.283.5403.810			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933156				2022-12-28	WOS:000078496800033
J	Jones, VA				Jones, VA			The white coat: Why not follow suit?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Jones, VA (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.							ANVIK T, 1990, Scandinavian Journal of Primary Health Care, V8, P91, DOI 10.3109/02813439008994937; BLUMHAGEN DW, 1979, ANN INTERN MED, V91, P111, DOI 10.7326/0003-4819-91-1-111; ENOCHS BE, 1998, J COLL PHYS SURG COL, V18, P11; LEWIS LD, 1994, COL U COLL PHYS SURG	4	18	19	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					478	478		10.1001/jama.281.5.478	http://dx.doi.org/10.1001/jama.281.5.478			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952213	hybrid			2022-12-28	WOS:000078318500043
J	Rylance, G				Rylance, G			Privacy, dignity, and confidentiality: interview study with structured questionnaire	BRITISH MEDICAL JOURNAL			English	Article									Birmingham Childrens Hosp NHS Trust, Birmingham B4 6NH, W Midlands, England		Rylance, G (corresponding author), Birmingham Childrens Hosp NHS Trust, Birmingham B4 6NH, W Midlands, England.							Berry RM, 1997, J LEGAL MED, V18, P401, DOI 10.1080/01947649709511044; *GEN MED COUNC, 1995, CONF GOOD MED PRACT; MacDonald WL, 1998, SOC SCI MED, V46, P73, DOI 10.1016/S0277-9536(97)00146-9; WOODWARD B, 1995, NEW ENGL J MED, V333, P1419, DOI 10.1056/NEJM199511233332112	4	14	14	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 30	1999	318	7179					301	301		10.1136/bmj.318.7179.301	http://dx.doi.org/10.1136/bmj.318.7179.301			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	163ZH	9924057	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000078436700023
J	Handgretinger, R; Geiselhart, A; Moris, A; Grau, R; Teuffel, O; Bethge, W; Kanz, L; Fisch, P				Handgretinger, R; Geiselhart, A; Moris, A; Grau, R; Teuffel, O; Bethge, W; Kanz, L; Fisch, P			Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLASS-I MOLECULES; PROGENITOR CELLS; HLA-A; GAMMA; LEUKEMIA; PATIENT; DIFFERENTIATION; ERYTHROPOIETIN; THERAPY; LINE		Univ Tubingen, Dept Pediat, Tubingen, Germany; Univ Tubingen, Dept Immunol, Tubingen, Germany; Univ Tubingen, Dept Med 2, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Handgretinger, R (corresponding author), Childrens Univ Hosp, Hoppe Seyler Str 1, D-72076 Tubingen, Germany.			Moris, Arnaud/0000-0002-5052-1678				ANDERSSON LC, 1979, INT J CANCER, V23, P143, DOI 10.1002/ijc.2910230202; Blomberg K, 1996, J IMMUNOL METHODS, V193, P199, DOI 10.1016/0022-1759(96)00063-4; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; BRUGGER W, 1993, BLOOD, V81, P2579; Casadevall N, 1996, NEW ENGL J MED, V334, P630, DOI 10.1056/NEJM199603073341004; Charles RJ, 1996, BLOOD, V87, P4831, DOI 10.1182/blood.V87.11.4831.bloodjournal87114831; CICCONE E, 1994, EUR J IMMUNOL, V24, P1003, DOI 10.1002/eji.1830240434; Colonna M, 1998, NATURE, V391, P642, DOI 10.1038/35515; DHODAPKAR MV, 1994, MAYO CLIN PROC, V69, P1085, DOI 10.1016/S0025-6196(12)61377-9; FISCH F, 1997, EUR J IMMUNOL, V27, P3368; FISCH P, 1990, J EXP MED, V171, P1567, DOI 10.1084/jem.171.5.1567; FITCHEN JH, 1982, BLOOD, V59, P188; FRICKHOFEN N, 1994, BRIT J HAEMATOL, V87, P818, DOI 10.1111/j.1365-2141.1994.tb06743.x; HANDA SI, 1994, J CLIN PATHOL, V47, P676, DOI 10.1136/jcp.47.7.676; HARA T, 1990, BLOOD, V75, P941; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KWONG YL, 1995, AM J CLIN PATHOL, V103, P76, DOI 10.1093/ajcp/103.1.76; Lacy MQ, 1996, BLOOD, V87, P3000, DOI 10.1182/blood.V87.7.3000.bloodjournal8773000; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; LEFRANC MP, 1990, RES IMMUNOL, V141, P565, DOI 10.1016/0923-2494(90)90058-7; LEFRANC MP, 1985, NATURE, V316, P464, DOI 10.1038/316464a0; LEVITT LJ, 1988, J CLIN INVEST, V81, P538, DOI 10.1172/JCI113352; LOUGHRAN TP, 1993, BLOOD, V82, P1; Moretta A, 1996, ANNU REV IMMUNOL, V14, P619, DOI 10.1146/annurev.immunol.14.1.619; PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542; Reyburn HT, 1997, NATURE, V386, P514, DOI 10.1038/386514a0; ROBINSON J, 1981, NATURE, V289, P68, DOI 10.1038/289068a0; SHIMIZU Y, 1989, J IMMUNOL, V142, P3320; SIEFF C, 1982, BLOOD, V60, P703; Valiante NM, 1997, IMMUNITY, V7, P739, DOI 10.1016/S1074-7613(00)80393-3	30	96	97	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1999	340	4					278	284		10.1056/NEJM199901283400405	http://dx.doi.org/10.1056/NEJM199901283400405			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YU	9920952				2022-12-28	WOS:000078318700005
J	Breen, A				Breen, A			Chiropractic for low back pain - Experts in both UK and US believe that chiropractic works	BRITISH MEDICAL JOURNAL			English	Letter									Angloeuropean Coll Chiropract, Bournemouth BH5 2DF, Dorset, England		Breen, A (corresponding author), Angloeuropean Coll Chiropract, Bournemouth BH5 2DF, Dorset, England.			Breen, Alan/0000-0003-4340-9167				Ernst E, 1998, BRIT MED J, V317, P160, DOI 10.1136/bmj.317.7152.160; MEADE TW, 1995, BRIT MED J, V311, P349, DOI 10.1136/bmj.311.7001.349; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; Waddell G, 1996, CLIN GUIDELINES MANA	4	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1999	318	7178					261	261						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915748				2022-12-28	WOS:000078292300049
J	Hall, M				Hall, M			Vernon Frederick ("Sam") Hall - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																		HALL VF, PUBLICATION LIST	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1999	318	7178					265	265						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915753				2022-12-28	WOS:000078292300059
J	Smolen, JS; Kalden, JR; Scott, DL; Rozman, B; Kvien, TK; Larsen, A; Loew-Friedrich, I; Oed, C; Rosenburg, R				Smolen, JS; Kalden, JR; Scott, DL; Rozman, B; Kvien, TK; Larsen, A; Loew-Friedrich, I; Oed, C; Rosenburg, R		European Leflunomide Study Grp	Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial	LANCET			English	Article							SULFASALAZINE; METHOTREXATE; PROGRESSION; DAMAGE; DRUGS; HYDROXYCHLOROQUINE; METAANALYSIS; CYCLOSPORINE; CELLS	Background Phase II trials of leflunomide, an inhibitor of de-novo pyrimidine synthesis, have shown efficacy in rheumatoid arthritis. This double-blind randomised trial compared leflunomide with placebo and sulphasalazine in active rheumatoid arthritis. Methods 358 patients were randomly assigned leflunomide (100 mg daily on days 1-3, then 20 mg daily), placebo, or sulphasalazine (0.5 g daily, titrated progressively to 2.0 g daily at week 4.). The primary endpoints were tender and swollen joint counts and investigator's and patient's overall assessments. Analyses were by intention to treat. Findings The mean changes in the leflunomide, placebo, and sulphasalazine groups were -9.7, -4.3, and -8.1 for tender joint count; -7.2, -3.4, and -6.2 for swollen joint count; -1.1, -0.3, and -1.0 for physician's overall assessment; and -1.1, -0.4, and -1.1 for patient's overall assessment. Leflunomide and sulphasalazine were significantly superior to placebo (p = 0.0001 for joint counts; p < 0.001 for assessments). Radiographic disease progression was significantly slower with leflunomide and sulphasalazine than with placebo (p < 0.01). Most common adverse events with leflunomide were diarrhoea (17%), nausea (10%), alopecia (8%), and rash (10%). Transiently abnormal liver function was seen in three leflunomide-group patients and five sulphasalazine-group patients. There were two cases of reversible agranulocytosis in the sulphasalazine group. Interpretation Leflunomide was more effective than placebo in treatment of rheumatoid arthritis and showed similar efficacy to sulphasalazine. Leflunomide was well tolerated, This drug may be a useful option as a disease-modifying antirheumatic drug.	Univ Vienna, Dept Internal Med 3, Div Rheumatol, A-1090 Vienna, Austria; Lainz Hosp, Ctr Rheumat Dis, Dept Med 2, A-1090 Vienna, Austria; Univ Erlangen Nurnberg, D-8520 Erlangen, Germany; Univ London Kings Coll Hosp, London, England; Med Ctr Ljubljana, Ljubljana, Slovenia; Diakonhjemmet Hosp, Oslo, Norway; Kongsvinger Sjukehus, Kongsvinger, Norway; Hoechst Marion Roussel, Frankfurt, Germany	University of Vienna; University of Erlangen Nuremberg; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University Medical Centre Ljubljana; Diakonhjemmet Hospital; Sanofi-Aventis	Smolen, JS (corresponding author), Univ Vienna, Dept Internal Med 3, Div Rheumatol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		emery, paul/B-3560-2013					ALARCON GS, 1992, J RHEUMATOL, V19, P1868; AMETT FC, 1988, ARTHRITIS RHEUM, V31, P315; BARTLETT RR, 1993, SPRINGER SEMIN IMMUN, V14, P381; BARTLETT RR, 1988, SCAND J RHEUMATOL S, V75, pS290; Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7; CASH JM, 1994, NEW ENGL J MED, V330, P1369; Dimitrijevic M, 1996, TRANSPL P, V28, P3086; EBERHARDT KB, 1990, RHEUMATOL INT, V10, P135, DOI 10.1007/BF02274837; Elder RT, 1997, J IMMUNOL, V159, P22; FELSON DT, 1992, ARTHRITIS RHEUM, V35, P1117, DOI 10.1002/art.1780351003; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P724; FORRE O, 1994, ARTHRITIS RHEUM, V37, P1506; Fox RI, 1998, J RHEUMATOL, V25, P20; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; HAMDY H, 1987, ARTHRITIS RHEUM, V30, P361, DOI 10.1002/art.1780300401; HANNONEN P, 1993, ARTHRITIS RHEUM-US, V36, P1501, DOI 10.1002/art.1780361104; LARSEN A, 1977, ACTA RADIOL DIAGN, V18, P481, DOI 10.1177/028418517701800415; LARSEN A, 1981, CONTROVERSIES CLIN E; MLADENOVIC V, 1995, ARTHRITIS RHEUM-US, V38, P1595, DOI 10.1002/art.1780381111; NEUMANN VC, 1983, BRIT MED J, V287, P1099, DOI 10.1136/bmj.287.6399.1099; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; OTTERNESS IG, 1994, SEMIN ARTHRITIS RHEU, V24, P91, DOI 10.1016/S0049-0172(05)80003-4; PANAYI GS, 1992, ARTHRITIS RHEUM-US, V35, P729, DOI 10.1002/art.1780350702; PAULUS HE, 1990, ARTHRITIS RHEUM, V33, P477, DOI 10.1002/art.1780330403; PINALS RS, 1986, ARTHRITIS RHEUM, V29, P1427, DOI 10.1002/art.1780291202; PINCUS T, 1992, J RHEUMATOL, V19, P1885; PINCUS T, 1993, RHEUM DIS CLIN N AM, V19, P123; RAINS CP, 1995, DRUGS, V50, P137, DOI 10.2165/00003495-199550010-00009; Ruckemann K, 1998, J BIOL CHEM, V273, P21682, DOI 10.1074/jbc.273.34.21682; Smolen JS, 1996, SCAND J RHEUMATOL, V25, P1; SMOLEN JS, 1995, ARTHRITIS RHEUM, V38, P38, DOI 10.1002/art.1780380106; STEINER G, IN PRESS BR J RHEUMA; van Ede AE, 1998, SEMIN ARTHRITIS RHEU, V27, P277, DOI 10.1016/S0049-0172(98)80049-8; VANDERHEIJDE DM, 1989, LANCET, V1, P1036, DOI 10.1016/S0140-6736(89)92442-2; VANDERHEIJDE DMFM, 1992, BRIT J RHEUMATOL, V31, P519; VANGERSTEL AM, 1996, ARTHRITIS RHEUM, V39, P4; vanLeeuwen MA, 1997, J RHEUMATOL, V24, P20; VanRiel PLCM, 1995, BRIT J RHEUMATOL, V34, P40; Ward MM, 1998, J RHEUMATOL, V25, P408; Weber W., 1997, Arthritis and Rheumatism, V40, pS153; WEINBLATT ME, 1998, RHEUM EUR S2, V27, pS110; WELLS G, 1993, BRIT J RHEUMATOL, V32, P51; WOLFE F, 1997, CLIN EXP RHEUMAT S17, V15, P75	43	602	647	0	22	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 23	1999	353	9149					259	266		10.1016/S0140-6736(98)09403-3	http://dx.doi.org/10.1016/S0140-6736(98)09403-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929017				2022-12-28	WOS:000078292200007
J	Jiang, YP; Woronicz, JD; Liu, W; Goeddel, DV				Jiang, YP; Woronicz, JD; Liu, W; Goeddel, DV			Prevention of constitutive TNF receptor 1 signaling by silencer of death domains	SCIENCE			English	Article							NF-KAPPA-B; CELL-DEATH; ACTIVATION; COMPLEX; APOPTOSIS; BETA	Tumor necrosis factor receptor type 1 (TNF-R1) contains a cytoplasmic death domain that is required for the signaling of TNF activities such as apoptosis and nuclear factor kappa B (NF-kappa B) activation. Normally, these signals are generated only after TNF-induced receptor aggregation. However, TNF-R1 self-associates and signals independently of Ligand when overexpressed. This apparent paradox may be explained by silencer of death domains (SODD), widely expressed similar to 60-kilodalton protein that was found to be associated with the death domain of TNF-R1. TNF treatment released SODD from TNF-R1, permitting the recruitment of proteins such as TRADD and TRAF2 to the active TNF-R1 signaling complex. SODD also interacted with death receptor-3 (DR3), another member of the TNF receptor superfamily. Thus, SODD association may be representative of a general mechanism for preventing spontaneous signaling by death domain-containing receptors.	Tularik, S San Francisco, CA 94080 USA		Goeddel, DV (corresponding author), Tularik, 2 Corp Dr, S San Francisco, CA 94080 USA.							Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; *GENB, H10621 GENB; *GENB, T33545 GENB; *GENB, AA319013 GENB; *GENB, AA362082 GENB; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; JIANG YH, UNPUB, P12720; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SONG HY, 1994, J BIOL CHEM, V269, P22492; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	22	323	348	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					543	546		10.1126/science.283.5401.543	http://dx.doi.org/10.1126/science.283.5401.543			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915703				2022-12-28	WOS:000078203300039
J	Davidson, MH; Hauptman, J; DiGirolamo, M; Foreyt, JP; Halsted, CH; Heber, D; Heimburger, DC; Lucas, CP; Robbins, DC; Chung, J; Heymsfield, SB				Davidson, MH; Hauptman, J; DiGirolamo, M; Foreyt, JP; Halsted, CH; Heber, D; Heimburger, DC; Lucas, CP; Robbins, DC; Chung, J; Heymsfield, SB			Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	North-American-Association-for-the-Study-of-Obesity Meeting	NOV 10, 1997	CANCUN, MEXICO	N Amer Assoc Study Obesity			LIPASE INHIBITOR; HEART-DISEASE; STATEMENT	Context Orlistat, a gastrointestinal lipase inhibitor that reduces dietary fat absorption by approximately 30%, may promote weight loss and reduce cardiovascular risk factors. Objective To test the hypothesis that orlistat combined with dietary intervention is more effective than placebo plus diet for weight loss and maintenance over 2 years. Design Randomized, double-blind, placebo-controlled study conducted from October 1992 to October 1995. Setting and Participants Obese adults (body mass index [weight in kilograms divided by the square of height in meters], 30-43 kg/m(2)) evaluated at 18 US research centers. Intervention Subjects received placebo plus a controlled-energy diet during a 4-week lead-in. On study day 1, the diet was continued and subjects were randomized to receive placebo 3 times a day or orlistat, 120 mg 3 times a day, for 52 weeks. After 52 weeks, subjects began a weight-maintenance diet, and the placebo group (n = 133) continued to receive placebo and orlistat-treated subjects were rerandomized to receive placebo 3 times a day (n = 138), orlistat, 60 mg (n = 152) or 120 mg (n = 153) 3 times a day, for an additional 52 weeks. Main Outcome Measures Body weight change and changes in blood pressure and serum lipid, glucose, and insulin levels. Results A total of 1187 subjects entered the protocol, and 892 were randomly assigned on day 1 to double-blind treatment. For intent-to-treat analysis, 223 placebo-treated subjects and 657 orlistat-treated subjects were evaluated. During the first year orlistat-treated subjects lost more weight (mean +/- SEM, 8.76 +/- 0.37 kg) than placebo-treated subjects (5.81 +/- 0.67 kg) (P<.001). Subjects treated with orlistat, 120 mg 3 times a day, during year 1 and year 2 regained less weight during year 2 (3.2 +/- 0.45 kg; 35.2% regain) than those who received orlistat, 60 mg (4.26 +/- 0.57 kg; 51.3% regain), or placebo (5.63 +/- 0.42 kg; 63.4% regain) in year 2 (P<.001). Treatment with orlistat, 120 mg 3 times a day, was associated with improvements in fasting low-density lipoprotein cholesterol and insulin levels. Conclusions Two-year treatment with orlistat plus diet significantly promotes weight loss, lessens weight regain, and improves some obesity-related disease risk factors.	Chicago Ctr Clin Res, Chicago, IL USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA USA; Baylor Coll Med, Nutr Res Clin, Houston, TX 77030 USA; Univ Calif Davis, Div Clin Nutr, Davis, CA USA; Univ Calif Los Angeles, Rehabil Ctr, Div Clin Nutr, Los Angeles, CA USA; William Beaumont Hosp, Birmingham, AL USA; Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL USA; Penn Med Labs, Medlantic Res Inst, Washington, DC USA; Hoffmann La Roche Inc, Nutley, NJ 07110 USA; Columbia Univ, St Lukes Roosevelt Hosp Ctr, New York, NY USA	Emory University; Baylor College of Medicine; University of California System; University of California Davis; University of California System; University of California Los Angeles; University of Alabama System; University of Alabama Birmingham; Roche Holding; Columbia University; Mount Sinai St. Luke's; Mount Sinai West	Heymsfield, SB (corresponding author), Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp, Obes Res Ctr, 1090 Amsterdam Ave, New York, NY 10025 USA.	SBH2@Columbia.edu	Heymsfield, Steven B/N-1968-2017	Heymsfield, Steven B/0000-0003-1127-9425				Allison D. B., 1997, Overweight and weight management: the health professional's guide to understanding and practice., P557; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bray GA, 1995, OBES RES, V3, pS425, DOI 10.1002/j.1550-8528.1995.tb00209.x; Bray GA, 1996, ENDOCRIN METAB CLIN, V25, P907, DOI 10.1016/S0889-8529(05)70361-3; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; DRENT ML, 1995, INT J OBESITY, V19, P221; Eckel RH, 1997, CIRCULATION, V96, P3248, DOI 10.1161/01.CIR.96.9.3248; *FDA CTR DRUG EV R, 1998, END MET DRUG ADV COM, P69; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397; Grundy SM, 1996, MED SCI SYMP SER, V10, P237; Guerciolini R, 1997, INT J OBESITY, V21, pS12; HARRIS M, 1979, DIABETES, V28, P1039; LANDSBERG L, 1992, HYPERTENSION, V19, pI61, DOI 10.1161/01.HYP.19.1_Suppl.I61; Lean MEJ, 1997, INT J OBESITY, V21, pS30; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Little R, 1996, BIOMETRICS, V52, P1324, DOI 10.2307/2532847; Meigs JB, 1998, ANN INTERN MED, V128, P524, DOI 10.7326/0003-4819-128-7-199804010-00002; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; Sjostrom L, 1998, LANCET, V352, P167, DOI 10.1016/S0140-6736(97)11509-4; Thomas PR, 1995, WEIGHING OPTIONS CRI; VOLKMAR FR, 1981, ARCH INTERN MED, V141, P426, DOI 10.1001/archinte.141.4.426; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P615, DOI 10.1038/clpt.1992.73; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76; Williamson DF, 1997, INT J OBESITY, V21, pS14; Winer BJ., 1970, STAT PRINCIPLES EXPT, V2nd; Wing RR, 1998, DIABETES CARE, V21, P350, DOI 10.2337/diacare.21.3.350; WING RR, 1994, DIABETES CARE, V17, P30, DOI 10.2337/diacare.17.1.30; Yanovski SZ, 1996, JAMA-J AM MED ASSOC, V276, P1907, DOI 10.1001/jama.276.23.1907; ZHI JG, 1995, J CLIN PHARMACOL, V35, P1103, DOI 10.1002/j.1552-4604.1995.tb04034.x	30	627	673	0	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1999	281	3					235	242		10.1001/jama.281.3.235	http://dx.doi.org/10.1001/jama.281.3.235			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	157GK	9918478	Bronze			2022-12-28	WOS:000078052800028
J	McCurdie, I; Perry, JD				McCurdie, I; Perry, JD			Lesson of the week - Haemochromatosis and exercise related joint pains	BRITISH MEDICAL JOURNAL			English	Review							HEREDITARY HEMOCHROMATOSIS; IRON OVERLOAD; ARTHROPATHY; ARTHRITIS; PREVALENCE; FEATURES		Royal Hosp NHS Trust, Mile End Hosp, Dept Rheumatol, London E1 4DG, England	University of London; Queen Mary University London	Perry, JD (corresponding author), Royal Hosp NHS Trust, Mile End Hosp, Dept Rheumatol, London E1 4DG, England.							Adams PC, 1996, J RHEUMATOL, V23, P707; AXFORD JS, 1991, ARTHRITIS RHEUM, V34, P357, DOI 10.1002/art.1780340314; DYMOCK IW, 1970, ANN RHEUM DIS, V29, P469, DOI 10.1136/ard.29.5.469; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; FARAAWI R, 1993, J RHEUMATOL, V20, P448; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; GORDON DA, 1973, ARTHRITIS RHEUM, V16, P305, DOI 10.1002/art.1780160304; HAMILTON EBD, 1981, Q J MED, V50, P321; MATHEWS JL, 1987, ARTHRITIS RHEUM, V30, P1137, DOI 10.1002/art.1780301008; McCarthy GM, 1996, J RHEUMATOL, V23, P1453; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; SCHUMACHER HR, 1982, ARTHRITIS RHEUM-US, V25, P1460, DOI 10.1002/art.1780251212; SCHUMACHER HR, 1964, ARTHRITIS RHEUM-US, V7, P41, DOI 10.1002/art.1780070106; WALKER RJ, 1972, ANN RHEUM DIS, V31, P98, DOI 10.1136/ard.31.2.98	15	13	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1999	318	7181					449	451		10.1136/bmj.318.7181.449	http://dx.doi.org/10.1136/bmj.318.7181.449			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BF	9974464	Green Published			2022-12-28	WOS:000078670100033
J	Eto, K; Tsubamoto, Y; Terauchi, Y; Sugiyama, T; Kishimoto, T; Takahashi, N; Yamauchi, N; Kubota, N; Murayama, S; Aizawa, S; Akanuma, Y; Aizawa, S; Kasai, H; Yazaki, Y; Kadowaki, T				Eto, K; Tsubamoto, Y; Terauchi, Y; Sugiyama, T; Kishimoto, T; Takahashi, N; Yamauchi, N; Kubota, N; Murayama, S; Aizawa, S; Akanuma, Y; Aizawa, S; Kasai, H; Yazaki, Y; Kadowaki, T			Role of NADH shuttle system in glucose-induced activation of mitochondrial metabolism and insulin secretion	SCIENCE			English	Article							PANCREATIC BETA-CELLS; CYTOSOLIC CA2+; ISLETS; RELEASE; DEHYDROGENASE; NUCLEOTIDES; GLYCOLYSIS; CHANNELS	Glucose metabolism in glycolysis and in mitochondria is pivotal to glucose-induced insulin secretion from pancreatic beta cells. One or more factors derived from glycolysis other than pyruvate appear to be required for the generation of mitochondrial signals that Lead to insulin secretion. The electrons of the glycolysis-derived reduced form of nicotinamide adenine dinucleotide (NADH) are transferred to mitochondria through the NADH shuttle system. By abolishing the NADH shuttle function, glucose-induced increases in NADH autofluorescence, mitochondrial membrane potential, and adenosine triphosphate content were reduced and glucose-induced insulin secretion was abrogated. The NADH shuttle evidently couples glycolysis with activation of mitochondrial energy metabolism to trigger insulin secretion.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Grad Sch Med, Dept Physiol, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Grad Sch Med, Dept Pathol, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Grad Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 113, Japan; Shinshu Univ, Sch Med, Dept Geriatr Endocrinol & Metab, Matsumoto, Nagano 390, Japan; Asahi Life Fdn, Inst Diabet Care & Res, Chiyoda Ku, Tokyo 100, Japan; Kumamoto Univ, Sch Med, Dept Morphogenesis, Inst Mol Embryol & Genet, Kumamoto 862, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Shinshu University; Asahi Life Foundation; Kumamoto University	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Terauchi, Yasuo/AAO-4347-2020; Kubota, Naoto/N-7892-2015	Kasai, Haruo/0000-0003-2327-9027				ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; DUKES ID, 1994, J BIOL CHEM, V269, P10979; ERECINSKA M, 1992, BIOCHIM BIOPHYS ACTA, V1101, P273, DOI 10.1016/0167-4838(92)90555-R; ETO K, UNPUB; GARDNER RS, 1974, ANAL BIOCHEM, V59, P272, DOI 10.1016/0003-2697(74)90033-5; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HAMAKAWA N, 1995, CELL CALCIUM, V17, P21, DOI 10.1016/0143-4160(95)90099-3; HEDESKOV CJ, 1987, BIOCHEM J, V241, P161, DOI 10.1042/bj2410161; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Litsky ML, 1997, BIOCHEMISTRY-US, V36, P7071, DOI 10.1021/bi970180y; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; MALAISSE WJ, 1979, METABOLISM, V28, P373, DOI 10.1016/0026-0495(79)90111-2; MALAISSE WJ, 1982, ENDOCRINOLOGY, V111, P392, DOI 10.1210/endo-111-2-392; MALAISSE WJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P190, DOI 10.1016/0167-4889(87)90134-0; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Mertz RJ, 1996, J BIOL CHEM, V271, P4838, DOI 10.1074/jbc.271.9.4838; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SENER A, 1978, BIOCHEM J, V176, P217, DOI 10.1042/bj1760217; Trollinger DR, 1997, BIOCHEM BIOPH RES CO, V236, P738, DOI 10.1006/bbrc.1997.7042; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; Zawalich WS, 1997, J BIOL CHEM, V272, P3527, DOI 10.1074/jbc.272.6.3527	27	372	377	3	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					981	985		10.1126/science.283.5404.981	http://dx.doi.org/10.1126/science.283.5404.981			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974390				2022-12-28	WOS:000078574800047
J	Gabay, C; Kushner, I				Gabay, C; Kushner, I			Mechanisms of disease: Acute-phase proteins and other systemic responses to inflammation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							C-REACTIVE PROTEIN; INTERLEUKIN-1 RECEPTOR ANTAGONIST; TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-I; AMYLOID-A SAA; TRANSGENIC MICE; PROINFLAMMATORY CYTOKINES; RHEUMATOID-ARTHRITIS; LUPUS-ERYTHEMATOSUS; HEPATOMA-CELLS		Case Western Reserve Univ, Metrohealth Med Ctr, Dept Med, Cleveland, OH 44109 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Rheumatol, Denver, CO 80262 USA; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44109 USA; Case Western Reserve Univ, Rammelkamp Ctr Res, Cleveland, OH 44109 USA	Case Western Reserve University; MetroHealth System; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Case Western Reserve University; Case Western Reserve University; MetroHealth System	Kushner, I (corresponding author), Case Western Reserve Univ, Metrohealth Med Ctr, Dept Med, Metrohealth Campus, Cleveland, OH 44109 USA.				NIA NIH HHS [AG 02467] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG002467] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmed N, 1996, AM J RESP CRIT CARE, V153, P1141, DOI 10.1164/ajrccm.153.3.8630558; AREND WP, 1994, J IMMUNOL, V153, P4766; BALLOU SP, 1992, CYTOKINE, V4, P361, DOI 10.1016/1043-4666(92)90079-7; BANKA CL, 1995, J LIPID RES, V36, P1058; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; BORISH L, 1992, INFLAMMATION, V16, P471, DOI 10.1007/BF00918973; CAMPOS SP, 1994, CYTOKINE, V6, P485, DOI 10.1016/1043-4666(94)90075-2; CERMAK J, 1993, BLOOD, V82, P513, DOI 10.1182/blood.V82.2.513.513; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; CID MC, 1993, J CLIN INVEST, V91, P977, DOI 10.1172/JCI116319; DeBenedetti F, 1997, J CLIN INVEST, V99, P643, DOI 10.1172/JCI119207; DEGRAAF TW, 1993, J EXP MED, V177, P657, DOI 10.1084/jem.177.3.657; DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dinarello Charles A., 1997, P87; DUBE R, 1990, GUT, V31, P431, DOI 10.1136/gut.31.4.431; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; GABAY C, 1994, ARTHRITIS RHEUM, V37, P1744, DOI 10.1002/art.1780371206; Gabay C, 1997, J RHEUMATOL, V24, P303; Gabay C, 1997, J CLIN INVEST, V99, P2930, DOI 10.1172/JCI119488; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GITLIN JD, 1987, LYMPHOKINES, V14, P123; Goldbach JM, 1997, AM J PHYSIOL-REG I, V272, pR675, DOI 10.1152/ajpregu.1997.272.2.R675; Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; JIANG SL, 1995, J CLIN INVEST, V95, P1253, DOI 10.1172/JCI117775; KILPATRICK L, 1992, J IMMUNOL, V149, P3059; Kluger Matthew J., 1997, P255; Kushner I, 1998, CYTOKINE GROWTH F R, V9, P191, DOI 10.1016/S1359-6101(98)00016-1; KUSHNER I, 1993, PERSPECT BIOL MED, V36, P611; LOYER P, 1993, FEBS LETT, V336, P215, DOI 10.1016/0014-5793(93)80806-6; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MACKIEWICZ A, 1991, J IMMUNOL, V146, P3032; Maes M, 1997, PSYCHIAT RES, V66, P1, DOI 10.1016/S0165-1781(96)02915-0; Malle E, 1996, EUR J CLIN INVEST, V26, P427, DOI 10.1046/j.1365-2362.1996.159291.x; MAY LT, 1992, J BIOL CHEM, V267, P19698; MEANS RT, 1995, STEM CELLS, V13, P32, DOI 10.1002/stem.5530130105; Moldawer LL, 1997, CANCER-AM CANCER SOC, V79, P1828; MORLEY JJ, 1982, ANN NY ACAD SCI, V389, P406, DOI 10.1111/j.1749-6632.1982.tb22153.x; MOUTSOPOULOS HM, 1983, CLIN EXP RHEUMATOL, V1, P53; PEPYS MB, 1982, CLIN RHEUM DIS, V8, P91; Richards CD, 1996, J INTERF CYTOK RES, V16, P69, DOI 10.1089/jir.1996.16.69; Ridker PM, 1997, NEW ENGL J MED, V337, P356; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; Sarraf P, 1997, J EXP MED, V185, P171, DOI 10.1084/jem.185.1.171; Spector TD, 1997, ARTHRITIS RHEUM, V40, P723, DOI 10.1002/art.1780400419; Tai H, 1997, ENDOCRINOLOGY, V138, P2372, DOI 10.1210/en.138.6.2372; TERBORG EJ, 1990, J RHEUMATOL, V17, P1642; TILLETT WILLIAM S., 1930, JOUR EXP MED, V52, P561, DOI 10.1084/jem.52.4.561; Van Dijk W, 1995, ANN NY ACAD SCI, V762, P319; VANLEEUWEN MA, 1994, J RHEUMATOL, V21, P425; Volanakis J.E., 1997, ARTHRITIS ALLIED CON, V13th ed., P505; Weiss G, 1997, J IMMUNOL, V158, P420; Wigmore SJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE720, DOI 10.1152/ajpendo.1997.273.4.E720; Wolf M, 1996, EUR J ENDOCRINOL, V135, P729, DOI 10.1530/eje.0.1350729; Xia DY, 1997, P NATL ACAD SCI USA, V94, P2575, DOI 10.1073/pnas.94.6.2575; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Yue CC, 1996, J BIOL CHEM, V271, P22245, DOI 10.1074/jbc.271.36.22245; ZEIDLER C, 1992, BLOOD, V80, P2740; ZHENG H, 1995, IMMUNITY, V3, P9, DOI 10.1016/1074-7613(95)90154-X; Zouki C, 1997, J CLIN INVEST, V100, P522, DOI 10.1172/JCI119561	65	4614	4819	10	388	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1999	340	6					448	454		10.1056/NEJM199902113400607	http://dx.doi.org/10.1056/NEJM199902113400607			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166HW	9971870				2022-12-28	WOS:000078571000007
J	Hebert, PC; Wells, G; Blajchman, MA; Marshall, J; Martin, C; Pagliarello, G; Tweeddale, M; Schweitzer, I; Yetisir, E				Hebert, PC; Wells, G; Blajchman, MA; Marshall, J; Martin, C; Pagliarello, G; Tweeddale, M; Schweitzer, I; Yetisir, E		Canadian Critical Care Trials Grp	A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OXYGEN DELIVERY; ILL PATIENTS; MORTALITY; DISEASE; MANAGEMENT; SYSTEM; RBC	Background To determine whether a restrictive strategy of red-cell transfusion and a liberal strategy produced equivalent results in critically ill patients, we compared the rates of death from all causes at 30 days and the severity of organ dysfunction. Methods We enrolled 838 critically ill patients with euvolemia after initial treatment who had hemoglobin concentrations of less than 9.0 g per deciliter within 72 hours after admission to the intensive care unit and randomly assigned 418 patients to a restrictive strategy of transfusion, in which red cells were transfused if the hemoglobin concentration dropped below 7.0 g per deciliter and hemoglobin concentrations were maintained at 7.0 to 9.0 g per deciliter, and 420 patients to a liberal strategy, in which transfusions were given when the hemoglobin concentration fell below 10.0 g per deciliter and hemoglobin concentrations were maintained at 10.0 to 12.0 g per deciliter. Results Overall, 30-day mortality was similar in the two groups (18.7 percent vs. 23.3 percent, P = 0.11). However, the rates were significantly lower with the restrictive transfusion strategy among patients who were less acutely ill - those with an Acute Physiology and Chronic Health Evaluation II score of less than or equal to 20 (8.7 percent in the restrictive-strategy group and 16.1 percent in the liberal-strategy group, P = 0.03) - and among patients who were less than 55 years of age (5.7 percent and 13.0 percent, respectively; P = 0.02), but not among patients with clinically significant cardiac disease (20.5 percent and 22.9 percent, respectively; P = 0.69). The mortality rate during hospitalization was significantly lower in the restrictive-strategy group (22.2 percent vs. 28.1 percent, P = 0.05). Conclusions A restrictive strategy of red-cell transfusion is at least as effective as and possibly superior to a liberal transfusion strategy in critically ill patients, with the possible exception of patients with acute myocardial infarction and unstable angina. (N Engl J Med 1999;340:409-17) (C) 1999. Massachusetts Medical Society.	Univ Ottawa, Crit Care Program, Ottawa, ON, Canada; Univ Ottawa, Clin Epidemiol Unit, Ottawa, ON, Canada; McMaster Univ, Dept Pathol, Hamilton, ON, Canada; Univ Toronto, Crit Care Program, Toronto, ON, Canada; Univ Western Ontario, Crit Care Program, London, ON, Canada; Univ British Columbia, Crit Care Program, Vancouver, BC V5Z 1M9, Canada	University of Ottawa; University of Ottawa; McMaster University; University of Toronto; Western University (University of Western Ontario); University of British Columbia	Hebert, PC (corresponding author), Ottawa Gen Hosp, Dept Med, 501 Smyth Rd,Box 205, Ottawa, ON K1H 8L6, Canada.		Wells, George A/M-4549-2017; Martin, Claudio/G-3327-2011	Wells, George A/0000-0002-2289-9139; 				BAKER CH, 1986, CIRC SHOCK, V20, P127; BLAIR SD, 1986, BRIT J SURG, V73, P783, DOI 10.1002/bjs.1800731007; BORDIN JO, 1994, BLOOD, V84, P1703; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; *CAN RED CROSS SOC, 1993, CLIN GUID TRANSF PRO; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; CORWIN HL, 1995, CHEST, V108, P767, DOI 10.1378/chest.108.3.767; FAITHFULL NS, 1992, ADV EXP MED BIOL, V317, P55; FRIEDMAN LM, 1996, FUNDAMENTALS CLIN TR; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; Hebert PC, 1997, CAN MED ASSOC J, V156, pS9; Hebert PC, 1998, CRIT CARE MED, V26, P482, DOI 10.1097/00003246-199803000-00019; HEBERT PC, 1993, CHEST, V104, P230, DOI 10.1378/chest.104.1.230; Hebert PC, 1997, AM J RESP CRIT CARE, V155, P1618, DOI 10.1164/ajrccm.155.5.9154866; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V273, P1439, DOI 10.1001/jama.273.18.1439; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V274, P944; Heyland DK, 1996, CRIT CARE MED, V24, P517, DOI 10.1097/00003246-199603000-00025; JOHNSON RG, 1992, J THORAC CARDIOV SUR, V104, P307; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANGENFELD JE, 1991, SURGERY, V110, P398; MARSHALL JC, 1992, CRIT CARE MED, V20, pS80; RUSSELL JA, 1994, AM J RESP CRIT CARE, V149, P533, DOI 10.1164/ajrccm.149.2.8306058; van de Watering LMG, 1998, CIRCULATION, V97, P562; VICHINSKY EP, 1995, NEW ENGL J MED, V333, P206, DOI 10.1056/NEJM199507273330402; WEISEL RD, 1984, J THORAC CARDIOV SUR, V88, P26	25	3347	3467	2	78	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1999	340	6					409	417		10.1056/NEJM199902113400601	http://dx.doi.org/10.1056/NEJM199902113400601			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166HW	9971864	Bronze			2022-12-28	WOS:000078571000001
J	Rajagopal, I				Rajagopal, I			Software - All-in-one sequence analysis	SCIENCE			English	Software Review									Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Rajagopal, I (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.								0	1	1	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					652	653		10.1126/science.283.5402.652	http://dx.doi.org/10.1126/science.283.5402.652			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9988660				2022-12-28	WOS:000078324400031
J	Dreyer, EB; Lipton, SA				Dreyer, EB; Lipton, SA			New perspectives on glaucoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							VISUAL-FIELD LOSS; NITRIC-OXIDE; INTRAOCULAR-PRESSURE; VITREOUS BODY; OPTIC-NERVE; CELL-DEATH; GLUTAMATE; APOPTOSIS; NECROSIS; RISK		Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Glaucoma Serv, Philadelphia, PA 19104 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Brigham & Womens Hosp, CNS Res Inst, Boston, MA USA	University of Pennsylvania; Pennsylvania Medicine; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Dreyer, EB (corresponding author), Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Glaucoma Serv, 51 N 39th St, Philadelphia, PA 19104 USA.	ebd@mail.med.upenn.edu		Lipton, Stuart/0000-0002-3490-1259	NATIONAL EYE INSTITUTE [R01EY010009, R01EY005477] Funding Source: NIH RePORTER; NEI NIH HHS [R01-EY10009, R01-EY05477] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON DR, 1974, INVEST OPHTH VISUAL, V13, P771; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Brooks DE, 1997, AM J VET RES, V58, P864; COCKBURN DM, 1983, AM J OPTOM PHYS OPT, V60, P705; Dreyer EB, 1997, VET COMP OPHTHALMOL, V7, P192; Dreyer EB, 1996, ARCH OPHTHALMOL-CHIC, V114, P299, DOI 10.1001/archopht.1996.01100130295012; DREYER EB, 1995, NEUROREPORT, V6, P942, DOI 10.1097/00001756-199504190-00029; HART WM, 1979, ARCH OPHTHALMOL-CHIC, V97, P1455; Hattenhauer MG, 1998, OPHTHALMOLOGY, V105, P2099, DOI 10.1016/S0161-6420(98)91133-2; LAMPERT PW, 1968, INVEST OPHTH VISUAL, V7, P199; LANDERS MB, 1982, GLAUCOMA; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LIPTON SA, 1993, TRENDS NEUROSCI, V16, P527, DOI 10.1016/0166-2236(93)90198-U; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LUCAS DR, 1957, ARCH OPHTHALMOL-CHIC, V58, P193; MULLER H, 1858, GRAEFES ARCH CLIN EX, V4, P1; Neufeld AH, 1997, ARCH OPHTHALMOL-CHIC, V115, P497, DOI 10.1001/archopht.1997.01100150499009; OBRIEN C, 1991, AM J OPHTHALMOL, V111, P491, DOI 10.1016/S0002-9394(14)72386-4; OLNEY JW, 1969, J NEUROPATH EXP NEUR, V28, P455, DOI 10.1097/00005072-196907000-00007; QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774; Sorsby A, 1963, MODERN OPHTHALMOLOGY; VonJaeger E, 1858, Z GES AERTZE WIEN, V14, P484; Vorwerk CK, 1996, INVEST OPHTH VIS SCI, V37, P1618; Wax MB, 1998, ARCH OPHTHALMOL-CHIC, V116, P993, DOI 10.1001/archopht.116.8.993; WILSON R, 1982, ARCH OPHTHALMOL-CHIC, V100, P737, DOI 10.1001/archopht.1982.01030030741002; [No title captured]	27	37	43	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1999	281	4					306	308		10.1001/jama.281.4.306	http://dx.doi.org/10.1001/jama.281.4.306			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158JB	9929066				2022-12-28	WOS:000078111300001
J	Johnson, FB; Sinclair, DA; Guarente, L				Johnson, FB; Sinclair, DA; Guarente, L			Molecular biology of aging	CELL			English	Review							NEMATODE CAENORHABDITIS-ELEGANS; WERNERS-SYNDROME GENES; PROGRAMMED CELL-DEATH; SACCHAROMYCES-CEREVISIAE; DNA HELICASE; LIFE-SPAN; MITOCHONDRIAL-DNA; SUPEROXIDE-DISMUTASE; HUMAN FIBROBLASTS; FOOD RESTRICTION		MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Johnson, FB (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	leng@mit.edu		Sinclair, David/0000-0002-9936-436X	NIA NIH HHS [R01 AG1119] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Apfeld J, 1998, CELL, V95, P199, DOI 10.1016/S0092-8674(00)81751-1; BARTON AA, 1950, J GEN MICROBIOL, V4, P84, DOI 10.1099/00221287-4-1-84; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2; Bohr V A, 1998, J Investig Dermatol Symp Proc, V3, P11; Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212; BROWN WT, 1992, AM J CLIN NUTR, V55, P1222; Campisi J, 1998, J Investig Dermatol Symp Proc, V3, P1; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Cristofalo VJ, 1998, P NATL ACAD SCI USA, V95, P10614, DOI 10.1073/pnas.95.18.10614; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dolle MET, 1997, NAT GENET, V17, P431, DOI 10.1038/ng1297-431; Effros RB, 1998, AM J HUM GENET, V62, P1003, DOI 10.1086/301845; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; Finch CE, 1990, LONGEVITY SENESCENCE; FRIEDMAN DB, 1988, GENETICS, V118, P75; Fry M, 1998, NAT GENET, V19, P308, DOI 10.1038/1188; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GAUBATZ JW, 1990, MUTAT RES, V237, P271, DOI 10.1016/0921-8734(90)90009-G; Goto M, 1997, MECH AGEING DEV, V98, P239, DOI 10.1016/S0047-6374(97)00111-5; GOTTLIEB S, 1994, GENETICS, V137, P107; GRASLKRAUPP B, 1994, P NATL ACAD SCI USA, V91, P9995, DOI 10.1073/pnas.91.21.9995; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRIST SA, 1992, MUTAT RES, V266, P189, DOI 10.1016/0027-5107(92)90186-6; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HAYES A, 1993, PEDIATR CLIN N AM, V40, P523; Hengartner MO, 1997, EXP GERONTOL, V32, P363, DOI 10.1016/S0531-5565(96)00167-2; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; JAZWINSKI SM, 1993, GENETICA, V91, P35, DOI 10.1007/BF01435986; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; Kajstura J, 1996, AM J PHYSIOL-HEART C, V271, pH1215, DOI 10.1152/ajpheart.1996.271.3.H1215; Kajstura J, 1998, P NATL ACAD SCI USA, V95, P8801, DOI 10.1073/pnas.95.15.8801; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KING CM, 1994, MUTAT RES-DNAGING G, V316, P79, DOI 10.1016/0921-8734(94)90010-8; KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KLASS MR, 1983, MECH AGEING DEV, V22, P279, DOI 10.1016/0047-6374(83)90082-9; Kopsidas G, 1998, MUTAT RES-FUND MOL M, V421, P27, DOI 10.1016/S0027-5107(98)00150-X; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Lamberts SWJ, 1997, SCIENCE, V278, P419, DOI 10.1126/science.278.5337.419; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; Lee CM, 1997, FREE RADICAL BIO MED, V22, P1259, DOI 10.1016/S0891-5849(96)00546-1; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; LITHGOW GJ, 1994, J GERONTOL, V49, pB270, DOI 10.1093/geronj/49.6.B270; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MARTIN GM, 1985, ISRAEL J MED SCI, V21, P296; MARTIN GM, 1970, LAB INVEST, V23, P86; Medawar P., 1952, UNSOLVED PROBLEM BIO; MELOV S, 1995, NUCLEIC ACIDS RES, V23, P1419, DOI 10.1093/nar/23.8.1419; MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; MULLERHOCKER J, 1993, VIRCHOWS ARCH A, V422, P7, DOI 10.1007/BF01605127; Murakami S, 1996, GENETICS, V143, P1207; MUSKHELISHVILI L, 1995, AM J PATHOL, V147, P20; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; OLIVETTI G, 1995, J AM COLL CARDIOL, V26, P1068, DOI 10.1016/0735-1097(95)00282-8; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; OSHIMA J, 1995, J CELL PHYSIOL, V162, P277, DOI 10.1002/jcp.1041620213; Pakkenberg B, 1997, J COMP NEUROL, V384, P312, DOI 10.1002/(SICI)1096-9861(19970728)384:2<312::AID-CNE10>3.0.CO;2-K; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; PROMISLOW DEL, 1993, J GERONTOL, V48, pB115, DOI 10.1093/geronj/48.4.B115; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; ROBBINS E, 1970, J EXP MED, V131, P1211, DOI 10.1084/jem.131.6.1211; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; Schachter F, 1998, AM J HUM GENET, V62, P1008, DOI 10.1086/301849; Schulz VP, 1996, HUM GENET, V97, P750; SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3; SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; STREHLER BL, 1986, EXP GERONTOL, V21, P283, DOI 10.1016/0531-5565(86)90038-0; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; SZILARD L, 1959, P NATL ACAD SCI USA, V45, P30, DOI 10.1073/pnas.45.1.30; TAKEDA K, 1992, J CELL PHYSIOL, V153, P450, DOI 10.1002/jcp.1041530303; Tissenbaum HA, 1998, GENETICS, V148, P703; Toda T, 1998, MECH AGEING DEV, V100, P133, DOI 10.1016/S0047-6374(97)00131-0; Vanfleteren JR, 1996, J EXP ZOOL, V274, P93, DOI 10.1002/(SICI)1097-010X(19960201)274:2&lt;93::AID-JEZ2&gt;3.0.CO;2-8; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wallace Douglas C., 1998, Biofactors, V7, P187; WANG E, 1995, CANCER RES, V55, P2284; Warner HR, 1997, J AM GERIATR SOC, V45, P1140, DOI 10.1111/j.1532-5415.1997.tb05981.x; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Weindruch R, 1996, TOXICOL PATHOL, V24, P742, DOI 10.1177/019262339602400618; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; WONG A, 1995, GENETICS, V139, P1247; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Ye L, 1997, AM J MED GENET, V68, P494, DOI 10.1002/(SICI)1096-8628(19970211)68:4<494::AID-AJMG30>3.0.CO;2-L; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	121	387	406	0	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 22	1999	96	2					291	302		10.1016/S0092-8674(00)80567-X	http://dx.doi.org/10.1016/S0092-8674(00)80567-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	160VM	9988222	Bronze			2022-12-28	WOS:000078252200011
J	Huang, JD; Brady, ST; Richards, BW; Stenoien, D; Resau, JH; Copeland, NG; Jenkins, NA				Huang, JD; Brady, ST; Richards, BW; Stenoien, D; Resau, JH; Copeland, NG; Jenkins, NA			Direct interaction of microtubule- and actin-based transport motors	NATURE			English	Article							ATAXIC MUTANT RAT; DILUTE COAT COLOR; BRAIN MYOSIN-V; UNCONVENTIONAL MYOSIN; AXONAL-TRANSPORT; PURKINJE-CELLS; KINESIN HEAVY; GENE; CLONING; PROTEIN	The microtubule network is thought to be used for long-range transport of cellular components in animal cells whereas the actin network is proposed to be used for short-range transport(1), although the mechanism(s) by which this transport is coordinated is poorly understood. For example, in sea urchins long-range Ca2+-regulated transport of exocytotic vesicles requires a microtubule-based motor, whereas an actin-based motor is used for short-range transport(2), In neurons, microtubule-based kinesin motor proteins are used for long-range vesicular transport(3) but microtubules do not extend into the neuronal termini, where actin filaments form the cytoskeletal framework(4), and kinesins are rapidly degraded upon their arrival in neuronal termini(5), indicating that vesicles may have to be transferred from microtubules to actin tracks to reach their final destination. Here we show that an actin-based vesicle-transport motor, MyoVA (ref. 6), can interact directly with a microtubule-based transport motor, KhcU. As would be expected if these complexes were functional, they also contain kinesin light chains and the localization of MyoVA and KhcU overlaps in the cell, These results indicate that cellular transport is, in part, coordinated through the direct interaction of different motor molecules.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Ft Detrick, MD 21702 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Jenkins, NA (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Ft Detrick, MD 21702 USA.		/C-4277-2009	/0000-0001-7531-2816				Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; BRADY ST, 1995, TRENDS CELL BIOL, V5, P159, DOI 10.1016/S0962-8924(00)88980-1; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; DEKKEROHNO K, 1993, LAB ANIM SCI, V43, P370; DekkerOhno K, 1996, BRAIN RES, V714, P226, DOI 10.1016/0006-8993(95)01560-4; Evans LL, 1997, J CELL SCI, V110, P439; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; LANGFORD GM, 1995, CURR OPIN CELL BIOL, V7, P82, DOI 10.1016/0955-0674(95)80048-4; LEBEUX YJ, 1975, CELL TISSUE RES, V160, P37; LEOPOLD PL, 1992, CELL MOTIL CYTOSKEL, V23, P19, DOI 10.1002/cm.970230104; LILLIE SH, 1992, NATURE, V356, P358, DOI 10.1038/356358a0; LILLIE SH, 1994, J CELL BIOL, V125, P825, DOI 10.1083/jcb.125.4.825; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265, DOI 10.1016/S0968-0004(00)89040-4; PRASAD R, 1993, CANCER RES, V53, P5624; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; Provance DW, 1996, P NATL ACAD SCI USA, V93, P14554, DOI 10.1073/pnas.93.25.14554; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; SEPERACK PK, 1995, EMBO J, V14, P2326, DOI 10.1002/j.1460-2075.1995.tb07227.x; Stenoien DL, 1997, MOL BIOL CELL, V8, P675, DOI 10.1091/mbc.8.4.675; Takagishi Y, 1996, NEUROSCI LETT, V215, P169, DOI 10.1016/S0304-3940(96)12967-0; TSAN JT, 1997, YEAST 2 HYBRID SYSTE, P217; Wu XF, 1997, J CELL SCI, V110, P847	30	289	296	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 21	1999	397	6716					267	270		10.1038/16722	http://dx.doi.org/10.1038/16722			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159QH	9930703				2022-12-28	WOS:000078184800056
J	Montefiori, DC; Moore, JP				Montefiori, DC; Moore, JP			HIV vaccines - Magic of the occult?	SCIENCE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; NEUTRALIZATION; GP41; ANTIBODIES; PROTEINS		Duke Univ, Med Ctr, Dept Surg, Ctr AIDS Res, Durham, NC 27710 USA; Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10021 USA	Duke University; Rockefeller University	Montefiori, DC (corresponding author), Duke Univ, Med Ctr, Dept Surg, Ctr AIDS Res, Durham, NC 27710 USA.							ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; BOUHABIB DC, 1994, J VIROL, V68, P6006, DOI 10.1128/JVI.68.9.6006-6013.1994; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Connor RI, 1998, J VIROL, V72, P1552, DOI 10.1128/JVI.72.2.1552-1576.1998; CRANAGE MP, 1993, AIDS RES HUM RETROV, V9, P13, DOI 10.1089/aid.1993.9.13; Ferrari G, 1997, P NATL ACAD SCI USA, V94, P1396, DOI 10.1073/pnas.94.4.1396; Graham BS, 1998, J INFECT DIS, V177, P310, DOI 10.1086/514209; HANSON CV, 1994, AIDS RES HUM RETROV, V10, P645, DOI 10.1089/aid.1994.10.645; Heilman CA, 1998, NAT MED, V4, P532, DOI 10.1038/nm0598supp-532; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LaCasse RA, 1999, SCIENCE, V283, P357, DOI 10.1126/science.283.5400.357; LANGLOIS AJ, 1992, SCIENCE, V255, P292, DOI 10.1126/science.1549775; Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340; MONTEFIORI DC, 1991, NATURE, V354, P439, DOI 10.1038/354439c0; MONTEFIORI DC, 1994, VIROLOGY, V205, P82, DOI 10.1006/viro.1994.1622; Moore JP, 1998, NATURE, V393, P630, DOI 10.1038/31359; MORRIS B, 1995, WILSON LIBR BULL, V69, P101; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; VANCOTT TC, 1995, AIDS RES HUM RETROV, V11, P1379, DOI 10.1089/aid.1995.11.1379; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514	24	24	26	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					336	337		10.1126/science.283.5400.336	http://dx.doi.org/10.1126/science.283.5400.336			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9925493				2022-12-28	WOS:000078067000029
J	Cates, W				Cates, W			Chlamydial infections and the risk of ectopic pregnancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							EPIDEMIOLOGY		Family Hlth Int, Res Triangle Pk, NC 27709 USA		Cates, W (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.							[Anonymous], [No title captured]; Burstein GR, 1998, JAMA-J AM MED ASSOC, V280, P521, DOI 10.1001/jama.280.6.521; CATES W, 1991, AM J OBSTET GYNECOL, V164, P1771, DOI 10.1016/0002-9378(91)90559-A; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P6; CHOW WH, 1987, EPIDEMIOL REV, V9, P70, DOI 10.1093/oxfordjournals.epirev.a036309; Egger M, 1998, BRIT MED J, V316, P1776, DOI 10.1136/bmj.316.7147.1776; Orr DP, 1997, J ADOLESCENT HEALTH, V20, P3, DOI 10.1016/S1054-139X(96)00220-0; Ostergaard L, 1998, BRIT MED J, V317, P26, DOI 10.1136/bmj.317.7150.26; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103	9	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					117	118		10.1001/jama.281.2.117	http://dx.doi.org/10.1001/jama.281.2.117			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155VJ	9917099				2022-12-28	WOS:000077966800003
J	Sawicki, PT				Sawicki, PT		Work Grp Study Patient Self-Management Oral	A structured teaching and self-management program for patients receiving oral anticoagulation - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTHROMBIN TIME MONITOR; WARFARIN THERAPY	Context Control of oral anticoagulation therapy has been reported to often be inadequate. Previous retrospective investigations suggest that patients' self-adjustment of oral anticoagulants may lead to improved control. Objective To investigate the effects of patients' self-management of oral anticoagulation therapy on accuracy of control and measures of treatment-related quality of life. Design Randomized, single-blind, multicenter trial. Setting and Participants A total of 179 patients receiving long-term oral anticoagulation treatment were enrolled at 5 referral centers in Germany. Intervention Patients were randomized to an oral anticoagulation selfmanagement group based on a structured treatment and teaching program and international normalized ratio (INR) self-monitoring. The control group received conventional care as provided by family physicians, including referral to specialists if necessary. Main Outcome Measures Deviation of INR values from the individual INR target range (squared) and the 5 categories of treatment-related quality of life. Results Deviation of INR value from the mean of the INR target range was significantly lower in the intervention group at 3-month (squared INR deviation, 0.59 vs 0.95; P < .001) and 6-month follow-up (0.65 vs 0.83; P = .03) compared with the control group. Also, the intervention group had INR values within the target range more often (repeated measurement analysis for categorical data, P = .006). The results were mainly due to less frequent suboptimal INR values in the intervention group (32.8% vs 50.0% [P = .03] at 3-month, and 33.7% vs 48.2% [P = .08] at 6-month follow-up). Treatment-related quality-of-life measures, especially treatment satisfaction scores, were significantly higher in the intervention group compared with controls. Conclusions An anticoagulation education program that includes selfmanagement of anticoagulation therapy results in improved accuracy of anticoagulation control and in treatment-related quality-of-life measures. Further studies are needed to describe whether the program will reduce risk of bleeding or thromboembolism.	Univ Dusseldorf, Dept Metab Dis & Nutr, D-40001 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Sawicki, PT (corresponding author), Univ Dusseldorf, Dept Metab Dis & Nutr, POB 101007, D-40001 Dusseldorf, Germany.	Sawicki@med.uni-duesseldorf.de						*AD HOC COMM WORK, 1993, J HEART VALVE DIS, V2, P398; ANDERSON DR, 1993, ARCH INTERN MED, V153, P1441, DOI 10.1001/archinte.153.12.1441; ANSELL J, 1989, ARCH INTERN MED, V149, P2509, DOI 10.1001/archinte.149.11.2509; ANSELL JE, 1995, ARCH INTERN MED, V155, P2185, DOI 10.1001/archinte.155.20.2185; BERNARDO A, 1992, THROMBOSIS EMBOLISM, P325; DUXBURY BM, 1982, BRIT MED J, V284, P702, DOI 10.1136/bmj.284.6317.702; HARRIES AD, 1981, LANCET, V1, P1320; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; KITCHEN S, 1994, THROMB HAEMOSTASIS, V72, P426; KOCH GG, 1977, BIOMETRICS, V33, P133, DOI 10.2307/2529309; KUMAR S, 1989, THROMB HAEMOSTASIS, V62, P729; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1989, J CLIN EPIDEMIOL, V42, P711, DOI 10.1016/0895-4356(89)90066-8; LOELIGER EA, 1985, THROMB HAEMOSTASIS, V53, P155; MASSICOTTE P, 1995, J PEDIATR-US, V127, P389, DOI 10.1016/S0022-3476(95)70069-2; MUHLHAUSER I, 1993, J INTERN MED, V233, P321; PATERSON CE, 1986, ARCH INTERN MED, V146, P581; Rosendaal FR, 1996, NEW ENGL J MED, V335, P587, DOI 10.1056/NEJM199608223350810; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; *SAS I INC, 1987, SAS STAT VERS 6 GUID; SAWICKI PT, 1995, J HYPERTENS, V13, P933, DOI 10.1097/00004872-199508000-00015; SCHULMAN S, 1994, J INTERN MED, V236, P143, DOI 10.1111/j.1365-2796.1994.tb01276.x; *STAND ADV COMM HA, 1982, BMJ-BRIT MED J, V285, P274; TODD C, 1994, HDB PSYCHOL DIABETES, P15; vandenBesselaar AMHP, 1995, BLOOD COAGUL FIBRIN, V6, P726, DOI 10.1097/00001721-199512000-00005; WHITE RH, 1989, ANN INTERN MED, V111, P730, DOI 10.7326/0003-4819-111-9-730	26	287	290	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					145	150		10.1001/jama.281.2.145	http://dx.doi.org/10.1001/jama.281.2.145			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155VJ	9917117				2022-12-28	WOS:000077966800034
J	Ravussin, E; Danforth, E				Ravussin, E; Danforth, E			Perspectives: Human physiology - Beyond sloth - Physical activity and weight gain	SCIENCE			English	Editorial Material							ENERGY-EXPENDITURE		Univ Vermont, Burlington, VT 05405 USA; Eli Lilly & Co, Indianapolis, IN 46285 USA	University of Vermont; Eli Lilly	Ravussin, E (corresponding author), Eli Lilly & Co, Indianapolis, IN 46285 USA.		Ravussin, Eric/N-1985-2017; Steib, Lori/B-6628-2014	Ravussin, Eric/0000-0003-2129-547X; Steib, Lori/0000-0001-8274-318X				BOOTHBY WM, 1992, AM J PHYSIOL, V90, P290; BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101; CHRISTIN L, 1993, METABOLISM, V42, P723, DOI 10.1016/0026-0495(93)90239-K; Hill JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/science.280.5368.1371; HIMMSHAGEN J, 1978, BIOCHEM BIOPH RES CO, V83, P628, DOI 10.1016/0006-291X(78)91036-7; Levine JA, 1999, SCIENCE, V283, P212, DOI 10.1126/science.283.5399.212; LIEBEL RL, 1995, NEW ENGL J MED, V332, P621; NEEL JV, 1962, AM J HUM GENET, V14, P353; Neumann RO, 1902, ARCH HYG, V45, P1; POMP D, 1902, IN PRESS OBES RES; RAVUSSIN E, 1986, J CLIN INVEST, V78, P1568, DOI 10.1172/JCI112749; ROBERTS SB, 1990, J PHYSL, V259, P461; Sims E A, 1973, Recent Prog Horm Res, V29, P457; WIDDOWSON EM, 1954, BRIT J NUTR, V8, P147, DOI 10.1079/BJN19540023; ZURLO F, 1992, AM J PHYSIOL, V263, pE296, DOI 10.1152/ajpendo.1992.263.2.E296	15	24	24	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 8	1999	283	5399					184	185		10.1126/science.283.5399.184	http://dx.doi.org/10.1126/science.283.5399.184			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9925477				2022-12-28	WOS:000077976700027
J	Tiedge, H; Bloom, FE; Richter, D				Tiedge, H; Bloom, FE; Richter, D			Perspectives: Neuroscience - RNA, whither goest thou?	SCIENCE			English	Editorial Material							VASOPRESSIN MESSENGER-RNA; ELECTRON-MICROSCOPIC EVIDENCE; AXONAL COMPARTMENTALIZATION; OLFACTORY-BULB; BC1 RNA; DENDRITES; PROTEIN; LOCALIZATION; NEURONS; TRANSPORT		SUNY Hlth Sci Ctr, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA; Univ Hamburg, Inst Zellbiochem & Klin Neurobiol, Hamburg, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Scripps Research Institute; University of Hamburg	Tiedge, H (corresponding author), SUNY Hlth Sci Ctr, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA.	tiedge@hscbklyn.edu; fbloom@scripps.edu; richter@uke.uni-hamburg.de						Crino P, 1998, P NATL ACAD SCI USA, V95, P2313, DOI 10.1073/pnas.95.5.2313; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Knowles RB, 1997, P NATL ACAD SCI USA, V94, P14804, DOI 10.1073/pnas.94.26.14804; Landry M, 1998, NEUROSCIENCE, V84, P897, DOI 10.1016/S0306-4522(97)00567-8; LINK W, 1995, P NATL ACAD SCI USA, V92, P5734, DOI 10.1073/pnas.92.12.5734; LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6; Mayford M, 1996, P NATL ACAD SCI USA, V93, P13250, DOI 10.1073/pnas.93.23.13250; MELIA KR, 1994, EXP NEUROL, V130, P394, DOI 10.1006/exnr.1994.1219; MOHR E, 1995, P NATL ACAD SCI USA, V92, P4377, DOI 10.1073/pnas.92.10.4377; MOHR E, 1993, VASOPRESSIN, P119; MOHR E, 1997, NEUROENDOCRINOLOGY R, P55; Muslimov IA, 1998, J CELL BIOL, V141, P1601, DOI 10.1083/jcb.141.7.1601; Muslimov IA, 1997, J NEUROSCI, V17, P4722; Prakash N, 1997, EUR J NEUROSCI, V9, P523, DOI 10.1111/j.1460-9568.1997.tb01629.x; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; SPIRIN AS, 1994, MOL REPROD DEV, V38, P107, DOI 10.1002/mrd.1080380117; Steward O, 1997, NEURON, V18, P9, DOI 10.1016/S0896-6273(01)80041-6; Steward O, 1998, NEURON, V21, P741, DOI 10.1016/S0896-6273(00)80591-7; TIEDGE H, 1993, J NEUROSCI, V13, P4214; Tongiorgi E, 1997, J NEUROSCI, V17, P9492; TREMBLEAU A, 1994, J NEUROSCI, V14, P39; TREMBLEAU A, 1995, EUR J NEUROSCI, V7, P2249, DOI 10.1111/j.1460-9568.1995.tb00646.x; Trembleau A, 1996, NEUROSCIENCE, V70, P113, DOI 10.1016/0306-4522(95)00328-G; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; Wallace CS, 1998, J NEUROSCI, V18, P26; Weiler IJ, 1997, P NATL ACAD SCI USA, V94, P5395, DOI 10.1073/pnas.94.10.5395; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3	28	81	81	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	1999	283	5399					186	187		10.1126/science.283.5399.186	http://dx.doi.org/10.1126/science.283.5399.186			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9925478				2022-12-28	WOS:000077976700028
J	Hedges, SB; Poling, LL				Hedges, SB; Poling, LL			A molecular phylogeny of reptiles	SCIENCE			English	Article							TURTLES; ORIGIN; SEQUENCES; POSITION; BIRDS	The classical phylogeny of Living reptiles pairs crocodilians with birds, tuataras with squamates, and places turtles at the base of the tree. New evidence from two nuclear genes, and analyses of mitochondrial DNA and 22 additional nuclear genes, join crocodilians with turtles and place squamates at the base of the tree. Morphological and paleontological evidence for this molecular phylogeny is unclear. Molecular time estimates support a Triassic origin for the major groups of Living reptiles.	Penn State Univ, Inst Mol Evolut Genet, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA; Penn State Univ, Astrobiol Res Ctr, Mueller Lab 208, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Hedges, SB (corresponding author), Penn State Univ, Inst Mol Evolut Genet, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA.							[Anonymous], 1966, VERTEBRATE PALEONTOL; Benton MJ, 1997, VERTEBRATE PALEONTOL; BENTON MJ, 1993, FOSSIL RECORD, V2; deBraga M, 1997, ZOOL J LINN SOC-LOND, V120, P281, DOI 10.1111/j.1096-3642.1997.tb01280.x; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Fushitani K, 1996, MOL BIOL EVOL, V13, P1039, DOI 10.1093/oxfordjournals.molbev.a025654; Gaffney E. S., 1990, B AM MUS NAT HIST, V194, P1; GAFFNEY ES, 1988, PHYLOGENY CLASSIFICA, V1, P157; GOODMAN M, 1987, MOL MORPHOLOGY EVOLU; Gorr TA, 1998, J MOL EVOL, V47, P471, DOI 10.1007/PL00006404; Gu X, 1997, MOL BIOL EVOL, V14, P1106, DOI 10.1093/oxfordjournals.molbev.a025720; HEDGES SB, 1990, MOL BIOL EVOL, V7, P607; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; HEDGES SB, 1994, P NATL ACAD SCI USA, V91, P2621, DOI 10.1073/pnas.91.7.2621; JAMIESON BGM, 1992, PHILOS T ROY SOC B, V335, P207, DOI 10.1098/rstb.1992.0019; Kirsch JAW, 1998, PHILOS T R SOC B, V353, P1221, DOI 10.1098/rstb.1998.0278; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; KUMAR S, 1996, PHYLTEST PROGRAM TES; Kumar S., 1993, MEGA MOL EVOLUTIONAR; LAURIN M, 1995, ZOOL J LINN SOC-LOND, V113, P165, DOI 10.1111/j.1096-3642.1995.tb00932.x; LAURIN M, 1997, COMPLETING TRANSITIO, P9; Lee MSY, 1997, ZOOL J LINN SOC-LOND, V120, P197; Lee MSY, 1996, NATURE, V379, P812, DOI 10.1038/379812a0; Lee MSY, 1997, NATURE, V389, P245, DOI 10.1038/38422; Mannen H, 1997, MOL BIOL EVOL, V14, P1081, DOI 10.1093/oxfordjournals.molbev.a025717; Platz JE, 1997, NATURE, V389, P246, DOI 10.1038/38425; Rieppel O, 1996, NATURE, V384, P453, DOI 10.1038/384453a0; Romer A, 1956, OSTEOLOGY REPTILES; RZHETSKY A, 1995, MOL BIOL EVOL, V12, P163, DOI 10.1093/oxfordjournals.molbev.a040185; Saita A., 1987, B ZOOL, V4, P307; SWOFFORD DL, 1998, PAUP PHYLOGENETIC AN; TAKEZAKI N, 1995, MOL BIOL EVOL, V12, P823; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wilkinson M, 1997, NATURE, V387, P466, DOI 10.1038/387466a0; Zardoya R, 1998, P NATL ACAD SCI USA, V95, P14226, DOI 10.1073/pnas.95.24.14226; [No title captured]; [No title captured]	37	264	287	1	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					998	1001		10.1126/science.283.5404.998	http://dx.doi.org/10.1126/science.283.5404.998			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974396				2022-12-28	WOS:000078574800053
J	Bradbury, A; Evans, C; Allan, P; Lee, A; Ruckley, CV; Fowkes, FGR				Bradbury, A; Evans, C; Allan, P; Lee, A; Ruckley, CV; Fowkes, FGR			What are the symptoms of varicose veins? Edinburgh vein study cross sectional population survey	BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE	Objective To define the relations between age, sex, lower limb symptoms, and the presence of trunk varicose veins on clinical examination. Design Cross sectional population study. Setting 12 general practices with catchment areas geographically and socioeconomically distributed throughout Edinburgh. Participants An age stratified random sample of 1566 people (699 men and 867 women) aged 18-64 selected from the computerised age-sex registers of participating practices. Main outcome measures Self administered questionnaire on the presence of lower limb symptoms and physical examination to determine the presence and severity of varicose veins. Results Women were significantly mole likely than men to report lower limb symptoms such as heaviness or tension, swelling, aching, restless legs, cramps, and itching. The prevalence of symptoms tended to increase with age in both sexes. In men, only itching was significantly related to the presence and severity of trunk varices (linear test for trend, P = 0.011). In women there was a significant relation between trunk varices and the symptoms of heaviness or tension (P less than or equal to 0.001), aching (P less than or equal to 0.001), and itching (P less than or equal to 0.005). However, the level of agreement between the presence of symptoms and trunk varices was too low to be of clinical value, especially in men. Conclusions Even in the presence of trunk varices, most lower limb symptoms probably have a non-venous cause. Surgical extirpation of trunk varices is unlikely to ameliorate such symptoms in most patients.	Univ Edinburgh, Wolfson Unit Prevent Peripheral Vasc Dis, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Royal Infirm, Dept Surg & Clin Sci, Vasc Surg Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Royal Infirm, Dept Med Imaging, Edinburgh, Midlothian, Scotland	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh	Fowkes, FGR (corresponding author), Univ Edinburgh, Wolfson Unit Prevent Peripheral Vasc Dis, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	gerry.fowkes@ed.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER DM, 1995, EUR J VASC ENDOVASC, V9, P299, DOI 10.1016/S1078-5884(05)80134-0; CALLAM MJ, 1994, BRIT J SURG, V81, P167, DOI 10.1002/bjs.1800810204; *DEP HLTH SOC SEC, 1988, HOSP EP STAT 1987 88; Evans CJ, 1997, PHLEBOLOGY, V12, P127, DOI 10.1177/026835559701200403; EVANS CJ, IN PRESS J EPIDEMIOL; EVANS CJ, IN PRESS J VASC SURG; FORREST APM, 1995, PRINCIPLES PRACTICE, P289; FOWKES FGR, 1996, PHLEBOLOGY, V41, P2; JOHNSON G, 1995, VASCULAR SURG, P1825; JONES HJS, 1997, EUR J VASC ENDOVASC, V14, P130; Nelzen O, 1996, BRIT J SURG, V83, P255, DOI 10.1046/j.1365-2168.1996.02099.x; Nelzen O, 1996, PHLEBOLOGY, V11, P50, DOI 10.1177/026835559601100204; Peripheral Venous Disorders LK, 1978, PREVALENCE SOCIO MED, P1; ROYLE JP, 1992, SURG MANAGEMENT VASC, P1239; Ruckley CV, 1997, ANGIOLOGY, V48, P67, DOI 10.1177/000331979704800111; TIBBS DT, 1994, OXFORD TXB SURG, P503	16	216	229	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					353	356		10.1136/bmj.318.7180.353	http://dx.doi.org/10.1136/bmj.318.7180.353			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933194	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000078572600022
J	Wang, C; Stewart, RJ; Kopecek, J				Wang, C; Stewart, RJ; Kopecek, J			Hybrid hydrogels assembled from synthetic polymers and coiled-coil protein domains	NATURE			English	Article							PHASE-TRANSITION; GEL; HETERODIMER; SWITCH	Stimuli-sensitive polymer hydrogels, which swell or shrink in response to changes in the environmental conditions, have been extensively investigated and used as 'smart' biomaterials and drug-delivery systems(1,2). Most of these responsive hydrogels are prepared from a limited number of synthetic polymers and their derivatives, such as copolymers of (meth)acrylic acid, acrylamide and N-isopropyl acrylamide(3-12). Water-soluble synthetic polymers have also been crosslinked with molecules of biological origin, such as oligopeptides(13) and oligodeoxyribonudeotides(14), or with intact native proteins(15). Very often there are several factors influencing the relationship between structure and properties in these systems, making it difficult to engineer hydrogels with specified responses to particular stimuli. Here we report a hybrid hydrogel system assembled from water-soluble synthetic polymers and a well-defined protein-folding motif, the coiled coil. These hydrogels undergo temperature-induced collapse owing to the cooperative conformational transition of the coiled-coil protein domain. This system shows that well-characterized water-soluble synthetic polymers can be combined with well-defined folding motifs of proteins in hydrogels with engineered volume-change properties(16,17).	Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Kopecek, J (corresponding author), Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA.	Jindrich.Kopecek@m.cc.utah.edu						Aggeli A, 1997, NATURE, V386, P259, DOI 10.1038/386259a0; CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P510, DOI 10.1038/nsb0696-510; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; Ho CH, 1998, LANGMUIR, V14, P3889, DOI 10.1021/la980148k; HOCHULI H, 1990, GENET ENG, V12, P87; Holtz JH, 1997, NATURE, V389, P829, DOI 10.1038/39834; Hu ZB, 1998, NATURE, V393, P149, DOI 10.1038/30205; ISER PF, 1998, NATURE, V394, P459; KOKUFATA E, 1991, NATURE, V351, P302, DOI 10.1038/351302a0; KOPECEK J, 1971, J POLYM SCI A1, V9, P2801, DOI 10.1002/pol.1971.150091005; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; Langer R, 1998, NATURE, V392, P5; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Nagahara S, 1996, POLYM GELS NETW, V4, P111, DOI 10.1016/0966-7822(96)00001-9; NG K, 1995, LANGMUIR, V11, P4048, DOI 10.1021/la00010a069; Obaidat AA, 1996, PHARM RES-DORDR, V13, P989, DOI 10.1023/A:1016090103979; OSADA Y, 1992, NATURE, V355, P242, DOI 10.1038/355242a0; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Peppas NA, 1997, CURR OPIN COLLOID IN, V2, P531, DOI 10.1016/S1359-0294(97)80103-3; Petka WA, 1998, SCIENCE, V281, P389, DOI 10.1126/science.281.5375.389; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; SUBR V, 1990, Journal of Biomaterials Science Polymer Edition, V1, P261; SUZUKI A, 1990, NATURE, V346, P345, DOI 10.1038/346345a0; WANG C, 1998, ACS POLYM PREPRINTS, V39, P194; WANG C, 1998, P INT S CONTR REL BI, V25, P54; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YOSHIDA R, 1995, NATURE, V374, P240, DOI 10.1038/374240a0	30	501	522	9	282	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 4	1999	397	6718					417	420		10.1038/17092	http://dx.doi.org/10.1038/17092			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164KA	9989405				2022-12-28	WOS:000078461700042
J	MacArthur, C				MacArthur, C			What does postnatal care do for women's health?	LANCET			English	Editorial Material									Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England	University of Birmingham	MacArthur, C (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England.			MacArthur, Christine/0000-0003-0434-2158				*AUD COMM, 1997, FIRST CLASS DEL IMPR; Billingham K, 1998, BRIT MED J, V316, P406, DOI 10.1136/bmj.316.7129.406; BORWN S, 1998, BRIT J OBSTET GYNAEC, V105, P156; Department of Health, 1993, CHANGING CHILDBIRTH; Enkin M., 1995, GUIDE EFFECTIVE CARE; Glazener CMA, 1997, BRIT J OBSTET GYNAEC, V104, P330, DOI 10.1111/j.1471-0528.1997.tb11463.x; GLAZENER CMA, 1995, BRIT J OBSTET GYNAEC, V102, P282, DOI 10.1111/j.1471-0528.1995.tb09132.x; Gunn J, 1998, BRIT J OBSTET GYNAEC, V105, P991, DOI 10.1111/j.1471-0528.1998.tb10263.x; MACARTHUR C, 1991, HLTH CHILDBIRTH; SHARIF K, 1993, J OBSTET GYNAECOL, V13, P251; SWEET B, 1997, MIDWIFERY TXB MIDWIV	11	30	30	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 30	1999	353	9150					343	344		10.1016/S0140-6736(05)74945-X	http://dx.doi.org/10.1016/S0140-6736(05)74945-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950436				2022-12-28	WOS:000078437000006
J	Chandna, SM; Schulz, J; Lawrence, C; Greenwood, RN; Farrington, K				Chandna, SM; Schulz, J; Lawrence, C; Greenwood, RN; Farrington, K			Is there a rationale for rationing chronic dialysis? A hospital based cohort study of factors affecting survival and morbidity	BRITISH MEDICAL JOURNAL			English	Article							RENAL-REPLACEMENT THERAPY; MAINTENANCE DIALYSIS; UREMIA THERAPY; FAILURE; DISEASE; NEED	Objectives To determine factors influencing survival and need for hospitalisation in patients needing dialysis, and to define the potential basis for rationing access to renal replacement therapy. Design Hospital based cohort study of all patients starting dialysis over a 4 year recruitment period (follow up 15-63 months). Groups were defined on the basis of age, comorbidity, functional status, and whether dialysis initiation was planned or unplanned. Setting Renal unit in a district general hospital, which acts as the main renal referral centre for four other such hospitals and serves a population of about 1.15 million people. Subjects 292 patients, mean age 61.3 years (18-92 years, SD 15.8), of whom 193 (66%) were male, and 59 (20%) were patients with diabetes. Dialysis initiation was planned in 163 (56%) patients and unplanned in 129 (44%). Main outcome measures Overall survival, 1 year survival, and hospitalisation rate. Results Factors affecting survival in the Cox's proportional hazard model were Karnofsky performance score at presentation (hazard ratio 0.979, 95% confidence inter val 0.972 to 0.986), comorbidity severity score (1.240, 1.131 to 1.340), age (1.036, 1.018 to 1.054), and myeloma (2.15, 1.140 to 4.042). The Karnofsky performance score used 3 months before presentation was signficant (0.970, 0.956 to 0.981), as was unplanned presentation in this model (1.796, 1.233 to 2.617). Using these factors, a high risk group of 26 patients was defined, with 19.2% 1 year survival. Denying dialysis to this group would save 3.2% of the total cost of the chronic programme but would sacrifice five long term survivors. Less rigorous definition of the high risk group would save more money but lose more long term survivors. Conclusions Severity of comorbid conditions and functional capacity are more important than age in predicting survival and morbidity of patients on dialysis. Late referral for dialysis affects survival adversely. Denial of dialysis to patients in an extremely high risk group, defined by a new stratification based on logistic regression, would be of debatable benefit.	Lister Hosp, Dept Nephrol, Stevenage SG1 4AB, Herts, England; Univ Hertfordshire, Dept Psychol, Hatfield AL10 9AB, Herts, England	Lister Hospital; University of Hertfordshire	Chandna, SM (corresponding author), Lister Hosp, Dept Nephrol, Stevenage SG1 4AB, Herts, England.	shahid.chandna@lister.org.uk	Farrington, Ken/V-1531-2019					ANDERSEN PK, 1991, STAT MED, V10, P1931, DOI 10.1002/sim.4780101208; BRINDLE D, 1997, GUARDIAN        0702, P6; BROWN JH, 1993, IRISH J MED SCI, V162, P213, DOI 10.1007/BF02945197; Catalano C, 1996, NEPHROL DIAL TRANSPL, V11, P133; Davies R, 1997, NEPHROL DIAL TRANSPL, V12, P2512, DOI 10.1093/ndt/12.12.2512; Farmery E., 1997, RENAL REPLACEMENT TH; FEEST TG, 1990, BRIT MED J, V301, P897, DOI 10.1136/bmj.301.6757.897; FRIEDMAN EA, 1992, ARTIF ORGANS, V16, P90; HIRSCH DJ, 1994, AM J KIDNEY DIS, V23, P463, DOI 10.1016/S0272-6386(12)81012-2; Hull AR, 1997, SEMIN NEPHROL, V17, P160; Ifudu O, 1996, AM J KIDNEY DIS, V28, P841, DOI 10.1016/S0272-6386(96)90383-2; INNES A, 1992, NEPHROL DIAL TRANSPL, V7, P467; JUNGERS P, 1993, NEPHROL DIAL TRANSPL, V8, P1089; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; KHAN IH, 1993, LANCET, V341, P415, DOI 10.1016/0140-6736(93)93003-J; KILNER JF, 1988, AM J PUBLIC HEALTH, V78, P144, DOI 10.2105/AJPH.78.2.144; KJELLSTRAND CM, 1994, CAN MED ASSOC J, V150, P1067; MCGEOWN MG, 1990, BRIT MED J, V301, P900, DOI 10.1136/bmj.301.6757.900; MENDELSSOHN DC, 1995, ARCH INTERN MED, V155, P2473, DOI 10.1001/archinte.155.22.2473; Parry RG, 1996, BRIT MED J, V313, P466; RATCLIFFE PJ, 1984, BRIT MED J, V288, P441, DOI 10.1136/bmj.288.6415.441; Sargent J. A., 1989, REPLACEMENT RENAL FU, P87; TATTERSALL J, 1995, AM J NEPHROL, V15, P283, DOI 10.1159/000168850; TISHER CC, 1994, ANN INTERN MED, V121, P62; WRIGHT LF, 1991, AM J KIDNEY DIS, V17, P25, DOI 10.1016/S0272-6386(12)80245-9	25	175	179	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1999	318	7178					217	223						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915728				2022-12-28	WOS:000078292300021
J	Grover, S				Grover, S			Gambling with cardiovascular risk: picking the winners and the losers	LANCET			English	Editorial Material							CORONARY-DISEASE; PRAVASTATIN; PREVENTION		Montreal Gen Hosp, Div Clin Epidemiol, Montreal, PQ H3G 1A4, Canada	McGill University	Grover, S (corresponding author), Montreal Gen Hosp, Div Clin Epidemiol, Montreal, PQ H3G 1A4, Canada.							*27 BETH C, 1996, J AM COLL CARDIOL, V27, P964; Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Grover SA, 1998, ARCH INTERN MED, V158, P655, DOI 10.1001/archinte.158.6.655; GROVER SA, 1995, JAMA-J AM MED ASSOC, V274, P801, DOI 10.1001/jama.274.10.801; LOWENSTEYN I, IN PRESS PREV MED; PEDERSEN TR, 1994, LANCET, V344, P1383; Ramsay LE, 1996, LANCET, V348, P387, DOI 10.1016/S0140-6736(96)05516-X; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837	12	10	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 23	1999	353	9149					254	255		10.1016/S0140-6736(05)74941-2	http://dx.doi.org/10.1016/S0140-6736(05)74941-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929013				2022-12-28	WOS:000078292200003
J	Kalra, PA; Kumwenda, M; MacDowall, P; Roland, MO				Kalra, PA; Kumwenda, M; MacDowall, P; Roland, MO			Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ARTERY STENOSIS; HEART-FAILURE; CAPTOPRIL	Objectives To determine the current pattern of use of angiotensin converting enzyme inhibitor and monitoring of renal function in general practice and to audit all admissions to a regional renal unit for. uraemia related to use of these drugs. Design Postal questionnaire sent to 400 general practitioners; audit of clinical notes of all patients receiving these drugs in one large general practice; audit of all cases of uraemia (creatinine concentration > 500 mu mol/l) related to treatment presenting to hospital renal services over 12 months. Setting General practices in the North Wales health authority and one in central Manchester. Regional renal unit in Salfold. Main outcome measures Proportion of general practitioners who regular ly monitored renal function before and after initiation of angiotensin converting enzyme inhibitors. Indications for treatment and details of monitoring of renal function in patients receiving these drugs. Incidence of related uraemia and evidence of comorbid disease, other aetiological factors, delayed detection, and patient outcome. Results 277 (69%) general practitioners replied; 235 (85%) checked renal function before but only 93 (34%) after the start of treatment, and 42 (15%) never checked renal function. Angiotensin converting enzyme inhibitors were prescribed for 162 patients from a total of 3625 aged >35 years (mean age 66.4 (SD 15.9) years). Monitoring of renal function occurred before treatment in 55 (45%) and after start of treatment in 35 (29%) of the 122 patients treated in general practice. Angiotensin converting enzyme inhibitors could be causally implicated in 9 (7%) of 135 admissions for uraemia (mean age 74.2 (7.2) v 62.1 (2.1) years; P < 0.01). 3 patients had renovascular disease and 6 had congestive cardiac failure with another intercurrent illness. Renal function had not been checked in any patient after the start of treatment; mean duration of illness before admission was 10.5 (3.2) days. Mean length of hospital stay was 20.9 (10.4) days; there were 8 survivors. Conclusion cases of uraemia related to treatment with angiotensin converting enzyme inhibitors are still encountered and are often detected late because of lack of judicious monitoring of renal function in vulnerable, often elderly, patients, especially at times of intercurrent illness. guidelines for appropriate monitoring of renal function may help to minimise the problem.	Hope Hosp, Dept Renal Med, Salford M6 8HD, Lancs, England; Glan Clwyd Hosp, Dept Renal Med, Rhyl LL18 5UJ, Wales; Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester, Lancs, England	University of Manchester	Kalra, PA (corresponding author), Hope Hosp, Dept Renal Med, Salford M6 8HD, Lancs, England.	phil@ren.srth.nwest.nhs.uk						CHOUDHRI AH, 1990, BRIT MED J, V301, P1197, DOI 10.1136/bmj.301.6762.1197; DARGIE HJ, 1994, BMJ-BRIT MED J, V308, P321, DOI 10.1136/bmj.308.6924.321; Eccles M, 1998, BMJ-BRIT MED J, V316, P1369, DOI 10.1136/bmj.316.7141.1369; HARDING MB, 1992, J AM SOC NEPHROL, V2, P1608; Hart W, 1993, BR J MED EC, V6, P91; HRICIK DE, 1983, NEW ENGL J MED, V308, P373, DOI 10.1056/NEJM198302173080706; KALRA PS, 1990, Q J MED, V282, P1013; MacDowall P, 1998, LANCET, V352, P13, DOI 10.1016/S0140-6736(97)11060-1; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; SCHWARTZ CJ, 1964, BRIT MED J, V2, P1415, DOI 10.1136/bmj.2.5422.1415; STRUTHERS AD, 1996, CLIN CARDIOL, V19, P2; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	12	38	40	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 23	1999	318	7178					234	237						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915733				2022-12-28	WOS:000078292300026
J	Quine, L				Quine, L			Workplace bullying in NHS community trust: staff questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article								Objectives To determine the prevalence of workplace bullying in an NHS community trust; to examine the association between bullying and occupational health outcomes, and to investigate the relation between support at work and bullying. Design Questionnaire survey Setting NHS community trust in the south east of England. Subjects Trust employees. Main outcome measures Measures included a 20 item inventory of bullying behaviours designed for the study, the job induced stress scale, the hospital anxiety and depression scale, the overall job, satisfaction scale, the support at work scale, and the propensity to leave scale. Results 1100 employees returned questionnaires-a response rare of 70%. 421 (38%) employees reported experiencing one or more types of bullying in the previous year. 460 (42%) had witnessed the bullying of others. When bullying occurred it was most likely to be by a manager. Two thirds of the vicitms of bullying had tried to take action when the bullying occurred, but most were dissatisfied with the outcome. Staff who had been bullied had significantly lower levels of job satisfaction (mean 10.5 (SD 2.7) v 12.2 (2.3), P < 0.001) and higher levels of job induced str-ess (mean 22.5 (SD 6.1) v 16.9 (5.8), P < 0.001), depression (8% (33) v 1% (7), P < 0.001), anxiety (30% (125) v 9% (60), P < 0.001). and intention to leave the job (8.5 (2.9) v 7.0 (2.7), P < 0.001). Support at work seemed to protect people from some of the damaging effects of bullying. Conclusions Bullying is a serious problem. Setting up systems for supporting staff and for dealing with interpersonal conflict may have benefits for both employers and staff.	Univ Kent, Dept Psychol, Ctr Res Hlth Behav, Canterbury CT2 7NP, Kent, England	University of Kent	Quine, L (corresponding author), Univ Kent, Dept Psychol, Ctr Res Hlth Behav, Canterbury CT2 7NP, Kent, England.		Winwood, Peter/A-6363-2008; Blewett, Verna L/A-5270-2012					Adams A., 1992, BULLYING WORK CONFRO; Alderman C., 1997, NURSING STANDARD, V11, P22; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BASSMAN F, 1992, ABUSE WORKPLACE; BJORKQVIST K, 1994, AGGRESSIVE BEHAV, V20, P173, DOI 10.1002/1098-2337(1994)20:3<173::AID-AB2480200304>3.0.CO;2-D; Cammann C., 1979, MICHIGAN ORG ASSESSM; COHEN S, 1983, J APPL SOC PSYCHOL, V13, P99, DOI 10.1111/j.1559-1816.1983.tb02325.x; Crawford N, 1997, J COMMUNITY APPL SOC, V7, P219, DOI 10.1002/(SICI)1099-1298(199706)7:3<219::AID-CASP420>3.0.CO;2-Q; Einarsen S., 1994, EUR J WORK ORGAN PSY, V4, P381, DOI DOI 10.1080/13594329408410497; Einarsen S., 1996, EUROPEAN J WORK ORG, V5, P185, DOI [10.1080/13594329608414854, DOI 10.1080/13594329608414854]; Health and Safety Executive, 1995, STRESS WORK GUID EMP; HOUSE RJ, 1972, ORGAN BEHAV HUM PERF, V7, P467, DOI 10.1016/0030-5073(72)90030-X; Lockhart K, 1997, J COMMUNITY APPL SOC, V7, P193; Lyons R., 1995, BULLYING WORK TACKLE; *MAN SCI FIN, 1995, BIG IS PROBL BULL WO; NACHMIAS C, 1981, RES METHODS SOCIAL S; *NAT ASS SCHOOLM U, 1995, WORKPL BULL REP NASU; National Association of Schoolmasters and Union of Women Teachers, 1996, NO PLAC HID CONFR WO; Niedl K., 1996, EUR J WORK ORGAN PSY, V5, P239, DOI DOI 10.1080/13594329608414857; PAYNE RL, 1979, RESPONSE STRESS OCCU; Quinn RP., 1979, 1977 QUALITY EMPLOYM; RANDALL P, 1997, ADULT BULLYING PETRA; Rayner C, 1997, J COMMUNITY APPL SOC, V7, P199; Rayner C, 1997, J COMMUNITY APPL SOC, V7, P181, DOI 10.1002/(SICI)1099-1298(199706)7:3<181::AID-CASP416>3.0.CO;2-Y; *UN, 1995, VIOL WORK HLTH SERV; Vartia M., 1996, EUR J WORK ORGAN PSY, V5, P203, DOI DOI 10.1080/13594329608414855; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	27	345	356	6	58	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1999	318	7178					228	232		10.1136/bmj.318.7178.228	http://dx.doi.org/10.1136/bmj.318.7178.228			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	161MG	9915730	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000078292300023
J	Smith, R; Hiatt, H; Berwick, D				Smith, R; Hiatt, H; Berwick, D			Shared ethical principles for everybody in health care: a working draft from the Tavistock Group	BRITISH MEDICAL JOURNAL			English	Article									Inst Healthcare Improvement, Boston, MA 02215 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Institute for Healthcare Improvement; Harvard University; Brigham & Women's Hospital	Berwick, D (corresponding author), Inst Healthcare Improvement, 135 Francis St, Boston, MA 02215 USA.							Berwick D, 1997, BRIT MED J, V315, P1633, DOI 10.1136/bmj.315.7123.1633	1	35	37	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1999	318	7178					248	249						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915738				2022-12-28	WOS:000078292300030
J	Magistretti, PJ; Pellerin, L; Rothman, DL; Shulman, RG				Magistretti, PJ; Pellerin, L; Rothman, DL; Shulman, RG			Neuroscience - Energy on demand	SCIENCE			English	Editorial Material							HUMAN BRAIN; ASTROCYTES		Univ Lausanne, Inst Physiol, CH-1005 Lausanne, Switzerland; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Diagnost Radiol, New Haven, CT 06520 USA	University of Lausanne; Yale University; Yale University	Magistretti, PJ (corresponding author), Univ Lausanne, Inst Physiol, CH-1005 Lausanne, Switzerland.	pierre.magistretti@iphysiol.unil.ch	Pellerin, Luc/A-8912-2017	Pellerin, Luc/0000-0002-1016-1970; Magistretti, Pierre Julius/0000-0002-6678-320X				Bergles DE, 1997, NEURON, V19, P1297, DOI 10.1016/S0896-6273(00)80420-1; Bittar PG, 1996, J CEREBR BLOOD F MET, V16, P1079, DOI 10.1097/00004647-199611000-00001; MASON GF, 1995, J CEREBR BLOOD F MET, V15, P12, DOI 10.1038/jcbfm.1995.2; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; ROTHMAN DL, 1993, P NATL ACAD SCI USA, V90, P5662, DOI 10.1073/pnas.90.12.5662; Schurr A, 1999, J NEUROSCI, V19, P34, DOI 10.1523/JNEUROSCI.19-01-00034.1999; Shulman RG, 1998, P NATL ACAD SCI USA, V95, P11993, DOI 10.1073/pnas.95.20.11993; Sibson NR, 1998, P NATL ACAD SCI USA, V95, P316, DOI 10.1073/pnas.95.1.316; TAKAHASHI S, 1995, P NATL ACAD SCI USA, V92, P4616, DOI 10.1073/pnas.92.10.4616	9	907	937	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 22	1999	283	5401					496	497		10.1126/science.283.5401.496	http://dx.doi.org/10.1126/science.283.5401.496			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9988650				2022-12-28	WOS:000078203300024
J	Gottlieb, S				Gottlieb, S			Inquiry says surgeons should stop operating if patient dies	BRITISH MEDICAL JOURNAL			English	News Item																			0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					349	349						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933184				2022-12-28	WOS:000078572600014
J	Jones, AH				Jones, AH			Narrative in medical ethics	BRITISH MEDICAL JOURNAL			English	Article									Univ Texas, Med Branch, Inst Med Humanities, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Jones, AH (corresponding author), Univ Texas, Med Branch, Inst Med Humanities, 2-210 Ashbel Smith Bldg,301 Univ Blvd, Galveston, TX 77555 USA.	ahjones@utmb.edu						[Anonymous], 1988, JAMA, V259, P272; Bakhtin M.M, 1981, DIALOGIC IMAGINATION; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; Bell Barbara Currier., 1984, LIT MED, V3, P143; BEST PC, 1994, LIT MED, V13, P93; BRODY H, 1994, LIT MED, V13, P79; CHAMBERS TS, 1994, LIT MED, V13, P60, DOI 10.1353/lm.2011.0160; CHARON R, 1995, ANN INTERN MED, V122, P599, DOI 10.7326/0003-4819-122-8-199504150-00008; CHARON R, 1989, SOUNDINGS, V72, P137; Charon R., 1994, MATTER PRINCIPLES FE, P260; Churchill L, 1979, Soundings, V62, P24; COLES R, 1979, NEW ENGL J MED, V301, P444, DOI 10.1056/NEJM197908233010831; COLES R, 1984, DOCTOR STORIES, pR7; Eco U., 1988, SIGN 3 DUPIN HOLMES; Frank AW., 2013, WOUNDED STORYTELLER; HAWKINS AH, 1992, LIT MED, V11, P200; Jones AH, 1997, LANCET, V349, P1243, DOI 10.1016/S0140-6736(97)03395-3; Jones AH, 1996, J MED PHILOS, V21, P267; JONES AH, 1990, ST COMPAR L, V22, P11; JONES AH, IN PRESS HEC FORUM; JONES AH, 1997, PHILOS MED BIOETHICS, P193; Jonsen A. R., 1988, ABUSE CASUISTRY HIST; KING NMP, 1992, LIT MED, V11, P185; Kleinman A., 1988, ILLNESS NARRATIVES; MCLELLAN MF, 1997, THESIS U TEXAS GALVE; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; Nelson Hilde Lindemann, 1997, STORIES THEIR LIMITS; Pickering N, 1998, J MED ETHICS, V24, P171, DOI 10.1136/jme.24.3.171; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; SELZER R, 1982, LETT YOUNG DOCTOR; TERRY JS, 1988, LIT MED, V7, P1, DOI 10.1353/lm.2011.0155; Tovey P, 1998, J MED ETHICS, V24, P176, DOI 10.1136/jme.24.3.176; Trautmann J., 1978, ROLE HUMANITIES MED, P32; Williams W. C., 1984, DOCTOR STORIES; Woodcock J, 1992, J Med Humanit, V13, P157, DOI 10.1007/BF01127374	35	65	68	1	13	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 23	1999	318	7178					253	256						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	161MG	18751168				2022-12-28	WOS:000078292300033
J	Gottlieb, S				Gottlieb, S			Heart attack patients do better in America's "best" hospitals	BRITISH MEDICAL JOURNAL			English	News Item																		Chen J, 1999, NEW ENGL J MED, V340, P286, DOI 10.1056/NEJM199901283400407; Kassirer JP, 1999, NEW ENGL J MED, V340, P309, DOI 10.1056/NEJM199901283400410	2	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					349	349						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933184				2022-12-28	WOS:000078572600012
J	Sorensen, HT; Rothman, KJ; Gillman, MW; Steffensen, FH; Fischer, P; Sabroe, S				Sorensen, HT; Rothman, KJ; Gillman, MW; Steffensen, FH; Fischer, P; Sabroe, S			Historical cohort study of in utero exposure to uterotonic drugs and cognitive function in young adult life	BRITISH MEDICAL JOURNAL			English	Article									Aarhus Univ Hosp, Dept Internal Med 5, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Epidemiol & Social Med, Danish Epidemiol Sci Ctr, DK-8000 Aarhus, Denmark; Boston Univ, Sch Med, Dept Epidemiol & Prevent Med, Boston, MA 02118 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA 02215 USA; Cty N Jutland, Conscript Adm, DK-9000 Aalborg, Denmark	Aarhus University; Aarhus University; Boston University; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care	Sorensen, HT (corresponding author), Aarhus Univ Hosp, Dept Internal Med 5, DK-8000 Aarhus C, Denmark.		Steffensen, Flemming Hald/AAH-8742-2020; Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Steffensen, Flemming Hald/0000-0003-0252-6631; Rothman, Kenneth/0000-0003-2398-1705				DAWOOD MY, 1989, AM J PERINAT, V6, P167, DOI 10.1055/s-2007-999569; FRIEDMAN EA, 1979, AM J OBSTET GYNECOL, V133, P718, DOI 10.1016/0002-9378(79)90025-5; JOHNSON JD, 1984, AM J DIS CHILD, V138, P1047, DOI 10.1001/archpedi.1984.02140490047011; Mortensen EL, 1989, SCAND J PSYCHOL, V30, P3115; SEIDMAN DS, 1991, PEDIATRICS, V88, P828	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1999	318	7181					433	434		10.1136/bmj.318.7181.433	http://dx.doi.org/10.1136/bmj.318.7181.433			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	168BF	18751140	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000078670100026
